{
    "605700d294d57fd879000021_1": [
        {
            "start_logit": 12.3046875,
            "end_logit": 12.5703125,
            "text": "MRJP1",
            "probability": 1.0
        },
        {
            "start_logit": -5.43359375,
            "end_logit": 12.5703125,
            "text": "P1",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -5.3359375,
            "text": "MRJP1, MRJP2, MRJP4, and MRJP5",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -5.390625,
            "text": "MRJP1, MRJP2, MRJP4, and MRJP",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -5.53515625,
            "text": "MR",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -6.0546875,
            "text": "MRJP1, MRJP2",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -6.3046875,
            "text": "MRJ",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -7.65625,
            "text": "MRJP1, MRJP2, MRJP4, and MRJP5)",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -7.65625,
            "text": "MRJP1, MRJP2, MRJP4",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -8.0234375,
            "text": "MRJP1, MRJP2, MRJP4, and MRJ",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -8.6015625,
            "text": "MRJP1, MRJP2, MRJP4, and MR",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -8.65625,
            "text": "MRJP1, MRJ",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -9.03125,
            "text": "MRJP1, MRJP2, MRJP4, and",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -9.1640625,
            "text": "MRJP1, MR",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -9.3125,
            "text": "MRJP1,",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 12.5703125,
            "text": "nurse bees to pesticides reduced the expression of four of the major royal jelly proteins (MRJP1",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 12.5703125,
            "text": "JP1",
            "probability": 0.0
        },
        {
            "start_logit": -5.43359375,
            "end_logit": -5.3359375,
            "text": "P1, MRJP2, MRJP4, and MRJP5",
            "probability": 0.0
        },
        {
            "start_logit": -5.43359375,
            "end_logit": -5.390625,
            "text": "P1, MRJP2, MRJP4, and MRJP",
            "probability": 0.0
        },
        {
            "start_logit": -5.43359375,
            "end_logit": -6.0546875,
            "text": "P1, MRJP2",
            "probability": 0.0
        }
    ],
    "5883bce3e56acf5176000003_1": [
        {
            "start_logit": 12.96875,
            "end_logit": 13.25,
            "text": "PeakXus",
            "probability": 1.0
        },
        {
            "start_logit": -5.1015625,
            "end_logit": 13.25,
            "text": "us",
            "probability": 0.0
        },
        {
            "start_logit": 12.96875,
            "end_logit": -5.203125,
            "text": "Peak",
            "probability": 0.0
        },
        {
            "start_logit": 12.96875,
            "end_logit": -7.55859375,
            "text": "PeakX",
            "probability": 0.0
        },
        {
            "start_logit": 12.96875,
            "end_logit": -7.76171875,
            "text": "PeakXus: comprehensive transcription factor binding site discovery from ChIP-Nexus and ChIP-Exo",
            "probability": 0.0
        },
        {
            "start_logit": 12.96875,
            "end_logit": -8.1484375,
            "text": "PeakXus: comprehensive transcription factor binding site",
            "probability": 0.0
        },
        {
            "start_logit": 12.96875,
            "end_logit": -8.2109375,
            "text": "PeakXus: comprehensive transcription factor binding site discovery",
            "probability": 0.0
        },
        {
            "start_logit": 12.96875,
            "end_logit": -8.640625,
            "text": "PeakXus: comprehensive transcription factor binding site discovery from ChIP-Nexus and ChIP-Exo experiments.",
            "probability": 0.0
        },
        {
            "start_logit": 12.96875,
            "end_logit": -9.0390625,
            "text": "PeakXus: comprehensive transcription factor",
            "probability": 0.0
        },
        {
            "start_logit": -9.328125,
            "end_logit": 13.25,
            "text": "Xus",
            "probability": 0.0
        },
        {
            "start_logit": 12.96875,
            "end_logit": -9.34375,
            "text": "PeakXus: comprehensive transcription factor binding",
            "probability": 0.0
        },
        {
            "start_logit": 12.96875,
            "end_logit": -9.6796875,
            "text": "PeakXus: comprehensive transcription factor binding site discovery from ChIP-Nexus and ChIP-",
            "probability": 0.0
        },
        {
            "start_logit": 12.96875,
            "end_logit": -9.703125,
            "text": "PeakXus: comprehensive transcription factor binding site discovery from ChIP-Nexus and ChIP-Exo experiments",
            "probability": 0.0
        },
        {
            "start_logit": 12.96875,
            "end_logit": -9.8515625,
            "text": "PeakXus: comprehensive transcription factor binding site discovery from ChIP-Nexus and ChIP",
            "probability": 0.0
        },
        {
            "start_logit": 12.96875,
            "end_logit": -9.8671875,
            "text": "PeakXus:",
            "probability": 0.0
        },
        {
            "start_logit": 12.96875,
            "end_logit": -10.1875,
            "text": "PeakXus: comprehensive transcription factor binding site discovery from ChIP-Nexus and",
            "probability": 0.0
        },
        {
            "start_logit": 12.96875,
            "end_logit": -10.265625,
            "text": "PeakXus: comprehensive transcription factor binding site discovery from ChIP-Nexus",
            "probability": 0.0
        },
        {
            "start_logit": -5.1015625,
            "end_logit": -7.76171875,
            "text": "us: comprehensive transcription factor binding site discovery from ChIP-Nexus and ChIP-Exo",
            "probability": 0.0
        },
        {
            "start_logit": -5.1015625,
            "end_logit": -8.1484375,
            "text": "us: comprehensive transcription factor binding site",
            "probability": 0.0
        },
        {
            "start_logit": -5.1015625,
            "end_logit": -8.2109375,
            "text": "us: comprehensive transcription factor binding site discovery",
            "probability": 0.0
        }
    ],
    "5883bce3e56acf5176000003_2": [
        {
            "start_logit": 13.2890625,
            "end_logit": 13.7421875,
            "text": "PeakXus",
            "probability": 1.0
        },
        {
            "start_logit": -4.30859375,
            "end_logit": 13.7421875,
            "text": "us",
            "probability": 0.0
        },
        {
            "start_logit": 13.2890625,
            "end_logit": -4.78125,
            "text": "Peak",
            "probability": 0.0
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 13.7421875,
            "text": "peak caller PeakXus",
            "probability": 0.0
        },
        {
            "start_logit": 13.2890625,
            "end_logit": -7.61328125,
            "text": "PeakX",
            "probability": 0.0
        },
        {
            "start_logit": 13.2890625,
            "end_logit": -7.82421875,
            "text": "PeakXus that is specifically designed to leverage the increased resolution",
            "probability": 0.0
        },
        {
            "start_logit": -8.75,
            "end_logit": 13.7421875,
            "text": "caller PeakXus",
            "probability": 0.0
        },
        {
            "start_logit": -9.3984375,
            "end_logit": 13.7421875,
            "text": "Xus",
            "probability": 0.0
        },
        {
            "start_logit": 13.2890625,
            "end_logit": -9.4296875,
            "text": "PeakXus that is specifically designed to leverage the increased resolution of ChIP-exo",
            "probability": 0.0
        },
        {
            "start_logit": 13.2890625,
            "end_logit": -9.5,
            "text": "PeakXus that is",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 13.7421875,
            "text": "er PeakXus",
            "probability": 0.0
        },
        {
            "start_logit": -7.3671875,
            "end_logit": -4.50390625,
            "text": "peak caller",
            "probability": 0.0
        },
        {
            "start_logit": -4.30859375,
            "end_logit": -7.82421875,
            "text": "us that is specifically designed to leverage the increased resolution",
            "probability": 0.0
        },
        {
            "start_logit": -7.3671875,
            "end_logit": -4.78125,
            "text": "peak caller Peak",
            "probability": 0.0
        },
        {
            "start_logit": -8.75,
            "end_logit": -4.50390625,
            "text": "caller",
            "probability": 0.0
        },
        {
            "start_logit": -4.30859375,
            "end_logit": -9.0390625,
            "text": "us that is specifically designed to leverage the increased resolution of ChIP-exo/Nexus and developed with the aim of making as few assumptions",
            "probability": 0.0
        },
        {
            "start_logit": -8.75,
            "end_logit": -4.78125,
            "text": "caller Peak",
            "probability": 0.0
        },
        {
            "start_logit": -4.30859375,
            "end_logit": -9.4296875,
            "text": "us that is specifically designed to leverage the increased resolution of ChIP-exo",
            "probability": 0.0
        },
        {
            "start_logit": -4.30859375,
            "end_logit": -9.5,
            "text": "us that is",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": -4.50390625,
            "text": "er",
            "probability": 0.0
        }
    ],
    "5883bce3e56acf5176000003_3": [
        {
            "start_logit": 13.109375,
            "end_logit": 13.265625,
            "text": "Q-nexus",
            "probability": 1.0
        },
        {
            "start_logit": 13.109375,
            "end_logit": -4.52734375,
            "text": "Q",
            "probability": 0.0
        },
        {
            "start_logit": -5.125,
            "end_logit": 13.265625,
            "text": "us",
            "probability": 0.0
        },
        {
            "start_logit": 13.109375,
            "end_logit": -5.09765625,
            "text": "Q-ne",
            "probability": 0.0
        },
        {
            "start_logit": 13.109375,
            "end_logit": -6.0390625,
            "text": "Q-nex",
            "probability": 0.0
        },
        {
            "start_logit": 13.109375,
            "end_logit": -7.48046875,
            "text": "Q-",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": 13.265625,
            "text": "nexus",
            "probability": 0.0
        },
        {
            "start_logit": -8.828125,
            "end_logit": 13.265625,
            "text": "xus",
            "probability": 0.0
        },
        {
            "start_logit": 13.109375,
            "end_logit": -9.140625,
            "text": "Q-nexus: a comprehensive and efficient analysis pipeline",
            "probability": 0.0
        },
        {
            "start_logit": 13.109375,
            "end_logit": -9.234375,
            "text": "Q-nexus: a comprehensive and efficient analysis pipeline designed for ChIP-nexus.",
            "probability": 0.0
        },
        {
            "start_logit": 13.109375,
            "end_logit": -9.28125,
            "text": "Q-nexus: a comprehensive and efficient analysis pipeline designed",
            "probability": 0.0
        },
        {
            "start_logit": 13.109375,
            "end_logit": -9.7265625,
            "text": "Q-nexus:",
            "probability": 0.0
        },
        {
            "start_logit": 13.109375,
            "end_logit": -9.7578125,
            "text": "Q-nexus: a comprehensive and efficient",
            "probability": 0.0
        },
        {
            "start_logit": 13.109375,
            "end_logit": -10.0390625,
            "text": "Q-nexus: a",
            "probability": 0.0
        },
        {
            "start_logit": 13.109375,
            "end_logit": -10.09375,
            "text": "Q-nexus: a comprehensive and efficient analysis pipeline designed for",
            "probability": 0.0
        },
        {
            "start_logit": 13.109375,
            "end_logit": -10.109375,
            "text": "Q-nexus: a comprehensive and efficient analysis pipeline designed for ChIP-nexus",
            "probability": 0.0
        },
        {
            "start_logit": 13.109375,
            "end_logit": -10.1484375,
            "text": "Q-nexus: a comprehensive and efficient analysis",
            "probability": 0.0
        },
        {
            "start_logit": 13.109375,
            "end_logit": -10.2109375,
            "text": "Q-nexus: a comprehensive",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": -5.09765625,
            "text": "ne",
            "probability": 0.0
        },
        {
            "start_logit": -5.125,
            "end_logit": -9.140625,
            "text": "us: a comprehensive and efficient analysis pipeline",
            "probability": 0.0
        }
    ],
    "5883bce3e56acf5176000003_4": [
        {
            "start_logit": 13.109375,
            "end_logit": 13.265625,
            "text": "Q-nexus",
            "probability": 1.0
        },
        {
            "start_logit": 13.109375,
            "end_logit": -4.52734375,
            "text": "Q",
            "probability": 0.0
        },
        {
            "start_logit": -5.125,
            "end_logit": 13.265625,
            "text": "us",
            "probability": 0.0
        },
        {
            "start_logit": 13.109375,
            "end_logit": -5.09765625,
            "text": "Q-ne",
            "probability": 0.0
        },
        {
            "start_logit": 13.109375,
            "end_logit": -6.0390625,
            "text": "Q-nex",
            "probability": 0.0
        },
        {
            "start_logit": 13.109375,
            "end_logit": -7.48046875,
            "text": "Q-",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": 13.265625,
            "text": "nexus",
            "probability": 0.0
        },
        {
            "start_logit": -8.828125,
            "end_logit": 13.265625,
            "text": "xus",
            "probability": 0.0
        },
        {
            "start_logit": 13.109375,
            "end_logit": -9.140625,
            "text": "Q-nexus: a comprehensive and efficient analysis pipeline",
            "probability": 0.0
        },
        {
            "start_logit": 13.109375,
            "end_logit": -9.234375,
            "text": "Q-nexus: a comprehensive and efficient analysis pipeline designed for ChIP-nexus.",
            "probability": 0.0
        },
        {
            "start_logit": 13.109375,
            "end_logit": -9.28125,
            "text": "Q-nexus: a comprehensive and efficient analysis pipeline designed",
            "probability": 0.0
        },
        {
            "start_logit": 13.109375,
            "end_logit": -9.7265625,
            "text": "Q-nexus:",
            "probability": 0.0
        },
        {
            "start_logit": 13.109375,
            "end_logit": -9.7578125,
            "text": "Q-nexus: a comprehensive and efficient",
            "probability": 0.0
        },
        {
            "start_logit": 13.109375,
            "end_logit": -10.0390625,
            "text": "Q-nexus: a",
            "probability": 0.0
        },
        {
            "start_logit": 13.109375,
            "end_logit": -10.09375,
            "text": "Q-nexus: a comprehensive and efficient analysis pipeline designed for",
            "probability": 0.0
        },
        {
            "start_logit": 13.109375,
            "end_logit": -10.109375,
            "text": "Q-nexus: a comprehensive and efficient analysis pipeline designed for ChIP-nexus",
            "probability": 0.0
        },
        {
            "start_logit": 13.109375,
            "end_logit": -10.1484375,
            "text": "Q-nexus: a comprehensive and efficient analysis",
            "probability": 0.0
        },
        {
            "start_logit": 13.109375,
            "end_logit": -10.2109375,
            "text": "Q-nexus: a comprehensive",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": -5.09765625,
            "text": "ne",
            "probability": 0.0
        },
        {
            "start_logit": -5.125,
            "end_logit": -9.140625,
            "text": "us: a comprehensive and efficient analysis pipeline",
            "probability": 0.0
        }
    ],
    "5883bce3e56acf5176000003_5": [
        {
            "start_logit": 12.96875,
            "end_logit": 13.25,
            "text": "PeakXus",
            "probability": 1.0
        },
        {
            "start_logit": -5.1015625,
            "end_logit": 13.25,
            "text": "us",
            "probability": 0.0
        },
        {
            "start_logit": 12.96875,
            "end_logit": -5.203125,
            "text": "Peak",
            "probability": 0.0
        },
        {
            "start_logit": 12.96875,
            "end_logit": -7.55859375,
            "text": "PeakX",
            "probability": 0.0
        },
        {
            "start_logit": 12.96875,
            "end_logit": -7.76171875,
            "text": "PeakXus: comprehensive transcription factor binding site discovery from ChIP-Nexus and ChIP-Exo",
            "probability": 0.0
        },
        {
            "start_logit": 12.96875,
            "end_logit": -8.1484375,
            "text": "PeakXus: comprehensive transcription factor binding site",
            "probability": 0.0
        },
        {
            "start_logit": 12.96875,
            "end_logit": -8.2109375,
            "text": "PeakXus: comprehensive transcription factor binding site discovery",
            "probability": 0.0
        },
        {
            "start_logit": 12.96875,
            "end_logit": -8.640625,
            "text": "PeakXus: comprehensive transcription factor binding site discovery from ChIP-Nexus and ChIP-Exo experiments.",
            "probability": 0.0
        },
        {
            "start_logit": 12.96875,
            "end_logit": -9.0390625,
            "text": "PeakXus: comprehensive transcription factor",
            "probability": 0.0
        },
        {
            "start_logit": -9.328125,
            "end_logit": 13.25,
            "text": "Xus",
            "probability": 0.0
        },
        {
            "start_logit": 12.96875,
            "end_logit": -9.34375,
            "text": "PeakXus: comprehensive transcription factor binding",
            "probability": 0.0
        },
        {
            "start_logit": 12.96875,
            "end_logit": -9.6796875,
            "text": "PeakXus: comprehensive transcription factor binding site discovery from ChIP-Nexus and ChIP-",
            "probability": 0.0
        },
        {
            "start_logit": 12.96875,
            "end_logit": -9.703125,
            "text": "PeakXus: comprehensive transcription factor binding site discovery from ChIP-Nexus and ChIP-Exo experiments",
            "probability": 0.0
        },
        {
            "start_logit": 12.96875,
            "end_logit": -9.8515625,
            "text": "PeakXus: comprehensive transcription factor binding site discovery from ChIP-Nexus and ChIP",
            "probability": 0.0
        },
        {
            "start_logit": 12.96875,
            "end_logit": -9.8671875,
            "text": "PeakXus:",
            "probability": 0.0
        },
        {
            "start_logit": 12.96875,
            "end_logit": -10.1875,
            "text": "PeakXus: comprehensive transcription factor binding site discovery from ChIP-Nexus and",
            "probability": 0.0
        },
        {
            "start_logit": 12.96875,
            "end_logit": -10.265625,
            "text": "PeakXus: comprehensive transcription factor binding site discovery from ChIP-Nexus",
            "probability": 0.0
        },
        {
            "start_logit": -5.1015625,
            "end_logit": -7.76171875,
            "text": "us: comprehensive transcription factor binding site discovery from ChIP-Nexus and ChIP-Exo",
            "probability": 0.0
        },
        {
            "start_logit": -5.1015625,
            "end_logit": -8.1484375,
            "text": "us: comprehensive transcription factor binding site",
            "probability": 0.0
        },
        {
            "start_logit": -5.1015625,
            "end_logit": -8.2109375,
            "text": "us: comprehensive transcription factor binding site discovery",
            "probability": 0.0
        }
    ],
    "58da14178acda34529000011_1": [
        {
            "start_logit": 11.421875,
            "end_logit": 11.578125,
            "text": "13",
            "probability": 1.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -3.744140625,
            "text": "13;22",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 11.421875,
            "end_logit": -7.66015625,
            "text": "13;22) Robertsonian translocation carrier by FISH: a comparison of locus-specific probe and whole chromosome painting",
            "probability": 0.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -7.8125,
            "text": "13;22) Robertsonian translocation carrier by FISH",
            "probability": 0.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -8.34375,
            "text": "13;22) Robertsonian translocation carrier by FISH: a comparison of locus-specific probe and whole chromosome pain",
            "probability": 0.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -8.5703125,
            "text": "13;22) Robertsonian translocation carrier by FISH: a comparison of locus-specific probe and whole chromosome",
            "probability": 0.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -8.703125,
            "text": "13;22) Robertsonian translocation carrier by FISH: a",
            "probability": 0.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -9.390625,
            "text": "13;22) Robertsonian translocation carrier by FISH: a comparison of locus-specific probe",
            "probability": 0.0
        },
        {
            "start_logit": -9.6875,
            "end_logit": 11.578125,
            "text": "Sperm segregation analysis of a (13",
            "probability": 0.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -9.5390625,
            "text": "13;22)",
            "probability": 0.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -9.875,
            "text": "13;22) Robertsonian translocation carrier by FISH:",
            "probability": 0.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -10.0390625,
            "text": "13;22) Robertsonian translocation carrier",
            "probability": 0.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -10.0625,
            "text": "13;22) Robertsonian translocation carrier by FISH: a comparison of locus-specific probe and",
            "probability": 0.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -10.0625,
            "text": "13;22) Robertsonian translocation carrier by FISH: a comparison of locus-specific probe and whole",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 11.578125,
            "text": "segregation analysis of a (13",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 11.578125,
            "text": "of a (13",
            "probability": 0.0
        },
        {
            "start_logit": -7.44921875,
            "end_logit": -3.744140625,
            "text": "22",
            "probability": 0.0
        },
        {
            "start_logit": -9.6875,
            "end_logit": -3.744140625,
            "text": "Sperm segregation analysis of a (13;22",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": -3.744140625,
            "text": "segregation analysis of a (13;22",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": -3.744140625,
            "text": "of a (13;22",
            "probability": 0.0
        }
    ],
    "58da14178acda34529000011_2": [
        {
            "start_logit": 10.4296875,
            "end_logit": 10.0546875,
            "text": "13",
            "probability": 1.0
        },
        {
            "start_logit": 10.4296875,
            "end_logit": -4.52734375,
            "text": "13;22) Robertsonian translocation constitutes",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 10.4296875,
            "end_logit": -5.9609375,
            "text": "13;22",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.4296875,
            "end_logit": -9.1640625,
            "text": "13;22) Robertsonian translocation constitutes a rare form of rearrangement between acrocentric human chromosomes. Most of the meiotic segregation studies",
            "probability": 0.0
        },
        {
            "start_logit": 10.4296875,
            "end_logit": -9.515625,
            "text": "13;22) Robertsonian translocation constitutes a",
            "probability": 0.0
        },
        {
            "start_logit": 10.4296875,
            "end_logit": -9.6015625,
            "text": "13;22) Robertsonian translocation constitutes a rare form of rearrangement between acrocentric human chromosomes",
            "probability": 0.0
        },
        {
            "start_logit": 10.4296875,
            "end_logit": -9.6640625,
            "text": "13;22) Robertsonian translocation constitutes a rare form",
            "probability": 0.0
        },
        {
            "start_logit": 10.4296875,
            "end_logit": -9.8046875,
            "text": "13;22)",
            "probability": 0.0
        },
        {
            "start_logit": -9.59375,
            "end_logit": 10.0546875,
            "text": "t(13",
            "probability": 0.0
        },
        {
            "start_logit": -4.9375,
            "end_logit": -1.162109375,
            "text": "14",
            "probability": 0.0
        },
        {
            "start_logit": -4.9375,
            "end_logit": -3.9609375,
            "text": "14) and t(14;21",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -1.162109375,
            "text": "t(13;14",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": -1.162109375,
            "text": ";14",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": -1.162109375,
            "text": "meiotic segregation studies of human Robertsonian translocations have been performed on common t(13;14",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": -1.162109375,
            "text": "of the meiotic segregation studies of human Robertsonian translocations have been performed on common t(13;14",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -3.9609375,
            "text": "21",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -3.9609375,
            "text": "t(13;14) and t(14;21",
            "probability": 0.0
        },
        {
            "start_logit": -4.9375,
            "end_logit": -8.2265625,
            "text": "14) and t(14",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": -3.9609375,
            "text": "t(14;21",
            "probability": 0.0
        },
        {
            "start_logit": -9.8671875,
            "end_logit": -3.9609375,
            "text": "and t(14;21",
            "probability": 0.0
        }
    ],
    "58da14178acda34529000011_3": [
        {
            "start_logit": 2.3984375,
            "end_logit": 6.96875,
            "text": "13-15",
            "probability": 0.9990234375
        },
        {
            "start_logit": -4.85546875,
            "end_logit": 6.96875,
            "text": "chromosomes 13-15",
            "probability": 0.0007071495056152344
        },
        {
            "start_logit": -8.4140625,
            "end_logit": 6.96875,
            "text": "15",
            "probability": 2.014636993408203e-05
        },
        {
            "start_logit": -9.40625,
            "end_logit": 6.96875,
            "text": "-15",
            "probability": 7.450580596923828e-06
        },
        {
            "start_logit": 2.3984375,
            "end_logit": -4.88671875,
            "text": "13-15, 21",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": 2.3984375,
            "end_logit": -6.44140625,
            "text": "13",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 2.3984375,
            "end_logit": -7.2890625,
            "text": "13-15, 21, and 22",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 2.3984375,
            "end_logit": -9.0234375,
            "text": "13-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 2.3984375,
            "end_logit": -9.3984375,
            "text": "13-15, 21, and 22. ROBs can be classified into two groups depending on their frequency of occurrence, common (rob(13q",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 2.3984375,
            "end_logit": -9.3984375,
            "text": "13-15, 21, and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 2.3984375,
            "end_logit": -9.640625,
            "text": "13-15, 21, and 22. ROBs can be classified into two groups depending on their frequency of occurrence, common",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.1871337890625,
            "end_logit": -7.73046875,
            "text": "and rob(14",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.1871337890625,
            "end_logit": -8.2734375,
            "text": "and rob(14q21q)), and rare (all remaining possible nonhomologous combinations)",
            "probability": 0.0
        },
        {
            "start_logit": -0.1871337890625,
            "end_logit": -8.3515625,
            "text": "and rob(14q21",
            "probability": 0.0
        },
        {
            "start_logit": -0.1871337890625,
            "end_logit": -9.3515625,
            "text": "and rob(14q21q",
            "probability": 0.0
        },
        {
            "start_logit": -4.85546875,
            "end_logit": -4.88671875,
            "text": "chromosomes 13-15, 21",
            "probability": 0.0
        },
        {
            "start_logit": -0.1871337890625,
            "end_logit": -9.65625,
            "text": "and rob(14q21q)), and rare (all remaining possible nonhomol",
            "probability": 0.0
        },
        {
            "start_logit": -0.1871337890625,
            "end_logit": -9.7734375,
            "text": "and rob(14q21q)), and rare (all remaining possible",
            "probability": 0.0
        },
        {
            "start_logit": -6.03515625,
            "end_logit": -4.88671875,
            "text": "21",
            "probability": 0.0
        },
        {
            "start_logit": -4.85546875,
            "end_logit": -6.44140625,
            "text": "chromosomes 13",
            "probability": 0.0
        }
    ],
    "58da14178acda34529000011_4": [
        {
            "start_logit": 7.21875,
            "end_logit": 9.953125,
            "text": "13",
            "probability": 1.0
        },
        {
            "start_logit": 7.21875,
            "end_logit": -1.337890625,
            "text": "13, 14, and 21",
            "probability": 1.2516975402832031e-05
        },
        {
            "start_logit": -5.64453125,
            "end_logit": 9.953125,
            "text": "chromosomes 13",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": 7.21875,
            "end_logit": -6.01171875,
            "text": "13, 14",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 9.953125,
            "text": "ROBs. Previous studies have shown that the breakpoints are consistently located within specific regions of the proximal short arms of chromosomes 13",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.90625,
            "end_logit": 9.953125,
            "text": "all ROBs. Previous studies have shown that the breakpoints are consistently located within specific regions of the proximal short arms of chromosomes 13",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.96484375,
            "end_logit": -8.359375,
            "text": "and rob(13q14q), which are formed predominantly during female meiosis, comprise",
            "probability": 0.0
        },
        {
            "start_logit": 7.96484375,
            "end_logit": -8.8046875,
            "text": "and rob(13",
            "probability": 0.0
        },
        {
            "start_logit": 7.96484375,
            "end_logit": -8.9296875,
            "text": "and",
            "probability": 0.0
        },
        {
            "start_logit": 7.96484375,
            "end_logit": -9.3515625,
            "text": "and rob(13q",
            "probability": 0.0
        },
        {
            "start_logit": 7.96484375,
            "end_logit": -9.7265625,
            "text": "and rob(13q14q), which are formed predominantly during female meiosis",
            "probability": 0.0
        },
        {
            "start_logit": 7.96484375,
            "end_logit": -9.7421875,
            "text": "and rob(13q14q), which are formed predominantly during female meiosis, comprise the majority (approximately 85%",
            "probability": 0.0
        },
        {
            "start_logit": -2.91796875,
            "end_logit": -1.337890625,
            "text": "21",
            "probability": 0.0
        },
        {
            "start_logit": -5.64453125,
            "end_logit": -1.337890625,
            "text": "chromosomes 13, 14, and 21",
            "probability": 0.0
        },
        {
            "start_logit": -6.92578125,
            "end_logit": -1.337890625,
            "text": "14, and 21",
            "probability": 0.0
        },
        {
            "start_logit": -7.05078125,
            "end_logit": -2.421875,
            "text": ". Rob(14",
            "probability": 0.0
        },
        {
            "start_logit": -8.578125,
            "end_logit": -2.421875,
            "text": "14",
            "probability": 0.0
        },
        {
            "start_logit": -9.7109375,
            "end_logit": -1.337890625,
            "text": "ROBs. Previous studies have shown that the breakpoints are consistently located within specific regions of the proximal short arms of chromosomes 13, 14, and 21",
            "probability": 0.0
        },
        {
            "start_logit": -9.90625,
            "end_logit": -1.337890625,
            "text": "all ROBs. Previous studies have shown that the breakpoints are consistently located within specific regions of the proximal short arms of chromosomes 13, 14, and 21",
            "probability": 0.0
        },
        {
            "start_logit": -8.8359375,
            "end_logit": -2.421875,
            "text": "Rob(14",
            "probability": 0.0
        }
    ],
    "58da14178acda34529000011_5": [
        {
            "start_logit": 10.1171875,
            "end_logit": 12.5078125,
            "text": "22",
            "probability": 1.0
        },
        {
            "start_logit": -8.46875,
            "end_logit": 12.5078125,
            "text": "Chromosome 22",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -8.875,
            "text": "22, most probably, is the only chromosome where chAB4",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -9.4140625,
            "text": "22, most probably, is",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -9.4921875,
            "text": "22, most probably, is the only chromosome",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -9.5625,
            "text": "22, most probably, is the only chromosome where chAB4 is found in the direct neighbourhood of the centromere",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -9.7265625,
            "text": "22, most probably",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -9.7734375,
            "text": "22, most probably, is the only",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -9.8515625,
            "text": "22, most probably, is the only chromosome where chA",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -9.9453125,
            "text": "22, most probably, is the only chromosome where chAB4 is",
            "probability": 0.0
        },
        {
            "start_logit": -8.40625,
            "end_logit": -5.12109375,
            "text": "21",
            "probability": 0.0
        },
        {
            "start_logit": -9.59375,
            "end_logit": -5.12109375,
            "text": "rob(21",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": -5.12109375,
            "text": "metaphase chromosomes of carriers of rob(21",
            "probability": 0.0
        },
        {
            "start_logit": -10.1171875,
            "end_logit": -5.12109375,
            "text": "carriers of rob(21",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": -5.12109375,
            "text": "chAB4 is found in the direct neighbourhood of the centromere. Fluorescence in situ hybridization analyses of metaphase chromosomes of carriers of rob(21",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": -5.12109375,
            "text": "analyses of metaphase chromosomes of carriers of rob(21",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": -5.12109375,
            "text": "(21",
            "probability": 0.0
        },
        {
            "start_logit": -8.40625,
            "end_logit": -8.25,
            "text": "21q22",
            "probability": 0.0
        },
        {
            "start_logit": -8.40625,
            "end_logit": -8.671875,
            "text": "21q22q) revealed breakpoint diversity",
            "probability": 0.0
        },
        {
            "start_logit": -8.46875,
            "end_logit": -8.875,
            "text": "Chromosome 22, most probably, is the only chromosome where chAB4",
            "probability": 0.0
        }
    ],
    "58da14178acda34529000011_6": [
        {
            "start_logit": 10.5234375,
            "end_logit": 12.2265625,
            "text": "13",
            "probability": 1.0
        },
        {
            "start_logit": 10.5234375,
            "end_logit": 2.892578125,
            "text": "13, 14",
            "probability": 8.821487426757812e-05
        },
        {
            "start_logit": 3.537109375,
            "end_logit": 2.892578125,
            "text": "14",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.5234375,
            "end_logit": -5.06640625,
            "text": "13, 14 and 21",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.8046875,
            "end_logit": 12.2265625,
            "text": "chromosomes 13",
            "probability": 0.0
        },
        {
            "start_logit": 10.5234375,
            "end_logit": -9.4453125,
            "text": "13, 14 and 21. The presence of this alpha subfamily may allow pairing between these chromosomes leading",
            "probability": 0.0
        },
        {
            "start_logit": 10.5234375,
            "end_logit": -9.6171875,
            "text": "13, 14 and",
            "probability": 0.0
        },
        {
            "start_logit": 10.5234375,
            "end_logit": -9.8828125,
            "text": "13, 14 and 21. The presence of this alpha subfamily may",
            "probability": 0.0
        },
        {
            "start_logit": 10.5234375,
            "end_logit": -9.9609375,
            "text": "13,",
            "probability": 0.0
        },
        {
            "start_logit": 10.5234375,
            "end_logit": -10.03125,
            "text": "13, 14 and 21. The presence of this alpha subfamily",
            "probability": 0.0
        },
        {
            "start_logit": 10.5234375,
            "end_logit": -10.1015625,
            "text": "13, 14 and 21. The presence of this alpha subfamily may allow pairing between these chromosomes",
            "probability": 0.0
        },
        {
            "start_logit": 3.537109375,
            "end_logit": -5.06640625,
            "text": "14 and 21",
            "probability": 0.0
        },
        {
            "start_logit": 3.537109375,
            "end_logit": -9.4453125,
            "text": "14 and 21. The presence of this alpha subfamily may allow pairing between these chromosomes leading",
            "probability": 0.0
        },
        {
            "start_logit": -8.8046875,
            "end_logit": 2.892578125,
            "text": "chromosomes 13, 14",
            "probability": 0.0
        },
        {
            "start_logit": 3.537109375,
            "end_logit": -9.6171875,
            "text": "14 and",
            "probability": 0.0
        },
        {
            "start_logit": 3.537109375,
            "end_logit": -9.8828125,
            "text": "14 and 21. The presence of this alpha subfamily may",
            "probability": 0.0
        },
        {
            "start_logit": 3.537109375,
            "end_logit": -10.03125,
            "text": "14 and 21. The presence of this alpha subfamily",
            "probability": 0.0
        },
        {
            "start_logit": 3.537109375,
            "end_logit": -10.1015625,
            "text": "14 and 21. The presence of this alpha subfamily may allow pairing between these chromosomes",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": 2.892578125,
            "text": ", 14",
            "probability": 0.0
        },
        {
            "start_logit": -7.52734375,
            "end_logit": -5.06640625,
            "text": "21",
            "probability": 0.0
        }
    ],
    "58da14178acda34529000011_7": [
        {
            "start_logit": 11.328125,
            "end_logit": 11.7109375,
            "text": "15",
            "probability": 1.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": 1.458984375,
            "text": "15/21",
            "probability": 3.5643577575683594e-05
        },
        {
            "start_logit": 11.328125,
            "end_logit": -4.859375,
            "text": "15/21 and a 13/14",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.328125,
            "end_logit": -6.59765625,
            "text": "15/21 and a 13",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": 11.7109375,
            "text": "carriers of a 15",
            "probability": 0.0
        },
        {
            "start_logit": 0.1812744140625,
            "end_logit": 1.458984375,
            "text": "21",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -9.7109375,
            "text": "15/21 and a 13/14 Robertsonian translocation, respectively, and was compared with that of the same numbers of relatives",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 11.7109375,
            "text": "of a 15",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 11.7109375,
            "text": "and five carriers of a 15",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": 11.7109375,
            "text": "examined in ten and five carriers of a 15",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -10.09375,
            "text": "15/21 and a 13/14 Robertsonian translocation, respectively, and was compared with that",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -10.09375,
            "text": "15/",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -10.2109375,
            "text": "15/21 and a 13/",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -10.2265625,
            "text": "15/21 and a 13/14 Robertsonian translocation, respectively, and was compared with that of the same numbers of relatives with normal karyotypes",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -10.2421875,
            "text": "15/21 and a",
            "probability": 0.0
        },
        {
            "start_logit": 0.1812744140625,
            "end_logit": -4.859375,
            "text": "21 and a 13/14",
            "probability": 0.0
        },
        {
            "start_logit": 0.1812744140625,
            "end_logit": -6.59765625,
            "text": "21 and a 13",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": 1.458984375,
            "text": "carriers of a 15/21",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 1.458984375,
            "text": "of a 15/21",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 1.458984375,
            "text": "and five carriers of a 15/21",
            "probability": 0.0
        }
    ],
    "58da14178acda34529000011_8": [
        {
            "start_logit": 11.0859375,
            "end_logit": 11.8984375,
            "text": "13",
            "probability": 1.0
        },
        {
            "start_logit": 11.0859375,
            "end_logit": -3.603515625,
            "text": "13, 14 and 21",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.0859375,
            "end_logit": -6.1328125,
            "text": "13, 14",
            "probability": 0.0
        },
        {
            "start_logit": -9.09375,
            "end_logit": 11.8984375,
            "text": "chromosomes 13",
            "probability": 0.0
        },
        {
            "start_logit": 11.0859375,
            "end_logit": -9.4375,
            "text": "13, 14 and 21: implications for recombination between nonhomologue",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 11.8984375,
            "text": "alpha satellite sequences on human acrocentric chromosomes with selectivity for chromosomes 13",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": 11.8984375,
            "text": "acrocentric chromosomes with selectivity for chromosomes 13",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 11.8984375,
            "text": "human acrocentric chromosomes with selectivity for chromosomes 13",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 11.8984375,
            "text": "ocentric chromosomes with selectivity for chromosomes 13",
            "probability": 0.0
        },
        {
            "start_logit": 11.0859375,
            "end_logit": -9.828125,
            "text": "13, 14 and 21: implications for recombination between nonhomol",
            "probability": 0.0
        },
        {
            "start_logit": 11.0859375,
            "end_logit": -9.890625,
            "text": "13, 14 and 21: implications for recombination between nonhomologues",
            "probability": 0.0
        },
        {
            "start_logit": 11.0859375,
            "end_logit": -9.9453125,
            "text": "13, 14 and 21: implications",
            "probability": 0.0
        },
        {
            "start_logit": -6.09375,
            "end_logit": -3.603515625,
            "text": "21",
            "probability": 0.0
        },
        {
            "start_logit": -7.6015625,
            "end_logit": -3.603515625,
            "text": "14 and 21",
            "probability": 0.0
        },
        {
            "start_logit": -9.09375,
            "end_logit": -3.603515625,
            "text": "chromosomes 13, 14 and 21",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": -3.603515625,
            "text": ", 14 and 21",
            "probability": 0.0
        },
        {
            "start_logit": -7.6015625,
            "end_logit": -6.1328125,
            "text": "14",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": -3.603515625,
            "text": "alpha satellite sequences on human acrocentric chromosomes with selectivity for chromosomes 13, 14 and 21",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": -3.603515625,
            "text": "acrocentric chromosomes with selectivity for chromosomes 13, 14 and 21",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": -3.603515625,
            "text": "human acrocentric chromosomes with selectivity for chromosomes 13, 14 and 21",
            "probability": 0.0
        }
    ],
    "58da14178acda34529000011_9": [
        {
            "start_logit": 3.14453125,
            "end_logit": 6.3515625,
            "text": "13",
            "probability": 0.9990234375
        },
        {
            "start_logit": -3.935546875,
            "end_logit": 6.3515625,
            "text": "trisomy 13",
            "probability": 0.0008358955383300781
        },
        {
            "start_logit": -9.34375,
            "end_logit": 6.3515625,
            "text": "associating trisomy 13",
            "probability": 3.7550926208496094e-06
        },
        {
            "start_logit": -9.4296875,
            "end_logit": 6.3515625,
            "text": "Robertsonian translocation associating trisomy 13",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": -9.890625,
            "end_logit": 6.3515625,
            "text": "acrocentric chromosomes, two duplications, two reciprocal translocations, two inversions, two additions, one Robertsonian translocation associating trisomy 13",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 6.3515625,
            "text": "additions, one Robertsonian translocation associating trisomy 13",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 3.14453125,
            "end_logit": -9.078125,
            "text": "13, one 9",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 3.14453125,
            "end_logit": -9.640625,
            "text": "13, one 9q",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 3.14453125,
            "end_logit": -9.8984375,
            "text": "13, one 9q heteromorphism and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 3.14453125,
            "end_logit": -10.296875,
            "text": "13, one 9q heteromorphism and one complex chromosome rearrangement were noticed",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 3.14453125,
            "end_logit": -10.3203125,
            "text": "13, one 9q heteromorphism and one complex chromosome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 3.14453125,
            "end_logit": -10.3359375,
            "text": "13, one 9q hetero",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.935546875,
            "end_logit": -7.875,
            "text": "trisomy",
            "probability": 0.0
        },
        {
            "start_logit": -3.935546875,
            "end_logit": -9.078125,
            "text": "trisomy 13, one 9",
            "probability": 0.0
        },
        {
            "start_logit": -3.935546875,
            "end_logit": -9.640625,
            "text": "trisomy 13, one 9q",
            "probability": 0.0
        },
        {
            "start_logit": -3.935546875,
            "end_logit": -9.8984375,
            "text": "trisomy 13, one 9q heteromorphism and",
            "probability": 0.0
        },
        {
            "start_logit": -3.935546875,
            "end_logit": -10.296875,
            "text": "trisomy 13, one 9q heteromorphism and one complex chromosome rearrangement were noticed",
            "probability": 0.0
        },
        {
            "start_logit": -3.935546875,
            "end_logit": -10.3203125,
            "text": "trisomy 13, one 9q heteromorphism and one complex chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -3.935546875,
            "end_logit": -10.3359375,
            "text": "trisomy 13, one 9q hetero",
            "probability": 0.0
        },
        {
            "start_logit": -9.34375,
            "end_logit": -7.875,
            "text": "associating trisomy",
            "probability": 0.0
        }
    ],
    "58da14178acda34529000011_10": [
        {
            "start_logit": 7.703125,
            "end_logit": 10.65625,
            "text": "14",
            "probability": 0.9990234375
        },
        {
            "start_logit": 4.70703125,
            "end_logit": 6.5234375,
            "text": "14",
            "probability": 0.0008039474487304688
        },
        {
            "start_logit": 7.703125,
            "end_logit": -4.87109375,
            "text": "14q",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.703125,
            "end_logit": -5.171875,
            "text": "14q and 21",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.5234375,
            "end_logit": 10.65625,
            "text": "chromosomes 14",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.703125,
            "end_logit": -7.15625,
            "text": "14q and 21q in human oogenesis with the use of dual color fluorescent in situ hybridization with whole chromosome paints",
            "probability": 0.0
        },
        {
            "start_logit": 7.703125,
            "end_logit": -7.62890625,
            "text": "14q and 21q in human oogenesis with the use of dual color fluorescent in situ hybridization",
            "probability": 0.0
        },
        {
            "start_logit": 4.70703125,
            "end_logit": -4.8828125,
            "text": "14 and 21",
            "probability": 0.0
        },
        {
            "start_logit": -6.80859375,
            "end_logit": 6.5234375,
            "text": "oocytes from a chromosomally normal fetus at 23.5 weeks of gestation underwent cohybridization with chromosome specific DNA libraries from chromosomes 14",
            "probability": 0.0
        },
        {
            "start_logit": 7.703125,
            "end_logit": -8.15625,
            "text": "14q and 21q",
            "probability": 0.0
        },
        {
            "start_logit": 7.703125,
            "end_logit": -9.2265625,
            "text": "14q and 21q in human oogenesis",
            "probability": 0.0
        },
        {
            "start_logit": 7.703125,
            "end_logit": -9.34375,
            "text": "14q and 21q in human oogenesis with the use of dual color fluorescent in situ hybridization with whole chromosome pain",
            "probability": 0.0
        },
        {
            "start_logit": 7.703125,
            "end_logit": -9.5859375,
            "text": "14q and 21q in human oogenesis with the use of dual color fluorescent in situ hybridization with whole chromosome paints.The oocytes",
            "probability": 0.0
        },
        {
            "start_logit": 7.703125,
            "end_logit": -9.765625,
            "text": "14q and 21q in human oogenesis with the use of dual color fluorescent in situ",
            "probability": 0.0
        },
        {
            "start_logit": -9.2890625,
            "end_logit": 6.5234375,
            "text": "fetus at 23.5 weeks of gestation underwent cohybridization with chromosome specific DNA libraries from chromosomes 14",
            "probability": 0.0
        },
        {
            "start_logit": -9.4140625,
            "end_logit": 6.5234375,
            "text": "with chromosome specific DNA libraries from chromosomes 14",
            "probability": 0.0
        },
        {
            "start_logit": -9.5390625,
            "end_logit": 6.5234375,
            "text": "The oocytes from a chromosomally normal fetus at 23.5 weeks of gestation underwent cohybridization with chromosome specific DNA libraries from chromosomes 14",
            "probability": 0.0
        },
        {
            "start_logit": -9.5859375,
            "end_logit": 6.5234375,
            "text": "chromosomes 14",
            "probability": 0.0
        },
        {
            "start_logit": -9.90625,
            "end_logit": 6.5234375,
            "text": "of gestation underwent cohybridization with chromosome specific DNA libraries from chromosomes 14",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": 6.5234375,
            "text": "cohybridization with chromosome specific DNA libraries from chromosomes 14",
            "probability": 0.0
        }
    ],
    "58da14178acda34529000011_11": [
        {
            "start_logit": 11.390625,
            "end_logit": 11.6015625,
            "text": "13",
            "probability": 1.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -4.59765625,
            "text": "13;22) Robertsonian translocation constitutes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.390625,
            "end_logit": -4.6953125,
            "text": "13;22",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.390625,
            "end_logit": -8.4765625,
            "text": "13;22) Robertsonian translocation constitutes a rare form of rearrangement between acrocentric human chromosomes",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -8.578125,
            "text": "13;22)",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -9.1796875,
            "text": "13;22) Robertsonian translocation constitutes a",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -9.53125,
            "text": "13;22) Robertsonian translocation constitutes a rare form",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -9.5390625,
            "text": "13;22) Robertsonian translocation constitutes a rare",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -9.78125,
            "text": "13;22) Robertsonian translocation",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 11.6015625,
            "text": "t(13",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -9.8359375,
            "text": "13;22) Robertsonian translocation constitutes a rare form of rearrangement between acrocentric",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -9.8359375,
            "text": "13;",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -10.1328125,
            "text": "13;22) Robertsonian translocation constitutes a rare form of rearrangement between",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -10.1640625,
            "text": "13;22) Robertsonian translocation constitutes a rare form of rearrangement",
            "probability": 0.0
        },
        {
            "start_logit": -8.9765625,
            "end_logit": -4.59765625,
            "text": "22) Robertsonian translocation constitutes",
            "probability": 0.0
        },
        {
            "start_logit": -8.9765625,
            "end_logit": -4.6953125,
            "text": "22",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": -4.59765625,
            "text": "t(13;22) Robertsonian translocation constitutes",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": -4.6953125,
            "text": "t(13;22",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": -4.59765625,
            "text": "Robertsonian translocation constitutes",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": -4.59765625,
            "text": "ertsonian translocation constitutes",
            "probability": 0.0
        }
    ],
    "58da14178acda34529000011_12": [
        {
            "start_logit": 11.0859375,
            "end_logit": 11.8984375,
            "text": "13",
            "probability": 1.0
        },
        {
            "start_logit": 11.0859375,
            "end_logit": -3.603515625,
            "text": "13, 14 and 21",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.0859375,
            "end_logit": -6.1328125,
            "text": "13, 14",
            "probability": 0.0
        },
        {
            "start_logit": -9.09375,
            "end_logit": 11.8984375,
            "text": "chromosomes 13",
            "probability": 0.0
        },
        {
            "start_logit": 11.0859375,
            "end_logit": -9.4375,
            "text": "13, 14 and 21: implications for recombination between nonhomologue",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 11.8984375,
            "text": "alpha satellite sequences on human acrocentric chromosomes with selectivity for chromosomes 13",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": 11.8984375,
            "text": "acrocentric chromosomes with selectivity for chromosomes 13",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 11.8984375,
            "text": "human acrocentric chromosomes with selectivity for chromosomes 13",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 11.8984375,
            "text": "ocentric chromosomes with selectivity for chromosomes 13",
            "probability": 0.0
        },
        {
            "start_logit": 11.0859375,
            "end_logit": -9.828125,
            "text": "13, 14 and 21: implications for recombination between nonhomol",
            "probability": 0.0
        },
        {
            "start_logit": 11.0859375,
            "end_logit": -9.890625,
            "text": "13, 14 and 21: implications for recombination between nonhomologues",
            "probability": 0.0
        },
        {
            "start_logit": 11.0859375,
            "end_logit": -9.9453125,
            "text": "13, 14 and 21: implications",
            "probability": 0.0
        },
        {
            "start_logit": -6.09375,
            "end_logit": -3.603515625,
            "text": "21",
            "probability": 0.0
        },
        {
            "start_logit": -7.6015625,
            "end_logit": -3.603515625,
            "text": "14 and 21",
            "probability": 0.0
        },
        {
            "start_logit": -9.09375,
            "end_logit": -3.603515625,
            "text": "chromosomes 13, 14 and 21",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": -3.603515625,
            "text": ", 14 and 21",
            "probability": 0.0
        },
        {
            "start_logit": -7.6015625,
            "end_logit": -6.1328125,
            "text": "14",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": -3.603515625,
            "text": "alpha satellite sequences on human acrocentric chromosomes with selectivity for chromosomes 13, 14 and 21",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": -3.603515625,
            "text": "acrocentric chromosomes with selectivity for chromosomes 13, 14 and 21",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": -3.603515625,
            "text": "human acrocentric chromosomes with selectivity for chromosomes 13, 14 and 21",
            "probability": 0.0
        }
    ],
    "58da14178acda34529000011_13": [
        {
            "start_logit": 11.28125,
            "end_logit": 11.8046875,
            "text": "13",
            "probability": 1.0
        },
        {
            "start_logit": 11.28125,
            "end_logit": -3.927734375,
            "text": "13;22",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.28125,
            "end_logit": -4.33203125,
            "text": "13;22) Robertsonian translocation constitutes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.28125,
            "end_logit": -8.4140625,
            "text": "13;22)",
            "probability": 0.0
        },
        {
            "start_logit": 11.28125,
            "end_logit": -9.1640625,
            "text": "13;22) Robertsonian translocation constitutes a rare form of rearrangement between acrocentric human chromosomes",
            "probability": 0.0
        },
        {
            "start_logit": -9.7578125,
            "end_logit": 11.8046875,
            "text": "t(13",
            "probability": 0.0
        },
        {
            "start_logit": 11.28125,
            "end_logit": -9.453125,
            "text": "13;22) Robertsonian translocation constitutes a",
            "probability": 0.0
        },
        {
            "start_logit": 11.28125,
            "end_logit": -9.578125,
            "text": "13;22) Robertsonian translocation",
            "probability": 0.0
        },
        {
            "start_logit": 11.28125,
            "end_logit": -9.59375,
            "text": "13;",
            "probability": 0.0
        },
        {
            "start_logit": 11.28125,
            "end_logit": -9.625,
            "text": "13;22) Robertsonian translocation constitutes a rare",
            "probability": 0.0
        },
        {
            "start_logit": 11.28125,
            "end_logit": -9.625,
            "text": "13;22) Robertsonian translocation constitutes a rare form",
            "probability": 0.0
        },
        {
            "start_logit": 11.28125,
            "end_logit": -9.84375,
            "text": "13;22) Robertsonian translocation constitutes a rare form of rearrangement between acrocentric human chromosomes.",
            "probability": 0.0
        },
        {
            "start_logit": 11.28125,
            "end_logit": -10.0078125,
            "text": "13;22) Robertsonian translocation constitutes a rare form of rearrangement between acrocentric",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": -3.927734375,
            "text": "22",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": -4.33203125,
            "text": "22) Robertsonian translocation constitutes",
            "probability": 0.0
        },
        {
            "start_logit": -9.7578125,
            "end_logit": -3.927734375,
            "text": "t(13;22",
            "probability": 0.0
        },
        {
            "start_logit": -9.7578125,
            "end_logit": -4.33203125,
            "text": "t(13;22) Robertsonian translocation constitutes",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": -4.33203125,
            "text": "Robertsonian translocation constitutes",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": -4.33203125,
            "text": "ertsonian translocation constitutes",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": -8.4140625,
            "text": "22)",
            "probability": 0.0
        }
    ],
    "5c6ffdd47c78d69471000058_1": [
        {
            "start_logit": 14.1328125,
            "end_logit": 13.6015625,
            "text": "miR-214",
            "probability": 1.0
        },
        {
            "start_logit": 14.1328125,
            "end_logit": -2.763671875,
            "text": "miR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.02734375,
            "end_logit": 13.6015625,
            "text": "214",
            "probability": 0.0
        },
        {
            "start_logit": 14.1328125,
            "end_logit": -6.9296875,
            "text": "miR-",
            "probability": 0.0
        },
        {
            "start_logit": 14.1328125,
            "end_logit": -8.4140625,
            "text": "miR-214 in various cardiac disease conditions, including ischaemic heart diseases, cardiac hypertrophy, pulmonary arterial hypertension (PAH), angiogenesis following vascular injury",
            "probability": 0.0
        },
        {
            "start_logit": 14.1328125,
            "end_logit": -8.765625,
            "text": "miR-214 in various cardiac disease conditions, including ischaemic heart diseases, cardiac hypertrophy, pulmonary arterial hypertension (PAH",
            "probability": 0.0
        },
        {
            "start_logit": 14.1328125,
            "end_logit": -8.8515625,
            "text": "miR-214 in various cardiac disease conditions, including ischaemic heart diseases, cardiac hypertrophy, pulmonary arterial hypertension (PAH), angiogenesis",
            "probability": 0.0
        },
        {
            "start_logit": 14.1328125,
            "end_logit": -9.453125,
            "text": "miR-214 in various cardiac disease conditions,",
            "probability": 0.0
        },
        {
            "start_logit": 14.1328125,
            "end_logit": -9.546875,
            "text": "miR-214 in various cardiac disease conditions, including ischaemic heart diseases",
            "probability": 0.0
        },
        {
            "start_logit": 14.1328125,
            "end_logit": -9.7265625,
            "text": "miR-214 in various cardiac disease conditions, including ischaemic heart diseases, cardiac hypertrophy, pulmonary arterial hypertension (PAH), angiogenesis following vascular injury and",
            "probability": 0.0
        },
        {
            "start_logit": 14.1328125,
            "end_logit": -9.796875,
            "text": "miR-214 in various cardiac disease conditions, including ischaemic heart diseases, cardiac hypertrophy, pulmonary arterial hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -4.02734375,
            "end_logit": -8.4140625,
            "text": "214 in various cardiac disease conditions, including ischaemic heart diseases, cardiac hypertrophy, pulmonary arterial hypertension (PAH), angiogenesis following vascular injury",
            "probability": 0.0
        },
        {
            "start_logit": -4.02734375,
            "end_logit": -8.765625,
            "text": "214 in various cardiac disease conditions, including ischaemic heart diseases, cardiac hypertrophy, pulmonary arterial hypertension (PAH",
            "probability": 0.0
        },
        {
            "start_logit": -4.02734375,
            "end_logit": -8.8515625,
            "text": "214 in various cardiac disease conditions, including ischaemic heart diseases, cardiac hypertrophy, pulmonary arterial hypertension (PAH), angiogenesis",
            "probability": 0.0
        },
        {
            "start_logit": -4.02734375,
            "end_logit": -9.453125,
            "text": "214 in various cardiac disease conditions,",
            "probability": 0.0
        },
        {
            "start_logit": -4.02734375,
            "end_logit": -9.546875,
            "text": "214 in various cardiac disease conditions, including ischaemic heart diseases",
            "probability": 0.0
        },
        {
            "start_logit": -4.02734375,
            "end_logit": -9.7265625,
            "text": "214 in various cardiac disease conditions, including ischaemic heart diseases, cardiac hypertrophy, pulmonary arterial hypertension (PAH), angiogenesis following vascular injury and",
            "probability": 0.0
        },
        {
            "start_logit": -4.02734375,
            "end_logit": -9.796875,
            "text": "214 in various cardiac disease conditions, including ischaemic heart diseases, cardiac hypertrophy, pulmonary arterial hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -9.3828125,
            "end_logit": -8.4140625,
            "text": "PAH), angiogenesis following vascular injury",
            "probability": 0.0
        },
        {
            "start_logit": -9.3828125,
            "end_logit": -8.765625,
            "text": "PAH",
            "probability": 0.0
        }
    ],
    "5c6ffdd47c78d69471000058_2": [
        {
            "start_logit": 12.921875,
            "end_logit": 12.7578125,
            "text": "miR-423-5p",
            "probability": 1.0
        },
        {
            "start_logit": 12.921875,
            "end_logit": -3.34375,
            "text": "miR",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.921875,
            "end_logit": -3.876953125,
            "text": "miR-423",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.921875,
            "end_logit": -5.56640625,
            "text": "miR-42",
            "probability": 0.0
        },
        {
            "start_logit": -5.6875,
            "end_logit": 12.7578125,
            "text": "5p",
            "probability": 0.0
        },
        {
            "start_logit": 12.921875,
            "end_logit": -6.36328125,
            "text": "miR-423-",
            "probability": 0.0
        },
        {
            "start_logit": -6.4453125,
            "end_logit": 12.7578125,
            "text": "3-5p",
            "probability": 0.0
        },
        {
            "start_logit": -6.81640625,
            "end_logit": 12.7578125,
            "text": "c-miRNAs such as miR-423-5p",
            "probability": 0.0
        },
        {
            "start_logit": 12.921875,
            "end_logit": -7.703125,
            "text": "miR-",
            "probability": 0.0
        },
        {
            "start_logit": 12.921875,
            "end_logit": -9.84375,
            "text": "miR-423-5p have been evaluated as potential biomarkers in the diagnosis and prognosis of heart failure",
            "probability": 0.0
        },
        {
            "start_logit": 12.921875,
            "end_logit": -10.0390625,
            "text": "miR-423-5p have been evaluated as potential biomarkers in the diagnosis and prognosis",
            "probability": 0.0
        },
        {
            "start_logit": 12.921875,
            "end_logit": -10.0546875,
            "text": "miR-423-5p have been evaluated as potential biomarkers",
            "probability": 0.0
        },
        {
            "start_logit": 12.921875,
            "end_logit": -10.1171875,
            "text": "miR-423-5p have",
            "probability": 0.0
        },
        {
            "start_logit": 12.921875,
            "end_logit": -10.140625,
            "text": "miR-423-5p have been evaluated",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 12.7578125,
            "text": "levels of c-miRNAs such as miR-423-5p",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 12.7578125,
            "text": "serum levels of c-miRNAs such as miR-423-5p",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 12.7578125,
            "text": "423-5p",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 12.7578125,
            "text": "miRNAs such as miR-423-5p",
            "probability": 0.0
        },
        {
            "start_logit": -6.81640625,
            "end_logit": -3.34375,
            "text": "c-miRNAs such as miR",
            "probability": 0.0
        },
        {
            "start_logit": -6.4453125,
            "end_logit": -3.876953125,
            "text": "3",
            "probability": 0.0
        }
    ],
    "5c6ffdd47c78d69471000058_3": [
        {
            "start_logit": 13.5234375,
            "end_logit": 13.1875,
            "text": "miR-423-5p",
            "probability": 1.0
        },
        {
            "start_logit": 13.5234375,
            "end_logit": -3.01171875,
            "text": "miR",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.5234375,
            "end_logit": -3.896484375,
            "text": "miR-423",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.1640625,
            "end_logit": 13.1875,
            "text": "5p",
            "probability": 0.0
        },
        {
            "start_logit": 13.5234375,
            "end_logit": -5.62890625,
            "text": "miR-42",
            "probability": 0.0
        },
        {
            "start_logit": 13.5234375,
            "end_logit": -6.55078125,
            "text": "miR-423-",
            "probability": 0.0
        },
        {
            "start_logit": -6.36328125,
            "end_logit": 13.1875,
            "text": "3-5p",
            "probability": 0.0
        },
        {
            "start_logit": 13.5234375,
            "end_logit": -7.65234375,
            "text": "miR-",
            "probability": 0.0
        },
        {
            "start_logit": 13.5234375,
            "end_logit": -9.640625,
            "text": "miR-423-5p are being",
            "probability": 0.0
        },
        {
            "start_logit": 13.5234375,
            "end_logit": -9.8828125,
            "text": "miR-423-5p are being evaluated as potential biomarkers",
            "probability": 0.0
        },
        {
            "start_logit": 13.5234375,
            "end_logit": -9.984375,
            "text": "miR-423-5p are being evaluated as potential biomarkers in the diagnosis and prognosis of heart failure.",
            "probability": 0.0
        },
        {
            "start_logit": 13.5234375,
            "end_logit": -9.984375,
            "text": "miR-423-5p are",
            "probability": 0.0
        },
        {
            "start_logit": 13.5234375,
            "end_logit": -10.015625,
            "text": "miR-423-5p are being evaluated",
            "probability": 0.0
        },
        {
            "start_logit": -9.703125,
            "end_logit": 13.1875,
            "text": "circulating miRNAs such as miR-423-5p",
            "probability": 0.0
        },
        {
            "start_logit": 13.5234375,
            "end_logit": -10.2421875,
            "text": "miR-423-5p are being evaluated as potential biomarkers in the diagnosis and prognosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 13.1875,
            "text": "Serum levels of circulating miRNAs such as miR-423-5p",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": 13.1875,
            "text": "miRNAs such as miR-423-5p",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 13.1875,
            "text": "levels of circulating miRNAs such as miR-423-5p",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 13.1875,
            "text": "423-5p",
            "probability": 0.0
        },
        {
            "start_logit": -6.36328125,
            "end_logit": -3.896484375,
            "text": "3",
            "probability": 0.0
        }
    ],
    "5c6ffdd47c78d69471000058_4": [
        {
            "start_logit": 13.1796875,
            "end_logit": 12.9921875,
            "text": "miR-423-5p",
            "probability": 1.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -3.279296875,
            "text": "miR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -3.923828125,
            "text": "miR-423",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.4453125,
            "end_logit": 12.9921875,
            "text": "5p",
            "probability": 0.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -5.64453125,
            "text": "miR-42",
            "probability": 0.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -6.27734375,
            "text": "miR-423-",
            "probability": 0.0
        },
        {
            "start_logit": -6.51953125,
            "end_logit": 12.9921875,
            "text": "3-5p",
            "probability": 0.0
        },
        {
            "start_logit": -6.70703125,
            "end_logit": 12.9921875,
            "text": "c-miRNAs such as miR-423-5p",
            "probability": 0.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -7.71484375,
            "text": "miR-",
            "probability": 0.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -9.953125,
            "text": "miR-423-5p have been evaluated as potential biomarkers",
            "probability": 0.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -10.0,
            "text": "miR-423-5p have been evaluated as potential biomarkers in the diagnosis and prognosis of heart failure.",
            "probability": 0.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -10.109375,
            "text": "miR-423-5p have",
            "probability": 0.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -10.1328125,
            "text": "miR-423-5p have been evaluated",
            "probability": 0.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -10.2265625,
            "text": "miR-423-5p have been",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 12.9921875,
            "text": "levels of c-miRNAs such as miR-423-5p",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 12.9921875,
            "text": "serum levels of c-miRNAs such as miR-423-5p",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 12.9921875,
            "text": "miRNAs such as miR-423-5p",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 12.9921875,
            "text": "423-5p",
            "probability": 0.0
        },
        {
            "start_logit": -6.70703125,
            "end_logit": -3.279296875,
            "text": "c-miRNAs such as miR",
            "probability": 0.0
        },
        {
            "start_logit": -6.51953125,
            "end_logit": -3.923828125,
            "text": "3",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_1": [
        {
            "start_logit": 11.328125,
            "end_logit": 12.03125,
            "text": "OCT4",
            "probability": 1.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -4.44140625,
            "text": "OCT4, SOX2, MYC, and KLF4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.328125,
            "end_logit": -4.47265625,
            "text": "OCT4, SOX2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.328125,
            "end_logit": -6.15625,
            "text": "OCT4, SOX2, MYC",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -8.171875,
            "text": "OCT4, SOX2, MYC, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -8.75,
            "text": "OCT4,",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -9.0390625,
            "text": "OCT4, SOX2, MYC, and KL",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 12.03125,
            "text": "Yamanaka factors (OCT4",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 12.03125,
            "text": "amanaka factors (OCT4",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 12.03125,
            "text": "naka factors (OCT4",
            "probability": 0.0
        },
        {
            "start_logit": -6.72265625,
            "end_logit": -4.44140625,
            "text": "SOX2, MYC, and KLF4",
            "probability": 0.0
        },
        {
            "start_logit": -6.72265625,
            "end_logit": -4.47265625,
            "text": "SOX2",
            "probability": 0.0
        },
        {
            "start_logit": -7.0078125,
            "end_logit": -4.44140625,
            "text": "KLF4",
            "probability": 0.0
        },
        {
            "start_logit": -7.71484375,
            "end_logit": -4.44140625,
            "text": "MYC, and KLF4",
            "probability": 0.0
        },
        {
            "start_logit": -6.72265625,
            "end_logit": -6.15625,
            "text": "SOX2, MYC",
            "probability": 0.0
        },
        {
            "start_logit": -7.71484375,
            "end_logit": -6.15625,
            "text": "MYC",
            "probability": 0.0
        },
        {
            "start_logit": -9.9453125,
            "end_logit": -4.44140625,
            "text": "F4",
            "probability": 0.0
        },
        {
            "start_logit": -6.72265625,
            "end_logit": -8.171875,
            "text": "SOX2, MYC, and",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": -4.44140625,
            "text": ", SOX2, MYC, and KLF4",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": -4.47265625,
            "text": ", SOX2",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_2": [
        {
            "start_logit": 11.3984375,
            "end_logit": 11.9765625,
            "text": "Oct4",
            "probability": 1.0
        },
        {
            "start_logit": 11.3984375,
            "end_logit": -4.8984375,
            "text": "Oct4, Sox2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.3984375,
            "end_logit": -5.7890625,
            "text": "Oct4, Sox2, Klf4 and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": 11.3984375,
            "end_logit": -6.15234375,
            "text": "Oct4, Sox2, Klf4",
            "probability": 0.0
        },
        {
            "start_logit": 11.3984375,
            "end_logit": -7.3828125,
            "text": "Oct4, Sox2, Klf4 and c-Myc)",
            "probability": 0.0
        },
        {
            "start_logit": 11.3984375,
            "end_logit": -8.4296875,
            "text": "Oct4, Sox2, Klf4 and",
            "probability": 0.0
        },
        {
            "start_logit": 11.3984375,
            "end_logit": -8.8203125,
            "text": "Oct4, Sox2, Klf4 and c",
            "probability": 0.0
        },
        {
            "start_logit": 11.3984375,
            "end_logit": -8.84375,
            "text": "Oct4,",
            "probability": 0.0
        },
        {
            "start_logit": 11.3984375,
            "end_logit": -8.8671875,
            "text": "Oct4, Sox2, Klf4 and c-",
            "probability": 0.0
        },
        {
            "start_logit": 11.3984375,
            "end_logit": -9.6875,
            "text": "Oct4, Sox2, Kl",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 11.9765625,
            "text": "Yamanaka factors' (Oct4",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 11.9765625,
            "text": "amanaka factors' (Oct4",
            "probability": 0.0
        },
        {
            "start_logit": -7.5859375,
            "end_logit": -4.8984375,
            "text": "Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -7.5859375,
            "end_logit": -5.7890625,
            "text": "Sox2, Klf4 and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -7.5859375,
            "end_logit": -6.15234375,
            "text": "Sox2, Klf4",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": -5.7890625,
            "text": "Klf4 and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -8.6015625,
            "end_logit": -5.7890625,
            "text": "c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": -6.15234375,
            "text": "Klf4",
            "probability": 0.0
        },
        {
            "start_logit": -7.5859375,
            "end_logit": -7.3828125,
            "text": "Sox2, Klf4 and c-Myc)",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": -4.8984375,
            "text": "Yamanaka factors' (Oct4, Sox2",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_3": [
        {
            "start_logit": 11.34375,
            "end_logit": 12.0234375,
            "text": "Oct4",
            "probability": 1.0
        },
        {
            "start_logit": 11.34375,
            "end_logit": -4.8046875,
            "text": "Oct4, Sox2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.34375,
            "end_logit": -5.34375,
            "text": "Oct4, Sox2, Klf4, and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": 11.34375,
            "end_logit": -5.7578125,
            "text": "Oct4, Sox2, Klf4",
            "probability": 0.0
        },
        {
            "start_logit": 11.34375,
            "end_logit": -8.0078125,
            "text": "Oct4, Sox2, Klf4, and c-Myc)",
            "probability": 0.0
        },
        {
            "start_logit": 11.34375,
            "end_logit": -8.1484375,
            "text": "Oct4, Sox2, Klf4, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.34375,
            "end_logit": -8.84375,
            "text": "Oct4, Sox2, Klf4, and c",
            "probability": 0.0
        },
        {
            "start_logit": 11.34375,
            "end_logit": -8.9140625,
            "text": "Oct4, Sox2, Klf4, and c-",
            "probability": 0.0
        },
        {
            "start_logit": 11.34375,
            "end_logit": -8.984375,
            "text": "Oct4,",
            "probability": 0.0
        },
        {
            "start_logit": 11.34375,
            "end_logit": -9.4921875,
            "text": "Oct4, Sox2, Kl",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 12.0234375,
            "text": "Yamanaka factors (Oct4",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 12.0234375,
            "text": "amanaka factors (Oct4",
            "probability": 0.0
        },
        {
            "start_logit": -7.16015625,
            "end_logit": -4.8046875,
            "text": "Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -7.16015625,
            "end_logit": -5.34375,
            "text": "Sox2, Klf4, and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -7.375,
            "end_logit": -5.34375,
            "text": "Klf4, and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -7.16015625,
            "end_logit": -5.7578125,
            "text": "Sox2, Klf4",
            "probability": 0.0
        },
        {
            "start_logit": -7.6640625,
            "end_logit": -5.34375,
            "text": "c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -7.375,
            "end_logit": -5.7578125,
            "text": "Klf4",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": -5.34375,
            "text": "Myc",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": -4.8046875,
            "text": ", Sox2",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_4": [
        {
            "start_logit": 13.90625,
            "end_logit": 13.1640625,
            "text": "c-myc",
            "probability": 1.0
        },
        {
            "start_logit": 13.90625,
            "end_logit": -1.4248046875,
            "text": "c-myc, KLF4",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 13.90625,
            "end_logit": -3.02734375,
            "text": "c",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.90625,
            "end_logit": -3.25390625,
            "text": "c-myc, KLF4, Oct3/4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.90625,
            "end_logit": -3.267578125,
            "text": "c-myc, KLF4, Oct3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.90625,
            "end_logit": -3.94140625,
            "text": "c-myc, KLF4, Oct3/4 and SOX2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.90625,
            "end_logit": -4.609375,
            "text": "c-myc, KLF4, Oct",
            "probability": 0.0
        },
        {
            "start_logit": -4.59765625,
            "end_logit": 13.1640625,
            "text": "myc",
            "probability": 0.0
        },
        {
            "start_logit": 13.90625,
            "end_logit": -6.21875,
            "text": "c-myc, KL",
            "probability": 0.0
        },
        {
            "start_logit": 13.90625,
            "end_logit": -7.1484375,
            "text": "c-",
            "probability": 0.0
        },
        {
            "start_logit": 13.90625,
            "end_logit": -7.3828125,
            "text": "c-myc, KLF4, Oct3/",
            "probability": 0.0
        },
        {
            "start_logit": 13.90625,
            "end_logit": -7.48828125,
            "text": "c-myc, KLF4, Oct3/4 and SOX2)",
            "probability": 0.0
        },
        {
            "start_logit": 13.90625,
            "end_logit": -7.51171875,
            "text": "c-myc, KLF4, Oct3/4 and",
            "probability": 0.0
        },
        {
            "start_logit": 13.90625,
            "end_logit": -8.859375,
            "text": "c-myc,",
            "probability": 0.0
        },
        {
            "start_logit": 13.90625,
            "end_logit": -8.921875,
            "text": "c-myc, KLF4,",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 13.1640625,
            "text": "Yamanaka factors (c-myc",
            "probability": 0.0
        },
        {
            "start_logit": -3.109375,
            "end_logit": -1.4248046875,
            "text": "KLF4",
            "probability": 0.0
        },
        {
            "start_logit": -4.59765625,
            "end_logit": -1.4248046875,
            "text": "myc, KLF4",
            "probability": 0.0
        },
        {
            "start_logit": -3.109375,
            "end_logit": -3.25390625,
            "text": "KLF4, Oct3/4",
            "probability": 0.0
        },
        {
            "start_logit": -3.109375,
            "end_logit": -3.267578125,
            "text": "KLF4, Oct3",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_5": [
        {
            "start_logit": 11.1953125,
            "end_logit": 12.1484375,
            "text": "Oct4",
            "probability": 1.0
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -4.53125,
            "text": "Oct4, Sox2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -5.00390625,
            "text": "Oct4, Sox2, Klf4, and c-Myc",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -6.03125,
            "text": "Oct4, Sox2, Klf4",
            "probability": 0.0
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -7.36328125,
            "text": "Oct4, Sox2, Klf4, and c-Myc)",
            "probability": 0.0
        },
        {
            "start_logit": -8.96875,
            "end_logit": 12.1484375,
            "text": "i.e., Oct4",
            "probability": 0.0
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -8.2890625,
            "text": "Oct4, Sox2, Klf4, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -8.296875,
            "text": "Oct4, Sox2, Klf4, and c",
            "probability": 0.0
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -8.5390625,
            "text": "Oct4, Sox2, Klf4, and c-",
            "probability": 0.0
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -8.921875,
            "text": "Oct4,",
            "probability": 0.0
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -9.3203125,
            "text": "Oct4, Sox2, Kl",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 12.1484375,
            "text": "e., Oct4",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 12.1484375,
            "text": "Yamanaka factors (i.e., Oct4",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 12.1484375,
            "text": "., Oct4",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 12.1484375,
            "text": "amanaka factors (i.e., Oct4",
            "probability": 0.0
        },
        {
            "start_logit": -7.34375,
            "end_logit": -4.53125,
            "text": "Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -7.15625,
            "end_logit": -5.00390625,
            "text": "c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -7.34375,
            "end_logit": -5.00390625,
            "text": "Sox2, Klf4, and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -7.34375,
            "end_logit": -6.03125,
            "text": "Sox2, Klf4",
            "probability": 0.0
        },
        {
            "start_logit": -8.96875,
            "end_logit": -4.53125,
            "text": "i.e., Oct4, Sox2",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_6": [
        {
            "start_logit": 12.0546875,
            "end_logit": 11.0078125,
            "text": "Sox2",
            "probability": 1.0
        },
        {
            "start_logit": 12.0546875,
            "end_logit": -5.30078125,
            "text": "Sox2, Klf4, and c-Myc",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.0546875,
            "end_logit": -5.8671875,
            "text": "Sox2, Klf4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8203125,
            "end_logit": 11.0078125,
            "text": "Oct3/4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": 12.0546875,
            "end_logit": -8.140625,
            "text": "Sox2, Klf4, and c-Myc)",
            "probability": 0.0
        },
        {
            "start_logit": 12.0546875,
            "end_logit": -8.5390625,
            "text": "Sox2, Klf4, and c",
            "probability": 0.0
        },
        {
            "start_logit": 12.0546875,
            "end_logit": -8.984375,
            "text": "Sox2, Klf4, and",
            "probability": 0.0
        },
        {
            "start_logit": 12.0546875,
            "end_logit": -9.0078125,
            "text": "Sox2, Klf4, and c-",
            "probability": 0.0
        },
        {
            "start_logit": 12.0546875,
            "end_logit": -9.015625,
            "text": "Sox2, Kl",
            "probability": 0.0
        },
        {
            "start_logit": -8.7109375,
            "end_logit": 11.0078125,
            "text": "3/4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -9.796875,
            "end_logit": 11.0078125,
            "text": "4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 11.0078125,
            "text": "/4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 11.0078125,
            "text": "Yamanaka factors (Oct3/4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 11.0078125,
            "text": ", Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -6.8203125,
            "end_logit": -1.21875,
            "text": "Oct3/4",
            "probability": 0.0
        },
        {
            "start_logit": -6.8203125,
            "end_logit": -1.384765625,
            "text": "Oct3",
            "probability": 0.0
        },
        {
            "start_logit": -8.7109375,
            "end_logit": -1.21875,
            "text": "3/4",
            "probability": 0.0
        },
        {
            "start_logit": -8.7109375,
            "end_logit": -1.384765625,
            "text": "3",
            "probability": 0.0
        },
        {
            "start_logit": -6.8203125,
            "end_logit": -3.369140625,
            "text": "Oct",
            "probability": 0.0
        },
        {
            "start_logit": -9.796875,
            "end_logit": -1.21875,
            "text": "4",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_7": [
        {
            "start_logit": 11.1875,
            "end_logit": 12.171875,
            "text": "OCT4",
            "probability": 1.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -4.90234375,
            "text": "OCT4, SOX2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.1875,
            "end_logit": -5.1015625,
            "text": "OCT4, SOX2, KLF4, cMYC - OSKM",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.1875,
            "end_logit": -6.74609375,
            "text": "OCT4, SOX2, KLF4",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -7.8515625,
            "text": "OCT4, SOX2, KLF4, cMYC",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -7.9375,
            "text": "OCT4,",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -8.671875,
            "text": "OCT4, SOX2, KLF4, cM",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -8.8984375,
            "text": "OCT4, SOX2, KLF4, cMYC - OSK",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -8.921875,
            "text": "OCT4, SOX2, KLF4, cMYC - OS",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -9.265625,
            "text": "OCT4, SOX2, KL",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -9.2890625,
            "text": "OCT4, SOX2, KLF4, cMYC -",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 12.171875,
            "text": "Yamanaka factors (OCT4",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -9.8515625,
            "text": "OCT4, SOX2, KLF4,",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -9.9921875,
            "text": "OCT4, SOX2,",
            "probability": 0.0
        },
        {
            "start_logit": -7.33984375,
            "end_logit": -4.90234375,
            "text": "SOX2",
            "probability": 0.0
        },
        {
            "start_logit": -7.33984375,
            "end_logit": -5.1015625,
            "text": "SOX2, KLF4, cMYC - OSKM",
            "probability": 0.0
        },
        {
            "start_logit": -7.66796875,
            "end_logit": -5.1015625,
            "text": "cMYC - OSKM",
            "probability": 0.0
        },
        {
            "start_logit": -7.81640625,
            "end_logit": -5.1015625,
            "text": "KLF4, cMYC - OSKM",
            "probability": 0.0
        },
        {
            "start_logit": -7.33984375,
            "end_logit": -6.74609375,
            "text": "SOX2, KLF4",
            "probability": 0.0
        },
        {
            "start_logit": -7.81640625,
            "end_logit": -6.74609375,
            "text": "KLF4",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_8": [
        {
            "start_logit": 11.390625,
            "end_logit": 11.984375,
            "text": "Oct4",
            "probability": 1.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -3.07421875,
            "text": "Oct4, Sox2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 11.390625,
            "end_logit": -4.34765625,
            "text": "Oct4, Sox2, Klf4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.390625,
            "end_logit": -4.44921875,
            "text": "Oct4, Sox2, Klf4 and cMyc",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.390625,
            "end_logit": -7.30859375,
            "text": "Oct4, Sox2, Klf4 and cMyc (4TF, Yamanaka factors)",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -7.875,
            "text": "Oct4, Sox2, Klf4 and cM",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -8.4609375,
            "text": "Oct4, Sox2, Klf4 and",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -8.5234375,
            "text": "Oct4, Sox2, Kl",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -8.921875,
            "text": "Oct4, Sox2, Klf4 and cMyc (4TF",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -8.9921875,
            "text": "Oct4, Sox2, Klf4 and cMyc (4",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -9.171875,
            "text": "Oct4, Sox2, Klf4 and cMyc (",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -9.40625,
            "text": "Oct4, Sox2, Klf4 and cMyc (4TF, Yamanaka factors",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -9.578125,
            "text": "Oct4,",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -9.890625,
            "text": "Oct4, Sox2, Klf4 and cMyc (4T",
            "probability": 0.0
        },
        {
            "start_logit": -6.1640625,
            "end_logit": -3.07421875,
            "text": "Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -6.1640625,
            "end_logit": -4.34765625,
            "text": "Sox2, Klf4",
            "probability": 0.0
        },
        {
            "start_logit": -6.1640625,
            "end_logit": -4.44921875,
            "text": "Sox2, Klf4 and cMyc",
            "probability": 0.0
        },
        {
            "start_logit": -6.296875,
            "end_logit": -4.34765625,
            "text": "Klf4",
            "probability": 0.0
        },
        {
            "start_logit": -6.296875,
            "end_logit": -4.44921875,
            "text": "Klf4 and cMyc",
            "probability": 0.0
        },
        {
            "start_logit": -7.3515625,
            "end_logit": -4.44921875,
            "text": "cMyc",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_9": [
        {
            "start_logit": 9.984375,
            "end_logit": 9.7109375,
            "text": "Myc",
            "probability": 0.998046875
        },
        {
            "start_logit": 9.984375,
            "end_logit": 3.5234375,
            "text": "Myc, Klf4, and Sox2",
            "probability": 0.00206756591796875
        },
        {
            "start_logit": 9.984375,
            "end_logit": -2.69140625,
            "text": "Myc, Klf4",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": -4.84375,
            "end_logit": 9.7109375,
            "text": "Pou5f1, Myc",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 0.03643798828125,
            "end_logit": 3.5234375,
            "text": "Sox2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.0625,
            "text": "Myc, Klf4, and Sox2)",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.390625,
            "text": "Myc, Kl",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -9.03125,
            "text": "Myc, Klf4, and",
            "probability": 0.0
        },
        {
            "start_logit": -8.9453125,
            "end_logit": 9.7109375,
            "text": "f1, Myc",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": 9.7109375,
            "text": "5f1, Myc",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -10.1953125,
            "text": "Myc, Klf4,",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": 9.7109375,
            "text": ", Myc",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 9.7109375,
            "text": "Yamanaka factors (Pou5f1, Myc",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 9.7109375,
            "text": "u5f1, Myc",
            "probability": 0.0
        },
        {
            "start_logit": -4.84375,
            "end_logit": 3.5234375,
            "text": "Pou5f1, Myc, Klf4, and Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -5.05859375,
            "end_logit": 3.5234375,
            "text": "Klf4, and Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -8.9453125,
            "end_logit": 3.5234375,
            "text": "f1, Myc, Klf4, and Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -4.84375,
            "end_logit": -0.91650390625,
            "text": "Pou5f1",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": 3.5234375,
            "text": "5f1, Myc, Klf4, and Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -9.90625,
            "end_logit": 3.5234375,
            "text": "f4, and Sox2",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_10": [
        {
            "start_logit": 10.5859375,
            "end_logit": 9.65625,
            "text": "Klf4",
            "probability": 0.9990234375
        },
        {
            "start_logit": 10.5859375,
            "end_logit": 2.265625,
            "text": "Klf4, Oct3/4, and Sox2",
            "probability": 0.0006117820739746094
        },
        {
            "start_logit": 0.403076171875,
            "end_logit": 9.65625,
            "text": "c-Myc, Klf4",
            "probability": 3.7550926208496094e-05
        },
        {
            "start_logit": 10.5859375,
            "end_logit": -1.7861328125,
            "text": "Klf4, Oct",
            "probability": 1.0609626770019531e-05
        },
        {
            "start_logit": 10.5859375,
            "end_logit": -1.845703125,
            "text": "Klf4, Oct3",
            "probability": 1.0073184967041016e-05
        },
        {
            "start_logit": 10.5859375,
            "end_logit": -2.3984375,
            "text": "Klf4, Oct3/4",
            "probability": 5.781650543212891e-06
        },
        {
            "start_logit": 10.5859375,
            "end_logit": -5.953125,
            "text": "Kl",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 10.5859375,
            "end_logit": -6.484375,
            "text": "Klf4, Oct3/",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.5859375,
            "end_logit": -7.8359375,
            "text": "Klf4, Oct3/4, and Sox2 (the so-called \"Yamanaka factors\")",
            "probability": 0.0
        },
        {
            "start_logit": 0.403076171875,
            "end_logit": 2.265625,
            "text": "c-Myc, Klf4, Oct3/4, and Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -6.98828125,
            "end_logit": 9.65625,
            "text": "f4",
            "probability": 0.0
        },
        {
            "start_logit": 0.403076171875,
            "end_logit": 2.181640625,
            "text": "c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": 10.5859375,
            "end_logit": -9.2109375,
            "text": "Klf4, Oct3/4, and",
            "probability": 0.0
        },
        {
            "start_logit": 10.5859375,
            "end_logit": -9.28125,
            "text": "Klf4, Oct3/4, and Sox2 (the so-",
            "probability": 0.0
        },
        {
            "start_logit": 10.5859375,
            "end_logit": -9.3671875,
            "text": "Klf4, Oct3/4, and Sox2 (the so-called \"Yamanaka factors\"",
            "probability": 0.0
        },
        {
            "start_logit": 10.5859375,
            "end_logit": -9.390625,
            "text": "Klf4,",
            "probability": 0.0
        },
        {
            "start_logit": -8.4609375,
            "end_logit": 9.65625,
            "text": "Myc, Klf4",
            "probability": 0.0
        },
        {
            "start_logit": 10.5859375,
            "end_logit": -9.5859375,
            "text": "Klf4, Oct3/4, and Sox2 (",
            "probability": 0.0
        },
        {
            "start_logit": 10.5859375,
            "end_logit": -9.8359375,
            "text": "Klf4, Oct3/4, and Sox2 (the so-called \"Yamanaka factors",
            "probability": 0.0
        },
        {
            "start_logit": -1.888671875,
            "end_logit": 2.265625,
            "text": "Sox2",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_11": [
        {
            "start_logit": 12.015625,
            "end_logit": 11.1640625,
            "text": "Sox2",
            "probability": 1.0
        },
        {
            "start_logit": 12.015625,
            "end_logit": -4.9453125,
            "text": "Sox2, Klf4, and c-Myc",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.015625,
            "end_logit": -5.640625,
            "text": "Sox2, Klf4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.015625,
            "end_logit": -8.0234375,
            "text": "Sox2, Klf4, and c",
            "probability": 0.0
        },
        {
            "start_logit": -7.5625,
            "end_logit": 11.1640625,
            "text": "Oct3/4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": 12.015625,
            "end_logit": -8.7734375,
            "text": "Sox2, Kl",
            "probability": 0.0
        },
        {
            "start_logit": 12.015625,
            "end_logit": -8.8515625,
            "text": "Sox2, Klf4, and c-",
            "probability": 0.0
        },
        {
            "start_logit": 12.015625,
            "end_logit": -9.0,
            "text": "Sox2, Klf4, and",
            "probability": 0.0
        },
        {
            "start_logit": -8.890625,
            "end_logit": 11.1640625,
            "text": "3/4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": 12.015625,
            "end_logit": -10.2265625,
            "text": "Sox2,",
            "probability": 0.0
        },
        {
            "start_logit": 12.015625,
            "end_logit": -10.265625,
            "text": "Sox2, Klf4,",
            "probability": 0.0
        },
        {
            "start_logit": -9.78125,
            "end_logit": 11.1640625,
            "text": "4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 11.1640625,
            "text": "Yamanaka factors, Oct3/4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 11.1640625,
            "text": "/4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 11.1640625,
            "text": ", Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -7.5625,
            "end_logit": -2.5859375,
            "text": "Oct3/4",
            "probability": 0.0
        },
        {
            "start_logit": -7.5625,
            "end_logit": -2.63671875,
            "text": "Oct3",
            "probability": 0.0
        },
        {
            "start_logit": -8.890625,
            "end_logit": -2.5859375,
            "text": "3/4",
            "probability": 0.0
        },
        {
            "start_logit": -8.890625,
            "end_logit": -2.63671875,
            "text": "3",
            "probability": 0.0
        },
        {
            "start_logit": -7.5625,
            "end_logit": -4.25,
            "text": "Oct",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_12": [
        {
            "start_logit": 11.359375,
            "end_logit": 12.03125,
            "text": "Sox2",
            "probability": 1.0
        },
        {
            "start_logit": 11.359375,
            "end_logit": -5.33984375,
            "text": "Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": 11.359375,
            "end_logit": -6.2109375,
            "text": "Sox2, Oct",
            "probability": 0.0
        },
        {
            "start_logit": 11.359375,
            "end_logit": -7.09375,
            "text": "Sox2, Oct3/4",
            "probability": 0.0
        },
        {
            "start_logit": 11.359375,
            "end_logit": -7.40625,
            "text": "Sox2, Oct3/4 (Pou5f1), Klf4",
            "probability": 0.0
        },
        {
            "start_logit": 11.359375,
            "end_logit": -7.5,
            "text": "Sox2, Oct3/4 (Pou5f1",
            "probability": 0.0
        },
        {
            "start_logit": 11.359375,
            "end_logit": -8.1640625,
            "text": "Sox2, Oct3",
            "probability": 0.0
        },
        {
            "start_logit": 11.359375,
            "end_logit": -8.3828125,
            "text": "Sox2, Oct3/4 (Pou5f1), Klf4, and c",
            "probability": 0.0
        },
        {
            "start_logit": 11.359375,
            "end_logit": -8.4140625,
            "text": "Sox2, Oct3/4 (Pou5f1)",
            "probability": 0.0
        },
        {
            "start_logit": 11.359375,
            "end_logit": -8.4140625,
            "text": "Sox2, Oct3/4 (Po",
            "probability": 0.0
        },
        {
            "start_logit": 11.359375,
            "end_logit": -8.734375,
            "text": "Sox2, Oct3/4 (",
            "probability": 0.0
        },
        {
            "start_logit": 11.359375,
            "end_logit": -9.0078125,
            "text": "Sox2, Oct3/4 (Pou5f1), Klf4, and c-",
            "probability": 0.0
        },
        {
            "start_logit": 11.359375,
            "end_logit": -9.03125,
            "text": "Sox2, Oct3/4 (Pou5f1), Klf4, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.359375,
            "end_logit": -9.078125,
            "text": "Sox2, Oct3/",
            "probability": 0.0
        },
        {
            "start_logit": 11.359375,
            "end_logit": -9.25,
            "text": "Sox2, Oct3/4 (Pou",
            "probability": 0.0
        },
        {
            "start_logit": 11.359375,
            "end_logit": -9.3046875,
            "text": "Sox2, Oct3/4 (Pou5",
            "probability": 0.0
        },
        {
            "start_logit": 11.359375,
            "end_logit": -9.390625,
            "text": "Sox2, Oct3/4 (Pou5f1), Kl",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 12.03125,
            "text": "namely Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -7.7578125,
            "end_logit": -5.33984375,
            "text": "c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -7.8984375,
            "end_logit": -5.33984375,
            "text": "Klf4, and c-Myc",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_13": [
        {
            "start_logit": 11.5859375,
            "end_logit": 11.8125,
            "text": "Oct4",
            "probability": 1.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -2.396484375,
            "text": "Oct4, Sox2",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -3.615234375,
            "text": "Oct4, Sox2, Klf4",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -4.34375,
            "text": "Oct4, Sox2, Klf4 and c-Myc",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -7.515625,
            "text": "Oct4, Sox2, Klf4 and c",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -7.8203125,
            "text": "Oct4, Sox2, Klf4 and",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -8.0703125,
            "text": "Oct4, Sox2, Kl",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -8.1484375,
            "text": "Oct4, Sox2, Klf4 and c-",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -8.3671875,
            "text": "Oct4, Sox2, Klf4 and c-Myc,",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -8.578125,
            "text": "Oct4, Sox2, Klf4 and c-Myc, also known",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -9.3984375,
            "text": "Oct4, Sox2, Klf4 and c-Myc, also known as the Yamanaka factors",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -9.5859375,
            "text": "Oct4, Sox2,",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -9.6328125,
            "text": "Oct4, Sox2, Klf4 and c-Myc, also known as the Yamanaka factors.",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -9.6796875,
            "text": "Oct4,",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -9.6953125,
            "text": "Oct4, Sox2, Klf4 and c-Myc, also",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -9.8515625,
            "text": "Oct4, Sox2, Klf4 and c-Myc, also known as the",
            "probability": 0.0
        },
        {
            "start_logit": -5.06640625,
            "end_logit": -2.396484375,
            "text": "Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -5.06640625,
            "end_logit": -3.615234375,
            "text": "Sox2, Klf4",
            "probability": 0.0
        },
        {
            "start_logit": -5.06640625,
            "end_logit": -4.34375,
            "text": "Sox2, Klf4 and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -5.9296875,
            "end_logit": -3.615234375,
            "text": "Klf4",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_14": [
        {
            "start_logit": 11.46875,
            "end_logit": 11.9296875,
            "text": "SOX2",
            "probability": 1.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -5.65234375,
            "text": "SOX2, OCT",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -5.95703125,
            "text": "SOX2, OCT3/4, and KLF4",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -5.9921875,
            "text": "SOX2, OCT3/4, and KLF4, with or without c-MYC",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -6.0078125,
            "text": "SOX2, OCT3/4",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -6.40234375,
            "text": "SOX2, OCT3",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -8.2890625,
            "text": "SOX2, OCT3/",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -8.3125,
            "text": "SOX2, OCT3/4, and KLF4, with or without c",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -8.3359375,
            "text": "SOX2, OCT3/4, and KL",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -8.359375,
            "text": "SOX2, OCT3/4, and KLF4, with or without c-MYC)",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -8.8671875,
            "text": "SOX2, OCT3/4, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -9.21875,
            "text": "SOX2, OCT3/4, and KLF4, with or without c-",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -9.28125,
            "text": "SOX2, OCT3/4, and KLF4, with or without",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -9.6171875,
            "text": "SOX2, OCT3/4, and KLF4,",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -9.6640625,
            "text": "SOX2,",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -9.8125,
            "text": "SOX2, OCT3/4,",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 11.9296875,
            "text": "Yamanaka factors (SOX2",
            "probability": 0.0
        },
        {
            "start_logit": -7.5546875,
            "end_logit": -5.65234375,
            "text": "OCT",
            "probability": 0.0
        },
        {
            "start_logit": -7.359375,
            "end_logit": -5.95703125,
            "text": "KLF4",
            "probability": 0.0
        },
        {
            "start_logit": -7.359375,
            "end_logit": -5.9921875,
            "text": "KLF4, with or without c-MYC",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_15": [
        {
            "start_logit": 11.484375,
            "end_logit": 11.8671875,
            "text": "Oct4",
            "probability": 1.0
        },
        {
            "start_logit": 11.484375,
            "end_logit": -3.720703125,
            "text": "Oct4, Sox2, Klf4, and c-Myc",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.484375,
            "end_logit": -3.984375,
            "text": "Oct4, Sox2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.484375,
            "end_logit": -4.59765625,
            "text": "Oct4, Sox2, Klf4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.484375,
            "end_logit": -7.80859375,
            "text": "Oct4, Sox2, Klf4, and c",
            "probability": 0.0
        },
        {
            "start_logit": 11.484375,
            "end_logit": -7.8125,
            "text": "Oct4, Sox2, Klf4, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.484375,
            "end_logit": -8.0,
            "text": "Oct4, Sox2, Klf4, and c-",
            "probability": 0.0
        },
        {
            "start_logit": 11.484375,
            "end_logit": -8.96875,
            "text": "Oct4, Sox2, Kl",
            "probability": 0.0
        },
        {
            "start_logit": 11.484375,
            "end_logit": -9.5234375,
            "text": "Oct4, Sox2, Klf4,",
            "probability": 0.0
        },
        {
            "start_logit": 11.484375,
            "end_logit": -9.53125,
            "text": "Oct4,",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 11.8671875,
            "text": "Yamanaka factors Oct4",
            "probability": 0.0
        },
        {
            "start_logit": -10.953125,
            "end_logit": 11.8671875,
            "text": "amanaka factors Oct4",
            "probability": 0.0
        },
        {
            "start_logit": -6.796875,
            "end_logit": -3.720703125,
            "text": "Klf4, and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -7.234375,
            "end_logit": -3.720703125,
            "text": "c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -6.796875,
            "end_logit": -4.59765625,
            "text": "Klf4",
            "probability": 0.0
        },
        {
            "start_logit": -7.6875,
            "end_logit": -3.720703125,
            "text": "Sox2, Klf4, and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -7.6875,
            "end_logit": -3.984375,
            "text": "Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -7.6875,
            "end_logit": -4.59765625,
            "text": "Sox2, Klf4",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": -3.720703125,
            "text": "Myc",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": -3.720703125,
            "text": ", Sox2, Klf4, and c-Myc",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_16": [
        {
            "start_logit": 11.90625,
            "end_logit": 10.8515625,
            "text": "Sox2",
            "probability": 1.0
        },
        {
            "start_logit": 11.90625,
            "end_logit": -4.14453125,
            "text": "Sox2, Klf4",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 11.90625,
            "end_logit": -4.84375,
            "text": "Sox2, Klf4, c-Myc",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.58203125,
            "end_logit": 10.8515625,
            "text": "Oct3/4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": 11.90625,
            "end_logit": -7.64453125,
            "text": "Sox2, Klf4, c",
            "probability": 0.0
        },
        {
            "start_logit": 11.90625,
            "end_logit": -8.3671875,
            "text": "Sox2, Klf4, c-Myc)",
            "probability": 0.0
        },
        {
            "start_logit": 11.90625,
            "end_logit": -8.671875,
            "text": "Sox2, Kl",
            "probability": 0.0
        },
        {
            "start_logit": 11.90625,
            "end_logit": -8.8671875,
            "text": "Sox2, Klf4, c-",
            "probability": 0.0
        },
        {
            "start_logit": -8.8359375,
            "end_logit": 10.8515625,
            "text": "3/4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": 11.90625,
            "end_logit": -10.203125,
            "text": "Sox2,",
            "probability": 0.0
        },
        {
            "start_logit": 11.90625,
            "end_logit": -10.4140625,
            "text": "Sox2, Klf4,",
            "probability": 0.0
        },
        {
            "start_logit": -9.796875,
            "end_logit": 10.8515625,
            "text": "4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 10.8515625,
            "text": "amanaka factors (Oct3/4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 10.8515625,
            "text": "anaka factors (Oct3/4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -5.58203125,
            "end_logit": -0.297607421875,
            "text": "Oct3",
            "probability": 0.0
        },
        {
            "start_logit": -5.58203125,
            "end_logit": -0.6787109375,
            "text": "Oct3/4",
            "probability": 0.0
        },
        {
            "start_logit": -5.58203125,
            "end_logit": -2.869140625,
            "text": "Oct",
            "probability": 0.0
        },
        {
            "start_logit": -8.8359375,
            "end_logit": -0.297607421875,
            "text": "3",
            "probability": 0.0
        },
        {
            "start_logit": -8.8359375,
            "end_logit": -0.6787109375,
            "text": "3/4",
            "probability": 0.0
        },
        {
            "start_logit": -5.58203125,
            "end_logit": -4.14453125,
            "text": "Oct3/4, Sox2, Klf4",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_17": [
        {
            "start_logit": 11.84375,
            "end_logit": 10.484375,
            "text": "Sox2",
            "probability": 1.0
        },
        {
            "start_logit": 11.84375,
            "end_logit": -2.787109375,
            "text": "Sox2, Klf4, c-Myc",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": 11.84375,
            "end_logit": -2.828125,
            "text": "Sox2, Klf4",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 11.84375,
            "end_logit": -6.71484375,
            "text": "Sox2, Klf4, c-Myc) are highly expressed in embryonic stem (ES) cells, and their over-expression can induce pluripotency",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.84375,
            "end_logit": -7.01171875,
            "text": "Sox2, Klf4, c",
            "probability": 0.0
        },
        {
            "start_logit": -6.33984375,
            "end_logit": 10.484375,
            "text": "Oct3/4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": 11.84375,
            "end_logit": -8.03125,
            "text": "Sox2, Kl",
            "probability": 0.0
        },
        {
            "start_logit": 11.84375,
            "end_logit": -9.2578125,
            "text": "Sox2, Klf4, c-Myc)",
            "probability": 0.0
        },
        {
            "start_logit": 11.84375,
            "end_logit": -9.3046875,
            "text": "Sox2, Klf4, c-",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 10.484375,
            "text": "3/4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -9.5078125,
            "end_logit": 10.484375,
            "text": "4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 10.484375,
            "text": ", Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 10.484375,
            "text": "Yamanaka factors (Oct3/4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -6.33984375,
            "end_logit": -0.5517578125,
            "text": "Oct3/4",
            "probability": 0.0
        },
        {
            "start_logit": -4.97265625,
            "end_logit": -2.787109375,
            "text": "c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -6.33984375,
            "end_logit": -1.4921875,
            "text": "Oct3",
            "probability": 0.0
        },
        {
            "start_logit": -5.83203125,
            "end_logit": -2.787109375,
            "text": "Klf4, c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -5.83203125,
            "end_logit": -2.828125,
            "text": "Klf4",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": -0.5517578125,
            "text": "3/4",
            "probability": 0.0
        },
        {
            "start_logit": -6.33984375,
            "end_logit": -2.787109375,
            "text": "Oct3/4, Sox2, Klf4, c-Myc",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_18": [
        {
            "start_logit": 11.5703125,
            "end_logit": 11.828125,
            "text": "Sox2",
            "probability": 1.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -6.7578125,
            "text": "Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -6.8671875,
            "text": "Sox2, Oct",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -7.37109375,
            "text": "Sox2, Oct3/4 (Pou5f1",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -7.3828125,
            "text": "Sox2, Oct3",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -7.72265625,
            "text": "Sox2, Oct3/4",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -7.94921875,
            "text": "Sox2, Oct3/4 (Pou5f1), Klf4",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -7.953125,
            "text": "Sox2, Oct3/4 (Po",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -8.234375,
            "text": "Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc, and the Thomson factors, namely Sox2",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -8.8671875,
            "text": "Sox2, Oct3/4 (Pou",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -8.8984375,
            "text": "Sox2, Oct3/4 (",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -8.9609375,
            "text": "Sox2, Oct3/4 (Pou5f1)",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -9.1328125,
            "text": "Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc,",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -9.2734375,
            "text": "Sox2, Oct3/",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": 11.828125,
            "text": "namely Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -8.625,
            "end_logit": -6.7578125,
            "text": "Klf4, and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -8.984375,
            "end_logit": -6.7578125,
            "text": "c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -9.1640625,
            "end_logit": -6.7578125,
            "text": "Oct3/4 (Pou5f1), Klf4, and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -9.1640625,
            "end_logit": -6.8671875,
            "text": "Oct",
            "probability": 0.0
        },
        {
            "start_logit": -9.28125,
            "end_logit": -6.7578125,
            "text": "Pou5f1), Klf4, and c-Myc",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_19": [
        {
            "start_logit": 11.6640625,
            "end_logit": 10.46875,
            "text": "Sox2",
            "probability": 1.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -3.060546875,
            "text": "Sox2, Klf4",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -3.291015625,
            "text": "Sox2, Klf4, c-Myc",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -6.02734375,
            "text": "Sox2, Klf4, c-Myc) are highly expressed in embryonic stem (ES) cells, and their over-expression can induce pluripotency",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.9453125,
            "end_logit": 10.46875,
            "text": "Oct3/4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -7.4765625,
            "text": "Sox2, Klf4, c",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -8.125,
            "text": "Sox2, Kl",
            "probability": 0.0
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 10.46875,
            "text": "3/4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -9.390625,
            "text": "Sox2, Klf4, c-",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -9.5078125,
            "text": "Sox2, Klf4, c-Myc)",
            "probability": 0.0
        },
        {
            "start_logit": -9.5078125,
            "end_logit": 10.46875,
            "text": "4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": 10.46875,
            "text": ", Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -5.9453125,
            "end_logit": 0.05279541015625,
            "text": "Oct3/4",
            "probability": 0.0
        },
        {
            "start_logit": -5.9453125,
            "end_logit": -1.005859375,
            "text": "Oct3",
            "probability": 0.0
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 0.05279541015625,
            "text": "3/4",
            "probability": 0.0
        },
        {
            "start_logit": -5.51171875,
            "end_logit": -3.291015625,
            "text": "c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -7.91015625,
            "end_logit": -1.005859375,
            "text": "3",
            "probability": 0.0
        },
        {
            "start_logit": -5.9453125,
            "end_logit": -3.060546875,
            "text": "Oct3/4, Sox2, Klf4",
            "probability": 0.0
        },
        {
            "start_logit": -6.0546875,
            "end_logit": -3.060546875,
            "text": "Klf4",
            "probability": 0.0
        },
        {
            "start_logit": -5.9453125,
            "end_logit": -3.291015625,
            "text": "Oct3/4, Sox2, Klf4, c-Myc",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_20": [
        {
            "start_logit": 11.234375,
            "end_logit": 12.1171875,
            "text": "Oct4",
            "probability": 1.0
        },
        {
            "start_logit": 11.234375,
            "end_logit": -5.31640625,
            "text": "Oct4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": 11.234375,
            "end_logit": -5.4296875,
            "text": "Oct4, Sox2, Klf4 and cMyc",
            "probability": 0.0
        },
        {
            "start_logit": 11.234375,
            "end_logit": -5.4453125,
            "text": "Oct4, Sox2, Klf4",
            "probability": 0.0
        },
        {
            "start_logit": 11.234375,
            "end_logit": -7.98828125,
            "text": "Oct4, Sox2, Klf4 and cM",
            "probability": 0.0
        },
        {
            "start_logit": 11.234375,
            "end_logit": -8.140625,
            "text": "Oct4, Sox2, Klf4 and cMyc (4TF",
            "probability": 0.0
        },
        {
            "start_logit": 11.234375,
            "end_logit": -8.765625,
            "text": "Oct4, Sox2, Klf4 and",
            "probability": 0.0
        },
        {
            "start_logit": 11.234375,
            "end_logit": -9.1796875,
            "text": "Oct4, Sox2, Klf4 and cMyc (4",
            "probability": 0.0
        },
        {
            "start_logit": 11.234375,
            "end_logit": -9.2421875,
            "text": "Oct4, Sox2, Klf4 and cMyc (4TF, Yamanaka factors) are used as basal conditions",
            "probability": 0.0
        },
        {
            "start_logit": 11.234375,
            "end_logit": -9.25,
            "text": "Oct4, Sox2, Kl",
            "probability": 0.0
        },
        {
            "start_logit": -10.234375,
            "end_logit": 12.1171875,
            "text": "Transcription factors, Oct4",
            "probability": 0.0
        },
        {
            "start_logit": 11.234375,
            "end_logit": -9.515625,
            "text": "Oct4, Sox2, Klf4 and cMyc (4TF, Yamanaka factors",
            "probability": 0.0
        },
        {
            "start_logit": 11.234375,
            "end_logit": -9.515625,
            "text": "Oct4, Sox2, Klf4 and cMyc (",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": 12.1171875,
            "text": ", Oct4",
            "probability": 0.0
        },
        {
            "start_logit": 11.234375,
            "end_logit": -9.5859375,
            "text": "Oct4, Sox2, Klf4 and cMyc (4TF, Yamanaka factors) are",
            "probability": 0.0
        },
        {
            "start_logit": 11.234375,
            "end_logit": -9.59375,
            "text": "Oct4, Sox2, Klf4 and cMyc (4TF, Yamanaka factors) are used",
            "probability": 0.0
        },
        {
            "start_logit": 11.234375,
            "end_logit": -9.75,
            "text": "Oct4, Sox2, Klf4 and cMyc (4TF, Yamanaka factors)",
            "probability": 0.0
        },
        {
            "start_logit": -6.99609375,
            "end_logit": -5.4296875,
            "text": "Klf4 and cMyc",
            "probability": 0.0
        },
        {
            "start_logit": -6.99609375,
            "end_logit": -5.4453125,
            "text": "Klf4",
            "probability": 0.0
        },
        {
            "start_logit": -7.26171875,
            "end_logit": -5.31640625,
            "text": "Sox2",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_21": [
        {
            "start_logit": 11.421875,
            "end_logit": 11.90625,
            "text": "Oct4",
            "probability": 1.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -4.83203125,
            "text": "Oct4, Sox2, Klf4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.421875,
            "end_logit": -5.96484375,
            "text": "Oct4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -5.9921875,
            "text": "Oct4, Sox2, Klf4 and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -8.8046875,
            "text": "Oct4, Sox2, Klf4 and",
            "probability": 0.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -9.0234375,
            "text": "Oct4, Sox2, Klf4 and c",
            "probability": 0.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -9.140625,
            "text": "Oct4, Sox2, Kl",
            "probability": 0.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -9.1796875,
            "text": "Oct4, Sox2, Klf4 and c-Myc,",
            "probability": 0.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -9.3046875,
            "text": "Oct4, Sox2, Klf4 and c-Myc, also known",
            "probability": 0.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -9.5,
            "text": "Oct4, Sox2, Klf4 and c-",
            "probability": 0.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -9.5,
            "text": "Oct4,",
            "probability": 0.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -9.578125,
            "text": "Oct4, Sox2, Klf4 and c-Myc, also",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": 11.90625,
            "text": "induced pluripotent stem (iPS) cells from somatic cells has been successfully achieved by ectopic expression of four transcription factors, Oct4",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 11.90625,
            "text": "iPS) cells from somatic cells has been successfully achieved by ectopic expression of four transcription factors, Oct4",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 11.90625,
            "text": "Generation of induced pluripotent stem (iPS) cells from somatic cells has been successfully achieved by ectopic expression of four transcription factors, Oct4",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 11.90625,
            "text": "transcription factors, Oct4",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 11.90625,
            "text": "pluripotent stem (iPS) cells from somatic cells has been successfully achieved by ectopic expression of four transcription factors, Oct4",
            "probability": 0.0
        },
        {
            "start_logit": -6.80078125,
            "end_logit": -4.83203125,
            "text": "Klf4",
            "probability": 0.0
        },
        {
            "start_logit": -6.80078125,
            "end_logit": -5.9921875,
            "text": "Klf4 and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -4.83203125,
            "text": "Sox2, Klf4",
            "probability": 0.0
        }
    ],
    "62755c2a56bf9aee6f000001_1": [
        {
            "start_logit": 14.3203125,
            "end_logit": 14.0625,
            "text": "breast cancer",
            "probability": 1.0
        },
        {
            "start_logit": 14.3203125,
            "end_logit": -3.15234375,
            "text": "breast",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.693359375,
            "end_logit": 14.0625,
            "text": "cancer",
            "probability": 0.0
        },
        {
            "start_logit": 14.3203125,
            "end_logit": -9.5078125,
            "text": "breast cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": 14.0625,
            "text": "tumors, including breast cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 14.0625,
            "text": "As a transcription factor and proto-oncogene, MYC is known to be deregulated in a variety of tumors, including breast cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 14.0625,
            "text": "proto-oncogene, MYC is known to be deregulated in a variety of tumors, including breast cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 14.0625,
            "text": "variety of tumors, including breast cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 14.0625,
            "text": "transcription factor and proto-oncogene, MYC is known to be deregulated in a variety of tumors, including breast cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": -3.15234375,
            "text": "tumors, including breast",
            "probability": 0.0
        },
        {
            "start_logit": -3.693359375,
            "end_logit": -9.5078125,
            "text": "cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -3.15234375,
            "text": "As a transcription factor and proto-oncogene, MYC is known to be deregulated in a variety of tumors, including breast",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": -3.15234375,
            "text": "proto-oncogene, MYC is known to be deregulated in a variety of tumors, including breast",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": -3.15234375,
            "text": "variety of tumors, including breast",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": -3.15234375,
            "text": "transcription factor and proto-oncogene, MYC is known to be deregulated in a variety of tumors, including breast",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": -7.84765625,
            "text": "tumors",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -7.84765625,
            "text": "As a transcription factor and proto-oncogene, MYC is known to be deregulated in a variety of tumors",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": -7.84765625,
            "text": "proto-oncogene, MYC is known to be deregulated in a variety of tumors",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": -8.71875,
            "text": "tumors,",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": -7.84765625,
            "text": "variety of tumors",
            "probability": 0.0
        }
    ],
    "62755c2a56bf9aee6f000001_2": [
        {
            "start_logit": 10.4765625,
            "end_logit": 12.2578125,
            "text": "NSCLC",
            "probability": 1.0
        },
        {
            "start_logit": 10.4765625,
            "end_logit": -6.95703125,
            "text": "NSCLC by targeting c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": 10.4765625,
            "end_logit": -8.2578125,
            "text": "NSCLC by",
            "probability": 0.0
        },
        {
            "start_logit": 10.4765625,
            "end_logit": -8.359375,
            "text": "NSCLC by targeting",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 12.2578125,
            "text": "tumor suppressor role of miR-376a in NSCLC",
            "probability": 0.0
        },
        {
            "start_logit": 10.4765625,
            "end_logit": -8.6875,
            "text": "NSCLC by targeting c-",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 12.2578125,
            "text": "miR-376a in NSCLC",
            "probability": 0.0
        },
        {
            "start_logit": 10.4765625,
            "end_logit": -9.4921875,
            "text": "NSCLC by targeting c",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": -6.95703125,
            "text": "tumor suppressor role of miR-376a in NSCLC by targeting c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": -6.95703125,
            "text": "miR-376a in NSCLC by targeting c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": -7.31640625,
            "text": "tumor",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": -8.1875,
            "text": "tumor suppressor role of miR-376a",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": -8.2578125,
            "text": "tumor suppressor role of miR-376a in NSCLC by",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": -8.34375,
            "text": "tumor suppressor role of miR-376a in",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": -8.359375,
            "text": "tumor suppressor role of miR-376a in NSCLC by targeting",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": -8.1875,
            "text": "miR-376a",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": -8.2578125,
            "text": "miR-376a in NSCLC by",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": -8.34375,
            "text": "miR-376a in",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": -8.359375,
            "text": "miR-376a in NSCLC by targeting",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": -8.6875,
            "text": "tumor suppressor role of miR-376a in NSCLC by targeting c-",
            "probability": 0.0
        }
    ],
    "62755c2a56bf9aee6f000001_3": [
        {
            "start_logit": 11.625,
            "end_logit": 11.4453125,
            "text": "PDA",
            "probability": 1.0
        },
        {
            "start_logit": 11.625,
            "end_logit": -9.4375,
            "text": "PDA.",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 11.4453125,
            "text": "chemotherapeutic agents for the treatment of PDA",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 11.4453125,
            "text": "treatment of PDA",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": -8.6796875,
            "text": "chemotherapeutic agents for the",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": -8.9921875,
            "text": "chemotherapeutic agents for the treatment of",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": -8.9921875,
            "text": "treatment of",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": -9.3125,
            "text": "chemotherapeutic agents",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": -9.421875,
            "text": "chemotherapeutic agents for",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": -9.4375,
            "text": "chemotherapeutic agents for the treatment of PDA.",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": -9.4375,
            "text": "treatment of PDA.",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": -9.6171875,
            "text": "chemotherapeutic",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": -9.6484375,
            "text": "chemotherapeutic agents for the treatment",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": -9.6484375,
            "text": "treatment",
            "probability": 0.0
        }
    ],
    "62755c2a56bf9aee6f000001_4": [
        {
            "start_logit": 14.4453125,
            "end_logit": 14.265625,
            "text": "breast cancer",
            "probability": 1.0
        },
        {
            "start_logit": 14.4453125,
            "end_logit": -2.8984375,
            "text": "breast",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.271484375,
            "end_logit": 14.265625,
            "text": "cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.4921875,
            "end_logit": 14.265625,
            "text": "cancer, including breast cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.1015625,
            "end_logit": 14.265625,
            "text": "human cancer, including breast cancer",
            "probability": 0.0
        },
        {
            "start_logit": 14.4453125,
            "end_logit": -9.34375,
            "text": "breast cancer.",
            "probability": 0.0
        },
        {
            "start_logit": 14.4453125,
            "end_logit": -9.7421875,
            "text": "breast cancer. U",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 14.265625,
            "text": "differentiation, and apoptosis and is frequently affected in human cancer, including breast cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 14.265625,
            "text": "apoptosis and is frequently affected in human cancer, including breast cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.4921875,
            "end_logit": -2.8984375,
            "text": "cancer, including breast",
            "probability": 0.0
        },
        {
            "start_logit": -9.1015625,
            "end_logit": -2.8984375,
            "text": "human cancer, including breast",
            "probability": 0.0
        },
        {
            "start_logit": -3.271484375,
            "end_logit": -9.34375,
            "text": "cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -3.271484375,
            "end_logit": -9.7421875,
            "text": "cancer. U",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": -2.8984375,
            "text": "differentiation, and apoptosis and is frequently affected in human cancer, including breast",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": -2.8984375,
            "text": "apoptosis and is frequently affected in human cancer, including breast",
            "probability": 0.0
        },
        {
            "start_logit": -8.4921875,
            "end_logit": -6.17578125,
            "text": "cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.1015625,
            "end_logit": -6.17578125,
            "text": "human cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": -6.17578125,
            "text": "differentiation, and apoptosis and is frequently affected in human cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": -6.17578125,
            "text": "apoptosis and is frequently affected in human cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.4921875,
            "end_logit": -9.0078125,
            "text": "cancer,",
            "probability": 0.0
        }
    ],
    "62755c2a56bf9aee6f000001_5": [
        {
            "start_logit": 14.5625,
            "end_logit": 14.2109375,
            "text": "breast cancer",
            "probability": 1.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -2.66015625,
            "text": "breast",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.423828125,
            "end_logit": 14.2109375,
            "text": "cancer",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -8.9921875,
            "text": "breast cancer and confers resistance to endocrine therapy in luminal",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.0703125,
            "text": "breast cancer and confers resistance to endocrine therapy",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.2890625,
            "text": "breast cancer and",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.3359375,
            "text": "breast cancer and confers resistance to endocrine therapy in luminal tumours",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.484375,
            "text": "breast cancer and confers resistance to endocrine therapy in luminal tumours.",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.828125,
            "text": "breast cancer and confers resistance to",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.875,
            "text": "breast cancer and confers resistance to endocrine therapy in",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.8984375,
            "text": "breast cancer and confers resistance",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.9296875,
            "text": "breast cancer and confers",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -10.09375,
            "text": "breast cancer and confers resistance to endocrine",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 14.2109375,
            "text": "subtypes of breast cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": 14.2109375,
            "text": "biological subtypes of breast cancer",
            "probability": 0.0
        },
        {
            "start_logit": -3.423828125,
            "end_logit": -8.9921875,
            "text": "cancer and confers resistance to endocrine therapy in luminal",
            "probability": 0.0
        },
        {
            "start_logit": -3.423828125,
            "end_logit": -9.0703125,
            "text": "cancer and confers resistance to endocrine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": -2.66015625,
            "text": "subtypes of breast",
            "probability": 0.0
        },
        {
            "start_logit": -3.423828125,
            "end_logit": -9.2890625,
            "text": "cancer and",
            "probability": 0.0
        },
        {
            "start_logit": -3.423828125,
            "end_logit": -9.3359375,
            "text": "cancer and confers resistance to endocrine therapy in luminal tumours",
            "probability": 0.0
        }
    ],
    "62755c2a56bf9aee6f000001_6": [
        {
            "start_logit": 14.6015625,
            "end_logit": 14.25,
            "text": "breast cancer",
            "probability": 1.0
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -2.54296875,
            "text": "breast",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.318359375,
            "end_logit": 14.25,
            "text": "cancer",
            "probability": 0.0
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -9.375,
            "text": "breast cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -9.1484375,
            "end_logit": 14.25,
            "text": "familial breast cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.9296875,
            "end_logit": 14.25,
            "text": "increased risk for familial breast cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 14.25,
            "text": "Asn11Ser is associated with increased risk for familial breast cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 14.25,
            "text": "for familial breast cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 14.25,
            "text": "risk for familial breast cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 14.25,
            "text": "c-MYC Asn11Ser is associated with increased risk for familial breast cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 14.25,
            "text": "with increased risk for familial breast cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.1484375,
            "end_logit": -2.54296875,
            "text": "familial breast",
            "probability": 0.0
        },
        {
            "start_logit": -9.9296875,
            "end_logit": -2.54296875,
            "text": "increased risk for familial breast",
            "probability": 0.0
        },
        {
            "start_logit": -3.318359375,
            "end_logit": -9.375,
            "text": "cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": -2.54296875,
            "text": "Asn11Ser is associated with increased risk for familial breast",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": -2.54296875,
            "text": "for familial breast",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": -2.54296875,
            "text": "risk for familial breast",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": -2.54296875,
            "text": "c-MYC Asn11Ser is associated with increased risk for familial breast",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": -2.54296875,
            "text": "with increased risk for familial breast",
            "probability": 0.0
        },
        {
            "start_logit": -9.1484375,
            "end_logit": -8.7890625,
            "text": "familial",
            "probability": 0.0
        }
    ],
    "60281b1c1cb411341a0000f3_1": [
        {
            "start_logit": 11.0546875,
            "end_logit": 12.34375,
            "text": "schizophrenia",
            "probability": 1.0
        },
        {
            "start_logit": 11.0546875,
            "end_logit": -7.8828125,
            "text": "schizophrenia, autism",
            "probability": 0.0
        },
        {
            "start_logit": 11.0546875,
            "end_logit": -7.9296875,
            "text": "schizophrenia, autism, mental retardation, ADHD and epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -9.890625,
            "end_logit": 12.34375,
            "text": "neuropsychiatric disorders, such as schizophrenia",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 12.34375,
            "text": "p13.11 genomic copy number variants are implicated in several neuropsychiatric disorders, such as schizophrenia",
            "probability": 0.0
        },
        {
            "start_logit": 11.0546875,
            "end_logit": -9.125,
            "text": "schizophrenia, autism, mental retardation, ADHD",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 12.34375,
            "text": "16p13.11 genomic copy number variants are implicated in several neuropsychiatric disorders, such as schizophrenia",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 12.34375,
            "text": "genomic copy number variants are implicated in several neuropsychiatric disorders, such as schizophrenia",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 12.34375,
            "text": "11 genomic copy number variants are implicated in several neuropsychiatric disorders, such as schizophrenia",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 12.34375,
            "text": "copy number variants are implicated in several neuropsychiatric disorders, such as schizophrenia",
            "probability": 0.0
        },
        {
            "start_logit": 11.0546875,
            "end_logit": -9.640625,
            "text": "schizophrenia,",
            "probability": 0.0
        },
        {
            "start_logit": 11.0546875,
            "end_logit": -9.84375,
            "text": "schizophrenia, autism, mental retardation, ADHD and",
            "probability": 0.0
        },
        {
            "start_logit": 11.0546875,
            "end_logit": -9.9140625,
            "text": "schizophrenia, autism, mental retardation, ADHD and epilepsy.",
            "probability": 0.0
        },
        {
            "start_logit": 11.0546875,
            "end_logit": -9.9765625,
            "text": "schizophrenia, autism, mental retardation",
            "probability": 0.0
        },
        {
            "start_logit": -8.9140625,
            "end_logit": -7.8828125,
            "text": "autism",
            "probability": 0.0
        },
        {
            "start_logit": -8.9140625,
            "end_logit": -7.9296875,
            "text": "autism, mental retardation, ADHD and epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -9.0390625,
            "end_logit": -7.9296875,
            "text": "epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -9.7265625,
            "end_logit": -7.9296875,
            "text": "mental retardation, ADHD and epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -9.8359375,
            "end_logit": -7.9296875,
            "text": "ADHD and epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -9.890625,
            "end_logit": -7.8828125,
            "text": "neuropsychiatric disorders, such as schizophrenia, autism",
            "probability": 0.0
        }
    ],
    "517a8c918ed59a060a000043_1": [
        {
            "start_logit": 10.515625,
            "end_logit": 12.59375,
            "text": "adenovirus",
            "probability": 1.0
        },
        {
            "start_logit": -10.0,
            "end_logit": 12.59375,
            "text": "n our study the adenovirus",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 12.59375,
            "text": "our study the adenovirus",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 12.59375,
            "text": "the adenovirus",
            "probability": 0.0
        },
        {
            "start_logit": 10.515625,
            "end_logit": -8.6953125,
            "text": "adenovirus genome",
            "probability": 0.0
        },
        {
            "start_logit": 10.515625,
            "end_logit": -8.953125,
            "text": "adenovirus genome was found to be the most frequent virus",
            "probability": 0.0
        },
        {
            "start_logit": 10.515625,
            "end_logit": -9.28125,
            "text": "adenovirus genome was found to be the most frequent virus genome",
            "probability": 0.0
        },
        {
            "start_logit": 10.515625,
            "end_logit": -9.40625,
            "text": "adenovirus genome was found to be",
            "probability": 0.0
        },
        {
            "start_logit": 10.515625,
            "end_logit": -9.5859375,
            "text": "adenovirus genome was found to be the most frequent",
            "probability": 0.0
        },
        {
            "start_logit": 10.515625,
            "end_logit": -9.75,
            "text": "adenovirus genome was",
            "probability": 0.0
        },
        {
            "start_logit": 10.515625,
            "end_logit": -9.875,
            "text": "adenovirus genome was found to be the",
            "probability": 0.0
        },
        {
            "start_logit": 10.515625,
            "end_logit": -10.0859375,
            "text": "adenovirus genome was found to be the most frequent virus genome in explanted heart tissues.",
            "probability": 0.0
        },
        {
            "start_logit": 10.515625,
            "end_logit": -10.296875,
            "text": "adenovirus genome was found to",
            "probability": 0.0
        },
        {
            "start_logit": 10.515625,
            "end_logit": -10.359375,
            "text": "adenovirus genome was found to be the most",
            "probability": 0.0
        },
        {
            "start_logit": 10.515625,
            "end_logit": -10.4375,
            "text": "adenovirus genome was found",
            "probability": 0.0
        },
        {
            "start_logit": -10.0,
            "end_logit": -8.6953125,
            "text": "n our study the adenovirus genome",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": -8.6953125,
            "text": "genome",
            "probability": 0.0
        },
        {
            "start_logit": -10.0,
            "end_logit": -8.953125,
            "text": "n our study the adenovirus genome was found to be the most frequent virus",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": -8.953125,
            "text": "genome was found to be the most frequent virus",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": -8.6953125,
            "text": "our study the adenovirus genome",
            "probability": 0.0
        }
    ],
    "550e9d2cb305b40c5c000001_1": [
        {
            "start_logit": 10.3984375,
            "end_logit": 12.765625,
            "text": "Age",
            "probability": 1.0
        },
        {
            "start_logit": -9.5234375,
            "end_logit": 12.765625,
            "text": "Stroke Prognostication using Age",
            "probability": 0.0
        },
        {
            "start_logit": 10.3984375,
            "end_logit": -7.57421875,
            "text": "Age and NIHSS",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 12.765625,
            "text": "MR-proADM levels significantly improved reclassification of patients in the prediction of outcome by the Stroke Prognostication using Age",
            "probability": 0.0
        },
        {
            "start_logit": -10.0859375,
            "end_logit": 12.765625,
            "text": "Prognostication using Age",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 12.765625,
            "text": "prediction of outcome by the Stroke Prognostication using Age",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 12.765625,
            "text": "of patients in the prediction of outcome by the Stroke Prognostication using Age",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 12.765625,
            "text": "reclassification of patients in the prediction of outcome by the Stroke Prognostication using Age",
            "probability": 0.0
        },
        {
            "start_logit": 10.3984375,
            "end_logit": -9.1171875,
            "text": "Age and NIH",
            "probability": 0.0
        },
        {
            "start_logit": 10.3984375,
            "end_logit": -9.140625,
            "text": "Age and NIHSS-100",
            "probability": 0.0
        },
        {
            "start_logit": 10.3984375,
            "end_logit": -9.3828125,
            "text": "Age and",
            "probability": 0.0
        },
        {
            "start_logit": 10.3984375,
            "end_logit": -9.484375,
            "text": "Age and NIHSS-100 (SPAN-100; NRI = 0.175",
            "probability": 0.0
        },
        {
            "start_logit": 10.3984375,
            "end_logit": -9.671875,
            "text": "Age and NIHSS-100 (SPAN-100; NRI = 0",
            "probability": 0.0
        },
        {
            "start_logit": 10.3984375,
            "end_logit": -9.7265625,
            "text": "Age and NIHSS-",
            "probability": 0.0
        },
        {
            "start_logit": 10.3984375,
            "end_logit": -9.828125,
            "text": "Age and NIHSS-100 (SPAN-100; NRI = 0.175; p = 0",
            "probability": 0.0
        },
        {
            "start_logit": 10.3984375,
            "end_logit": -9.9609375,
            "text": "Age and NIHSS-100 (SPAN-100; NRI = 0.",
            "probability": 0.0
        },
        {
            "start_logit": 10.3984375,
            "end_logit": -10.0703125,
            "text": "Age and NIHSS-100 (SPAN-100;",
            "probability": 0.0
        },
        {
            "start_logit": 10.3984375,
            "end_logit": -10.0703125,
            "text": "Age and NIHSS-100 (SPAN-100; NRI = 0.175; p = 0.04",
            "probability": 0.0
        },
        {
            "start_logit": 10.3984375,
            "end_logit": -10.0859375,
            "text": "Age and NIHSS-100 (SPAN-100; NRI =",
            "probability": 0.0
        },
        {
            "start_logit": -6.35546875,
            "end_logit": -7.57421875,
            "text": "NIHSS",
            "probability": 0.0
        }
    ],
    "550e9d2cb305b40c5c000001_2": [
        {
            "start_logit": 10.6796875,
            "end_logit": 12.5625,
            "text": "Age",
            "probability": 1.0
        },
        {
            "start_logit": 10.6796875,
            "end_logit": -5.6328125,
            "text": "Age and NIH Stroke Scale",
            "probability": 0.0
        },
        {
            "start_logit": 10.6796875,
            "end_logit": -5.890625,
            "text": "Age and NIH Stroke",
            "probability": 0.0
        },
        {
            "start_logit": -8.59375,
            "end_logit": 12.5625,
            "text": "Stroke Prognostication using Age",
            "probability": 0.0
        },
        {
            "start_logit": 10.6796875,
            "end_logit": -7.41015625,
            "text": "Age and NIH",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": 12.5625,
            "text": "Prognostication using Age",
            "probability": 0.0
        },
        {
            "start_logit": 10.6796875,
            "end_logit": -8.484375,
            "text": "Age and NIH Stroke Scale: SPAN-100.",
            "probability": 0.0
        },
        {
            "start_logit": 10.6796875,
            "end_logit": -9.21875,
            "text": "Age and",
            "probability": 0.0
        },
        {
            "start_logit": 10.6796875,
            "end_logit": -10.03125,
            "text": "Age and NIH Stroke Scale:",
            "probability": 0.0
        },
        {
            "start_logit": 10.6796875,
            "end_logit": -10.6484375,
            "text": "Age and NIH Stroke Scale: SPAN-",
            "probability": 0.0
        },
        {
            "start_logit": -4.69140625,
            "end_logit": -5.6328125,
            "text": "NIH Stroke Scale",
            "probability": 0.0
        },
        {
            "start_logit": -4.69140625,
            "end_logit": -5.890625,
            "text": "NIH Stroke",
            "probability": 0.0
        },
        {
            "start_logit": -4.69140625,
            "end_logit": -7.41015625,
            "text": "NIH",
            "probability": 0.0
        },
        {
            "start_logit": -4.69140625,
            "end_logit": -8.484375,
            "text": "NIH Stroke Scale: SPAN-100.",
            "probability": 0.0
        },
        {
            "start_logit": -8.59375,
            "end_logit": -5.6328125,
            "text": "Stroke Prognostication using Age and NIH Stroke Scale",
            "probability": 0.0
        },
        {
            "start_logit": -8.59375,
            "end_logit": -5.890625,
            "text": "Stroke Prognostication using Age and NIH Stroke",
            "probability": 0.0
        },
        {
            "start_logit": -4.69140625,
            "end_logit": -10.03125,
            "text": "NIH Stroke Scale:",
            "probability": 0.0
        },
        {
            "start_logit": -9.5,
            "end_logit": -5.6328125,
            "text": "Stroke Scale",
            "probability": 0.0
        },
        {
            "start_logit": -4.69140625,
            "end_logit": -10.6484375,
            "text": "NIH Stroke Scale: SPAN-",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": -5.6328125,
            "text": "Prognostication using Age and NIH Stroke Scale",
            "probability": 0.0
        }
    ],
    "550e9d2cb305b40c5c000001_3": [
        {
            "start_logit": 10.6015625,
            "end_logit": 12.6328125,
            "text": "Age",
            "probability": 1.0
        },
        {
            "start_logit": 10.6015625,
            "end_logit": -5.83203125,
            "text": "Age and NIH Stroke Scale",
            "probability": 0.0
        },
        {
            "start_logit": 10.6015625,
            "end_logit": -5.96875,
            "text": "Age and NIH Stroke",
            "probability": 0.0
        },
        {
            "start_logit": 10.6015625,
            "end_logit": -6.1171875,
            "text": "Age and NIH Stroke Scale (SPAN) index by combining age in years plus NIH Stroke Scale (NIHSS",
            "probability": 0.0
        },
        {
            "start_logit": -9.25,
            "end_logit": 12.6328125,
            "text": "Stroke Prognostication using Age",
            "probability": 0.0
        },
        {
            "start_logit": 10.6015625,
            "end_logit": -7.40625,
            "text": "Age and NIH",
            "probability": 0.0
        },
        {
            "start_logit": 10.6015625,
            "end_logit": -7.4375,
            "text": "Age and NIH Stroke Scale (SPAN) index by combining age in years plus NIH Stroke",
            "probability": 0.0
        },
        {
            "start_logit": 10.6015625,
            "end_logit": -7.72265625,
            "text": "Age and NIH Stroke Scale (SPAN) index by combining age in years plus NIH Stroke Scale",
            "probability": 0.0
        },
        {
            "start_logit": -9.8828125,
            "end_logit": 12.6328125,
            "text": "Prognostication using Age",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 12.6328125,
            "text": ": We created the Stroke Prognostication using Age",
            "probability": 0.0
        },
        {
            "start_logit": 10.6015625,
            "end_logit": -8.15625,
            "text": "Age and NIH Stroke Scale (SPAN) index by combining age in years plus NIH Stroke Scale (NIHSS) \u2265100",
            "probability": 0.0
        },
        {
            "start_logit": 10.6015625,
            "end_logit": -8.4921875,
            "text": "Age and NIH Stroke Scale (SPAN) index by combining age in years plus NIH",
            "probability": 0.0
        },
        {
            "start_logit": 10.6015625,
            "end_logit": -8.6953125,
            "text": "Age and NIH Stroke Scale (SPAN) index by combining age in years plus NIH Stroke Scale (NIHSS)",
            "probability": 0.0
        },
        {
            "start_logit": 10.6015625,
            "end_logit": -9.0390625,
            "text": "Age and",
            "probability": 0.0
        },
        {
            "start_logit": 10.6015625,
            "end_logit": -9.078125,
            "text": "Age and NIH Stroke Scale (SPAN) index by combining age in years plus NIH Stroke Scale (",
            "probability": 0.0
        },
        {
            "start_logit": 10.6015625,
            "end_logit": -9.1015625,
            "text": "Age and NIH Stroke Scale (SPAN) index by combining age in years plus NIH Stroke Scale (NIH",
            "probability": 0.0
        },
        {
            "start_logit": 10.6015625,
            "end_logit": -9.34375,
            "text": "Age and NIH Stroke Scale (SPAN) index",
            "probability": 0.0
        },
        {
            "start_logit": 10.6015625,
            "end_logit": -9.4140625,
            "text": "Age and NIH Stroke Scale (SPAN)",
            "probability": 0.0
        },
        {
            "start_logit": 10.6015625,
            "end_logit": -9.5703125,
            "text": "Age and NIH Stroke Scale (SPAN) index by combining age in years plus NIH Stroke Scale (NIHSS) \u2265100.",
            "probability": 0.0
        },
        {
            "start_logit": 10.6015625,
            "end_logit": -9.6484375,
            "text": "Age and NIH Stroke Scale (SPAN) index by combining age in years plus NIH Stroke Scale (NIHSS) \u226510",
            "probability": 0.0
        }
    ],
    "550e9d2cb305b40c5c000001_4": [
        {
            "start_logit": 9.9765625,
            "end_logit": 13.09375,
            "text": "age",
            "probability": 1.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -6.03125,
            "text": "age and the NIH Stroke",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 13.09375,
            "text": "if the sum of the age",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -7.921875,
            "text": "age and the NIH Stroke Scale",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2109375,
            "text": "age and the NIH",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.5390625,
            "text": "age and the NIH Stroke Scale (a 15-item neurological examination scale with scores ranging from 0 to 42, with higher scores indicating more severe strokes",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.9453125,
            "text": "age and the NIH Stroke Scale (a 15-item neurological examination scale with scores ranging from 0 to 42, with higher scores indicating more severe",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -9.1796875,
            "text": "age and the NIH Stroke Scale (a 15-item neurological examination scale with scores ranging from 0 to 42",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -9.234375,
            "text": "age and the NIH Stroke Scale (a 15-item neurological examination scale",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -9.2890625,
            "text": "age and the NIH Stroke Scale (a 15-item",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -9.3828125,
            "text": "age and the NIH Stroke Scale (a 15-item neurological examination scale with scores ranging from 0 to 42, with higher scores indicating more severe strokes)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -9.5078125,
            "text": "age and the NIH Stroke Scale (a 15-item neurological examination",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -9.546875,
            "text": "age and the NIH Stroke Scale (a 15-item neurological",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -9.7265625,
            "text": "age and the NIH Stroke Scale (a 15",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -9.7421875,
            "text": "age and",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -9.8515625,
            "text": "age and the NIH Stroke Scale (",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -6.03125,
            "text": "NIH Stroke",
            "probability": 0.0
        },
        {
            "start_logit": -8.984375,
            "end_logit": -6.03125,
            "text": "Stroke",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -7.921875,
            "text": "NIH Stroke Scale",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": -6.03125,
            "text": "if the sum of the age and the NIH Stroke",
            "probability": 0.0
        }
    ],
    "550e9d2cb305b40c5c000001_5": [
        {
            "start_logit": 10.4453125,
            "end_logit": 12.7578125,
            "text": "Age",
            "probability": 1.0
        },
        {
            "start_logit": -9.5546875,
            "end_logit": 12.7578125,
            "text": "using Age",
            "probability": 0.0
        },
        {
            "start_logit": -9.5859375,
            "end_logit": 12.7578125,
            "text": "Stroke Prognostication using Age",
            "probability": 0.0
        },
        {
            "start_logit": -9.6875,
            "end_logit": 12.7578125,
            "text": "Prognostication using Age",
            "probability": 0.0
        },
        {
            "start_logit": 10.4453125,
            "end_logit": -8.7890625,
            "text": "Age and the NIH Stroke Scale index, created by combining age in years plus a National Institutes of Health",
            "probability": 0.0
        },
        {
            "start_logit": 10.4453125,
            "end_logit": -9.0546875,
            "text": "Age and the NIH Stroke Scale",
            "probability": 0.0
        },
        {
            "start_logit": 10.4453125,
            "end_logit": -9.2890625,
            "text": "Age and the NIH Stroke Scale index, created by combining age in years plus a National Institutes of Health (NIH) Stroke",
            "probability": 0.0
        },
        {
            "start_logit": 10.4453125,
            "end_logit": -9.34375,
            "text": "Age and the NIH Stroke Scale index, created by combining age in years plus a National Institutes of Health (NIH",
            "probability": 0.0
        },
        {
            "start_logit": 10.4453125,
            "end_logit": -9.359375,
            "text": "Age and the NIH Stroke",
            "probability": 0.0
        },
        {
            "start_logit": 10.4453125,
            "end_logit": -9.3828125,
            "text": "Age and the NIH Stroke Scale index, created by combining age in years plus a National Institutes of Health (NIH) Stroke Scale",
            "probability": 0.0
        },
        {
            "start_logit": 10.4453125,
            "end_logit": -9.3984375,
            "text": "Age and the NIH Stroke Scale index, created by combining age in years plus a National Institutes of Health (NIH) Stroke Scale score of 100 or higher",
            "probability": 0.0
        },
        {
            "start_logit": 10.4453125,
            "end_logit": -9.703125,
            "text": "Age and the NIH",
            "probability": 0.0
        },
        {
            "start_logit": 10.4453125,
            "end_logit": -9.734375,
            "text": "Age and the NIH Stroke Scale index",
            "probability": 0.0
        },
        {
            "start_logit": 10.4453125,
            "end_logit": -9.78125,
            "text": "Age and the NIH Stroke Scale index, created by combining age in years plus a National Institutes of Health (",
            "probability": 0.0
        },
        {
            "start_logit": 10.4453125,
            "end_logit": -10.0078125,
            "text": "Age and the NIH Stroke Scale index, created by combining age in years plus a",
            "probability": 0.0
        },
        {
            "start_logit": -7.7578125,
            "end_logit": -8.7890625,
            "text": "National Institutes of Health",
            "probability": 0.0
        },
        {
            "start_logit": -7.7578125,
            "end_logit": -9.2890625,
            "text": "National Institutes of Health (NIH) Stroke",
            "probability": 0.0
        },
        {
            "start_logit": -7.7578125,
            "end_logit": -9.34375,
            "text": "National Institutes of Health (NIH",
            "probability": 0.0
        },
        {
            "start_logit": -7.7578125,
            "end_logit": -9.3828125,
            "text": "National Institutes of Health (NIH) Stroke Scale",
            "probability": 0.0
        },
        {
            "start_logit": -7.7578125,
            "end_logit": -9.3984375,
            "text": "National Institutes of Health (NIH) Stroke Scale score of 100 or higher",
            "probability": 0.0
        }
    ],
    "601f19d11cb411341a000073_1": [
        {
            "start_logit": 13.078125,
            "end_logit": 12.7109375,
            "text": "Emmanuelle Charpentier",
            "probability": 1.0
        },
        {
            "start_logit": 13.078125,
            "end_logit": -4.22265625,
            "text": "Emmanuelle Charpentier and Jennifer Doudna",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.078125,
            "end_logit": -4.35546875,
            "text": "Em",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.078125,
            "end_logit": -4.9921875,
            "text": "Emmanuelle",
            "probability": 0.0
        },
        {
            "start_logit": 13.078125,
            "end_logit": -5.53125,
            "text": "Emmanuelle Charpent",
            "probability": 0.0
        },
        {
            "start_logit": -5.296875,
            "end_logit": 12.7109375,
            "text": "ier",
            "probability": 0.0
        },
        {
            "start_logit": 13.078125,
            "end_logit": -5.8359375,
            "text": "Emmanuel",
            "probability": 0.0
        },
        {
            "start_logit": 13.078125,
            "end_logit": -6.06640625,
            "text": "Emmanuelle Charpe",
            "probability": 0.0
        },
        {
            "start_logit": 13.078125,
            "end_logit": -6.07421875,
            "text": "Emmanuelle Charpentier and Jennifer Doudna for their discovery of the CRISPR/Cas9",
            "probability": 0.0
        },
        {
            "start_logit": 13.078125,
            "end_logit": -6.26171875,
            "text": "Emmanuelle Charpentier and Jennifer",
            "probability": 0.0
        },
        {
            "start_logit": 13.078125,
            "end_logit": -7.16796875,
            "text": "Emmanuelle Charpentier and Jennifer Do",
            "probability": 0.0
        },
        {
            "start_logit": 13.078125,
            "end_logit": -7.35546875,
            "text": "Emman",
            "probability": 0.0
        },
        {
            "start_logit": 13.078125,
            "end_logit": -7.8515625,
            "text": "Emmanuelle Charpentier and Jennifer Doudna for their discovery of the CRISPR/Cas9 genetic scissors",
            "probability": 0.0
        },
        {
            "start_logit": 13.078125,
            "end_logit": -8.0625,
            "text": "Emmanuelle Charpentier and Jennifer Doud",
            "probability": 0.0
        },
        {
            "start_logit": 13.078125,
            "end_logit": -8.421875,
            "text": "Emmanuelle Charpentier and Je",
            "probability": 0.0
        },
        {
            "start_logit": 13.078125,
            "end_logit": -8.5,
            "text": "Emmanuelle Charpentier and",
            "probability": 0.0
        },
        {
            "start_logit": 13.078125,
            "end_logit": -8.5703125,
            "text": "Emmanuelle Charpentier and Jennifer Doudna for",
            "probability": 0.0
        },
        {
            "start_logit": 13.078125,
            "end_logit": -8.703125,
            "text": "Emmanuelle Char",
            "probability": 0.0
        },
        {
            "start_logit": 13.078125,
            "end_logit": -8.7421875,
            "text": "Emmanuelle Charpentier and Jennifer Doudna for their discovery of the",
            "probability": 0.0
        },
        {
            "start_logit": -8.6171875,
            "end_logit": 12.7109375,
            "text": "Charpentier",
            "probability": 0.0
        }
    ],
    "601f19d11cb411341a000073_2": [
        {
            "start_logit": 10.375,
            "end_logit": 10.390625,
            "text": "Emmanuelle Charpentier",
            "probability": 1.0
        },
        {
            "start_logit": 10.375,
            "end_logit": 2.5390625,
            "text": "Emmanuelle Charpentier and Jennifer Doudna",
            "probability": 0.00038909912109375
        },
        {
            "start_logit": 10.375,
            "end_logit": -3.89453125,
            "text": "Emmanuelle Charpentier and Jennifer Do",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 10.375,
            "end_logit": -4.45703125,
            "text": "Emmanuelle Charpent",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 10.375,
            "end_logit": -4.53515625,
            "text": "Emmanuelle Charpe",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 10.375,
            "end_logit": -4.640625,
            "text": "Emmanuelle Charpentier and Jennifer",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 10.375,
            "end_logit": -5.27734375,
            "text": "Emmanuelle",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 10.375,
            "end_logit": -5.5859375,
            "text": "Emmanuelle Charpentier and Jennifer Doud",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.375,
            "end_logit": -6.0078125,
            "text": "Emmanuel",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.375,
            "end_logit": -6.375,
            "text": "Emmanuelle Charpentier and Je",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.375,
            "end_logit": -6.6796875,
            "text": "Em",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.7890625,
            "end_logit": 10.390625,
            "text": "ier",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.375,
            "end_logit": -6.97265625,
            "text": "Emmanuelle Charpentier and Jenn",
            "probability": 0.0
        },
        {
            "start_logit": 10.375,
            "end_logit": -7.76953125,
            "text": "Emmanuelle Char",
            "probability": 0.0
        },
        {
            "start_logit": 10.375,
            "end_logit": -8.3671875,
            "text": "Emman",
            "probability": 0.0
        },
        {
            "start_logit": -8.546875,
            "end_logit": 10.390625,
            "text": "ers Emmanuelle Charpentier",
            "probability": 0.0
        },
        {
            "start_logit": 10.375,
            "end_logit": -9.3125,
            "text": "Emmanuelle Charpentier and Jennifer Doudna,",
            "probability": 0.0
        },
        {
            "start_logit": 10.375,
            "end_logit": -9.5078125,
            "text": "Emmanuelle Charpentier and",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": 10.390625,
            "text": "Charpentier",
            "probability": 0.0
        },
        {
            "start_logit": -10.140625,
            "end_logit": 10.390625,
            "text": "Chemistry was awarded to CRISPR-Cas pioneers Emmanuelle Charpentier",
            "probability": 0.0
        }
    ],
    "601f19d11cb411341a000073_3": [
        {
            "start_logit": 12.6796875,
            "end_logit": 12.75,
            "text": "Emmanuelle Charpentier",
            "probability": 1.0
        },
        {
            "start_logit": 12.6796875,
            "end_logit": -3.431640625,
            "text": "Emmanuelle Charpentier, PhD",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.6796875,
            "end_logit": -4.05078125,
            "text": "Emmanuelle Charpentier, PhD, and Jennifer Doudna",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.6796875,
            "end_logit": -4.98828125,
            "text": "Em",
            "probability": 0.0
        },
        {
            "start_logit": 12.6796875,
            "end_logit": -5.0625,
            "text": "Emmanuelle",
            "probability": 0.0
        },
        {
            "start_logit": -5.1953125,
            "end_logit": 12.75,
            "text": "ier",
            "probability": 0.0
        },
        {
            "start_logit": 12.6796875,
            "end_logit": -5.9296875,
            "text": "Emmanuelle Charpent",
            "probability": 0.0
        },
        {
            "start_logit": 12.6796875,
            "end_logit": -5.94140625,
            "text": "Emmanuelle Charpe",
            "probability": 0.0
        },
        {
            "start_logit": 12.6796875,
            "end_logit": -6.29296875,
            "text": "Emmanuel",
            "probability": 0.0
        },
        {
            "start_logit": 12.6796875,
            "end_logit": -6.5703125,
            "text": "Emmanuelle Charpentier, PhD, and Jennifer",
            "probability": 0.0
        },
        {
            "start_logit": 12.6796875,
            "end_logit": -6.8828125,
            "text": "Emmanuelle Charpentier, PhD, and Jennifer Doudna, PhD",
            "probability": 0.0
        },
        {
            "start_logit": 12.6796875,
            "end_logit": -7.37109375,
            "text": "Emmanuelle Charpentier, PhD, and Jennifer Do",
            "probability": 0.0
        },
        {
            "start_logit": 12.6796875,
            "end_logit": -7.6171875,
            "text": "Emmanuelle Charpentier, PhD, and Je",
            "probability": 0.0
        },
        {
            "start_logit": 12.6796875,
            "end_logit": -7.77734375,
            "text": "Emman",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 12.75,
            "text": "Charpentier",
            "probability": 0.0
        },
        {
            "start_logit": 12.6796875,
            "end_logit": -8.1171875,
            "text": "Emmanuelle Charpentier, PhD,",
            "probability": 0.0
        },
        {
            "start_logit": 12.6796875,
            "end_logit": -8.2578125,
            "text": "Emmanuelle Charpentier, PhD, and Jennifer Doud",
            "probability": 0.0
        },
        {
            "start_logit": 12.6796875,
            "end_logit": -8.5234375,
            "text": "Emmanuelle Charpentier, Ph",
            "probability": 0.0
        },
        {
            "start_logit": 12.6796875,
            "end_logit": -8.609375,
            "text": "Emmanuelle Charpentier, PhD, and Jenn",
            "probability": 0.0
        },
        {
            "start_logit": -8.921875,
            "end_logit": 12.75,
            "text": "manuelle Charpentier",
            "probability": 0.0
        }
    ],
    "601f19d11cb411341a000073_4": [
        {
            "start_logit": 5.890625,
            "end_logit": 7.46484375,
            "text": "Dr. Emmanuelle Charpentier",
            "probability": 0.9990234375
        },
        {
            "start_logit": 5.890625,
            "end_logit": -0.319580078125,
            "text": "Dr. Emmanuelle Charpentier and Dr. Jennifer Doudna",
            "probability": 0.00041365623474121094
        },
        {
            "start_logit": -4.01953125,
            "end_logit": 7.46484375,
            "text": "Emmanuelle Charpentier",
            "probability": 4.941225051879883e-05
        },
        {
            "start_logit": 5.890625,
            "end_logit": -3.912109375,
            "text": "Dr. Emmanuelle",
            "probability": 1.138448715209961e-05
        },
        {
            "start_logit": 5.890625,
            "end_logit": -4.0859375,
            "text": "Dr. Emmanuelle Charpentier and Dr. Jennifer Do",
            "probability": 9.59634780883789e-06
        },
        {
            "start_logit": 5.890625,
            "end_logit": -4.16015625,
            "text": "Dr",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": 5.890625,
            "end_logit": -5.47265625,
            "text": "Dr. Emmanuelle Charpentier and Dr. Jennifer",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": 5.890625,
            "end_logit": -5.83984375,
            "text": "Dr. Emmanuel",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 7.46484375,
            "text": "ier",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 5.890625,
            "end_logit": -6.2578125,
            "text": "Dr. Emmanuelle Charpentier and Dr. Jennifer Doud",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 5.890625,
            "end_logit": -6.3984375,
            "text": "Dr. Emmanuelle Charpent",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 5.890625,
            "end_logit": -6.71875,
            "text": "Dr. Emmanuelle Charpentier and Dr. Je",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 5.890625,
            "end_logit": -6.828125,
            "text": "Dr. Emman",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 5.890625,
            "end_logit": -7.1015625,
            "text": "Dr. Emmanuelle Charpe",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 5.890625,
            "end_logit": -7.26171875,
            "text": "Dr. Emmanuelle Charpentier and Dr. Jennifer Doudna won the Nobel Prize in Chemistry",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 5.890625,
            "end_logit": -7.7421875,
            "text": "Dr. Emmanuelle Charpentier and Dr. Jenn",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -9.6171875,
            "end_logit": 7.46484375,
            "text": "Charpentier",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 5.890625,
            "end_logit": -8.2890625,
            "text": "Dr. Emmanuelle Char",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.890625,
            "end_logit": -8.359375,
            "text": "Dr. Emmanuelle Charpentier and Dr. Jennifer Doudna won the Nobel Prize",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.890625,
            "end_logit": -8.375,
            "text": "Dr. Em",
            "probability": 1.1920928955078125e-07
        }
    ],
    "601f19d11cb411341a000073_5": [
        {
            "start_logit": 10.375,
            "end_logit": 10.390625,
            "text": "Emmanuelle Charpentier",
            "probability": 1.0
        },
        {
            "start_logit": 10.375,
            "end_logit": 2.5390625,
            "text": "Emmanuelle Charpentier and Jennifer Doudna",
            "probability": 0.00038909912109375
        },
        {
            "start_logit": 10.375,
            "end_logit": -3.89453125,
            "text": "Emmanuelle Charpentier and Jennifer Do",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 10.375,
            "end_logit": -4.45703125,
            "text": "Emmanuelle Charpent",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 10.375,
            "end_logit": -4.53515625,
            "text": "Emmanuelle Charpe",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 10.375,
            "end_logit": -4.640625,
            "text": "Emmanuelle Charpentier and Jennifer",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 10.375,
            "end_logit": -5.27734375,
            "text": "Emmanuelle",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 10.375,
            "end_logit": -5.5859375,
            "text": "Emmanuelle Charpentier and Jennifer Doud",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.375,
            "end_logit": -6.0078125,
            "text": "Emmanuel",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.375,
            "end_logit": -6.375,
            "text": "Emmanuelle Charpentier and Je",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.375,
            "end_logit": -6.6796875,
            "text": "Em",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.7890625,
            "end_logit": 10.390625,
            "text": "ier",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.375,
            "end_logit": -6.97265625,
            "text": "Emmanuelle Charpentier and Jenn",
            "probability": 0.0
        },
        {
            "start_logit": 10.375,
            "end_logit": -7.76953125,
            "text": "Emmanuelle Char",
            "probability": 0.0
        },
        {
            "start_logit": 10.375,
            "end_logit": -8.3671875,
            "text": "Emman",
            "probability": 0.0
        },
        {
            "start_logit": -8.546875,
            "end_logit": 10.390625,
            "text": "ers Emmanuelle Charpentier",
            "probability": 0.0
        },
        {
            "start_logit": 10.375,
            "end_logit": -9.3125,
            "text": "Emmanuelle Charpentier and Jennifer Doudna,",
            "probability": 0.0
        },
        {
            "start_logit": 10.375,
            "end_logit": -9.5078125,
            "text": "Emmanuelle Charpentier and",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": 10.390625,
            "text": "Charpentier",
            "probability": 0.0
        },
        {
            "start_logit": -10.140625,
            "end_logit": 10.390625,
            "text": "Chemistry was awarded to CRISPR-Cas pioneers Emmanuelle Charpentier",
            "probability": 0.0
        }
    ],
    "601f19d11cb411341a000073_6": [
        {
            "start_logit": 11.8984375,
            "end_logit": 11.359375,
            "text": "Emmanuelle Charpentier",
            "probability": 1.0
        },
        {
            "start_logit": 11.8984375,
            "end_logit": 0.148681640625,
            "text": "Emmanuelle Charpentier and Jennifer Doudna",
            "probability": 1.3649463653564453e-05
        },
        {
            "start_logit": 11.8984375,
            "end_logit": -4.65625,
            "text": "Emmanuelle Charpent",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.8984375,
            "end_logit": -4.796875,
            "text": "Emmanuelle Charpe",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.8984375,
            "end_logit": -5.03125,
            "text": "Emmanuelle",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.8984375,
            "end_logit": -5.07421875,
            "text": "Emmanuelle Charpentier and Jennifer Do",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.8984375,
            "end_logit": -5.55078125,
            "text": "Em",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.8984375,
            "end_logit": -6.05859375,
            "text": "Emmanuelle Charpentier and Jennifer",
            "probability": 0.0
        },
        {
            "start_logit": 11.8984375,
            "end_logit": -6.2265625,
            "text": "Emmanuel",
            "probability": 0.0
        },
        {
            "start_logit": 11.8984375,
            "end_logit": -6.3125,
            "text": "Emmanuelle Charpentier and Jennifer Doud",
            "probability": 0.0
        },
        {
            "start_logit": -6.19921875,
            "end_logit": 11.359375,
            "text": "ier",
            "probability": 0.0
        },
        {
            "start_logit": 11.8984375,
            "end_logit": -7.3671875,
            "text": "Emmanuelle Charpentier and Je",
            "probability": 0.0
        },
        {
            "start_logit": 11.8984375,
            "end_logit": -7.84375,
            "text": "Emman",
            "probability": 0.0
        },
        {
            "start_logit": 11.8984375,
            "end_logit": -8.0,
            "text": "Emmanuelle Charpentier and Jenn",
            "probability": 0.0
        },
        {
            "start_logit": 11.8984375,
            "end_logit": -8.4921875,
            "text": "Emmanuelle Char",
            "probability": 0.0
        },
        {
            "start_logit": 11.8984375,
            "end_logit": -9.078125,
            "text": "Emmanuelle Charpentier and",
            "probability": 0.0
        },
        {
            "start_logit": -9.25,
            "end_logit": 11.359375,
            "text": "Charpentier",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": 11.359375,
            "text": "ers Emmanuelle Charpentier",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 11.359375,
            "text": "manuelle Charpentier",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 11.359375,
            "text": "CRISPR-Cas pioneers Emmanuelle Charpentier",
            "probability": 0.0
        }
    ],
    "601f19d11cb411341a000073_7": [
        {
            "start_logit": 12.625,
            "end_logit": 12.78125,
            "text": "Emmanuelle Charpentier",
            "probability": 1.0
        },
        {
            "start_logit": 12.625,
            "end_logit": -3.4140625,
            "text": "Emmanuelle Charpentier, PhD",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.625,
            "end_logit": -4.00390625,
            "text": "Emmanuelle Charpentier, PhD, and Jennifer Doudna",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.125,
            "end_logit": 12.78125,
            "text": "ier",
            "probability": 0.0
        },
        {
            "start_logit": 12.625,
            "end_logit": -5.00390625,
            "text": "Em",
            "probability": 0.0
        },
        {
            "start_logit": 12.625,
            "end_logit": -5.15234375,
            "text": "Emmanuelle",
            "probability": 0.0
        },
        {
            "start_logit": 12.625,
            "end_logit": -5.79296875,
            "text": "Emmanuelle Charpent",
            "probability": 0.0
        },
        {
            "start_logit": 12.625,
            "end_logit": -5.8359375,
            "text": "Emmanuelle Charpe",
            "probability": 0.0
        },
        {
            "start_logit": 12.625,
            "end_logit": -6.2734375,
            "text": "Emmanuel",
            "probability": 0.0
        },
        {
            "start_logit": 12.625,
            "end_logit": -6.4921875,
            "text": "Emmanuelle Charpentier, PhD, and Jennifer",
            "probability": 0.0
        },
        {
            "start_logit": 12.625,
            "end_logit": -6.6015625,
            "text": "Emmanuelle Charpentier, PhD, and Jennifer Doudna, PhD",
            "probability": 0.0
        },
        {
            "start_logit": 12.625,
            "end_logit": -7.32421875,
            "text": "Emmanuelle Charpentier, PhD, and Jennifer Do",
            "probability": 0.0
        },
        {
            "start_logit": 12.625,
            "end_logit": -7.54296875,
            "text": "Emmanuelle Charpentier, PhD, and Je",
            "probability": 0.0
        },
        {
            "start_logit": 12.625,
            "end_logit": -7.73828125,
            "text": "Emman",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 12.78125,
            "text": "Charpentier",
            "probability": 0.0
        },
        {
            "start_logit": 12.625,
            "end_logit": -7.9140625,
            "text": "Emmanuelle Charpentier, PhD,",
            "probability": 0.0
        },
        {
            "start_logit": 12.625,
            "end_logit": -8.1640625,
            "text": "Emmanuelle Charpentier, PhD, and Jennifer Doud",
            "probability": 0.0
        },
        {
            "start_logit": 12.625,
            "end_logit": -8.5703125,
            "text": "Emmanuelle Charpentier, Ph",
            "probability": 0.0
        },
        {
            "start_logit": 12.625,
            "end_logit": -8.6171875,
            "text": "Emmanuelle Charpentier, PhD, and Jenn",
            "probability": 0.0
        },
        {
            "start_logit": -8.90625,
            "end_logit": 12.78125,
            "text": "manuelle Charpentier",
            "probability": 0.0
        }
    ],
    "601f19d11cb411341a000073_8": [
        {
            "start_logit": 2.28515625,
            "end_logit": 1.9794921875,
            "text": "Emmanuelle Charpentier",
            "probability": 0.9462890625
        },
        {
            "start_logit": -2.537109375,
            "end_logit": 3.48828125,
            "text": "Jean Bennett",
            "probability": 0.034393310546875
        },
        {
            "start_logit": 2.28515625,
            "end_logit": -2.814453125,
            "text": "Emmanuelle Charpentier and Jennifer Doudna for their discovery of the CRISPR/Cas9",
            "probability": 0.0078125
        },
        {
            "start_logit": -2.537109375,
            "end_logit": 1.9794921875,
            "text": "Jean Bennett share their perspective on the 2020 Nobel Prize in Chemistry awarded to Emmanuelle Charpentier",
            "probability": 0.007602691650390625
        },
        {
            "start_logit": 2.28515625,
            "end_logit": -4.97265625,
            "text": "Emmanuelle Charpentier and Jennifer Doudna",
            "probability": 0.0009045600891113281
        },
        {
            "start_logit": -6.3125,
            "end_logit": 3.48828125,
            "text": "Katherine Uyhazi and renowned gene therapy pioneer Jean Bennett",
            "probability": 0.0007886886596679688
        },
        {
            "start_logit": 2.28515625,
            "end_logit": -5.578125,
            "text": "Emmanuelle Charpe",
            "probability": 0.0004935264587402344
        },
        {
            "start_logit": 2.28515625,
            "end_logit": -5.8828125,
            "text": "Emmanuelle Charpent",
            "probability": 0.00036406517028808594
        },
        {
            "start_logit": 2.28515625,
            "end_logit": -5.97265625,
            "text": "Emmanuelle Charpentier and Jennifer Do",
            "probability": 0.00033283233642578125
        },
        {
            "start_logit": 2.28515625,
            "end_logit": -6.11328125,
            "text": "Emmanuelle Charpentier and Jennifer Doudna for their discovery of the CRISPR/Cas9 genetic scissors",
            "probability": 0.00028896331787109375
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 3.48828125,
            "text": "t",
            "probability": 0.00028443336486816406
        },
        {
            "start_logit": 2.28515625,
            "end_logit": -6.20703125,
            "text": "Emmanuelle",
            "probability": 0.00026297569274902344
        },
        {
            "start_logit": 2.28515625,
            "end_logit": -7.2421875,
            "text": "Emmanuel",
            "probability": 9.387731552124023e-05
        },
        {
            "start_logit": -8.5078125,
            "end_logit": 3.48828125,
            "text": "Bennett",
            "probability": 8.815526962280273e-05
        },
        {
            "start_logit": 2.28515625,
            "end_logit": -7.609375,
            "text": "Emmanuelle Charpentier and Jennifer Doudna for their discovery of the",
            "probability": 6.449222564697266e-05
        },
        {
            "start_logit": 2.28515625,
            "end_logit": -7.63671875,
            "text": "Emmanuelle Charpentier and Jennifer",
            "probability": 6.300210952758789e-05
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 1.9794921875,
            "text": "t share their perspective on the 2020 Nobel Prize in Chemistry awarded to Emmanuelle Charpentier",
            "probability": 6.252527236938477e-05
        },
        {
            "start_logit": -8.90625,
            "end_logit": 3.48828125,
            "text": "gene therapy pioneer Jean Bennett",
            "probability": 5.8710575103759766e-05
        },
        {
            "start_logit": 2.28515625,
            "end_logit": -7.80859375,
            "text": "Emmanuelle Char",
            "probability": 5.310773849487305e-05
        },
        {
            "start_logit": 2.28515625,
            "end_logit": -7.96484375,
            "text": "Emmanuelle Charpentier and Jennifer Doudna for their discovery of the CRISPR/Cas9 genetic sciss",
            "probability": 4.5359134674072266e-05
        }
    ],
    "601f19d11cb411341a000073_9": [
        {
            "start_logit": 12.328125,
            "end_logit": 11.1171875,
            "text": "Jennifer Doudna",
            "probability": 1.0
        },
        {
            "start_logit": 12.328125,
            "end_logit": -5.171875,
            "text": "Je",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.328125,
            "end_logit": -5.671875,
            "text": "Jennifer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.328125,
            "end_logit": -6.1953125,
            "text": "Jennifer Doud",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.328125,
            "end_logit": -7.16015625,
            "text": "Jennifer Do",
            "probability": 0.0
        },
        {
            "start_logit": 12.328125,
            "end_logit": -7.55859375,
            "text": "Jenn",
            "probability": 0.0
        },
        {
            "start_logit": 12.328125,
            "end_logit": -7.71484375,
            "text": "Jennifer Doudna won the Nobel Prize in Chemistry",
            "probability": 0.0
        },
        {
            "start_logit": 12.328125,
            "end_logit": -8.0703125,
            "text": "Jennifer Doudna won the Nobel Prize",
            "probability": 0.0
        },
        {
            "start_logit": 12.328125,
            "end_logit": -8.1328125,
            "text": "Jennifer Doudna won the Nobel Prize in Chemistry for their pioneering work in precise genome editing",
            "probability": 0.0
        },
        {
            "start_logit": -6.99609375,
            "end_logit": 11.1171875,
            "text": "Doudna",
            "probability": 0.0
        },
        {
            "start_logit": -7.578125,
            "end_logit": 11.1171875,
            "text": "na",
            "probability": 0.0
        },
        {
            "start_logit": 12.328125,
            "end_logit": -8.9609375,
            "text": "Jennifer Doudna won the Nobel Prize in Chemistry for their pioneering work",
            "probability": 0.0
        },
        {
            "start_logit": 12.328125,
            "end_logit": -9.1015625,
            "text": "Jennifer Doudna won the Nobel Prize in Chemistry for",
            "probability": 0.0
        },
        {
            "start_logit": 12.328125,
            "end_logit": -9.7265625,
            "text": "Jennifer Doudna won the Nobel Prize in",
            "probability": 0.0
        },
        {
            "start_logit": -8.5390625,
            "end_logit": 11.1171875,
            "text": "nnifer Doudna",
            "probability": 0.0
        },
        {
            "start_logit": 12.328125,
            "end_logit": -9.90625,
            "text": "Jennifer Doudna won the Nobel Prize in Chemistry for their pioneering",
            "probability": 0.0
        },
        {
            "start_logit": 12.328125,
            "end_logit": -9.9375,
            "text": "Jennifer Doudna won the Nobel Prize in Chemistry for their pioneering work in",
            "probability": 0.0
        },
        {
            "start_logit": 12.328125,
            "end_logit": -9.953125,
            "text": "Jennifer Doudna won",
            "probability": 0.0
        },
        {
            "start_logit": 12.328125,
            "end_logit": -9.9609375,
            "text": "Jennifer Doudna won the Nobel Pri",
            "probability": 0.0
        },
        {
            "start_logit": 12.328125,
            "end_logit": -9.9765625,
            "text": "Jennifer Doudna w",
            "probability": 0.0
        }
    ],
    "601f19d11cb411341a000073_10": [
        {
            "start_logit": 4.10546875,
            "end_logit": 3.63671875,
            "text": "Emmanuelle Charpentier",
            "probability": 0.9580078125
        },
        {
            "start_logit": -0.23876953125,
            "end_logit": 4.2890625,
            "text": "Jean Bennett",
            "probability": 0.0238800048828125
        },
        {
            "start_logit": -0.23876953125,
            "end_logit": 3.63671875,
            "text": "Jean Bennett share their perspective on the 2020 Nobel Prize in Chemistry awarded to Emmanuelle Charpentier",
            "probability": 0.0124359130859375
        },
        {
            "start_logit": 4.10546875,
            "end_logit": -1.740234375,
            "text": "Emmanuelle Charpentier and Jennifer Doudna for their discovery of the CRISPR/Cas9",
            "probability": 0.004436492919921875
        },
        {
            "start_logit": 4.10546875,
            "end_logit": -4.265625,
            "text": "Emmanuelle Charpentier and Jennifer Doudna",
            "probability": 0.0003542900085449219
        },
        {
            "start_logit": 4.10546875,
            "end_logit": -4.875,
            "text": "Emmanuelle Charpentier and Jennifer Doudna for their discovery of the CRISPR/Cas9 genetic scissors",
            "probability": 0.00019180774688720703
        },
        {
            "start_logit": 4.10546875,
            "end_logit": -5.4375,
            "text": "Emmanuelle Charpe",
            "probability": 0.0001093149185180664
        },
        {
            "start_logit": -5.8125,
            "end_logit": 4.2890625,
            "text": "Katherine Uyhazi and renowned gene therapy pioneer Jean Bennett",
            "probability": 9.059906005859375e-05
        },
        {
            "start_logit": 4.10546875,
            "end_logit": -5.7734375,
            "text": "Emmanuelle Charpentier and Jennifer Do",
            "probability": 7.873773574829102e-05
        },
        {
            "start_logit": 4.10546875,
            "end_logit": -5.96484375,
            "text": "Emmanuelle Charpent",
            "probability": 6.479024887084961e-05
        },
        {
            "start_logit": 4.10546875,
            "end_logit": -6.20703125,
            "text": "Emmanuelle",
            "probability": 5.08427619934082e-05
        },
        {
            "start_logit": -6.86328125,
            "end_logit": 4.2890625,
            "text": "t",
            "probability": 3.1828880310058594e-05
        },
        {
            "start_logit": 4.10546875,
            "end_logit": -6.96875,
            "text": "Emmanuel",
            "probability": 2.3663043975830078e-05
        },
        {
            "start_logit": 4.10546875,
            "end_logit": -7.25390625,
            "text": "Emmanuelle Charpentier and Jennifer",
            "probability": 1.7881393432617188e-05
        },
        {
            "start_logit": -6.86328125,
            "end_logit": 3.63671875,
            "text": "t share their perspective on the 2020 Nobel Prize in Chemistry awarded to Emmanuelle Charpentier",
            "probability": 1.6510486602783203e-05
        },
        {
            "start_logit": 4.10546875,
            "end_logit": -7.37890625,
            "text": "Emmanuelle Charpentier and Jennifer Doudna for their discovery of the CRISPR/Cas9 genetic sciss",
            "probability": 1.5735626220703125e-05
        },
        {
            "start_logit": 4.10546875,
            "end_logit": -7.67578125,
            "text": "Emmanuelle Char",
            "probability": 1.1682510375976562e-05
        },
        {
            "start_logit": 4.10546875,
            "end_logit": -7.80859375,
            "text": "Emmanuelle Charpentier and Jennifer Doudna for their discovery of the",
            "probability": 1.0251998901367188e-05
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 4.2890625,
            "text": "Bennett",
            "probability": 9.655952453613281e-06
        },
        {
            "start_logit": 4.10546875,
            "end_logit": -7.875,
            "text": "Emmanuelle Charpentier and Jennifer Doud",
            "probability": 9.5367431640625e-06
        }
    ],
    "52eea509c8da89891000000d_1": [
        {
            "start_logit": 13.296875,
            "end_logit": 12.1640625,
            "text": "KCNQ1",
            "probability": 1.0
        },
        {
            "start_logit": 13.296875,
            "end_logit": -3.841796875,
            "text": "KCNQ",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.296875,
            "end_logit": -4.1171875,
            "text": "KCN",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.296875,
            "end_logit": -6.39453125,
            "text": "KCNQ1 gene",
            "probability": 0.0
        },
        {
            "start_logit": -6.12890625,
            "end_logit": 12.1640625,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": 13.296875,
            "end_logit": -9.6015625,
            "text": "KCNQ1 gene.",
            "probability": 0.0
        },
        {
            "start_logit": -9.7265625,
            "end_logit": 12.1640625,
            "text": "Q1",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 12.1640625,
            "text": "LQTS) 1 is the most common type of inherited LQTS and is linked to mutations in the KCNQ1",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 12.1640625,
            "text": "LQTS and is linked to mutations in the KCNQ1",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 12.1640625,
            "text": "Long QT syndrome (LQTS) 1 is the most common type of inherited LQTS and is linked to mutations in the KCNQ1",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 12.1640625,
            "text": "1 is the most common type of inherited LQTS and is linked to mutations in the KCNQ1",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 12.1640625,
            "text": "syndrome (LQTS) 1 is the most common type of inherited LQTS and is linked to mutations in the KCNQ1",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 12.1640625,
            "text": "QT syndrome (LQTS) 1 is the most common type of inherited LQTS and is linked to mutations in the KCNQ1",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 12.1640625,
            "text": "(LQTS) 1 is the most common type of inherited LQTS and is linked to mutations in the KCNQ1",
            "probability": 0.0
        },
        {
            "start_logit": -6.12890625,
            "end_logit": -6.39453125,
            "text": "1 gene",
            "probability": 0.0
        },
        {
            "start_logit": -9.7265625,
            "end_logit": -3.841796875,
            "text": "Q",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": -3.841796875,
            "text": "LQTS) 1 is the most common type of inherited LQTS and is linked to mutations in the KCNQ",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": -3.841796875,
            "text": "LQTS and is linked to mutations in the KCNQ",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": -3.841796875,
            "text": "Long QT syndrome (LQTS) 1 is the most common type of inherited LQTS and is linked to mutations in the KCNQ",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": -4.1171875,
            "text": "LQTS) 1 is the most common type of inherited LQTS and is linked to mutations in the KCN",
            "probability": 0.0
        }
    ],
    "52eea509c8da89891000000d_2": [
        {
            "start_logit": 9.6171875,
            "end_logit": 9.546875,
            "text": "KCNQ1",
            "probability": 0.90869140625
        },
        {
            "start_logit": 7.30859375,
            "end_logit": 9.546875,
            "text": "KQT-like, voltage-gated potassium channel-1 gene (KCNQ1",
            "probability": 0.09136962890625
        },
        {
            "start_logit": 7.30859375,
            "end_logit": 3.234375,
            "text": "KQT-like, voltage-gated potassium channel-1",
            "probability": 0.00016570091247558594
        },
        {
            "start_logit": -3.109375,
            "end_logit": 9.546875,
            "text": "voltage-gated potassium channel-1 gene (KCNQ1",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -3.984375,
            "text": "KCNQ",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -5.6328125,
            "text": "KCN",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.30859375,
            "end_logit": -3.984375,
            "text": "KQT-like, voltage-gated potassium channel-1 gene (KCNQ",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -6.6328125,
            "text": "KCNQ1; MIM 607542)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.30859375,
            "end_logit": -4.84375,
            "text": "KQT",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -7.3203125,
            "text": "KCNQ1;",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -7.33984375,
            "text": "KCNQ1; MIM 607542",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 9.546875,
            "text": "1 gene (KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -7.55859375,
            "text": "KCNQ1; MIM",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 9.546875,
            "text": "1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.30859375,
            "end_logit": -5.6328125,
            "text": "KQT-like, voltage-gated potassium channel-1 gene (KCN",
            "probability": 0.0
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -7.984375,
            "text": "KCNQ1; MIM 60",
            "probability": 0.0
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -8.2578125,
            "text": "KCNQ1; MIM 6075",
            "probability": 0.0
        },
        {
            "start_logit": 7.30859375,
            "end_logit": -5.9609375,
            "text": "KQT-like",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 9.546875,
            "text": "channel-1 gene (KCNQ1",
            "probability": 0.0
        },
        {
            "start_logit": 7.30859375,
            "end_logit": -6.3515625,
            "text": "KQT-like, voltage-gated potassium channel-1 gene",
            "probability": 0.0
        }
    ],
    "52eea509c8da89891000000d_3": [
        {
            "start_logit": 5.98828125,
            "end_logit": 3.5,
            "text": "KCNQ1",
            "probability": 1.0
        },
        {
            "start_logit": 5.98828125,
            "end_logit": -6.5,
            "text": "KCNQ",
            "probability": 4.5418739318847656e-05
        },
        {
            "start_logit": 5.98828125,
            "end_logit": -7.9140625,
            "text": "KCNQ1, account",
            "probability": 1.1146068572998047e-05
        },
        {
            "start_logit": 5.98828125,
            "end_logit": -8.078125,
            "text": "KCN",
            "probability": 9.357929229736328e-06
        },
        {
            "start_logit": 5.98828125,
            "end_logit": -8.5625,
            "text": "KCNQ1,",
            "probability": 5.781650543212891e-06
        },
        {
            "start_logit": 5.98828125,
            "end_logit": -9.3125,
            "text": "KCNQ1, account for the most common",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": -7.08984375,
            "end_logit": 3.5,
            "text": "voltage-gated potassium channel, KCNQ1",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 5.98828125,
            "end_logit": -9.671875,
            "text": "KCNQ1, account for the most common form of LQTS, LQTS1.",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 5.98828125,
            "end_logit": -10.078125,
            "text": "KCNQ1, account for the most common form of LQTS",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 5.98828125,
            "end_logit": -10.1953125,
            "text": "KCNQ1, account for the most",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 5.98828125,
            "end_logit": -10.34375,
            "text": "KCNQ1, account for the most common form",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -9.015625,
            "end_logit": 3.5,
            "text": ", KCNQ1",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -9.390625,
            "end_logit": 3.5,
            "text": "1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -9.65625,
            "end_logit": 3.5,
            "text": "potassium channel, KCNQ1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.015625,
            "end_logit": 3.5,
            "text": "cardiac voltage-gated potassium channel, KCNQ1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 3.5,
            "text": "in a cardiac voltage-gated potassium channel, KCNQ1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.28125,
            "end_logit": 3.5,
            "text": "channel, KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.53125,
            "end_logit": 3.5,
            "text": "Mutations in a cardiac voltage-gated potassium channel, KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.08984375,
            "end_logit": -5.9609375,
            "text": "voltage-gated potassium channel",
            "probability": 0.0
        },
        {
            "start_logit": -7.08984375,
            "end_logit": -6.5,
            "text": "voltage-gated potassium channel, KCNQ",
            "probability": 0.0
        }
    ],
    "52eea509c8da89891000000d_4": [
        {
            "start_logit": 12.8359375,
            "end_logit": 11.7578125,
            "text": "HERG",
            "probability": 1.0
        },
        {
            "start_logit": 12.8359375,
            "end_logit": -5.18359375,
            "text": "HER",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.5234375,
            "end_logit": 11.7578125,
            "text": "KCNH2 (HERG",
            "probability": 0.0
        },
        {
            "start_logit": 12.8359375,
            "end_logit": -7.79296875,
            "text": "HERG)",
            "probability": 0.0
        },
        {
            "start_logit": -7.0,
            "end_logit": 11.7578125,
            "text": "G",
            "probability": 0.0
        },
        {
            "start_logit": -8.4375,
            "end_logit": 11.7578125,
            "text": "H2 (HERG",
            "probability": 0.0
        },
        {
            "start_logit": -8.921875,
            "end_logit": 11.7578125,
            "text": "KCNQ1 and KCNH2 (HERG",
            "probability": 0.0
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 11.7578125,
            "text": "mSSCP and sequencing), genomic DNA was obtained from patients to determine the expression levels of the genes KCNQ1 and KCNH2 (HERG",
            "probability": 0.0
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 11.7578125,
            "text": "and KCNH2 (HERG",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": 11.7578125,
            "text": "(HERG",
            "probability": 0.0
        },
        {
            "start_logit": -5.5234375,
            "end_logit": -2.923828125,
            "text": "KCNH2",
            "probability": 0.0
        },
        {
            "start_logit": -5.5234375,
            "end_logit": -5.18359375,
            "text": "KCNH2 (HER",
            "probability": 0.0
        },
        {
            "start_logit": -5.5234375,
            "end_logit": -5.625,
            "text": "KCNH2 (",
            "probability": 0.0
        },
        {
            "start_logit": -8.4375,
            "end_logit": -2.923828125,
            "text": "H2",
            "probability": 0.0
        },
        {
            "start_logit": -5.5234375,
            "end_logit": -6.25,
            "text": "KCN",
            "probability": 0.0
        },
        {
            "start_logit": -8.921875,
            "end_logit": -2.923828125,
            "text": "KCNQ1 and KCNH2",
            "probability": 0.0
        },
        {
            "start_logit": -9.8203125,
            "end_logit": -2.923828125,
            "text": "mSSCP and sequencing), genomic DNA was obtained from patients to determine the expression levels of the genes KCNQ1 and KCNH2",
            "probability": 0.0
        },
        {
            "start_logit": -9.828125,
            "end_logit": -2.923828125,
            "text": "using mSSCP and sequencing), genomic DNA was obtained from patients to determine the expression levels of the genes KCNQ1 and KCNH2",
            "probability": 0.0
        },
        {
            "start_logit": -10.0390625,
            "end_logit": -2.923828125,
            "text": "and KCNH2",
            "probability": 0.0
        },
        {
            "start_logit": -5.5234375,
            "end_logit": -7.79296875,
            "text": "KCNH2 (HERG)",
            "probability": 0.0
        }
    ],
    "52eea509c8da89891000000d_5": [
        {
            "start_logit": 11.5859375,
            "end_logit": 10.4453125,
            "text": "KCNJ5",
            "probability": 1.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -4.16015625,
            "text": "KCNJ",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -4.82421875,
            "text": "KCN",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -6.75390625,
            "text": "KCNJ5 (locus name LQT13",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.32421875,
            "end_logit": 10.4453125,
            "text": "5",
            "probability": 0.0
        },
        {
            "start_logit": -0.33642578125,
            "end_logit": 1.2470703125,
            "text": "KCNE1",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": 10.4453125,
            "text": "J5",
            "probability": 0.0
        },
        {
            "start_logit": -5.3359375,
            "end_logit": 1.2470703125,
            "text": "SCN5A (locus name LQT3) are the most common. Other, less frequently involved genes are KCNE1",
            "probability": 0.0
        },
        {
            "start_logit": -0.33642578125,
            "end_logit": -4.41015625,
            "text": "KCN",
            "probability": 0.0
        },
        {
            "start_logit": -6.9609375,
            "end_logit": 1.2470703125,
            "text": "E1",
            "probability": 0.0
        },
        {
            "start_logit": -8.6953125,
            "end_logit": 1.2470703125,
            "text": "and SCN5A (locus name LQT3) are the most common. Other, less frequently involved genes are KCNE1",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": 1.2470703125,
            "text": "5A (locus name LQT3) are the most common. Other, less frequently involved genes are KCNE1",
            "probability": 0.0
        },
        {
            "start_logit": -5.3359375,
            "end_logit": -3.04296875,
            "text": "SCN5A",
            "probability": 0.0
        },
        {
            "start_logit": -5.3359375,
            "end_logit": -4.41015625,
            "text": "SCN5A (locus name LQT3) are the most common. Other, less frequently involved genes are KCN",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": -3.04296875,
            "text": "KCNQ1 (locus name LQT1), KCNH2 (locus name LQT2) and SCN5A",
            "probability": 0.0
        },
        {
            "start_logit": -8.609375,
            "end_logit": -3.04296875,
            "text": "of which KCNQ1 (locus name LQT1), KCNH2 (locus name LQT2) and SCN5A",
            "probability": 0.0
        },
        {
            "start_logit": -8.640625,
            "end_logit": -3.04296875,
            "text": ", KCNH2 (locus name LQT2) and SCN5A",
            "probability": 0.0
        },
        {
            "start_logit": -8.6953125,
            "end_logit": -3.04296875,
            "text": "and SCN5A",
            "probability": 0.0
        },
        {
            "start_logit": -8.8984375,
            "end_logit": -3.04296875,
            "text": "KCNH2 (locus name LQT2) and SCN5A",
            "probability": 0.0
        },
        {
            "start_logit": -5.3359375,
            "end_logit": -6.66015625,
            "text": "SCN",
            "probability": 0.0
        }
    ],
    "52eea509c8da89891000000d_6": [
        {
            "start_logit": 12.6484375,
            "end_logit": 11.75,
            "text": "KCNQ1",
            "probability": 1.0
        },
        {
            "start_logit": 12.6484375,
            "end_logit": -3.142578125,
            "text": "KCNQ",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 12.6484375,
            "end_logit": -4.48046875,
            "text": "KCN",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.6484375,
            "end_logit": -4.921875,
            "text": "KCNQ1 gene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.47265625,
            "end_logit": 11.75,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": 12.6484375,
            "end_logit": -9.5,
            "text": "KCNQ1 gene.",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": 11.75,
            "text": "Q1",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 11.75,
            "text": "LQT1) is caused by mutations in the KCNQ1",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 11.75,
            "text": "long-QT syndrome (LQT1) is caused by mutations in the KCNQ1",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 11.75,
            "text": "1 long-QT syndrome (LQT1) is caused by mutations in the KCNQ1",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 11.75,
            "text": "Type-1 long-QT syndrome (LQT1) is caused by mutations in the KCNQ1",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 11.75,
            "text": "-1 long-QT syndrome (LQT1) is caused by mutations in the KCNQ1",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 11.75,
            "text": "syndrome (LQT1) is caused by mutations in the KCNQ1",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 11.75,
            "text": "QT syndrome (LQT1) is caused by mutations in the KCNQ1",
            "probability": 0.0
        },
        {
            "start_logit": -6.47265625,
            "end_logit": -4.921875,
            "text": "1 gene",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": -3.142578125,
            "text": "Q",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": -3.142578125,
            "text": "LQT1) is caused by mutations in the KCNQ",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": -3.142578125,
            "text": "long-QT syndrome (LQT1) is caused by mutations in the KCNQ",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": -3.142578125,
            "text": "1 long-QT syndrome (LQT1) is caused by mutations in the KCNQ",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": -3.142578125,
            "text": "Type-1 long-QT syndrome (LQT1) is caused by mutations in the KCNQ",
            "probability": 0.0
        }
    ],
    "52eea509c8da89891000000d_7": [
        {
            "start_logit": 13.3046875,
            "end_logit": 12.734375,
            "text": "human ether-a-go-go-related gene",
            "probability": 1.0
        },
        {
            "start_logit": -0.163330078125,
            "end_logit": 12.734375,
            "text": "HERG (human ether-a-go-go-related gene",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 13.3046875,
            "end_logit": -2.6953125,
            "text": "human ether-a-go-go",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.3046875,
            "end_logit": -3.9296875,
            "text": "human ether-a-go-go-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.3046875,
            "end_logit": -3.9375,
            "text": "human ether-a-go",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.3046875,
            "end_logit": -4.0390625,
            "text": "human",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.25,
            "end_logit": 12.734375,
            "text": "gene",
            "probability": 0.0
        },
        {
            "start_logit": 13.3046875,
            "end_logit": -6.95703125,
            "text": "human ether-a-go-go-related gene)",
            "probability": 0.0
        },
        {
            "start_logit": -6.609375,
            "end_logit": 12.734375,
            "text": "ether-a-go-go-related gene",
            "probability": 0.0
        },
        {
            "start_logit": 13.3046875,
            "end_logit": -7.75,
            "text": "human ether",
            "probability": 0.0
        },
        {
            "start_logit": 13.3046875,
            "end_logit": -7.81640625,
            "text": "human ether-",
            "probability": 0.0
        },
        {
            "start_logit": 13.3046875,
            "end_logit": -7.89453125,
            "text": "human ether-a-go-go-",
            "probability": 0.0
        },
        {
            "start_logit": 13.3046875,
            "end_logit": -8.203125,
            "text": "human ether-a",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 12.734375,
            "text": "G (human ether-a-go-go-related gene",
            "probability": 0.0
        },
        {
            "start_logit": -9.0390625,
            "end_logit": 12.734375,
            "text": "Kv7.1), whereas drug-induced LQTS is a consequence of HERG (human ether-a-go-go-related gene",
            "probability": 0.0
        },
        {
            "start_logit": -9.734375,
            "end_logit": 12.734375,
            "text": "a-go-go-related gene",
            "probability": 0.0
        },
        {
            "start_logit": -9.78125,
            "end_logit": 12.734375,
            "text": "go-related gene",
            "probability": 0.0
        },
        {
            "start_logit": -9.8046875,
            "end_logit": 12.734375,
            "text": "go-go-related gene",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 12.734375,
            "text": "LQTS is a consequence of HERG (human ether-a-go-go-related gene",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 12.734375,
            "text": "1), whereas drug-induced LQTS is a consequence of HERG (human ether-a-go-go-related gene",
            "probability": 0.0
        }
    ],
    "52eea509c8da89891000000d_8": [
        {
            "start_logit": 12.1328125,
            "end_logit": 11.046875,
            "text": "KCNQ1",
            "probability": 1.0
        },
        {
            "start_logit": 12.1328125,
            "end_logit": -4.453125,
            "text": "KCNQ",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 12.1328125,
            "end_logit": -4.96875,
            "text": "KCN",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.1328125,
            "end_logit": -7.1328125,
            "text": "KCNQ1 induce",
            "probability": 0.0
        },
        {
            "start_logit": -6.59375,
            "end_logit": 11.046875,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": -7.796875,
            "end_logit": 11.046875,
            "text": "voltage-gated potassium channel subunit KCNQ1",
            "probability": 0.0
        },
        {
            "start_logit": -7.8046875,
            "end_logit": 11.046875,
            "text": "subunit KCNQ1",
            "probability": 0.0
        },
        {
            "start_logit": 12.1328125,
            "end_logit": -9.3046875,
            "text": "KCNQ1 induce the most common",
            "probability": 0.0
        },
        {
            "start_logit": 12.1328125,
            "end_logit": -9.3671875,
            "text": "KCNQ1 induce the most common form of LQTS.",
            "probability": 0.0
        },
        {
            "start_logit": 12.1328125,
            "end_logit": -9.734375,
            "text": "KCNQ1 induce the most common form of LQTS",
            "probability": 0.0
        },
        {
            "start_logit": 12.1328125,
            "end_logit": -10.03125,
            "text": "KCNQ1 induce the most",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": 11.046875,
            "text": "potassium channel subunit KCNQ1",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": 11.046875,
            "text": "in the voltage-gated potassium channel subunit KCNQ1",
            "probability": 0.0
        },
        {
            "start_logit": -7.796875,
            "end_logit": -4.453125,
            "text": "voltage-gated potassium channel subunit KCNQ",
            "probability": 0.0
        },
        {
            "start_logit": -7.8046875,
            "end_logit": -4.453125,
            "text": "subunit KCNQ",
            "probability": 0.0
        },
        {
            "start_logit": -7.796875,
            "end_logit": -4.96875,
            "text": "voltage-gated potassium channel subunit KCN",
            "probability": 0.0
        },
        {
            "start_logit": -7.8046875,
            "end_logit": -4.96875,
            "text": "subunit KCN",
            "probability": 0.0
        },
        {
            "start_logit": -7.796875,
            "end_logit": -5.515625,
            "text": "voltage-gated potassium channel",
            "probability": 0.0
        },
        {
            "start_logit": -6.59375,
            "end_logit": -7.1328125,
            "text": "1 induce",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": -4.453125,
            "text": "potassium channel subunit KCNQ",
            "probability": 0.0
        }
    ],
    "52eea509c8da89891000000d_9": [
        {
            "start_logit": 12.78125,
            "end_logit": 12.7421875,
            "text": "KCNE1",
            "probability": 1.0
        },
        {
            "start_logit": 12.78125,
            "end_logit": -1.7548828125,
            "text": "KCNE1 and KCNE2",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 12.78125,
            "end_logit": -4.4296875,
            "text": "KCNE1 and KCNE2 and the accessory protein Ankyrin-B",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.78125,
            "end_logit": -5.10546875,
            "text": "KCN",
            "probability": 0.0
        },
        {
            "start_logit": -5.3828125,
            "end_logit": 12.7421875,
            "text": "E1",
            "probability": 0.0
        },
        {
            "start_logit": 12.78125,
            "end_logit": -6.015625,
            "text": "KCNE1 and KCN",
            "probability": 0.0
        },
        {
            "start_logit": 12.78125,
            "end_logit": -6.5234375,
            "text": "KCNE1 and KCNE2 and the accessory protein Ankyrin-B gene",
            "probability": 0.0
        },
        {
            "start_logit": 12.78125,
            "end_logit": -6.94921875,
            "text": "KCNE1 and KCNE2 and the accessory protein",
            "probability": 0.0
        },
        {
            "start_logit": 12.78125,
            "end_logit": -7.046875,
            "text": "KCNE1 and KCNE2 and the accessory protein Ankyrin",
            "probability": 0.0
        },
        {
            "start_logit": 12.78125,
            "end_logit": -7.421875,
            "text": "KCNE1 and",
            "probability": 0.0
        },
        {
            "start_logit": 12.78125,
            "end_logit": -7.5625,
            "text": "KCNE1 and KCNE2 and the accessory protein Ankyrin-B gene,",
            "probability": 0.0
        },
        {
            "start_logit": 12.78125,
            "end_logit": -7.83984375,
            "text": "KCNE1 and KCNE2 and the accessory protein Ank",
            "probability": 0.0
        },
        {
            "start_logit": 12.78125,
            "end_logit": -8.1796875,
            "text": "KCNE1 and KCNE2 and the accessory protein Ankyrin-",
            "probability": 0.0
        },
        {
            "start_logit": 12.78125,
            "end_logit": -8.234375,
            "text": "KCNE1 and KCNE2 and",
            "probability": 0.0
        },
        {
            "start_logit": -9.1953125,
            "end_logit": 12.7421875,
            "text": "SCN5A, KCNE1",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": 12.7421875,
            "text": "KCNH2, SCN5A, KCNE1",
            "probability": 0.0
        },
        {
            "start_logit": -9.7890625,
            "end_logit": 12.7421875,
            "text": "KCNQ1, KCNH2, SCN5A, KCNE1",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": 12.7421875,
            "text": "ion channel genes, KCNQ1, KCNH2, SCN5A, KCNE1",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 12.7421875,
            "text": ", KCNE1",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 12.7421875,
            "text": "Q1, KCNH2, SCN5A, KCNE1",
            "probability": 0.0
        }
    ],
    "52eea509c8da89891000000d_10": [
        {
            "start_logit": 13.171875,
            "end_logit": 12.625,
            "text": "KCNQ1",
            "probability": 1.0
        },
        {
            "start_logit": 13.171875,
            "end_logit": -4.33203125,
            "text": "KCN",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.171875,
            "end_logit": -4.95703125,
            "text": "KCNQ",
            "probability": 0.0
        },
        {
            "start_logit": -5.796875,
            "end_logit": 12.625,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": -9.0859375,
            "end_logit": 12.625,
            "text": "potassium channel gene KCNQ1",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": 12.625,
            "text": "Q1",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 12.625,
            "text": "carriers of two amino acid alterations in cis (V254M-V417M) in the cardiac potassium channel gene KCNQ1",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": 12.625,
            "text": "cardiac potassium channel gene KCNQ1",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 12.625,
            "text": "V254M-V417M) in the cardiac potassium channel gene KCNQ1",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 12.625,
            "text": "amino acid alterations in cis (V254M-V417M) in the cardiac potassium channel gene KCNQ1",
            "probability": 0.0
        },
        {
            "start_logit": -9.0859375,
            "end_logit": -4.33203125,
            "text": "potassium channel gene KCN",
            "probability": 0.0
        },
        {
            "start_logit": -9.0859375,
            "end_logit": -4.95703125,
            "text": "potassium channel gene KCNQ",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": -4.33203125,
            "text": "carriers of two amino acid alterations in cis (V254M-V417M) in the cardiac potassium channel gene KCN",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": -4.33203125,
            "text": "cardiac potassium channel gene KCN",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": -4.95703125,
            "text": "Q",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": -4.33203125,
            "text": "V254M-V417M) in the cardiac potassium channel gene KCN",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": -4.33203125,
            "text": "Seven family members were carriers of two amino acid alterations in cis (V254M-V417M) in the cardiac potassium channel gene KCN",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": -4.95703125,
            "text": "carriers of two amino acid alterations in cis (V254M-V417M) in the cardiac potassium channel gene KCNQ",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": -4.95703125,
            "text": "cardiac potassium channel gene KCNQ",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": -4.33203125,
            "text": "amino acid alterations in cis (V254M-V417M) in the cardiac potassium channel gene KCN",
            "probability": 0.0
        }
    ],
    "52eea509c8da89891000000d_11": [
        {
            "start_logit": 11.9921875,
            "end_logit": 11.765625,
            "text": "KVLQT1",
            "probability": 1.0
        },
        {
            "start_logit": 11.9921875,
            "end_logit": -4.07421875,
            "text": "KVL",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.015625,
            "end_logit": 11.765625,
            "text": "KCNQ1 (formerly called KVLQT1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.9921875,
            "end_logit": -5.7265625,
            "text": "KV",
            "probability": 0.0
        },
        {
            "start_logit": 11.9921875,
            "end_logit": -6.20703125,
            "text": "KVLQ",
            "probability": 0.0
        },
        {
            "start_logit": -6.640625,
            "end_logit": 11.765625,
            "text": "T1",
            "probability": 0.0
        },
        {
            "start_logit": 11.9921875,
            "end_logit": -7.234375,
            "text": "KVLQT1)",
            "probability": 0.0
        },
        {
            "start_logit": 11.9921875,
            "end_logit": -7.609375,
            "text": "KVLQT1) is a Shaker-like voltage-gated potassium channel gene",
            "probability": 0.0
        },
        {
            "start_logit": 11.9921875,
            "end_logit": -7.828125,
            "text": "KVLQT1) is a Shaker",
            "probability": 0.0
        },
        {
            "start_logit": 11.9921875,
            "end_logit": -8.171875,
            "text": "KVLQT1) is a Shaker-like voltage-gated potassium channel",
            "probability": 0.0
        },
        {
            "start_logit": -8.8125,
            "end_logit": 11.765625,
            "text": "1 (formerly called KVLQT1",
            "probability": 0.0
        },
        {
            "start_logit": 11.9921875,
            "end_logit": -9.1875,
            "text": "KVLQT1) is a Shaker-like",
            "probability": 0.0
        },
        {
            "start_logit": 11.9921875,
            "end_logit": -9.2890625,
            "text": "KVLQT1) is a Shaker-like voltage-gated potassium channel gene responsible",
            "probability": 0.0
        },
        {
            "start_logit": 11.9921875,
            "end_logit": -9.2890625,
            "text": "KVLQT1) is a",
            "probability": 0.0
        },
        {
            "start_logit": -9.1796875,
            "end_logit": 11.765625,
            "text": "QT1",
            "probability": 0.0
        },
        {
            "start_logit": 11.9921875,
            "end_logit": -9.4453125,
            "text": "KVLQT1) is",
            "probability": 0.0
        },
        {
            "start_logit": 11.9921875,
            "end_logit": -9.4453125,
            "text": "KVLQT1) is a Sh",
            "probability": 0.0
        },
        {
            "start_logit": 11.9921875,
            "end_logit": -9.59375,
            "text": "KVLQT1) is a Shaker-like voltage-gated potassium channel gene responsible for the LQT1 sub-type of LQTS",
            "probability": 0.0
        },
        {
            "start_logit": -9.4140625,
            "end_logit": 11.765625,
            "text": "Q1 (formerly called KVLQT1",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 11.765625,
            "text": "LQT1",
            "probability": 0.0
        }
    ],
    "52eea509c8da89891000000d_12": [
        {
            "start_logit": 13.1484375,
            "end_logit": 12.734375,
            "text": "KCNE1",
            "probability": 1.0
        },
        {
            "start_logit": 13.1484375,
            "end_logit": 0.244873046875,
            "text": "KCNE1, and KCNE2",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": 13.1484375,
            "end_logit": -4.79296875,
            "text": "KCN",
            "probability": 0.0
        },
        {
            "start_logit": 13.1484375,
            "end_logit": -4.8203125,
            "text": "KCNE1, and KCN",
            "probability": 0.0
        },
        {
            "start_logit": -4.66015625,
            "end_logit": 12.734375,
            "text": "HERG, SCN5A, KCNE1",
            "probability": 0.0
        },
        {
            "start_logit": -5.4375,
            "end_logit": 12.734375,
            "text": "E1",
            "probability": 0.0
        },
        {
            "start_logit": 13.1484375,
            "end_logit": -6.74609375,
            "text": "KCNE1, and",
            "probability": 0.0
        },
        {
            "start_logit": -7.33984375,
            "end_logit": 12.734375,
            "text": "SCN5A, KCNE1",
            "probability": 0.0
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 12.734375,
            "text": "KVLQT1, HERG, SCN5A, KCNE1",
            "probability": 0.0
        },
        {
            "start_logit": 13.1484375,
            "end_logit": -8.375,
            "text": "KCNE1,",
            "probability": 0.0
        },
        {
            "start_logit": 13.1484375,
            "end_logit": -9.0703125,
            "text": "KCNE1, and KCNE2.",
            "probability": 0.0
        },
        {
            "start_logit": -9.078125,
            "end_logit": 12.734375,
            "text": "G, SCN5A, KCNE1",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 12.734375,
            "text": "QT1, HERG, SCN5A, KCNE1",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 12.734375,
            "text": "T1, HERG, SCN5A, KCNE1",
            "probability": 0.0
        },
        {
            "start_logit": -10.328125,
            "end_logit": 12.734375,
            "text": "LQTS: KVLQT1, HERG, SCN5A, KCNE1",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": 12.734375,
            "text": ", KCNE1",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 12.734375,
            "text": "LQT1, HERG, SCN5A, KCNE1",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 12.734375,
            "text": ", HERG, SCN5A, KCNE1",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 12.734375,
            "text": ", SCN5A, KCNE1",
            "probability": 0.0
        },
        {
            "start_logit": -2.744140625,
            "end_logit": 0.244873046875,
            "text": "KCNE2",
            "probability": 0.0
        }
    ],
    "52eea509c8da89891000000d_13": [
        {
            "start_logit": 11.3125,
            "end_logit": 11.5859375,
            "text": "KVLQT1",
            "probability": 1.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -3.380859375,
            "text": "KVL",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 11.3125,
            "end_logit": -5.2734375,
            "text": "KVLQ",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.3125,
            "end_logit": -6.05078125,
            "text": "KV",
            "probability": 0.0
        },
        {
            "start_logit": -6.546875,
            "end_logit": 11.5859375,
            "text": "T1",
            "probability": 0.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -7.078125,
            "text": "KVLQT1, a gene that encodes",
            "probability": 0.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -7.0859375,
            "text": "KVLQT1, a gene",
            "probability": 0.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -7.64453125,
            "text": "KVLQT1, a",
            "probability": 0.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -7.8125,
            "text": "KVLQT1,",
            "probability": 0.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -8.375,
            "text": "KVLQT1, a gene that encodes the pore-forming alpha-subunit of a K+ channel",
            "probability": 0.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -8.5625,
            "text": "KVLQT1, a gene that encodes the",
            "probability": 0.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -8.65625,
            "text": "KVLQT1, a gene that",
            "probability": 0.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -8.734375,
            "text": "KVLQT1, a gene that encodes the pore-forming alpha-subunit",
            "probability": 0.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -8.890625,
            "text": "KVLQT1, a gene that encodes the pore-forming alpha-subunit of",
            "probability": 0.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -8.8984375,
            "text": "KVLQT1, a gene that encodes the pore-forming alpha-subunit of a",
            "probability": 0.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -8.9140625,
            "text": "KVLQT1, a gene that encodes the pore-forming alpha",
            "probability": 0.0
        },
        {
            "start_logit": -9.2734375,
            "end_logit": 11.5859375,
            "text": "QT1",
            "probability": 0.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -9.1171875,
            "text": "KVLQT1, a gene that encodes the pore-forming alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 11.5859375,
            "text": "LQT1 is a mutation in KVLQT1",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 11.5859375,
            "text": "LQT1",
            "probability": 0.0
        }
    ],
    "52eea509c8da89891000000d_14": [
        {
            "start_logit": 13.0625,
            "end_logit": 11.4296875,
            "text": "HERG",
            "probability": 1.0
        },
        {
            "start_logit": 13.0625,
            "end_logit": -4.7109375,
            "text": "HER",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.2109375,
            "end_logit": 11.4296875,
            "text": "human ether-a-go-go-related gene (HERG",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.0625,
            "end_logit": -6.94921875,
            "text": "HERG)",
            "probability": 0.0
        },
        {
            "start_logit": -5.375,
            "end_logit": 11.4296875,
            "text": "ether-a-go-go-related gene (HERG",
            "probability": 0.0
        },
        {
            "start_logit": -7.30859375,
            "end_logit": 11.4296875,
            "text": "G",
            "probability": 0.0
        },
        {
            "start_logit": -9.8671875,
            "end_logit": 11.4296875,
            "text": "gene (HERG",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 11.4296875,
            "text": "go-related gene (HERG",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": 11.4296875,
            "text": "related gene (HERG",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 11.4296875,
            "text": "a-go-go-related gene (HERG",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 11.4296875,
            "text": "go-go-related gene (HERG",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 11.4296875,
            "text": "Taiwanese kindred. Clinical and genetic analyses revealed that a mutation was linked to the human ether-a-go-go-related gene (HERG",
            "probability": 0.0
        },
        {
            "start_logit": -3.2109375,
            "end_logit": -0.411865234375,
            "text": "human ether-a-go-go-related gene",
            "probability": 0.0
        },
        {
            "start_logit": -5.375,
            "end_logit": -0.411865234375,
            "text": "ether-a-go-go-related gene",
            "probability": 0.0
        },
        {
            "start_logit": -3.2109375,
            "end_logit": -3.224609375,
            "text": "human ether-a-go-go-related",
            "probability": 0.0
        },
        {
            "start_logit": -3.2109375,
            "end_logit": -3.830078125,
            "text": "human ether-a-go-go",
            "probability": 0.0
        },
        {
            "start_logit": -3.2109375,
            "end_logit": -4.7109375,
            "text": "human ether-a-go-go-related gene (HER",
            "probability": 0.0
        },
        {
            "start_logit": -3.2109375,
            "end_logit": -5.16015625,
            "text": "human ether-a-go-go-related gene (",
            "probability": 0.0
        },
        {
            "start_logit": -5.375,
            "end_logit": -3.224609375,
            "text": "ether-a-go-go-related",
            "probability": 0.0
        },
        {
            "start_logit": -3.2109375,
            "end_logit": -5.4296875,
            "text": "human ether-a-go",
            "probability": 0.0
        }
    ],
    "52eea509c8da89891000000d_15": [
        {
            "start_logit": 11.375,
            "end_logit": 11.4140625,
            "text": "KVLQT1",
            "probability": 1.0
        },
        {
            "start_logit": 11.375,
            "end_logit": 2.57421875,
            "text": "KVLQT1 (also known as KCNQ1 and KCNA9",
            "probability": 0.00014650821685791016
        },
        {
            "start_logit": 11.375,
            "end_logit": -2.529296875,
            "text": "KVLQT1 (also known as KCNQ1",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 11.375,
            "end_logit": -2.748046875,
            "text": "KVL",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 11.375,
            "end_logit": -3.5390625,
            "text": "KVLQT1 (also known as KCNQ1 and KCNA9)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 11.375,
            "end_logit": -3.693359375,
            "text": "KVLQ",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 11.375,
            "end_logit": -4.4296875,
            "text": "KVLQT1 (also known as KCNQ1 and KCNA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.375,
            "end_logit": -5.171875,
            "text": "KVLQT1 (also known as KCNQ1 and KCN",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.375,
            "end_logit": -5.62109375,
            "text": "KVLQT1 (also known as KCNQ",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.375,
            "end_logit": -5.6953125,
            "text": "KVLQT1 (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.375,
            "end_logit": -5.734375,
            "text": "KV",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.375,
            "end_logit": -6.0625,
            "text": "KVLQT1 (also known as KCN",
            "probability": 0.0
        },
        {
            "start_logit": -6.60546875,
            "end_logit": 11.4140625,
            "text": "T1",
            "probability": 0.0
        },
        {
            "start_logit": 11.375,
            "end_logit": -6.78515625,
            "text": "KVLQT1 (also known as KCNQ1 and",
            "probability": 0.0
        },
        {
            "start_logit": 1.1591796875,
            "end_logit": 2.57421875,
            "text": "KCNA9",
            "probability": 0.0
        },
        {
            "start_logit": 11.375,
            "end_logit": -7.6796875,
            "text": "KVLQT1 (also known",
            "probability": 0.0
        },
        {
            "start_logit": -9.359375,
            "end_logit": 11.4140625,
            "text": "QT1",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 11.4140625,
            "text": "LQT1",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 11.4140625,
            "text": "RWS) associated with compound heterozygosity for two mutations in the KVLQT1",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 11.4140625,
            "text": "Romano-Ward syndome (RWS) associated with compound heterozygosity for two mutations in the KVLQT1",
            "probability": 0.0
        }
    ],
    "52eea509c8da89891000000d_16": [
        {
            "start_logit": 13.34375,
            "end_logit": 13.015625,
            "text": "SCN5A",
            "probability": 1.0
        },
        {
            "start_logit": 13.34375,
            "end_logit": -4.7890625,
            "text": "SCN",
            "probability": 0.0
        },
        {
            "start_logit": -5.5234375,
            "end_logit": 13.015625,
            "text": "5A",
            "probability": 0.0
        },
        {
            "start_logit": 13.34375,
            "end_logit": -8.484375,
            "text": "SCN5A, is also mutated",
            "probability": 0.0
        },
        {
            "start_logit": 13.34375,
            "end_logit": -8.59375,
            "text": "SCN5A,",
            "probability": 0.0
        },
        {
            "start_logit": -8.8046875,
            "end_logit": 13.015625,
            "text": "sodium channel gene, SCN5A",
            "probability": 0.0
        },
        {
            "start_logit": 13.34375,
            "end_logit": -9.3828125,
            "text": "SCN5A, is also mutated in some Romano-Ward cases to produce defects in INa, the cardiac inward Na+ current",
            "probability": 0.0
        },
        {
            "start_logit": 13.34375,
            "end_logit": -9.421875,
            "text": "SCN5A, is also mutated in some Romano-Ward cases to produce defects in INa",
            "probability": 0.0
        },
        {
            "start_logit": 13.34375,
            "end_logit": -9.578125,
            "text": "SCN5A, is",
            "probability": 0.0
        },
        {
            "start_logit": 13.34375,
            "end_logit": -9.5859375,
            "text": "SCN5A, is also mutated in some Romano-Ward cases to produce defects in INa, the cardiac inward Na+ current.",
            "probability": 0.0
        },
        {
            "start_logit": 13.34375,
            "end_logit": -9.78125,
            "text": "SCN5A, is also mutated in some Romano-Ward cases to produce defects in INa, the",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": 13.015625,
            "text": "cardiac sodium channel gene, SCN5A",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 13.015625,
            "text": "channel gene, SCN5A",
            "probability": 0.0
        },
        {
            "start_logit": -8.8046875,
            "end_logit": -4.7890625,
            "text": "sodium channel gene, SCN",
            "probability": 0.0
        },
        {
            "start_logit": -5.5234375,
            "end_logit": -8.484375,
            "text": "5A, is also mutated",
            "probability": 0.0
        },
        {
            "start_logit": -5.5234375,
            "end_logit": -8.59375,
            "text": "5A,",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": -4.7890625,
            "text": "cardiac sodium channel gene, SCN",
            "probability": 0.0
        },
        {
            "start_logit": -5.5234375,
            "end_logit": -9.3828125,
            "text": "5A, is also mutated in some Romano-Ward cases to produce defects in INa, the cardiac inward Na+ current",
            "probability": 0.0
        },
        {
            "start_logit": -5.5234375,
            "end_logit": -9.421875,
            "text": "5A, is also mutated in some Romano-Ward cases to produce defects in INa",
            "probability": 0.0
        },
        {
            "start_logit": -5.5234375,
            "end_logit": -9.578125,
            "text": "5A, is",
            "probability": 0.0
        }
    ],
    "52eea509c8da89891000000d_17": [
        {
            "start_logit": 11.4296875,
            "end_logit": 11.3515625,
            "text": "KVLQT1",
            "probability": 1.0
        },
        {
            "start_logit": 11.4296875,
            "end_logit": -2.96875,
            "text": "KVL",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 11.4296875,
            "end_logit": -3.876953125,
            "text": "KVLQ",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 11.4296875,
            "end_logit": -5.8203125,
            "text": "KV",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.6328125,
            "end_logit": 11.3515625,
            "text": "T1",
            "probability": 0.0
        },
        {
            "start_logit": 11.4296875,
            "end_logit": -9.3671875,
            "text": "KVLQT1 do not invariably produce the Jervell and Lange-",
            "probability": 0.0
        },
        {
            "start_logit": 11.4296875,
            "end_logit": -9.390625,
            "text": "KVLQT1 do",
            "probability": 0.0
        },
        {
            "start_logit": 11.4296875,
            "end_logit": -9.6171875,
            "text": "KVLQT1 do not",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": 11.3515625,
            "text": "QT1",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 11.3515625,
            "text": "LQT1",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 11.3515625,
            "text": "Romano-Ward long-QT syndrome and indicate that homozygous mutations on KVLQT1",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 11.3515625,
            "text": "Ward long-QT syndrome and indicate that homozygous mutations on KVLQT1",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": -2.96875,
            "text": "L",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": -3.876953125,
            "text": "Q",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": -2.96875,
            "text": "Romano-Ward long-QT syndrome and indicate that homozygous mutations on KVL",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": -2.96875,
            "text": "Ward long-QT syndrome and indicate that homozygous mutations on KVL",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": -3.876953125,
            "text": "LQ",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": -3.876953125,
            "text": "Romano-Ward long-QT syndrome and indicate that homozygous mutations on KVLQ",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": -3.876953125,
            "text": "Ward long-QT syndrome and indicate that homozygous mutations on KVLQ",
            "probability": 0.0
        },
        {
            "start_logit": -6.6328125,
            "end_logit": -9.3671875,
            "text": "T1 do not invariably produce the Jervell and Lange-",
            "probability": 0.0
        }
    ],
    "602346eb1cb411341a000090_1": [
        {
            "start_logit": 14.03125,
            "end_logit": 12.9296875,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": 0.65380859375,
            "text": "atezolizumab and bevacizumab",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": 14.03125,
            "end_logit": -3.197265625,
            "text": "atezoliz",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.03125,
            "end_logit": -3.80859375,
            "text": "ate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.03125,
            "end_logit": -5.40625,
            "text": "atezo",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -6.23046875,
            "text": "atezoli",
            "probability": 0.0
        },
        {
            "start_logit": -5.625,
            "end_logit": 12.9296875,
            "text": "umab",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -7.7421875,
            "text": "atezolizumab and",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -8.4140625,
            "text": "atezolizumab and bevacizumab (the IMbrave150 trial) in advanced hepatocellular carcinoma has recently been reported",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -8.4296875,
            "text": "atezolizumab and bevacizumab (the IMbrave150 trial)",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -8.6328125,
            "text": "atezolizumab and bevacizumab (the IMbrave150 trial) in advanced hepatocellular carcinoma",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -8.640625,
            "text": "atezolizumab and bevacizumab (the IMbrave150 trial) in",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.0,
            "text": "atezolizumab and bevacizumab (the IMbrave150 trial) in advanced hepatocellular carcinoma has",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.2890625,
            "text": "atezolizumab and bevacizumab (the IMbrave150 trial) in advanced hepatocellular carcinoma has recently",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.3359375,
            "text": "atezolizumab and bevacizumab (the IMbrave150 trial) in advanced hepatocellular carcinoma has recently been",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.5234375,
            "text": "atezolizumab and bevacizumab (the IMbrave150 trial) in advanced hepatocellular",
            "probability": 0.0
        },
        {
            "start_logit": -8.65625,
            "end_logit": 12.9296875,
            "text": "zumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": 12.9296875,
            "text": "zolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 12.9296875,
            "text": "lizumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 12.9296875,
            "text": "of atezolizumab",
            "probability": 0.0
        }
    ],
    "602346eb1cb411341a000090_2": [
        {
            "start_logit": 9.984375,
            "end_logit": 10.140625,
            "text": "lenvatinib",
            "probability": 0.91845703125
        },
        {
            "start_logit": 9.984375,
            "end_logit": 7.68359375,
            "text": "lenvatinib plus pembrolizumab",
            "probability": 0.0789794921875
        },
        {
            "start_logit": 6.68359375,
            "end_logit": 7.68359375,
            "text": "pembrolizumab",
            "probability": 0.0029010772705078125
        },
        {
            "start_logit": 9.984375,
            "end_logit": -1.9697265625,
            "text": "lenvatinib plus pembroliz",
            "probability": 5.0067901611328125e-06
        },
        {
            "start_logit": 9.984375,
            "end_logit": -2.8125,
            "text": "lenvatinib plus pembrolizumab and atezolizumab",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": 9.984375,
            "end_logit": -4.8125,
            "text": "lenvatinib plus pem",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 6.68359375,
            "end_logit": -1.9697265625,
            "text": "pembroliz",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.984375,
            "end_logit": -5.32421875,
            "text": "lenvatinib plus pembroli",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.984375,
            "end_logit": -5.57421875,
            "text": "lenvatinib plus pembrolizumab and atezolizumab plus bevacizumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.984375,
            "end_logit": -5.79296875,
            "text": "lenvatinib plus pembrolizumab and atezoli",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.984375,
            "end_logit": -5.9140625,
            "text": "lenvatinib plus pembrolizumab and atezoliz",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.984375,
            "end_logit": -6.0390625,
            "text": "lenvatinib plus pembrolizumab and atezo",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.68359375,
            "end_logit": -2.8125,
            "text": "pembrolizumab and atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.5234375,
            "end_logit": 10.140625,
            "text": "tinib",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.984375,
            "end_logit": -6.55859375,
            "text": "len",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.984375,
            "end_logit": -6.66796875,
            "text": "lenvatinib plus pembr",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.984375,
            "end_logit": -6.75390625,
            "text": "lenva",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.26171875,
            "text": "lenvatinib plus pembrolizumab and ate",
            "probability": 0.0
        },
        {
            "start_logit": 6.68359375,
            "end_logit": -4.8125,
            "text": "pem",
            "probability": 0.0
        },
        {
            "start_logit": 6.68359375,
            "end_logit": -5.32421875,
            "text": "pembroli",
            "probability": 0.0
        }
    ],
    "602346eb1cb411341a000090_3": [
        {
            "start_logit": 13.5546875,
            "end_logit": 12.125,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -1.0712890625,
            "text": "atezolizumab plus bevacizumab",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -2.763671875,
            "text": "atezoliz",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -4.3984375,
            "text": "ate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -4.4375,
            "text": "atezolizumab plus bevacizumab (atezolizumab-bevacizumab) or sorafenib",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -5.07421875,
            "text": "atezo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -6.0078125,
            "text": "atezoli",
            "probability": 0.0
        },
        {
            "start_logit": -6.43359375,
            "end_logit": 12.125,
            "text": "umab",
            "probability": 0.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -8.28125,
            "text": "atezolizumab plus bevacizumab (",
            "probability": 0.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -8.28125,
            "text": "atezolizumab plus",
            "probability": 0.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -8.6171875,
            "text": "atezolizumab plus bevacizumab (atezolizumab-bevacizumab) or",
            "probability": 0.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -8.71875,
            "text": "atezolizumab plus bevacizumab (atezolizumab-bevacizumab",
            "probability": 0.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -8.96875,
            "text": "atezolizumab plus bevacizumab (atezolizumab-bevacizumab)",
            "probability": 0.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -9.1015625,
            "text": "atezolizumab plus bevacizumab (atezolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -8.875,
            "end_logit": 12.125,
            "text": "zumab",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 12.125,
            "text": "zolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 12.125,
            "text": "lizumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 12.125,
            "text": "allocated (2:1) patients to receive either atezolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 12.125,
            "text": "IMbrave150, which randomly allocated (2:1) patients to receive either atezolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -3.71875,
            "end_logit": -1.0712890625,
            "text": "bevacizumab",
            "probability": 0.0
        }
    ],
    "602346eb1cb411341a000090_4": [
        {
            "start_logit": 13.8984375,
            "end_logit": 12.9921875,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -1.037109375,
            "text": "atezolizumab and bevacizumab",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -2.45703125,
            "text": "atezoliz",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -3.765625,
            "text": "atezolizumab and bevacizumab was successfully used compared to sorafenib",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -4.015625,
            "text": "ate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -5.28515625,
            "text": "atezo",
            "probability": 0.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -6.01953125,
            "text": "atezoli",
            "probability": 0.0
        },
        {
            "start_logit": -5.4296875,
            "end_logit": 12.9921875,
            "text": "umab",
            "probability": 0.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -7.98828125,
            "text": "atezolizumab and",
            "probability": 0.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -9.09375,
            "text": "atezolizumab and bevacizumab was successfully used compared to",
            "probability": 0.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -9.2578125,
            "text": "atezolizumab and bevacizumab was successfully used compared to sorafenib in the first-",
            "probability": 0.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -9.2890625,
            "text": "atezolizumab and bevacizumab was",
            "probability": 0.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -9.3671875,
            "text": "atezolizumab and bevacizumab was successfully used compared to sorafenib in the first-line treatment",
            "probability": 0.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -9.484375,
            "text": "atezolizumab and bevacizumab was successfully used compared to sorafenib in the",
            "probability": 0.0
        },
        {
            "start_logit": -8.640625,
            "end_logit": 12.9921875,
            "text": "zumab",
            "probability": 0.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -9.6328125,
            "text": "atezolizumab and bevacizumab was successfully used compared",
            "probability": 0.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -9.7265625,
            "text": "atezolizumab and bevacizumab was successfully used compared to sorafenib in the first-line",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": 12.9921875,
            "text": "zolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 12.9921875,
            "text": "lizumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 12.9921875,
            "text": "of atezolizumab",
            "probability": 0.0
        }
    ],
    "602346eb1cb411341a000090_5": [
        {
            "start_logit": 12.6484375,
            "end_logit": 11.015625,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": 12.6484375,
            "end_logit": 2.046875,
            "text": "atezolizumab plus bevacizumab",
            "probability": 0.00012826919555664062
        },
        {
            "start_logit": 12.6484375,
            "end_logit": -0.77392578125,
            "text": "atezolizumab plus bevacizumab increases overall survival compared with sorafenib",
            "probability": 7.62939453125e-06
        },
        {
            "start_logit": 12.6484375,
            "end_logit": -3.154296875,
            "text": "atezoliz",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 12.6484375,
            "end_logit": -5.11328125,
            "text": "ate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.6484375,
            "end_logit": -5.67578125,
            "text": "atezoli",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.6484375,
            "end_logit": -5.79296875,
            "text": "atezo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.40625,
            "end_logit": 11.015625,
            "text": "immunotherapy with atezolizumab",
            "probability": 0.0
        },
        {
            "start_logit": 12.6484375,
            "end_logit": -7.7421875,
            "text": "atezolizumab plus bevacizumab increases",
            "probability": 0.0
        },
        {
            "start_logit": 12.6484375,
            "end_logit": -7.9375,
            "text": "atezolizumab plus",
            "probability": 0.0
        },
        {
            "start_logit": -7.375,
            "end_logit": 11.015625,
            "text": "umab",
            "probability": 0.0
        },
        {
            "start_logit": 12.6484375,
            "end_logit": -9.2890625,
            "text": "atezolizumab plus bevacizumab increases overall survival compared",
            "probability": 0.0
        },
        {
            "start_logit": 12.6484375,
            "end_logit": -9.3203125,
            "text": "atezolizumab plus bevacizumab increases overall survival",
            "probability": 0.0
        },
        {
            "start_logit": 12.6484375,
            "end_logit": -9.34375,
            "text": "atezolizumab plus bevacizumab increases overall survival compared with sorafenib therapy",
            "probability": 0.0
        },
        {
            "start_logit": 12.6484375,
            "end_logit": -9.609375,
            "text": "atezolizumab plus bevacizumab increases overall survival compared with sorafenib therapy; Food and Drug Agency already approved",
            "probability": 0.0
        },
        {
            "start_logit": 12.6484375,
            "end_logit": -9.7734375,
            "text": "atezolizumab plus bevacizumab increases overall survival compared with sorafenib therapy; Food and Drug Agency already",
            "probability": 0.0
        },
        {
            "start_logit": 12.6484375,
            "end_logit": -9.8203125,
            "text": "atezolizumab plus bevacizumab increases overall survival compared with sorafenib therapy; Food and Drug Agency",
            "probability": 0.0
        },
        {
            "start_logit": 12.6484375,
            "end_logit": -9.9453125,
            "text": "atezolizumab plus bevacizumab increases overall survival compared with sorafenib therapy; Food and Drug Agency already approved this combination therapy, and worldwide approval is expected",
            "probability": 0.0
        },
        {
            "start_logit": -9.453125,
            "end_logit": 11.015625,
            "text": "zumab",
            "probability": 0.0
        },
        {
            "start_logit": -9.546875,
            "end_logit": 11.015625,
            "text": "combination immunotherapy with atezolizumab",
            "probability": 0.0
        }
    ],
    "602346eb1cb411341a000090_6": [
        {
            "start_logit": 14.2109375,
            "end_logit": 13.234375,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -2.74609375,
            "text": "atezoliz",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -3.40234375,
            "text": "ate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -4.44921875,
            "text": "atezolizumab (anti-programmed death-ligand 1 [PD-L1]) and bevacizumab",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -5.11328125,
            "text": "atezo",
            "probability": 0.0
        },
        {
            "start_logit": -5.046875,
            "end_logit": 13.234375,
            "text": "umab",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -6.234375,
            "text": "atezoli",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -8.0078125,
            "text": "atezolizumab (anti-programmed death-ligand 1 [PD-L1]) and bevacizumab (anti-vascular endothelial growth factor [VEGF",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -8.0859375,
            "text": "atezolizumab (anti-programmed death-ligand 1 [PD-L1])",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -8.2734375,
            "text": "atezolizumab (anti-programmed death-ligand 1 [PD",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -8.578125,
            "text": "atezolizumab (anti-programmed death-ligand 1 [PD-L1]) and",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -8.65625,
            "text": "atezolizumab (anti-programmed death-ligand 1",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -8.6953125,
            "text": "atezolizumab (anti-programmed",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -8.703125,
            "text": "atezolizumab (anti-programmed death-ligand 1 [PD-L1",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -8.8828125,
            "text": "atezolizumab (",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -8.9921875,
            "text": "atezolizumab (anti-programmed death-ligand 1 [PD-L1]) and bevacizumab (",
            "probability": 0.0
        },
        {
            "start_logit": -8.7265625,
            "end_logit": 13.234375,
            "text": "zumab",
            "probability": 0.0
        },
        {
            "start_logit": -9.21875,
            "end_logit": 13.234375,
            "text": "therapy of atezolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.0234375,
            "end_logit": 13.234375,
            "text": "of atezolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": 13.234375,
            "text": "zolizumab",
            "probability": 0.0
        }
    ],
    "602346eb1cb411341a000090_7": [
        {
            "start_logit": 14.046875,
            "end_logit": 13.1328125,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -0.91015625,
            "text": "atezolizumab and bevacizumab",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 14.046875,
            "end_logit": -2.978515625,
            "text": "atezoliz",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.046875,
            "end_logit": -3.78125,
            "text": "atezolizumab and bevacizumab over sorafenib",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.046875,
            "end_logit": -3.82421875,
            "text": "ate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.046875,
            "end_logit": -5.6328125,
            "text": "atezo",
            "probability": 0.0
        },
        {
            "start_logit": -5.37890625,
            "end_logit": 13.1328125,
            "text": "umab",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -6.46875,
            "text": "atezoli",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -7.42578125,
            "text": "atezolizumab and",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -7.4296875,
            "text": "atezolizumab and bevacizumab over sorafenib as a standard of care in advanced unresectable HCC",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -8.46875,
            "text": "atezolizumab and bevacizumab over sorafenib as a",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -8.6015625,
            "text": "atezolizumab and bevacizumab over sorafenib as a standard of",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -8.9765625,
            "text": "atezolizumab and bevacizumab over sorafenib as a standard of care",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -9.2890625,
            "text": "atezolizumab and bevacizumab over",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -9.4375,
            "text": "atezolizumab and bevacizumab over sorafenib as a standard of care in",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -9.5625,
            "text": "atezolizumab and bevacizumab over sorafenib as",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -9.6015625,
            "text": "atezolizumab and bevacizumab over sorafenib as a standard of care in advanced",
            "probability": 0.0
        },
        {
            "start_logit": -8.71875,
            "end_logit": 13.1328125,
            "text": "zumab",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": 13.1328125,
            "text": "zolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 13.1328125,
            "text": "of atezolizumab",
            "probability": 0.0
        }
    ],
    "602346eb1cb411341a000090_8": [
        {
            "start_logit": 13.546875,
            "end_logit": 11.8125,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": 13.546875,
            "end_logit": 0.485595703125,
            "text": "atezolizumab and bevacizumab",
            "probability": 1.2040138244628906e-05
        },
        {
            "start_logit": 13.546875,
            "end_logit": -1.109375,
            "text": "atezolizumab and bevacizumab over sorafenib as a standard of care in advanced unresectable HCC. While only lenvatinib",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": 13.546875,
            "end_logit": -2.095703125,
            "text": "atezolizumab and bevacizumab over sorafenib",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 13.546875,
            "end_logit": -2.970703125,
            "text": "atezoliz",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 13.546875,
            "end_logit": -4.328125,
            "text": "ate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.546875,
            "end_logit": -5.25390625,
            "text": "atezo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.546875,
            "end_logit": -5.98046875,
            "text": "atezoli",
            "probability": 0.0
        },
        {
            "start_logit": 13.546875,
            "end_logit": -7.4296875,
            "text": "atezolizumab and bevacizumab over sorafenib as a standard of care in advanced unresectable HCC. While only lenva",
            "probability": 0.0
        },
        {
            "start_logit": 13.546875,
            "end_logit": -7.46875,
            "text": "atezolizumab and bevacizumab over sorafenib as a standard of care in advanced unresectable HCC. While only len",
            "probability": 0.0
        },
        {
            "start_logit": 13.546875,
            "end_logit": -7.921875,
            "text": "atezolizumab and",
            "probability": 0.0
        },
        {
            "start_logit": 13.546875,
            "end_logit": -8.1171875,
            "text": "atezolizumab and bevacizumab over sorafenib as a standard of care in advanced unresectable HCC. While only",
            "probability": 0.0
        },
        {
            "start_logit": 13.546875,
            "end_logit": -8.15625,
            "text": "atezolizumab and bevacizumab over sorafenib as a standard of care in advanced unresectable HCC",
            "probability": 0.0
        },
        {
            "start_logit": -6.48046875,
            "end_logit": 11.8125,
            "text": "umab",
            "probability": 0.0
        },
        {
            "start_logit": 13.546875,
            "end_logit": -8.96875,
            "text": "atezolizumab and bevacizumab over sorafenib as",
            "probability": 0.0
        },
        {
            "start_logit": 13.546875,
            "end_logit": -8.9765625,
            "text": "atezolizumab and bevacizumab over sorafenib as a",
            "probability": 0.0
        },
        {
            "start_logit": 13.546875,
            "end_logit": -9.1328125,
            "text": "atezolizumab and bevacizumab over sorafenib as a standard of care in advanced unresectable HCC. While",
            "probability": 0.0
        },
        {
            "start_logit": 13.546875,
            "end_logit": -9.3203125,
            "text": "atezolizumab and bevacizumab over sorafenib as a standard of",
            "probability": 0.0
        },
        {
            "start_logit": 13.546875,
            "end_logit": -9.4296875,
            "text": "atezolizumab and bevacizumab over sorafenib as a standard of care",
            "probability": 0.0
        },
        {
            "start_logit": -8.5,
            "end_logit": 11.8125,
            "text": "zumab",
            "probability": 0.0
        }
    ],
    "602346eb1cb411341a000090_9": [
        {
            "start_logit": 13.921875,
            "end_logit": 12.8671875,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": 13.921875,
            "end_logit": -2.56640625,
            "text": "atezolizumab (targeting PD-L1) and bevacizumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.921875,
            "end_logit": -3.462890625,
            "text": "atezoliz",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.921875,
            "end_logit": -3.955078125,
            "text": "ate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.921875,
            "end_logit": -5.5234375,
            "text": "atezo",
            "probability": 0.0
        },
        {
            "start_logit": 13.921875,
            "end_logit": -5.55859375,
            "text": "atezoli",
            "probability": 0.0
        },
        {
            "start_logit": 13.921875,
            "end_logit": -5.84765625,
            "text": "atezolizumab (targeting PD-L1) and bevacizumab (targeting VEGF",
            "probability": 0.0
        },
        {
            "start_logit": -5.5234375,
            "end_logit": 12.8671875,
            "text": "umab",
            "probability": 0.0
        },
        {
            "start_logit": 13.921875,
            "end_logit": -7.01171875,
            "text": "atezolizumab (targeting PD-L1",
            "probability": 0.0
        },
        {
            "start_logit": 13.921875,
            "end_logit": -7.43359375,
            "text": "atezolizumab (targeting PD",
            "probability": 0.0
        },
        {
            "start_logit": 13.921875,
            "end_logit": -7.67578125,
            "text": "atezolizumab (targeting PD-L1)",
            "probability": 0.0
        },
        {
            "start_logit": 13.921875,
            "end_logit": -7.984375,
            "text": "atezolizumab (",
            "probability": 0.0
        },
        {
            "start_logit": 13.921875,
            "end_logit": -8.0390625,
            "text": "atezolizumab (targeting PD-L1) and bevacizumab (",
            "probability": 0.0
        },
        {
            "start_logit": -7.00390625,
            "end_logit": 12.8671875,
            "text": "ation treatment with atezolizumab",
            "probability": 0.0
        },
        {
            "start_logit": 13.921875,
            "end_logit": -8.1328125,
            "text": "atezolizumab (targeting",
            "probability": 0.0
        },
        {
            "start_logit": 13.921875,
            "end_logit": -8.390625,
            "text": "atezolizumab (targeting PD-L1) and",
            "probability": 0.0
        },
        {
            "start_logit": 13.921875,
            "end_logit": -8.6796875,
            "text": "atezolizumab (targeting PD-L1) and bevacizumab (targeting",
            "probability": 0.0
        },
        {
            "start_logit": 13.921875,
            "end_logit": -9.59375,
            "text": "atezolizumab (targeting PD-L1) and bevacizumab (targeting VEGF) in the recent IMbrave150 study was shown to be",
            "probability": 0.0
        },
        {
            "start_logit": -8.6796875,
            "end_logit": 12.8671875,
            "text": "zumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": 12.8671875,
            "text": "with atezolizumab",
            "probability": 0.0
        }
    ],
    "602346eb1cb411341a000090_10": [
        {
            "start_logit": 13.3046875,
            "end_logit": 12.1875,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": 13.3046875,
            "end_logit": -0.5400390625,
            "text": "atezolizumab plus bevacizumab",
            "probability": 2.9206275939941406e-06
        },
        {
            "start_logit": 13.3046875,
            "end_logit": -2.888671875,
            "text": "atezoliz",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 13.3046875,
            "end_logit": -4.8828125,
            "text": "ate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.3046875,
            "end_logit": -5.74609375,
            "text": "atezo",
            "probability": 0.0
        },
        {
            "start_logit": 13.3046875,
            "end_logit": -6.75390625,
            "text": "atezoli",
            "probability": 0.0
        },
        {
            "start_logit": -6.4453125,
            "end_logit": 12.1875,
            "text": "umab",
            "probability": 0.0
        },
        {
            "start_logit": 13.3046875,
            "end_logit": -7.88671875,
            "text": "atezolizumab plus bevacizumab, this novel combination has become the preferred first-line standard of care for patients with unresectable hepatocellular carcinoma (HCC",
            "probability": 0.0
        },
        {
            "start_logit": 13.3046875,
            "end_logit": -9.1484375,
            "text": "atezolizumab plus",
            "probability": 0.0
        },
        {
            "start_logit": 13.3046875,
            "end_logit": -9.3125,
            "text": "atezolizumab plus bevacizumab, this novel combination has become the preferred first-line standard of care for patients with unresectable hepatocellular carcinoma (",
            "probability": 0.0
        },
        {
            "start_logit": 13.3046875,
            "end_logit": -9.3359375,
            "text": "atezolizumab plus bevacizumab, this novel combination has become the preferred first-line standard of care for patients with unresectable hepatocellular carcinoma (HCC)",
            "probability": 0.0
        },
        {
            "start_logit": 13.3046875,
            "end_logit": -9.5625,
            "text": "atezolizumab plus bevacizumab, this novel combination has become the preferred first-line standard",
            "probability": 0.0
        },
        {
            "start_logit": 13.3046875,
            "end_logit": -9.6015625,
            "text": "atezolizumab plus bevacizumab,",
            "probability": 0.0
        },
        {
            "start_logit": 13.3046875,
            "end_logit": -9.6875,
            "text": "atezolizumab plus bevacizumab, this novel combination has become the preferred first-line standard of care",
            "probability": 0.0
        },
        {
            "start_logit": -8.609375,
            "end_logit": 12.1875,
            "text": "zumab",
            "probability": 0.0
        },
        {
            "start_logit": 13.3046875,
            "end_logit": -9.734375,
            "text": "atezolizumab plus bevacizumab, this novel combination has become the",
            "probability": 0.0
        },
        {
            "start_logit": 13.3046875,
            "end_logit": -9.734375,
            "text": "atezolizumab plus bevacizumab, this novel combination has become the preferred first-line standard of care for patients with unresectable hepatocellular carcinoma",
            "probability": 0.0
        },
        {
            "start_logit": 13.3046875,
            "end_logit": -9.8203125,
            "text": "atezolizumab plus bevacizumab, this novel combination has become the preferred first-",
            "probability": 0.0
        },
        {
            "start_logit": 13.3046875,
            "end_logit": -9.9296875,
            "text": "atezolizumab plus bevacizumab, this novel combination has",
            "probability": 0.0
        },
        {
            "start_logit": 13.3046875,
            "end_logit": -9.953125,
            "text": "atezolizumab plus bevacizumab, this novel combination has become the preferred first-line standard of care for",
            "probability": 0.0
        }
    ],
    "602346eb1cb411341a000090_11": [
        {
            "start_logit": 13.390625,
            "end_logit": 12.1171875,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": 13.390625,
            "end_logit": -0.83984375,
            "text": "atezolizumab plus bevacizumab",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": 13.390625,
            "end_logit": -3.1796875,
            "text": "atezoliz",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 13.390625,
            "end_logit": -3.986328125,
            "text": "atezolizumab plus bevacizumab resulted in significantly longer overall survival and progression-free survival compared to sorafenib",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.390625,
            "end_logit": -4.59375,
            "text": "ate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.390625,
            "end_logit": -6.06640625,
            "text": "atezo",
            "probability": 0.0
        },
        {
            "start_logit": 13.390625,
            "end_logit": -6.4453125,
            "text": "atezoli",
            "probability": 0.0
        },
        {
            "start_logit": 13.390625,
            "end_logit": -6.69140625,
            "text": "atezolizumab plus bevacizumab resulted in significantly longer overall survival and progression-free survival compared to sorafenib monotherapy. In addition, t",
            "probability": 0.0
        },
        {
            "start_logit": -6.4375,
            "end_logit": 12.1171875,
            "text": "umab",
            "probability": 0.0
        },
        {
            "start_logit": 13.390625,
            "end_logit": -8.0703125,
            "text": "atezolizumab plus bevacizumab resulted",
            "probability": 0.0
        },
        {
            "start_logit": 13.390625,
            "end_logit": -8.8359375,
            "text": "atezolizumab plus",
            "probability": 0.0
        },
        {
            "start_logit": 13.390625,
            "end_logit": -9.0234375,
            "text": "atezolizumab plus bevacizumab resulted in significantly longer overall survival and progression-free survival compared to sorafenib monotherapy. In addition",
            "probability": 0.0
        },
        {
            "start_logit": 13.390625,
            "end_logit": -9.109375,
            "text": "atezolizumab plus bevacizumab resulted in significantly longer overall survival and progression-free survival",
            "probability": 0.0
        },
        {
            "start_logit": 13.390625,
            "end_logit": -9.15625,
            "text": "atezolizumab plus bevacizumab resulted in significantly longer overall survival and progression-free survival compared to sorafenib monotherapy",
            "probability": 0.0
        },
        {
            "start_logit": 13.390625,
            "end_logit": -9.2421875,
            "text": "atezolizumab plus bevacizumab resulted in significantly longer overall survival and progression-free survival compared",
            "probability": 0.0
        },
        {
            "start_logit": 13.390625,
            "end_logit": -9.2734375,
            "text": "atezolizumab plus bevacizumab resulted in significantly longer overall survival and progression-free survival compared to sorafenib monotherapy. In addition,",
            "probability": 0.0
        },
        {
            "start_logit": -8.5703125,
            "end_logit": 12.1171875,
            "text": "zumab",
            "probability": 0.0
        },
        {
            "start_logit": -8.890625,
            "end_logit": 12.1171875,
            "text": "HCC, treatment with atezolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": 12.1171875,
            "text": "zolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 12.1171875,
            "text": "he IMbrave150 trial recently showed that, among patients with previously untreated unresectable HCC, treatment with atezolizumab",
            "probability": 0.0
        }
    ],
    "602346eb1cb411341a000090_12": [
        {
            "start_logit": 9.3828125,
            "end_logit": 6.828125,
            "text": "atezolizumab",
            "probability": 0.62646484375
        },
        {
            "start_logit": 6.828125,
            "end_logit": 8.734375,
            "text": "bevacizumab",
            "probability": 0.324951171875
        },
        {
            "start_logit": 6.828125,
            "end_logit": 6.828125,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects when combined with atezolizumab",
            "probability": 0.048309326171875
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -2.28125,
            "text": "atezoliz",
            "probability": 6.878376007080078e-05
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -4.46484375,
            "text": "atezoli",
            "probability": 7.748603820800781e-06
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -4.4921875,
            "text": "atezo",
            "probability": 7.569789886474609e-06
        },
        {
            "start_logit": 6.828125,
            "end_logit": -2.28125,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects when combined with atezoliz",
            "probability": 5.364418029785156e-06
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -6.15234375,
            "text": "ate",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 6.828125,
            "end_logit": -4.46484375,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects when combined with atezoli",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 6.828125,
            "end_logit": -4.4921875,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects when combined with atezo",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -8.1640625,
            "text": "atezolizumab. The anal",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 6.828125,
            "end_logit": -6.15234375,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects when combined with ate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.921875,
            "end_logit": 8.734375,
            "text": "3 IMbrave150 clinical trial was successful because of the direct antitumor effect of bevacizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0625,
            "end_logit": 6.828125,
            "text": "umab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -9.6640625,
            "text": "atezolizumab. The",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.4453125,
            "end_logit": 8.734375,
            "text": "e 3 IMbrave150 clinical trial was successful because of the direct antitumor effect of bevacizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.125,
            "end_logit": 8.734375,
            "text": "IMbrave150 clinical trial was successful because of the direct antitumor effect of bevacizumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": 8.734375,
            "text": "direct antitumor effect of bevacizumab",
            "probability": 0.0
        },
        {
            "start_logit": -8.5390625,
            "end_logit": 6.828125,
            "text": "zumab",
            "probability": 0.0
        },
        {
            "start_logit": 6.828125,
            "end_logit": -9.0390625,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic",
            "probability": 0.0
        }
    ],
    "602346eb1cb411341a000090_13": [
        {
            "start_logit": 12.140625,
            "end_logit": 10.3828125,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": 12.140625,
            "end_logit": 0.73828125,
            "text": "atezolizumab plus bevacizumab",
            "probability": 6.401538848876953e-05
        },
        {
            "start_logit": 12.140625,
            "end_logit": -0.92626953125,
            "text": "atezolizumab plus bevacizumab increases overall survival compared with sorafenib",
            "probability": 1.2099742889404297e-05
        },
        {
            "start_logit": 12.140625,
            "end_logit": -2.634765625,
            "text": "atezoliz",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": 12.140625,
            "end_logit": -4.9140625,
            "text": "atezo",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 12.140625,
            "end_logit": -5.16796875,
            "text": "atezoli",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 12.140625,
            "end_logit": -5.25,
            "text": "ate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -4.890625,
            "end_logit": 10.3828125,
            "text": "immunotherapy with atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.140625,
            "end_logit": -7.8203125,
            "text": "atezolizumab plus",
            "probability": 0.0
        },
        {
            "start_logit": 12.140625,
            "end_logit": -7.98046875,
            "text": "atezolizumab plus bevacizumab increases",
            "probability": 0.0
        },
        {
            "start_logit": 12.140625,
            "end_logit": -9.2578125,
            "text": "atezolizumab plus bevacizumab increases overall survival compared with sorafenib therapy",
            "probability": 0.0
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 10.3828125,
            "text": "umab",
            "probability": 0.0
        },
        {
            "start_logit": 12.140625,
            "end_logit": -9.328125,
            "text": "atezolizumab plus bevacizumab increases overall survival compared",
            "probability": 0.0
        },
        {
            "start_logit": 12.140625,
            "end_logit": -9.5078125,
            "text": "atezolizumab plus bevacizumab increases overall survival",
            "probability": 0.0
        },
        {
            "start_logit": 12.140625,
            "end_logit": -9.6484375,
            "text": "atezolizumab plus bevacizumab increases overall survival compared with sorafenib therapy; Food and Drug Agency",
            "probability": 0.0
        },
        {
            "start_logit": -9.265625,
            "end_logit": 10.3828125,
            "text": "combination immunotherapy with atezolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -9.3515625,
            "end_logit": 10.3828125,
            "text": "zumab",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": 10.3828125,
            "text": "I trial (IMbrave150) showed that combination immunotherapy with atezolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.0,
            "end_logit": 10.3828125,
            "text": "that combination immunotherapy with atezolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 10.3828125,
            "text": "zolizumab",
            "probability": 0.0
        }
    ],
    "602346eb1cb411341a000090_14": [
        {
            "start_logit": 13.4296875,
            "end_logit": 12.0234375,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": 13.4296875,
            "end_logit": -2.37890625,
            "text": "atezolizumab + bevacizumab",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 13.4296875,
            "end_logit": -2.474609375,
            "text": "atezoliz",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 13.4296875,
            "end_logit": -4.62890625,
            "text": "ate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.4296875,
            "end_logit": -5.21484375,
            "text": "atezolizumab + bevacizumab (ATEZO/BEV) versus sorafenib",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.4296875,
            "end_logit": -5.41015625,
            "text": "atezo",
            "probability": 0.0
        },
        {
            "start_logit": 13.4296875,
            "end_logit": -5.94921875,
            "text": "atezoli",
            "probability": 0.0
        },
        {
            "start_logit": -6.43359375,
            "end_logit": 12.0234375,
            "text": "umab",
            "probability": 0.0
        },
        {
            "start_logit": 13.4296875,
            "end_logit": -8.25,
            "text": "atezolizumab + bevacizumab (ATEZO/BEV) versus sorafenib (SOR) in patients with unresectable hepatocellular carcinoma (HCC",
            "probability": 0.0
        },
        {
            "start_logit": 13.4296875,
            "end_logit": -8.375,
            "text": "atezolizumab + bevacizumab (ATEZO/BEV)",
            "probability": 0.0
        },
        {
            "start_logit": 13.4296875,
            "end_logit": -8.4375,
            "text": "atezolizumab +",
            "probability": 0.0
        },
        {
            "start_logit": 13.4296875,
            "end_logit": -8.625,
            "text": "atezolizumab + bevacizumab (ATEZO/BE",
            "probability": 0.0
        },
        {
            "start_logit": 13.4296875,
            "end_logit": -8.7890625,
            "text": "atezolizumab + bevacizumab (ATEZO/BEV) versus sorafenib (SOR) in patients with unresectable hepatocellular carcinoma (HCC)",
            "probability": 0.0
        },
        {
            "start_logit": 13.4296875,
            "end_logit": -8.7890625,
            "text": "atezolizumab + bevacizumab (ATEZO",
            "probability": 0.0
        },
        {
            "start_logit": 13.4296875,
            "end_logit": -8.859375,
            "text": "atezolizumab + bevacizumab (",
            "probability": 0.0
        },
        {
            "start_logit": 13.4296875,
            "end_logit": -8.859375,
            "text": "atezolizumab + bevacizumab (ATEZO/BEV",
            "probability": 0.0
        },
        {
            "start_logit": 13.4296875,
            "end_logit": -9.09375,
            "text": "atezolizumab + bevacizumab (ATEZO/BEV) versus sorafenib (SOR)",
            "probability": 0.0
        },
        {
            "start_logit": 13.4296875,
            "end_logit": -9.2578125,
            "text": "atezolizumab + bevacizumab (ATEZO/BEV) versus sorafenib (SOR) in",
            "probability": 0.0
        },
        {
            "start_logit": -8.6640625,
            "end_logit": 12.0234375,
            "text": "zumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 12.0234375,
            "text": "zolizumab",
            "probability": 0.0
        }
    ],
    "602346eb1cb411341a000090_15": [
        {
            "start_logit": 14.03125,
            "end_logit": 12.9296875,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": 0.65380859375,
            "text": "atezolizumab and bevacizumab",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": 14.03125,
            "end_logit": -3.197265625,
            "text": "atezoliz",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.03125,
            "end_logit": -3.80859375,
            "text": "ate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.03125,
            "end_logit": -5.40625,
            "text": "atezo",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -6.23046875,
            "text": "atezoli",
            "probability": 0.0
        },
        {
            "start_logit": -5.625,
            "end_logit": 12.9296875,
            "text": "umab",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -7.7421875,
            "text": "atezolizumab and",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -8.4140625,
            "text": "atezolizumab and bevacizumab (the IMbrave150 trial) in advanced hepatocellular carcinoma has recently been reported",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -8.4296875,
            "text": "atezolizumab and bevacizumab (the IMbrave150 trial)",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -8.6328125,
            "text": "atezolizumab and bevacizumab (the IMbrave150 trial) in advanced hepatocellular carcinoma",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -8.640625,
            "text": "atezolizumab and bevacizumab (the IMbrave150 trial) in",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.0,
            "text": "atezolizumab and bevacizumab (the IMbrave150 trial) in advanced hepatocellular carcinoma has",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.2890625,
            "text": "atezolizumab and bevacizumab (the IMbrave150 trial) in advanced hepatocellular carcinoma has recently",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.3359375,
            "text": "atezolizumab and bevacizumab (the IMbrave150 trial) in advanced hepatocellular carcinoma has recently been",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.5234375,
            "text": "atezolizumab and bevacizumab (the IMbrave150 trial) in advanced hepatocellular",
            "probability": 0.0
        },
        {
            "start_logit": -8.65625,
            "end_logit": 12.9296875,
            "text": "zumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": 12.9296875,
            "text": "zolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 12.9296875,
            "text": "lizumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 12.9296875,
            "text": "of atezolizumab",
            "probability": 0.0
        }
    ],
    "602346eb1cb411341a000090_16": [
        {
            "start_logit": 13.3359375,
            "end_logit": 11.5703125,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -1.251953125,
            "text": "atezolizumab plus bevacizumab",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -2.009765625,
            "text": "atezolizumab plus bevacizumab versus sorafenib",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -3.05078125,
            "text": "atezoliz",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -4.7265625,
            "text": "ate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -4.8671875,
            "text": "atezo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -5.8828125,
            "text": "atezoli",
            "probability": 0.0
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -7.46484375,
            "text": "atezolizumab plus bevacizumab versus sorafenib in patients with advanced hepatocellular carcinoma",
            "probability": 0.0
        },
        {
            "start_logit": -6.67578125,
            "end_logit": 11.5703125,
            "text": "umab",
            "probability": 0.0
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -9.0625,
            "text": "atezolizumab plus",
            "probability": 0.0
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -9.2265625,
            "text": "atezolizumab plus bevacizumab versus sorafenib in patients with advanced hepatocellular",
            "probability": 0.0
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -9.3515625,
            "text": "atezolizumab plus bevacizumab versus sorafenib in patients with advanced",
            "probability": 0.0
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -9.390625,
            "text": "atezolizumab plus bevacizumab versus sorafenib in patients with",
            "probability": 0.0
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -9.5703125,
            "text": "atezolizumab plus bevacizumab versus sorafenib in patients with advanced hepatocellular carcinoma in the IMbrave150 trial, which has",
            "probability": 0.0
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -9.5859375,
            "text": "atezolizumab plus bevacizumab versus sorafenib in patients with advanced hepatocellular carcinoma in the IMbrave150 trial, which has already",
            "probability": 0.0
        },
        {
            "start_logit": -8.6796875,
            "end_logit": 11.5703125,
            "text": "zumab",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 11.5703125,
            "text": "zolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 11.5703125,
            "text": ". We aimed to evaluate patient-reported outcomes (PROs) with atezolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 11.5703125,
            "text": "lizumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 11.5703125,
            "text": "with atezolizumab",
            "probability": 0.0
        }
    ],
    "602346eb1cb411341a000090_17": [
        {
            "start_logit": 12.9609375,
            "end_logit": 11.21875,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": 12.9609375,
            "end_logit": -0.72216796875,
            "text": "atezolizumab plus bevacizumab",
            "probability": 6.496906280517578e-06
        },
        {
            "start_logit": 12.9609375,
            "end_logit": -2.8203125,
            "text": "atezoliz",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 12.9609375,
            "end_logit": -4.91015625,
            "text": "ate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.9609375,
            "end_logit": -5.56640625,
            "text": "atezo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.9609375,
            "end_logit": -6.24609375,
            "text": "atezoli",
            "probability": 0.0
        },
        {
            "start_logit": 12.9609375,
            "end_logit": -7.37109375,
            "text": "atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma",
            "probability": 0.0
        },
        {
            "start_logit": 12.9609375,
            "end_logit": -7.89453125,
            "text": "atezolizumab plus bevacizumab for",
            "probability": 0.0
        },
        {
            "start_logit": 12.9609375,
            "end_logit": -8.6328125,
            "text": "atezolizumab plus bevacizumab for patients with",
            "probability": 0.0
        },
        {
            "start_logit": -7.0078125,
            "end_logit": 11.21875,
            "text": "umab",
            "probability": 0.0
        },
        {
            "start_logit": 12.9609375,
            "end_logit": -8.9140625,
            "text": "atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma (",
            "probability": 0.0
        },
        {
            "start_logit": 12.9609375,
            "end_logit": -8.9453125,
            "text": "atezolizumab plus",
            "probability": 0.0
        },
        {
            "start_logit": 12.9609375,
            "end_logit": -9.1015625,
            "text": "atezolizumab plus bevacizumab for patients with unresectable",
            "probability": 0.0
        },
        {
            "start_logit": 12.9609375,
            "end_logit": -9.1328125,
            "text": "atezolizumab plus bevacizumab for patients with unresectable hepatocellular",
            "probability": 0.0
        },
        {
            "start_logit": 12.9609375,
            "end_logit": -9.703125,
            "text": "atezolizumab plus bevacizumab for patients",
            "probability": 0.0
        },
        {
            "start_logit": -8.71875,
            "end_logit": 11.21875,
            "text": "zumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 11.21875,
            "text": "zolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.328125,
            "end_logit": 11.21875,
            "text": "lizumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 11.21875,
            "text": ": A clinical trial (IMbrave150) indicated the efficacy and safety of atezolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 11.21875,
            "text": "of atezolizumab",
            "probability": 0.0
        }
    ],
    "602346eb1cb411341a000090_18": [
        {
            "start_logit": 7.15625,
            "end_logit": 9.0703125,
            "text": "bevacizumab",
            "probability": 0.7802734375
        },
        {
            "start_logit": 8.5,
            "end_logit": 6.21875,
            "text": "atezolizumab",
            "probability": 0.1741943359375
        },
        {
            "start_logit": 7.15625,
            "end_logit": 6.21875,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects when combined with atezolizumab",
            "probability": 0.04541015625
        },
        {
            "start_logit": 8.5,
            "end_logit": -2.5859375,
            "text": "atezoliz",
            "probability": 2.6166439056396484e-05
        },
        {
            "start_logit": 7.15625,
            "end_logit": -2.5859375,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects when combined with atezoliz",
            "probability": 6.854534149169922e-06
        },
        {
            "start_logit": 8.5,
            "end_logit": -4.7265625,
            "text": "atezo",
            "probability": 3.0994415283203125e-06
        },
        {
            "start_logit": 8.5,
            "end_logit": -5.37109375,
            "text": "atezoli",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": 8.5,
            "end_logit": -6.0703125,
            "text": "ate",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 7.15625,
            "end_logit": -4.7265625,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects when combined with atezo",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 7.15625,
            "end_logit": -5.37109375,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects when combined with atezoli",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.15625,
            "end_logit": -6.0703125,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects when combined with ate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.23828125,
            "end_logit": 6.21875,
            "text": "umab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.53125,
            "end_logit": 9.0703125,
            "text": "IMbrave150 clinical trial was successful because of the direct antitumor effect of bevacizumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 9.0703125,
            "text": "because of the direct antitumor effect of bevacizumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 9.0703125,
            "text": "direct antitumor effect of bevacizumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 9.0703125,
            "text": "brave150 clinical trial was successful because of the direct antitumor effect of bevacizumab",
            "probability": 0.0
        },
        {
            "start_logit": 7.15625,
            "end_logit": -8.9765625,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic",
            "probability": 0.0
        },
        {
            "start_logit": 7.15625,
            "end_logit": -9.0078125,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 6.21875,
            "text": "zumab",
            "probability": 0.0
        },
        {
            "start_logit": 7.15625,
            "end_logit": -9.3046875,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment,",
            "probability": 0.0
        }
    ],
    "602346eb1cb411341a000090_19": [
        {
            "start_logit": 12.6328125,
            "end_logit": 10.6171875,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": 12.6328125,
            "end_logit": -1.5947265625,
            "text": "atezolizumab plus bevacizumab",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": 12.6328125,
            "end_logit": -3.119140625,
            "text": "atezoliz",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 12.6328125,
            "end_logit": -4.69140625,
            "text": "atezo",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 12.6328125,
            "end_logit": -4.94921875,
            "text": "ate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 12.6328125,
            "end_logit": -5.68359375,
            "text": "atezoli",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.6328125,
            "end_logit": -8.2890625,
            "text": "atezolizumab plus bevacizumab between October 2020 and May 2021",
            "probability": 0.0
        },
        {
            "start_logit": 12.6328125,
            "end_logit": -8.9765625,
            "text": "atezolizumab plus",
            "probability": 0.0
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 10.6171875,
            "text": "umab",
            "probability": 0.0
        },
        {
            "start_logit": 12.6328125,
            "end_logit": -9.4140625,
            "text": "atezolizumab plus bevacizumab between October 2020 and",
            "probability": 0.0
        },
        {
            "start_logit": 12.6328125,
            "end_logit": -9.546875,
            "text": "atezolizumab plus bevacizumab between October 2020 and May 202",
            "probability": 0.0
        },
        {
            "start_logit": 12.6328125,
            "end_logit": -9.625,
            "text": "atezolizumab plus bevacizumab between",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 10.6171875,
            "text": "zumab",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 10.6171875,
            "text": ", patients with unresectable HCC treated with atezolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 10.6171875,
            "text": "HCC treated with atezolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -9.796875,
            "end_logit": 10.6171875,
            "text": "zolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -9.9296875,
            "end_logit": 10.6171875,
            "text": "patients with unresectable HCC treated with atezolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 10.6171875,
            "text": "unresectable HCC treated with atezolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 10.6171875,
            "text": ": In this multicenter study, patients with unresectable HCC treated with atezolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 10.6171875,
            "text": "lizumab",
            "probability": 0.0
        }
    ],
    "602346eb1cb411341a000090_20": [
        {
            "start_logit": 13.984375,
            "end_logit": 13.0859375,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -3.474609375,
            "text": "atezoliz",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.984375,
            "end_logit": -3.521484375,
            "text": "atezolizumab and bevacizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.984375,
            "end_logit": -3.73046875,
            "text": "ate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.14453125,
            "end_logit": 13.0859375,
            "text": "sorafenib, in the phase III IMbrave150 trial.Areas covered: This article focuses on the mechanism of action of atezolizumab",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -5.859375,
            "text": "atezo",
            "probability": 0.0
        },
        {
            "start_logit": -5.375,
            "end_logit": 13.0859375,
            "text": "umab",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -6.51953125,
            "text": "atezoli",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -8.984375,
            "text": "atezolizumab and bevacizumab, their synergistic action, and the two clinical trials leading to approval",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -9.34375,
            "text": "atezolizumab and",
            "probability": 0.0
        },
        {
            "start_logit": -8.9296875,
            "end_logit": 13.0859375,
            "text": "zumab",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": 13.0859375,
            "text": "zolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 13.0859375,
            "text": "IMbrave150 trial.Areas covered: This article focuses on the mechanism of action of atezolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -4.14453125,
            "end_logit": -2.208984375,
            "text": "sorafenib",
            "probability": 0.0
        },
        {
            "start_logit": -4.14453125,
            "end_logit": -3.474609375,
            "text": "sorafenib, in the phase III IMbrave150 trial.Areas covered: This article focuses on the mechanism of action of atezoliz",
            "probability": 0.0
        },
        {
            "start_logit": -4.14453125,
            "end_logit": -3.73046875,
            "text": "sorafenib, in the phase III IMbrave150 trial.Areas covered: This article focuses on the mechanism of action of ate",
            "probability": 0.0
        },
        {
            "start_logit": -5.04296875,
            "end_logit": -3.521484375,
            "text": "bevacizumab",
            "probability": 0.0
        },
        {
            "start_logit": -5.375,
            "end_logit": -3.521484375,
            "text": "umab and bevacizumab",
            "probability": 0.0
        },
        {
            "start_logit": -4.14453125,
            "end_logit": -5.859375,
            "text": "sorafenib, in the phase III IMbrave150 trial.Areas covered: This article focuses on the mechanism of action of atezo",
            "probability": 0.0
        },
        {
            "start_logit": -4.14453125,
            "end_logit": -6.51953125,
            "text": "sorafenib, in the phase III IMbrave150 trial.Areas covered: This article focuses on the mechanism of action of atezoli",
            "probability": 0.0
        }
    ],
    "602346eb1cb411341a000090_21": [
        {
            "start_logit": 14.0234375,
            "end_logit": 13.125,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -2.869140625,
            "text": "atezolizumab (targeting PD-L1) and bevacizumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -3.609375,
            "text": "atezoliz",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -3.77734375,
            "text": "ate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -6.01171875,
            "text": "atezolizumab (targeting PD-L1) and bevacizumab (targeting VEGF",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -6.0390625,
            "text": "atezoli",
            "probability": 0.0
        },
        {
            "start_logit": -5.1953125,
            "end_logit": 13.125,
            "text": "umab",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -6.3671875,
            "text": "atezo",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -7.73046875,
            "text": "atezolizumab (targeting PD-L1",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -7.859375,
            "text": "atezolizumab (targeting PD-L1) and bevacizumab (",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -7.90234375,
            "text": "atezolizumab (targeting PD",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -7.90625,
            "text": "atezolizumab (",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -7.953125,
            "text": "atezolizumab (targeting PD-L1)",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -8.09375,
            "text": "atezolizumab (targeting PD-L1) and",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -8.1171875,
            "text": "atezolizumab (targeting",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -8.4765625,
            "text": "atezolizumab (targeting PD-L1) and bevacizumab (targeting",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -9.28125,
            "text": "atezolizumab (targeting PD-L1) and bevacizumab (targeting VEGF) in the recent IMbrave150 study was",
            "probability": 0.0
        },
        {
            "start_logit": -8.75,
            "end_logit": 13.125,
            "text": "zumab",
            "probability": 0.0
        },
        {
            "start_logit": -9.828125,
            "end_logit": 13.125,
            "text": "zolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": 13.125,
            "text": "treatment with atezolizumab",
            "probability": 0.0
        }
    ],
    "5713b0a51174fb175500000e_1": [
        {
            "start_logit": 14.1171875,
            "end_logit": 13.6015625,
            "text": "X-linked Charcot-Marie-Tooth disease",
            "probability": 1.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -0.08154296875,
            "text": "X-linked",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -1.619140625,
            "end_logit": 13.6015625,
            "text": "Charcot-Marie-Tooth disease",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -3.02734375,
            "text": "X",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.958984375,
            "end_logit": 13.6015625,
            "text": "disease",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -5.46875,
            "text": "X-linked Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -6.1875,
            "text": "X-linked Charcot-Marie-Tooth",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -6.68359375,
            "text": "X-linked Charcot-Marie-Tooth disease, Arts syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -7.19140625,
            "text": "X-linked Charco",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -7.578125,
            "text": "X-",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -7.625,
            "text": "X-linked Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -7.62890625,
            "text": "X-linked Charcot",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -8.34375,
            "text": "X-linked Charcot-Marie-Tooth disease, Arts",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -8.625,
            "text": "X-linked Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form a disease continuum",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -8.6953125,
            "text": "X-linked Charcot-Mari",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -8.9296875,
            "text": "X-linked Charcot-Marie-Tooth disease, Art",
            "probability": 0.0
        },
        {
            "start_logit": -9.6171875,
            "end_logit": 13.6015625,
            "text": "Tooth disease",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 13.6015625,
            "text": "Marie-Tooth disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 13.6015625,
            "text": "t-Marie-Tooth disease",
            "probability": 0.0
        },
        {
            "start_logit": -1.619140625,
            "end_logit": -5.46875,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness",
            "probability": 0.0
        }
    ],
    "5713b0a51174fb175500000e_2": [
        {
            "start_logit": 14.2421875,
            "end_logit": 11.703125,
            "text": "X-linked Charcot-Marie-Tooth disease type 5",
            "probability": 0.9853515625
        },
        {
            "start_logit": 14.2421875,
            "end_logit": 7.48828125,
            "text": "X-linked Charcot-Marie-Tooth disease type 5 (CMTX5)",
            "probability": 0.01473236083984375
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -0.023193359375,
            "text": "X-linked",
            "probability": 8.046627044677734e-06
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -1.90625,
            "text": "X-linked Charcot-Marie-Tooth disease type 5 (CMTX5), Arts syndrome, and non-syndromic sensorineural deafness",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -3.162109375,
            "text": "X",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -3.330078125,
            "text": "X-linked Charcot-Marie-Tooth disease",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -1.5009765625,
            "end_logit": 11.703125,
            "text": "Charcot-Marie-Tooth disease type 5",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -4.32421875,
            "text": "X-linked Charcot-Marie-Tooth disease type 5 (CMT",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -4.76953125,
            "text": "X-linked Charcot-Marie-Tooth disease type 5 (CMTX5), Arts syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -6.0390625,
            "text": "X-linked Charcot-Marie-Tooth disease type 5 (CMTX5), Arts",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -6.453125,
            "text": "X-linked Charcot-Marie-Tooth disease type 5 (",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -6.84375,
            "text": "X-linked Charcot-Marie-Tooth",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -6.953125,
            "text": "X-linked Charcot-Marie-Tooth disease type",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -7.0390625,
            "text": "X-linked Charcot",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -7.05859375,
            "text": "X-linked Charcot-Marie-Tooth disease type 5 (CMTX5",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -7.9296875,
            "text": "X-linked Charcot-Marie-Tooth disease type 5 (CMTX5), Arts syndrome, and non",
            "probability": 0.0
        },
        {
            "start_logit": -1.5009765625,
            "end_logit": 7.48828125,
            "text": "Charcot-Marie-Tooth disease type 5 (CMTX5)",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -8.359375,
            "text": "X-linked Charco",
            "probability": 0.0
        },
        {
            "start_logit": -6.234375,
            "end_logit": 11.703125,
            "text": "5",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 11.703125,
            "text": "type 5",
            "probability": 0.0
        }
    ],
    "5713b0a51174fb175500000e_3": [
        {
            "start_logit": 12.3125,
            "end_logit": 10.40625,
            "text": "CMTX5",
            "probability": 1.0
        },
        {
            "start_logit": 12.3125,
            "end_logit": 0.0201873779296875,
            "text": "CMTX5, Arts syndrome",
            "probability": 3.0934810638427734e-05
        },
        {
            "start_logit": 12.3125,
            "end_logit": -2.384765625,
            "text": "CMTX5, Arts syndrome and DFN2",
            "probability": 2.8014183044433594e-06
        },
        {
            "start_logit": 12.3125,
            "end_logit": -3.3046875,
            "text": "CMTX5, Arts",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 12.3125,
            "end_logit": -4.796875,
            "text": "CMT",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 12.3125,
            "end_logit": -5.44140625,
            "text": "CMTX5, Arts syndrome and DFN2 are",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.3125,
            "end_logit": -6.72265625,
            "text": "CMTX5, Arts syndrome and DF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.3125,
            "end_logit": -6.82421875,
            "text": "CMTX5, Art",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.3125,
            "end_logit": -7.51953125,
            "text": "CMTX",
            "probability": 0.0
        },
        {
            "start_logit": 12.3125,
            "end_logit": -8.03125,
            "text": "CMTX5, Arts syndrome and",
            "probability": 0.0
        },
        {
            "start_logit": -7.01953125,
            "end_logit": 10.40625,
            "text": "5",
            "probability": 0.0
        },
        {
            "start_logit": 12.3125,
            "end_logit": -9.0625,
            "text": "CMTX5, Arts syndrome and DFN2 are phenotypic clusters on an intrafamilial continuum",
            "probability": 0.0
        },
        {
            "start_logit": 12.3125,
            "end_logit": -9.71875,
            "text": "CMTX5, Arts syndrome and DFN2 are phenotypic clusters on",
            "probability": 0.0
        },
        {
            "start_logit": 12.3125,
            "end_logit": -9.796875,
            "text": "CMTX5,",
            "probability": 0.0
        },
        {
            "start_logit": 12.3125,
            "end_logit": -9.796875,
            "text": "CMTX5, Arts syndrome and DFN2 are phenotypic clusters on an",
            "probability": 0.0
        },
        {
            "start_logit": -9.515625,
            "end_logit": 10.40625,
            "text": "X5",
            "probability": 0.0
        },
        {
            "start_logit": -0.7861328125,
            "end_logit": 0.0201873779296875,
            "text": "Arts syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -0.7861328125,
            "end_logit": -2.384765625,
            "text": "Arts syndrome and DFN2",
            "probability": 0.0
        },
        {
            "start_logit": -0.7861328125,
            "end_logit": -3.3046875,
            "text": "Arts",
            "probability": 0.0
        },
        {
            "start_logit": -3.50390625,
            "end_logit": -2.384765625,
            "text": "DFN2",
            "probability": 0.0
        }
    ],
    "5713b0a51174fb175500000e_4": [
        {
            "start_logit": 11.921875,
            "end_logit": 6.0859375,
            "text": "X-linked",
            "probability": 0.84765625
        },
        {
            "start_logit": 11.921875,
            "end_logit": 4.3671875,
            "text": "X-linked nonsyndromic sensorineural deafness type 2",
            "probability": 0.1519775390625
        },
        {
            "start_logit": 11.921875,
            "end_logit": -2.24609375,
            "text": "X-linked nonsyndromic sensorineural deafness",
            "probability": 0.0002048015594482422
        },
        {
            "start_logit": 11.921875,
            "end_logit": -2.4453125,
            "text": "X-linked nonsyndromic sensorineural deafness type 2 (DF",
            "probability": 0.0001684427261352539
        },
        {
            "start_logit": 11.921875,
            "end_logit": -3.693359375,
            "text": "X-linked nonsyndromic sensorineural deafness type 2 (DFN2",
            "probability": 4.8279762268066406e-05
        },
        {
            "start_logit": 11.921875,
            "end_logit": -4.48828125,
            "text": "X-linked nonsyndromic sensorineural deafness type 2 (DFN2), or in syndromic deafness including Arts syndrome",
            "probability": 2.193450927734375e-05
        },
        {
            "start_logit": 11.921875,
            "end_logit": -5.1171875,
            "text": "X-linked nonsyndromic sensorineural deafness type 2 (DFN2), or in syndromic deafness including Arts",
            "probability": 1.1622905731201172e-05
        },
        {
            "start_logit": 11.921875,
            "end_logit": -5.453125,
            "text": "X-linked nonsyndromic sensorineural deafness type 2 (DFN2), or in syndromic deafness",
            "probability": 8.344650268554688e-06
        },
        {
            "start_logit": 11.921875,
            "end_logit": -5.9140625,
            "text": "X",
            "probability": 5.245208740234375e-06
        },
        {
            "start_logit": 11.921875,
            "end_logit": -6.38671875,
            "text": "X-linked nonsyndromic sensorineural deafness type 2 (DFN2), or in syndromic deafness including Arts syndrome and X-linked",
            "probability": 3.2782554626464844e-06
        },
        {
            "start_logit": 11.921875,
            "end_logit": -7.21484375,
            "text": "X-linked nonsyndromic sensorineural deafness type 2 (DFN2)",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 11.921875,
            "end_logit": -7.484375,
            "text": "X-linked nonsyndromic sensorineural deafness type 2 (DFN2), or in syndromic deafness including Arts syndrome and X-linked Charco",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 11.921875,
            "end_logit": -8.109375,
            "text": "X-linked nonsyndromic sensorineural deafness type 2 (",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 11.921875,
            "end_logit": -8.2109375,
            "text": "X-linked nonsyndromic sensorineural deafness type",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 11.921875,
            "end_logit": -8.546875,
            "text": "X-linked nonsyndromic sensorineural deafness type 2 (DFN2), or in syndromic deafness including Art",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 11.921875,
            "end_logit": -8.8515625,
            "text": "X-linked nonsyndromic",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -4.92578125,
            "end_logit": 4.3671875,
            "text": "sensorineural deafness type 2",
            "probability": 0.0
        },
        {
            "start_logit": -6.16796875,
            "end_logit": 4.3671875,
            "text": "deafness type 2",
            "probability": 0.0
        },
        {
            "start_logit": -9.609375,
            "end_logit": 6.0859375,
            "text": "linked",
            "probability": 0.0
        },
        {
            "start_logit": -9.859375,
            "end_logit": 6.0859375,
            "text": "PRS-I protein whereas the loss-of-function mutations result in X-linked",
            "probability": 0.0
        }
    ],
    "5713b0a51174fb175500000e_5": [
        {
            "start_logit": 14.1015625,
            "end_logit": 13.5390625,
            "text": "X-linked Charcot-Marie-Tooth disease",
            "probability": 1.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -0.00876617431640625,
            "text": "X-linked",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -0.56103515625,
            "end_logit": 13.5390625,
            "text": "Charcot-Marie-Tooth disease",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -3.107421875,
            "text": "X",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.9296875,
            "end_logit": 13.5390625,
            "text": "disease",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -5.01953125,
            "text": "X-linked Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -6.2890625,
            "text": "X-linked Charcot-Marie-Tooth",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -6.6171875,
            "text": "X-linked Charcot-Marie-Tooth disease, Arts syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -6.984375,
            "text": "X-linked Charco",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -7.0390625,
            "text": "X-linked Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -7.44140625,
            "text": "X-linked Charcot",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -7.49609375,
            "text": "X-",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -8.234375,
            "text": "X-linked Charcot-Marie-Tooth disease, Arts",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -8.421875,
            "text": "X-linked Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form a disease continuum",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -8.5625,
            "text": "X-linked Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form a disease continuum: evidence",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -8.6015625,
            "text": "X-linked Charcot-Mari",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -8.8203125,
            "text": "X-linked Charcot-Marie-Tooth disease, Art",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -8.96875,
            "text": "X-linked Charcot-Marie-Tooth disease, Arts syndrome, and prelingual",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -9.0625,
            "text": "X-linked Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -9.1015625,
            "text": "X-linked Charcot-",
            "probability": 0.0
        }
    ],
    "5713b0a51174fb175500000e_6": [
        {
            "start_logit": 12.0859375,
            "end_logit": 5.59765625,
            "text": "X-linked",
            "probability": 0.955078125
        },
        {
            "start_logit": 12.0859375,
            "end_logit": 2.00390625,
            "text": "X-linked Charcot-Marie-Tooth disease-5",
            "probability": 0.0262603759765625
        },
        {
            "start_logit": 12.0859375,
            "end_logit": 1.6396484375,
            "text": "X-linked Charcot-Marie-Tooth disease-5 (CMTX5)",
            "probability": 0.0181884765625
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -2.158203125,
            "text": "X-linked Charcot-Marie-Tooth disease-5 (CMTX5), Arts syndrome",
            "probability": 0.00040841102600097656
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -3.39453125,
            "text": "X-linked Charcot-Marie-Tooth disease-5 (CMTX5), Arts",
            "probability": 0.00011783838272094727
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -4.7578125,
            "text": "X-linked Charcot-Marie-Tooth disease-5 (CMTX5), Arts syndrome, and X-linked",
            "probability": 3.0279159545898438e-05
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -4.7734375,
            "text": "X-linked Charcot-Marie-Tooth disease-5 (CMT",
            "probability": 2.9802322387695312e-05
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -5.0234375,
            "text": "X-linked Charcot-Marie-Tooth disease",
            "probability": 2.3245811462402344e-05
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -5.62890625,
            "text": "X",
            "probability": 1.2636184692382812e-05
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -6.49609375,
            "text": "X-linked Charcot-Marie-Tooth disease-5 (CMTX5",
            "probability": 5.364418029785156e-06
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -6.70703125,
            "text": "X-linked Charcot-Marie-Tooth",
            "probability": 4.291534423828125e-06
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -6.875,
            "text": "X-linked Charco",
            "probability": 3.635883331298828e-06
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -6.8828125,
            "text": "X-linked Charcot",
            "probability": 3.635883331298828e-06
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -7.0859375,
            "text": "X-linked Charcot-Marie-Tooth disease-",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -7.3046875,
            "text": "X-linked Charcot-Marie-Tooth disease-5 (",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -7.7109375,
            "text": "X-linked Charcot-Marie-Tooth disease-5 (CMTX5), Art",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -8.03125,
            "text": "X-linked Charcot-Marie-Tooth disease-5 (CMTX5), Arts syndrome, and X",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -6.6484375,
            "end_logit": 2.00390625,
            "text": "Charcot-Marie-Tooth disease-5",
            "probability": 0.0
        },
        {
            "start_logit": -6.6484375,
            "end_logit": 1.6396484375,
            "text": "Charcot-Marie-Tooth disease-5 (CMTX5)",
            "probability": 0.0
        },
        {
            "start_logit": -3.65234375,
            "end_logit": -2.09765625,
            "text": "X-linked nonsyndromic sensorineural deafness",
            "probability": 0.0
        }
    ],
    "5713b0a51174fb175500000e_7": [
        {
            "start_logit": 12.0546875,
            "end_logit": 5.81640625,
            "text": "X-linked",
            "probability": 0.798828125
        },
        {
            "start_logit": 12.0546875,
            "end_logit": 4.41796875,
            "text": "X-linked Charcot-Marie-Tooth disease-5 (CMTX5)",
            "probability": 0.19580078125
        },
        {
            "start_logit": 12.0546875,
            "end_logit": 0.74658203125,
            "text": "X-linked Charcot-Marie-Tooth disease-5",
            "probability": 0.005016326904296875
        },
        {
            "start_logit": 12.0546875,
            "end_logit": -4.5078125,
            "text": "X-linked Charcot-Marie-Tooth disease-5 (CMTX5), Arts syndrome",
            "probability": 2.6166439056396484e-05
        },
        {
            "start_logit": 12.0546875,
            "end_logit": -5.0625,
            "text": "X-linked Charcot-Marie-Tooth disease-5 (CMTX5), Arts",
            "probability": 1.5020370483398438e-05
        },
        {
            "start_logit": 12.0546875,
            "end_logit": -5.296875,
            "text": "X-linked Charcot-Marie-Tooth disease-5 (CMT",
            "probability": 1.1861324310302734e-05
        },
        {
            "start_logit": 12.0546875,
            "end_logit": -5.578125,
            "text": "X-linked Charcot-Marie-Tooth disease",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": 12.0546875,
            "end_logit": -5.5859375,
            "text": "X-linked Charcot-Marie-Tooth disease-5 (CMTX5), Arts syndrome, and X-linked",
            "probability": 8.881092071533203e-06
        },
        {
            "start_logit": 12.0546875,
            "end_logit": -5.81640625,
            "text": "X",
            "probability": 7.033348083496094e-06
        },
        {
            "start_logit": 12.0546875,
            "end_logit": -7.01171875,
            "text": "X-linked Charcot-Marie-Tooth disease-5 (CMTX5",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 12.0546875,
            "end_logit": -7.05078125,
            "text": "X-linked Charcot",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": 12.0546875,
            "end_logit": -7.13671875,
            "text": "X-linked Charco",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 12.0546875,
            "end_logit": -7.3359375,
            "text": "X-linked Charcot-Marie-Tooth",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 12.0546875,
            "end_logit": -7.55078125,
            "text": "X-linked Charcot-Marie-Tooth disease-",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 12.0546875,
            "end_logit": -8.1796875,
            "text": "X-linked Charcot-Marie-Tooth disease-5 (",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 12.0546875,
            "end_logit": -8.5078125,
            "text": "X-",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.72265625,
            "end_logit": 4.41796875,
            "text": "Charcot-Marie-Tooth disease-5 (CMTX5)",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": 5.81640625,
            "text": "linked",
            "probability": 0.0
        },
        {
            "start_logit": -8.8828125,
            "end_logit": 4.41796875,
            "text": "5)",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": 4.41796875,
            "text": "CMTX5)",
            "probability": 0.0
        }
    ],
    "5713b0a51174fb175500000e_8": [
        {
            "start_logit": 14.2421875,
            "end_logit": 11.703125,
            "text": "X-linked Charcot-Marie-Tooth disease type 5",
            "probability": 0.9853515625
        },
        {
            "start_logit": 14.2421875,
            "end_logit": 7.48828125,
            "text": "X-linked Charcot-Marie-Tooth disease type 5 (CMTX5)",
            "probability": 0.01473236083984375
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -0.023193359375,
            "text": "X-linked",
            "probability": 8.046627044677734e-06
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -1.90625,
            "text": "X-linked Charcot-Marie-Tooth disease type 5 (CMTX5), Arts syndrome, and non-syndromic sensorineural deafness",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -3.162109375,
            "text": "X",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -3.330078125,
            "text": "X-linked Charcot-Marie-Tooth disease",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -1.5009765625,
            "end_logit": 11.703125,
            "text": "Charcot-Marie-Tooth disease type 5",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -4.32421875,
            "text": "X-linked Charcot-Marie-Tooth disease type 5 (CMT",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -4.76953125,
            "text": "X-linked Charcot-Marie-Tooth disease type 5 (CMTX5), Arts syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -6.0390625,
            "text": "X-linked Charcot-Marie-Tooth disease type 5 (CMTX5), Arts",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -6.453125,
            "text": "X-linked Charcot-Marie-Tooth disease type 5 (",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -6.84375,
            "text": "X-linked Charcot-Marie-Tooth",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -6.953125,
            "text": "X-linked Charcot-Marie-Tooth disease type",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -7.0390625,
            "text": "X-linked Charcot",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -7.05859375,
            "text": "X-linked Charcot-Marie-Tooth disease type 5 (CMTX5",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -7.9296875,
            "text": "X-linked Charcot-Marie-Tooth disease type 5 (CMTX5), Arts syndrome, and non",
            "probability": 0.0
        },
        {
            "start_logit": -1.5009765625,
            "end_logit": 7.48828125,
            "text": "Charcot-Marie-Tooth disease type 5 (CMTX5)",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -8.359375,
            "text": "X-linked Charco",
            "probability": 0.0
        },
        {
            "start_logit": -6.234375,
            "end_logit": 11.703125,
            "text": "5",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 11.703125,
            "text": "type 5",
            "probability": 0.0
        }
    ],
    "5713b0a51174fb175500000e_9": [
        {
            "start_logit": 11.96875,
            "end_logit": 10.34375,
            "text": "X-linked Charcot-Marie-Tooth disease type 5",
            "probability": 1.0
        },
        {
            "start_logit": 4.06640625,
            "end_logit": 10.34375,
            "text": "Charcot-Marie-Tooth disease type 5",
            "probability": 0.00036835670471191406
        },
        {
            "start_logit": 11.96875,
            "end_logit": -0.63671875,
            "text": "X-linked Charcot-Marie-Tooth disease",
            "probability": 1.6987323760986328e-05
        },
        {
            "start_logit": 11.96875,
            "end_logit": -0.98193359375,
            "text": "X-linked",
            "probability": 1.2040138244628906e-05
        },
        {
            "start_logit": 11.96875,
            "end_logit": -3.591796875,
            "text": "X-linked Charcot-Marie-Tooth disease type 5 (CMT",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 11.96875,
            "end_logit": -5.078125,
            "text": "X",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.96875,
            "end_logit": -5.15625,
            "text": "X-linked Charcot-Marie-Tooth disease type",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.96875,
            "end_logit": -5.234375,
            "text": "X-linked Charcot-Marie-Tooth",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.96875,
            "end_logit": -5.34765625,
            "text": "X-linked Charcot-Marie-Tooth disease type 5 (",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.96875,
            "end_logit": -5.375,
            "text": "X-linked Charcot-Marie-Tooth disease type 5 (CMTX5)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.96875,
            "end_logit": -6.3828125,
            "text": "X-linked Charcot-Marie-Tooth disease type 5 (CMTX5",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.96875,
            "end_logit": -6.8515625,
            "text": "X-linked Charcot",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.96875,
            "end_logit": -7.39453125,
            "text": "X-",
            "probability": 0.0
        },
        {
            "start_logit": 11.96875,
            "end_logit": -8.15625,
            "text": "X-linked Charcot-",
            "probability": 0.0
        },
        {
            "start_logit": 11.96875,
            "end_logit": -8.1875,
            "text": "X-linked Charco",
            "probability": 0.0
        },
        {
            "start_logit": -6.6015625,
            "end_logit": 10.34375,
            "text": "5",
            "probability": 0.0
        },
        {
            "start_logit": 11.96875,
            "end_logit": -8.296875,
            "text": "X-linked Charcot-Mari",
            "probability": 0.0
        },
        {
            "start_logit": 4.06640625,
            "end_logit": -0.63671875,
            "text": "Charcot-Marie-Tooth disease",
            "probability": 0.0
        },
        {
            "start_logit": 11.96875,
            "end_logit": -8.6640625,
            "text": "X-linked Charcot-Marie-Tooth disease type 5 (CMTX",
            "probability": 0.0
        },
        {
            "start_logit": 11.96875,
            "end_logit": -9.1640625,
            "text": "X-linked Charcot-Marie-Tooth disease type 5 (CMTX5) is",
            "probability": 0.0
        }
    ],
    "5713b0a51174fb175500000e_10": [
        {
            "start_logit": 12.296875,
            "end_logit": 6.1875,
            "text": "X-linked",
            "probability": 0.82373046875
        },
        {
            "start_logit": 12.296875,
            "end_logit": 4.6484375,
            "text": "X-linked nonsyndromic sensorineural deafness type 2",
            "probability": 0.1754150390625
        },
        {
            "start_logit": 12.296875,
            "end_logit": -1.69140625,
            "text": "X-linked nonsyndromic sensorineural deafness",
            "probability": 0.00031304359436035156
        },
        {
            "start_logit": 12.296875,
            "end_logit": -2.2890625,
            "text": "X-linked nonsyndromic sensorineural deafness type 2 (DF",
            "probability": 0.00017154216766357422
        },
        {
            "start_logit": 12.296875,
            "end_logit": -3.46484375,
            "text": "X-linked nonsyndromic sensorineural deafness type 2 (DFN2",
            "probability": 5.27501106262207e-05
        },
        {
            "start_logit": 12.296875,
            "end_logit": -4.48046875,
            "text": "X-linked nonsyndromic sensorineural deafness type 2 (DFN2), or in syndromic deafness including Arts syndrome",
            "probability": 1.9073486328125e-05
        },
        {
            "start_logit": 12.296875,
            "end_logit": -4.84375,
            "text": "X-linked nonsyndromic sensorineural deafness type 2 (DFN2), or in syndromic deafness including Arts",
            "probability": 1.33514404296875e-05
        },
        {
            "start_logit": 12.296875,
            "end_logit": -5.44140625,
            "text": "X-linked nonsyndromic sensorineural deafness type 2 (DFN2), or in syndromic deafness",
            "probability": 7.3909759521484375e-06
        },
        {
            "start_logit": 12.296875,
            "end_logit": -5.67578125,
            "text": "X",
            "probability": 5.841255187988281e-06
        },
        {
            "start_logit": 12.296875,
            "end_logit": -6.12109375,
            "text": "X-linked nonsyndromic sensorineural deafness type 2 (DFN2), or in syndromic deafness including Arts syndrome and X-linked",
            "probability": 3.6954879760742188e-06
        },
        {
            "start_logit": 12.296875,
            "end_logit": -7.67578125,
            "text": "X-linked nonsyndromic sensorineural deafness type 2 (DFN2), or in syndromic deafness including Arts syndrome and X-linked Charco",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 12.296875,
            "end_logit": -7.828125,
            "text": "X-linked nonsyndromic sensorineural deafness type 2 (",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 12.296875,
            "end_logit": -7.99609375,
            "text": "X-linked nonsyndromic sensorineural deafness type 2 (DFN2)",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 12.296875,
            "end_logit": -8.2265625,
            "text": "X-linked nonsyndromic sensorineural deafness type",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 12.296875,
            "end_logit": -8.359375,
            "text": "X-linked nonsyndromic sensorineural deafness type 2 (DFN2), or in syndromic deafness including Art",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 12.296875,
            "end_logit": -8.828125,
            "text": "X-linked nonsyndromic",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 12.296875,
            "end_logit": -8.84375,
            "text": "X-linked nonsyndromic sensorineural deafness type 2 (DFN2), or",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -4.4453125,
            "end_logit": 4.6484375,
            "text": "sensorineural deafness type 2",
            "probability": 0.0
        },
        {
            "start_logit": -6.30859375,
            "end_logit": 4.6484375,
            "text": "deafness type 2",
            "probability": 0.0
        },
        {
            "start_logit": -9.5859375,
            "end_logit": 6.1875,
            "text": "linked",
            "probability": 0.0
        }
    ],
    "5713b0a51174fb175500000e_11": [
        {
            "start_logit": 12.546875,
            "end_logit": 12.9921875,
            "text": "Arts syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 12.546875,
            "end_logit": -2.3046875,
            "text": "Arts syndrome, Charcot-Marie-Tooth disease-5 (CMTX5) and X-linked non-syndromic sensorineural deafness",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 12.546875,
            "end_logit": -4.078125,
            "text": "Arts syndrome, Charcot-Marie-Tooth disease-5 (CMTX5) and X-linked",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.00390625,
            "end_logit": 12.9921875,
            "text": "syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 12.546875,
            "end_logit": -5.203125,
            "text": "Arts syndrome, Charcot-Marie-Tooth disease",
            "probability": 0.0
        },
        {
            "start_logit": 12.546875,
            "end_logit": -5.3203125,
            "text": "Arts",
            "probability": 0.0
        },
        {
            "start_logit": 12.546875,
            "end_logit": -5.44140625,
            "text": "Art",
            "probability": 0.0
        },
        {
            "start_logit": 12.546875,
            "end_logit": -5.52734375,
            "text": "Arts syndrome, Charco",
            "probability": 0.0
        },
        {
            "start_logit": 12.546875,
            "end_logit": -5.87109375,
            "text": "Arts syndrome, Charcot-Marie-Tooth disease-5 (CMTX5",
            "probability": 0.0
        },
        {
            "start_logit": 12.546875,
            "end_logit": -6.09375,
            "text": "Arts syndrome, Charcot-Marie-Tooth disease-5 (CMT",
            "probability": 0.0
        },
        {
            "start_logit": 12.546875,
            "end_logit": -6.39453125,
            "text": "Arts syndrome, Charcot-Marie-Tooth",
            "probability": 0.0
        },
        {
            "start_logit": 12.546875,
            "end_logit": -6.6015625,
            "text": "Arts syndrome, Charcot-Marie-Tooth disease-5 (CMTX5) and X-linked non-syndromic sensorineural deafness (DF",
            "probability": 0.0
        },
        {
            "start_logit": 12.546875,
            "end_logit": -6.84765625,
            "text": "Arts syndrome, Charcot-Marie-Tooth disease-5",
            "probability": 0.0
        },
        {
            "start_logit": 12.546875,
            "end_logit": -7.03125,
            "text": "Arts syndrome, Charcot-Marie-Tooth disease-5 (CMTX5) and X",
            "probability": 0.0
        },
        {
            "start_logit": 12.546875,
            "end_logit": -7.33203125,
            "text": "Arts syndrome, Charcot",
            "probability": 0.0
        },
        {
            "start_logit": 12.546875,
            "end_logit": -7.390625,
            "text": "Arts syndrome, Charcot-Marie-Tooth disease-5 (CMTX5)",
            "probability": 0.0
        },
        {
            "start_logit": 12.546875,
            "end_logit": -7.6953125,
            "text": "Arts syndrome, Charcot-Mari",
            "probability": 0.0
        },
        {
            "start_logit": 12.546875,
            "end_logit": -7.84765625,
            "text": "Arts syndrome, Charcot-Marie-Tooth disease-5 (CMTX5) and X-linked non-syndromic sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": 12.546875,
            "end_logit": -7.8828125,
            "text": "Arts syndrome, Charcot-Marie-Tooth disease-5 (CMTX",
            "probability": 0.0
        },
        {
            "start_logit": 12.546875,
            "end_logit": -8.0703125,
            "text": "Arts syndrome, Charcot-Marie-Tooth disease-5 (",
            "probability": 0.0
        }
    ],
    "5713b0a51174fb175500000e_12": [
        {
            "start_logit": 14.1015625,
            "end_logit": 13.5390625,
            "text": "X-linked Charcot-Marie-Tooth disease",
            "probability": 1.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -0.00876617431640625,
            "text": "X-linked",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -0.56103515625,
            "end_logit": 13.5390625,
            "text": "Charcot-Marie-Tooth disease",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -3.107421875,
            "text": "X",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.9296875,
            "end_logit": 13.5390625,
            "text": "disease",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -5.01953125,
            "text": "X-linked Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -6.2890625,
            "text": "X-linked Charcot-Marie-Tooth",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -6.6171875,
            "text": "X-linked Charcot-Marie-Tooth disease, Arts syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -6.984375,
            "text": "X-linked Charco",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -7.0390625,
            "text": "X-linked Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -7.44140625,
            "text": "X-linked Charcot",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -7.49609375,
            "text": "X-",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -8.234375,
            "text": "X-linked Charcot-Marie-Tooth disease, Arts",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -8.421875,
            "text": "X-linked Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form a disease continuum",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -8.5625,
            "text": "X-linked Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form a disease continuum: evidence",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -8.6015625,
            "text": "X-linked Charcot-Mari",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -8.8203125,
            "text": "X-linked Charcot-Marie-Tooth disease, Art",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -8.96875,
            "text": "X-linked Charcot-Marie-Tooth disease, Arts syndrome, and prelingual",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -9.0625,
            "text": "X-linked Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -9.1015625,
            "text": "X-linked Charcot-",
            "probability": 0.0
        }
    ],
    "5543a1b2ee40ea110c000001_1": [
        {
            "start_logit": 9.6171875,
            "end_logit": 12.5546875,
            "text": "chloroplasts",
            "probability": 1.0
        },
        {
            "start_logit": -8.5546875,
            "end_logit": 12.5546875,
            "text": "etioplasts but also in chloroplasts",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": 12.5546875,
            "text": "wheat leaves was characterized. PLBs are formed not only in etioplasts but also in chloroplasts",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": 12.5546875,
            "text": "PLB) proteome of dark-grown wheat leaves was characterized. PLBs are formed not only in etioplasts but also in chloroplasts",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 12.5546875,
            "text": "not only in etioplasts but also in chloroplasts",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 12.5546875,
            "text": "prolamellar body (PLB) proteome of dark-grown wheat leaves was characterized. PLBs are formed not only in etioplasts but also in chloroplasts",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": 12.5546875,
            "text": "PLBs are formed not only in etioplasts but also in chloroplasts",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 12.5546875,
            "text": "grown wheat leaves was characterized. PLBs are formed not only in etioplasts but also in chloroplasts",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 12.5546875,
            "text": "of dark-grown wheat leaves was characterized. PLBs are formed not only in etioplasts but also in chloroplasts",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 12.5546875,
            "text": "amellar body (PLB) proteome of dark-grown wheat leaves was characterized. PLBs are formed not only in etioplasts but also in chloroplasts",
            "probability": 0.0
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -8.53125,
            "text": "chloroplasts in young developing leaves during the night",
            "probability": 0.0
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -9.8046875,
            "text": "chloroplasts in young developing leaves during",
            "probability": 0.0
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -10.0,
            "text": "chloroplasts in young developing leaves",
            "probability": 0.0
        },
        {
            "start_logit": -8.5546875,
            "end_logit": -7.3671875,
            "text": "etioplasts",
            "probability": 0.0
        },
        {
            "start_logit": -8.5546875,
            "end_logit": -8.53125,
            "text": "etioplasts but also in chloroplasts in young developing leaves during the night",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": -7.3671875,
            "text": "wheat leaves was characterized. PLBs are formed not only in etioplasts",
            "probability": 0.0
        },
        {
            "start_logit": -8.5546875,
            "end_logit": -8.9765625,
            "text": "etioplasts but also in",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": -7.3671875,
            "text": "PLB) proteome of dark-grown wheat leaves was characterized. PLBs are formed not only in etioplasts",
            "probability": 0.0
        },
        {
            "start_logit": -8.5546875,
            "end_logit": -9.1015625,
            "text": "etioplasts but",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": -7.3671875,
            "text": "not only in etioplasts",
            "probability": 0.0
        }
    ],
    "58e0035f6fddd3e83e000009_1": [
        {
            "start_logit": 11.4140625,
            "end_logit": 10.46875,
            "text": "microtubules",
            "probability": 0.9931640625
        },
        {
            "start_logit": 6.390625,
            "end_logit": 10.46875,
            "text": "actin filaments, microtubules",
            "probability": 0.006587982177734375
        },
        {
            "start_logit": 6.390625,
            "end_logit": 6.41015625,
            "text": "actin filaments",
            "probability": 0.00011336803436279297
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -5.703125,
            "text": "microtubules, and intermediate filaments",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.7265625,
            "end_logit": 10.46875,
            "text": ", microtubules",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -8.0703125,
            "text": "microtubules, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -8.6640625,
            "text": "microtubules, and intermediate filaments-are major constituents of the cytoskeleton,",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -9.4921875,
            "text": "microtubules, and intermediate filaments-",
            "probability": 0.0
        },
        {
            "start_logit": -8.625,
            "end_logit": 10.46875,
            "text": "Fibrillar polymers-actin filaments, microtubules",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -9.6796875,
            "text": "microtubules, and intermediate",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -9.796875,
            "text": "microtubules,",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -10.171875,
            "text": "microtubules, and intermediate filaments-are major",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -10.1875,
            "text": "microtubules, and intermediate filaments-are major constituents of the cytoskeleton",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -10.3828125,
            "text": "microtubules, and intermediate filaments-are major constituents",
            "probability": 0.0
        },
        {
            "start_logit": -9.4453125,
            "end_logit": 10.46875,
            "text": "-actin filaments, microtubules",
            "probability": 0.0
        },
        {
            "start_logit": -9.453125,
            "end_logit": 10.46875,
            "text": "filaments, microtubules",
            "probability": 0.0
        },
        {
            "start_logit": 6.390625,
            "end_logit": -5.703125,
            "text": "actin filaments, microtubules, and intermediate filaments",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 10.46875,
            "text": "polymers-actin filaments, microtubules",
            "probability": 0.0
        },
        {
            "start_logit": 6.390625,
            "end_logit": -6.8203125,
            "text": "actin",
            "probability": 0.0
        },
        {
            "start_logit": 6.390625,
            "end_logit": -8.0703125,
            "text": "actin filaments, microtubules, and",
            "probability": 0.0
        }
    ],
    "5a86ebf2faa1ab7d2e000038_1": [
        {
            "start_logit": 11.4453125,
            "end_logit": 11.875,
            "text": "CLOCK",
            "probability": 1.0
        },
        {
            "start_logit": 11.4453125,
            "end_logit": -2.787109375,
            "text": "CLOCK and BMAL1",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 11.4453125,
            "end_logit": -5.796875,
            "text": "CLOCK and BMAL",
            "probability": 0.0
        },
        {
            "start_logit": 11.4453125,
            "end_logit": -6.234375,
            "text": "CLOCK and BM",
            "probability": 0.0
        },
        {
            "start_logit": 11.4453125,
            "end_logit": -8.0546875,
            "text": "CLOCK and BMAL1 are two members of bHLH-PAS-containing family of transcription factors",
            "probability": 0.0
        },
        {
            "start_logit": 11.4453125,
            "end_logit": -8.359375,
            "text": "CLOCK and BMAL1 are two",
            "probability": 0.0
        },
        {
            "start_logit": 11.4453125,
            "end_logit": -8.453125,
            "text": "CLOCK and BMAL1 are two members of bHLH-PAS-containing family of",
            "probability": 0.0
        },
        {
            "start_logit": 11.4453125,
            "end_logit": -8.5859375,
            "text": "CLOCK and",
            "probability": 0.0
        },
        {
            "start_logit": 11.4453125,
            "end_logit": -8.671875,
            "text": "CLOCK and BMAL1 are two members of bHLH-PAS",
            "probability": 0.0
        },
        {
            "start_logit": 11.4453125,
            "end_logit": -8.6953125,
            "text": "CLOCK and BMAL1 are two members of bHLH-PAS-containing family",
            "probability": 0.0
        },
        {
            "start_logit": 11.4453125,
            "end_logit": -8.953125,
            "text": "CLOCK and BMAL1 are",
            "probability": 0.0
        },
        {
            "start_logit": 11.4453125,
            "end_logit": -8.9921875,
            "text": "CLOCK and BMAL1 are two members of bHLH-PAS-containing family of transcription factors that represent",
            "probability": 0.0
        },
        {
            "start_logit": 11.4453125,
            "end_logit": -9.265625,
            "text": "CLOCK and BMAL1 are two members of bHLH",
            "probability": 0.0
        },
        {
            "start_logit": -9.71875,
            "end_logit": 11.875,
            "text": "Mammalian CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": 11.4453125,
            "end_logit": -9.3671875,
            "text": "CLOCK and BMAL1 are two members of bHL",
            "probability": 0.0
        },
        {
            "start_logit": 11.4453125,
            "end_logit": -9.3671875,
            "text": "CLOCK and BMAL1 are two members of bHLH-PAS-containing family of transcription factors that represent the positive",
            "probability": 0.0
        },
        {
            "start_logit": 11.4453125,
            "end_logit": -9.3984375,
            "text": "CLOCK and BMAL1 are two members of bHLH-PAS-containing",
            "probability": 0.0
        },
        {
            "start_logit": 11.4453125,
            "end_logit": -9.4609375,
            "text": "CLOCK and BMAL1 are two members of bHLH-PAS-containing family of transcription factors that represent the positive elements",
            "probability": 0.0
        },
        {
            "start_logit": -5.6171875,
            "end_logit": -2.787109375,
            "text": "BMAL1",
            "probability": 0.0
        },
        {
            "start_logit": -5.6171875,
            "end_logit": -5.796875,
            "text": "BMAL",
            "probability": 0.0
        }
    ],
    "5a86ebf2faa1ab7d2e000038_2": [
        {
            "start_logit": 11.1328125,
            "end_logit": 12.0546875,
            "text": "CLOCK",
            "probability": 1.0
        },
        {
            "start_logit": 11.1328125,
            "end_logit": -4.4375,
            "text": "CLOCK and BMAL1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.1328125,
            "end_logit": -6.1015625,
            "text": "CLOCK and BMAL1 proteins. Nuclear/cytoplasm distribution of CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": 11.1328125,
            "end_logit": -6.65234375,
            "text": "CLOCK and BM",
            "probability": 0.0
        },
        {
            "start_logit": 11.1328125,
            "end_logit": -6.91796875,
            "text": "CLOCK and BMAL",
            "probability": 0.0
        },
        {
            "start_logit": 11.1328125,
            "end_logit": -8.359375,
            "text": "CLOCK and BMAL1 proteins. Nuclear/cytoplasm",
            "probability": 0.0
        },
        {
            "start_logit": 11.1328125,
            "end_logit": -8.5546875,
            "text": "CLOCK and BMAL1 proteins",
            "probability": 0.0
        },
        {
            "start_logit": 11.1328125,
            "end_logit": -9.3046875,
            "text": "CLOCK and",
            "probability": 0.0
        },
        {
            "start_logit": 11.1328125,
            "end_logit": -9.359375,
            "text": "CLOCK and BMAL1 proteins.",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 12.0546875,
            "text": "examined abundance, posttranslational modifications, cellular localization of endogenous and ectopically expressed CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": 11.1328125,
            "end_logit": -9.7109375,
            "text": "CLOCK and BMAL1 proteins. Nuclear/cytoplasm distribution of CLOCK was found to be under circadian regulation.",
            "probability": 0.0
        },
        {
            "start_logit": 11.1328125,
            "end_logit": -9.796875,
            "text": "CLOCK and BMAL1 proteins. Nuclear/cytoplasm distribution of",
            "probability": 0.0
        },
        {
            "start_logit": 11.1328125,
            "end_logit": -9.8515625,
            "text": "CLOCK and BMAL1 proteins. Nuclear",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 12.0546875,
            "text": "abundance, posttranslational modifications, cellular localization of endogenous and ectopically expressed CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": 11.1328125,
            "end_logit": -9.921875,
            "text": "CLOCK and BMAL1 proteins. Nuclear/cytoplasm distribution of CLOCK was found to be",
            "probability": 0.0
        },
        {
            "start_logit": 11.1328125,
            "end_logit": -9.953125,
            "text": "CLOCK and BMAL1 proteins. Nuclear/cytoplasm distribution of CLOCK was",
            "probability": 0.0
        },
        {
            "start_logit": -6.66015625,
            "end_logit": -4.4375,
            "text": "BMAL1",
            "probability": 0.0
        },
        {
            "start_logit": -6.66015625,
            "end_logit": -6.1015625,
            "text": "BMAL1 proteins. Nuclear/cytoplasm distribution of CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": -6.66015625,
            "end_logit": -6.65234375,
            "text": "BM",
            "probability": 0.0
        },
        {
            "start_logit": -6.66015625,
            "end_logit": -6.91796875,
            "text": "BMAL",
            "probability": 0.0
        }
    ],
    "5a86ebf2faa1ab7d2e000038_3": [
        {
            "start_logit": 10.90625,
            "end_logit": 12.25,
            "text": "CLOCK",
            "probability": 1.0
        },
        {
            "start_logit": 10.90625,
            "end_logit": -4.1171875,
            "text": "CLOCK/BMAL1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.90625,
            "end_logit": -7.08984375,
            "text": "CLOCK/BM",
            "probability": 0.0
        },
        {
            "start_logit": 10.90625,
            "end_logit": -7.109375,
            "text": "CLOCK/BMAL",
            "probability": 0.0
        },
        {
            "start_logit": 10.90625,
            "end_logit": -7.859375,
            "text": "CLOCK/BMAL1 complex following ectopic coexpression of both proteins is followed by their codependent phosphorylation, which is tightly coupled to CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": 10.90625,
            "end_logit": -8.0078125,
            "text": "CLOCK/BMAL1 complex following ectopic coexpression of both proteins",
            "probability": 0.0
        },
        {
            "start_logit": 10.90625,
            "end_logit": -8.4375,
            "text": "CLOCK/BMAL1 complex following ectopic coexpression of both proteins is followed by their codependent phosphorylation",
            "probability": 0.0
        },
        {
            "start_logit": 10.90625,
            "end_logit": -8.7109375,
            "text": "CLOCK/BMAL1 complex",
            "probability": 0.0
        },
        {
            "start_logit": 10.90625,
            "end_logit": -9.03125,
            "text": "CLOCK/BMAL1 complex following ectopic coexpression of both proteins is followed by their",
            "probability": 0.0
        },
        {
            "start_logit": 10.90625,
            "end_logit": -9.1640625,
            "text": "CLOCK/BMAL1 complex following ectopic coexpression of",
            "probability": 0.0
        },
        {
            "start_logit": 10.90625,
            "end_logit": -9.390625,
            "text": "CLOCK/BMAL1 complex following ectopic coexpression of both proteins is followed by their codependent phosphorylation, which is tightly coupled to CLOCK nuclear translocation",
            "probability": 0.0
        },
        {
            "start_logit": 10.90625,
            "end_logit": -9.453125,
            "text": "CLOCK/BMAL1 complex following ectopic coexpression of both proteins is followed by their codependent phosphorylation,",
            "probability": 0.0
        },
        {
            "start_logit": 10.90625,
            "end_logit": -9.6015625,
            "text": "CLOCK/BMAL1 complex following ectopic coexpression of both proteins is followed by their codependent phosphorylation, which is tightly coupled to CLOCK nuclear",
            "probability": 0.0
        },
        {
            "start_logit": 10.90625,
            "end_logit": -9.65625,
            "text": "CLOCK/BMAL1 complex following ectopic coexpression of both proteins is followed by their code",
            "probability": 0.0
        },
        {
            "start_logit": 10.90625,
            "end_logit": -9.703125,
            "text": "CLOCK/BMAL1 complex following ectopic coexpression of both proteins is followed by their codependent",
            "probability": 0.0
        },
        {
            "start_logit": -8.75,
            "end_logit": -4.1171875,
            "text": "BMAL1",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": -4.1171875,
            "text": "AL1",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": -4.1171875,
            "text": "/BMAL1",
            "probability": 0.0
        },
        {
            "start_logit": -10.984375,
            "end_logit": -4.1171875,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": -8.75,
            "end_logit": -7.08984375,
            "text": "BM",
            "probability": 0.0
        }
    ],
    "5a86ebf2faa1ab7d2e000038_4": [
        {
            "start_logit": 10.9140625,
            "end_logit": 12.1875,
            "text": "CLOCK",
            "probability": 1.0
        },
        {
            "start_logit": 10.9140625,
            "end_logit": -2.060546875,
            "text": "CLOCK/BMAL1",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 10.9140625,
            "end_logit": -4.8125,
            "text": "CLOCK/BMAL1 complex",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.9140625,
            "end_logit": -5.15625,
            "text": "CLOCK/BM",
            "probability": 0.0
        },
        {
            "start_logit": 10.9140625,
            "end_logit": -5.546875,
            "text": "CLOCK/BMAL",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 12.1875,
            "text": "/and availability of CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": 10.9140625,
            "end_logit": -9.53125,
            "text": "CLOCK/",
            "probability": 0.0
        },
        {
            "start_logit": 10.9140625,
            "end_logit": -9.625,
            "text": "CLOCK/BMAL1 complex.",
            "probability": 0.0
        },
        {
            "start_logit": -6.2734375,
            "end_logit": -2.060546875,
            "text": "BMAL1",
            "probability": 0.0
        },
        {
            "start_logit": -6.2734375,
            "end_logit": -4.8125,
            "text": "BMAL1 complex",
            "probability": 0.0
        },
        {
            "start_logit": -6.2734375,
            "end_logit": -5.15625,
            "text": "BM",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": -2.060546875,
            "text": "AL1",
            "probability": 0.0
        },
        {
            "start_logit": -6.2734375,
            "end_logit": -5.546875,
            "text": "BMAL",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": -2.060546875,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": -2.060546875,
            "text": "/BMAL1",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": -2.060546875,
            "text": "/and availability of CLOCK/BMAL1",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": -4.8125,
            "text": "AL1 complex",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": -4.8125,
            "text": "1 complex",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": -4.8125,
            "text": "complex",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": -5.546875,
            "text": "AL",
            "probability": 0.0
        }
    ],
    "5a86ebf2faa1ab7d2e000038_5": [
        {
            "start_logit": 11.265625,
            "end_logit": 12.03125,
            "text": "CLOCK",
            "probability": 1.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -2.654296875,
            "text": "CLOCK and BMAL1",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 11.265625,
            "end_logit": -6.39453125,
            "text": "CLOCK and BMAL",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -6.41796875,
            "text": "CLOCK and BM",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -8.5859375,
            "text": "CLOCK and BMAL1, are known to regulate gene expression by interacting with a promoter element termed the E-box (CACGTG",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -8.6015625,
            "text": "CLOCK and BMAL1,",
            "probability": 0.0
        },
        {
            "start_logit": -9.46875,
            "end_logit": 12.03125,
            "text": "basic helix-loop-helix (bHLH) PAS (for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -8.9375,
            "text": "CLOCK and",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -9.234375,
            "text": "CLOCK and BMAL1, are known",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -9.3359375,
            "text": "CLOCK and BMAL1, are known to regulate gene expression by interacting with a promoter element termed the E-box",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 12.03125,
            "text": "bHLH) PAS (for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -9.3984375,
            "text": "CLOCK and BMAL1, are",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": 12.03125,
            "text": "PAS (for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 12.03125,
            "text": "for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 12.03125,
            "text": "Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 12.03125,
            "text": "(for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 12.03125,
            "text": "transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 12.03125,
            "text": "LH) PAS (for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": -6.6484375,
            "end_logit": -2.654296875,
            "text": "BMAL1",
            "probability": 0.0
        },
        {
            "start_logit": -9.5390625,
            "end_logit": -2.654296875,
            "text": "1",
            "probability": 0.0
        }
    ],
    "5a86ebf2faa1ab7d2e000038_6": [
        {
            "start_logit": 11.25,
            "end_logit": 11.890625,
            "text": "CLOCK",
            "probability": 1.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -3.08984375,
            "text": "CLOCK and BMAL1",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 11.25,
            "end_logit": -6.29296875,
            "text": "CLOCK and BM",
            "probability": 0.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -6.46484375,
            "text": "CLOCK and BMAL",
            "probability": 0.0
        },
        {
            "start_logit": -8.5859375,
            "end_logit": 11.890625,
            "text": "PER and CRY, which inhibit their own transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": -9.2109375,
            "end_logit": 11.890625,
            "text": "CRY, which inhibit their own transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -8.9296875,
            "text": "CLOCK and",
            "probability": 0.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -9.3828125,
            "text": "CLOCK and BMAL1.",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 11.890625,
            "text": "oscillations of PER and CRY, which inhibit their own transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 11.890625,
            "text": "inhibit their own transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 11.890625,
            "text": "of PER and CRY, which inhibit their own transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 11.890625,
            "text": "transcriptional negative feedback loop that is driven primarily by oscillations of PER and CRY, which inhibit their own transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 11.890625,
            "text": "negative feedback loop that is driven primarily by oscillations of PER and CRY, which inhibit their own transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 11.890625,
            "text": "activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": -6.1875,
            "end_logit": -3.08984375,
            "text": "BMAL1",
            "probability": 0.0
        },
        {
            "start_logit": -8.5859375,
            "end_logit": -3.08984375,
            "text": "PER and CRY, which inhibit their own transcriptional activators, CLOCK and BMAL1",
            "probability": 0.0
        },
        {
            "start_logit": -9.2109375,
            "end_logit": -3.08984375,
            "text": "CRY, which inhibit their own transcriptional activators, CLOCK and BMAL1",
            "probability": 0.0
        },
        {
            "start_logit": -9.2734375,
            "end_logit": -3.08984375,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": -6.1875,
            "end_logit": -6.29296875,
            "text": "BM",
            "probability": 0.0
        },
        {
            "start_logit": -6.1875,
            "end_logit": -6.46484375,
            "text": "BMAL",
            "probability": 0.0
        }
    ],
    "5a86ebf2faa1ab7d2e000038_7": [
        {
            "start_logit": 10.9453125,
            "end_logit": 12.0546875,
            "text": "CLOCK",
            "probability": 1.0
        },
        {
            "start_logit": 10.9453125,
            "end_logit": -2.87109375,
            "text": "CLOCK:BMAL1",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 10.9453125,
            "end_logit": -6.54296875,
            "text": "CLOCK:BMAL1, while CRY",
            "probability": 0.0
        },
        {
            "start_logit": 10.9453125,
            "end_logit": -6.703125,
            "text": "CLOCK:BMAL1, while CRY only interacts indirectly; PER2 bridges CRY and CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": 10.9453125,
            "end_logit": -6.76171875,
            "text": "CLOCK:BM",
            "probability": 0.0
        },
        {
            "start_logit": 10.9453125,
            "end_logit": -6.90234375,
            "text": "CLOCK:BMAL",
            "probability": 0.0
        },
        {
            "start_logit": 10.9453125,
            "end_logit": -7.95703125,
            "text": "CLOCK:BMAL1, while CRY only interacts indirectly; PER2 bridges CRY and CLOCK:BMAL1",
            "probability": 0.0
        },
        {
            "start_logit": 10.9453125,
            "end_logit": -8.7109375,
            "text": "CLOCK:BMAL1, while CRY only interacts indirectly; PER2 bridges CRY and CLOCK:BM",
            "probability": 0.0
        },
        {
            "start_logit": 10.9453125,
            "end_logit": -8.8046875,
            "text": "CLOCK:BMAL1, while CRY only interacts indirectly; PER2 bridges CRY and CLOCK:BMAL1 to drive the circadian negative feedback loop",
            "probability": 0.0
        },
        {
            "start_logit": 10.9453125,
            "end_logit": -9.078125,
            "text": "CLOCK:BMAL1, while CRY only interacts indirectly; PER2 bridges CRY and CLOCK:BMAL",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 12.0546875,
            "text": ": PER2 directly and rhythmically binds to CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": 10.9453125,
            "end_logit": -9.296875,
            "text": "CLOCK:BMAL1, while CRY only interacts indirectly; PER2 bridges CRY",
            "probability": 0.0
        },
        {
            "start_logit": 10.9453125,
            "end_logit": -9.4375,
            "text": "CLOCK:BMAL1,",
            "probability": 0.0
        },
        {
            "start_logit": 10.9453125,
            "end_logit": -9.6875,
            "text": "CLOCK:BMAL1, while CRY only interacts indirectly; PER2 bridges CRY and CLOCK:BMAL1 to drive the circadian negative feedback loop.",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -2.87109375,
            "text": "BMAL1",
            "probability": 0.0
        },
        {
            "start_logit": -9.3828125,
            "end_logit": -2.87109375,
            "text": ":BMAL1",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": -2.87109375,
            "text": "AL1",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": -2.87109375,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": -2.87109375,
            "text": ": PER2 directly and rhythmically binds to CLOCK:BMAL1",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -6.54296875,
            "text": "BMAL1, while CRY",
            "probability": 0.0
        }
    ],
    "5a86ebf2faa1ab7d2e000038_8": [
        {
            "start_logit": 11.265625,
            "end_logit": 12.03125,
            "text": "CLOCK",
            "probability": 1.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -2.654296875,
            "text": "CLOCK and BMAL1",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 11.265625,
            "end_logit": -6.39453125,
            "text": "CLOCK and BMAL",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -6.41796875,
            "text": "CLOCK and BM",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -8.5859375,
            "text": "CLOCK and BMAL1, are known to regulate gene expression by interacting with a promoter element termed the E-box (CACGTG",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -8.6015625,
            "text": "CLOCK and BMAL1,",
            "probability": 0.0
        },
        {
            "start_logit": -9.46875,
            "end_logit": 12.03125,
            "text": "basic helix-loop-helix (bHLH) PAS (for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -8.9375,
            "text": "CLOCK and",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -9.234375,
            "text": "CLOCK and BMAL1, are known",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -9.3359375,
            "text": "CLOCK and BMAL1, are known to regulate gene expression by interacting with a promoter element termed the E-box",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 12.03125,
            "text": "bHLH) PAS (for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -9.3984375,
            "text": "CLOCK and BMAL1, are",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": 12.03125,
            "text": "PAS (for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 12.03125,
            "text": "for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 12.03125,
            "text": "Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 12.03125,
            "text": "(for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 12.03125,
            "text": "transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 12.03125,
            "text": "LH) PAS (for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": -6.6484375,
            "end_logit": -2.654296875,
            "text": "BMAL1",
            "probability": 0.0
        },
        {
            "start_logit": -9.5390625,
            "end_logit": -2.654296875,
            "text": "1",
            "probability": 0.0
        }
    ],
    "5a86ebf2faa1ab7d2e000038_9": [
        {
            "start_logit": 11.1796875,
            "end_logit": 12.0234375,
            "text": "CLOCK",
            "probability": 1.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -3.63671875,
            "text": "CLOCK:BMAL",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -5.8125,
            "text": "CLOCK:BM",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": 12.0234375,
            "text": "CRY proteins in turn inhibit CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -7.39453125,
            "text": "CLOCK:BMAL-",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -7.64453125,
            "text": "CLOCK:BMAL-mediated transcription closing the negative feedback loop",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -8.9765625,
            "text": "CLOCK:BMAL-mediated transcription closing the",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -9.28125,
            "text": "CLOCK:BMAL-mediated transcription closing",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -9.2890625,
            "text": "CLOCK:BMAL-mediated transcription closing the negative feedback loop.",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -9.4453125,
            "text": "CLOCK:BMAL-mediated",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 12.0234375,
            "text": "inhibit CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -9.5,
            "text": "CLOCK:BMAL-mediated transcription closing the negative feedback",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -9.7734375,
            "text": "CLOCK:BMAL-mediated transcription",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -9.984375,
            "text": "CLOCK:BMAL-mediated transcription closing the negative",
            "probability": 0.0
        },
        {
            "start_logit": -5.96484375,
            "end_logit": -3.63671875,
            "text": "BMAL",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": -3.63671875,
            "text": "CRY proteins in turn inhibit CLOCK:BMAL",
            "probability": 0.0
        },
        {
            "start_logit": -5.96484375,
            "end_logit": -5.8125,
            "text": "BM",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": -4.4453125,
            "text": "CRY",
            "probability": 0.0
        },
        {
            "start_logit": -9.21875,
            "end_logit": -3.63671875,
            "text": "AL",
            "probability": 0.0
        },
        {
            "start_logit": -9.703125,
            "end_logit": -3.63671875,
            "text": ":BMAL",
            "probability": 0.0
        }
    ],
    "5a86ebf2faa1ab7d2e000038_10": [
        {
            "start_logit": 11.265625,
            "end_logit": 12.0,
            "text": "CLOCK",
            "probability": 1.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -3.298828125,
            "text": "CLOCK:BMAL",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 11.265625,
            "end_logit": -6.65234375,
            "text": "CLOCK:BM",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -6.71484375,
            "text": "CLOCK:BMAL heterodimers induce the expression of Cry",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -6.86328125,
            "text": "CLOCK:BMAL heterodimer",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -8.3125,
            "text": "CLOCK:BMAL heterodimers",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -8.34375,
            "text": "CLOCK:BMAL heterodimers induce the expression of Cry genes",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -9.515625,
            "text": "CLOCK:BMAL heterodimers induce the expression of",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -9.609375,
            "text": "CLOCK:BMAL heterodimers induce the expression of Cry genes.",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -9.6328125,
            "text": "CLOCK:BMAL heterodimers induce",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -9.8359375,
            "text": "CLOCK:BMAL heterodimers induce the expression",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": 12.0,
            "text": "vertebrate circadian feedback loop, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": -6.29296875,
            "end_logit": -3.298828125,
            "text": "BMAL",
            "probability": 0.0
        },
        {
            "start_logit": -9.4765625,
            "end_logit": -3.298828125,
            "text": "AL",
            "probability": 0.0
        },
        {
            "start_logit": -9.5546875,
            "end_logit": -3.298828125,
            "text": ":BMAL",
            "probability": 0.0
        },
        {
            "start_logit": -6.29296875,
            "end_logit": -6.65234375,
            "text": "BM",
            "probability": 0.0
        },
        {
            "start_logit": -6.29296875,
            "end_logit": -6.71484375,
            "text": "BMAL heterodimers induce the expression of Cry",
            "probability": 0.0
        },
        {
            "start_logit": -6.29296875,
            "end_logit": -6.86328125,
            "text": "BMAL heterodimer",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": -3.298828125,
            "text": "vertebrate circadian feedback loop, CLOCK:BMAL",
            "probability": 0.0
        },
        {
            "start_logit": -6.29296875,
            "end_logit": -8.3125,
            "text": "BMAL heterodimers",
            "probability": 0.0
        }
    ],
    "5a86ebf2faa1ab7d2e000038_11": [
        {
            "start_logit": 11.265625,
            "end_logit": 12.03125,
            "text": "CLOCK",
            "probability": 1.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -2.654296875,
            "text": "CLOCK and BMAL1",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 11.265625,
            "end_logit": -6.39453125,
            "text": "CLOCK and BMAL",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -6.41796875,
            "text": "CLOCK and BM",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -8.5859375,
            "text": "CLOCK and BMAL1, are known to regulate gene expression by interacting with a promoter element termed the E-box (CACGTG",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -8.6015625,
            "text": "CLOCK and BMAL1,",
            "probability": 0.0
        },
        {
            "start_logit": -9.46875,
            "end_logit": 12.03125,
            "text": "basic helix-loop-helix (bHLH) PAS (for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -8.9375,
            "text": "CLOCK and",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -9.234375,
            "text": "CLOCK and BMAL1, are known",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -9.3359375,
            "text": "CLOCK and BMAL1, are known to regulate gene expression by interacting with a promoter element termed the E-box",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 12.03125,
            "text": "bHLH) PAS (for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -9.3984375,
            "text": "CLOCK and BMAL1, are",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": 12.03125,
            "text": "PAS (for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 12.03125,
            "text": "for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 12.03125,
            "text": "Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 12.03125,
            "text": "(for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 12.03125,
            "text": "transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 12.03125,
            "text": "LH) PAS (for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": -6.6484375,
            "end_logit": -2.654296875,
            "text": "BMAL1",
            "probability": 0.0
        },
        {
            "start_logit": -9.5390625,
            "end_logit": -2.654296875,
            "text": "1",
            "probability": 0.0
        }
    ],
    "5a86ebf2faa1ab7d2e000038_12": [
        {
            "start_logit": 10.7734375,
            "end_logit": 12.0703125,
            "text": "clock",
            "probability": 1.0
        },
        {
            "start_logit": 10.7734375,
            "end_logit": -0.99169921875,
            "text": "clock genes Clock",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 10.7734375,
            "end_logit": -3.30859375,
            "text": "clock genes Clock and Bmal1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 10.7734375,
            "end_logit": -6.08984375,
            "text": "clock genes Clock and Bmal",
            "probability": 0.0
        },
        {
            "start_logit": 10.7734375,
            "end_logit": -6.95703125,
            "text": "clock genes Clock and Bm",
            "probability": 0.0
        },
        {
            "start_logit": 10.7734375,
            "end_logit": -8.40625,
            "text": "clock genes",
            "probability": 0.0
        },
        {
            "start_logit": 10.7734375,
            "end_logit": -8.5078125,
            "text": "clock genes Clock and",
            "probability": 0.0
        },
        {
            "start_logit": -9.90625,
            "end_logit": 12.0703125,
            "text": "Id2 is involved in stabilization of the amplitudes of the circadian oscillations by suppressing transcriptional activation of clock",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 12.0703125,
            "text": "amplitudes of the circadian oscillations by suppressing transcriptional activation of clock",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 12.0703125,
            "text": "suppressing transcriptional activation of clock",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 12.0703125,
            "text": "present study, we demonstrate that Id2 is involved in stabilization of the amplitudes of the circadian oscillations by suppressing transcriptional activation of clock",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 12.0703125,
            "text": "transcriptional activation of clock",
            "probability": 0.0
        },
        {
            "start_logit": 10.7734375,
            "end_logit": -9.875,
            "text": "clock genes Clock and Bmal1.",
            "probability": 0.0
        },
        {
            "start_logit": -4.01171875,
            "end_logit": -0.99169921875,
            "text": "Clock",
            "probability": 0.0
        },
        {
            "start_logit": -4.01171875,
            "end_logit": -3.30859375,
            "text": "Clock and Bmal1",
            "probability": 0.0
        },
        {
            "start_logit": -6.7421875,
            "end_logit": -3.30859375,
            "text": "Bmal1",
            "probability": 0.0
        },
        {
            "start_logit": -4.01171875,
            "end_logit": -6.08984375,
            "text": "Clock and Bmal",
            "probability": 0.0
        },
        {
            "start_logit": -9.90625,
            "end_logit": -0.99169921875,
            "text": "Id2 is involved in stabilization of the amplitudes of the circadian oscillations by suppressing transcriptional activation of clock genes Clock",
            "probability": 0.0
        },
        {
            "start_logit": -4.01171875,
            "end_logit": -6.95703125,
            "text": "Clock and Bm",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": -0.99169921875,
            "text": "amplitudes of the circadian oscillations by suppressing transcriptional activation of clock genes Clock",
            "probability": 0.0
        }
    ],
    "5a86ebf2faa1ab7d2e000038_13": [
        {
            "start_logit": 8.046875,
            "end_logit": 11.5234375,
            "text": "clock",
            "probability": 1.0
        },
        {
            "start_logit": -4.32421875,
            "end_logit": 11.5234375,
            "text": "bmal1 is an essential transcriptional activator within the mammalian circadian clock",
            "probability": 4.291534423828125e-06
        },
        {
            "start_logit": -7.1171875,
            "end_logit": 11.5234375,
            "text": "circadian clock",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.78515625,
            "end_logit": 11.5234375,
            "text": "mammalian circadian clock",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.5859375,
            "end_logit": 11.5234375,
            "text": "1 is an essential transcriptional activator within the mammalian circadian clock",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.08984375,
            "text": "clock we report here that the suprachiasmatic",
            "probability": 0.0
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.1796875,
            "text": "clock we report here that the suprachiasmatic nucleus",
            "probability": 0.0
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.39453125,
            "text": "clock we report here that the suprachiasmatic nucleus scn",
            "probability": 0.0
        },
        {
            "start_logit": -4.32421875,
            "end_logit": -1.5556640625,
            "text": "bmal1",
            "probability": 0.0
        },
        {
            "start_logit": -8.5859375,
            "end_logit": -1.5556640625,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": -4.32421875,
            "end_logit": -6.51171875,
            "text": "bm",
            "probability": 0.0
        },
        {
            "start_logit": -4.32421875,
            "end_logit": -7.08984375,
            "text": "bmal1 is an essential transcriptional activator within the mammalian circadian clock we report here that the suprachiasmatic",
            "probability": 0.0
        },
        {
            "start_logit": -4.32421875,
            "end_logit": -7.1796875,
            "text": "bmal1 is an essential transcriptional activator within the mammalian circadian clock we report here that the suprachiasmatic nucleus",
            "probability": 0.0
        },
        {
            "start_logit": -4.32421875,
            "end_logit": -7.3359375,
            "text": "bmal",
            "probability": 0.0
        },
        {
            "start_logit": -4.32421875,
            "end_logit": -7.39453125,
            "text": "bmal1 is an essential transcriptional activator within the mammalian circadian clock we report here that the suprachiasmatic nucleus scn",
            "probability": 0.0
        },
        {
            "start_logit": -4.32421875,
            "end_logit": -8.421875,
            "text": "bmal1 is an essential transcriptional activator within the",
            "probability": 0.0
        },
        {
            "start_logit": -7.1171875,
            "end_logit": -7.08984375,
            "text": "circadian clock we report here that the suprachiasmatic",
            "probability": 0.0
        },
        {
            "start_logit": -7.1171875,
            "end_logit": -7.1796875,
            "text": "circadian clock we report here that the suprachiasmatic nucleus",
            "probability": 0.0
        },
        {
            "start_logit": -8.53125,
            "end_logit": -5.91015625,
            "text": "dissociated scn neurons expressed fluctuating levels of per2",
            "probability": 0.0
        },
        {
            "start_logit": -7.1171875,
            "end_logit": -7.39453125,
            "text": "circadian clock we report here that the suprachiasmatic nucleus scn",
            "probability": 0.0
        }
    ],
    "5a86ebf2faa1ab7d2e000038_14": [
        {
            "start_logit": 9.5390625,
            "end_logit": 11.28125,
            "text": "clock",
            "probability": 1.0
        },
        {
            "start_logit": -1.123046875,
            "end_logit": 7.33203125,
            "text": "clock",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.5390625,
            "end_logit": -5.89453125,
            "text": "clock gene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.13671875,
            "end_logit": 7.33203125,
            "text": "bmal1 clock",
            "probability": 0.0
        },
        {
            "start_logit": -5.671875,
            "end_logit": 7.33203125,
            "text": "1 cry2 and per2 and was repressed by bmal1 clock",
            "probability": 0.0
        },
        {
            "start_logit": -7.01953125,
            "end_logit": 7.33203125,
            "text": "cry1 cry2 and per2 and was repressed by bmal1 clock",
            "probability": 0.0
        },
        {
            "start_logit": -7.3515625,
            "end_logit": 7.33203125,
            "text": "2 and per2 and was repressed by bmal1 clock",
            "probability": 0.0
        },
        {
            "start_logit": -7.421875,
            "end_logit": 7.33203125,
            "text": "1 clock",
            "probability": 0.0
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 7.33203125,
            "text": "and per2 and was repressed by bmal1 clock",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": 7.33203125,
            "text": "activated by cry1 cry2 and per2 and was repressed by bmal1 clock",
            "probability": 0.0
        },
        {
            "start_logit": -8.53125,
            "end_logit": 7.33203125,
            "text": "per2 and was repressed by bmal1 clock",
            "probability": 0.0
        },
        {
            "start_logit": -1.123046875,
            "end_logit": -4.109375,
            "text": "clock dimers therefore cry per2 and bmal1 clock",
            "probability": 0.0
        },
        {
            "start_logit": -4.98828125,
            "end_logit": -1.1748046875,
            "text": "bmal1",
            "probability": 0.0
        },
        {
            "start_logit": -5.79296875,
            "end_logit": -1.1748046875,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": -4.98828125,
            "end_logit": -2.34765625,
            "text": "bmal1 gene mbmal1 and defined the mbmal1 promoter region transcription of mbmal1 was activated by cry1 cry2 and per2",
            "probability": 0.0
        },
        {
            "start_logit": -1.123046875,
            "end_logit": -6.26171875,
            "text": "clock dimers",
            "probability": 0.0
        },
        {
            "start_logit": -5.671875,
            "end_logit": -2.34765625,
            "text": "1 cry2 and per2",
            "probability": 0.0
        },
        {
            "start_logit": -5.79296875,
            "end_logit": -2.34765625,
            "text": "1 gene mbmal1 and defined the mbmal1 promoter region transcription of mbmal1 was activated by cry1 cry2 and per2",
            "probability": 0.0
        },
        {
            "start_logit": -4.1796875,
            "end_logit": -4.109375,
            "text": "and bmal1 clock",
            "probability": 0.0
        },
        {
            "start_logit": -5.13671875,
            "end_logit": -4.109375,
            "text": "bmal1 clock dimers therefore cry per2 and bmal1 clock",
            "probability": 0.0
        }
    ],
    "5a86ebf2faa1ab7d2e000038_15": [
        {
            "start_logit": 11.6484375,
            "end_logit": 6.56640625,
            "text": "clock",
            "probability": 0.9541015625
        },
        {
            "start_logit": 11.6484375,
            "end_logit": 3.515625,
            "text": "clock genes is based on transcriptional feedback loops two basic helix loop helix bhlh pas for period arnt sim domain containing transcriptional activators clock",
            "probability": 0.04498291015625
        },
        {
            "start_logit": 11.6484375,
            "end_logit": -1.5517578125,
            "text": "clock genes",
            "probability": 0.00028252601623535156
        },
        {
            "start_logit": 11.6484375,
            "end_logit": -5.87109375,
            "text": "clock genes is based on transcriptional feedback loops two basic helix loop helix bhlh pas for period arnt sim domain containing transcriptional activators clock and bmal",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": 11.6484375,
            "end_logit": -6.0546875,
            "text": "clock genes is based on transcriptional feedback loops two basic helix loop helix bhlh pas for period arnt sim domain containing transcriptional activators clock and bm",
            "probability": 3.0994415283203125e-06
        },
        {
            "start_logit": 1.7568359375,
            "end_logit": 3.515625,
            "text": "clock",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": 11.6484375,
            "end_logit": -6.84375,
            "text": "clock genes is based on transcriptional feedback loops two basic helix loop helix bhlh pas for",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 11.6484375,
            "end_logit": -7.25390625,
            "text": "clock genes is based on transcriptional feedback loops two basic helix loop helix bhlh pas for period arnt",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 1.7568359375,
            "end_logit": -1.4072265625,
            "text": "clock and bmal1",
            "probability": 0.0
        },
        {
            "start_logit": -5.91015625,
            "end_logit": 3.515625,
            "text": "activators clock",
            "probability": 0.0
        },
        {
            "start_logit": 1.7568359375,
            "end_logit": -5.87109375,
            "text": "clock and bmal",
            "probability": 0.0
        },
        {
            "start_logit": 1.7568359375,
            "end_logit": -6.0546875,
            "text": "clock and bm",
            "probability": 0.0
        },
        {
            "start_logit": -8.7265625,
            "end_logit": 3.515625,
            "text": "for period arnt sim domain containing transcriptional activators clock",
            "probability": 0.0
        },
        {
            "start_logit": 1.7568359375,
            "end_logit": -6.9765625,
            "text": "clock and bmal1 are known to regulate gene expression by interacting with a promoter element termed the e box cacgtg",
            "probability": 0.0
        },
        {
            "start_logit": -5.76953125,
            "end_logit": -1.4072265625,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": -5.953125,
            "end_logit": -1.3603515625,
            "text": "clock",
            "probability": 0.0
        },
        {
            "start_logit": -5.91015625,
            "end_logit": -1.4072265625,
            "text": "activators clock and bmal1",
            "probability": 0.0
        },
        {
            "start_logit": -6.43359375,
            "end_logit": -1.4072265625,
            "text": "bmal1",
            "probability": 0.0
        },
        {
            "start_logit": -8.7265625,
            "end_logit": -1.4072265625,
            "text": "for period arnt sim domain containing transcriptional activators clock and bmal1",
            "probability": 0.0
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -3.197265625,
            "text": "clock",
            "probability": 0.0
        }
    ],
    "5a86ebf2faa1ab7d2e000038_16": [
        {
            "start_logit": 10.765625,
            "end_logit": 12.296875,
            "text": "clock",
            "probability": 1.0
        },
        {
            "start_logit": 10.765625,
            "end_logit": -2.228515625,
            "text": "clock bmal",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 10.765625,
            "end_logit": -4.5859375,
            "text": "clock bmal independent circadian oscillation of zebrafish cryptochrome1a gene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.765625,
            "end_logit": -6.2109375,
            "text": "clock bmal independent circadian oscillation of zebrafish cryptochrome1a",
            "probability": 0.0
        },
        {
            "start_logit": 10.765625,
            "end_logit": -7.41015625,
            "text": "clock bmal independent circadian oscillation of zebrafish cryptochrome",
            "probability": 0.0
        },
        {
            "start_logit": 10.765625,
            "end_logit": -7.65625,
            "text": "clock bm",
            "probability": 0.0
        },
        {
            "start_logit": 10.765625,
            "end_logit": -8.2890625,
            "text": "clock bmal independent circadian oscillation of zebrafish crypt",
            "probability": 0.0
        },
        {
            "start_logit": 10.765625,
            "end_logit": -8.875,
            "text": "clock bmal independent circadian oscillation of zebrafish",
            "probability": 0.0
        },
        {
            "start_logit": 10.765625,
            "end_logit": -9.3671875,
            "text": "clock bmal independent",
            "probability": 0.0
        },
        {
            "start_logit": 10.765625,
            "end_logit": -9.4140625,
            "text": "clock bmal independent circadian oscillation",
            "probability": 0.0
        },
        {
            "start_logit": 10.765625,
            "end_logit": -9.5703125,
            "text": "clock bmal independent circadian oscillation of",
            "probability": 0.0
        },
        {
            "start_logit": 10.765625,
            "end_logit": -9.8203125,
            "text": "clock bmal independent circadian",
            "probability": 0.0
        },
        {
            "start_logit": -6.92578125,
            "end_logit": -2.228515625,
            "text": "bmal",
            "probability": 0.0
        },
        {
            "start_logit": -6.92578125,
            "end_logit": -4.5859375,
            "text": "bmal independent circadian oscillation of zebrafish cryptochrome1a gene",
            "probability": 0.0
        },
        {
            "start_logit": -7.859375,
            "end_logit": -4.5859375,
            "text": "cryptochrome1a gene",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": -2.228515625,
            "text": "al",
            "probability": 0.0
        },
        {
            "start_logit": -6.92578125,
            "end_logit": -6.2109375,
            "text": "bmal independent circadian oscillation of zebrafish cryptochrome1a",
            "probability": 0.0
        },
        {
            "start_logit": -7.859375,
            "end_logit": -6.2109375,
            "text": "cryptochrome1a",
            "probability": 0.0
        },
        {
            "start_logit": -6.92578125,
            "end_logit": -7.41015625,
            "text": "bmal independent circadian oscillation of zebrafish cryptochrome",
            "probability": 0.0
        },
        {
            "start_logit": -6.92578125,
            "end_logit": -7.65625,
            "text": "bm",
            "probability": 0.0
        }
    ],
    "5324cf139b2d7acc7e00001f_1": [
        {
            "start_logit": -0.51806640625,
            "end_logit": 3.052734375,
            "text": "depression",
            "probability": 0.9970703125
        },
        {
            "start_logit": -0.51806640625,
            "end_logit": -3.12890625,
            "text": "depression during childhood and adolescence",
            "probability": 0.0020656585693359375
        },
        {
            "start_logit": -7.72265625,
            "end_logit": 3.052734375,
            "text": "inpatients with depression",
            "probability": 0.0007390975952148438
        },
        {
            "start_logit": -9.6484375,
            "end_logit": 3.052734375,
            "text": "with depression",
            "probability": 0.00010859966278076172
        },
        {
            "start_logit": -9.875,
            "end_logit": 3.052734375,
            "text": "medication use in inpatients with depression",
            "probability": 8.589029312133789e-05
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 3.052734375,
            "text": "prevalence and medication use in inpatients with depression",
            "probability": 5.7220458984375e-05
        },
        {
            "start_logit": -10.390625,
            "end_logit": 3.052734375,
            "text": "and medication use in inpatients with depression",
            "probability": 5.125999450683594e-05
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 3.052734375,
            "text": "in inpatients with depression",
            "probability": 3.361701965332031e-05
        },
        {
            "start_logit": -0.51806640625,
            "end_logit": -7.5390625,
            "text": "depression during childhood",
            "probability": 2.5033950805664062e-05
        },
        {
            "start_logit": -0.51806640625,
            "end_logit": -8.7890625,
            "text": "depression during",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": -0.51806640625,
            "end_logit": -8.9765625,
            "text": "depression during childhood and",
            "probability": 5.9604644775390625e-06
        },
        {
            "start_logit": -7.72265625,
            "end_logit": -3.12890625,
            "text": "inpatients with depression during childhood and adolescence",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -9.1015625,
            "end_logit": -3.12890625,
            "text": "childhood and adolescence",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -9.6484375,
            "end_logit": -3.12890625,
            "text": "with depression during childhood and adolescence",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -9.875,
            "end_logit": -3.12890625,
            "text": "medication use in inpatients with depression during childhood and adolescence",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.2890625,
            "end_logit": -3.12890625,
            "text": "prevalence and medication use in inpatients with depression during childhood and adolescence",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.390625,
            "end_logit": -3.12890625,
            "text": "and medication use in inpatients with depression during childhood and adolescence",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.515625,
            "end_logit": -3.12890625,
            "text": "during childhood and adolescence",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.8203125,
            "end_logit": -3.12890625,
            "text": "in inpatients with depression during childhood and adolescence",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.72265625,
            "end_logit": -7.5390625,
            "text": "inpatients with depression during childhood",
            "probability": 0.0
        }
    ],
    "5324cf139b2d7acc7e00001f_2": [
        {
            "start_logit": 2.96484375,
            "end_logit": 4.59765625,
            "text": "Premature ejaculation",
            "probability": 1.0
        },
        {
            "start_logit": 2.96484375,
            "end_logit": -5.46484375,
            "text": "Premature ejaculation (PE) is a common sexual dysfunction affecting 20% to 30% of men worldwide",
            "probability": 4.267692565917969e-05
        },
        {
            "start_logit": 2.96484375,
            "end_logit": -5.953125,
            "text": "Premature ejaculation (PE",
            "probability": 2.6285648345947266e-05
        },
        {
            "start_logit": 2.96484375,
            "end_logit": -6.328125,
            "text": "Premature ejaculation (PE) is a common sexual dysfunction",
            "probability": 1.806020736694336e-05
        },
        {
            "start_logit": 2.96484375,
            "end_logit": -6.9140625,
            "text": "Premature ejaculation (PE)",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": -8.8984375,
            "end_logit": 4.59765625,
            "text": "ejaculation",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": 2.96484375,
            "end_logit": -7.57421875,
            "text": "Premature ejaculation (",
            "probability": 5.185604095458984e-06
        },
        {
            "start_logit": 2.96484375,
            "end_logit": -7.8359375,
            "text": "Premature ejaculation (PE) is a common sexual dysfunction affecting 20% to 30% of men",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": 2.96484375,
            "end_logit": -8.4921875,
            "text": "Premature ejaculation (PE) is a common sexual dysfunction affecting 20% to 30",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 2.96484375,
            "end_logit": -8.5546875,
            "text": "Premature ejaculation (PE) is a",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 2.96484375,
            "end_logit": -8.6015625,
            "text": "Premature ejaculation (PE) is",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": 2.96484375,
            "end_logit": -8.8125,
            "text": "Premature ejaculation (PE) is a common",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 2.96484375,
            "end_logit": -9.0703125,
            "text": "Premature ejaculation (PE) is a common sexual",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 2.96484375,
            "end_logit": -9.1953125,
            "text": "Premature ejaculation (PE) is a common sexual dysfunction affecting 20% to 30%",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 2.96484375,
            "end_logit": -9.375,
            "text": "Premature",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 2.96484375,
            "end_logit": -9.3984375,
            "text": "Premature ejaculation (PE) is a common sexual dysfunction affecting",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 2.96484375,
            "end_logit": -9.734375,
            "text": "Premature ejaculation (PE) is a common sexual dysfunction affecting 20% to 30% of",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 2.96484375,
            "end_logit": -10.0703125,
            "text": "Premature ejaculation (PE) is a common sexual dysfunction affecting 20%",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 2.96484375,
            "end_logit": -10.1328125,
            "text": "Premature ejaculation (PE) is a common sexual dysfunction affecting 20% to",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.359375,
            "end_logit": -5.46484375,
            "text": "sexual dysfunction affecting 20% to 30% of men worldwide",
            "probability": 0.0
        }
    ],
    "5324cf139b2d7acc7e00001f_3": [
        {
            "start_logit": 10.125,
            "end_logit": 8.65625,
            "text": "dapoxetine",
            "probability": 1.0
        },
        {
            "start_logit": 10.125,
            "end_logit": -3.169921875,
            "text": "dapoxetine (SSRI",
            "probability": 7.271766662597656e-06
        },
        {
            "start_logit": 10.125,
            "end_logit": -5.484375,
            "text": "dapoxetine (SSRI)",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 10.125,
            "end_logit": -5.87890625,
            "text": "dap",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 10.125,
            "end_logit": -7.9453125,
            "text": "dapoxetine (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.671875,
            "end_logit": 8.65625,
            "text": "PSD502 and dapoxetine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.859375,
            "end_logit": 8.65625,
            "text": "oxetine",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": 8.65625,
            "text": "and other compounds, only 2 treatments have been evaluated in randomized controlled phase 3 clinical trials: PSD502 and dapoxetine",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 8.65625,
            "text": "and dapoxetine",
            "probability": 0.0
        },
        {
            "start_logit": -6.671875,
            "end_logit": -3.169921875,
            "text": "PSD502 and dapoxetine (SSRI",
            "probability": 0.0
        },
        {
            "start_logit": -7.859375,
            "end_logit": -3.169921875,
            "text": "oxetine (SSRI",
            "probability": 0.0
        },
        {
            "start_logit": -6.671875,
            "end_logit": -5.484375,
            "text": "PSD502 and dapoxetine (SSRI)",
            "probability": 0.0
        },
        {
            "start_logit": -6.671875,
            "end_logit": -5.66796875,
            "text": "PSD502",
            "probability": 0.0
        },
        {
            "start_logit": -6.671875,
            "end_logit": -5.87890625,
            "text": "PSD502 and dap",
            "probability": 0.0
        },
        {
            "start_logit": -7.859375,
            "end_logit": -5.484375,
            "text": "oxetine (SSRI)",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": -3.169921875,
            "text": "and other compounds, only 2 treatments have been evaluated in randomized controlled phase 3 clinical trials: PSD502 and dapoxetine (SSRI",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": -3.169921875,
            "text": "and dapoxetine (SSRI",
            "probability": 0.0
        },
        {
            "start_logit": -8.921875,
            "end_logit": -5.66796875,
            "text": "selective serotonin reuptake inhibitors (SSRIs) and other compounds, only 2 treatments have been evaluated in randomized controlled phase 3 clinical trials: PSD502",
            "probability": 0.0
        },
        {
            "start_logit": -6.671875,
            "end_logit": -7.9453125,
            "text": "PSD502 and dapoxetine (",
            "probability": 0.0
        },
        {
            "start_logit": -8.921875,
            "end_logit": -5.87890625,
            "text": "selective serotonin reuptake inhibitors (SSRIs) and other compounds, only 2 treatments have been evaluated in randomized controlled phase 3 clinical trials: PSD502 and dap",
            "probability": 0.0
        }
    ],
    "5324cf139b2d7acc7e00001f_4": [
        {
            "start_logit": -5.16015625,
            "end_logit": 5.6640625,
            "text": "fibromyalgia syndrome. Systematic review, meta-analysis and guideline].",
            "probability": 0.927734375
        },
        {
            "start_logit": -5.16015625,
            "end_logit": 2.6640625,
            "text": "fibromyalgia syndrome. Systematic review, meta-analysis and guideline]",
            "probability": 0.046173095703125
        },
        {
            "start_logit": -9.546875,
            "end_logit": 5.6640625,
            "text": "Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline].",
            "probability": 0.01154327392578125
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 5.6640625,
            "text": "Systematic review, meta-analysis and guideline].",
            "probability": 0.0062255859375
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 5.6640625,
            "text": ".",
            "probability": 0.003719329833984375
        },
        {
            "start_logit": -10.765625,
            "end_logit": 5.6640625,
            "text": "].",
            "probability": 0.00341033935546875
        },
        {
            "start_logit": -9.546875,
            "end_logit": 2.6640625,
            "text": "Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline]",
            "probability": 0.0005745887756347656
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 2.6640625,
            "text": "Systematic review, meta-analysis and guideline]",
            "probability": 0.00031113624572753906
        },
        {
            "start_logit": -5.16015625,
            "end_logit": -2.7578125,
            "text": "fibromyalgia syndrome. Systematic review, meta-analysis and guideline",
            "probability": 0.0002040863037109375
        },
        {
            "start_logit": -5.16015625,
            "end_logit": -2.90625,
            "text": "fibromyalgia syndrome. Systematic review, meta-analysis",
            "probability": 0.00017726421356201172
        },
        {
            "start_logit": -10.765625,
            "end_logit": 2.6640625,
            "text": "]",
            "probability": 0.0001691579818725586
        },
        {
            "start_logit": -5.16015625,
            "end_logit": -3.798828125,
            "text": "fibromyalgia syndrome. Systematic review, meta-analysis and",
            "probability": 7.164478302001953e-05
        },
        {
            "start_logit": -5.16015625,
            "end_logit": -6.10546875,
            "text": "fibromyalgia syndrome",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": -5.16015625,
            "end_logit": -6.56640625,
            "text": "fibromyalgia syndrome. Systematic review,",
            "probability": 4.5299530029296875e-06
        },
        {
            "start_logit": -5.16015625,
            "end_logit": -6.609375,
            "text": "fibromyalgia",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": -5.16015625,
            "end_logit": -6.80859375,
            "text": "fibromyalgia syndrome. Systematic review, meta",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": -5.16015625,
            "end_logit": -6.8984375,
            "text": "fibromyalgia syndrome.",
            "probability": 3.2782554626464844e-06
        },
        {
            "start_logit": -9.546875,
            "end_logit": -2.7578125,
            "text": "Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": -9.546875,
            "end_logit": -2.90625,
            "text": "Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": -5.16015625,
            "end_logit": -7.30078125,
            "text": "fibromyalgia syndrome. Systematic review",
            "probability": 2.1457672119140625e-06
        }
    ],
    "5324cf139b2d7acc7e00001f_5": [
        {
            "start_logit": 7.8359375,
            "end_logit": 11.359375,
            "text": "depression",
            "probability": 1.0
        },
        {
            "start_logit": 7.8359375,
            "end_logit": -2.138671875,
            "text": "depression. Insomnia",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -5.8515625,
            "end_logit": 11.359375,
            "text": "Trazodone is an antidepressant belonging to the class of serotonin receptor antagonists and reuptake inhibitors. It is approved by the FDA for the treatment of depression",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -8.6015625,
            "end_logit": 11.359375,
            "text": "one is an antidepressant belonging to the class of serotonin receptor antagonists and reuptake inhibitors. It is approved by the FDA for the treatment of depression",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.9921875,
            "end_logit": 11.359375,
            "text": "of depression",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.0234375,
            "end_logit": 11.359375,
            "text": "treatment of depression",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.125,
            "end_logit": 11.359375,
            "text": "antidepressant belonging to the class of serotonin receptor antagonists and reuptake inhibitors. It is approved by the FDA for the treatment of depression",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.8359375,
            "end_logit": -7.99609375,
            "text": "depression. Insomnia is the most frequent reason for prescription of trazodone. It has also been proven useful in the treatment of anxiety disorders",
            "probability": 0.0
        },
        {
            "start_logit": 7.8359375,
            "end_logit": -9.640625,
            "text": "depression. Insomnia is the most frequent reason for prescription of trazodone. It has also been proven useful",
            "probability": 0.0
        },
        {
            "start_logit": 7.8359375,
            "end_logit": -9.8046875,
            "text": "depression. Insomnia is the most frequent reason for prescription of trazodone",
            "probability": 0.0
        },
        {
            "start_logit": -2.716796875,
            "end_logit": -2.138671875,
            "text": "Insomnia",
            "probability": 0.0
        },
        {
            "start_logit": -5.8515625,
            "end_logit": -2.43359375,
            "text": "Trazodone",
            "probability": 0.0
        },
        {
            "start_logit": -2.716796875,
            "end_logit": -7.99609375,
            "text": "Insomnia is the most frequent reason for prescription of trazodone. It has also been proven useful in the treatment of anxiety disorders",
            "probability": 0.0
        },
        {
            "start_logit": -8.6015625,
            "end_logit": -2.138671875,
            "text": "one is an antidepressant belonging to the class of serotonin receptor antagonists and reuptake inhibitors. It is approved by the FDA for the treatment of depression. Insomnia",
            "probability": 0.0
        },
        {
            "start_logit": -8.6015625,
            "end_logit": -2.43359375,
            "text": "one",
            "probability": 0.0
        },
        {
            "start_logit": -8.9921875,
            "end_logit": -2.138671875,
            "text": "of depression. Insomnia",
            "probability": 0.0
        },
        {
            "start_logit": -9.0234375,
            "end_logit": -2.138671875,
            "text": "treatment of depression. Insomnia",
            "probability": 0.0
        },
        {
            "start_logit": -9.125,
            "end_logit": -2.138671875,
            "text": "antidepressant belonging to the class of serotonin receptor antagonists and reuptake inhibitors. It is approved by the FDA for the treatment of depression. Insomnia",
            "probability": 0.0
        },
        {
            "start_logit": -6.7578125,
            "end_logit": -5.4609375,
            "text": "schizophrenia, chronic pain disease and diabetic neuropathy",
            "probability": 0.0
        },
        {
            "start_logit": -2.716796875,
            "end_logit": -9.640625,
            "text": "Insomnia is the most frequent reason for prescription of trazodone. It has also been proven useful",
            "probability": 0.0
        }
    ],
    "5324cf139b2d7acc7e00001f_6": [
        {
            "start_logit": 8.28125,
            "end_logit": 8.953125,
            "text": "hot flashes",
            "probability": 1.0
        },
        {
            "start_logit": 8.28125,
            "end_logit": -5.30859375,
            "text": "hot flashes) associated with the menopausal transition",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -6.91796875,
            "text": "hot",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -6.9375,
            "text": "hot flash",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -6.96875,
            "text": "hot flashes) associated with the menopausal transition and sex hormone deprivation",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.4296875,
            "end_logit": 8.953125,
            "text": "es",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.28125,
            "end_logit": -8.5546875,
            "text": "hot flashes) associated",
            "probability": 0.0
        },
        {
            "start_logit": 8.28125,
            "end_logit": -8.7890625,
            "text": "hot flashes) associated with the menopausal",
            "probability": 0.0
        },
        {
            "start_logit": 8.28125,
            "end_logit": -8.8828125,
            "text": "hot flashes) associated with the menopausal transition and sex hormone",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 8.953125,
            "text": "flashes",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 8.953125,
            "text": "vasomotor dysregulation (hot flashes",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 8.953125,
            "text": "symptoms of vasomotor dysregulation (hot flashes",
            "probability": 0.0
        },
        {
            "start_logit": 8.28125,
            "end_logit": -9.7421875,
            "text": "hot flashes) associated with",
            "probability": 0.0
        },
        {
            "start_logit": -7.21875,
            "end_logit": -4.6796875,
            "text": "\u03b3-aminobutyric acid-ergic drugs",
            "probability": 0.0
        },
        {
            "start_logit": -7.2265625,
            "end_logit": -5.30859375,
            "text": "menopausal transition",
            "probability": 0.0
        },
        {
            "start_logit": -6.21484375,
            "end_logit": -6.96875,
            "text": "sex hormone deprivation",
            "probability": 0.0
        },
        {
            "start_logit": -8.4296875,
            "end_logit": -5.30859375,
            "text": "es) associated with the menopausal transition",
            "probability": 0.0
        },
        {
            "start_logit": -9.359375,
            "end_logit": -4.6796875,
            "text": "serotonergic and \u03b3-aminobutyric acid-ergic drugs",
            "probability": 0.0
        },
        {
            "start_logit": -7.2265625,
            "end_logit": -6.96875,
            "text": "menopausal transition and sex hormone deprivation",
            "probability": 0.0
        },
        {
            "start_logit": -7.21875,
            "end_logit": -7.23046875,
            "text": "\u03b3-aminobutyric acid-ergic drugs as a therapeutic alternative,",
            "probability": 0.0
        }
    ],
    "5324cf139b2d7acc7e00001f_7": [
        {
            "start_logit": 7.6015625,
            "end_logit": 7.9140625,
            "text": "duloxetine is a possible alternative treatment of postprostatectomy established stress urinary incontinence",
            "probability": 0.456787109375
        },
        {
            "start_logit": 7.36328125,
            "end_logit": 7.9140625,
            "text": "stress urinary incontinence",
            "probability": 0.361328125
        },
        {
            "start_logit": 7.6015625,
            "end_logit": 6.98828125,
            "text": "duloxetine",
            "probability": 0.181640625
        },
        {
            "start_logit": -3.287109375,
            "end_logit": 7.9140625,
            "text": "urinary incontinence",
            "probability": 8.52346420288086e-06
        },
        {
            "start_logit": -5.26171875,
            "end_logit": 7.9140625,
            "text": "postprostatectomy established stress urinary incontinence",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 7.6015625,
            "end_logit": -5.49609375,
            "text": "dul",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.6015625,
            "end_logit": -6.35546875,
            "text": "duloxetine is a possible alternative treatment of postprostatectomy",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.6015625,
            "end_logit": -6.86328125,
            "text": "duloxetine is a possible alternative treatment of postprostatectomy established stress",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.36328125,
            "end_logit": -6.86328125,
            "text": "stress",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 7.9140625,
            "text": "incontinence",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 7.9140625,
            "text": "oxetine is a possible alternative treatment of postprostatectomy established stress urinary incontinence",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.6015625,
            "end_logit": -7.9609375,
            "text": "duloxetine is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.6015625,
            "end_logit": -8.484375,
            "text": "duloxetine is a",
            "probability": 0.0
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 6.98828125,
            "text": "oxetine",
            "probability": 0.0
        },
        {
            "start_logit": 7.6015625,
            "end_logit": -8.5625,
            "text": "duloxetine is a possible alternative treatment of postprostatectomy established stress urinary",
            "probability": 0.0
        },
        {
            "start_logit": 7.6015625,
            "end_logit": -8.625,
            "text": "duloxetine is a possible alternative treatment of postprostatectomy established",
            "probability": 0.0
        },
        {
            "start_logit": 7.6015625,
            "end_logit": -8.671875,
            "text": "duloxetine is a possible alternative treatment of postprostatectomy established stress urinary incontinence.",
            "probability": 0.0
        },
        {
            "start_logit": 7.36328125,
            "end_logit": -8.5625,
            "text": "stress urinary",
            "probability": 0.0
        },
        {
            "start_logit": 7.6015625,
            "end_logit": -8.875,
            "text": "duloxetine is a possible",
            "probability": 0.0
        },
        {
            "start_logit": 7.36328125,
            "end_logit": -8.671875,
            "text": "stress urinary incontinence.",
            "probability": 0.0
        }
    ],
    "5324cf139b2d7acc7e00001f_8": [
        {
            "start_logit": 3.16015625,
            "end_logit": 6.390625,
            "text": "fibromyalgia",
            "probability": 1.0
        },
        {
            "start_logit": 3.16015625,
            "end_logit": -3.80859375,
            "text": "fibromyalgia.",
            "probability": 3.737211227416992e-05
        },
        {
            "start_logit": -8.0,
            "end_logit": 6.390625,
            "text": "Pharmacological treatment of fibromyalgia",
            "probability": 1.430511474609375e-05
        },
        {
            "start_logit": -8.0,
            "end_logit": -3.80859375,
            "text": "Pharmacological treatment of fibromyalgia.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": -7.51953125,
            "text": "Pharmacological treatment",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": -8.15625,
            "text": "Pharmacological treatment of",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": -10.28125,
            "text": "Pharmacological",
            "probability": 0.0
        }
    ],
    "5324cf139b2d7acc7e00001f_9": [
        {
            "start_logit": 0.253662109375,
            "end_logit": -3.134765625,
            "text": "antidepressants, gabapentine",
            "probability": 0.4921875
        },
        {
            "start_logit": 0.253662109375,
            "end_logit": -3.900390625,
            "text": "antidepressants, gabapentine and clonidine. The main limits to the use of these drugs in controlling hot flashes",
            "probability": 0.22900390625
        },
        {
            "start_logit": 0.253662109375,
            "end_logit": -4.1015625,
            "text": "antidepressants",
            "probability": 0.187255859375
        },
        {
            "start_logit": 0.253662109375,
            "end_logit": -5.19921875,
            "text": "antidepressants, gabapentine and clonidine",
            "probability": 0.06243896484375
        },
        {
            "start_logit": 0.253662109375,
            "end_logit": -6.7421875,
            "text": "antidepressants, gabapentine and",
            "probability": 0.0133514404296875
        },
        {
            "start_logit": 0.253662109375,
            "end_logit": -8.1484375,
            "text": "antidepressants, gabapentin",
            "probability": 0.003265380859375
        },
        {
            "start_logit": -4.703125,
            "end_logit": -3.57421875,
            "text": "hot flashes are the off-label use for this purpose,",
            "probability": 0.002227783203125
        },
        {
            "start_logit": 0.253662109375,
            "end_logit": -8.6015625,
            "text": "antidepressants, gabapentine and clonidine. The main limits to the use of these drugs in controlling hot flash",
            "probability": 0.0020751953125
        },
        {
            "start_logit": -4.703125,
            "end_logit": -3.900390625,
            "text": "hot flashes",
            "probability": 0.001617431640625
        },
        {
            "start_logit": 0.253662109375,
            "end_logit": -9.0,
            "text": "antidepressants, gabapentine and clonidine. The main limits to the use of these drugs in controlling hot flashes are the off-label use for this purpose",
            "probability": 0.0013933181762695312
        },
        {
            "start_logit": 0.253662109375,
            "end_logit": -9.2734375,
            "text": "antidepressants, gabapentine and clonidine. The main limits to the use of these drugs in controlling hot flashes are the",
            "probability": 0.00106048583984375
        },
        {
            "start_logit": -6.01953125,
            "end_logit": -3.134765625,
            "text": "gabapentine",
            "probability": 0.0009284019470214844
        },
        {
            "start_logit": 0.253662109375,
            "end_logit": -9.59375,
            "text": "antidepressants, gabapentine and clonidine. The main limits to the use of these drugs in controlling hot flashes are",
            "probability": 0.0007696151733398438
        },
        {
            "start_logit": -6.01953125,
            "end_logit": -3.57421875,
            "text": "gabapentine and clonidine. The main limits to the use of these drugs in controlling hot flashes are the off-label use for this purpose,",
            "probability": 0.0005993843078613281
        },
        {
            "start_logit": -6.296875,
            "end_logit": -3.57421875,
            "text": "clonidine. The main limits to the use of these drugs in controlling hot flashes are the off-label use for this purpose,",
            "probability": 0.00045228004455566406
        },
        {
            "start_logit": -6.01953125,
            "end_logit": -3.900390625,
            "text": "gabapentine and clonidine. The main limits to the use of these drugs in controlling hot flashes",
            "probability": 0.0004317760467529297
        },
        {
            "start_logit": -6.296875,
            "end_logit": -3.900390625,
            "text": "clonidine. The main limits to the use of these drugs in controlling hot flashes",
            "probability": 0.00032830238342285156
        },
        {
            "start_logit": -6.01953125,
            "end_logit": -5.19921875,
            "text": "gabapentine and clonidine",
            "probability": 0.00011801719665527344
        },
        {
            "start_logit": -6.296875,
            "end_logit": -5.19921875,
            "text": "clonidine",
            "probability": 8.910894393920898e-05
        },
        {
            "start_logit": -8.375,
            "end_logit": -3.134765625,
            "text": ", gabapentine",
            "probability": 8.83936882019043e-05
        }
    ],
    "5324cf139b2d7acc7e00001f_10": [
        {
            "start_logit": 10.8515625,
            "end_logit": 9.90625,
            "text": "erectile dysfunction",
            "probability": 1.0
        },
        {
            "start_logit": 1.677734375,
            "end_logit": 9.90625,
            "text": "ymptomatic therapy for patients with erectile dysfunction",
            "probability": 0.00010472536087036133
        },
        {
            "start_logit": 10.8515625,
            "end_logit": -5.2734375,
            "text": "erectile",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 10.8515625,
            "end_logit": -5.80078125,
            "text": "erectile dysfunction.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.640625,
            "end_logit": 9.90625,
            "text": "dysfunction",
            "probability": 0.0
        },
        {
            "start_logit": 1.677734375,
            "end_logit": -1.7294921875,
            "text": "ymptomatic",
            "probability": 0.0
        },
        {
            "start_logit": -9.9921875,
            "end_logit": 9.90625,
            "text": "patients with erectile dysfunction",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 9.90625,
            "text": "with erectile dysfunction",
            "probability": 0.0
        },
        {
            "start_logit": 1.677734375,
            "end_logit": -5.2734375,
            "text": "ymptomatic therapy for patients with erectile",
            "probability": 0.0
        },
        {
            "start_logit": 1.677734375,
            "end_logit": -5.80078125,
            "text": "ymptomatic therapy for patients with erectile dysfunction.",
            "probability": 0.0
        },
        {
            "start_logit": 1.677734375,
            "end_logit": -6.0,
            "text": "ymptomatic therapy",
            "probability": 0.0
        },
        {
            "start_logit": 1.677734375,
            "end_logit": -8.3046875,
            "text": "ymptomatic therapy for",
            "probability": 0.0
        },
        {
            "start_logit": 1.677734375,
            "end_logit": -8.3671875,
            "text": "ym",
            "probability": 0.0
        },
        {
            "start_logit": 1.677734375,
            "end_logit": -9.671875,
            "text": "ymptomatic therapy for patients with",
            "probability": 0.0
        },
        {
            "start_logit": 1.677734375,
            "end_logit": -10.8984375,
            "text": "ymptomatic therapy for patients",
            "probability": 0.0
        },
        {
            "start_logit": -7.640625,
            "end_logit": -5.80078125,
            "text": "dysfunction.",
            "probability": 0.0
        },
        {
            "start_logit": -9.9921875,
            "end_logit": -5.2734375,
            "text": "patients with erectile",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": -5.2734375,
            "text": "with erectile",
            "probability": 0.0
        },
        {
            "start_logit": -9.9921875,
            "end_logit": -5.80078125,
            "text": "patients with erectile dysfunction.",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": -5.80078125,
            "text": "with erectile dysfunction.",
            "probability": 0.0
        }
    ],
    "5324cf139b2d7acc7e00001f_11": [
        {
            "start_logit": 13.5234375,
            "end_logit": 12.390625,
            "text": "dapoxetine",
            "probability": 1.0
        },
        {
            "start_logit": 13.5234375,
            "end_logit": -4.27734375,
            "text": "dap",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.5234375,
            "end_logit": 12.390625,
            "text": "oxetine",
            "probability": 0.0
        },
        {
            "start_logit": 13.5234375,
            "end_logit": -8.1953125,
            "text": "dapoxetine, as well as other SSRIs in PE",
            "probability": 0.0
        },
        {
            "start_logit": 13.5234375,
            "end_logit": -8.6015625,
            "text": "dapoxetine, as well as other SSRIs",
            "probability": 0.0
        },
        {
            "start_logit": 13.5234375,
            "end_logit": -8.8671875,
            "text": "dapoxetine, as well as other SSRIs in PE,",
            "probability": 0.0
        },
        {
            "start_logit": 13.5234375,
            "end_logit": -9.0078125,
            "text": "dapoxetine,",
            "probability": 0.0
        },
        {
            "start_logit": 13.5234375,
            "end_logit": -9.2109375,
            "text": "dapoxetine, as well as other SSRIs in PE, is an off-label drug for PE",
            "probability": 0.0
        },
        {
            "start_logit": 13.5234375,
            "end_logit": -9.484375,
            "text": "dapoxetine, as well as other SSRIs in PE, is an off-label drug",
            "probability": 0.0
        },
        {
            "start_logit": 13.5234375,
            "end_logit": -9.4921875,
            "text": "dapoxetine, as well as other SSRIs in PE, is",
            "probability": 0.0
        },
        {
            "start_logit": 13.5234375,
            "end_logit": -9.4921875,
            "text": "dapoxetine, as well as other SSRIs in",
            "probability": 0.0
        },
        {
            "start_logit": 13.5234375,
            "end_logit": -9.6484375,
            "text": "dapoxetine, as well as other SSRIs in PE, is an off-label drug for",
            "probability": 0.0
        },
        {
            "start_logit": 13.5234375,
            "end_logit": -9.8671875,
            "text": "dapoxetine, as well as",
            "probability": 0.0
        },
        {
            "start_logit": 13.5234375,
            "end_logit": -10.0,
            "text": "dapoxetine, as well as other SSRIs in PE, is an off-label drug for PE.",
            "probability": 0.0
        },
        {
            "start_logit": 13.5234375,
            "end_logit": -10.0078125,
            "text": "dapoxetine, as well as other",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 12.390625,
            "text": "Food and Drug Administration approval, dapoxetine",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 12.390625,
            "text": "Without the Food and Drug Administration approval, dapoxetine",
            "probability": 0.0
        },
        {
            "start_logit": -5.5234375,
            "end_logit": -8.1953125,
            "text": "oxetine, as well as other SSRIs in PE",
            "probability": 0.0
        },
        {
            "start_logit": -5.5234375,
            "end_logit": -8.6015625,
            "text": "oxetine, as well as other SSRIs",
            "probability": 0.0
        },
        {
            "start_logit": -5.5234375,
            "end_logit": -8.8671875,
            "text": "oxetine, as well as other SSRIs in PE,",
            "probability": 0.0
        }
    ],
    "5324cf139b2d7acc7e00001f_12": [
        {
            "start_logit": 0.1976318359375,
            "end_logit": -4.18359375,
            "text": "oral selective serotonin reuptake inhibitors (SSRIs",
            "probability": 0.87841796875
        },
        {
            "start_logit": 0.1976318359375,
            "end_logit": -7.36328125,
            "text": "oral",
            "probability": 0.03662109375
        },
        {
            "start_logit": 0.1976318359375,
            "end_logit": -7.36328125,
            "text": "oral selective serotonin reuptake inhibitors (SSRIs)",
            "probability": 0.03662109375
        },
        {
            "start_logit": 0.1976318359375,
            "end_logit": -8.515625,
            "text": "oral selective serotonin reuptake inhibitors",
            "probability": 0.01149749755859375
        },
        {
            "start_logit": 0.1976318359375,
            "end_logit": -8.7265625,
            "text": "oral selective serotonin",
            "probability": 0.009307861328125
        },
        {
            "start_logit": 0.1976318359375,
            "end_logit": -8.796875,
            "text": "oral selective serotonin reuptake inhibitors (SSRIs) via either on-demand or daily delivery",
            "probability": 0.00867462158203125
        },
        {
            "start_logit": 0.1976318359375,
            "end_logit": -9.390625,
            "text": "oral selective serotonin reuptake",
            "probability": 0.004791259765625
        },
        {
            "start_logit": 0.1976318359375,
            "end_logit": -9.7734375,
            "text": "oral selective serotonin reuptake inhibitors (SSRIs) via either on-demand or daily delivery.",
            "probability": 0.0032672882080078125
        },
        {
            "start_logit": 0.1976318359375,
            "end_logit": -9.859375,
            "text": "oral selective serotonin reuptake inhibitors (SSRIs) via either on-demand or",
            "probability": 0.00299835205078125
        },
        {
            "start_logit": 0.1976318359375,
            "end_logit": -9.890625,
            "text": "oral selective serotonin reuptake inhibitors (SSRIs) via",
            "probability": 0.00290679931640625
        },
        {
            "start_logit": 0.1976318359375,
            "end_logit": -9.9921875,
            "text": "oral selective serotonin reuptake inhibitors (SSRIs) via either on-demand",
            "probability": 0.0026264190673828125
        },
        {
            "start_logit": 0.1976318359375,
            "end_logit": -10.3671875,
            "text": "oral selective serotonin reuptake inhibitors (SSRIs) via either on-demand or daily",
            "probability": 0.001804351806640625
        },
        {
            "start_logit": -7.36328125,
            "end_logit": -4.18359375,
            "text": "selective serotonin reuptake inhibitors (SSRIs",
            "probability": 0.0004565715789794922
        },
        {
            "start_logit": -7.77734375,
            "end_logit": -4.18359375,
            "text": "PE consists of primarily off-label use of oral selective serotonin reuptake inhibitors (SSRIs",
            "probability": 0.00030159950256347656
        },
        {
            "start_logit": -10.1796875,
            "end_logit": -4.18359375,
            "text": "SSRIs",
            "probability": 2.7358531951904297e-05
        },
        {
            "start_logit": -10.203125,
            "end_logit": -4.18359375,
            "text": "treatment of PE consists of primarily off-label use of oral selective serotonin reuptake inhibitors (SSRIs",
            "probability": 2.6524066925048828e-05
        },
        {
            "start_logit": -10.4140625,
            "end_logit": -4.18359375,
            "text": "use of oral selective serotonin reuptake inhibitors (SSRIs",
            "probability": 2.1696090698242188e-05
        },
        {
            "start_logit": -7.36328125,
            "end_logit": -7.36328125,
            "text": "selective serotonin reuptake inhibitors (SSRIs)",
            "probability": 1.901388168334961e-05
        },
        {
            "start_logit": -10.5546875,
            "end_logit": -4.18359375,
            "text": "of oral selective serotonin reuptake inhibitors (SSRIs",
            "probability": 1.8835067749023438e-05
        },
        {
            "start_logit": -10.5859375,
            "end_logit": -4.18359375,
            "text": "off-label use of oral selective serotonin reuptake inhibitors (SSRIs",
            "probability": 1.823902130126953e-05
        }
    ],
    "5324cf139b2d7acc7e00001f_13": [
        {
            "start_logit": 13.9453125,
            "end_logit": 13.4453125,
            "text": "Duloxetine",
            "probability": 1.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -2.89453125,
            "text": "Duloxetine is effective in men with SUI after prostate surgery",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -3.5,
            "text": "Dul",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.328125,
            "end_logit": 13.4453125,
            "text": "oxetine",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -4.96484375,
            "text": "Duloxetine is effective in men with SUI",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -6.8828125,
            "text": "Duloxetine is effective in men with SUI after prostate surgery even if standard pelvic floor exercises",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -8.453125,
            "text": "Duloxetine is effective in men with SUI after prostate surgery even if standard pelvic floor exercises have failed",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -8.6484375,
            "text": "Duloxetine is effective in men with SUI after prostate surgery even if standard pelvic floor",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -8.9765625,
            "text": "Duloxetine is effective in men with SUI after prostate surgery even if standard pelvic floor exercises have",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -9.0859375,
            "text": "Duloxetine is effective in men with SUI after prostate surgery even",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -9.1484375,
            "text": "Duloxetine is effective",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -9.2421875,
            "text": "Duloxetine is effective in men with SUI after prostate",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -9.375,
            "text": "Duloxetine is effective in men with SUI after",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -9.4140625,
            "text": "Duloxetine is effective in men with SU",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -9.4609375,
            "text": "Duloxetine is effective in men with SUI after prostate surgery even if",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -9.6328125,
            "text": "Duloxetine is",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -9.6640625,
            "text": "Duloxetine is effective in men with SUI after prostate surgery even if standard",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 13.4453125,
            "text": "that Duloxetine",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 13.4453125,
            "text": "off-label use show that Duloxetine",
            "probability": 0.0
        },
        {
            "start_logit": -4.328125,
            "end_logit": -2.89453125,
            "text": "oxetine is effective in men with SUI after prostate surgery",
            "probability": 0.0
        }
    ],
    "5324cf139b2d7acc7e00001f_14": [
        {
            "start_logit": 13.203125,
            "end_logit": 12.625,
            "text": "trazodone",
            "probability": 1.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -2.931640625,
            "text": "trazodone, for treating insomnia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.203125,
            "end_logit": -4.28515625,
            "text": "tra",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.203125,
            "end_logit": -5.01953125,
            "text": "trazo",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -5.80078125,
            "text": "trazod",
            "probability": 0.0
        },
        {
            "start_logit": -5.8984375,
            "end_logit": 12.625,
            "text": "one",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -9.0625,
            "text": "trazodone, for",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -9.78125,
            "text": "trazodone, for treating insomnia.",
            "probability": 0.0
        },
        {
            "start_logit": -9.359375,
            "end_logit": 12.625,
            "text": "zodone",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -10.125,
            "text": "trazodone,",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": 12.625,
            "text": "antidepressants, particularly trazodone",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 12.625,
            "text": "done",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 12.625,
            "text": "off-label use of antidepressants, particularly trazodone",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 12.625,
            "text": "-1980s there has been a rapid rise in the off-label use of antidepressants, particularly trazodone",
            "probability": 0.0
        },
        {
            "start_logit": -5.8984375,
            "end_logit": -2.931640625,
            "text": "one, for treating insomnia",
            "probability": 0.0
        },
        {
            "start_logit": -6.50390625,
            "end_logit": -2.931640625,
            "text": "insomnia",
            "probability": 0.0
        },
        {
            "start_logit": -7.84375,
            "end_logit": -2.931640625,
            "text": "treating insomnia",
            "probability": 0.0
        },
        {
            "start_logit": -9.359375,
            "end_logit": -2.931640625,
            "text": "zodone, for treating insomnia",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": -2.931640625,
            "text": "antidepressants, particularly trazodone, for treating insomnia",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": -2.931640625,
            "text": "done, for treating insomnia",
            "probability": 0.0
        }
    ],
    "5c5f03371a4c55d80b000009_1": [
        {
            "start_logit": 13.046875,
            "end_logit": 12.4609375,
            "text": "PARL",
            "probability": 1.0
        },
        {
            "start_logit": 13.046875,
            "end_logit": -5.1875,
            "text": "PAR",
            "probability": 0.0
        },
        {
            "start_logit": -6.31640625,
            "end_logit": 12.4609375,
            "text": "L",
            "probability": 0.0
        },
        {
            "start_logit": -11.140625,
            "end_logit": 12.4609375,
            "text": "rhomboid protease PARL",
            "probability": 0.0
        },
        {
            "start_logit": -11.4609375,
            "end_logit": 12.4609375,
            "text": "mboid protease PARL",
            "probability": 0.0
        },
        {
            "start_logit": -11.140625,
            "end_logit": -5.1875,
            "text": "rhomboid protease PAR",
            "probability": 0.0
        },
        {
            "start_logit": -11.4609375,
            "end_logit": -5.1875,
            "text": "mboid protease PAR",
            "probability": 0.0
        },
        {
            "start_logit": -11.140625,
            "end_logit": -8.1640625,
            "text": "rhomboid protease",
            "probability": 0.0
        },
        {
            "start_logit": -11.4609375,
            "end_logit": -8.1640625,
            "text": "mboid protease",
            "probability": 0.0
        },
        {
            "start_logit": -11.140625,
            "end_logit": -9.046875,
            "text": "rhomb",
            "probability": 0.0
        },
        {
            "start_logit": -11.140625,
            "end_logit": -9.046875,
            "text": "rhomboid",
            "probability": 0.0
        },
        {
            "start_logit": -11.4609375,
            "end_logit": -9.046875,
            "text": "mb",
            "probability": 0.0
        },
        {
            "start_logit": -11.4609375,
            "end_logit": -9.046875,
            "text": "mboid",
            "probability": 0.0
        },
        {
            "start_logit": -11.140625,
            "end_logit": -9.8984375,
            "text": "rho",
            "probability": 0.0
        }
    ],
    "5c5f03371a4c55d80b000009_2": [
        {
            "start_logit": 12.8828125,
            "end_logit": 12.65625,
            "text": "Pcp1",
            "probability": 1.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": 0.8837890625,
            "text": "Pcp1 protein belongs to the rhomboid-GlpG",
            "probability": 7.748603820800781e-06
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -5.1875,
            "text": "Pcp",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -5.31640625,
            "text": "Pcp1 protein belongs to the rhomboid-Glp",
            "probability": 0.0
        },
        {
            "start_logit": -5.44921875,
            "end_logit": 12.65625,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -7.140625,
            "text": "Pcp1 protein belongs",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -7.26171875,
            "text": "Pcp1 protein",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -7.81640625,
            "text": "Pcp1 protein belongs to the rhomboid-GlpG superfamily",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -8.296875,
            "text": "Pcp1 protein belongs to",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -8.4453125,
            "text": "Pcp1 protein belongs to the rhomboid",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -8.5,
            "text": "Pcp1 protein belongs to the rhomboid-",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -8.7265625,
            "text": "Pcp1 protein belongs to the",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -9.078125,
            "text": "Pcp1 protein belongs to the rhomb",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -9.1328125,
            "text": "Pcp1 protein belongs to the rhomboid-GlpG superfamily of putative intramembrane peptidases",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -9.2734375,
            "text": "Pcp1 protein belongs to the rhomboid-GlpG superfamily of",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -9.28125,
            "text": "Pcp1 protein belongs to the rhomboid-GlpG superfamily of putative intramembrane",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -9.375,
            "text": "Pcp1 protein belongs to the rhomboid-GlpG superfamily of putative intramembrane peptidases.",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -9.4765625,
            "text": "Pcp1 protein belongs to the rho",
            "probability": 0.0
        },
        {
            "start_logit": -11.0234375,
            "end_logit": 12.65625,
            "text": "newly identified Pcp1",
            "probability": 0.0
        },
        {
            "start_logit": -5.44921875,
            "end_logit": 0.8837890625,
            "text": "1 protein belongs to the rhomboid-GlpG",
            "probability": 0.0
        }
    ],
    "5c5f03371a4c55d80b000009_3": [
        {
            "start_logit": 12.421875,
            "end_logit": 11.75,
            "text": "GlpG",
            "probability": 1.0
        },
        {
            "start_logit": 12.421875,
            "end_logit": -5.37109375,
            "text": "Glp",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.421875,
            "end_logit": -6.765625,
            "text": "GlpG (ecGlpG) and Bacillus subtilis (YqgP",
            "probability": 0.0
        },
        {
            "start_logit": -6.77734375,
            "end_logit": 11.75,
            "text": "G",
            "probability": 0.0
        },
        {
            "start_logit": -8.640625,
            "end_logit": 11.75,
            "text": "Escherichia coli GlpG",
            "probability": 0.0
        },
        {
            "start_logit": 12.421875,
            "end_logit": -9.515625,
            "text": "GlpG (ecGlpG",
            "probability": 0.0
        },
        {
            "start_logit": 12.421875,
            "end_logit": -9.84375,
            "text": "GlpG (ecG",
            "probability": 0.0
        },
        {
            "start_logit": -9.1796875,
            "end_logit": 11.75,
            "text": ", Escherichia coli GlpG",
            "probability": 0.0
        },
        {
            "start_logit": 12.421875,
            "end_logit": -9.875,
            "text": "GlpG (ecGlpG) and",
            "probability": 0.0
        },
        {
            "start_logit": 12.421875,
            "end_logit": -9.96875,
            "text": "GlpG (ecGlpG) and Bacillus subtilis (YqgP)",
            "probability": 0.0
        },
        {
            "start_logit": 12.421875,
            "end_logit": -10.0625,
            "text": "GlpG (ecGlpG) and Bacillus subtilis",
            "probability": 0.0
        },
        {
            "start_logit": 12.421875,
            "end_logit": -10.21875,
            "text": "GlpG (ecGlpG) and Bacillus subtilis (Y",
            "probability": 0.0
        },
        {
            "start_logit": 12.421875,
            "end_logit": -10.25,
            "text": "GlpG (ecGlpG) and Bacillus subtilis (Yq",
            "probability": 0.0
        },
        {
            "start_logit": 12.421875,
            "end_logit": -10.3125,
            "text": "GlpG (ecGlpG)",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": 11.75,
            "text": "hiGlpG), Escherichia coli GlpG",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 11.75,
            "text": "lpG), Escherichia coli GlpG",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": 11.75,
            "text": "Haemophilus influenzae, (hiGlpG), Escherichia coli GlpG",
            "probability": 0.0
        },
        {
            "start_logit": -6.77734375,
            "end_logit": -6.765625,
            "text": "G (ecGlpG) and Bacillus subtilis (YqgP",
            "probability": 0.0
        },
        {
            "start_logit": -8.640625,
            "end_logit": -5.37109375,
            "text": "Escherichia coli Glp",
            "probability": 0.0
        },
        {
            "start_logit": -9.1796875,
            "end_logit": -5.37109375,
            "text": ", Escherichia coli Glp",
            "probability": 0.0
        }
    ],
    "5c5f03371a4c55d80b000009_4": [
        {
            "start_logit": 12.7578125,
            "end_logit": 12.6328125,
            "text": "GlpG",
            "probability": 1.0
        },
        {
            "start_logit": 12.7578125,
            "end_logit": -4.86328125,
            "text": "Glp",
            "probability": 0.0
        },
        {
            "start_logit": 12.7578125,
            "end_logit": -6.18359375,
            "text": "GlpG (ecGlpG) rhomboids have revealed a structure with six transmembrane helices",
            "probability": 0.0
        },
        {
            "start_logit": -6.078125,
            "end_logit": 12.6328125,
            "text": "G",
            "probability": 0.0
        },
        {
            "start_logit": 12.7578125,
            "end_logit": -7.40625,
            "text": "GlpG (ecGlpG) rhomboids have revealed a structure with six transmembrane helices and a Ser-His",
            "probability": 0.0
        },
        {
            "start_logit": 12.7578125,
            "end_logit": -7.5859375,
            "text": "GlpG (ecGlpG",
            "probability": 0.0
        },
        {
            "start_logit": 12.7578125,
            "end_logit": -8.296875,
            "text": "GlpG (ecGlpG) rhomboids have revealed a structure with six transmembrane helices and a Ser-His catalytic dyad",
            "probability": 0.0
        },
        {
            "start_logit": 12.7578125,
            "end_logit": -8.3359375,
            "text": "GlpG (ecGlpG)",
            "probability": 0.0
        },
        {
            "start_logit": 12.7578125,
            "end_logit": -8.6171875,
            "text": "GlpG (ecG",
            "probability": 0.0
        },
        {
            "start_logit": 12.7578125,
            "end_logit": -8.8828125,
            "text": "GlpG (ecGlpG) rhomboids have revealed a structure with six transmembrane",
            "probability": 0.0
        },
        {
            "start_logit": 12.7578125,
            "end_logit": -8.8828125,
            "text": "GlpG (ecGlpG) rhomboids have revealed a structure with six transmembrane helices and a Ser",
            "probability": 0.0
        },
        {
            "start_logit": 12.7578125,
            "end_logit": -8.9375,
            "text": "GlpG (ecGlpG) rhomboids have revealed a",
            "probability": 0.0
        },
        {
            "start_logit": -8.875,
            "end_logit": 12.6328125,
            "text": "E. coli GlpG",
            "probability": 0.0
        },
        {
            "start_logit": 12.7578125,
            "end_logit": -9.0546875,
            "text": "GlpG (ecGlpG) rhomboids have revealed a structure with six transmembrane helices and a Ser-His catalytic dyad buried within the membrane",
            "probability": 0.0
        },
        {
            "start_logit": 12.7578125,
            "end_logit": -9.09375,
            "text": "GlpG (ecGlpG) rhomboids have revealed a structure",
            "probability": 0.0
        },
        {
            "start_logit": 12.7578125,
            "end_logit": -9.140625,
            "text": "GlpG (ecGlpG) rhomboids have revealed a structure with six transmembrane helices and a Ser-His catalytic dy",
            "probability": 0.0
        },
        {
            "start_logit": -9.3984375,
            "end_logit": 12.6328125,
            "text": "hiGlpG) and E. coli GlpG",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": 12.6328125,
            "text": "H. influenzae (hiGlpG) and E. coli GlpG",
            "probability": 0.0
        },
        {
            "start_logit": -9.9921875,
            "end_logit": 12.6328125,
            "text": "and E. coli GlpG",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 12.6328125,
            "text": "lpG) and E. coli GlpG",
            "probability": 0.0
        }
    ],
    "5c72b6be7c78d69471000072_1": [
        {
            "start_logit": 12.3046875,
            "end_logit": 11.8359375,
            "text": "phosphoinositide 3-kinase-\u03b4",
            "probability": 1.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -3.875,
            "text": "phosphoinositide 3-kinase",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -4.28515625,
            "text": "phosphoinositide",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -4.7421875,
            "text": "phosphoinositide 3-kinase-\u03b4 (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -4.74609375,
            "text": "phosphoinositide 3-kinase-\u03b4 (PI3K-\u03b4)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -5.125,
            "text": "phosphoinositide 3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -5.3828125,
            "text": "phosphoinositide 3-kinase-\u03b4 (PI3K-\u03b4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -5.421875,
            "text": "phosphoinositide 3-kinase-\u03b4 (PI3K",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -5.88671875,
            "text": "phosphoinositide 3-kinase-\u03b4 (PI3K-\u03b4) and PI3K-\u03b3",
            "probability": 0.0
        },
        {
            "start_logit": -6.48046875,
            "end_logit": 11.8359375,
            "text": "\u03b4",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -7.11328125,
            "text": "phosphoinositide 3-kinase-",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -7.8671875,
            "text": "phosphoinositide 3-",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -7.95703125,
            "text": "phosphoinositide 3-kinase-\u03b4 (PI3K-\u03b4) and PI3K",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -8.09375,
            "text": "phosphoinositide 3-kinase-\u03b4 (PI3K-",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -9.0234375,
            "text": "phosphoinositide 3-kinase-\u03b4 (PI3K-\u03b4) and",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -9.125,
            "text": "phosphoinositide 3-kinase-\u03b4 (PI3K-\u03b4) and PI3K-",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -9.359375,
            "text": "phosphoinositide 3-kinase-\u03b4 (PI3K-\u03b4) and PI3K-\u03b3 in",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -9.5625,
            "text": "phosphoinositide 3-kinase-\u03b4 (PI3K-\u03b4) and PI3K-\u03b3 in late-stage clinical development for hematologic malignancy",
            "probability": 0.0
        },
        {
            "start_logit": -9.1015625,
            "end_logit": 11.8359375,
            "text": "3-kinase-\u03b4",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -9.78125,
            "text": "phosphoinositide 3-kinase-\u03b4 (PI3K-\u03b4) and PI3K-\u03b3 in late-stage clinical development",
            "probability": 0.0
        }
    ],
    "5c72b6be7c78d69471000072_2": [
        {
            "start_logit": 10.3671875,
            "end_logit": 11.796875,
            "text": "phosphoinositide-3 kinase \u03b4",
            "probability": 1.0
        },
        {
            "start_logit": 10.3671875,
            "end_logit": 0.515625,
            "text": "phosphoinositide-3 kinase \u03b4/\u03b3",
            "probability": 1.2695789337158203e-05
        },
        {
            "start_logit": 10.3671875,
            "end_logit": -1.041015625,
            "text": "phosphoinositide-3 kinase",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": 10.3671875,
            "end_logit": -2.5078125,
            "text": "phosphoinositide-3",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -5.76171875,
            "end_logit": 11.796875,
            "text": "\u03b4",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.3671875,
            "end_logit": -4.8671875,
            "text": "phosphoinositide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.3671875,
            "end_logit": -5.85546875,
            "text": "phosphoinositide-3 kinase \u03b4/\u03b3 inhibitor for chronic lymphocytic leukemia",
            "probability": 0.0
        },
        {
            "start_logit": 10.3671875,
            "end_logit": -7.0703125,
            "text": "phosphoinositide-",
            "probability": 0.0
        },
        {
            "start_logit": -9.3515625,
            "end_logit": 11.796875,
            "text": "kinase \u03b4",
            "probability": 0.0
        },
        {
            "start_logit": 10.3671875,
            "end_logit": -9.109375,
            "text": "phosphoinositide-3 kinase \u03b4/\u03b3 inhibitor for chronic lymphocytic",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 11.796875,
            "text": "3 kinase \u03b4",
            "probability": 0.0
        },
        {
            "start_logit": 10.3671875,
            "end_logit": -9.375,
            "text": "phosphoinositide-3 kinase \u03b4/",
            "probability": 0.0
        },
        {
            "start_logit": 10.3671875,
            "end_logit": -9.4140625,
            "text": "phosphoinositide-3 kinase \u03b4/\u03b3 inhibitor for chronic lymphocytic leukemia.",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 11.796875,
            "text": "Duvelisib: a phosphoinositide-3 kinase \u03b4",
            "probability": 0.0
        },
        {
            "start_logit": 10.3671875,
            "end_logit": -9.5234375,
            "text": "phosphoinositide-3 kinase \u03b4/\u03b3 inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 11.796875,
            "text": "velisib: a phosphoinositide-3 kinase \u03b4",
            "probability": 0.0
        },
        {
            "start_logit": -11.0625,
            "end_logit": 11.796875,
            "text": "isib: a phosphoinositide-3 kinase \u03b4",
            "probability": 0.0
        },
        {
            "start_logit": 10.3671875,
            "end_logit": -9.7109375,
            "text": "phosphoinositide-3 kinase \u03b4/\u03b3 inhibitor for chronic",
            "probability": 0.0
        },
        {
            "start_logit": 10.3671875,
            "end_logit": -9.8671875,
            "text": "phosphoinositide-3 kinase \u03b4/\u03b3 inhibitor for",
            "probability": 0.0
        },
        {
            "start_logit": -5.76171875,
            "end_logit": 0.515625,
            "text": "\u03b4/\u03b3",
            "probability": 0.0
        }
    ],
    "5548da00f35db7552600000b_1": [
        {
            "start_logit": 6.91015625,
            "end_logit": 3.369140625,
            "text": "myosins-Ibeta, -VI, and -VIIa",
            "probability": 0.59619140625
        },
        {
            "start_logit": 6.91015625,
            "end_logit": 2.623046875,
            "text": "myosins-Ibeta, -VI",
            "probability": 0.281494140625
        },
        {
            "start_logit": 6.91015625,
            "end_logit": 1.78515625,
            "text": "myosins-Ibeta",
            "probability": 0.12200927734375
        },
        {
            "start_logit": 6.91015625,
            "end_logit": -5.1171875,
            "text": "myosins-Ibeta, -VI, and -VII",
            "probability": 0.0001232624053955078
        },
        {
            "start_logit": 6.91015625,
            "end_logit": -5.546875,
            "text": "myosins-Ib",
            "probability": 7.95125961303711e-05
        },
        {
            "start_logit": 6.91015625,
            "end_logit": -6.1015625,
            "text": "myosin",
            "probability": 4.601478576660156e-05
        },
        {
            "start_logit": 6.91015625,
            "end_logit": -6.76953125,
            "text": "myosins",
            "probability": 2.3543834686279297e-05
        },
        {
            "start_logit": 6.91015625,
            "end_logit": -6.9453125,
            "text": "myosins-",
            "probability": 1.9788742065429688e-05
        },
        {
            "start_logit": 6.91015625,
            "end_logit": -7.796875,
            "text": "myosins-Ibeta, -VI, and -VIIa are located in a",
            "probability": 8.404254913330078e-06
        },
        {
            "start_logit": 6.91015625,
            "end_logit": -8.296875,
            "text": "myosins-Ibeta, -VI, and -VIIa are located in a pericuticular necklace",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": 6.91015625,
            "end_logit": -8.5546875,
            "text": "myosins-Ibeta, -VI, and",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": -5.3828125,
            "end_logit": 3.369140625,
            "text": ", -VI, and -VIIa",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": 6.91015625,
            "end_logit": -9.0546875,
            "text": "myosins-Ibeta, -VI, and -VIIa are",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": 6.91015625,
            "end_logit": -9.5703125,
            "text": "myosins-Ibeta, -VI, and -",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 6.91015625,
            "end_logit": -9.6015625,
            "text": "myosins-Ibeta, -VI, and -VIIa are located",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -5.3828125,
            "end_logit": 2.623046875,
            "text": ", -VI",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -7.9375,
            "end_logit": 3.369140625,
            "text": "a",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -8.9375,
            "end_logit": 3.369140625,
            "text": "and -VIIa",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.3515625,
            "end_logit": 3.369140625,
            "text": "s-Ibeta, -VI, and -VIIa",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.4375,
            "end_logit": 3.369140625,
            "text": "VI, and -VIIa",
            "probability": 5.960464477539063e-08
        }
    ],
    "5548da00f35db7552600000b_2": [
        {
            "start_logit": 6.875,
            "end_logit": 2.52734375,
            "text": "myosins-Ibeta, -VI, and -VIIa",
            "probability": 0.67919921875
        },
        {
            "start_logit": 6.875,
            "end_logit": 1.2470703125,
            "text": "myosins-Ibeta, -VI",
            "probability": 0.1884765625
        },
        {
            "start_logit": 6.875,
            "end_logit": 0.888671875,
            "text": "myosins-Ibeta",
            "probability": 0.131591796875
        },
        {
            "start_logit": 6.875,
            "end_logit": -5.57421875,
            "text": "myosins-Ibeta, -VI, and -VII",
            "probability": 0.00020420551300048828
        },
        {
            "start_logit": 6.875,
            "end_logit": -5.765625,
            "text": "myosin",
            "probability": 0.00016939640045166016
        },
        {
            "start_logit": 6.875,
            "end_logit": -5.9609375,
            "text": "myosins-Ib",
            "probability": 0.0001392364501953125
        },
        {
            "start_logit": 6.875,
            "end_logit": -7.17578125,
            "text": "myosins",
            "probability": 4.1484832763671875e-05
        },
        {
            "start_logit": 6.875,
            "end_logit": -7.81640625,
            "text": "myosins-",
            "probability": 2.187490463256836e-05
        },
        {
            "start_logit": 6.875,
            "end_logit": -8.4921875,
            "text": "myosins-Ibeta, -VI, and",
            "probability": 1.1086463928222656e-05
        },
        {
            "start_logit": 6.875,
            "end_logit": -9.1953125,
            "text": "myosins-Ibeta, -VI, and -VIIa are",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": -5.34375,
            "end_logit": 2.52734375,
            "text": ", -VI, and -VIIa",
            "probability": 3.337860107421875e-06
        },
        {
            "start_logit": -5.34375,
            "end_logit": 1.2470703125,
            "text": ", -VI",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -8.046875,
            "end_logit": 2.52734375,
            "text": "a",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -8.9296875,
            "end_logit": 2.52734375,
            "text": "and -VIIa",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.109375,
            "end_logit": 2.52734375,
            "text": "-VI, and -VIIa",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.453125,
            "end_logit": 2.52734375,
            "text": "VI, and -VIIa",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.5,
            "end_logit": 2.52734375,
            "text": "s-Ibeta, -VI, and -VIIa",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.109375,
            "end_logit": 1.2470703125,
            "text": "-VI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.453125,
            "end_logit": 1.2470703125,
            "text": "VI",
            "probability": 0.0
        },
        {
            "start_logit": -9.5,
            "end_logit": 1.2470703125,
            "text": "s-Ibeta, -VI",
            "probability": 0.0
        }
    ],
    "5548da00f35db7552600000b_3": [
        {
            "start_logit": 14.203125,
            "end_logit": 13.9296875,
            "text": "myosin VI",
            "probability": 1.0
        },
        {
            "start_logit": 14.203125,
            "end_logit": -3.12109375,
            "text": "myosin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.7109375,
            "end_logit": 13.9296875,
            "text": "VI",
            "probability": 0.0
        },
        {
            "start_logit": 14.203125,
            "end_logit": -4.00390625,
            "text": "myosin VI and myosin VIIa",
            "probability": 0.0
        },
        {
            "start_logit": 14.203125,
            "end_logit": -5.515625,
            "text": "myosin VI and myosin",
            "probability": 0.0
        },
        {
            "start_logit": 14.203125,
            "end_logit": -6.76171875,
            "text": "myosin VI and myosin VIIa, two unconventional myosin",
            "probability": 0.0
        },
        {
            "start_logit": 14.203125,
            "end_logit": -6.8671875,
            "text": "myosin VI and myosin VIIa, two unconventional myosins",
            "probability": 0.0
        },
        {
            "start_logit": 14.203125,
            "end_logit": -7.40234375,
            "text": "myosin VI and myosin VII",
            "probability": 0.0
        },
        {
            "start_logit": 14.203125,
            "end_logit": -8.0390625,
            "text": "myosin VI and",
            "probability": 0.0
        },
        {
            "start_logit": 14.203125,
            "end_logit": -8.296875,
            "text": "myosin VI and myosin VIIa, two unconventional myosins that are critical",
            "probability": 0.0
        },
        {
            "start_logit": 14.203125,
            "end_logit": -8.4375,
            "text": "myosin VI and myosin VIIa,",
            "probability": 0.0
        },
        {
            "start_logit": 14.203125,
            "end_logit": -8.578125,
            "text": "myosin VI and myosin VIIa, two unconventional",
            "probability": 0.0
        },
        {
            "start_logit": 14.203125,
            "end_logit": -8.890625,
            "text": "myosin VI and myosin VIIa, two unconventional myosins that are critical for normal hair cell formation and function, during hair cell death and regeneration",
            "probability": 0.0
        },
        {
            "start_logit": 14.203125,
            "end_logit": -8.9296875,
            "text": "myosin VI and myosin VIIa, two unconventional myosins that are critical for normal hair cell formation and function,",
            "probability": 0.0
        },
        {
            "start_logit": 14.203125,
            "end_logit": -9.0703125,
            "text": "myosin VI and myosin VIIa, two",
            "probability": 0.0
        },
        {
            "start_logit": 14.203125,
            "end_logit": -9.09375,
            "text": "myosin VI and myosin VIIa, two unconventional myosins that are",
            "probability": 0.0
        },
        {
            "start_logit": -3.7109375,
            "end_logit": -4.00390625,
            "text": "VI and myosin VIIa",
            "probability": 0.0
        },
        {
            "start_logit": -3.7109375,
            "end_logit": -5.515625,
            "text": "VI and myosin",
            "probability": 0.0
        },
        {
            "start_logit": -5.75390625,
            "end_logit": -4.00390625,
            "text": "myosin VIIa",
            "probability": 0.0
        },
        {
            "start_logit": -3.7109375,
            "end_logit": -6.76171875,
            "text": "VI and myosin VIIa, two unconventional myosin",
            "probability": 0.0
        }
    ],
    "5548da00f35db7552600000b_4": [
        {
            "start_logit": 6.875,
            "end_logit": 2.52734375,
            "text": "myosins-Ibeta, -VI, and -VIIa",
            "probability": 0.67919921875
        },
        {
            "start_logit": 6.875,
            "end_logit": 1.2470703125,
            "text": "myosins-Ibeta, -VI",
            "probability": 0.1884765625
        },
        {
            "start_logit": 6.875,
            "end_logit": 0.888671875,
            "text": "myosins-Ibeta",
            "probability": 0.131591796875
        },
        {
            "start_logit": 6.875,
            "end_logit": -5.57421875,
            "text": "myosins-Ibeta, -VI, and -VII",
            "probability": 0.00020420551300048828
        },
        {
            "start_logit": 6.875,
            "end_logit": -5.765625,
            "text": "myosin",
            "probability": 0.00016939640045166016
        },
        {
            "start_logit": 6.875,
            "end_logit": -5.9609375,
            "text": "myosins-Ib",
            "probability": 0.0001392364501953125
        },
        {
            "start_logit": 6.875,
            "end_logit": -7.17578125,
            "text": "myosins",
            "probability": 4.1484832763671875e-05
        },
        {
            "start_logit": 6.875,
            "end_logit": -7.81640625,
            "text": "myosins-",
            "probability": 2.187490463256836e-05
        },
        {
            "start_logit": 6.875,
            "end_logit": -8.4921875,
            "text": "myosins-Ibeta, -VI, and",
            "probability": 1.1086463928222656e-05
        },
        {
            "start_logit": 6.875,
            "end_logit": -9.1953125,
            "text": "myosins-Ibeta, -VI, and -VIIa are",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": -5.34375,
            "end_logit": 2.52734375,
            "text": ", -VI, and -VIIa",
            "probability": 3.337860107421875e-06
        },
        {
            "start_logit": -5.34375,
            "end_logit": 1.2470703125,
            "text": ", -VI",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -8.046875,
            "end_logit": 2.52734375,
            "text": "a",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -8.9296875,
            "end_logit": 2.52734375,
            "text": "and -VIIa",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.109375,
            "end_logit": 2.52734375,
            "text": "-VI, and -VIIa",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.453125,
            "end_logit": 2.52734375,
            "text": "VI, and -VIIa",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.5,
            "end_logit": 2.52734375,
            "text": "s-Ibeta, -VI, and -VIIa",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.109375,
            "end_logit": 1.2470703125,
            "text": "-VI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.453125,
            "end_logit": 1.2470703125,
            "text": "VI",
            "probability": 0.0
        },
        {
            "start_logit": -9.5,
            "end_logit": 1.2470703125,
            "text": "s-Ibeta, -VI",
            "probability": 0.0
        }
    ],
    "5548da00f35db7552600000b_5": [
        {
            "start_logit": 6.5234375,
            "end_logit": 2.29296875,
            "text": "myosins-Ibeta, -VI, and -VIIa",
            "probability": 0.7431640625
        },
        {
            "start_logit": 6.5234375,
            "end_logit": 0.8095703125,
            "text": "myosins-Ibeta",
            "probability": 0.1690673828125
        },
        {
            "start_logit": 6.5234375,
            "end_logit": 0.1463623046875,
            "text": "myosins-Ibeta, -VI",
            "probability": 0.0870361328125
        },
        {
            "start_logit": 6.5234375,
            "end_logit": -5.8203125,
            "text": "myosins-Ibeta, -VI, and -VII",
            "probability": 0.00022339820861816406
        },
        {
            "start_logit": 6.5234375,
            "end_logit": -5.95703125,
            "text": "myosin",
            "probability": 0.00019419193267822266
        },
        {
            "start_logit": 6.5234375,
            "end_logit": -6.19921875,
            "text": "myosins-Ib",
            "probability": 0.00015366077423095703
        },
        {
            "start_logit": 6.5234375,
            "end_logit": -7.21875,
            "text": "myosins",
            "probability": 5.519390106201172e-05
        },
        {
            "start_logit": 6.5234375,
            "end_logit": -7.87109375,
            "text": "myosins-",
            "probability": 2.8908252716064453e-05
        },
        {
            "start_logit": 6.5234375,
            "end_logit": -8.5703125,
            "text": "myosins-Ibeta, -VI, and",
            "probability": 1.430511474609375e-05
        },
        {
            "start_logit": -5.47265625,
            "end_logit": 2.29296875,
            "text": ", -VI, and -VIIa",
            "probability": 4.589557647705078e-06
        },
        {
            "start_logit": -5.47265625,
            "end_logit": 0.1463623046875,
            "text": ", -VI",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 2.29296875,
            "text": "a",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -8.8515625,
            "end_logit": 2.29296875,
            "text": "and -VIIa",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -9.25,
            "end_logit": 2.29296875,
            "text": "-VI, and -VIIa",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.6328125,
            "end_logit": 2.29296875,
            "text": "VI, and -VIIa",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.640625,
            "end_logit": 2.29296875,
            "text": "s-Ibeta, -VI, and -VIIa",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 2.29296875,
            "text": "Substantial amounts of myosins-Ibeta, -VI, and -VIIa",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.84765625,
            "end_logit": -3.06640625,
            "text": "cuticular plate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.640625,
            "end_logit": 0.8095703125,
            "text": "s-Ibeta",
            "probability": 0.0
        },
        {
            "start_logit": -4.84765625,
            "end_logit": -4.078125,
            "text": "cuticular plate and the circumferential belt",
            "probability": 0.0
        }
    ],
    "6278dd4c56bf9aee6f000011_1": [
        {
            "start_logit": 9.453125,
            "end_logit": 10.046875,
            "text": "MD STARnet",
            "probability": 1.0
        },
        {
            "start_logit": 9.453125,
            "end_logit": -5.625,
            "text": "MD",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.33984375,
            "end_logit": 10.046875,
            "text": "net",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.453125,
            "end_logit": -6.8125,
            "text": "MD STARnet)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.734375,
            "end_logit": 10.046875,
            "text": "Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet",
            "probability": 0.0
        },
        {
            "start_logit": 9.453125,
            "end_logit": -8.1875,
            "text": "MD STAR",
            "probability": 0.0
        },
        {
            "start_logit": -9.109375,
            "end_logit": 10.046875,
            "text": "STARnet",
            "probability": 0.0
        },
        {
            "start_logit": -9.5625,
            "end_logit": 10.046875,
            "text": "Surveillance, Tracking, and Research Network (MD STARnet",
            "probability": 0.0
        },
        {
            "start_logit": -9.6875,
            "end_logit": 10.046875,
            "text": "Using data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": 10.046875,
            "text": ", Tracking, and Research Network (MD STARnet",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": 10.046875,
            "text": "Tracking, and Research Network (MD STARnet",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 10.046875,
            "text": "Network (MD STARnet",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 10.046875,
            "text": "(MD STARnet",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 10.046875,
            "text": "the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 10.046875,
            "text": "and Research Network (MD STARnet",
            "probability": 0.0
        },
        {
            "start_logit": -6.33984375,
            "end_logit": -6.8125,
            "text": "net)",
            "probability": 0.0
        },
        {
            "start_logit": -8.734375,
            "end_logit": -5.30859375,
            "text": "Muscular Dystrophy Surveillance, Tracking, and Research Network",
            "probability": 0.0
        },
        {
            "start_logit": -8.734375,
            "end_logit": -5.625,
            "text": "Muscular Dystrophy Surveillance, Tracking, and Research Network (MD",
            "probability": 0.0
        },
        {
            "start_logit": -9.5625,
            "end_logit": -5.30859375,
            "text": "Surveillance, Tracking, and Research Network",
            "probability": 0.0
        },
        {
            "start_logit": -9.6875,
            "end_logit": -5.30859375,
            "text": "Using data from the Muscular Dystrophy Surveillance, Tracking, and Research Network",
            "probability": 0.0
        }
    ],
    "6278dd4c56bf9aee6f000011_2": [
        {
            "start_logit": 7.87109375,
            "end_logit": 7.49609375,
            "text": "ImagingDMD",
            "probability": 1.0
        },
        {
            "start_logit": -6.11328125,
            "end_logit": 7.49609375,
            "text": "Universitaire Ziekenhuizen Leuven, DMD Italian Group, The Cooperative International Neuromuscular Research Group, ImagingDMD",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 7.87109375,
            "end_logit": -7.19140625,
            "text": "ImagingDM",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.87109375,
            "end_logit": -8.1484375,
            "text": "ImagingDMD, and the PRO-DMD-01 study",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.87109375,
            "end_logit": -8.4140625,
            "text": "ImagingDMD, and the PRO",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.87109375,
            "end_logit": -8.625,
            "text": "ImagingDMD, and the PRO-DMD-01 study (n = 430 patients",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.265625,
            "end_logit": 7.49609375,
            "text": "DMD",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.87109375,
            "end_logit": -8.8046875,
            "text": "Imaging",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.87109375,
            "end_logit": -9.296875,
            "text": "ImagingDMD, and the PRO-DMD-01",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.0546875,
            "end_logit": 7.49609375,
            "text": "D",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.3046875,
            "end_logit": 7.49609375,
            "text": "Neuromuscular Research Group, ImagingDMD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.390625,
            "end_logit": 7.49609375,
            "text": "DMD Italian Group, The Cooperative International Neuromuscular Research Group, ImagingDMD",
            "probability": 0.0
        },
        {
            "start_logit": -5.34375,
            "end_logit": -4.2734375,
            "text": "RWD/NHD were contributed by Universitaire Ziekenhuizen Leuven",
            "probability": 0.0
        },
        {
            "start_logit": -6.11328125,
            "end_logit": -4.2734375,
            "text": "Universitaire Ziekenhuizen Leuven",
            "probability": 0.0
        },
        {
            "start_logit": -5.34375,
            "end_logit": -5.3828125,
            "text": "RWD/NHD",
            "probability": 0.0
        },
        {
            "start_logit": -7.4765625,
            "end_logit": -4.2734375,
            "text": "NHD were contributed by Universitaire Ziekenhuizen Leuven",
            "probability": 0.0
        },
        {
            "start_logit": -5.34375,
            "end_logit": -6.48046875,
            "text": "RWD",
            "probability": 0.0
        },
        {
            "start_logit": -5.34375,
            "end_logit": -6.70703125,
            "text": "RWD/NHD were contributed by Universitaire Ziekenhuizen Leuven, DMD Italian Group",
            "probability": 0.0
        },
        {
            "start_logit": -5.34375,
            "end_logit": -6.9609375,
            "text": "RWD/NHD were contributed by Universitaire Ziekenhuizen Leuven, DMD Italian Group, The Cooperative International Neuromuscular Research Group",
            "probability": 0.0
        },
        {
            "start_logit": -5.34375,
            "end_logit": -6.99609375,
            "text": "RWD/NH",
            "probability": 0.0
        }
    ],
    "6278dd4c56bf9aee6f000011_3": [
        {
            "start_logit": 11.4140625,
            "end_logit": 12.2578125,
            "text": "GSE38417",
            "probability": 1.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -1.46484375,
            "text": "GSE38417, GSE3307, and GSE6011",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -5.66796875,
            "end_logit": 12.2578125,
            "text": "7",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -5.91015625,
            "text": "GSE3841",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -5.94140625,
            "text": "GSE",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -5.99609375,
            "text": "GS",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -6.17578125,
            "text": "GSE38417, GSE3307, and GSE60",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -6.56640625,
            "text": "GSE38417, GSE33",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -6.67578125,
            "text": "GSE38",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -6.6796875,
            "text": "GSE38417, GSE3307",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -7.04296875,
            "text": "GSE38417, GSE330",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 12.2578125,
            "text": "meta-analysis of three microarray datasets, GSE38417",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -7.80078125,
            "text": "GSE38417, GSE3307, and GSE",
            "probability": 0.0
        },
        {
            "start_logit": -9.6171875,
            "end_logit": 12.2578125,
            "text": "microarray datasets, GSE38417",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 12.2578125,
            "text": "conducted a meta-analysis of three microarray datasets, GSE38417",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 12.2578125,
            "text": "417",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 12.2578125,
            "text": ", GSE38417",
            "probability": 0.0
        },
        {
            "start_logit": -4.4375,
            "end_logit": -1.46484375,
            "text": "GSE6011",
            "probability": 0.0
        },
        {
            "start_logit": -5.66796875,
            "end_logit": -1.46484375,
            "text": "7, GSE3307, and GSE6011",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -1.46484375,
            "text": "meta-analysis of three microarray datasets, GSE38417, GSE3307, and GSE6011",
            "probability": 0.0
        }
    ],
    "6278dd4c56bf9aee6f000011_4": [
        {
            "start_logit": 9.796875,
            "end_logit": 8.625,
            "text": "MD STARnet",
            "probability": 1.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -5.0625,
            "text": "MD",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -6.2890625,
            "end_logit": 8.625,
            "text": "net",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.796875,
            "end_logit": -7.61328125,
            "text": "MD STAR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.5078125,
            "text": "MD STARnet)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.796875,
            "text": "MD STARnet), a multistate, multiple-source, population-based surveillance system that identifies and gathers information",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -9.0625,
            "text": "MD STARnet), a multistate, multiple-source, population-based surveillance system",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 8.625,
            "text": "Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -9.7421875,
            "text": "MD STARnet), a multistate, multiple-source, population-based surveillance",
            "probability": 0.0
        },
        {
            "start_logit": -9.25,
            "end_logit": 8.625,
            "text": "Surveillance, Tracking, and Research Network (MD STARnet",
            "probability": 0.0
        },
        {
            "start_logit": -9.4765625,
            "end_logit": 8.625,
            "text": "STARnet",
            "probability": 0.0
        },
        {
            "start_logit": -9.75,
            "end_logit": 8.625,
            "text": "cohort comes from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet",
            "probability": 0.0
        },
        {
            "start_logit": -9.8515625,
            "end_logit": 8.625,
            "text": "Network (MD STARnet",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": 8.625,
            "text": "(MD STARnet",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 8.625,
            "text": "comes from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -4.63671875,
            "text": "Muscular Dystrophy Surveillance, Tracking, and Research Network",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -5.0625,
            "text": "Muscular Dystrophy Surveillance, Tracking, and Research Network (MD",
            "probability": 0.0
        },
        {
            "start_logit": -9.25,
            "end_logit": -4.63671875,
            "text": "Surveillance, Tracking, and Research Network",
            "probability": 0.0
        },
        {
            "start_logit": -9.25,
            "end_logit": -5.0625,
            "text": "Surveillance, Tracking, and Research Network (MD",
            "probability": 0.0
        },
        {
            "start_logit": -9.75,
            "end_logit": -4.63671875,
            "text": "cohort comes from the Muscular Dystrophy Surveillance, Tracking, and Research Network",
            "probability": 0.0
        }
    ],
    "6278dd4c56bf9aee6f000011_5": [
        {
            "start_logit": 13.03125,
            "end_logit": 13.1171875,
            "text": "Remudy",
            "probability": 1.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -4.23046875,
            "text": "Rem",
            "probability": 0.0
        },
        {
            "start_logit": -5.17578125,
            "end_logit": 13.1171875,
            "text": "y",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -6.15234375,
            "text": "Remud",
            "probability": 0.0
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 13.1171875,
            "text": "Japanese Registry of Muscular Dystrophy (Remudy",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -7.48046875,
            "text": "Remudy)",
            "probability": 0.0
        },
        {
            "start_logit": -10.140625,
            "end_logit": 13.1171875,
            "text": "Muscular Dystrophy (Remudy",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 13.1171875,
            "text": "Registry of Muscular Dystrophy (Remudy",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 13.1171875,
            "text": "udy",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 13.1171875,
            "text": "used the data from the Japanese Registry of Muscular Dystrophy (Remudy",
            "probability": 0.0
        },
        {
            "start_logit": -7.34765625,
            "end_logit": -4.23046875,
            "text": "Japanese Registry of Muscular Dystrophy (Rem",
            "probability": 0.0
        },
        {
            "start_logit": -5.17578125,
            "end_logit": -7.48046875,
            "text": "y)",
            "probability": 0.0
        },
        {
            "start_logit": -7.34765625,
            "end_logit": -6.15234375,
            "text": "Japanese Registry of Muscular Dystrophy (Remud",
            "probability": 0.0
        },
        {
            "start_logit": -7.34765625,
            "end_logit": -6.48828125,
            "text": "Japanese",
            "probability": 0.0
        },
        {
            "start_logit": -7.34765625,
            "end_logit": -6.6484375,
            "text": "Japanese Registry",
            "probability": 0.0
        },
        {
            "start_logit": -10.140625,
            "end_logit": -4.23046875,
            "text": "Muscular Dystrophy (Rem",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": -4.23046875,
            "text": "Registry of Muscular Dystrophy (Rem",
            "probability": 0.0
        },
        {
            "start_logit": -7.34765625,
            "end_logit": -7.2421875,
            "text": "Japanese Registry of Muscular Dystrophy (",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": -4.23046875,
            "text": "used the data from the Japanese Registry of Muscular Dystrophy (Rem",
            "probability": 0.0
        },
        {
            "start_logit": -7.34765625,
            "end_logit": -7.48046875,
            "text": "Japanese Registry of Muscular Dystrophy (Remudy)",
            "probability": 0.0
        }
    ],
    "6278dd4c56bf9aee6f000011_6": [
        {
            "start_logit": 12.1953125,
            "end_logit": 12.953125,
            "text": "Remudy",
            "probability": 1.0
        },
        {
            "start_logit": -5.55078125,
            "end_logit": 12.953125,
            "text": "y",
            "probability": 0.0
        },
        {
            "start_logit": 12.1953125,
            "end_logit": -4.98046875,
            "text": "Rem",
            "probability": 0.0
        },
        {
            "start_logit": 12.1953125,
            "end_logit": -6.08984375,
            "text": "Remudy\"",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 12.953125,
            "text": "dystrophinopathies mutation dataset in Japan from a national patient registry, \"Remudy",
            "probability": 0.0
        },
        {
            "start_logit": 12.1953125,
            "end_logit": -7.43359375,
            "text": "Remud",
            "probability": 0.0
        },
        {
            "start_logit": -8.90625,
            "end_logit": 12.953125,
            "text": "national patient registry, \"Remudy",
            "probability": 0.0
        },
        {
            "start_logit": -9.8671875,
            "end_logit": 12.953125,
            "text": "patient registry, \"Remudy",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 12.953125,
            "text": "udy",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 12.953125,
            "text": "\"Remudy",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 12.953125,
            "text": "a national patient registry, \"Remudy",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 12.953125,
            "text": "Japan from a national patient registry, \"Remudy",
            "probability": 0.0
        },
        {
            "start_logit": -5.55078125,
            "end_logit": -6.08984375,
            "text": "y\"",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": -4.7421875,
            "text": "dystrophinopathies mutation dataset in Japan from a national patient registry",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": -4.98046875,
            "text": "dystrophinopathies mutation dataset in Japan from a national patient registry, \"Rem",
            "probability": 0.0
        },
        {
            "start_logit": -8.90625,
            "end_logit": -4.7421875,
            "text": "national patient registry",
            "probability": 0.0
        },
        {
            "start_logit": -8.90625,
            "end_logit": -4.98046875,
            "text": "national patient registry, \"Rem",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": -6.08984375,
            "text": "dystrophinopathies mutation dataset in Japan from a national patient registry, \"Remudy\"",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": -6.43359375,
            "text": "dystrophinopathies mutation dataset in Japan",
            "probability": 0.0
        },
        {
            "start_logit": -9.8671875,
            "end_logit": -4.7421875,
            "text": "patient registry",
            "probability": 0.0
        }
    ],
    "6278dd4c56bf9aee6f000011_7": [
        {
            "start_logit": 9.6875,
            "end_logit": 11.3984375,
            "text": "GSE38417 of DMD was obtained from the Gene Expression Omnibus",
            "probability": 0.96875
        },
        {
            "start_logit": 9.6875,
            "end_logit": 7.328125,
            "text": "GSE38417",
            "probability": 0.0164031982421875
        },
        {
            "start_logit": 5.53125,
            "end_logit": 11.3984375,
            "text": "Gene Expression Omnibus",
            "probability": 0.0151824951171875
        },
        {
            "start_logit": 9.6875,
            "end_logit": -3.4140625,
            "text": "GSE38417 of DMD was obtained from the Gene Expression Omnibus (GEO",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.6875,
            "end_logit": -4.328125,
            "text": "GSE38417 of DMD was obtained from the Gene Expression Omnibus (GEO) database",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.6875,
            "end_logit": -5.5546875,
            "text": "GSE3841",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.28515625,
            "end_logit": 11.3984375,
            "text": "us",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.47265625,
            "end_logit": 11.3984375,
            "text": "gene expression profile dataset GSE38417 of DMD was obtained from the Gene Expression Omnibus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6875,
            "end_logit": -5.765625,
            "text": "GSE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6875,
            "end_logit": -5.77734375,
            "text": "GSE38",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6875,
            "end_logit": -5.88671875,
            "text": "GSE38417 of DMD was obtained from the Gene Expression Omn",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.75,
            "end_logit": 11.3984375,
            "text": "7 of DMD was obtained from the Gene Expression Omnibus",
            "probability": 0.0
        },
        {
            "start_logit": -8.875,
            "end_logit": 11.3984375,
            "text": "dataset GSE38417 of DMD was obtained from the Gene Expression Omnibus",
            "probability": 0.0
        },
        {
            "start_logit": 9.6875,
            "end_logit": -7.36328125,
            "text": "GSE38417 of DMD was obtained from the Gene Expression Omnibus (GEO)",
            "probability": 0.0
        },
        {
            "start_logit": 9.6875,
            "end_logit": -7.41015625,
            "text": "GS",
            "probability": 0.0
        },
        {
            "start_logit": -9.140625,
            "end_logit": 11.3984375,
            "text": "ibus",
            "probability": 0.0
        },
        {
            "start_logit": 5.53125,
            "end_logit": -3.4140625,
            "text": "Gene Expression Omnibus (GEO",
            "probability": 0.0
        },
        {
            "start_logit": 9.6875,
            "end_logit": -7.65625,
            "text": "GSE38417 of DMD was obtained from the Gene Expression Omnibus (",
            "probability": 0.0
        },
        {
            "start_logit": 9.6875,
            "end_logit": -7.6875,
            "text": "GSE38417 of DMD was obtained from the Gene Expression Omnib",
            "probability": 0.0
        },
        {
            "start_logit": 9.6875,
            "end_logit": -7.71484375,
            "text": "GSE38417 of DMD was obtained from the Gene",
            "probability": 0.0
        }
    ],
    "6278dd4c56bf9aee6f000011_8": [
        {
            "start_logit": 11.9375,
            "end_logit": 12.6328125,
            "text": "MD STARnet",
            "probability": 1.0
        },
        {
            "start_logit": -5.51171875,
            "end_logit": 12.6328125,
            "text": "net",
            "probability": 0.0
        },
        {
            "start_logit": 11.9375,
            "end_logit": -5.6171875,
            "text": "MD STARnet, DuchenneConnect, and TREAT-NMD",
            "probability": 0.0
        },
        {
            "start_logit": 11.9375,
            "end_logit": -5.9921875,
            "text": "MD",
            "probability": 0.0
        },
        {
            "start_logit": 11.9375,
            "end_logit": -6.26171875,
            "text": "MD STARnet, DuchenneConnect",
            "probability": 0.0
        },
        {
            "start_logit": 11.9375,
            "end_logit": -7.3203125,
            "text": "MD STAR",
            "probability": 0.0
        },
        {
            "start_logit": 11.9375,
            "end_logit": -7.51171875,
            "text": "MD STARnet, DuchenneConnect, and TREAT",
            "probability": 0.0
        },
        {
            "start_logit": 11.9375,
            "end_logit": -7.7265625,
            "text": "MD STARnet, DuchenneCon",
            "probability": 0.0
        },
        {
            "start_logit": 11.9375,
            "end_logit": -7.85546875,
            "text": "MD STARnet, DuchenneConne",
            "probability": 0.0
        },
        {
            "start_logit": -8.59375,
            "end_logit": 12.6328125,
            "text": "STARnet",
            "probability": 0.0
        },
        {
            "start_logit": 11.9375,
            "end_logit": -8.046875,
            "text": "MD STARnet, DuchenneConnect, and TREAT-NMD)",
            "probability": 0.0
        },
        {
            "start_logit": 11.9375,
            "end_logit": -8.8125,
            "text": "MD STARnet, Duchenne",
            "probability": 0.0
        },
        {
            "start_logit": 11.9375,
            "end_logit": -9.5625,
            "text": "MD STARnet, DuchenneConnect, and TREAT-",
            "probability": 0.0
        },
        {
            "start_logit": 11.9375,
            "end_logit": -9.765625,
            "text": "MD STARnet, DuchenneConnect, and",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 12.6328125,
            "text": "DMD patient information (MD STARnet",
            "probability": 0.0
        },
        {
            "start_logit": -5.51171875,
            "end_logit": -5.6171875,
            "text": "net, DuchenneConnect, and TREAT-NMD",
            "probability": 0.0
        },
        {
            "start_logit": -5.51171875,
            "end_logit": -6.26171875,
            "text": "net, DuchenneConnect",
            "probability": 0.0
        },
        {
            "start_logit": -6.765625,
            "end_logit": -5.6171875,
            "text": "DuchenneConnect, and TREAT-NMD",
            "probability": 0.0
        },
        {
            "start_logit": -5.51171875,
            "end_logit": -7.51171875,
            "text": "net, DuchenneConnect, and TREAT",
            "probability": 0.0
        },
        {
            "start_logit": -6.765625,
            "end_logit": -6.26171875,
            "text": "DuchenneConnect",
            "probability": 0.0
        }
    ],
    "6278dd4c56bf9aee6f000011_9": [
        {
            "start_logit": 1.923828125,
            "end_logit": 5.52734375,
            "text": "patient registry",
            "probability": 0.9990234375
        },
        {
            "start_logit": 1.923828125,
            "end_logit": -1.2265625,
            "text": "patient registry is under development for the Muscular Dystrophy Association (MDA) clinic network",
            "probability": 0.0011606216430664062
        },
        {
            "start_logit": 1.923828125,
            "end_logit": -3.91796875,
            "text": "patient registry is under development for the Muscular Dystrophy Association (MDA",
            "probability": 7.897615432739258e-05
        },
        {
            "start_logit": -9.46875,
            "end_logit": 5.52734375,
            "text": "similar patient registry",
            "probability": 1.1324882507324219e-05
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 5.52734375,
            "text": "registry",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": 1.923828125,
            "end_logit": -6.86328125,
            "text": "patient registry is under development for the Muscular Dystrophy Association (MDA)",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": 1.923828125,
            "end_logit": -6.890625,
            "text": "patient registry is under development for the Muscular Dystrophy Association (MDA) clinic",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": 1.923828125,
            "end_logit": -7.3828125,
            "text": "patient registry is under development for the Muscular Dystrophy Association",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": -4.58984375,
            "end_logit": -1.2265625,
            "text": "MDA) clinic network",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": 1.923828125,
            "end_logit": -7.98046875,
            "text": "patient registry is under development for",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 1.923828125,
            "end_logit": -8.15625,
            "text": "patient registry is under development",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 1.923828125,
            "end_logit": -8.5625,
            "text": "patient registry is",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 1.923828125,
            "end_logit": -8.5625,
            "text": "patient registry is under",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 1.923828125,
            "end_logit": -9.2734375,
            "text": "patient registry is under development for the Muscular Dystrophy Association (MDA) clinic network.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 1.923828125,
            "end_logit": -9.3984375,
            "text": "patient registry is under development for the Muscular Dystrophy Association (",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 1.923828125,
            "end_logit": -9.8671875,
            "text": "patient registry is under development for the",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -4.58984375,
            "end_logit": -3.91796875,
            "text": "MDA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.44921875,
            "end_logit": -1.2265625,
            "text": "Muscular Dystrophy Association (MDA) clinic network",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.2890625,
            "end_logit": -1.2265625,
            "text": "clinic network",
            "probability": 0.0
        },
        {
            "start_logit": -9.46875,
            "end_logit": -1.2265625,
            "text": "similar patient registry is under development for the Muscular Dystrophy Association (MDA) clinic network",
            "probability": 0.0
        }
    ],
    "6278dd4c56bf9aee6f000011_10": [
        {
            "start_logit": -2.138671875,
            "end_logit": -1.59375,
            "text": "Developmental Delay",
            "probability": 0.9091796875
        },
        {
            "start_logit": -4.65234375,
            "end_logit": -1.59375,
            "text": "Detection by Developmental Delay",
            "probability": 0.07366943359375
        },
        {
            "start_logit": -6.77734375,
            "end_logit": -1.59375,
            "text": "case-control 4D-DMD study (Detection by Developmental Delay",
            "probability": 0.0087738037109375
        },
        {
            "start_logit": -7.34765625,
            "end_logit": -1.59375,
            "text": "4D-DMD study (Detection by Developmental Delay",
            "probability": 0.005001068115234375
        },
        {
            "start_logit": -9.2734375,
            "end_logit": -1.59375,
            "text": "by Developmental Delay",
            "probability": 0.0007262229919433594
        },
        {
            "start_logit": -2.138671875,
            "end_logit": -9.2578125,
            "text": "Developmental Delay in Dutch boys with Duchenne Muscular Dystrophy), data on developmental milestones",
            "probability": 0.00042700767517089844
        },
        {
            "start_logit": -2.138671875,
            "end_logit": -9.3203125,
            "text": "Developmental Delay in Dutch boys with Duchenne Muscular Dystrophy),",
            "probability": 0.0004010200500488281
        },
        {
            "start_logit": -6.77734375,
            "end_logit": -5.09765625,
            "text": "case-control 4D-DMD study",
            "probability": 0.00026488304138183594
        },
        {
            "start_logit": -2.138671875,
            "end_logit": -10.0,
            "text": "Developmental Delay in Dutch boys with Duchenne Muscular Dystrophy), data on developmental milestones for 76 young males with DMD",
            "probability": 0.00020325183868408203
        },
        {
            "start_logit": -2.138671875,
            "end_logit": -10.171875,
            "text": "Developmental Delay in Dutch boys with Duchenne Muscular Dystrophy), data on developmental milestones for 76 young males with DMD and 12",
            "probability": 0.00017118453979492188
        },
        {
            "start_logit": -2.138671875,
            "end_logit": -10.2421875,
            "text": "Developmental Delay in Dutch boys with Duchenne Muscular Dystrophy), data",
            "probability": 0.0001595020294189453
        },
        {
            "start_logit": -7.34765625,
            "end_logit": -5.09765625,
            "text": "4D-DMD study",
            "probability": 0.00014984607696533203
        },
        {
            "start_logit": -5.63671875,
            "end_logit": -7.203125,
            "text": "health care records",
            "probability": 0.00010061264038085938
        },
        {
            "start_logit": -6.55859375,
            "end_logit": -7.203125,
            "text": "data on developmental milestones for 76 young males with DMD and 12 414 young males from a control group were extracted from the health care records",
            "probability": 3.999471664428711e-05
        },
        {
            "start_logit": -5.63671875,
            "end_logit": -8.15625,
            "text": "health care records of youth health care services",
            "probability": 3.88026237487793e-05
        },
        {
            "start_logit": -4.65234375,
            "end_logit": -9.2578125,
            "text": "Detection by Developmental Delay in Dutch boys with Duchenne Muscular Dystrophy), data on developmental milestones",
            "probability": 3.4749507904052734e-05
        },
        {
            "start_logit": -4.65234375,
            "end_logit": -9.3203125,
            "text": "Detection by Developmental Delay in Dutch boys with Duchenne Muscular Dystrophy),",
            "probability": 3.266334533691406e-05
        },
        {
            "start_logit": -6.55859375,
            "end_logit": -7.7890625,
            "text": "data on developmental milestones for 76 young males with DMD and 12 414 young males from a control group",
            "probability": 2.2411346435546875e-05
        },
        {
            "start_logit": -4.65234375,
            "end_logit": -10.0,
            "text": "Detection by Developmental Delay in Dutch boys with Duchenne Muscular Dystrophy), data on developmental milestones for 76 young males with DMD",
            "probability": 1.6450881958007812e-05
        },
        {
            "start_logit": -7.609375,
            "end_logit": -7.203125,
            "text": "young males with DMD and 12 414 young males from a control group were extracted from the health care records",
            "probability": 1.4066696166992188e-05
        }
    ],
    "6278dd4c56bf9aee6f000011_11": [
        {
            "start_logit": 10.1953125,
            "end_logit": 9.7890625,
            "text": "MD STARnet",
            "probability": 1.0
        },
        {
            "start_logit": 0.1807861328125,
            "end_logit": 9.7890625,
            "text": "Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet",
            "probability": 4.470348358154297e-05
        },
        {
            "start_logit": 10.1953125,
            "end_logit": -4.94140625,
            "text": "MD",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 10.1953125,
            "end_logit": -4.9921875,
            "text": "MD STARnet); Dutch Natural History Survey (DNHS); and Parent Project Muscular Dystrophy (PPMD",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 10.1953125,
            "end_logit": -5.49609375,
            "text": "MD STARnet)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 10.1953125,
            "end_logit": -6.33984375,
            "text": "MD STARnet); Dutch Natural History Survey (DNHS); and Parent Project",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.1953125,
            "end_logit": -6.51953125,
            "text": "MD STARnet); Dutch Natural History Survey (DNHS",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.203125,
            "end_logit": 9.7890625,
            "text": "net",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1953125,
            "end_logit": -7.05859375,
            "text": "MD STARnet); Dutch Natural History",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1953125,
            "end_logit": -7.58984375,
            "text": "MD STARnet); Dutch Natural History Survey (DNHS); and Parent Project Muscular Dystrophy (PPM",
            "probability": 0.0
        },
        {
            "start_logit": 10.1953125,
            "end_logit": -7.7265625,
            "text": "MD STARnet); Dutch Natural History Survey",
            "probability": 0.0
        },
        {
            "start_logit": 10.1953125,
            "end_logit": -7.953125,
            "text": "MD STARnet); Dutch Natural History Survey (DN",
            "probability": 0.0
        },
        {
            "start_logit": 10.1953125,
            "end_logit": -8.0078125,
            "text": "MD STAR",
            "probability": 0.0
        },
        {
            "start_logit": 10.1953125,
            "end_logit": -8.8515625,
            "text": "MD STARnet); Dutch Natural History Survey (DNHS); and Parent",
            "probability": 0.0
        },
        {
            "start_logit": -8.8359375,
            "end_logit": 9.7890625,
            "text": "Surveillance, Tracking, and Research Network (MD STARnet",
            "probability": 0.0
        },
        {
            "start_logit": -8.9765625,
            "end_logit": 9.7890625,
            "text": "Network (MD STARnet",
            "probability": 0.0
        },
        {
            "start_logit": -9.6875,
            "end_logit": 9.7890625,
            "text": "STARnet",
            "probability": 0.0
        },
        {
            "start_logit": -9.9921875,
            "end_logit": 9.7890625,
            "text": ", Tracking, and Research Network (MD STARnet",
            "probability": 0.0
        },
        {
            "start_logit": 0.1807861328125,
            "end_logit": -1.140625,
            "text": "Muscular Dystrophy Surveillance, Tracking, and Research Network",
            "probability": 0.0
        },
        {
            "start_logit": 0.1807861328125,
            "end_logit": -4.94140625,
            "text": "Muscular Dystrophy Surveillance, Tracking, and Research Network (MD",
            "probability": 0.0
        }
    ],
    "6278dd4c56bf9aee6f000011_12": [
        {
            "start_logit": 12.578125,
            "end_logit": 12.953125,
            "text": "Gene Expression Omnibus",
            "probability": 1.0
        },
        {
            "start_logit": 12.578125,
            "end_logit": -0.54931640625,
            "text": "Gene Expression Omnibus (GEO) with the accession number GSE64420",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 12.578125,
            "end_logit": -2.20703125,
            "text": "Gene Expression Omnibus (GEO",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 12.578125,
            "end_logit": -4.015625,
            "text": "Gene Expression Omnibus (GEO) with the accession number GSE64",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.578125,
            "end_logit": -4.41796875,
            "text": "Gene",
            "probability": 0.0
        },
        {
            "start_logit": -5.74609375,
            "end_logit": 12.953125,
            "text": "us",
            "probability": 0.0
        },
        {
            "start_logit": 12.578125,
            "end_logit": -6.1875,
            "text": "Gene Expression Omnibus (GEO) with the accession number GSE",
            "probability": 0.0
        },
        {
            "start_logit": 12.578125,
            "end_logit": -6.32421875,
            "text": "Gene Expression Omnibus (GEO) with the accession number GSE6442",
            "probability": 0.0
        },
        {
            "start_logit": 12.578125,
            "end_logit": -6.4609375,
            "text": "Gene Expression Omn",
            "probability": 0.0
        },
        {
            "start_logit": 12.578125,
            "end_logit": -7.3828125,
            "text": "Gene Expression Omnib",
            "probability": 0.0
        },
        {
            "start_logit": 12.578125,
            "end_logit": -7.81640625,
            "text": "Gene Expression Omnibus (GE",
            "probability": 0.0
        },
        {
            "start_logit": 12.578125,
            "end_logit": -7.9921875,
            "text": "Gene Expression Omnibus (GEO)",
            "probability": 0.0
        },
        {
            "start_logit": 12.578125,
            "end_logit": -8.203125,
            "text": "Gene Expression Omnibus (",
            "probability": 0.0
        },
        {
            "start_logit": 12.578125,
            "end_logit": -8.9140625,
            "text": "Gene Expression Omnibus (GEO) with the accession number GS",
            "probability": 0.0
        },
        {
            "start_logit": -9.296875,
            "end_logit": 12.953125,
            "text": "ibus",
            "probability": 0.0
        },
        {
            "start_logit": 12.578125,
            "end_logit": -8.9296875,
            "text": "Gene Expression Omnibus (GEO) with the accession number",
            "probability": 0.0
        },
        {
            "start_logit": 12.578125,
            "end_logit": -8.9765625,
            "text": "Gene Expression",
            "probability": 0.0
        },
        {
            "start_logit": 12.578125,
            "end_logit": -9.171875,
            "text": "Gene Expression Omnibus (GEO) with the accession",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 12.953125,
            "text": "deposited in the Gene Expression Omnibus",
            "probability": 0.0
        },
        {
            "start_logit": 2.359375,
            "end_logit": -0.54931640625,
            "text": "GSE64420",
            "probability": 0.0
        }
    ],
    "6278dd4c56bf9aee6f000011_13": [
        {
            "start_logit": 12.0546875,
            "end_logit": 12.2109375,
            "text": "drisapersen",
            "probability": 1.0
        },
        {
            "start_logit": 12.0546875,
            "end_logit": -5.49609375,
            "text": "dr",
            "probability": 0.0
        },
        {
            "start_logit": 12.0546875,
            "end_logit": -5.88671875,
            "text": "drisa",
            "probability": 0.0
        },
        {
            "start_logit": -6.40234375,
            "end_logit": 12.2109375,
            "text": "en",
            "probability": 0.0
        },
        {
            "start_logit": -7.54296875,
            "end_logit": 12.2109375,
            "text": "PRO051-02) with drisapersen",
            "probability": 0.0
        },
        {
            "start_logit": 12.0546875,
            "end_logit": -7.890625,
            "text": "drisapersen.",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 12.2109375,
            "text": "persen",
            "probability": 0.0
        },
        {
            "start_logit": 12.0546875,
            "end_logit": -8.015625,
            "text": "drisapers",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": 12.2109375,
            "text": "02) with drisapersen",
            "probability": 0.0
        },
        {
            "start_logit": -9.2265625,
            "end_logit": 12.2109375,
            "text": "escalating dose pilot study (PRO051-02) with drisapersen",
            "probability": 0.0
        },
        {
            "start_logit": -9.5078125,
            "end_logit": 12.2109375,
            "text": "pilot study (PRO051-02) with drisapersen",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": 12.2109375,
            "text": "isapersen",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": 12.2109375,
            "text": "with drisapersen",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 12.2109375,
            "text": "ating dose pilot study (PRO051-02) with drisapersen",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 12.2109375,
            "text": "dose pilot study (PRO051-02) with drisapersen",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 12.2109375,
            "text": "1-02) with drisapersen",
            "probability": 0.0
        },
        {
            "start_logit": -7.54296875,
            "end_logit": -5.1640625,
            "text": "PRO051-02",
            "probability": 0.0
        },
        {
            "start_logit": -7.54296875,
            "end_logit": -5.49609375,
            "text": "PRO051-02) with dr",
            "probability": 0.0
        },
        {
            "start_logit": -7.54296875,
            "end_logit": -5.88671875,
            "text": "PRO051-02) with drisa",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": -5.1640625,
            "text": "02",
            "probability": 0.0
        }
    ],
    "6278dd4c56bf9aee6f000011_14": [
        {
            "start_logit": 8.109375,
            "end_logit": 8.75,
            "text": "PRO051-02",
            "probability": 1.0
        },
        {
            "start_logit": -7.47265625,
            "end_logit": 8.75,
            "text": "02",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.109375,
            "end_logit": -7.40625,
            "text": "PRO051",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.109375,
            "end_logit": -7.93359375,
            "text": "PRO",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.109375,
            "end_logit": -7.96875,
            "text": "PRO051-02)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.109375,
            "end_logit": -8.15625,
            "text": "PRO051-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.9921875,
            "end_logit": 8.75,
            "text": "escalating dose pilot study (PRO051-02",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.109375,
            "end_logit": -8.4140625,
            "text": "PRO05",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.15625,
            "end_logit": 8.75,
            "text": "(PRO051-02",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 8.75,
            "text": "051-02",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 8.75,
            "text": "pilot study (PRO051-02",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 8.75,
            "text": "ating dose pilot study (PRO051-02",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 8.75,
            "text": "in the escalating dose pilot study (PRO051-02",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 8.75,
            "text": "1-02",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 8.75,
            "text": "dose pilot study (PRO051-02",
            "probability": 0.0
        },
        {
            "start_logit": -7.47265625,
            "end_logit": -7.96875,
            "text": "02)",
            "probability": 0.0
        },
        {
            "start_logit": -8.9921875,
            "end_logit": -7.30859375,
            "text": "escalating dose pilot study",
            "probability": 0.0
        },
        {
            "start_logit": -8.9921875,
            "end_logit": -7.40625,
            "text": "escalating dose pilot study (PRO051",
            "probability": 0.0
        },
        {
            "start_logit": -8.9921875,
            "end_logit": -7.93359375,
            "text": "escalating dose pilot study (PRO",
            "probability": 0.0
        },
        {
            "start_logit": -8.9921875,
            "end_logit": -7.96875,
            "text": "escalating dose pilot study (PRO051-02)",
            "probability": 0.0
        }
    ],
    "5a8afbf2fcd1d6a10c00001c_1": [
        {
            "start_logit": 10.421875,
            "end_logit": 11.609375,
            "text": "femur",
            "probability": 0.998046875
        },
        {
            "start_logit": 4.2890625,
            "end_logit": 11.609375,
            "text": "tiger stifle. SE T1-weighted sequence provided excellent resolution of the subchondral bones of the femur",
            "probability": 0.002166748046875
        },
        {
            "start_logit": 10.421875,
            "end_logit": -1.861328125,
            "text": "femur, tibia",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 4.2890625,
            "end_logit": 3.29296875,
            "text": "tiger",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 10.421875,
            "end_logit": -6.35546875,
            "text": "femur, tibia and patella",
            "probability": 0.0
        },
        {
            "start_logit": -9.15625,
            "end_logit": 11.609375,
            "text": "subchondral bones of the femur",
            "probability": 0.0
        },
        {
            "start_logit": 4.2890625,
            "end_logit": -1.861328125,
            "text": "tiger stifle. SE T1-weighted sequence provided excellent resolution of the subchondral bones of the femur, tibia",
            "probability": 0.0
        },
        {
            "start_logit": -9.421875,
            "end_logit": 11.609375,
            "text": "menisci and ligaments of the normal tiger stifle. SE T1-weighted sequence provided excellent resolution of the subchondral bones of the femur",
            "probability": 0.0
        },
        {
            "start_logit": -9.546875,
            "end_logit": 11.609375,
            "text": "stifle. SE T1-weighted sequence provided excellent resolution of the subchondral bones of the femur",
            "probability": 0.0
        },
        {
            "start_logit": -9.578125,
            "end_logit": 11.609375,
            "text": "ligaments of the normal tiger stifle. SE T1-weighted sequence provided excellent resolution of the subchondral bones of the femur",
            "probability": 0.0
        },
        {
            "start_logit": -9.5859375,
            "end_logit": 11.609375,
            "text": "normal tiger stifle. SE T1-weighted sequence provided excellent resolution of the subchondral bones of the femur",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 11.609375,
            "text": "SE T1-weighted sequence provided excellent resolution of the subchondral bones of the femur",
            "probability": 0.0
        },
        {
            "start_logit": -10.0859375,
            "end_logit": 11.609375,
            "text": "of the femur",
            "probability": 0.0
        },
        {
            "start_logit": 10.421875,
            "end_logit": -9.15625,
            "text": "femur, tibia and",
            "probability": 0.0
        },
        {
            "start_logit": 10.421875,
            "end_logit": -9.4765625,
            "text": "femur, tibia and patella compared",
            "probability": 0.0
        },
        {
            "start_logit": 10.421875,
            "end_logit": -9.90625,
            "text": "femur, tibia and patella compared with the GE STIR T2-weighted MR images",
            "probability": 0.0
        },
        {
            "start_logit": 4.2890625,
            "end_logit": -6.35546875,
            "text": "tiger stifle. SE T1-weighted sequence provided excellent resolution of the subchondral bones of the femur, tibia and patella",
            "probability": 0.0
        },
        {
            "start_logit": 4.2890625,
            "end_logit": -7.08984375,
            "text": "tiger stifle. SE T1-weighted sequence provided excellent resolution",
            "probability": 0.0
        },
        {
            "start_logit": 4.2890625,
            "end_logit": -8.828125,
            "text": "tiger stifle. SE T1-weighted sequence provided excellent resolution of the subchondral bones",
            "probability": 0.0
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 3.29296875,
            "text": "articular cartilage, menisci and ligaments of the normal tiger",
            "probability": 0.0
        }
    ],
    "621218fc3a8413c653000014_1": [
        {
            "start_logit": 9.921875,
            "end_logit": 8.609375,
            "text": "BCMA",
            "probability": 1.0
        },
        {
            "start_logit": 0.437255859375,
            "end_logit": 8.609375,
            "text": "B-cell maturation antigen (BCMA",
            "probability": 7.605552673339844e-05
        },
        {
            "start_logit": 9.921875,
            "end_logit": -1.912109375,
            "text": "BCMA) and CD3",
            "probability": 2.6881694793701172e-05
        },
        {
            "start_logit": 9.921875,
            "end_logit": -4.49609375,
            "text": "BCMA)",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": 9.921875,
            "end_logit": -5.18359375,
            "text": "BC",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.28125,
            "text": "BCMA) and CD3, and compare its antitumor activities vs those of anti-BCMA CAR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.328125,
            "end_logit": 8.609375,
            "text": "bsAb (REGN5458) that binds to B-cell maturation antigen (BCMA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.765625,
            "text": "BCMA) and CD3, and compare its antitumor activities vs those of anti-BCMA CAR T cells",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.9609375,
            "text": "BCMA) and",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -9.140625,
            "text": "BCMA) and CD3,",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -9.2578125,
            "text": "BCMA) and CD3, and compare its antitumor activities vs those of anti-BCMA",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 8.609375,
            "text": "MA",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -9.8203125,
            "text": "BCMA) and CD3, and compare its antitumor activities vs those of anti-BCMA CAR T cells to",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 8.609375,
            "text": "maturation antigen (BCMA",
            "probability": 0.0
        },
        {
            "start_logit": 0.437255859375,
            "end_logit": -1.912109375,
            "text": "B-cell maturation antigen (BCMA) and CD3",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 8.609375,
            "text": "cell maturation antigen (BCMA",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 8.609375,
            "text": "(BCMA",
            "probability": 0.0
        },
        {
            "start_logit": 0.437255859375,
            "end_logit": -2.306640625,
            "text": "B-cell maturation antigen",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 8.609375,
            "text": "fully human bsAb (REGN5458) that binds to B-cell maturation antigen (BCMA",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 8.609375,
            "text": "REGN5458) that binds to B-cell maturation antigen (BCMA",
            "probability": 0.0
        }
    ],
    "58a2fac960087bc10a000009_1": [
        {
            "start_logit": 10.7109375,
            "end_logit": 12.3828125,
            "text": "hepatotoxicity",
            "probability": 1.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": 12.3828125,
            "text": "cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 12.3828125,
            "text": "Tacrine, the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 12.3828125,
            "text": "adverse effects including hepatotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 12.3828125,
            "text": "the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 12.3828125,
            "text": "of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 12.3828125,
            "text": "with significant adverse effects including hepatotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -10.0078125,
            "text": "hepatotoxicity.",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": -9.015625,
            "text": "cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": -9.015625,
            "text": "Tacrine, the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": -9.015625,
            "text": "adverse effects",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": -9.5390625,
            "text": "cholinesterase inhibitors to undergo extensive trials for this purpose,",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": -9.015625,
            "text": "the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": -9.015625,
            "text": "of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": -9.5390625,
            "text": "Tacrine, the first of the cholinesterase inhibitors to undergo extensive trials for this purpose,",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": -9.734375,
            "text": "cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": -9.015625,
            "text": "with significant adverse effects",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": -9.734375,
            "text": "Tacrine, the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": -9.734375,
            "text": "adverse effects including",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": -10.0078125,
            "text": "cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity.",
            "probability": 0.0
        }
    ],
    "58a2fac960087bc10a000009_2": [
        {
            "start_logit": 10.7109375,
            "end_logit": 12.3828125,
            "text": "hepatotoxicity",
            "probability": 1.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": 12.3828125,
            "text": "cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 12.3828125,
            "text": "Tacrine, the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 12.3828125,
            "text": "adverse effects including hepatotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 12.3828125,
            "text": "the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 12.3828125,
            "text": "of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 12.3828125,
            "text": "with significant adverse effects including hepatotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -10.0078125,
            "text": "hepatotoxicity.",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": -9.015625,
            "text": "cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": -9.015625,
            "text": "Tacrine, the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": -9.015625,
            "text": "adverse effects",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": -9.5390625,
            "text": "cholinesterase inhibitors to undergo extensive trials for this purpose,",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": -9.015625,
            "text": "the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": -9.015625,
            "text": "of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": -9.5390625,
            "text": "Tacrine, the first of the cholinesterase inhibitors to undergo extensive trials for this purpose,",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": -9.734375,
            "text": "cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": -9.015625,
            "text": "with significant adverse effects",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": -9.734375,
            "text": "Tacrine, the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": -9.734375,
            "text": "adverse effects including",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": -10.0078125,
            "text": "cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity.",
            "probability": 0.0
        }
    ],
    "58a2fac960087bc10a000009_3": [
        {
            "start_logit": 10.7109375,
            "end_logit": 12.578125,
            "text": "Nausea",
            "probability": 1.0
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -5.78125,
            "text": "Nausea, diarrhea, vomiting, and weight loss",
            "probability": 0.0
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -6.0859375,
            "text": "Nausea, diarrhea",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 12.578125,
            "text": "gastrointestinal side effects of donepezil, rivastigmine, galantamin and tacrine that result from acetylcholinesterase inhibition. Nausea",
            "probability": 0.0
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -6.7109375,
            "text": "Nausea, diarrhea, vomiting",
            "probability": 0.0
        },
        {
            "start_logit": -9.03125,
            "end_logit": 12.578125,
            "text": "galantamin and tacrine that result from acetylcholinesterase inhibition. Nausea",
            "probability": 0.0
        },
        {
            "start_logit": -9.171875,
            "end_logit": 12.578125,
            "text": "that result from acetylcholinesterase inhibition. Nausea",
            "probability": 0.0
        },
        {
            "start_logit": -9.4609375,
            "end_logit": 12.578125,
            "text": "donepezil, rivastigmine, galantamin and tacrine that result from acetylcholinesterase inhibition. Nausea",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": 12.578125,
            "text": "rivastigmine, galantamin and tacrine that result from acetylcholinesterase inhibition. Nausea",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": 12.578125,
            "text": "tacrine and gastrointestinal side effects of donepezil, rivastigmine, galantamin and tacrine that result from acetylcholinesterase inhibition. Nausea",
            "probability": 0.0
        },
        {
            "start_logit": -10.0,
            "end_logit": 12.578125,
            "text": "side effects of donepezil, rivastigmine, galantamin and tacrine that result from acetylcholinesterase inhibition. Nausea",
            "probability": 0.0
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -8.3515625,
            "text": "Nausea, diarrhea, vomiting, and",
            "probability": 0.0
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -8.6640625,
            "text": "Nausea, diarrhea, vomiting, and weight",
            "probability": 0.0
        },
        {
            "start_logit": -6.94140625,
            "end_logit": -5.78125,
            "text": "diarrhea, vomiting, and weight loss",
            "probability": 0.0
        },
        {
            "start_logit": -6.94140625,
            "end_logit": -6.0859375,
            "text": "diarrhea",
            "probability": 0.0
        },
        {
            "start_logit": -7.56640625,
            "end_logit": -5.78125,
            "text": "vomiting, and weight loss",
            "probability": 0.0
        },
        {
            "start_logit": -6.94140625,
            "end_logit": -6.7109375,
            "text": "diarrhea, vomiting",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": -5.78125,
            "text": "weight loss",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -6.046875,
            "text": "gastrointestinal side effects of donepezil",
            "probability": 0.0
        },
        {
            "start_logit": -7.56640625,
            "end_logit": -6.7109375,
            "text": "vomiting",
            "probability": 0.0
        }
    ],
    "58a2fac960087bc10a000009_4": [
        {
            "start_logit": 11.2265625,
            "end_logit": 11.96875,
            "text": "diarrhoea",
            "probability": 1.0
        },
        {
            "start_logit": 11.2265625,
            "end_logit": -1.8935546875,
            "text": "diarrhoea, anorexia",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 11.2265625,
            "end_logit": -4.52734375,
            "text": "diarrhoea, anorexia, dyspepsia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.2265625,
            "end_logit": -4.69921875,
            "text": "diarrhoea, anorexia, dyspepsia and abdominal pain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7734375,
            "end_logit": 11.96875,
            "text": "Gastrointestinal side effects (diarrhoea",
            "probability": 0.0
        },
        {
            "start_logit": 11.2265625,
            "end_logit": -7.5859375,
            "text": "diarrhoea, anorexia, dyspepsia and",
            "probability": 0.0
        },
        {
            "start_logit": 11.2265625,
            "end_logit": -7.95703125,
            "text": "diarrhoea, anorexia, dyspepsia and abdominal pain)",
            "probability": 0.0
        },
        {
            "start_logit": 11.2265625,
            "end_logit": -8.53125,
            "text": "diarrhoea, anorexia,",
            "probability": 0.0
        },
        {
            "start_logit": 11.2265625,
            "end_logit": -8.734375,
            "text": "diarrhoea, anorexia, dyspepsia and abdominal pain) were the other major cause of adverse events",
            "probability": 0.0
        },
        {
            "start_logit": 11.2265625,
            "end_logit": -8.84375,
            "text": "diarrhoea, anorexia, dyspepsia and abdominal pain) were the other major cause of adverse events and for",
            "probability": 0.0
        },
        {
            "start_logit": 11.2265625,
            "end_logit": -9.0234375,
            "text": "diarrhoea,",
            "probability": 0.0
        },
        {
            "start_logit": 11.2265625,
            "end_logit": -9.046875,
            "text": "diarrhoea, anorexia, dyspepsia and abdominal pain) were",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": 11.96875,
            "text": "side effects (diarrhoea",
            "probability": 0.0
        },
        {
            "start_logit": 11.2265625,
            "end_logit": -9.4296875,
            "text": "diarrhoea, anorexia, dyspepsia and abdominal pain) were the other major",
            "probability": 0.0
        },
        {
            "start_logit": 11.2265625,
            "end_logit": -9.4296875,
            "text": "diarrhoea, anorexia, dyspepsia and abdominal pain) were the other major cause",
            "probability": 0.0
        },
        {
            "start_logit": -2.4296875,
            "end_logit": -1.8935546875,
            "text": "anorexia",
            "probability": 0.0
        },
        {
            "start_logit": -2.4296875,
            "end_logit": -4.52734375,
            "text": "anorexia, dyspepsia",
            "probability": 0.0
        },
        {
            "start_logit": -2.4296875,
            "end_logit": -4.69921875,
            "text": "anorexia, dyspepsia and abdominal pain",
            "probability": 0.0
        },
        {
            "start_logit": -5.09375,
            "end_logit": -4.52734375,
            "text": "dyspepsia",
            "probability": 0.0
        },
        {
            "start_logit": -7.7734375,
            "end_logit": -1.8935546875,
            "text": "Gastrointestinal side effects (diarrhoea, anorexia",
            "probability": 0.0
        }
    ],
    "58a2fac960087bc10a000009_5": [
        {
            "start_logit": 10.8046875,
            "end_logit": 12.4765625,
            "text": "nausea",
            "probability": 1.0
        },
        {
            "start_logit": 10.8046875,
            "end_logit": -4.30078125,
            "text": "nausea, vomiting",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.8046875,
            "end_logit": -5.0234375,
            "text": "nausea, vomiting, diarrhea, anorexia",
            "probability": 0.0
        },
        {
            "start_logit": 10.8046875,
            "end_logit": -5.59375,
            "text": "nausea, vomiting, diarrhea",
            "probability": 0.0
        },
        {
            "start_logit": 10.8046875,
            "end_logit": -6.8984375,
            "text": "nausea, vomiting, diarrhea, anorexia, and dizziness. Tacrine, the leading anticholinesterase, caused frequent hepatic enzyme elevation",
            "probability": 0.0
        },
        {
            "start_logit": 10.8046875,
            "end_logit": -7.12109375,
            "text": "nausea, vomiting, diarrhea, anorexia, and dizziness",
            "probability": 0.0
        },
        {
            "start_logit": -9.5859375,
            "end_logit": 12.4765625,
            "text": ", Side effects, in 5% to 15% of cases, include nausea",
            "probability": 0.0
        },
        {
            "start_logit": -9.75,
            "end_logit": 12.4765625,
            "text": "itive Section (ADAS-Cog), Side effects, in 5% to 15% of cases, include nausea",
            "probability": 0.0
        },
        {
            "start_logit": -9.7578125,
            "end_logit": 12.4765625,
            "text": "ADAS-Cog), Side effects, in 5% to 15% of cases, include nausea",
            "probability": 0.0
        },
        {
            "start_logit": -9.796875,
            "end_logit": 12.4765625,
            "text": "5% to 15% of cases, include nausea",
            "probability": 0.0
        },
        {
            "start_logit": 10.8046875,
            "end_logit": -8.75,
            "text": "nausea, vomiting, diarrhea, anorexia, and dizziness. Tacrine, the leading anticholinesterase, caused frequent hepatic enzyme",
            "probability": 0.0
        },
        {
            "start_logit": 10.8046875,
            "end_logit": -8.7578125,
            "text": "nausea, vomiting, diarrhea, anorexia, and dizziness. Tacrine",
            "probability": 0.0
        },
        {
            "start_logit": 10.8046875,
            "end_logit": -8.96875,
            "text": "nausea, vomiting, diarrhea, anorexia, and",
            "probability": 0.0
        },
        {
            "start_logit": 10.8046875,
            "end_logit": -9.515625,
            "text": "nausea, vomiting, diarrhea, anorexia, and dizziness. Tacrine, the leading anticholinesterase,",
            "probability": 0.0
        },
        {
            "start_logit": -5.25,
            "end_logit": -4.30078125,
            "text": "vomiting",
            "probability": 0.0
        },
        {
            "start_logit": -5.25,
            "end_logit": -5.0234375,
            "text": "vomiting, diarrhea, anorexia",
            "probability": 0.0
        },
        {
            "start_logit": -5.25,
            "end_logit": -5.59375,
            "text": "vomiting, diarrhea",
            "probability": 0.0
        },
        {
            "start_logit": -5.86328125,
            "end_logit": -5.0234375,
            "text": "anorexia",
            "probability": 0.0
        },
        {
            "start_logit": -5.92578125,
            "end_logit": -5.0234375,
            "text": "diarrhea, anorexia",
            "probability": 0.0
        },
        {
            "start_logit": -5.92578125,
            "end_logit": -5.59375,
            "text": "diarrhea",
            "probability": 0.0
        }
    ],
    "58a2fac960087bc10a000009_6": [
        {
            "start_logit": 10.78125,
            "end_logit": 12.3515625,
            "text": "hepatotoxicity",
            "probability": 1.0
        },
        {
            "start_logit": -9.375,
            "end_logit": 12.3515625,
            "text": "reversible hepatotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": 12.3515625,
            "text": "tacrine (THA) for the treatment of Alzheimer's disease results in a reversible hepatotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 12.3515625,
            "text": "THA) for the treatment of Alzheimer's disease results in a reversible hepatotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 12.3515625,
            "text": "Administration of tacrine (THA) for the treatment of Alzheimer's disease results in a reversible hepatotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 12.3515625,
            "text": "Alzheimer's disease results in a reversible hepatotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": 10.78125,
            "end_logit": -9.25,
            "text": "hepatotoxicity in 30-50",
            "probability": 0.0
        },
        {
            "start_logit": 10.78125,
            "end_logit": -9.640625,
            "text": "hepatotoxicity in 30-50%",
            "probability": 0.0
        },
        {
            "start_logit": 10.78125,
            "end_logit": -9.6484375,
            "text": "hepatotoxicity in",
            "probability": 0.0
        },
        {
            "start_logit": 10.78125,
            "end_logit": -9.7578125,
            "text": "hepatotoxicity in 30-50% of patients, as",
            "probability": 0.0
        },
        {
            "start_logit": 10.78125,
            "end_logit": -9.84375,
            "text": "hepatotoxicity in 30-50% of patients, as indicated by an increase in transaminase levels",
            "probability": 0.0
        },
        {
            "start_logit": 10.78125,
            "end_logit": -9.890625,
            "text": "hepatotoxicity in 30-50% of patients,",
            "probability": 0.0
        },
        {
            "start_logit": 10.78125,
            "end_logit": -9.8984375,
            "text": "hepatotoxicity in 30-50% of patients, as indicated by an increase in transaminase",
            "probability": 0.0
        },
        {
            "start_logit": 10.78125,
            "end_logit": -10.0625,
            "text": "hepatotoxicity in 30-50% of patients, as indicated",
            "probability": 0.0
        },
        {
            "start_logit": 10.78125,
            "end_logit": -10.3125,
            "text": "hepatotoxicity in 30-50% of patients, as indicated by an increase in",
            "probability": 0.0
        },
        {
            "start_logit": -9.375,
            "end_logit": -9.25,
            "text": "reversible hepatotoxicity in 30-50",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": -8.8984375,
            "text": "tacrine (THA) for the treatment of Alzheimer's disease results",
            "probability": 0.0
        },
        {
            "start_logit": -9.375,
            "end_logit": -9.640625,
            "text": "reversible hepatotoxicity in 30-50%",
            "probability": 0.0
        },
        {
            "start_logit": -9.375,
            "end_logit": -9.6484375,
            "text": "reversible hepatotoxicity in",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": -8.9453125,
            "text": "tacrine (THA) for the treatment of Alzheimer's disease results in",
            "probability": 0.0
        }
    ],
    "5c6e01af7c78d69471000048_1": [
        {
            "start_logit": 9.96875,
            "end_logit": 6.8515625,
            "text": "CMV infection and disease",
            "probability": 0.9892578125
        },
        {
            "start_logit": 9.96875,
            "end_logit": 2.333984375,
            "text": "CMV infection",
            "probability": 0.0109100341796875
        },
        {
            "start_logit": 1.0361328125,
            "end_logit": 6.8515625,
            "text": "prophylaxis of CMV infection and disease",
            "probability": 0.00013196468353271484
        },
        {
            "start_logit": 9.96875,
            "end_logit": -4.9765625,
            "text": "CMV",
            "probability": 7.271766662597656e-06
        },
        {
            "start_logit": 9.96875,
            "end_logit": -5.4375,
            "text": "CMV infection and disease in adult CMV-seropositive recipients of an allogeneic haematopoietic stem cell transplant",
            "probability": 4.589557647705078e-06
        },
        {
            "start_logit": 1.0361328125,
            "end_logit": 2.333984375,
            "text": "prophylaxis of CMV infection",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 9.96875,
            "end_logit": -7.7109375,
            "text": "CMV infection and disease in adult CMV-seropositive recipients of an allogeneic haematopoietic stem cell transplant (HSCT",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.09375,
            "text": "CMV infection and disease in adult CMV-seropositive recipients of an allogeneic haematopoietic stem cell transplant (HSCT)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.8359375,
            "text": "CMV infection and disease in",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.890625,
            "text": "CMV infection and disease in adult CMV-seropositive recipients of an",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.96875,
            "end_logit": -9.3828125,
            "text": "CMV infection and disease in adult CMV-seropositive recipients of an allogeneic haematopoietic stem cell transplant (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.3515625,
            "end_logit": 6.8515625,
            "text": "and disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.96875,
            "end_logit": -9.625,
            "text": "CMV infection and disease in adult CMV-seropositive",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.96875,
            "end_logit": -9.90625,
            "text": "CMV infection and disease in adult CMV-seropositive recipients of an allogeneic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.96875,
            "end_logit": -10.15625,
            "text": "CMV infection and disease in adult CMV-seropositive recipients of an allogeneic haematopoietic stem cell transplant (HSCT).",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.375,
            "end_logit": 6.8515625,
            "text": "of CMV infection and disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.90625,
            "end_logit": 6.8515625,
            "text": "disease",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": 6.8515625,
            "text": "infection and disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 6.8515625,
            "text": "Letermovir has been approved in Canada and the USA for the prophylaxis of CMV infection and disease",
            "probability": 0.0
        },
        {
            "start_logit": 1.0361328125,
            "end_logit": -4.9765625,
            "text": "prophylaxis of CMV",
            "probability": 0.0
        }
    ],
    "5c6e01af7c78d69471000048_2": [
        {
            "start_logit": 10.4765625,
            "end_logit": 6.07421875,
            "text": "CMV infection",
            "probability": 0.6962890625
        },
        {
            "start_logit": 10.4765625,
            "end_logit": 5.24609375,
            "text": "CMV infection and disease",
            "probability": 0.303955078125
        },
        {
            "start_logit": 10.4765625,
            "end_logit": -2.587890625,
            "text": "CMV infection and disease in adult CMV-seropositive recipients of an allogeneic HSCT",
            "probability": 0.00012117624282836914
        },
        {
            "start_logit": 10.4765625,
            "end_logit": -3.8671875,
            "text": "CMV",
            "probability": 3.36766242980957e-05
        },
        {
            "start_logit": 10.4765625,
            "end_logit": -8.4375,
            "text": "CMV infection and disease in adult CMV-seropositive recipients of an",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -4.421875,
            "end_logit": 6.07421875,
            "text": "prophylaxis of CMV infection",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 10.4765625,
            "end_logit": -8.9375,
            "text": "CMV infection and disease in adult CMV-seropositive recipients of an allogeneic",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 10.4765625,
            "end_logit": -9.1640625,
            "text": "CMV infection and disease in",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 10.4765625,
            "end_logit": -9.3359375,
            "text": "CMV infection and disease in adult CMV-seropositive",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.421875,
            "end_logit": 5.24609375,
            "text": "prophylaxis of CMV infection and disease",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.4765625,
            "end_logit": -9.671875,
            "text": "CMV infection and disease in adult CMV-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.4765625,
            "end_logit": -9.796875,
            "text": "CMV infection and disease in adult CMV-seropositive recipients of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.60546875,
            "end_logit": 5.24609375,
            "text": "and disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.7734375,
            "end_logit": 6.07421875,
            "text": "of CMV infection",
            "probability": 0.0
        },
        {
            "start_logit": -7.7734375,
            "end_logit": 5.24609375,
            "text": "of CMV infection and disease",
            "probability": 0.0
        },
        {
            "start_logit": -9.5625,
            "end_logit": 6.07421875,
            "text": "infection",
            "probability": 0.0
        },
        {
            "start_logit": -9.578125,
            "end_logit": 6.07421875,
            "text": "the prophylaxis of CMV infection",
            "probability": 0.0
        },
        {
            "start_logit": -9.2890625,
            "end_logit": 5.24609375,
            "text": "disease",
            "probability": 0.0
        },
        {
            "start_logit": -9.5625,
            "end_logit": 5.24609375,
            "text": "infection and disease",
            "probability": 0.0
        },
        {
            "start_logit": -9.578125,
            "end_logit": 5.24609375,
            "text": "the prophylaxis of CMV infection and disease",
            "probability": 0.0
        }
    ],
    "5c6e01af7c78d69471000048_3": [
        {
            "start_logit": 5.74609375,
            "end_logit": 6.28125,
            "text": "CMV infection and disease",
            "probability": 0.9990234375
        },
        {
            "start_logit": -1.7373046875,
            "end_logit": 6.28125,
            "text": "prophylaxis of CMV infection and disease",
            "probability": 0.0005593299865722656
        },
        {
            "start_logit": 5.74609375,
            "end_logit": -2.189453125,
            "text": "CMV infection",
            "probability": 0.00020802021026611328
        },
        {
            "start_logit": -7.5625,
            "end_logit": 6.28125,
            "text": "and disease",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 5.74609375,
            "end_logit": -7.03515625,
            "text": "CMV",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": -8.390625,
            "end_logit": 6.28125,
            "text": "of CMV infection and disease",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -9.21875,
            "end_logit": 6.28125,
            "text": "disease",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -9.265625,
            "end_logit": 6.28125,
            "text": "a favorable new option in the prophylaxis of CMV infection and disease",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -9.78125,
            "end_logit": 6.28125,
            "text": "well tolerated, thus providing a favorable new option in the prophylaxis of CMV infection and disease",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -9.96875,
            "end_logit": 6.28125,
            "text": "Letermovir has shown promising clinical efficacy and is generally well tolerated, thus providing a favorable new option in the prophylaxis of CMV infection and disease",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.15625,
            "end_logit": 6.28125,
            "text": "clinical efficacy and is generally well tolerated, thus providing a favorable new option in the prophylaxis of CMV infection and disease",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.171875,
            "end_logit": 6.28125,
            "text": "the prophylaxis of CMV infection and disease",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.7373046875,
            "end_logit": -2.189453125,
            "text": "prophylaxis of CMV infection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.74609375,
            "end_logit": -9.9296875,
            "text": "CMV infection and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 6.28125,
            "text": "ermovir has shown promising clinical efficacy and is generally well tolerated, thus providing a favorable new option in the prophylaxis of CMV infection and disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.609375,
            "end_logit": 6.28125,
            "text": "new option in the prophylaxis of CMV infection and disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.74609375,
            "end_logit": -10.2734375,
            "text": "CMV infection and disease.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.7373046875,
            "end_logit": -7.03515625,
            "text": "prophylaxis of CMV",
            "probability": 0.0
        },
        {
            "start_logit": -8.390625,
            "end_logit": -2.189453125,
            "text": "of CMV infection",
            "probability": 0.0
        },
        {
            "start_logit": -1.7373046875,
            "end_logit": -9.6015625,
            "text": "prophylaxis",
            "probability": 0.0
        }
    ],
    "5171651e8ed59a060a000009_1": [
        {
            "start_logit": 6.13671875,
            "end_logit": 10.0859375,
            "text": "prostate-specific antigen",
            "probability": 1.0
        },
        {
            "start_logit": -6.421875,
            "end_logit": 10.0859375,
            "text": "kallikrein-related peptidase 3, prostate-specific antigen",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": -7.59375,
            "end_logit": 10.0859375,
            "text": "antigen",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -8.5625,
            "end_logit": 10.0859375,
            "text": "human kallikrein-related peptidase 3, prostate-specific antigen",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -10.203125,
            "end_logit": 10.0859375,
            "text": "peptidase 3, prostate-specific antigen",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 10.0859375,
            "text": "expression of human kallikrein-related peptidase 3, prostate-specific antigen",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 10.0859375,
            "text": ", prostate-specific antigen",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 10.0859375,
            "text": "specific antigen",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.984375,
            "end_logit": 10.0859375,
            "text": "3, prostate-specific antigen",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.13671875,
            "end_logit": -8.515625,
            "text": "prostate-specific",
            "probability": 0.0
        },
        {
            "start_logit": 6.13671875,
            "end_logit": -8.609375,
            "text": "prostate",
            "probability": 0.0
        },
        {
            "start_logit": 6.13671875,
            "end_logit": -8.6328125,
            "text": "prostate-specific antigen, in the brain.",
            "probability": 0.0
        },
        {
            "start_logit": 6.13671875,
            "end_logit": -9.0390625,
            "text": "prostate-specific antigen, in the brain",
            "probability": 0.0
        },
        {
            "start_logit": 6.13671875,
            "end_logit": -9.1875,
            "text": "prostate-specific antigen, in",
            "probability": 0.0
        },
        {
            "start_logit": 6.13671875,
            "end_logit": -9.4921875,
            "text": "prostate-specific antigen,",
            "probability": 0.0
        },
        {
            "start_logit": -6.421875,
            "end_logit": -6.328125,
            "text": "kallikrein-related peptidase 3",
            "probability": 0.0
        },
        {
            "start_logit": -6.421875,
            "end_logit": -6.8828125,
            "text": "kallikrein-related peptidase",
            "probability": 0.0
        },
        {
            "start_logit": -6.421875,
            "end_logit": -7.65625,
            "text": "kallikrein-related",
            "probability": 0.0
        },
        {
            "start_logit": -6.421875,
            "end_logit": -8.1171875,
            "text": "kallikrein",
            "probability": 0.0
        },
        {
            "start_logit": -8.5625,
            "end_logit": -6.328125,
            "text": "human kallikrein-related peptidase 3",
            "probability": 0.0
        }
    ],
    "5171651e8ed59a060a000009_2": [
        {
            "start_logit": 4.56640625,
            "end_logit": 8.21875,
            "text": "PSA",
            "probability": 0.849609375
        },
        {
            "start_logit": 2.830078125,
            "end_logit": 8.21875,
            "text": "as prostate-specific antigen (PSA",
            "probability": 0.1500244140625
        },
        {
            "start_logit": -7.52734375,
            "end_logit": 8.21875,
            "text": "prostate-specific antigen (PSA",
            "probability": 4.76837158203125e-06
        },
        {
            "start_logit": -8.5390625,
            "end_logit": 8.21875,
            "text": "Human kallikrein-related peptidase 3 (hK3), also known as prostate-specific antigen (PSA",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": -9.109375,
            "end_logit": 8.21875,
            "text": "kallikrein-related peptidase 3 (hK3), also known as prostate-specific antigen (PSA",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -9.2734375,
            "end_logit": 8.21875,
            "text": "hK3), also known as prostate-specific antigen (PSA",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 4.56640625,
            "end_logit": -5.85546875,
            "text": "PSA)",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 4.56640625,
            "end_logit": -5.96484375,
            "text": "PSA), is a 33",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -10.28125,
            "end_logit": 8.21875,
            "text": "3), also known as prostate-specific antigen (PSA",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -10.359375,
            "end_logit": 8.21875,
            "text": "specific antigen (PSA",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 8.21875,
            "text": "-specific antigen (PSA",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 2.830078125,
            "end_logit": -5.85546875,
            "text": "as prostate-specific antigen (PSA)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 2.830078125,
            "end_logit": -5.96484375,
            "text": "as prostate-specific antigen (PSA), is a 33",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 4.56640625,
            "end_logit": -8.046875,
            "text": "PSA),",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.56640625,
            "end_logit": -8.328125,
            "text": "PSA), is a 33 kDa single chain glycoprotein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.56640625,
            "end_logit": -8.4765625,
            "text": "PSA), is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.56640625,
            "end_logit": -8.8203125,
            "text": "PSA), is a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.56640625,
            "end_logit": -9.2578125,
            "text": "PSA), is a 33 kDa",
            "probability": 0.0
        },
        {
            "start_logit": 4.56640625,
            "end_logit": -9.5078125,
            "text": "PSA), is a 33 kDa single chain glycoprotein belonging",
            "probability": 0.0
        },
        {
            "start_logit": 2.830078125,
            "end_logit": -8.046875,
            "text": "as prostate-specific antigen (PSA),",
            "probability": 0.0
        }
    ],
    "626aecc6e764a53204000042_1": [
        {
            "start_logit": 11.9375,
            "end_logit": 13.6015625,
            "text": "United States Food and Drug Agency",
            "probability": 1.0
        },
        {
            "start_logit": -4.45703125,
            "end_logit": 13.6015625,
            "text": "Agency",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.73828125,
            "end_logit": 13.6015625,
            "text": "IONIS-TTRRX, has been approved by the United States Food and Drug Agency",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.9375,
            "end_logit": -5.74609375,
            "text": "United",
            "probability": 0.0
        },
        {
            "start_logit": -7.82421875,
            "end_logit": 13.6015625,
            "text": "Drug Agency",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 13.6015625,
            "text": "Food and Drug Agency",
            "probability": 0.0
        },
        {
            "start_logit": 11.9375,
            "end_logit": -6.45703125,
            "text": "United States Food and Drug Agency, Health Canada, and European Commission",
            "probability": 0.0
        },
        {
            "start_logit": -8.9609375,
            "end_logit": 13.6015625,
            "text": "and Drug Agency",
            "probability": 0.0
        },
        {
            "start_logit": -9.2109375,
            "end_logit": 13.6015625,
            "text": "TTRRX, has been approved by the United States Food and Drug Agency",
            "probability": 0.0
        },
        {
            "start_logit": 11.9375,
            "end_logit": -7.5625,
            "text": "United States Food and Drug Agency, Health Canada",
            "probability": 0.0
        },
        {
            "start_logit": 11.9375,
            "end_logit": -8.5546875,
            "text": "United States Food and Drug Agency, Health Canada, and European Commission in 2018, and introduced to the market for patients in stage 1 and stage 2",
            "probability": 0.0
        },
        {
            "start_logit": 11.9375,
            "end_logit": -9.4921875,
            "text": "United States",
            "probability": 0.0
        },
        {
            "start_logit": -4.45703125,
            "end_logit": -2.677734375,
            "text": "Agency, Health Canada, and European Commission in 2018, and introduced to the market for patients in stage 1 and stage 2 hATTR polyneuropathy",
            "probability": 0.0
        },
        {
            "start_logit": -4.609375,
            "end_logit": -2.677734375,
            "text": "TR polyneuropathy",
            "probability": 0.0
        },
        {
            "start_logit": -5.12109375,
            "end_logit": -2.677734375,
            "text": "hATTR polyneuropathy",
            "probability": 0.0
        },
        {
            "start_logit": -7.12109375,
            "end_logit": -2.677734375,
            "text": "Health Canada, and European Commission in 2018, and introduced to the market for patients in stage 1 and stage 2 hATTR polyneuropathy",
            "probability": 0.0
        },
        {
            "start_logit": -7.6171875,
            "end_logit": -2.677734375,
            "text": "polyneuropathy",
            "probability": 0.0
        },
        {
            "start_logit": -4.73828125,
            "end_logit": -5.74609375,
            "text": "IONIS-TTRRX, has been approved by the United",
            "probability": 0.0
        },
        {
            "start_logit": -7.82421875,
            "end_logit": -2.677734375,
            "text": "Drug Agency, Health Canada, and European Commission in 2018, and introduced to the market for patients in stage 1 and stage 2 hATTR polyneuropathy",
            "probability": 0.0
        },
        {
            "start_logit": -7.8828125,
            "end_logit": -2.677734375,
            "text": "European Commission in 2018, and introduced to the market for patients in stage 1 and stage 2 hATTR polyneuropathy",
            "probability": 0.0
        }
    ],
    "5e31b575fbd6abf43b00004c_1": [
        {
            "start_logit": 7.6640625,
            "end_logit": 6.3984375,
            "text": "sensorineural deafness",
            "probability": 1.0
        },
        {
            "start_logit": -1.826171875,
            "end_logit": 6.3984375,
            "text": "nephritic syndrome, sensorineural deafness",
            "probability": 7.545948028564453e-05
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -5.61328125,
            "text": "sensorineural",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": -4.98046875,
            "end_logit": 6.3984375,
            "text": "deafness",
            "probability": 3.2186508178710938e-06
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -6.28125,
            "text": "sensorineural deafness, and ophthalmological alterations",
            "probability": 3.0994415283203125e-06
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -8.1875,
            "text": "sensorineural deafness, and",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -9.2734375,
            "text": "sensorineural deafness,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -9.484375,
            "text": "sensorineural deafness, and ophthalmological",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -9.765625,
            "text": "sensorineural deafness, and ophthalm",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -9.9453125,
            "text": "sensorineural deafness, and ophthalmological alterations.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 6.3984375,
            "text": "syndrome, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.0859375,
            "end_logit": 6.3984375,
            "text": ": Alport syndrome is a rare condition characterized by the clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 6.3984375,
            "text": "Alport syndrome is a rare condition characterized by the clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 6.3984375,
            "text": ", sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 6.3984375,
            "text": "of nephritic syndrome, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": 6.3984375,
            "text": "itic syndrome, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -11.1015625,
            "end_logit": 6.3984375,
            "text": "PURPOSE: Alport syndrome is a rare condition characterized by the clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -1.826171875,
            "end_logit": -5.61328125,
            "text": "nephritic syndrome, sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -1.826171875,
            "end_logit": -5.79296875,
            "text": "nephritic syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -1.826171875,
            "end_logit": -5.875,
            "text": "nephritic",
            "probability": 0.0
        }
    ],
    "5e31b575fbd6abf43b00004c_2": [
        {
            "start_logit": 11.2421875,
            "end_logit": 10.3828125,
            "text": "sensorineural deafness",
            "probability": 1.0
        },
        {
            "start_logit": -2.42578125,
            "end_logit": 10.3828125,
            "text": "nephritis, sensorineural deafness",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 11.2421875,
            "end_logit": -4.7109375,
            "text": "sensorineural",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.734375,
            "end_logit": 10.3828125,
            "text": "hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.98046875,
            "end_logit": 10.3828125,
            "text": "deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.2421875,
            "end_logit": -6.9140625,
            "text": "sensorineural deafness, and ocular abnormalities",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.2421875,
            "end_logit": -8.9296875,
            "text": "sensorineural deafness, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.2421875,
            "end_logit": -9.6015625,
            "text": "sensorineural deafness,",
            "probability": 0.0
        },
        {
            "start_logit": 11.2421875,
            "end_logit": -9.7265625,
            "text": "sensorineural deafness, and ocular",
            "probability": 0.0
        },
        {
            "start_logit": 11.2421875,
            "end_logit": -10.015625,
            "text": "sensorineural deafness, and ocular abnormalities.",
            "probability": 0.0
        },
        {
            "start_logit": -9.8359375,
            "end_logit": 10.3828125,
            "text": ", sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": 10.3828125,
            "text": ": Alport syndrome refers to the clinical triad of hereditary nephritis, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 10.3828125,
            "text": "Alport syndrome refers to the clinical triad of hereditary nephritis, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 10.3828125,
            "text": "of hereditary nephritis, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -2.42578125,
            "end_logit": -0.9404296875,
            "text": "nephritis",
            "probability": 0.0
        },
        {
            "start_logit": -5.734375,
            "end_logit": -0.9404296875,
            "text": "hereditary nephritis",
            "probability": 0.0
        },
        {
            "start_logit": -2.42578125,
            "end_logit": -4.7109375,
            "text": "nephritis, sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -2.42578125,
            "end_logit": -6.9140625,
            "text": "nephritis, sensorineural deafness, and ocular abnormalities",
            "probability": 0.0
        },
        {
            "start_logit": -5.734375,
            "end_logit": -4.7109375,
            "text": "hereditary nephritis, sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": -0.9404296875,
            "text": ": Alport syndrome refers to the clinical triad of hereditary nephritis",
            "probability": 0.0
        }
    ],
    "5e31b575fbd6abf43b00004c_3": [
        {
            "start_logit": 7.6640625,
            "end_logit": 6.3984375,
            "text": "sensorineural deafness",
            "probability": 1.0
        },
        {
            "start_logit": -1.826171875,
            "end_logit": 6.3984375,
            "text": "nephritic syndrome, sensorineural deafness",
            "probability": 7.545948028564453e-05
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -5.61328125,
            "text": "sensorineural",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": -4.98046875,
            "end_logit": 6.3984375,
            "text": "deafness",
            "probability": 3.2186508178710938e-06
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -6.28125,
            "text": "sensorineural deafness, and ophthalmological alterations",
            "probability": 3.0994415283203125e-06
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -8.1875,
            "text": "sensorineural deafness, and",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -9.2734375,
            "text": "sensorineural deafness,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -9.484375,
            "text": "sensorineural deafness, and ophthalmological",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -9.765625,
            "text": "sensorineural deafness, and ophthalm",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -9.9453125,
            "text": "sensorineural deafness, and ophthalmological alterations.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 6.3984375,
            "text": "syndrome, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.0859375,
            "end_logit": 6.3984375,
            "text": ":  Alport syndrome is a rare condition characterized by the clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 6.3984375,
            "text": "Alport syndrome is a rare condition characterized by the clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 6.3984375,
            "text": ", sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 6.3984375,
            "text": "of nephritic syndrome, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": 6.3984375,
            "text": "itic syndrome, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -11.1015625,
            "end_logit": 6.3984375,
            "text": "PURPOSE:  Alport syndrome is a rare condition characterized by the clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -1.826171875,
            "end_logit": -5.61328125,
            "text": "nephritic syndrome, sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -1.826171875,
            "end_logit": -5.79296875,
            "text": "nephritic syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -1.826171875,
            "end_logit": -5.875,
            "text": "nephritic",
            "probability": 0.0
        }
    ],
    "5e31b575fbd6abf43b00004c_4": [
        {
            "start_logit": 12.21875,
            "end_logit": 11.8203125,
            "text": "sensorineural deafness",
            "probability": 1.0
        },
        {
            "start_logit": 12.21875,
            "end_logit": -4.3203125,
            "text": "sensorineural",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.48046875,
            "end_logit": 11.8203125,
            "text": "nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.3125,
            "end_logit": 11.8203125,
            "text": "deafness",
            "probability": 0.0
        },
        {
            "start_logit": -5.65234375,
            "end_logit": 11.8203125,
            "text": "hereditary nephritis, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": 12.21875,
            "end_logit": -7.1171875,
            "text": "sensorineural deafness, and ocular abnormalities",
            "probability": 0.0
        },
        {
            "start_logit": 12.21875,
            "end_logit": -9.0390625,
            "text": "sensorineural deafness, and",
            "probability": 0.0
        },
        {
            "start_logit": 12.21875,
            "end_logit": -9.6015625,
            "text": "sensorineural deafness, and ocular",
            "probability": 0.0
        },
        {
            "start_logit": 12.21875,
            "end_logit": -9.765625,
            "text": "sensorineural deafness,",
            "probability": 0.0
        },
        {
            "start_logit": 12.21875,
            "end_logit": -10.171875,
            "text": "sensorineural deafness, and ocular abnormalities.",
            "probability": 0.0
        },
        {
            "start_logit": -9.8515625,
            "end_logit": 11.8203125,
            "text": ", sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 11.8203125,
            "text": "BACKGROUND  Alport syndrome refers to the clinical triad of hereditary nephritis, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 11.8203125,
            "text": "Alport syndrome refers to the clinical triad of hereditary nephritis, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 11.8203125,
            "text": "of hereditary nephritis, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -4.48046875,
            "end_logit": -2.447265625,
            "text": "nephritis",
            "probability": 0.0
        },
        {
            "start_logit": -5.65234375,
            "end_logit": -2.447265625,
            "text": "hereditary nephritis",
            "probability": 0.0
        },
        {
            "start_logit": -4.48046875,
            "end_logit": -4.3203125,
            "text": "nephritis, sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -5.65234375,
            "end_logit": -4.3203125,
            "text": "hereditary nephritis, sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -4.48046875,
            "end_logit": -7.1171875,
            "text": "nephritis, sensorineural deafness, and ocular abnormalities",
            "probability": 0.0
        },
        {
            "start_logit": -5.3125,
            "end_logit": -7.1171875,
            "text": "deafness, and ocular abnormalities",
            "probability": 0.0
        }
    ],
    "5e31b575fbd6abf43b00004c_5": [
        {
            "start_logit": 12.21875,
            "end_logit": 11.8203125,
            "text": "sensorineural deafness",
            "probability": 1.0
        },
        {
            "start_logit": 12.21875,
            "end_logit": -4.3203125,
            "text": "sensorineural",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.48046875,
            "end_logit": 11.8203125,
            "text": "nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.3125,
            "end_logit": 11.8203125,
            "text": "deafness",
            "probability": 0.0
        },
        {
            "start_logit": -5.65234375,
            "end_logit": 11.8203125,
            "text": "hereditary nephritis, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": 12.21875,
            "end_logit": -7.1171875,
            "text": "sensorineural deafness, and ocular abnormalities",
            "probability": 0.0
        },
        {
            "start_logit": 12.21875,
            "end_logit": -9.0390625,
            "text": "sensorineural deafness, and",
            "probability": 0.0
        },
        {
            "start_logit": 12.21875,
            "end_logit": -9.6015625,
            "text": "sensorineural deafness, and ocular",
            "probability": 0.0
        },
        {
            "start_logit": 12.21875,
            "end_logit": -9.765625,
            "text": "sensorineural deafness,",
            "probability": 0.0
        },
        {
            "start_logit": 12.21875,
            "end_logit": -10.171875,
            "text": "sensorineural deafness, and ocular abnormalities.",
            "probability": 0.0
        },
        {
            "start_logit": -9.8515625,
            "end_logit": 11.8203125,
            "text": ", sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 11.8203125,
            "text": "BACKGROUND Alport syndrome refers to the clinical triad of hereditary nephritis, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 11.8203125,
            "text": "Alport syndrome refers to the clinical triad of hereditary nephritis, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 11.8203125,
            "text": "of hereditary nephritis, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -4.48046875,
            "end_logit": -2.447265625,
            "text": "nephritis",
            "probability": 0.0
        },
        {
            "start_logit": -5.65234375,
            "end_logit": -2.447265625,
            "text": "hereditary nephritis",
            "probability": 0.0
        },
        {
            "start_logit": -4.48046875,
            "end_logit": -4.3203125,
            "text": "nephritis, sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -5.65234375,
            "end_logit": -4.3203125,
            "text": "hereditary nephritis, sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -4.48046875,
            "end_logit": -7.1171875,
            "text": "nephritis, sensorineural deafness, and ocular abnormalities",
            "probability": 0.0
        },
        {
            "start_logit": -5.3125,
            "end_logit": -7.1171875,
            "text": "deafness, and ocular abnormalities",
            "probability": 0.0
        }
    ],
    "5e31b575fbd6abf43b00004c_6": [
        {
            "start_logit": 11.75,
            "end_logit": 10.8515625,
            "text": "sensorineural deafness",
            "probability": 1.0
        },
        {
            "start_logit": -3.318359375,
            "end_logit": 10.8515625,
            "text": "nephritis , sensorineural deafness",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 11.75,
            "end_logit": -4.51953125,
            "text": "sensorineural",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 11.75,
            "end_logit": -5.14453125,
            "text": "sensorineural deafness , and ocular abnormalities",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.01171875,
            "end_logit": 10.8515625,
            "text": "hereditary nephritis , sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.26171875,
            "end_logit": 10.8515625,
            "text": "deafness",
            "probability": 0.0
        },
        {
            "start_logit": 11.75,
            "end_logit": -8.703125,
            "text": "sensorineural deafness , and",
            "probability": 0.0
        },
        {
            "start_logit": 11.75,
            "end_logit": -9.0,
            "text": "sensorineural deafness ,",
            "probability": 0.0
        },
        {
            "start_logit": 11.75,
            "end_logit": -9.5078125,
            "text": "sensorineural deafness , and ocular",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": 10.8515625,
            "text": ", sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 10.8515625,
            "text": "Alport syndrome refers to the clinical triad of hereditary nephritis , sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 10.8515625,
            "text": "of hereditary nephritis , sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 10.8515625,
            "text": "ort syndrome refers to the clinical triad of hereditary nephritis , sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -11.0,
            "end_logit": 10.8515625,
            "text": "clinical triad of hereditary nephritis , sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -3.318359375,
            "end_logit": -1.2080078125,
            "text": "nephritis",
            "probability": 0.0
        },
        {
            "start_logit": -5.01171875,
            "end_logit": -1.2080078125,
            "text": "hereditary nephritis",
            "probability": 0.0
        },
        {
            "start_logit": -3.318359375,
            "end_logit": -4.51953125,
            "text": "nephritis , sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -3.318359375,
            "end_logit": -5.14453125,
            "text": "nephritis , sensorineural deafness , and ocular abnormalities",
            "probability": 0.0
        },
        {
            "start_logit": -5.01171875,
            "end_logit": -4.51953125,
            "text": "hereditary nephritis , sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -5.01171875,
            "end_logit": -5.14453125,
            "text": "hereditary nephritis , sensorineural deafness , and ocular abnormalities",
            "probability": 0.0
        }
    ],
    "5e31b575fbd6abf43b00004c_7": [
        {
            "start_logit": 7.6640625,
            "end_logit": 6.3984375,
            "text": "sensorineural deafness",
            "probability": 1.0
        },
        {
            "start_logit": -1.826171875,
            "end_logit": 6.3984375,
            "text": "nephritic syndrome, sensorineural deafness",
            "probability": 7.545948028564453e-05
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -5.61328125,
            "text": "sensorineural",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": -4.98046875,
            "end_logit": 6.3984375,
            "text": "deafness",
            "probability": 3.2186508178710938e-06
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -6.28125,
            "text": "sensorineural deafness, and ophthalmological alterations",
            "probability": 3.0994415283203125e-06
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -8.1875,
            "text": "sensorineural deafness, and",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -9.2734375,
            "text": "sensorineural deafness,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -9.484375,
            "text": "sensorineural deafness, and ophthalmological",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -9.765625,
            "text": "sensorineural deafness, and ophthalm",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -9.9453125,
            "text": "sensorineural deafness, and ophthalmological alterations.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 6.3984375,
            "text": "syndrome, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.0859375,
            "end_logit": 6.3984375,
            "text": ": Alport syndrome is a rare condition characterized by the clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 6.3984375,
            "text": "Alport syndrome is a rare condition characterized by the clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 6.3984375,
            "text": ", sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 6.3984375,
            "text": "of nephritic syndrome, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": 6.3984375,
            "text": "itic syndrome, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -11.1015625,
            "end_logit": 6.3984375,
            "text": "PURPOSE: Alport syndrome is a rare condition characterized by the clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -1.826171875,
            "end_logit": -5.61328125,
            "text": "nephritic syndrome, sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -1.826171875,
            "end_logit": -5.79296875,
            "text": "nephritic syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -1.826171875,
            "end_logit": -5.875,
            "text": "nephritic",
            "probability": 0.0
        }
    ],
    "5e31b575fbd6abf43b00004c_8": [
        {
            "start_logit": 7.9921875,
            "end_logit": 6.72265625,
            "text": "sensorineural deafness",
            "probability": 1.0
        },
        {
            "start_logit": -3.552734375,
            "end_logit": 6.72265625,
            "text": "nephritic syndrome, sensorineural deafness",
            "probability": 9.655952453613281e-06
        },
        {
            "start_logit": 7.9921875,
            "end_logit": -5.390625,
            "text": "sensorineural",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": -4.9765625,
            "end_logit": 6.72265625,
            "text": "deafness",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": 7.9921875,
            "end_logit": -6.421875,
            "text": "sensorineural deafness, and ophthalmological alterations",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": 7.9921875,
            "end_logit": -8.3359375,
            "text": "sensorineural deafness, and",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.9921875,
            "end_logit": -9.2421875,
            "text": "sensorineural deafness,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.9921875,
            "end_logit": -9.4375,
            "text": "sensorineural deafness, and ophthalmological",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.9921875,
            "end_logit": -9.8828125,
            "text": "sensorineural deafness, and ophthalmological alterations.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.9921875,
            "end_logit": -9.90625,
            "text": "sensorineural deafness, and ophthalm",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.421875,
            "end_logit": 6.72265625,
            "text": "syndrome, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 6.72265625,
            "text": ": Alport syndrome is a rare condition characterized by the clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 6.72265625,
            "text": ", sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 6.72265625,
            "text": "of nephritic syndrome, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 6.72265625,
            "text": "Alport syndrome is a rare condition characterized by the clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -11.03125,
            "end_logit": 6.72265625,
            "text": "PURPOSE:: Alport syndrome is a rare condition characterized by the clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -3.552734375,
            "end_logit": -5.390625,
            "text": "nephritic syndrome, sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -3.552734375,
            "end_logit": -6.265625,
            "text": "nephritic syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -3.552734375,
            "end_logit": -6.421875,
            "text": "nephritic syndrome, sensorineural deafness, and ophthalmological alterations",
            "probability": 0.0
        },
        {
            "start_logit": -3.552734375,
            "end_logit": -6.53125,
            "text": "nephritic",
            "probability": 0.0
        }
    ],
    "5e31b575fbd6abf43b00004c_9": [
        {
            "start_logit": 11.2421875,
            "end_logit": 10.3828125,
            "text": "sensorineural deafness",
            "probability": 1.0
        },
        {
            "start_logit": -2.42578125,
            "end_logit": 10.3828125,
            "text": "nephritis, sensorineural deafness",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 11.2421875,
            "end_logit": -4.7109375,
            "text": "sensorineural",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.734375,
            "end_logit": 10.3828125,
            "text": "hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.98046875,
            "end_logit": 10.3828125,
            "text": "deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.2421875,
            "end_logit": -6.9140625,
            "text": "sensorineural deafness, and ocular abnormalities",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.2421875,
            "end_logit": -8.9296875,
            "text": "sensorineural deafness, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.2421875,
            "end_logit": -9.6015625,
            "text": "sensorineural deafness,",
            "probability": 0.0
        },
        {
            "start_logit": 11.2421875,
            "end_logit": -9.7265625,
            "text": "sensorineural deafness, and ocular",
            "probability": 0.0
        },
        {
            "start_logit": 11.2421875,
            "end_logit": -10.015625,
            "text": "sensorineural deafness, and ocular abnormalities.",
            "probability": 0.0
        },
        {
            "start_logit": -9.8359375,
            "end_logit": 10.3828125,
            "text": ", sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": 10.3828125,
            "text": ": Alport syndrome refers to the clinical triad of hereditary nephritis, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 10.3828125,
            "text": "Alport syndrome refers to the clinical triad of hereditary nephritis, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 10.3828125,
            "text": "of hereditary nephritis, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -2.42578125,
            "end_logit": -0.9404296875,
            "text": "nephritis",
            "probability": 0.0
        },
        {
            "start_logit": -5.734375,
            "end_logit": -0.9404296875,
            "text": "hereditary nephritis",
            "probability": 0.0
        },
        {
            "start_logit": -2.42578125,
            "end_logit": -4.7109375,
            "text": "nephritis, sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -2.42578125,
            "end_logit": -6.9140625,
            "text": "nephritis, sensorineural deafness, and ocular abnormalities",
            "probability": 0.0
        },
        {
            "start_logit": -5.734375,
            "end_logit": -4.7109375,
            "text": "hereditary nephritis, sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": -0.9404296875,
            "text": ": Alport syndrome refers to the clinical triad of hereditary nephritis",
            "probability": 0.0
        }
    ],
    "5e31b575fbd6abf43b00004c_10": [
        {
            "start_logit": 11.9765625,
            "end_logit": 11.2421875,
            "text": "sensorineural deafness",
            "probability": 1.0
        },
        {
            "start_logit": -2.984375,
            "end_logit": 11.2421875,
            "text": "nephritis, sensorineural deafness",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 11.9765625,
            "end_logit": -4.41796875,
            "text": "sensorineural",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -4.21484375,
            "end_logit": 11.2421875,
            "text": "hereditary nephritis, sensorineural deafness",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.88671875,
            "end_logit": 11.2421875,
            "text": "deafness",
            "probability": 0.0
        },
        {
            "start_logit": 11.9765625,
            "end_logit": -7.015625,
            "text": "sensorineural deafness, and ocular abnormalities",
            "probability": 0.0
        },
        {
            "start_logit": 11.9765625,
            "end_logit": -8.9453125,
            "text": "sensorineural deafness, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.9765625,
            "end_logit": -9.359375,
            "text": "sensorineural deafness,",
            "probability": 0.0
        },
        {
            "start_logit": 11.9765625,
            "end_logit": -9.6328125,
            "text": "sensorineural deafness, and ocular",
            "probability": 0.0
        },
        {
            "start_logit": 11.9765625,
            "end_logit": -10.0078125,
            "text": "sensorineural deafness, and ocular abnormalities.",
            "probability": 0.0
        },
        {
            "start_logit": -9.9921875,
            "end_logit": 11.2421875,
            "text": ", sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 11.2421875,
            "text": "Alport syndrome refers to the clinical triad of hereditary nephritis, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 11.2421875,
            "text": "of hereditary nephritis, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -2.984375,
            "end_logit": -0.732421875,
            "text": "nephritis",
            "probability": 0.0
        },
        {
            "start_logit": -4.21484375,
            "end_logit": -0.732421875,
            "text": "hereditary nephritis",
            "probability": 0.0
        },
        {
            "start_logit": -2.984375,
            "end_logit": -4.41796875,
            "text": "nephritis, sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -4.21484375,
            "end_logit": -4.41796875,
            "text": "hereditary nephritis, sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -2.984375,
            "end_logit": -7.015625,
            "text": "nephritis, sensorineural deafness, and ocular abnormalities",
            "probability": 0.0
        },
        {
            "start_logit": -4.21484375,
            "end_logit": -7.015625,
            "text": "hereditary nephritis, sensorineural deafness, and ocular abnormalities",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": -0.732421875,
            "text": "Alport syndrome refers to the clinical triad of hereditary nephritis",
            "probability": 0.0
        }
    ],
    "5e31b575fbd6abf43b00004c_11": [
        {
            "start_logit": 9.6171875,
            "end_logit": 8.4921875,
            "text": "sensorineural deafness",
            "probability": 1.0
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -4.76953125,
            "text": "sensorineural",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": -4.08203125,
            "end_logit": 8.4921875,
            "text": "nephritic syndrome, sensorineural deafness",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -4.12890625,
            "end_logit": 8.4921875,
            "text": "deafness",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -6.625,
            "text": "sensorineural deafness, and ophthalmological alterations",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -8.2421875,
            "text": "sensorineural deafness, and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -8.953125,
            "text": "sensorineural deafness,",
            "probability": 0.0
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -9.484375,
            "text": "sensorineural deafness, and ophthalmological",
            "probability": 0.0
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -9.546875,
            "text": "sensorineural deafness, and ophthalm",
            "probability": 0.0
        },
        {
            "start_logit": 9.6171875,
            "end_logit": -9.828125,
            "text": "sensorineural deafness, and ophthalmological alterations.",
            "probability": 0.0
        },
        {
            "start_logit": -9.703125,
            "end_logit": 8.4921875,
            "text": "syndrome, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 8.4921875,
            "text": ", sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 8.4921875,
            "text": "of nephritic syndrome, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 8.4921875,
            "text": "Alport syndrome is a rare condition characterized by the clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 8.4921875,
            "text": "itic syndrome, sensorineural deafness",
            "probability": 0.0
        },
        {
            "start_logit": -4.08203125,
            "end_logit": -4.76953125,
            "text": "nephritic syndrome, sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -4.08203125,
            "end_logit": -6.3359375,
            "text": "nephritic syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -4.08203125,
            "end_logit": -6.5234375,
            "text": "nephritic",
            "probability": 0.0
        },
        {
            "start_logit": -4.08203125,
            "end_logit": -6.625,
            "text": "nephritic syndrome, sensorineural deafness, and ophthalmological alterations",
            "probability": 0.0
        },
        {
            "start_logit": -4.12890625,
            "end_logit": -6.625,
            "text": "deafness, and ophthalmological alterations",
            "probability": 0.0
        }
    ],
    "5e92005c2d3121100d000003_1": [
        {
            "start_logit": 14.0625,
            "end_logit": 12.8828125,
            "text": "Ebola virus",
            "probability": 1.0
        },
        {
            "start_logit": -0.5185546875,
            "end_logit": 12.8828125,
            "text": "filoviruses, Ebola virus",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 14.0625,
            "end_logit": -2.447265625,
            "text": "Ebola",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 14.0625,
            "end_logit": -2.751953125,
            "text": "Ebola virus (EBOV)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.0,
            "end_logit": 12.8828125,
            "text": "virus",
            "probability": 0.0
        },
        {
            "start_logit": 14.0625,
            "end_logit": -6.75,
            "text": "Ebola virus (EBOV) and Marburg virus (MARV), are",
            "probability": 0.0
        },
        {
            "start_logit": 14.0625,
            "end_logit": -7.27734375,
            "text": "Ebola virus (EBOV",
            "probability": 0.0
        },
        {
            "start_logit": 14.0625,
            "end_logit": -7.7265625,
            "text": "Ebola virus (EBOV) and Marburg",
            "probability": 0.0
        },
        {
            "start_logit": 14.0625,
            "end_logit": -7.76171875,
            "text": "Ebola virus (EB",
            "probability": 0.0
        },
        {
            "start_logit": 14.0625,
            "end_logit": -7.7890625,
            "text": "Ebola virus (",
            "probability": 0.0
        },
        {
            "start_logit": 14.0625,
            "end_logit": -7.875,
            "text": "Ebola virus (EBOV) and Marburg virus (MARV),",
            "probability": 0.0
        },
        {
            "start_logit": 14.0625,
            "end_logit": -7.9140625,
            "text": "Ebola virus (EBOV) and Marburg virus (MARV",
            "probability": 0.0
        },
        {
            "start_logit": 14.0625,
            "end_logit": -8.40625,
            "text": "Ebola virus (EBOV) and Marburg virus (MAR",
            "probability": 0.0
        },
        {
            "start_logit": 14.0625,
            "end_logit": -8.4609375,
            "text": "Ebola virus (EBOV) and Marburg virus",
            "probability": 0.0
        },
        {
            "start_logit": 14.0625,
            "end_logit": -9.0234375,
            "text": "Ebola virus (EBOV) and Marburg virus (MARV)",
            "probability": 0.0
        },
        {
            "start_logit": 14.0625,
            "end_logit": -9.34375,
            "text": "Ebola virus (EBOV) and Marburg virus (",
            "probability": 0.0
        },
        {
            "start_logit": 14.0625,
            "end_logit": -9.9453125,
            "text": "Ebola virus (EBOV) and Marburg virus (MARV), are among the deadliest viruses",
            "probability": 0.0
        },
        {
            "start_logit": 14.0625,
            "end_logit": -9.96875,
            "text": "Ebola virus (EBOV) and Mar",
            "probability": 0.0
        },
        {
            "start_logit": -9.234375,
            "end_logit": 12.8828125,
            "text": ", Ebola virus",
            "probability": 0.0
        },
        {
            "start_logit": -0.5185546875,
            "end_logit": -0.257568359375,
            "text": "filoviruses",
            "probability": 0.0
        }
    ],
    "5e92005c2d3121100d000003_2": [
        {
            "start_logit": 10.9375,
            "end_logit": 12.1640625,
            "text": "HIV",
            "probability": 1.0
        },
        {
            "start_logit": -9.734375,
            "end_logit": 12.1640625,
            "text": "ranks HIV",
            "probability": 0.0
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 12.1640625,
            "text": "WHO ranks HIV",
            "probability": 0.0
        },
        {
            "start_logit": 10.9375,
            "end_logit": -9.0,
            "text": "HIV as one of the deadliest diseases",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 12.1640625,
            "text": "s HIV",
            "probability": 0.0
        },
        {
            "start_logit": 10.9375,
            "end_logit": -9.53125,
            "text": "HIV as one",
            "probability": 0.0
        },
        {
            "start_logit": 10.9375,
            "end_logit": -9.5703125,
            "text": "HIV as",
            "probability": 0.0
        },
        {
            "start_logit": 10.9375,
            "end_logit": -9.71875,
            "text": "HIV as one of the deadliest",
            "probability": 0.0
        },
        {
            "start_logit": 10.9375,
            "end_logit": -9.75,
            "text": "HIV as one of the",
            "probability": 0.0
        },
        {
            "start_logit": 10.9375,
            "end_logit": -10.171875,
            "text": "HIV as one of the dead",
            "probability": 0.0
        },
        {
            "start_logit": 10.9375,
            "end_logit": -10.1953125,
            "text": "HIV as one of the deadli",
            "probability": 0.0
        },
        {
            "start_logit": -10.0390625,
            "end_logit": -8.46875,
            "text": "WHO",
            "probability": 0.0
        },
        {
            "start_logit": -9.734375,
            "end_logit": -9.0,
            "text": "ranks HIV as one of the deadliest diseases",
            "probability": 0.0
        },
        {
            "start_logit": -10.0390625,
            "end_logit": -9.0,
            "text": "WHO ranks HIV as one of the deadliest diseases",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": -9.0,
            "text": "deadliest diseases",
            "probability": 0.0
        },
        {
            "start_logit": -9.734375,
            "end_logit": -9.53125,
            "text": "ranks HIV as one",
            "probability": 0.0
        },
        {
            "start_logit": -9.734375,
            "end_logit": -9.5703125,
            "text": "ranks HIV as",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": -9.0,
            "text": "one of the deadliest diseases",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": -9.0,
            "text": "s HIV as one of the deadliest diseases",
            "probability": 0.0
        },
        {
            "start_logit": -9.734375,
            "end_logit": -9.71875,
            "text": "ranks HIV as one of the deadliest",
            "probability": 0.0
        }
    ],
    "550312b4e9bde6963400001c_1": [
        {
            "start_logit": 11.109375,
            "end_logit": 11.4296875,
            "text": "GATA1",
            "probability": 1.0
        },
        {
            "start_logit": 11.109375,
            "end_logit": -6.33203125,
            "text": "GATA",
            "probability": 0.0
        },
        {
            "start_logit": -6.81640625,
            "end_logit": 11.4296875,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": -8.9296875,
            "end_logit": 11.4296875,
            "text": "and GATA1",
            "probability": 0.0
        },
        {
            "start_logit": 11.109375,
            "end_logit": -9.359375,
            "text": "GATA1 in",
            "probability": 0.0
        },
        {
            "start_logit": -9.6875,
            "end_logit": 11.4296875,
            "text": "RPL26 and GATA1",
            "probability": 0.0
        },
        {
            "start_logit": -9.7265625,
            "end_logit": 11.4296875,
            "text": "and RPL26 and GATA1",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": 11.4296875,
            "text": "RPS26, and RPL26 and GATA1",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 11.4296875,
            "text": "RPS10, RPS26, and RPL26 and GATA1",
            "probability": 0.0
        },
        {
            "start_logit": -8.9296875,
            "end_logit": -6.33203125,
            "text": "and GATA",
            "probability": 0.0
        },
        {
            "start_logit": -9.6875,
            "end_logit": -6.33203125,
            "text": "RPL26 and GATA",
            "probability": 0.0
        },
        {
            "start_logit": -9.7265625,
            "end_logit": -6.33203125,
            "text": "and RPL26 and GATA",
            "probability": 0.0
        },
        {
            "start_logit": -6.81640625,
            "end_logit": -9.359375,
            "text": "1 in",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": -6.33203125,
            "text": "RPS26, and RPL26 and GATA",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": -6.33203125,
            "text": "RPS10, RPS26, and RPL26 and GATA",
            "probability": 0.0
        },
        {
            "start_logit": -8.9296875,
            "end_logit": -8.484375,
            "text": "and",
            "probability": 0.0
        },
        {
            "start_logit": -9.6875,
            "end_logit": -8.25,
            "text": "RPL26",
            "probability": 0.0
        },
        {
            "start_logit": -9.7265625,
            "end_logit": -8.25,
            "text": "and RPL26",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": -8.0859375,
            "text": "RPS19",
            "probability": 0.0
        },
        {
            "start_logit": -9.6875,
            "end_logit": -8.484375,
            "text": "RPL26 and",
            "probability": 0.0
        }
    ],
    "550312b4e9bde6963400001c_2": [
        {
            "start_logit": 7.02734375,
            "end_logit": 10.0859375,
            "text": "RPS19",
            "probability": 1.0
        },
        {
            "start_logit": 7.02734375,
            "end_logit": -1.23046875,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11, RPS7, RPL35a",
            "probability": 1.2218952178955078e-05
        },
        {
            "start_logit": 7.02734375,
            "end_logit": -2.123046875,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11, RPS7",
            "probability": 5.0067901611328125e-06
        },
        {
            "start_logit": 7.02734375,
            "end_logit": -2.162109375,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11, RPS7, RPL35a, RPS10 and RPS26",
            "probability": 4.827976226806641e-06
        },
        {
            "start_logit": 7.02734375,
            "end_logit": -2.875,
            "text": "RPS19, RPS24",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": -6.921875,
            "end_logit": 10.0859375,
            "text": "19",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -7.40234375,
            "end_logit": 10.0859375,
            "text": ": RPS19",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.02734375,
            "end_logit": -4.65625,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11, RPS7, RPL35a, RPS10",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -8.203125,
            "end_logit": 10.0859375,
            "text": "screened by PCR for mutations in the nine known genes associated with DBA: RPS19",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -8.71875,
            "end_logit": 10.0859375,
            "text": "for mutations in the nine known genes associated with DBA: RPS19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.359375,
            "end_logit": 10.0859375,
            "text": "genes associated with DBA: RPS19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.02734375,
            "end_logit": -6.45703125,
            "text": "RPS19, RPS24, RPS17",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.02734375,
            "end_logit": -6.71484375,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11, RPS7, RPL35",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.02734375,
            "end_logit": -6.8203125,
            "text": "RPS19, RPS24, RPS17, RPL5",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.02734375,
            "end_logit": -7.37109375,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11",
            "probability": 0.0
        },
        {
            "start_logit": 7.02734375,
            "end_logit": -7.49609375,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11, RPS7, RPL35a, RPS10 and",
            "probability": 0.0
        },
        {
            "start_logit": 7.02734375,
            "end_logit": -8.9375,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11, RPS7, RPL",
            "probability": 0.0
        },
        {
            "start_logit": 7.02734375,
            "end_logit": -9.1875,
            "text": "RPS19, RPS24, RPS17, RPL",
            "probability": 0.0
        },
        {
            "start_logit": -3.9609375,
            "end_logit": -1.23046875,
            "text": "RPL35a",
            "probability": 0.0
        },
        {
            "start_logit": -4.71484375,
            "end_logit": -1.23046875,
            "text": "RPS24, RPS17, RPL5, RPL11, RPS7, RPL35a",
            "probability": 0.0
        }
    ],
    "550312b4e9bde6963400001c_3": [
        {
            "start_logit": 10.140625,
            "end_logit": 12.609375,
            "text": "RPS19",
            "probability": 1.0
        },
        {
            "start_logit": -5.3984375,
            "end_logit": 12.609375,
            "text": "19",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 10.140625,
            "end_logit": -3.80859375,
            "text": "RPS19 mutation was identified in 3 patients, RPS24, RPS7",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.140625,
            "end_logit": -5.390625,
            "text": "RPS19 mutation was identified in 3 patients, RPS24",
            "probability": 0.0
        },
        {
            "start_logit": -9.1953125,
            "end_logit": 12.609375,
            "text": "had mutations in the genes coding for ribosomal protein, in which RPS19",
            "probability": 0.0
        },
        {
            "start_logit": -9.484375,
            "end_logit": 12.609375,
            "text": "in the genes coding for ribosomal protein, in which RPS19",
            "probability": 0.0
        },
        {
            "start_logit": -9.59375,
            "end_logit": 12.609375,
            "text": "ribosomal protein, in which RPS19",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": 12.609375,
            "text": "patients (38.1%) with DBA had mutations in the genes coding for ribosomal protein, in which RPS19",
            "probability": 0.0
        },
        {
            "start_logit": -9.828125,
            "end_logit": 12.609375,
            "text": "in which RPS19",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.4296875,
            "text": "RPS19 mutation",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.51171875,
            "text": "RPS",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.796875,
            "text": "RPS19 mutation was identified in 3 patients, RPS24, RPS7, RPL5",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.953125,
            "text": "RPS19 mutation was identified in 3 patients, RPS24, RPS",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -8.0390625,
            "text": "RPS19 mutation was identified in 3 patients, RPS24, RPS7, RPL5, RPL11",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -9.28125,
            "text": "RPS19 mutation was identified in 3 patients, RPS",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -9.3515625,
            "text": "RPS19 mutation was identified in 3 patients, RPS24, RPS7, RPL5, RPL11 and RPL35A mutations were identified respectively in 1",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -9.3984375,
            "text": "RPS19 mutation was identified in 3 patients, RPS24, RPS7, RPL",
            "probability": 0.0
        },
        {
            "start_logit": -5.3984375,
            "end_logit": -3.80859375,
            "text": "19 mutation was identified in 3 patients, RPS24, RPS7",
            "probability": 0.0
        },
        {
            "start_logit": -5.75390625,
            "end_logit": -3.80859375,
            "text": "RPS7",
            "probability": 0.0
        },
        {
            "start_logit": -5.3984375,
            "end_logit": -5.390625,
            "text": "19 mutation was identified in 3 patients, RPS24",
            "probability": 0.0
        }
    ],
    "550312b4e9bde6963400001c_4": [
        {
            "start_logit": 3.2421875,
            "end_logit": 8.046875,
            "text": "GATA1",
            "probability": 0.89892578125
        },
        {
            "start_logit": 4.03125,
            "end_logit": 4.9140625,
            "text": "ribosomal protein gene",
            "probability": 0.08624267578125
        },
        {
            "start_logit": 4.03125,
            "end_logit": 3.173828125,
            "text": "ribosomal protein",
            "probability": 0.015106201171875
        },
        {
            "start_logit": -8.46875,
            "end_logit": 8.046875,
            "text": "mutation in the gene encoding the hematopoietic transcription factor GATA1",
            "probability": 7.3909759521484375e-06
        },
        {
            "start_logit": -9.0859375,
            "end_logit": 8.046875,
            "text": "pathogenic mutations for DBA and identified a mutation in the gene encoding the hematopoietic transcription factor GATA1",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": -9.59375,
            "end_logit": 8.046875,
            "text": "1",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": -9.671875,
            "end_logit": 8.046875,
            "text": "exome sequencing on two siblings who had no known pathogenic mutations for DBA and identified a mutation in the gene encoding the hematopoietic transcription factor GATA1",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 8.046875,
            "text": "for DBA and identified a mutation in the gene encoding the hematopoietic transcription factor GATA1",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": -9.921875,
            "end_logit": 8.046875,
            "text": "in the gene encoding the hematopoietic transcription factor GATA1",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": -10.1796875,
            "end_logit": 8.046875,
            "text": "mutations for DBA and identified a mutation in the gene encoding the hematopoietic transcription factor GATA1",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 8.046875,
            "text": "hematopoietic transcription factor GATA1",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -10.296875,
            "end_logit": 8.046875,
            "text": "identified a mutation in the gene encoding the hematopoietic transcription factor GATA1",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -10.453125,
            "end_logit": 8.046875,
            "text": "encoding the hematopoietic transcription factor GATA1",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 4.03125,
            "end_logit": -8.4765625,
            "text": "ribosomal protein gene mutations. We performed exome sequencing on two siblings who had no known pathogenic mutations for DBA and identified a mutation in the gene",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 4.03125,
            "end_logit": -8.6953125,
            "text": "ribosomal protein gene mutations. We performed exome sequencing on two siblings who had no known pathogenic mutations for DBA and identified a mutation in the gene encoding the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.8515625,
            "end_logit": 4.9140625,
            "text": "gene",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.109375,
            "end_logit": 4.9140625,
            "text": "of all cases attributed to ribosomal protein gene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.03125,
            "end_logit": -9.4140625,
            "text": "ribosomal protein gene mutations. We performed exome sequencing on two siblings who had no known pathogenic mutations for DBA and identified a mutation in the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.03125,
            "end_logit": -9.46875,
            "text": "ribosomal protein gene mutations. We performed exome sequencing on two siblings who had no known",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.03125,
            "end_logit": -9.5625,
            "text": "ribosomal protein gene mutations",
            "probability": 5.960464477539063e-08
        }
    ],
    "550312b4e9bde6963400001c_5": [
        {
            "start_logit": 12.1953125,
            "end_logit": 13.078125,
            "text": "RPS17",
            "probability": 1.0
        },
        {
            "start_logit": 12.1953125,
            "end_logit": -1.791015625,
            "text": "RPS17, RPS19",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 12.1953125,
            "end_logit": -2.24609375,
            "text": "RPS17, RPS19, RPS26",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 12.1953125,
            "end_logit": -2.3203125,
            "text": "RPS17, RPS19, RPS26, RPL5, RPL11, and RPL35A",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -4.984375,
            "end_logit": 13.078125,
            "text": "17",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.1953125,
            "end_logit": -4.12109375,
            "text": "RPS17, RPS19, RPS26, RPL5",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.1953125,
            "end_logit": -5.7109375,
            "text": "RPS",
            "probability": 0.0
        },
        {
            "start_logit": 12.1953125,
            "end_logit": -5.83984375,
            "text": "RPS17, RPS19, RPS26, RPL5, RPL11",
            "probability": 0.0
        },
        {
            "start_logit": 12.1953125,
            "end_logit": -6.53515625,
            "text": "RPS17, RPS19, RPS",
            "probability": 0.0
        },
        {
            "start_logit": 12.1953125,
            "end_logit": -6.7578125,
            "text": "RPS17, RPS",
            "probability": 0.0
        },
        {
            "start_logit": 12.1953125,
            "end_logit": -6.96484375,
            "text": "RPS17, RPS19, RPS26, RPL",
            "probability": 0.0
        },
        {
            "start_logit": 12.1953125,
            "end_logit": -7.53125,
            "text": "RPS17, RPS19, RPS26, RPL5, RPL11, and RPL35",
            "probability": 0.0
        },
        {
            "start_logit": -8.5078125,
            "end_logit": 13.078125,
            "text": "screen the six genes that are most frequently mutated in Diamond-Blackfan anemia patients: RPS17",
            "probability": 0.0
        },
        {
            "start_logit": 12.1953125,
            "end_logit": -8.0546875,
            "text": "RPS17, RPS19, RPS26, RPL5, RPL11, and RPL",
            "probability": 0.0
        },
        {
            "start_logit": 12.1953125,
            "end_logit": -8.4375,
            "text": "RPS17, RPS19, RPS26, RPL5, RPL11, and",
            "probability": 0.0
        },
        {
            "start_logit": 12.1953125,
            "end_logit": -8.4453125,
            "text": "RPS17, RPS19, RPS26, RPL5, RPL11, and RPL35A. Using this assay we showed that deletions represent approximately 20",
            "probability": 0.0
        },
        {
            "start_logit": 12.1953125,
            "end_logit": -8.6953125,
            "text": "RPS17, RPS19, RPS26, RPL5, RPL11, and RPL35A. Using this assay we showed that deletions",
            "probability": 0.0
        },
        {
            "start_logit": 12.1953125,
            "end_logit": -8.8984375,
            "text": "RPS17, RPS19, RPS26, RPL5, RPL11, and RPL35A. Using this assay we showed that deletions represent",
            "probability": 0.0
        },
        {
            "start_logit": 12.1953125,
            "end_logit": -8.921875,
            "text": "RPS17,",
            "probability": 0.0
        },
        {
            "start_logit": -3.7421875,
            "end_logit": -2.24609375,
            "text": "RPS26",
            "probability": 0.0
        }
    ],
    "550312b4e9bde6963400001c_6": [
        {
            "start_logit": 12.0859375,
            "end_logit": 13.4609375,
            "text": "RPS19",
            "probability": 1.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": 2.95703125,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11, and RPL35A",
            "probability": 2.753734588623047e-05
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -1.818359375,
            "text": "RPS19, RPS24, RPS17, RPL5",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -2.595703125,
            "text": "RPS19, RPS24, RPS17",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.3046875,
            "end_logit": 13.4609375,
            "text": "19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -2.95703125,
            "text": "RPS19, RPS24",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -4.0078125,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -4.94921875,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11, and RPL35",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -5.73046875,
            "text": "RPS",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -6.421875,
            "text": "RPS19, RPS24, RPS17, RPL",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -6.9765625,
            "text": "RPS19, RPS",
            "probability": 0.0
        },
        {
            "start_logit": -8.390625,
            "end_logit": 13.4609375,
            "text": "for mutations in the six known genes associated with Diamond-Blackfan anemia: RPS19",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -7.42578125,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11, and",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -7.5,
            "text": "RPS19, RPS24, RPS",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -7.7421875,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11, and RPL",
            "probability": 0.0
        },
        {
            "start_logit": -9.9296875,
            "end_logit": 13.4609375,
            "text": "45 probands) for mutations in the six known genes associated with Diamond-Blackfan anemia: RPS19",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -8.65625,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -9.171875,
            "text": "RPS19,",
            "probability": 0.0
        },
        {
            "start_logit": -0.11907958984375,
            "end_logit": 2.95703125,
            "text": "RPL35A",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -9.296875,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11,",
            "probability": 0.0
        }
    ],
    "550312b4e9bde6963400001c_7": [
        {
            "start_logit": 12.0859375,
            "end_logit": 13.0546875,
            "text": "RPS19",
            "probability": 1.0
        },
        {
            "start_logit": -5.2109375,
            "end_logit": 13.0546875,
            "text": "19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -5.69140625,
            "text": "RPS19 gene, encoding the ribosomal protein S19",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -6.02734375,
            "text": "RPS",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -8.8203125,
            "text": "RPS19 gene",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -8.828125,
            "text": "RPS19 gene, encoding the ribosomal protein",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -9.2265625,
            "text": "RPS19 gene, encoding the ribosomal protein S19, are",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -9.4140625,
            "text": "RPS19 gene, encoding the ribosomal protein S19,",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -9.546875,
            "text": "RPS19 gene,",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -9.5625,
            "text": "RPS19 gene, encoding",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -9.734375,
            "text": "RPS19 gene, encoding the",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -9.7890625,
            "text": "RPS19 gene, encoding the ribosomal protein S19, are the main known cause of Diamond-Blackfan anemia and account",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -9.859375,
            "text": "RPS19 gene, encoding the ribosomal protein S19, are the main",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -9.875,
            "text": "RPS19 gene, encoding the ribosomal protein S19, are the main known cause of Diamond-Blackfan anemia and account for more than 25",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -9.921875,
            "text": "RPS19 gene, encoding the ribosomal protein S19, are the main known",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -9.96875,
            "text": "RPS19 gene, encoding the ribosomal protein S19, are the main known cause of Diamond-Blackfan anemia and",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -9.9765625,
            "text": "RPS19 gene, encoding the ribosomal protein S19, are the main known cause",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -10.0625,
            "text": "RPS19 gene, encoding the ribosomal protein S1",
            "probability": 0.0
        },
        {
            "start_logit": -5.2109375,
            "end_logit": -5.69140625,
            "text": "19 gene, encoding the ribosomal protein S19",
            "probability": 0.0
        },
        {
            "start_logit": -5.2109375,
            "end_logit": -8.8203125,
            "text": "19 gene",
            "probability": 0.0
        }
    ],
    "550312b4e9bde6963400001c_8": [
        {
            "start_logit": 12.734375,
            "end_logit": 13.6328125,
            "text": "RPS19",
            "probability": 1.0
        },
        {
            "start_logit": -4.41796875,
            "end_logit": 13.6328125,
            "text": "19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.734375,
            "end_logit": -5.2421875,
            "text": "RPS",
            "probability": 0.0
        },
        {
            "start_logit": -9.2109375,
            "end_logit": 13.6328125,
            "text": "ribosomal protein RPS19",
            "probability": 0.0
        },
        {
            "start_logit": 12.734375,
            "end_logit": -9.328125,
            "text": "RPS19 have been identified",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 13.6328125,
            "text": "Mutations in the gene coding for the ribosomal protein RPS19",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 13.6328125,
            "text": "in the gene coding for the ribosomal protein RPS19",
            "probability": 0.0
        },
        {
            "start_logit": 12.734375,
            "end_logit": -9.6953125,
            "text": "RPS19 have",
            "probability": 0.0
        },
        {
            "start_logit": 12.734375,
            "end_logit": -9.703125,
            "text": "RPS19 have been identified in 25% of patients with DBA, with resulting impairment of 18S rRNA processing",
            "probability": 0.0
        },
        {
            "start_logit": 12.734375,
            "end_logit": -9.7109375,
            "text": "RPS19 have been identified in 25% of patients with DBA,",
            "probability": 0.0
        },
        {
            "start_logit": 12.734375,
            "end_logit": -9.734375,
            "text": "RPS19 have been identified in 25% of patients with DBA, with resulting impairment of 18S rRNA",
            "probability": 0.0
        },
        {
            "start_logit": 12.734375,
            "end_logit": -9.765625,
            "text": "RPS19 have been identified in 25% of patients with DBA, with resulting impairment of 18S rRNA processing and 40S ribosomal subunit",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 13.6328125,
            "text": "coding for the ribosomal protein RPS19",
            "probability": 0.0
        },
        {
            "start_logit": 12.734375,
            "end_logit": -9.8359375,
            "text": "RPS19 have been identified in 25% of patients with DBA, with resulting impairment of 18S rRNA processing and 40S ribosomal",
            "probability": 0.0
        },
        {
            "start_logit": 12.734375,
            "end_logit": -9.8671875,
            "text": "RPS19 have been identified in 25% of patients with DBA, with resulting impairment of 18S rRNA processing and 40S ribosomal subunit formation",
            "probability": 0.0
        },
        {
            "start_logit": -4.41796875,
            "end_logit": -9.328125,
            "text": "19 have been identified",
            "probability": 0.0
        },
        {
            "start_logit": -4.41796875,
            "end_logit": -9.6953125,
            "text": "19 have",
            "probability": 0.0
        },
        {
            "start_logit": -4.41796875,
            "end_logit": -9.703125,
            "text": "19 have been identified in 25% of patients with DBA, with resulting impairment of 18S rRNA processing",
            "probability": 0.0
        },
        {
            "start_logit": -4.41796875,
            "end_logit": -9.7109375,
            "text": "19 have been identified in 25% of patients with DBA,",
            "probability": 0.0
        },
        {
            "start_logit": -4.41796875,
            "end_logit": -9.734375,
            "text": "19 have been identified in 25% of patients with DBA, with resulting impairment of 18S rRNA",
            "probability": 0.0
        }
    ],
    "550312b4e9bde6963400001c_9": [
        {
            "start_logit": 12.828125,
            "end_logit": 13.765625,
            "text": "RPS19",
            "probability": 1.0
        },
        {
            "start_logit": 12.828125,
            "end_logit": -1.77734375,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11, and RPL35A",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -3.978515625,
            "end_logit": 13.765625,
            "text": "19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.828125,
            "end_logit": -3.1015625,
            "text": "RPS19, RPS24, RPS17, RPL5",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.828125,
            "end_logit": -3.724609375,
            "text": "RPS19, RPS24",
            "probability": 0.0
        },
        {
            "start_logit": 12.828125,
            "end_logit": -3.81640625,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11",
            "probability": 0.0
        },
        {
            "start_logit": 12.828125,
            "end_logit": -3.85546875,
            "text": "RPS19, RPS24, RPS17",
            "probability": 0.0
        },
        {
            "start_logit": 12.828125,
            "end_logit": -5.13671875,
            "text": "RPS",
            "probability": 0.0
        },
        {
            "start_logit": 12.828125,
            "end_logit": -7.0234375,
            "text": "RPS19, RPS24, RPS17, RPL",
            "probability": 0.0
        },
        {
            "start_logit": 12.828125,
            "end_logit": -7.11328125,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11, and RPL35",
            "probability": 0.0
        },
        {
            "start_logit": 12.828125,
            "end_logit": -7.4453125,
            "text": "RPS19, RPS",
            "probability": 0.0
        },
        {
            "start_logit": 12.828125,
            "end_logit": -7.5703125,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11, and",
            "probability": 0.0
        },
        {
            "start_logit": 12.828125,
            "end_logit": -7.91796875,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL",
            "probability": 0.0
        },
        {
            "start_logit": 12.828125,
            "end_logit": -8.3125,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11, and RPL",
            "probability": 0.0
        },
        {
            "start_logit": 12.828125,
            "end_logit": -8.34375,
            "text": "RPS19, RPS24, RPS",
            "probability": 0.0
        },
        {
            "start_logit": -9.4140625,
            "end_logit": 13.765625,
            "text": "for mutations in the six known genes associated with Diamond-Blackfan anemia: RPS19",
            "probability": 0.0
        },
        {
            "start_logit": 12.828125,
            "end_logit": -8.6015625,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11,",
            "probability": 0.0
        },
        {
            "start_logit": 12.828125,
            "end_logit": -8.8515625,
            "text": "RPS19,",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 13.765625,
            "text": "45 probands) for mutations in the six known genes associated with Diamond-Blackfan anemia: RPS19",
            "probability": 0.0
        },
        {
            "start_logit": -3.978515625,
            "end_logit": -1.77734375,
            "text": "19, RPS24, RPS17, RPL5, RPL11, and RPL35A",
            "probability": 0.0
        }
    ],
    "550312b4e9bde6963400001c_10": [
        {
            "start_logit": 12.1015625,
            "end_logit": 12.9921875,
            "text": "RPS19",
            "probability": 1.0
        },
        {
            "start_logit": -5.28125,
            "end_logit": 12.9921875,
            "text": "19",
            "probability": 0.0
        },
        {
            "start_logit": 12.1015625,
            "end_logit": -5.6171875,
            "text": "RPS19 gene, encoding the ribosomal protein S19",
            "probability": 0.0
        },
        {
            "start_logit": 12.1015625,
            "end_logit": -5.95703125,
            "text": "RPS",
            "probability": 0.0
        },
        {
            "start_logit": 12.1015625,
            "end_logit": -8.796875,
            "text": "RPS19 gene, encoding the ribosomal protein",
            "probability": 0.0
        },
        {
            "start_logit": 12.1015625,
            "end_logit": -8.8125,
            "text": "RPS19 gene",
            "probability": 0.0
        },
        {
            "start_logit": 12.1015625,
            "end_logit": -9.296875,
            "text": "RPS19 gene, encoding the ribosomal protein S19,",
            "probability": 0.0
        },
        {
            "start_logit": 12.1015625,
            "end_logit": -9.296875,
            "text": "RPS19 gene, encoding the ribosomal protein S19, are",
            "probability": 0.0
        },
        {
            "start_logit": 12.1015625,
            "end_logit": -9.453125,
            "text": "RPS19 gene, encoding",
            "probability": 0.0
        },
        {
            "start_logit": 12.1015625,
            "end_logit": -9.5234375,
            "text": "RPS19 gene,",
            "probability": 0.0
        },
        {
            "start_logit": 12.1015625,
            "end_logit": -9.6953125,
            "text": "RPS19 gene, encoding the",
            "probability": 0.0
        },
        {
            "start_logit": 12.1015625,
            "end_logit": -9.84375,
            "text": "RPS19 gene, encoding the ribosomal protein S19, are the main",
            "probability": 0.0
        },
        {
            "start_logit": 12.1015625,
            "end_logit": -9.8671875,
            "text": "RPS19 gene, encoding the ribosomal protein S19, are the main known cause of Diamond-Blackfan anemia and account",
            "probability": 0.0
        },
        {
            "start_logit": 12.1015625,
            "end_logit": -9.890625,
            "text": "RPS19 gene, encoding the ribosomal protein S19, are the main known",
            "probability": 0.0
        },
        {
            "start_logit": 12.1015625,
            "end_logit": -9.9765625,
            "text": "RPS19 gene, encoding the ribosomal protein S19, are the main known cause",
            "probability": 0.0
        },
        {
            "start_logit": 12.1015625,
            "end_logit": -9.9921875,
            "text": "RPS19 gene, encoding the ribosomal protein S1",
            "probability": 0.0
        },
        {
            "start_logit": 12.1015625,
            "end_logit": -10.0,
            "text": "RPS19 gene, encoding the ribosomal protein S19, are the main known cause of Diamond-Blackfan anemia and",
            "probability": 0.0
        },
        {
            "start_logit": -5.28125,
            "end_logit": -5.6171875,
            "text": "19 gene, encoding the ribosomal protein S19",
            "probability": 0.0
        },
        {
            "start_logit": -5.28125,
            "end_logit": -8.796875,
            "text": "19 gene, encoding the ribosomal protein",
            "probability": 0.0
        },
        {
            "start_logit": -5.28125,
            "end_logit": -8.8125,
            "text": "19 gene",
            "probability": 0.0
        }
    ],
    "550312b4e9bde6963400001c_11": [
        {
            "start_logit": 7.05859375,
            "end_logit": 8.5,
            "text": "RPS19",
            "probability": 0.98828125
        },
        {
            "start_logit": 2.59375,
            "end_logit": 8.5,
            "text": "ribosomal protein (RP) gene S19 (RPS19",
            "probability": 0.01132965087890625
        },
        {
            "start_logit": 2.59375,
            "end_logit": 5.23828125,
            "text": "ribosomal protein (RP) gene S19",
            "probability": 0.0004341602325439453
        },
        {
            "start_logit": 7.05859375,
            "end_logit": -1.4931640625,
            "text": "RPS19 gene",
            "probability": 4.488229751586914e-05
        },
        {
            "start_logit": -5.046875,
            "end_logit": 8.5,
            "text": "S19 (RPS19",
            "probability": 5.424022674560547e-06
        },
        {
            "start_logit": 2.59375,
            "end_logit": -1.4931640625,
            "text": "ribosomal protein (RP) gene S19 (RPS19 gene",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -5.046875,
            "end_logit": 5.23828125,
            "text": "S19",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -8.875,
            "end_logit": 8.5,
            "text": "ribosomal gene involved in DBA, ribosomal protein (RP) gene S19 (RPS19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.8984375,
            "end_logit": 8.5,
            "text": "19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.8984375,
            "end_logit": 8.5,
            "text": "9 (RPS19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.05859375,
            "end_logit": -8.203125,
            "text": "RPS19 gene)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.7578125,
            "end_logit": 8.5,
            "text": "gene S19 (RPS19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.0859375,
            "end_logit": 8.5,
            "text": ", ribosomal protein (RP) gene S19 (RPS19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.05859375,
            "end_logit": -9.125,
            "text": "RPS19 gene),",
            "probability": 0.0
        },
        {
            "start_logit": 7.05859375,
            "end_logit": -9.2578125,
            "text": "RPS19 gene), was identified",
            "probability": 0.0
        },
        {
            "start_logit": 7.05859375,
            "end_logit": -9.2734375,
            "text": "RPS19 gene), was identified in 1999",
            "probability": 0.0
        },
        {
            "start_logit": 7.05859375,
            "end_logit": -9.2890625,
            "text": "RPS",
            "probability": 0.0
        },
        {
            "start_logit": 7.05859375,
            "end_logit": -9.3515625,
            "text": "RPS19 gene), was",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 8.5,
            "text": "RP) gene S19 (RPS19",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 8.5,
            "text": "protein (RP) gene S19 (RPS19",
            "probability": 0.0
        }
    ],
    "5e46f9683f54159529000010_1": [
        {
            "start_logit": 13.6328125,
            "end_logit": 13.9296875,
            "text": "radiation necrosis",
            "probability": 1.0
        },
        {
            "start_logit": -4.0859375,
            "end_logit": 13.9296875,
            "text": "necrosis",
            "probability": 0.0
        },
        {
            "start_logit": 13.6328125,
            "end_logit": -4.21484375,
            "text": "radiation",
            "probability": 0.0
        },
        {
            "start_logit": 13.6328125,
            "end_logit": -6.84375,
            "text": "radiation necrosis, microangiopathy, and progressive leukencephalopathy",
            "probability": 0.0
        },
        {
            "start_logit": 13.6328125,
            "end_logit": -8.078125,
            "text": "radiation necrosis, microangiopathy",
            "probability": 0.0
        },
        {
            "start_logit": 13.6328125,
            "end_logit": -8.53125,
            "text": "radiation necrosis, microangiopathy, and progressive leukencephal",
            "probability": 0.0
        },
        {
            "start_logit": 13.6328125,
            "end_logit": -8.703125,
            "text": "radiation necrosis, microangiopathy, and",
            "probability": 0.0
        },
        {
            "start_logit": 13.6328125,
            "end_logit": -8.703125,
            "text": "radiation necrosis,",
            "probability": 0.0
        },
        {
            "start_logit": 13.6328125,
            "end_logit": -9.046875,
            "text": "radiation necrosis, microangiopathy, and progressive leuk",
            "probability": 0.0
        },
        {
            "start_logit": 13.6328125,
            "end_logit": -9.1953125,
            "text": "radiation necrosis, microangiopathy, and progressive",
            "probability": 0.0
        },
        {
            "start_logit": 13.6328125,
            "end_logit": -10.0,
            "text": "radiation necrosis, microangiopathy, and progressive leukencephalopathy.",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 13.9296875,
            "text": "central nervous system are uncommon and include radiation necrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 13.9296875,
            "text": "side effects of radiation therapy on the head or central nervous system are uncommon and include radiation necrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 13.9296875,
            "text": "head or central nervous system are uncommon and include radiation necrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 13.9296875,
            "text": "nervous system are uncommon and include radiation necrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 13.9296875,
            "text": "on the head or central nervous system are uncommon and include radiation necrosis",
            "probability": 0.0
        },
        {
            "start_logit": -4.0859375,
            "end_logit": -6.84375,
            "text": "necrosis, microangiopathy, and progressive leukencephalopathy",
            "probability": 0.0
        },
        {
            "start_logit": -4.0859375,
            "end_logit": -8.078125,
            "text": "necrosis, microangiopathy",
            "probability": 0.0
        },
        {
            "start_logit": -4.0859375,
            "end_logit": -8.53125,
            "text": "necrosis, microangiopathy, and progressive leukencephal",
            "probability": 0.0
        },
        {
            "start_logit": -4.0859375,
            "end_logit": -8.703125,
            "text": "necrosis, microangiopathy, and",
            "probability": 0.0
        }
    ],
    "5e46f9683f54159529000010_2": [
        {
            "start_logit": 11.375,
            "end_logit": 11.1171875,
            "text": "gliomas",
            "probability": 1.0
        },
        {
            "start_logit": 11.375,
            "end_logit": -4.671875,
            "text": "gliomas (RIGs)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.30859375,
            "end_logit": 11.1171875,
            "text": "radiation-induced gliomas",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.9296875,
            "end_logit": 11.1171875,
            "text": "meningiomas, followed by radiation-induced gliomas",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.375,
            "end_logit": -7.82421875,
            "text": "gliomas (RIGs",
            "probability": 0.0
        },
        {
            "start_logit": 11.375,
            "end_logit": -7.83984375,
            "text": "gliomas (RIGs) and sarcomas",
            "probability": 0.0
        },
        {
            "start_logit": 11.375,
            "end_logit": -9.5546875,
            "text": "gliomas (RIGs) and",
            "probability": 0.0
        },
        {
            "start_logit": -9.3046875,
            "end_logit": 11.1171875,
            "text": "induced gliomas",
            "probability": 0.0
        },
        {
            "start_logit": 11.375,
            "end_logit": -9.703125,
            "text": "gliomas (",
            "probability": 0.0
        },
        {
            "start_logit": 11.375,
            "end_logit": -9.8515625,
            "text": "gliomas (RIG",
            "probability": 0.0
        },
        {
            "start_logit": -9.625,
            "end_logit": 11.1171875,
            "text": "tumors, a majority of which are meningiomas, followed by radiation-induced gliomas",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": 11.1171875,
            "text": "radiation-induced tumors, a majority of which are meningiomas, followed by radiation-induced gliomas",
            "probability": 0.0
        },
        {
            "start_logit": 11.375,
            "end_logit": -10.1640625,
            "text": "gliomas (RIGs) and sarcomas.",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": 11.1171875,
            "text": "followed by radiation-induced gliomas",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": 11.1171875,
            "text": "induced tumors, a majority of which are meningiomas, followed by radiation-induced gliomas",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 11.1171875,
            "text": "of which are meningiomas, followed by radiation-induced gliomas",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 11.1171875,
            "text": "a majority of which are meningiomas, followed by radiation-induced gliomas",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 11.1171875,
            "text": "-induced gliomas",
            "probability": 0.0
        },
        {
            "start_logit": -5.30859375,
            "end_logit": -4.671875,
            "text": "radiation-induced gliomas (RIGs)",
            "probability": 0.0
        },
        {
            "start_logit": -5.9296875,
            "end_logit": -4.671875,
            "text": "meningiomas, followed by radiation-induced gliomas (RIGs)",
            "probability": 0.0
        }
    ],
    "5e46f9683f54159529000010_3": [
        {
            "start_logit": 11.40625,
            "end_logit": 11.9296875,
            "text": "pneumonitis",
            "probability": 1.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -5.21875,
            "text": "pneumonitis, disturbance of the blood-brain barrier, radionecrosis of brain tissue, radiogenic liver damage, mucositis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.40625,
            "end_logit": -7.3359375,
            "text": "pneumonitis, disturbance of the blood-brain barrier, radionecrosis of brain tissue, radiogenic liver damage",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -7.86328125,
            "text": "pneumonitis, disturbance of the blood-brain barrier, radionecrosis of brain tissue, radiogenic liver damage, mucositis, colitis",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -8.0390625,
            "text": "pneumonitis, disturbance of the blood-brain barrier, radionecrosis of brain tissue, radiogenic liver damage, mucositis, colitis, osteitis",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -8.125,
            "text": "pneumonitis, disturbance of the blood-brain barrier, radionecrosis of brain tissue, radiogenic liver",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -8.3046875,
            "text": "pneumonitis, disturbance of the blood-brain barrier, radionecrosis of brain tissue",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -8.3984375,
            "text": "pneumonitis, disturbance of the blood-brain barrier, radionecrosis of brain tissue, radiogenic",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -8.5390625,
            "text": "pneumonitis, disturbance of the blood-brain barrier",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -8.7421875,
            "text": "pneumonitis, disturbance of the blood-brain barrier, radionecrosis",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -8.78125,
            "text": "pneumonitis,",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -8.953125,
            "text": "pneumonitis, disturbance of the blood-brain barrier, radionecrosis of brain",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -9.2265625,
            "text": "pneumonitis, disturbance of the blood-brain",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 11.9296875,
            "text": "tissue alterations found by imaging are pneumonitis",
            "probability": 0.0
        },
        {
            "start_logit": -6.38671875,
            "end_logit": -5.21875,
            "text": "mucositis",
            "probability": 0.0
        },
        {
            "start_logit": -6.38671875,
            "end_logit": -7.86328125,
            "text": "mucositis, colitis",
            "probability": 0.0
        },
        {
            "start_logit": -6.38671875,
            "end_logit": -8.0390625,
            "text": "mucositis, colitis, osteitis",
            "probability": 0.0
        },
        {
            "start_logit": -6.38671875,
            "end_logit": -8.28125,
            "text": "mucositis, colitis, osteitis, osteoradionecrosis and myositis",
            "probability": 0.0
        },
        {
            "start_logit": -9.5234375,
            "end_logit": -5.21875,
            "text": "radionecrosis of brain tissue, radiogenic liver damage, mucositis",
            "probability": 0.0
        },
        {
            "start_logit": -9.6953125,
            "end_logit": -5.21875,
            "text": "liver damage, mucositis",
            "probability": 0.0
        }
    ],
    "5e46f9683f54159529000010_4": [
        {
            "start_logit": 6.98046875,
            "end_logit": 10.234375,
            "text": "fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 10.234375,
            "text": "Radiation-induced fibrosis",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -9.28125,
            "end_logit": 10.234375,
            "text": "induced fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -6.51953125,
            "text": "fibrosis (RIF)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 10.234375,
            "text": "-induced fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -8.203125,
            "text": "fibrosis (RIF) is one of the severe long-term side effects of radiation therapy (RT)",
            "probability": 0.0
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -8.4765625,
            "text": "fibrosis (RIF) is",
            "probability": 0.0
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -8.8359375,
            "text": "fibrosis (",
            "probability": 0.0
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -8.96875,
            "text": "fibrosis (RIF) is one",
            "probability": 0.0
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -9.0078125,
            "text": "fibrosis (RIF",
            "probability": 0.0
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -9.3671875,
            "text": "fibrosis (RIF) is one of the severe long-term side effects",
            "probability": 0.0
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -9.4765625,
            "text": "fibrosis (RIF) is one of the",
            "probability": 0.0
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -9.5,
            "text": "fibrosis (RIF) is one of the severe",
            "probability": 0.0
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -9.7578125,
            "text": "fibrosis (RIF) is one of the severe long-term",
            "probability": 0.0
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -10.078125,
            "text": "fibrosis (RIF) is one of",
            "probability": 0.0
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -10.234375,
            "text": "fibrosis (RIF) is one of the severe long-",
            "probability": 0.0
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -10.453125,
            "text": "fibrosis (RIF) is one of the severe long-term side effects of radiation therapy (RT",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -6.51953125,
            "text": "Radiation-induced fibrosis (RIF)",
            "probability": 0.0
        },
        {
            "start_logit": -9.28125,
            "end_logit": -6.51953125,
            "text": "induced fibrosis (RIF)",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -8.203125,
            "text": "Radiation-induced fibrosis (RIF) is one of the severe long-term side effects of radiation therapy (RT)",
            "probability": 0.0
        }
    ],
    "5e46f9683f54159529000010_5": [
        {
            "start_logit": 13.4921875,
            "end_logit": 11.4140625,
            "text": "skin reactions",
            "probability": 1.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -2.58984375,
            "text": "skin",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -7.13671875,
            "text": "skin reactions are one of the most common side effects of radiation therapy,",
            "probability": 0.0
        },
        {
            "start_logit": -6.703125,
            "end_logit": 11.4140625,
            "text": "reactions",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -9.0078125,
            "text": "skin reactions are",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -9.3671875,
            "text": "skin reactions are one of the most common",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -9.578125,
            "text": "skin reactions are one of the most common side effects",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -10.0625,
            "text": "skin reactions are one of the",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -10.1171875,
            "text": "skin reactions are one",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -10.3671875,
            "text": "skin reactions are one of the most",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 11.4140625,
            "text": "Acute skin reactions",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": -2.58984375,
            "text": "Acute skin",
            "probability": 0.0
        },
        {
            "start_logit": -6.703125,
            "end_logit": -7.13671875,
            "text": "reactions are one of the most common side effects of radiation therapy,",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": -7.13671875,
            "text": "Acute skin reactions are one of the most common side effects of radiation therapy,",
            "probability": 0.0
        },
        {
            "start_logit": -6.703125,
            "end_logit": -9.0078125,
            "text": "reactions are",
            "probability": 0.0
        },
        {
            "start_logit": -6.703125,
            "end_logit": -9.3671875,
            "text": "reactions are one of the most common",
            "probability": 0.0
        },
        {
            "start_logit": -6.703125,
            "end_logit": -9.578125,
            "text": "reactions are one of the most common side effects",
            "probability": 0.0
        },
        {
            "start_logit": -6.703125,
            "end_logit": -10.0625,
            "text": "reactions are one of the",
            "probability": 0.0
        },
        {
            "start_logit": -6.703125,
            "end_logit": -10.1171875,
            "text": "reactions are one",
            "probability": 0.0
        },
        {
            "start_logit": -6.703125,
            "end_logit": -10.3671875,
            "text": "reactions are one of the most",
            "probability": 0.0
        }
    ],
    "56bf487def6e394741000011_1": [
        {
            "start_logit": 12.7109375,
            "end_logit": 12.8125,
            "text": "Aip1",
            "probability": 1.0
        },
        {
            "start_logit": 12.7109375,
            "end_logit": -4.875,
            "text": "Aip1, Ede1 and Inn1",
            "probability": 0.0
        },
        {
            "start_logit": 12.7109375,
            "end_logit": -5.0078125,
            "text": "Aip",
            "probability": 0.0
        },
        {
            "start_logit": -5.296875,
            "end_logit": 12.8125,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": 12.7109375,
            "end_logit": -5.87109375,
            "text": "Aip1, Ede1 and Inn1 as cytokinetic regulators. Our results suggest that cytokinesis is coordinately controlled by the master cell cycle",
            "probability": 0.0
        },
        {
            "start_logit": 12.7109375,
            "end_logit": -6.50390625,
            "text": "Aip1, Ede1",
            "probability": 0.0
        },
        {
            "start_logit": 12.7109375,
            "end_logit": -8.1328125,
            "text": "Aip1, Ede1 and",
            "probability": 0.0
        },
        {
            "start_logit": 12.7109375,
            "end_logit": -8.4453125,
            "text": "Aip1, Ede1 and Inn1 as cytokinetic regulators. Our results suggest that cytokinesis is coordinately controlled by the master cell cycle regulator Cdk",
            "probability": 0.0
        },
        {
            "start_logit": 12.7109375,
            "end_logit": -9.0,
            "text": "Aip1, Ed",
            "probability": 0.0
        },
        {
            "start_logit": 12.7109375,
            "end_logit": -9.2734375,
            "text": "Aip1, Ede1 and Inn",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 12.8125,
            "text": "identifies Aip1",
            "probability": 0.0
        },
        {
            "start_logit": -5.296875,
            "end_logit": -4.875,
            "text": "1, Ede1 and Inn1",
            "probability": 0.0
        },
        {
            "start_logit": -5.296875,
            "end_logit": -5.87109375,
            "text": "1, Ede1 and Inn1 as cytokinetic regulators. Our results suggest that cytokinesis is coordinately controlled by the master cell cycle",
            "probability": 0.0
        },
        {
            "start_logit": -5.296875,
            "end_logit": -6.50390625,
            "text": "1, Ede1",
            "probability": 0.0
        },
        {
            "start_logit": -5.296875,
            "end_logit": -8.1328125,
            "text": "1, Ede1 and",
            "probability": 0.0
        },
        {
            "start_logit": -8.8046875,
            "end_logit": -4.875,
            "text": "Ede1 and Inn1",
            "probability": 0.0
        },
        {
            "start_logit": -5.296875,
            "end_logit": -8.4453125,
            "text": "1, Ede1 and Inn1 as cytokinetic regulators. Our results suggest that cytokinesis is coordinately controlled by the master cell cycle regulator Cdk",
            "probability": 0.0
        },
        {
            "start_logit": -8.96875,
            "end_logit": -4.875,
            "text": ", Ede1 and Inn1",
            "probability": 0.0
        },
        {
            "start_logit": -9.1328125,
            "end_logit": -4.875,
            "text": "Inn1",
            "probability": 0.0
        },
        {
            "start_logit": -5.296875,
            "end_logit": -9.0,
            "text": "1, Ed",
            "probability": 0.0
        }
    ],
    "5e52900d6d0a277941000041_1": [
        {
            "start_logit": 4.2421875,
            "end_logit": 0.1531982421875,
            "text": "protease-activated receptor1&2",
            "probability": 0.9873046875
        },
        {
            "start_logit": 4.2421875,
            "end_logit": -4.6640625,
            "text": "protease-activated receptor1&2 (PAR1&2)",
            "probability": 0.00799560546875
        },
        {
            "start_logit": 4.2421875,
            "end_logit": -6.45703125,
            "text": "protease-activated receptor1",
            "probability": 0.0013303756713867188
        },
        {
            "start_logit": 4.2421875,
            "end_logit": -6.49609375,
            "text": "protease-activated receptor1&2 (PAR1&2",
            "probability": 0.0012798309326171875
        },
        {
            "start_logit": 4.2421875,
            "end_logit": -7.1015625,
            "text": "protease-activated receptor",
            "probability": 0.0006985664367675781
        },
        {
            "start_logit": 4.2421875,
            "end_logit": -7.609375,
            "text": "protease-activated receptor1&2 (PAR",
            "probability": 0.00042057037353515625
        },
        {
            "start_logit": 4.2421875,
            "end_logit": -7.65234375,
            "text": "protease",
            "probability": 0.0004029273986816406
        },
        {
            "start_logit": -7.2734375,
            "end_logit": 0.1531982421875,
            "text": "1&2",
            "probability": 9.834766387939453e-06
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 0.1531982421875,
            "text": "receptor1&2",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": -6.45703125,
            "end_logit": -3.375,
            "text": "Vav3",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -6.52734375,
            "end_logit": -3.375,
            "text": "Etk/Bmx and Vav3",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -6.6015625,
            "end_logit": -3.375,
            "text": "3",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.03125,
            "end_logit": -4.8515625,
            "text": "placental extravillous trophoblast (EVT) invasion",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2734375,
            "end_logit": -4.6640625,
            "text": "1&2 (PAR1&2)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.6015625,
            "end_logit": -3.375,
            "text": "Bmx and Vav3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.52734375,
            "end_logit": -5.6875,
            "text": "Etk/Bmx",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.52734375,
            "end_logit": -5.9765625,
            "text": "Etk/Bm",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -4.6640625,
            "text": "receptor1&2 (PAR1&2)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": -4.8515625,
            "text": "invasion",
            "probability": 0.0
        },
        {
            "start_logit": -7.03125,
            "end_logit": -6.39453125,
            "text": "placental extravillous trophoblast (EVT) invasion in vitro. Similarly, the PAR1 mutant hPar1-7A",
            "probability": 0.0
        }
    ],
    "5e9208702d3121100d000009_1": [
        {
            "start_logit": 14.7578125,
            "end_logit": 10.3984375,
            "text": "\u03b1 and \u03b2-defensins",
            "probability": 1.0
        },
        {
            "start_logit": 14.7578125,
            "end_logit": -0.79345703125,
            "text": "\u03b1",
            "probability": 1.3709068298339844e-05
        },
        {
            "start_logit": 14.7578125,
            "end_logit": -2.501953125,
            "text": "\u03b1 and \u03b2-defensin",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": 14.7578125,
            "end_logit": -6.66015625,
            "text": "\u03b1 and \u03b2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.7578125,
            "end_logit": -7.046875,
            "text": "\u03b1 and \u03b2-def",
            "probability": 0.0
        },
        {
            "start_logit": 14.7578125,
            "end_logit": -7.48828125,
            "text": "\u03b1 and",
            "probability": 0.0
        },
        {
            "start_logit": 14.7578125,
            "end_logit": -7.8203125,
            "text": "\u03b1 and \u03b2-",
            "probability": 0.0
        },
        {
            "start_logit": -5.5234375,
            "end_logit": 10.3984375,
            "text": "\u03b2-defensins",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 10.3984375,
            "text": "defensins",
            "probability": 0.0
        },
        {
            "start_logit": -8.5703125,
            "end_logit": 10.3984375,
            "text": "s",
            "probability": 0.0
        },
        {
            "start_logit": -9.2265625,
            "end_logit": 10.3984375,
            "text": "ensins",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 10.3984375,
            "text": "Human \u03b1 and \u03b2-defensins",
            "probability": 0.0
        },
        {
            "start_logit": -5.5234375,
            "end_logit": -2.501953125,
            "text": "\u03b2-defensin",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": -2.501953125,
            "text": "defensin",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": -0.79345703125,
            "text": "Human \u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -9.2265625,
            "end_logit": -2.501953125,
            "text": "ensin",
            "probability": 0.0
        },
        {
            "start_logit": -5.5234375,
            "end_logit": -6.66015625,
            "text": "\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -5.5234375,
            "end_logit": -7.046875,
            "text": "\u03b2-def",
            "probability": 0.0
        },
        {
            "start_logit": -5.5234375,
            "end_logit": -7.8203125,
            "text": "\u03b2-",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": -2.501953125,
            "text": "Human \u03b1 and \u03b2-defensin",
            "probability": 0.0
        }
    ],
    "5e9208702d3121100d000009_2": [
        {
            "start_logit": 12.9765625,
            "end_logit": 6.39453125,
            "text": "\u03b1- and \u03b2-defensins",
            "probability": 0.998046875
        },
        {
            "start_logit": 12.9765625,
            "end_logit": -0.430908203125,
            "text": "\u03b1- and \u03b2-defensin",
            "probability": 0.0010805130004882812
        },
        {
            "start_logit": 12.9765625,
            "end_logit": -0.52294921875,
            "text": "\u03b1-",
            "probability": 0.00098419189453125
        },
        {
            "start_logit": 12.9765625,
            "end_logit": -4.8046875,
            "text": "\u03b1",
            "probability": 1.3649463653564453e-05
        },
        {
            "start_logit": 12.9765625,
            "end_logit": -6.1640625,
            "text": "\u03b1- and \u03b2-def",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": 12.9765625,
            "end_logit": -6.62890625,
            "text": "\u03b1- and \u03b2",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": 12.9765625,
            "end_logit": -7.2265625,
            "text": "\u03b1- and \u03b2-",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -0.876953125,
            "end_logit": 6.39453125,
            "text": "\u03b2-defensins",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 12.9765625,
            "end_logit": -7.65625,
            "text": "\u03b1- and \u03b2-defensins,",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 12.9765625,
            "end_logit": -8.0859375,
            "text": "\u03b1- and",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 12.9765625,
            "end_logit": -9.3828125,
            "text": "\u03b1- and \u03b2-defensins, which are",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.9765625,
            "end_logit": -9.3984375,
            "text": "\u03b1- and \u03b2-defensins, which are known",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.9765625,
            "end_logit": -9.6328125,
            "text": "\u03b1- and \u03b2-defensins, which are known for their",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -0.876953125,
            "end_logit": -0.430908203125,
            "text": "\u03b2-defensin",
            "probability": 0.0
        },
        {
            "start_logit": -8.4609375,
            "end_logit": 6.39453125,
            "text": "and \u03b2-defensins",
            "probability": 0.0
        },
        {
            "start_logit": -8.53125,
            "end_logit": 6.39453125,
            "text": "defensins",
            "probability": 0.0
        },
        {
            "start_logit": -8.71875,
            "end_logit": 6.39453125,
            "text": "s",
            "probability": 0.0
        },
        {
            "start_logit": -9.2734375,
            "end_logit": 6.39453125,
            "text": "express \u03b1- and \u03b2-defensins",
            "probability": 0.0
        },
        {
            "start_logit": -9.546875,
            "end_logit": 6.39453125,
            "text": "ensins",
            "probability": 0.0
        },
        {
            "start_logit": -9.890625,
            "end_logit": 6.39453125,
            "text": "antimicrobial peptides that participate in the innate immunity of hosts. Humans constitutively and/or inducibly express \u03b1- and \u03b2-defensins",
            "probability": 0.0
        }
    ],
    "5c658a8f7c78d69471000007_1": [
        {
            "start_logit": 11.203125,
            "end_logit": 11.96875,
            "text": "diarrhea",
            "probability": 1.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -6.69140625,
            "text": "diarrhea, differentiation syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -8.3828125,
            "text": "diarrhea, differentiation",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -8.4921875,
            "text": "diarrhea, differentiation syndrome, decreased potassium and calcium levels etc",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -8.6328125,
            "text": "diarrhea,",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": 11.96875,
            "text": "elevated bilirubin level, diarrhea",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -9.0078125,
            "text": "diarrhea, differentiation syndrome, decreased potassium and calcium levels etc.",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -9.375,
            "text": "diarrhea, differentiation syndrome,",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -9.3828125,
            "text": "diarrhea, differentiation syndrome, decreased potassium and calcium levels",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 11.96875,
            "text": "adverse effects like elevated bilirubin level, diarrhea",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 11.96875,
            "text": ", diarrhea",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -9.546875,
            "text": "diarrhea, differentiation syndrome, decreased potassium and",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 11.96875,
            "text": "like elevated bilirubin level, diarrhea",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 11.96875,
            "text": "bilirubin level, diarrhea",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -9.8515625,
            "text": "diarrhea, differentiation syndrome, decreased potassium",
            "probability": 0.0
        },
        {
            "start_logit": -8.546875,
            "end_logit": -6.69140625,
            "text": "differentiation syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": -6.69140625,
            "text": "elevated bilirubin level, diarrhea, differentiation syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": -6.69140625,
            "text": "adverse effects like elevated bilirubin level, diarrhea, differentiation syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.546875,
            "end_logit": -8.3828125,
            "text": "differentiation",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": -6.69140625,
            "text": ", diarrhea, differentiation syndrome",
            "probability": 0.0
        }
    ],
    "532b15ecd6d3ac6a34000014_1": [
        {
            "start_logit": 11.71875,
            "end_logit": 11.578125,
            "text": "bortezomib",
            "probability": 1.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -7.1015625,
            "text": "bortezomib with topoisomerase I and II inhibitors",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -7.19921875,
            "text": "bortezomib with topoisomerase I and II inhibitors increased the therapeutic potency in U-CH2",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -7.86328125,
            "text": "bortezomib with topoisomerase I and II inhibitors increased",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -8.25,
            "text": "bortezomib with topoisomerase I and II inhibitors increased the therapeutic potency",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -8.765625,
            "text": "bortezomib with topoisomerase I and II inhibitors increased the",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -8.9921875,
            "text": "bortezomib with topoisomerase I and II inhibitors increased the therapeutic potency in U",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -9.1328125,
            "text": "bortezomib with topoisomerase I and II",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -9.15625,
            "text": "bortezomib with topoisomerase I and II inhibitors increased the therapeutic potency in U-",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -9.1796875,
            "text": "bortezomib with topoisomerase I",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -9.2421875,
            "text": "bortezomib with topoisomerase",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -9.3046875,
            "text": "bortezomib with topoisomerase I and II inhibitors increased the therapeutic potency in U-CH2 and patient-",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -9.4296875,
            "text": "bortezomib with topoisomerase I and",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -9.4453125,
            "text": "bortezomib with",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -9.453125,
            "text": "bortezomib with topoisomerase I and II inhibitors increased the therapeutic",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -9.5234375,
            "text": "bortezomib with topoisomerase I and II inhibitors increased the therapeutic potency in",
            "probability": 0.0
        },
        {
            "start_logit": -8.78125,
            "end_logit": -7.19921875,
            "text": "U-CH2",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": -7.1015625,
            "text": "topoisomerase I and II inhibitors",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": -7.19921875,
            "text": "topoisomerase I and II inhibitors increased the therapeutic potency in U-CH2",
            "probability": 0.0
        },
        {
            "start_logit": -8.78125,
            "end_logit": -8.9921875,
            "text": "U",
            "probability": 0.0
        }
    ],
    "532b15ecd6d3ac6a34000014_2": [
        {
            "start_logit": 5.92578125,
            "end_logit": 7.13671875,
            "text": "cisplatin",
            "probability": 0.529296875
        },
        {
            "start_logit": 4.97265625,
            "end_logit": 7.13671875,
            "text": "Vincristine, doxorubicin, etoposide, cisplatin",
            "probability": 0.2039794921875
        },
        {
            "start_logit": 4.265625,
            "end_logit": 7.13671875,
            "text": "doxorubicin, etoposide, cisplatin",
            "probability": 0.1009521484375
        },
        {
            "start_logit": 5.92578125,
            "end_logit": 5.4140625,
            "text": "cisplatin, and fludarabine",
            "probability": 0.09490966796875
        },
        {
            "start_logit": 4.97265625,
            "end_logit": 5.4140625,
            "text": "Vincristine, doxorubicin, etoposide, cisplatin, and fludarabine",
            "probability": 0.036590576171875
        },
        {
            "start_logit": 4.265625,
            "end_logit": 5.4140625,
            "text": "doxorubicin, etoposide, cisplatin, and fludarabine",
            "probability": 0.017974853515625
        },
        {
            "start_logit": 4.97265625,
            "end_logit": 4.34765625,
            "text": "Vincristine",
            "probability": 0.012542724609375
        },
        {
            "start_logit": 4.97265625,
            "end_logit": 2.365234375,
            "text": "Vincristine, doxorubicin",
            "probability": 0.0017242431640625
        },
        {
            "start_logit": 4.265625,
            "end_logit": 2.365234375,
            "text": "doxorubicin",
            "probability": 0.0008535385131835938
        },
        {
            "start_logit": 1.0732421875,
            "end_logit": 5.4140625,
            "text": "fludarabine",
            "probability": 0.0007386207580566406
        },
        {
            "start_logit": -1.353515625,
            "end_logit": 7.13671875,
            "text": "etoposide, cisplatin",
            "probability": 0.0003643035888671875
        },
        {
            "start_logit": -1.353515625,
            "end_logit": 5.4140625,
            "text": "etoposide, cisplatin, and fludarabine",
            "probability": 6.526708602905273e-05
        },
        {
            "start_logit": 4.97265625,
            "end_logit": -2.962890625,
            "text": "Vincristine, doxorubicin, etoposide",
            "probability": 8.344650268554688e-06
        },
        {
            "start_logit": 4.265625,
            "end_logit": -2.962890625,
            "text": "doxorubicin, etoposide",
            "probability": 4.112720489501953e-06
        },
        {
            "start_logit": 5.92578125,
            "end_logit": -7.5625,
            "text": "cisplatin, and fludarabin",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 5.92578125,
            "end_logit": -7.67578125,
            "text": "cisplatin, and fluda",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.2734375,
            "end_logit": 5.4140625,
            "text": "e",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 5.92578125,
            "end_logit": -7.91796875,
            "text": "cisplatin, and fludara",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 5.92578125,
            "end_logit": -8.328125,
            "text": "cisplatin, and flu",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 4.97265625,
            "end_logit": -7.5625,
            "text": "Vincristine, doxorubicin, etoposide, cisplatin, and fludarabin",
            "probability": 1.1920928955078125e-07
        }
    ],
    "532b15ecd6d3ac6a34000014_3": [
        {
            "start_logit": 12.2578125,
            "end_logit": 12.25,
            "text": "pingyangmycin",
            "probability": 1.0
        },
        {
            "start_logit": 12.2578125,
            "end_logit": -4.3671875,
            "text": "pin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.2578125,
            "end_logit": -4.42578125,
            "text": "pingyangmy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.2578125,
            "end_logit": -4.99609375,
            "text": "pingyangmycin lipiodol",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.2578125,
            "end_logit": -5.375,
            "text": "pingyangmycin lipiodol emulsion",
            "probability": 0.0
        },
        {
            "start_logit": -6.04296875,
            "end_logit": 12.25,
            "text": "cin",
            "probability": 0.0
        },
        {
            "start_logit": 12.2578125,
            "end_logit": -6.82421875,
            "text": "pingyang",
            "probability": 0.0
        },
        {
            "start_logit": 12.2578125,
            "end_logit": -7.30078125,
            "text": "pingy",
            "probability": 0.0
        },
        {
            "start_logit": -7.625,
            "end_logit": 12.25,
            "text": "mycin",
            "probability": 0.0
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 12.25,
            "text": "angmycin",
            "probability": 0.0
        },
        {
            "start_logit": 12.2578125,
            "end_logit": -8.3125,
            "text": "pingyangmycin lipiod",
            "probability": 0.0
        },
        {
            "start_logit": 12.2578125,
            "end_logit": -8.3203125,
            "text": "pingyangmycin lipiodol emulsion for the treatment of recurrent sacrococcygeal",
            "probability": 0.0
        },
        {
            "start_logit": 12.2578125,
            "end_logit": -8.609375,
            "text": "pingyangmycin lipiodol emulsion for the treatment of recurrent sacrococcygeal chordomas",
            "probability": 0.0
        },
        {
            "start_logit": 12.2578125,
            "end_logit": -8.6484375,
            "text": "pingyangmycin lip",
            "probability": 0.0
        },
        {
            "start_logit": 12.2578125,
            "end_logit": -8.8203125,
            "text": "pingyangmycin lipiodol emulsion for the treatment of recurrent sacrococcyg",
            "probability": 0.0
        },
        {
            "start_logit": 12.2578125,
            "end_logit": -8.8671875,
            "text": "pingyangmycin lipiodol emulsion for",
            "probability": 0.0
        },
        {
            "start_logit": -8.875,
            "end_logit": 12.25,
            "text": "gyangmycin",
            "probability": 0.0
        },
        {
            "start_logit": 12.2578125,
            "end_logit": -9.2734375,
            "text": "pingyangmycin lipiodol emulsion for the",
            "probability": 0.0
        },
        {
            "start_logit": 12.2578125,
            "end_logit": -9.375,
            "text": "pingyangmycin lipiodol emulsion for the treatment of recurrent sacrococc",
            "probability": 0.0
        },
        {
            "start_logit": 12.2578125,
            "end_logit": -9.4765625,
            "text": "pingyangmycin lipiodol emulsion for the treatment of recurrent",
            "probability": 0.0
        }
    ],
    "532b15ecd6d3ac6a34000014_4": [
        {
            "start_logit": 11.6640625,
            "end_logit": 11.515625,
            "text": "pingyangmycin",
            "probability": 1.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -0.90771484375,
            "text": "pingyangmycin lipiodol",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -3.435546875,
            "text": "pingyangmycin lipiodol emulsion",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -4.15234375,
            "text": "pingyangmy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -4.62109375,
            "text": "pin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.4765625,
            "end_logit": 11.515625,
            "text": "PIIT with pingyangmycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -6.2734375,
            "text": "pingyangmycin lipiod",
            "probability": 0.0
        },
        {
            "start_logit": -6.26953125,
            "end_logit": 11.515625,
            "text": "cin",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -6.6640625,
            "text": "pingy",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -6.875,
            "text": "pingyang",
            "probability": 0.0
        },
        {
            "start_logit": -7.2421875,
            "end_logit": 11.515625,
            "text": "mycin",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -7.5,
            "text": "pingyangmycin lip",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -7.68359375,
            "text": "pingyangmycin lipiodol emulsion under fluoroscopic guidance is effective and safe",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -8.3671875,
            "text": "pingyangmycin lipiodol emulsion under fluoroscopic guidance",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 11.515625,
            "text": "angmycin",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -8.515625,
            "text": "pingyangmycin lipiodol emulsion under fluoroscopic guidance is",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -8.9921875,
            "text": "pingyangmycin lipiodol emulsion under fluoroscopic guidance is effective and safe and may be considered as a treatment option",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -9.0546875,
            "text": "pingyangmycin lipiodol emulsion under fluoroscopic guidance is effective and safe and",
            "probability": 0.0
        },
        {
            "start_logit": -9.2890625,
            "end_logit": 11.515625,
            "text": "gyangmycin",
            "probability": 0.0
        },
        {
            "start_logit": -10.234375,
            "end_logit": 11.515625,
            "text": "with pingyangmycin",
            "probability": 0.0
        }
    ],
    "532b15ecd6d3ac6a34000014_5": [
        {
            "start_logit": 12.21875,
            "end_logit": 12.2109375,
            "text": "pingyangmycin",
            "probability": 1.0
        },
        {
            "start_logit": 12.21875,
            "end_logit": -4.41015625,
            "text": "pin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.21875,
            "end_logit": -4.5,
            "text": "pingyangmy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.21875,
            "end_logit": -5.18359375,
            "text": "pingyangmycin lipiodol",
            "probability": 0.0
        },
        {
            "start_logit": 12.21875,
            "end_logit": -5.38671875,
            "text": "pingyangmycin lipiodol emulsion",
            "probability": 0.0
        },
        {
            "start_logit": -6.0546875,
            "end_logit": 12.2109375,
            "text": "cin",
            "probability": 0.0
        },
        {
            "start_logit": 12.21875,
            "end_logit": -6.73046875,
            "text": "pingyang",
            "probability": 0.0
        },
        {
            "start_logit": 12.21875,
            "end_logit": -7.2421875,
            "text": "pingy",
            "probability": 0.0
        },
        {
            "start_logit": -7.5,
            "end_logit": 12.2109375,
            "text": "mycin",
            "probability": 0.0
        },
        {
            "start_logit": -7.77734375,
            "end_logit": 12.2109375,
            "text": "angmycin",
            "probability": 0.0
        },
        {
            "start_logit": 12.21875,
            "end_logit": -8.40625,
            "text": "pingyangmycin lipiod",
            "probability": 0.0
        },
        {
            "start_logit": 12.21875,
            "end_logit": -8.421875,
            "text": "pingyangmycin lipiodol emulsion for treatment of recurrent sacrococcygeal",
            "probability": 0.0
        },
        {
            "start_logit": 12.21875,
            "end_logit": -8.640625,
            "text": "pingyangmycin lip",
            "probability": 0.0
        },
        {
            "start_logit": 12.21875,
            "end_logit": -8.6875,
            "text": "pingyangmycin lipiodol emulsion for treatment of recurrent sacrococcygeal chordomas",
            "probability": 0.0
        },
        {
            "start_logit": -8.75,
            "end_logit": 12.2109375,
            "text": "gyangmycin",
            "probability": 0.0
        },
        {
            "start_logit": 12.21875,
            "end_logit": -8.890625,
            "text": "pingyangmycin lipiodol emulsion for treatment of recurrent sacrococcyg",
            "probability": 0.0
        },
        {
            "start_logit": 12.21875,
            "end_logit": -8.90625,
            "text": "pingyangmycin lipiodol emulsion for",
            "probability": 0.0
        },
        {
            "start_logit": 12.21875,
            "end_logit": -9.390625,
            "text": "pingyangmycin lipiodol emulsion for treatment of recurrent sacrococc",
            "probability": 0.0
        },
        {
            "start_logit": 12.21875,
            "end_logit": -9.5390625,
            "text": "pingyangmycin lipiodol emulsion for treatment of recurrent",
            "probability": 0.0
        },
        {
            "start_logit": 12.21875,
            "end_logit": -9.5703125,
            "text": "pingyangmycin lipiodol emulsion for treatment of",
            "probability": 0.0
        }
    ],
    "5e80caeb835f4e477700002b_1": [
        {
            "start_logit": 7.01953125,
            "end_logit": 10.78125,
            "text": "malaria",
            "probability": 0.9970703125
        },
        {
            "start_logit": 1.265625,
            "end_logit": 10.78125,
            "text": "Chloroquine (CQ) has been used for decades as the primary chemotherapeutic drug for the treatment of malaria",
            "probability": 0.003173828125
        },
        {
            "start_logit": -8.890625,
            "end_logit": 10.78125,
            "text": "CQ) has been used for decades as the primary chemotherapeutic drug for the treatment of malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.296875,
            "end_logit": 10.78125,
            "text": "of malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.578125,
            "end_logit": 10.78125,
            "text": "chemotherapeutic drug for the treatment of malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.03125,
            "end_logit": 10.78125,
            "text": "treatment of malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.265625,
            "end_logit": -1.5126953125,
            "text": "Chloroquine",
            "probability": 0.0
        },
        {
            "start_logit": 1.265625,
            "end_logit": -6.3984375,
            "text": "Chloroquine (CQ",
            "probability": 0.0
        },
        {
            "start_logit": 1.265625,
            "end_logit": -7.62890625,
            "text": "Chloroquine (CQ) has been used for decades as the primary chemotherapeutic drug",
            "probability": 0.0
        },
        {
            "start_logit": 1.265625,
            "end_logit": -8.09375,
            "text": "Chloroquine (CQ) has been used for decades as the",
            "probability": 0.0
        },
        {
            "start_logit": 1.265625,
            "end_logit": -8.1015625,
            "text": "Chloroquine (CQ) has been used for decades as the primary chemotherapeutic drug for the treatment of",
            "probability": 0.0
        },
        {
            "start_logit": 1.265625,
            "end_logit": -8.21875,
            "text": "Chloroquine (CQ) has been used for decades as the primary chemotherapeutic drug for the",
            "probability": 0.0
        },
        {
            "start_logit": 1.265625,
            "end_logit": -8.3515625,
            "text": "Chloroquine (CQ)",
            "probability": 0.0
        },
        {
            "start_logit": 1.265625,
            "end_logit": -8.90625,
            "text": "Chloroquine (CQ) has been used for decades as the primary chemotherapeutic drug for",
            "probability": 0.0
        },
        {
            "start_logit": 1.265625,
            "end_logit": -9.03125,
            "text": "Chloroquine (CQ) has been used for decades as the primary chemotherapeutic drug for the treatment",
            "probability": 0.0
        },
        {
            "start_logit": 1.265625,
            "end_logit": -9.0625,
            "text": "Chloroquine (CQ) has been used",
            "probability": 0.0
        },
        {
            "start_logit": 1.265625,
            "end_logit": -9.375,
            "text": "Chloroquine (CQ) has been used for decades",
            "probability": 0.0
        },
        {
            "start_logit": 1.265625,
            "end_logit": -9.484375,
            "text": "Chloroquine (CQ) has been used for decades as the primary chemotherapeutic",
            "probability": 0.0
        },
        {
            "start_logit": 1.265625,
            "end_logit": -9.7109375,
            "text": "Chloroquine (CQ) has",
            "probability": 0.0
        },
        {
            "start_logit": 1.265625,
            "end_logit": -9.8125,
            "text": "Chloroquine (CQ) has been used for decades as",
            "probability": 0.0
        }
    ],
    "5e80caeb835f4e477700002b_2": [
        {
            "start_logit": 5.33203125,
            "end_logit": 8.96875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": -8.5625,
            "end_logit": 8.96875,
            "text": "treat the most deadly form of malaria",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 8.96875,
            "text": "of malaria",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 5.33203125,
            "end_logit": -7.453125,
            "text": "malaria, caused by the parasite Plasmodium falciparum",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.33203125,
            "end_logit": -9.453125,
            "text": "malaria, caused",
            "probability": 0.0
        },
        {
            "start_logit": 5.33203125,
            "end_logit": -9.765625,
            "text": "malaria,",
            "probability": 0.0
        },
        {
            "start_logit": 5.33203125,
            "end_logit": -9.9453125,
            "text": "malaria, caused by the",
            "probability": 0.0
        },
        {
            "start_logit": 5.33203125,
            "end_logit": -10.0,
            "text": "malaria, caused by the parasite Plasmodium falciparum.",
            "probability": 0.0
        },
        {
            "start_logit": 5.33203125,
            "end_logit": -10.1796875,
            "text": "malaria, caused by the parasite",
            "probability": 0.0
        },
        {
            "start_logit": -8.5625,
            "end_logit": -7.453125,
            "text": "treat the most deadly form of malaria, caused by the parasite Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -9.21875,
            "end_logit": -7.453125,
            "text": "Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -8.5625,
            "end_logit": -8.2265625,
            "text": "treat the",
            "probability": 0.0
        },
        {
            "start_logit": -8.5625,
            "end_logit": -8.7265625,
            "text": "treat the most deadly form",
            "probability": 0.0
        },
        {
            "start_logit": -8.5625,
            "end_logit": -8.875,
            "text": "treat the most deadly form of",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": -7.453125,
            "text": "of malaria, caused by the parasite Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -8.5625,
            "end_logit": -9.453125,
            "text": "treat the most deadly form of malaria, caused",
            "probability": 0.0
        },
        {
            "start_logit": -8.5625,
            "end_logit": -9.765625,
            "text": "treat the most deadly form of malaria,",
            "probability": 0.0
        },
        {
            "start_logit": -8.5625,
            "end_logit": -9.9453125,
            "text": "treat the most deadly form of malaria, caused by the",
            "probability": 0.0
        },
        {
            "start_logit": -8.5625,
            "end_logit": -10.0,
            "text": "treat the most deadly form of malaria, caused by the parasite Plasmodium falciparum.",
            "probability": 0.0
        },
        {
            "start_logit": -8.5625,
            "end_logit": -10.1796875,
            "text": "treat the most deadly form of malaria, caused by the parasite",
            "probability": 0.0
        }
    ],
    "5e80caeb835f4e477700002b_3": [
        {
            "start_logit": 3.71875,
            "end_logit": 2.984375,
            "text": "systemic lupus erythematosus (SLE",
            "probability": 0.994140625
        },
        {
            "start_logit": -2.234375,
            "end_logit": 2.984375,
            "text": "SLE",
            "probability": 0.002582550048828125
        },
        {
            "start_logit": 3.71875,
            "end_logit": -3.22265625,
            "text": "systemic lupus",
            "probability": 0.0020046234130859375
        },
        {
            "start_logit": 3.71875,
            "end_logit": -4.37890625,
            "text": "systemic lupus erythematosus (SLE)",
            "probability": 0.0006303787231445312
        },
        {
            "start_logit": 3.71875,
            "end_logit": -6.27734375,
            "text": "systemic lupus erythematosus (SLE). It is also licensed for rheumatoid arthritis",
            "probability": 9.40561294555664e-05
        },
        {
            "start_logit": 3.71875,
            "end_logit": -7.1484375,
            "text": "systemic lupus erythematosus",
            "probability": 3.9517879486083984e-05
        },
        {
            "start_logit": 3.71875,
            "end_logit": -7.2265625,
            "text": "systemic lupus erythematosus (",
            "probability": 3.653764724731445e-05
        },
        {
            "start_logit": -6.65625,
            "end_logit": 2.984375,
            "text": "lupus erythematosus (SLE",
            "probability": 3.0994415283203125e-05
        },
        {
            "start_logit": 3.71875,
            "end_logit": -8.3671875,
            "text": "systemic lupus erythematosus (SLE). It is also licensed for rheumatoid arthritis (RA",
            "probability": 1.1682510375976562e-05
        },
        {
            "start_logit": 3.71875,
            "end_logit": -8.671875,
            "text": "systemic lupus erythematosus (SLE). It is also licensed for",
            "probability": 8.58306884765625e-06
        },
        {
            "start_logit": -2.234375,
            "end_logit": -4.37890625,
            "text": "SLE)",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": -9.6015625,
            "end_logit": 2.984375,
            "text": "HCQ), a 4-aminoquinolone antimalarial, is regarded as the oral therapy of choice for cutaneous and systemic lupus erythematosus (SLE",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": -10.0234375,
            "end_logit": 2.984375,
            "text": "oral therapy of choice for cutaneous and systemic lupus erythematosus (SLE",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -10.203125,
            "end_logit": 2.984375,
            "text": "and systemic lupus erythematosus (SLE",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 2.984375,
            "text": "for cutaneous and systemic lupus erythematosus (SLE",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -4.5078125,
            "end_logit": -3.22265625,
            "text": "Hydroxychloroquine (HCQ), a 4-aminoquinolone antimalarial, is regarded as the oral therapy of choice for cutaneous and systemic lupus",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -2.234375,
            "end_logit": -6.27734375,
            "text": "SLE). It is also licensed for rheumatoid arthritis",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.65625,
            "end_logit": -3.22265625,
            "text": "lupus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.234375,
            "end_logit": -8.3671875,
            "text": "SLE). It is also licensed for rheumatoid arthritis (RA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.5078125,
            "end_logit": -6.25,
            "text": "Hydroxychloroquine",
            "probability": 0.0
        }
    ],
    "5e80caeb835f4e477700002b_4": [
        {
            "start_logit": 2.75390625,
            "end_logit": -0.493408203125,
            "text": "SARS",
            "probability": 0.59033203125
        },
        {
            "start_logit": 1.6962890625,
            "end_logit": -0.493408203125,
            "text": "Chloroquine is a potent inhibitor of SARS",
            "probability": 0.2052001953125
        },
        {
            "start_logit": 1.6962890625,
            "end_logit": -0.5498046875,
            "text": "Chloroquine",
            "probability": 0.19384765625
        },
        {
            "start_logit": 2.75390625,
            "end_logit": -5.953125,
            "text": "SARS coronavirus",
            "probability": 0.0025081634521484375
        },
        {
            "start_logit": 2.75390625,
            "end_logit": -5.99609375,
            "text": "SARS coronavirus infection",
            "probability": 0.002410888671875
        },
        {
            "start_logit": 2.75390625,
            "end_logit": -6.484375,
            "text": "SARS coronavirus infection and",
            "probability": 0.0014743804931640625
        },
        {
            "start_logit": 2.75390625,
            "end_logit": -6.6015625,
            "text": "SARS coronavirus infection and spread",
            "probability": 0.0013113021850585938
        },
        {
            "start_logit": 1.6962890625,
            "end_logit": -5.953125,
            "text": "Chloroquine is a potent inhibitor of SARS coronavirus",
            "probability": 0.000873565673828125
        },
        {
            "start_logit": 1.6962890625,
            "end_logit": -5.99609375,
            "text": "Chloroquine is a potent inhibitor of SARS coronavirus infection",
            "probability": 0.0008335113525390625
        },
        {
            "start_logit": 1.6962890625,
            "end_logit": -6.484375,
            "text": "Chloroquine is a potent inhibitor of SARS coronavirus infection and",
            "probability": 0.0005135536193847656
        },
        {
            "start_logit": 1.6962890625,
            "end_logit": -6.6015625,
            "text": "Chloroquine is a potent inhibitor of SARS coronavirus infection and spread",
            "probability": 0.00045680999755859375
        },
        {
            "start_logit": 1.6962890625,
            "end_logit": -7.0859375,
            "text": "Chloroquine is a",
            "probability": 0.00028133392333984375
        },
        {
            "start_logit": 1.6962890625,
            "end_logit": -8.015625,
            "text": "Chloroquine is",
            "probability": 0.00011110305786132812
        },
        {
            "start_logit": 2.75390625,
            "end_logit": -9.0859375,
            "text": "SARS coronavirus infection and spread.",
            "probability": 0.0001093149185180664
        },
        {
            "start_logit": 1.6962890625,
            "end_logit": -8.7890625,
            "text": "Chloroquine is a potent inhibitor of",
            "probability": 5.125999450683594e-05
        },
        {
            "start_logit": 1.6962890625,
            "end_logit": -9.0859375,
            "text": "Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.",
            "probability": 3.808736801147461e-05
        },
        {
            "start_logit": 1.6962890625,
            "end_logit": -9.28125,
            "text": "Chloroquine is a potent",
            "probability": 3.129243850708008e-05
        },
        {
            "start_logit": 1.6962890625,
            "end_logit": -9.96875,
            "text": "Chloroquine is a potent inhibitor",
            "probability": 1.5735626220703125e-05
        },
        {
            "start_logit": -9.875,
            "end_logit": -0.493408203125,
            "text": "inhibitor of SARS",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -9.875,
            "end_logit": -5.953125,
            "text": "inhibitor of SARS coronavirus",
            "probability": 0.0
        }
    ],
    "5a86c938faa1ab7d2e000034_1": [
        {
            "start_logit": 10.859375,
            "end_logit": 6.71875,
            "text": "SCFTIR1-IAA6",
            "probability": 1.0
        },
        {
            "start_logit": 10.859375,
            "end_logit": -4.12890625,
            "text": "SCFTIR1-IAA",
            "probability": 1.9550323486328125e-05
        },
        {
            "start_logit": 10.859375,
            "end_logit": -4.390625,
            "text": "SCFTIR1-IAA6 and SCFTIR1-IAA19",
            "probability": 1.4960765838623047e-05
        },
        {
            "start_logit": 10.859375,
            "end_logit": -4.59375,
            "text": "SCFTIR1-IAA6 and SCFTIR1-IAA19 co-receptor complexes, and assess IAA",
            "probability": 1.2218952178955078e-05
        },
        {
            "start_logit": 10.859375,
            "end_logit": -5.5546875,
            "text": "SCFTIR1-IAA6 and SCFTIR1-IAA19 co-receptor complexes, and assess IAA6",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": 10.859375,
            "end_logit": -6.1640625,
            "text": "SCFTIR1",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": 10.859375,
            "end_logit": -6.30859375,
            "text": "SCFTIR1-IAA6 and SCFTIR1-IAA19 co-receptor complexes, and assess IAA6/IAA19",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": 10.859375,
            "end_logit": -6.35546875,
            "text": "SCF",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 10.859375,
            "end_logit": -6.51953125,
            "text": "SCFTIR1-IAA6 and SCFTIR1-IAA19 co-receptor",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 10.859375,
            "end_logit": -6.8984375,
            "text": "SCFTIR1-",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 10.859375,
            "end_logit": -7.1875,
            "text": "SCFTIR1-IAA6 and SCFTIR1-IAA19 co-receptor complexes",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 10.859375,
            "end_logit": -7.296875,
            "text": "SCFTIR",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 10.859375,
            "end_logit": -7.59765625,
            "text": "SCFTIR1-IAA6 and SCFTIR1-IAA19 co-receptor complexes, and assess IAA6/IAA",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 10.859375,
            "end_logit": -7.69921875,
            "text": "SCFTIR1-IAA6 and SCF",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 10.859375,
            "end_logit": -8.15625,
            "text": "SCFTIR1-IAA6 and SCFTIR1",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 10.859375,
            "end_logit": -8.390625,
            "text": "SCFTIR1-IAA6 and SCFTIR1-IAA19 co-receptor complexes, and assess IAA6/IAA19 ubiquit",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 10.859375,
            "end_logit": -8.5234375,
            "text": "SCFTIR1-IAA6 and SCFTIR",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 6.71875,
            "text": "1-IAA6",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 6.71875,
            "text": "IAA6",
            "probability": 0.0
        },
        {
            "start_logit": -8.6953125,
            "end_logit": 6.71875,
            "text": "TIR1-IAA6",
            "probability": 0.0
        }
    ],
    "5a86c938faa1ab7d2e000034_2": [
        {
            "start_logit": 5.328125,
            "end_logit": 7.96875,
            "text": "SHY2/IAA3",
            "probability": 0.96337890625
        },
        {
            "start_logit": 5.328125,
            "end_logit": 4.24609375,
            "text": "SHY2",
            "probability": 0.02337646484375
        },
        {
            "start_logit": 5.328125,
            "end_logit": 3.6328125,
            "text": "SHY2/IAA3 and BDL",
            "probability": 0.01261138916015625
        },
        {
            "start_logit": 5.328125,
            "end_logit": 0.53271484375,
            "text": "SHY2/IAA3 and BDL/IAA12",
            "probability": 0.0005674362182617188
        },
        {
            "start_logit": -0.33837890625,
            "end_logit": 3.6328125,
            "text": "BDL",
            "probability": 4.374980926513672e-05
        },
        {
            "start_logit": -5.67578125,
            "end_logit": 7.96875,
            "text": "3",
            "probability": 1.609325408935547e-05
        },
        {
            "start_logit": 5.328125,
            "end_logit": -3.296875,
            "text": "SHY2/IAA",
            "probability": 1.233816146850586e-05
        },
        {
            "start_logit": 5.328125,
            "end_logit": -3.900390625,
            "text": "SHY2/IAA3 and BDL/IAA",
            "probability": 6.794929504394531e-06
        },
        {
            "start_logit": 5.328125,
            "end_logit": -4.6484375,
            "text": "SHY",
            "probability": 3.2186508178710938e-06
        },
        {
            "start_logit": -0.33837890625,
            "end_logit": 0.53271484375,
            "text": "BDL/IAA12",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": 5.328125,
            "end_logit": -6.0390625,
            "text": "SHY2/IAA3 and BD",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 5.328125,
            "end_logit": -6.60546875,
            "text": "SHY2/IAA3 and",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -9.7734375,
            "end_logit": 7.96875,
            "text": "2/IAA3",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -9.96875,
            "end_logit": 7.96875,
            "text": "IAA3",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.67578125,
            "end_logit": 3.6328125,
            "text": "3 and BDL",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -10.140625,
            "end_logit": 7.96875,
            "text": "SCF(TIR1)-mediated ubiquitination of the Aux/IAA proteins SHY2/IAA3",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 5.328125,
            "end_logit": -7.7890625,
            "text": "SHY2/",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.578125,
            "end_logit": 7.96875,
            "text": "/IAA3",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.328125,
            "end_logit": -7.94921875,
            "text": "SHY2/IAA3 and BDL/",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.625,
            "end_logit": 7.96875,
            "text": "Aux/IAA proteins SHY2/IAA3",
            "probability": 1.1920928955078125e-07
        }
    ],
    "5a86c938faa1ab7d2e000034_3": [
        {
            "start_logit": 12.6640625,
            "end_logit": 13.0234375,
            "text": "IAA9",
            "probability": 1.0
        },
        {
            "start_logit": -5.4375,
            "end_logit": 13.0234375,
            "text": "9",
            "probability": 0.0
        },
        {
            "start_logit": 12.6640625,
            "end_logit": -5.30078125,
            "text": "IAA",
            "probability": 0.0
        },
        {
            "start_logit": 12.6640625,
            "end_logit": -5.78515625,
            "text": "IAA9 is involved in fruit development and leaf morphogenesis",
            "probability": 0.0
        },
        {
            "start_logit": 12.6640625,
            "end_logit": -7.625,
            "text": "IAA9 is involved in fruit development",
            "probability": 0.0
        },
        {
            "start_logit": 12.6640625,
            "end_logit": -7.76953125,
            "text": "IAA9 is involved in fruit development and leaf",
            "probability": 0.0
        },
        {
            "start_logit": 12.6640625,
            "end_logit": -8.453125,
            "text": "IAA9 is involved",
            "probability": 0.0
        },
        {
            "start_logit": 12.6640625,
            "end_logit": -8.5234375,
            "text": "IAA9 is",
            "probability": 0.0
        },
        {
            "start_logit": 12.6640625,
            "end_logit": -8.7734375,
            "text": "IAA9 is involved in fruit",
            "probability": 0.0
        },
        {
            "start_logit": -9.2421875,
            "end_logit": 13.0234375,
            "text": "tomato Aux/IAA transcription factor IAA9",
            "probability": 0.0
        },
        {
            "start_logit": 12.6640625,
            "end_logit": -8.9375,
            "text": "IAA9 is involved in",
            "probability": 0.0
        },
        {
            "start_logit": 12.6640625,
            "end_logit": -9.0859375,
            "text": "IAA9 is involved in fruit development and",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 13.0234375,
            "text": "Aux/IAA transcription factor IAA9",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 13.0234375,
            "text": "transcription factor IAA9",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 13.0234375,
            "text": "/IAA transcription factor IAA9",
            "probability": 0.0
        },
        {
            "start_logit": -11.03125,
            "end_logit": 13.0234375,
            "text": "IAA transcription factor IAA9",
            "probability": 0.0
        },
        {
            "start_logit": -5.4375,
            "end_logit": -5.78515625,
            "text": "9 is involved in fruit development and leaf morphogenesis",
            "probability": 0.0
        },
        {
            "start_logit": -5.4375,
            "end_logit": -7.625,
            "text": "9 is involved in fruit development",
            "probability": 0.0
        },
        {
            "start_logit": -5.4375,
            "end_logit": -7.76953125,
            "text": "9 is involved in fruit development and leaf",
            "probability": 0.0
        },
        {
            "start_logit": -5.4375,
            "end_logit": -8.453125,
            "text": "9 is involved",
            "probability": 0.0
        }
    ],
    "5a86c938faa1ab7d2e000034_4": [
        {
            "start_logit": 12.0390625,
            "end_logit": 11.890625,
            "text": "IAA9",
            "probability": 1.0
        },
        {
            "start_logit": 12.0390625,
            "end_logit": -5.3203125,
            "text": "IAA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.2890625,
            "end_logit": 11.890625,
            "text": "9",
            "probability": 0.0
        },
        {
            "start_logit": 12.0390625,
            "end_logit": -8.234375,
            "text": "IAA9, a tomato (Solanum lycopersicum) gene",
            "probability": 0.0
        },
        {
            "start_logit": 12.0390625,
            "end_logit": -8.3671875,
            "text": "IAA9, a tomato (Solanum lycopersicum)",
            "probability": 0.0
        },
        {
            "start_logit": 12.0390625,
            "end_logit": -8.5234375,
            "text": "IAA9, a tomato (Solanum lycopersicum) gene from a distinct",
            "probability": 0.0
        },
        {
            "start_logit": 12.0390625,
            "end_logit": -8.6796875,
            "text": "IAA9, a tomato (Solanum lycopersicum) gene from a distinct subfamily of Aux/IAA genes,",
            "probability": 0.0
        },
        {
            "start_logit": 12.0390625,
            "end_logit": -8.828125,
            "text": "IAA9, a tomato (Solanum lycopersicum) gene from",
            "probability": 0.0
        },
        {
            "start_logit": 12.0390625,
            "end_logit": -8.8828125,
            "text": "IAA9, a tomato (Solanum lycopersicum",
            "probability": 0.0
        },
        {
            "start_logit": 12.0390625,
            "end_logit": -8.984375,
            "text": "IAA9, a",
            "probability": 0.0
        },
        {
            "start_logit": 12.0390625,
            "end_logit": -9.0078125,
            "text": "IAA9,",
            "probability": 0.0
        },
        {
            "start_logit": 12.0390625,
            "end_logit": -9.0078125,
            "text": "IAA9, a tomato (Solanum lycopersicum) gene from a",
            "probability": 0.0
        },
        {
            "start_logit": 12.0390625,
            "end_logit": -9.234375,
            "text": "IAA9, a tomato (Solanum lycop",
            "probability": 0.0
        },
        {
            "start_logit": 12.0390625,
            "end_logit": -9.3125,
            "text": "IAA9, a tomato (Solanum lycopersicum) gene from a distinct subfamily of Aux/IAA genes",
            "probability": 0.0
        },
        {
            "start_logit": 12.0390625,
            "end_logit": -9.3515625,
            "text": "IAA9, a tomato (Solanum lycopersicum) gene from a distinct subfamily",
            "probability": 0.0
        },
        {
            "start_logit": 12.0390625,
            "end_logit": -9.375,
            "text": "IAA9, a tomato (Solanum lycopersicum) gene from a distinct subfamily of Aux/IAA genes, results",
            "probability": 0.0
        },
        {
            "start_logit": 12.0390625,
            "end_logit": -9.390625,
            "text": "IAA9, a tomato (Solanum lycopersicum) gene from a distinct subfamily of Aux/IAA genes, results in a pleiotropic phenotype",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 11.890625,
            "text": "downregulation of IAA9",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -8.234375,
            "text": "9, a tomato (Solanum lycopersicum) gene",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -8.3671875,
            "text": "9, a tomato (Solanum lycopersicum)",
            "probability": 0.0
        }
    ],
    "5a86c938faa1ab7d2e000034_5": [
        {
            "start_logit": 11.609375,
            "end_logit": 10.671875,
            "text": "IAA9",
            "probability": 1.0
        },
        {
            "start_logit": 11.609375,
            "end_logit": 2.05078125,
            "text": "IAA9 downregulated lines were hypersensitive to auxin, although the only early auxin-responsive gene that was found to be upregulated in the antisense lines was IAA3",
            "probability": 0.00017952919006347656
        },
        {
            "start_logit": 11.609375,
            "end_logit": -5.6796875,
            "text": "IAA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.609375,
            "end_logit": -6.84375,
            "text": "IAA9 downregulated lines were hypersensitive to auxin, although the only early auxin-responsive gene that was found to be upregulated in the antisense lines was IAA",
            "probability": 0.0
        },
        {
            "start_logit": 11.609375,
            "end_logit": -7.94140625,
            "text": "IAA9 downregulated lines were hypersensitive to auxin, although the only early auxin-responsive gene",
            "probability": 0.0
        },
        {
            "start_logit": -7.21484375,
            "end_logit": 10.671875,
            "text": "9",
            "probability": 0.0
        },
        {
            "start_logit": 11.609375,
            "end_logit": -8.296875,
            "text": "IAA9 downregulated lines were hypersensitive to auxin, although the only early auxin-responsive gene that was found to be upregulated in the antisense lines was",
            "probability": 0.0
        },
        {
            "start_logit": 11.609375,
            "end_logit": -8.6953125,
            "text": "IAA9 downregulated lines were hypersensitive to auxin, although the only early auxin-responsive gene that",
            "probability": 0.0
        },
        {
            "start_logit": 11.609375,
            "end_logit": -8.7421875,
            "text": "IAA9 downregulated lines were hypersensitive to auxin,",
            "probability": 0.0
        },
        {
            "start_logit": 11.609375,
            "end_logit": -8.9296875,
            "text": "IAA9 downregulated lines were hypersensitive to auxin, although the",
            "probability": 0.0
        },
        {
            "start_logit": 11.609375,
            "end_logit": -9.0078125,
            "text": "IAA9 downregulated lines were hypersensitive to auxin, although the only early auxin-",
            "probability": 0.0
        },
        {
            "start_logit": 11.609375,
            "end_logit": -9.1015625,
            "text": "IAA9 downregulated lines were hypersensitive to auxin, although the only",
            "probability": 0.0
        },
        {
            "start_logit": 11.609375,
            "end_logit": -9.2578125,
            "text": "IAA9 downregulated lines were hypersensitive to auxin",
            "probability": 0.0
        },
        {
            "start_logit": 11.609375,
            "end_logit": -9.3515625,
            "text": "IAA9 downregulated lines were hypersensitive to auxin, although the only early auxin-responsive",
            "probability": 0.0
        },
        {
            "start_logit": 11.609375,
            "end_logit": -9.4296875,
            "text": "IAA9 downregulated lines were hypersensitive to auxin, although the only early",
            "probability": 0.0
        },
        {
            "start_logit": 11.609375,
            "end_logit": -9.5234375,
            "text": "IAA9 downregulated lines were hypersensitive",
            "probability": 0.0
        },
        {
            "start_logit": 11.609375,
            "end_logit": -9.609375,
            "text": "IAA9 downregulated lines were hypersensitive to auxin, although the only early auxin-responsive gene that was found to be",
            "probability": 0.0
        },
        {
            "start_logit": 11.609375,
            "end_logit": -9.640625,
            "text": "IAA9 downregulated lines were hypersensitive to auxin, although the only early auxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 10.671875,
            "text": "dose-response assays revealed that IAA9",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 10.671875,
            "text": "that IAA9",
            "probability": 0.0
        }
    ],
    "5a86c938faa1ab7d2e000034_6": [
        {
            "start_logit": 10.5,
            "end_logit": 10.3046875,
            "text": "IAA3",
            "probability": 1.0
        },
        {
            "start_logit": 10.5,
            "end_logit": -5.32421875,
            "text": "IAA",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 10.5,
            "end_logit": -6.48828125,
            "text": "IAA3 promoter was stimulated in the IAA9",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.58203125,
            "end_logit": 10.3046875,
            "text": "3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.5,
            "end_logit": -7.390625,
            "text": "IAA3 promoter was stimulated in the IAA9 antisense genetic background, indicating that IAA9 acts in planta as a transcriptional repressor of auxin",
            "probability": 0.0
        },
        {
            "start_logit": 10.5,
            "end_logit": -8.796875,
            "text": "IAA3 promoter was stimulated in the IAA9 antisense genetic background",
            "probability": 0.0
        },
        {
            "start_logit": 10.5,
            "end_logit": -9.046875,
            "text": "IAA3 promoter was stimulated in the IAA9 antisense genetic background, indicating that IAA9",
            "probability": 0.0
        },
        {
            "start_logit": 10.5,
            "end_logit": -9.09375,
            "text": "IAA3 promoter was stimulated in the IAA9 antisense",
            "probability": 0.0
        },
        {
            "start_logit": 10.5,
            "end_logit": -9.1328125,
            "text": "IAA3 promoter",
            "probability": 0.0
        },
        {
            "start_logit": 10.5,
            "end_logit": -9.1640625,
            "text": "IAA3 promoter was stimulated in the IAA9 antisense genetic background, indicating that IAA9 acts in planta as a transcriptional repressor of auxin signaling",
            "probability": 0.0
        },
        {
            "start_logit": 10.5,
            "end_logit": -9.4453125,
            "text": "IAA3 promoter was stimulated in the IAA9 antisense genetic",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": 10.3046875,
            "text": "activity of the IAA3",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 10.3046875,
            "text": "of the IAA3",
            "probability": 0.0
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 0.3271484375,
            "text": "subfamily IV",
            "probability": 0.0
        },
        {
            "start_logit": -9.078125,
            "end_logit": 0.3271484375,
            "text": "IV",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 0.3271484375,
            "text": "that IAA9 acts in planta as a transcriptional repressor of auxin signaling. While no mutation in any member of subfamily IV",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 0.3271484375,
            "text": "auxin signaling. While no mutation in any member of subfamily IV",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 0.3271484375,
            "text": "IAA9 acts in planta as a transcriptional repressor of auxin signaling. While no mutation in any member of subfamily IV",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 0.3271484375,
            "text": "transcriptional repressor of auxin signaling. While no mutation in any member of subfamily IV",
            "probability": 0.0
        },
        {
            "start_logit": -6.58203125,
            "end_logit": -6.48828125,
            "text": "3 promoter was stimulated in the IAA9",
            "probability": 0.0
        }
    ],
    "5a86c938faa1ab7d2e000034_7": [
        {
            "start_logit": -4.796875,
            "end_logit": -6.17578125,
            "text": "1 also exhibit wild type phenotypes global gene expression analysis reveals that the molecular phenotypes of auxin treated and untreated light grown seedlings are unaffected in the iaa17",
            "probability": 0.179931640625
        },
        {
            "start_logit": -6.5625,
            "end_logit": -4.5234375,
            "text": "or iaa5 1 iaa6 1 iaa19",
            "probability": 0.1600341796875
        },
        {
            "start_logit": -7.20703125,
            "end_logit": -4.5234375,
            "text": "1 iaa19",
            "probability": 0.08367919921875
        },
        {
            "start_logit": -7.296875,
            "end_logit": -4.5,
            "text": "with the gain of function axr3",
            "probability": 0.07855224609375
        },
        {
            "start_logit": -5.3359375,
            "end_logit": -6.86328125,
            "text": "that enhanced stability of the axr3 iaa17",
            "probability": 0.0523681640625
        },
        {
            "start_logit": -7.69921875,
            "end_logit": -4.5234375,
            "text": "1 or iaa5 1 iaa6 1 iaa19",
            "probability": 0.05157470703125
        },
        {
            "start_logit": -5.96484375,
            "end_logit": -6.44140625,
            "text": "arabidopsis response regulator genes",
            "probability": 0.042724609375
        },
        {
            "start_logit": -7.9609375,
            "end_logit": -4.5,
            "text": "contrast similar analysis with the gain of function axr3",
            "probability": 0.04046630859375
        },
        {
            "start_logit": -5.96484375,
            "end_logit": -6.578125,
            "text": "arabidopsis response regulator genes and a number of genes involved in cell wall biosynthesis and degradation",
            "probability": 0.037139892578125
        },
        {
            "start_logit": -5.96484375,
            "end_logit": -6.60546875,
            "text": "arabidopsis response regulator genes and a",
            "probability": 0.0362548828125
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -4.5234375,
            "text": "1 iaa6 1 iaa19",
            "probability": 0.03277587890625
        },
        {
            "start_logit": -5.96484375,
            "end_logit": -6.8515625,
            "text": "arabidopsis response regulator genes and a number of",
            "probability": 0.0284576416015625
        },
        {
            "start_logit": -8.328125,
            "end_logit": -4.5,
            "text": "1 mutants by contrast similar analysis with the gain of function axr3",
            "probability": 0.02801513671875
        },
        {
            "start_logit": -5.96484375,
            "end_logit": -7.03515625,
            "text": "arabidopsis response regulator genes and a number of genes involved in cell wall biosynthesis and degradation is",
            "probability": 0.0236053466796875
        },
        {
            "start_logit": -5.96484375,
            "end_logit": -7.05078125,
            "text": "arabidopsis",
            "probability": 0.0232391357421875
        },
        {
            "start_logit": -5.96484375,
            "end_logit": -7.08984375,
            "text": "arabidopsis response regulator genes and a number of genes involved in cell wall",
            "probability": 0.0223388671875
        },
        {
            "start_logit": -5.96484375,
            "end_logit": -7.09765625,
            "text": "arabidopsis response regulator",
            "probability": 0.0221710205078125
        },
        {
            "start_logit": -8.6015625,
            "end_logit": -4.5,
            "text": "axr3",
            "probability": 0.0213165283203125
        },
        {
            "start_logit": -6.80859375,
            "end_logit": -6.44140625,
            "text": "type a arabidopsis response regulator genes",
            "probability": 0.0183868408203125
        },
        {
            "start_logit": -5.96484375,
            "end_logit": -7.359375,
            "text": "arabidopsis response regulator genes and a number of genes involved in cell wall biosynthesis and degradation is repressed in axr3 1 iaa17 1 the data suggest",
            "probability": 0.016998291015625
        }
    ],
    "5a86c938faa1ab7d2e000034_8": [
        {
            "start_logit": 11.7109375,
            "end_logit": 10.5546875,
            "text": "tashy2",
            "probability": 1.0
        },
        {
            "start_logit": 11.7109375,
            "end_logit": 1.1826171875,
            "text": "tashy2 and taiaa7",
            "probability": 8.481740951538086e-05
        },
        {
            "start_logit": 11.7109375,
            "end_logit": -4.5859375,
            "text": "tashy",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 11.7109375,
            "end_logit": -4.7265625,
            "text": "tashy2 and tai",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 11.7109375,
            "end_logit": -5.21484375,
            "text": "tashy2 and taiaa7 which are from the auxin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.7109375,
            "end_logit": -5.31640625,
            "text": "tas",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.7109375,
            "end_logit": -5.71875,
            "text": "tashy2 and taiaa",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.3203125,
            "end_logit": 10.5546875,
            "text": "2",
            "probability": 0.0
        },
        {
            "start_logit": 11.7109375,
            "end_logit": -7.64453125,
            "text": "tashy2 and",
            "probability": 0.0
        },
        {
            "start_logit": 11.7109375,
            "end_logit": -7.7109375,
            "text": "tashy2 and taiaa7 which are",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 10.5546875,
            "text": "expression of tashy2",
            "probability": 0.0
        },
        {
            "start_logit": -1.119140625,
            "end_logit": 1.1826171875,
            "text": "taiaa7",
            "probability": 0.0
        },
        {
            "start_logit": -6.3203125,
            "end_logit": 1.1826171875,
            "text": "2 and taiaa7",
            "probability": 0.0
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 1.1826171875,
            "text": "7",
            "probability": 0.0
        },
        {
            "start_logit": -1.119140625,
            "end_logit": -4.7265625,
            "text": "tai",
            "probability": 0.0
        },
        {
            "start_logit": -1.119140625,
            "end_logit": -5.21484375,
            "text": "taiaa7 which are from the auxin",
            "probability": 0.0
        },
        {
            "start_logit": -1.119140625,
            "end_logit": -5.71875,
            "text": "taiaa",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 1.1826171875,
            "text": "expression of tashy2 and taiaa7",
            "probability": 0.0
        },
        {
            "start_logit": -1.119140625,
            "end_logit": -7.7109375,
            "text": "taiaa7 which are",
            "probability": 0.0
        },
        {
            "start_logit": -7.65234375,
            "end_logit": -3.15234375,
            "text": "osrsp3",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_1": [
        {
            "start_logit": 12.5859375,
            "end_logit": 12.5234375,
            "text": "LigandScout",
            "probability": 1.0
        },
        {
            "start_logit": 12.5859375,
            "end_logit": -5.3515625,
            "text": "LigandS",
            "probability": 0.0
        },
        {
            "start_logit": -5.65234375,
            "end_logit": 12.5234375,
            "text": "ut",
            "probability": 0.0
        },
        {
            "start_logit": 12.5859375,
            "end_logit": -6.72265625,
            "text": "LigandSco",
            "probability": 0.0
        },
        {
            "start_logit": 12.5859375,
            "end_logit": -7.140625,
            "text": "LigandScout program",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": 12.5234375,
            "text": "cout",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 12.5234375,
            "text": "thermolysin binding modes and activity profiles were generated using the LigandScout",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 12.5234375,
            "text": "lysin binding modes and activity profiles were generated using the LigandScout",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 12.5234375,
            "text": "Pharmacophore models based on thermolysin binding modes and activity profiles were generated using the LigandScout",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 12.5234375,
            "text": "activity profiles were generated using the LigandScout",
            "probability": 0.0
        },
        {
            "start_logit": -11.0859375,
            "end_logit": 12.5234375,
            "text": "profiles were generated using the LigandScout",
            "probability": 0.0
        },
        {
            "start_logit": -5.65234375,
            "end_logit": -7.140625,
            "text": "ut program",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": -5.3515625,
            "text": "thermolysin binding modes and activity profiles were generated using the LigandS",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": -5.3515625,
            "text": "lysin binding modes and activity profiles were generated using the LigandS",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": -5.3515625,
            "text": "Pharmacophore models based on thermolysin binding modes and activity profiles were generated using the LigandS",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": -5.3515625,
            "text": "activity profiles were generated using the LigandS",
            "probability": 0.0
        },
        {
            "start_logit": -11.0859375,
            "end_logit": -5.3515625,
            "text": "profiles were generated using the LigandS",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": -6.72265625,
            "text": "co",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": -6.72265625,
            "text": "thermolysin binding modes and activity profiles were generated using the LigandSco",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": -7.140625,
            "text": "cout program",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_2": [
        {
            "start_logit": 13.28125,
            "end_logit": 13.390625,
            "text": "Discovery Studio",
            "probability": 1.0
        },
        {
            "start_logit": 13.28125,
            "end_logit": -4.44140625,
            "text": "Discovery",
            "probability": 0.0
        },
        {
            "start_logit": -4.80078125,
            "end_logit": 13.390625,
            "text": "io",
            "probability": 0.0
        },
        {
            "start_logit": 13.28125,
            "end_logit": -6.7890625,
            "text": "Discovery Studio program",
            "probability": 0.0
        },
        {
            "start_logit": 13.28125,
            "end_logit": -7.60546875,
            "text": "Discovery Stud",
            "probability": 0.0
        },
        {
            "start_logit": -8.390625,
            "end_logit": 13.390625,
            "text": "Studio",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": 13.390625,
            "text": "pharmacophore generation protocol available in Discovery Studio",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 13.390625,
            "text": "common feature pharmacophore generation protocol available in Discovery Studio",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 13.390625,
            "text": "pharmacophore hypotheses based on known inhibitors were generated using common feature pharmacophore generation protocol available in Discovery Studio",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 13.390625,
            "text": "feature pharmacophore generation protocol available in Discovery Studio",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 13.390625,
            "text": "inhibitors were generated using common feature pharmacophore generation protocol available in Discovery Studio",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 13.390625,
            "text": "known inhibitors were generated using common feature pharmacophore generation protocol available in Discovery Studio",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 13.390625,
            "text": "ophore generation protocol available in Discovery Studio",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": 13.390625,
            "text": "protocol available in Discovery Studio",
            "probability": 0.0
        },
        {
            "start_logit": -4.80078125,
            "end_logit": -6.7890625,
            "text": "io program",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": -4.44140625,
            "text": "pharmacophore generation protocol available in Discovery",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": -4.44140625,
            "text": "common feature pharmacophore generation protocol available in Discovery",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": -4.44140625,
            "text": "pharmacophore hypotheses based on known inhibitors were generated using common feature pharmacophore generation protocol available in Discovery",
            "probability": 0.0
        },
        {
            "start_logit": -8.390625,
            "end_logit": -6.7890625,
            "text": "Studio program",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": -4.44140625,
            "text": "feature pharmacophore generation protocol available in Discovery",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_3": [
        {
            "start_logit": -2.875,
            "end_logit": 13.59375,
            "text": "Catalyst",
            "probability": 0.9990234375
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 13.59375,
            "text": "pharmacophore-based screening was then carried out using the program Catalyst",
            "probability": 0.000583648681640625
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 13.59375,
            "text": "program Catalyst",
            "probability": 0.0004763603210449219
        },
        {
            "start_logit": -11.015625,
            "end_logit": 13.59375,
            "text": "based screening was then carried out using the program Catalyst",
            "probability": 0.0002911090850830078
        },
        {
            "start_logit": -10.3203125,
            "end_logit": -8.140625,
            "text": "pharmacophore-based screening was then carried out using the program",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": -8.2421875,
            "text": "pharmacophore-based screening was then carried out using the",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": -8.140625,
            "text": "program",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": -8.140625,
            "text": "based screening was then carried out using the program",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": -8.2421875,
            "text": "based screening was then carried out using the",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": -9.421875,
            "text": "pharmacophore-",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": -9.5625,
            "text": "pharmacophore-based screening",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": -9.8203125,
            "text": "pharmacophore",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": -9.9140625,
            "text": "pharmacophore-based screening was",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": -9.96875,
            "text": "pharmacophore-based screening was then carried out using",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": -10.015625,
            "text": "pharmacophore-based screening was then",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": -10.1328125,
            "text": "pharmacophore-based screening was then carried out",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": -9.5625,
            "text": "based screening",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": -10.546875,
            "text": "pharmacophore-based screening was then carried",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": -9.9140625,
            "text": "based screening was",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": -9.96875,
            "text": "based screening was then carried out using",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_4": [
        {
            "start_logit": 14.4453125,
            "end_logit": 13.546875,
            "text": "PharmaGist",
            "probability": 1.0
        },
        {
            "start_logit": 14.4453125,
            "end_logit": -2.765625,
            "text": "Pharm",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.45703125,
            "end_logit": 13.546875,
            "text": "ist",
            "probability": 0.0
        },
        {
            "start_logit": 14.4453125,
            "end_logit": -7.6015625,
            "text": "PharmaG",
            "probability": 0.0
        },
        {
            "start_logit": 14.4453125,
            "end_logit": -8.484375,
            "text": "PharmaGist employed algorithm",
            "probability": 0.0
        },
        {
            "start_logit": 14.4453125,
            "end_logit": -8.5390625,
            "text": "PharmaGist employed algorithm to identify the best pharmacophores by computing multiple flexible",
            "probability": 0.0
        },
        {
            "start_logit": 14.4453125,
            "end_logit": -8.703125,
            "text": "PharmaGist employed algorithm to identify the best pharmacophores by computing multiple flexible alignments",
            "probability": 0.0
        },
        {
            "start_logit": -8.9765625,
            "end_logit": 13.546875,
            "text": "aGist",
            "probability": 0.0
        },
        {
            "start_logit": -4.45703125,
            "end_logit": -8.484375,
            "text": "ist employed algorithm",
            "probability": 0.0
        },
        {
            "start_logit": -4.45703125,
            "end_logit": -8.5390625,
            "text": "ist employed algorithm to identify the best pharmacophores by computing multiple flexible",
            "probability": 0.0
        },
        {
            "start_logit": -4.45703125,
            "end_logit": -8.703125,
            "text": "ist employed algorithm to identify the best pharmacophores by computing multiple flexible alignments",
            "probability": 0.0
        },
        {
            "start_logit": -8.71875,
            "end_logit": -6.609375,
            "text": "gliptin",
            "probability": 0.0
        },
        {
            "start_logit": -9.2421875,
            "end_logit": -6.609375,
            "text": "other gliptin",
            "probability": 0.0
        },
        {
            "start_logit": -8.71875,
            "end_logit": -7.2421875,
            "text": "gliptin as ligand",
            "probability": 0.0
        },
        {
            "start_logit": -9.484375,
            "end_logit": -6.609375,
            "text": "gliptin input ligands, which acts as pivot and the other gliptin",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": -6.609375,
            "text": "input ligands, which acts as pivot and the other gliptin",
            "probability": 0.0
        },
        {
            "start_logit": -9.8359375,
            "end_logit": -6.609375,
            "text": "in",
            "probability": 0.0
        },
        {
            "start_logit": -9.2421875,
            "end_logit": -7.2421875,
            "text": "other gliptin as ligand",
            "probability": 0.0
        },
        {
            "start_logit": -9.2421875,
            "end_logit": -7.2421875,
            "text": "as ligand",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": -6.609375,
            "text": "combining alignments pair-wise between one of the gliptin input ligands, which acts as pivot and the other gliptin",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_5": [
        {
            "start_logit": 10.796875,
            "end_logit": 11.9140625,
            "text": "Discovery studio",
            "probability": 0.45263671875
        },
        {
            "start_logit": 10.796875,
            "end_logit": 11.9140625,
            "text": "HypoGen algorithm implemented in Discovery studio",
            "probability": 0.45263671875
        },
        {
            "start_logit": 10.796875,
            "end_logit": 10.3515625,
            "text": "HypoGen",
            "probability": 0.09490966796875
        },
        {
            "start_logit": -6.234375,
            "end_logit": 11.9140625,
            "text": "io",
            "probability": 0.0
        },
        {
            "start_logit": 10.796875,
            "end_logit": -5.96875,
            "text": "Discovery",
            "probability": 0.0
        },
        {
            "start_logit": 10.796875,
            "end_logit": -5.96875,
            "text": "HypoGen algorithm implemented in Discovery",
            "probability": 0.0
        },
        {
            "start_logit": -7.26171875,
            "end_logit": 11.9140625,
            "text": "en algorithm implemented in Discovery studio",
            "probability": 0.0
        },
        {
            "start_logit": 10.796875,
            "end_logit": -6.3359375,
            "text": "HypoG",
            "probability": 0.0
        },
        {
            "start_logit": 10.796875,
            "end_logit": -7.515625,
            "text": "HypoGen algorithm",
            "probability": 0.0
        },
        {
            "start_logit": -7.26171875,
            "end_logit": 10.3515625,
            "text": "en",
            "probability": 0.0
        },
        {
            "start_logit": -9.0078125,
            "end_logit": 11.9140625,
            "text": "studio",
            "probability": 0.0
        },
        {
            "start_logit": 10.796875,
            "end_logit": -7.90234375,
            "text": "Discovery stud",
            "probability": 0.0
        },
        {
            "start_logit": 10.796875,
            "end_logit": -7.90234375,
            "text": "HypoGen algorithm implemented in Discovery stud",
            "probability": 0.0
        },
        {
            "start_logit": 10.796875,
            "end_logit": -8.09375,
            "text": "Discovery studio program package",
            "probability": 0.0
        },
        {
            "start_logit": 10.796875,
            "end_logit": -8.09375,
            "text": "HypoGen algorithm implemented in Discovery studio program package",
            "probability": 0.0
        },
        {
            "start_logit": 10.796875,
            "end_logit": -8.2421875,
            "text": "Discovery studio program",
            "probability": 0.0
        },
        {
            "start_logit": 10.796875,
            "end_logit": -8.2421875,
            "text": "HypoGen algorithm implemented in Discovery studio program",
            "probability": 0.0
        },
        {
            "start_logit": 10.796875,
            "end_logit": -8.546875,
            "text": "Discovery studio program package.",
            "probability": 0.0
        },
        {
            "start_logit": 10.796875,
            "end_logit": -8.546875,
            "text": "HypoGen algorithm implemented in Discovery studio program package.",
            "probability": 0.0
        },
        {
            "start_logit": 10.796875,
            "end_logit": -8.5859375,
            "text": "HypoGen algorithm implemented in",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_6": [
        {
            "start_logit": 10.5390625,
            "end_logit": 11.6796875,
            "text": "Catalyst",
            "probability": 1.0
        },
        {
            "start_logit": 0.11260986328125,
            "end_logit": 11.6796875,
            "text": "HypoGen module within Catalyst",
            "probability": 2.956390380859375e-05
        },
        {
            "start_logit": 10.5390625,
            "end_logit": -7.05859375,
            "text": "Catalyst program package",
            "probability": 0.0
        },
        {
            "start_logit": 10.5390625,
            "end_logit": -7.5859375,
            "text": "Catalyst program",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 11.6796875,
            "text": "en module within Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 11.6796875,
            "text": "MMP-1, MMP-8 and MMP-13 inhibitors have been developed with the aid of HypoGen module within Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 11.6796875,
            "text": "MMP-13 inhibitors have been developed with the aid of HypoGen module within Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": 11.6796875,
            "text": "within Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 11.6796875,
            "text": "MMP-8 and MMP-13 inhibitors have been developed with the aid of HypoGen module within Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 11.6796875,
            "text": "pharmacophore models of MMP-1, MMP-8 and MMP-13 inhibitors have been developed with the aid of HypoGen module within Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 11.6796875,
            "text": ", MMP-8 and MMP-13 inhibitors have been developed with the aid of HypoGen module within Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": 0.11260986328125,
            "end_logit": 0.912109375,
            "text": "HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 11.6796875,
            "text": "13 inhibitors have been developed with the aid of HypoGen module within Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": 0.11260986328125,
            "end_logit": -7.05859375,
            "text": "HypoGen module within Catalyst program package",
            "probability": 0.0
        },
        {
            "start_logit": 0.11260986328125,
            "end_logit": -7.5859375,
            "text": "HypoGen module within Catalyst program",
            "probability": 0.0
        },
        {
            "start_logit": 0.11260986328125,
            "end_logit": -7.83984375,
            "text": "HypoG",
            "probability": 0.0
        },
        {
            "start_logit": 0.11260986328125,
            "end_logit": -7.9765625,
            "text": "HypoGen module",
            "probability": 0.0
        },
        {
            "start_logit": 0.11260986328125,
            "end_logit": -9.25,
            "text": "HypoGen module within",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 0.912109375,
            "text": "en",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 0.912109375,
            "text": "MMP-1, MMP-8 and MMP-13 inhibitors have been developed with the aid of HypoGen",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_7": [
        {
            "start_logit": 12.03125,
            "end_logit": 12.3984375,
            "text": "GASP",
            "probability": 1.0
        },
        {
            "start_logit": -3.43359375,
            "end_logit": 12.3984375,
            "text": "Genetic Algorithm Similarity Program (GASP",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.1953125,
            "end_logit": 12.3984375,
            "text": "P",
            "probability": 0.0
        },
        {
            "start_logit": 12.03125,
            "end_logit": -6.00390625,
            "text": "GAS",
            "probability": 0.0
        },
        {
            "start_logit": 12.03125,
            "end_logit": -7.58203125,
            "text": "GASP) was used to derive a 3D pharmacophore model",
            "probability": 0.0
        },
        {
            "start_logit": 12.03125,
            "end_logit": -8.046875,
            "text": "GASP) was used to derive a 3D pharmacophore",
            "probability": 0.0
        },
        {
            "start_logit": 12.03125,
            "end_logit": -8.1953125,
            "text": "GASP)",
            "probability": 0.0
        },
        {
            "start_logit": 12.03125,
            "end_logit": -8.90625,
            "text": "GASP) was used to derive a 3D pharmacophore model which was used in effective alignment",
            "probability": 0.0
        },
        {
            "start_logit": 12.03125,
            "end_logit": -9.03125,
            "text": "GASP) was used to derive a 3D pharmacophore model which was used in effective alignment of data set",
            "probability": 0.0
        },
        {
            "start_logit": 12.03125,
            "end_logit": -9.171875,
            "text": "GASP) was used to derive a 3D pharmacophore model which was used in effective alignment of data set.",
            "probability": 0.0
        },
        {
            "start_logit": 12.03125,
            "end_logit": -9.2890625,
            "text": "GASP) was",
            "probability": 0.0
        },
        {
            "start_logit": 12.03125,
            "end_logit": -9.4140625,
            "text": "GASP) was used",
            "probability": 0.0
        },
        {
            "start_logit": 12.03125,
            "end_logit": -9.4609375,
            "text": "GASP) was used to derive a",
            "probability": 0.0
        },
        {
            "start_logit": 12.03125,
            "end_logit": -9.46875,
            "text": "GASP) was used to derive a 3D pharmacophore model which was used",
            "probability": 0.0
        },
        {
            "start_logit": 12.03125,
            "end_logit": -9.5234375,
            "text": "GASP) was used to",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": 12.3984375,
            "text": "Algorithm Similarity Program (GASP",
            "probability": 0.0
        },
        {
            "start_logit": 12.03125,
            "end_logit": -9.7265625,
            "text": "GASP) was used to derive a 3D pharmacophore model which",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 12.3984375,
            "text": "Program (GASP",
            "probability": 0.0
        },
        {
            "start_logit": -3.43359375,
            "end_logit": -2.134765625,
            "text": "Genetic Algorithm Similarity Program",
            "probability": 0.0
        },
        {
            "start_logit": -3.43359375,
            "end_logit": -6.00390625,
            "text": "Genetic Algorithm Similarity Program (GAS",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_8": [
        {
            "start_logit": 12.7421875,
            "end_logit": 13.1875,
            "text": "Discovery studio",
            "probability": 1.0
        },
        {
            "start_logit": -5.1484375,
            "end_logit": 13.1875,
            "text": "io",
            "probability": 0.0
        },
        {
            "start_logit": 12.7421875,
            "end_logit": -5.125,
            "text": "Discovery",
            "probability": 0.0
        },
        {
            "start_logit": 12.7421875,
            "end_logit": -7.30078125,
            "text": "Discovery stud",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 13.1875,
            "text": "3D QSAR Pharmacophore Generation module available in Discovery studio",
            "probability": 0.0
        },
        {
            "start_logit": 12.7421875,
            "end_logit": -8.3671875,
            "text": "Discovery studio.",
            "probability": 0.0
        },
        {
            "start_logit": -9.0859375,
            "end_logit": 13.1875,
            "text": "Pharmacophore Generation module available in Discovery studio",
            "probability": 0.0
        },
        {
            "start_logit": -9.328125,
            "end_logit": 13.1875,
            "text": "studio",
            "probability": 0.0
        },
        {
            "start_logit": -9.625,
            "end_logit": 13.1875,
            "text": "training set of 20 compounds with known experimental activity was used to generate pharmacophore hypotheses using 3D QSAR Pharmacophore Generation module available in Discovery studio",
            "probability": 0.0
        },
        {
            "start_logit": -10.0,
            "end_logit": 13.1875,
            "text": "QSAR Pharmacophore Generation module available in Discovery studio",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 13.1875,
            "text": "pharmacophore hypotheses using 3D QSAR Pharmacophore Generation module available in Discovery studio",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 13.1875,
            "text": "20 compounds with known experimental activity was used to generate pharmacophore hypotheses using 3D QSAR Pharmacophore Generation module available in Discovery studio",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 13.1875,
            "text": "experimental activity was used to generate pharmacophore hypotheses using 3D QSAR Pharmacophore Generation module available in Discovery studio",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 13.1875,
            "text": "module available in Discovery studio",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 13.1875,
            "text": "Generation module available in Discovery studio",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -5.125,
            "text": "3D QSAR Pharmacophore Generation module available in Discovery",
            "probability": 0.0
        },
        {
            "start_logit": -5.1484375,
            "end_logit": -8.3671875,
            "text": "io.",
            "probability": 0.0
        },
        {
            "start_logit": -9.0859375,
            "end_logit": -5.125,
            "text": "Pharmacophore Generation module available in Discovery",
            "probability": 0.0
        },
        {
            "start_logit": -9.625,
            "end_logit": -5.125,
            "text": "training set of 20 compounds with known experimental activity was used to generate pharmacophore hypotheses using 3D QSAR Pharmacophore Generation module available in Discovery",
            "probability": 0.0
        },
        {
            "start_logit": -10.0,
            "end_logit": -5.125,
            "text": "QSAR Pharmacophore Generation module available in Discovery",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_9": [
        {
            "start_logit": 11.8671875,
            "end_logit": 9.59375,
            "text": "CATALYST HypoRefine",
            "probability": 1.0
        },
        {
            "start_logit": 11.8671875,
            "end_logit": -5.73828125,
            "text": "CATALYST",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 11.8671875,
            "end_logit": -7.0234375,
            "text": "CATALYST Hypo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.8671875,
            "end_logit": -7.6015625,
            "text": "CATALYST HypoRef",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.8671875,
            "end_logit": -7.828125,
            "text": "CATALYST HypoRefine program",
            "probability": 0.0
        },
        {
            "start_logit": 11.8671875,
            "end_logit": -8.4453125,
            "text": "CATALYST HypoRefine program.",
            "probability": 0.0
        },
        {
            "start_logit": -7.59375,
            "end_logit": 9.59375,
            "text": "HypoRefine",
            "probability": 0.0
        },
        {
            "start_logit": -7.65625,
            "end_logit": 9.59375,
            "text": "ine",
            "probability": 0.0
        },
        {
            "start_logit": -8.71875,
            "end_logit": 9.59375,
            "text": "Refine",
            "probability": 0.0
        },
        {
            "start_logit": -9.3515625,
            "end_logit": 9.59375,
            "text": "CCR3 antagonists, using CATALYST HypoRefine",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 9.59375,
            "text": "training data set of 22 CCR3 antagonists, using CATALYST HypoRefine",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 9.59375,
            "text": "Pharmacophore model was developed for the first time, on a training data set of 22 CCR3 antagonists, using CATALYST HypoRefine",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 9.59375,
            "text": "22 CCR3 antagonists, using CATALYST HypoRefine",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 9.59375,
            "text": "data set of 22 CCR3 antagonists, using CATALYST HypoRefine",
            "probability": 0.0
        },
        {
            "start_logit": -7.59375,
            "end_logit": -7.0234375,
            "text": "Hypo",
            "probability": 0.0
        },
        {
            "start_logit": -9.3515625,
            "end_logit": -5.73828125,
            "text": "CCR3 antagonists, using CATALYST",
            "probability": 0.0
        },
        {
            "start_logit": -7.59375,
            "end_logit": -7.6015625,
            "text": "HypoRef",
            "probability": 0.0
        },
        {
            "start_logit": -7.59375,
            "end_logit": -7.828125,
            "text": "HypoRefine program",
            "probability": 0.0
        },
        {
            "start_logit": -7.65625,
            "end_logit": -7.828125,
            "text": "ine program",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": -5.73828125,
            "text": "training data set of 22 CCR3 antagonists, using CATALYST",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_10": [
        {
            "start_logit": 10.4921875,
            "end_logit": 12.09375,
            "text": "catalyst",
            "probability": 1.0
        },
        {
            "start_logit": -7.7421875,
            "end_logit": 12.09375,
            "text": "NS3 protease hypothesis using catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -8.9375,
            "end_logit": 12.09375,
            "text": "HCV NS3 protease hypothesis using catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -8.953125,
            "end_logit": 12.09375,
            "text": "protease hypothesis using catalyst",
            "probability": 0.0
        },
        {
            "start_logit": 10.4921875,
            "end_logit": -7.80078125,
            "text": "catalyst program",
            "probability": 0.0
        },
        {
            "start_logit": -9.5234375,
            "end_logit": 12.09375,
            "text": "hypothesis using catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -9.6875,
            "end_logit": 12.09375,
            "text": "3 protease hypothesis using catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": 12.09375,
            "text": "with HCV NS3 protease hypothesis using catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -10.03125,
            "end_logit": 12.09375,
            "text": "10a-g), with HCV NS3 protease hypothesis using catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": 12.09375,
            "text": "g), with HCV NS3 protease hypothesis using catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 12.09375,
            "text": "pharmacophore model of the designed molecules (10a-g), with HCV NS3 protease hypothesis using catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 12.09375,
            "text": "3D-pharmacophore model of the designed molecules (10a-g), with HCV NS3 protease hypothesis using catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 12.09375,
            "text": "a-g), with HCV NS3 protease hypothesis using catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": 12.09375,
            "text": "using catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 12.09375,
            "text": "designed molecules (10a-g), with HCV NS3 protease hypothesis using catalyst",
            "probability": 0.0
        },
        {
            "start_logit": 10.4921875,
            "end_logit": -9.140625,
            "text": "catalyst program was fulfilled",
            "probability": 0.0
        },
        {
            "start_logit": 10.4921875,
            "end_logit": -9.4921875,
            "text": "catalyst program was",
            "probability": 0.0
        },
        {
            "start_logit": 10.4921875,
            "end_logit": -9.734375,
            "text": "catalyst program was fulfilled.",
            "probability": 0.0
        },
        {
            "start_logit": -7.7421875,
            "end_logit": -6.48046875,
            "text": "NS3 protease hypothesis",
            "probability": 0.0
        },
        {
            "start_logit": -7.7421875,
            "end_logit": -6.8515625,
            "text": "NS3 protease",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_11": [
        {
            "start_logit": 12.7421875,
            "end_logit": 12.625,
            "text": "HypoGen",
            "probability": 1.0
        },
        {
            "start_logit": 12.7421875,
            "end_logit": -4.84375,
            "text": "HypoG",
            "probability": 0.0
        },
        {
            "start_logit": -4.76953125,
            "end_logit": 12.625,
            "text": "Catalyst/HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -5.98828125,
            "end_logit": 12.625,
            "text": "en",
            "probability": 0.0
        },
        {
            "start_logit": 12.7421875,
            "end_logit": -6.33203125,
            "text": "HypoGen program",
            "probability": 0.0
        },
        {
            "start_logit": 12.7421875,
            "end_logit": -8.7421875,
            "text": "HypoGen program.",
            "probability": 0.0
        },
        {
            "start_logit": -9.8515625,
            "end_logit": 12.625,
            "text": "CysLT(1) antagonists was developed using Catalyst/HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 12.625,
            "text": "Hypo1) with a well prediction capacity for CysLT(1) antagonists was developed using Catalyst/HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 12.625,
            "text": "LT(1) antagonists was developed using Catalyst/HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 12.625,
            "text": "/HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 12.625,
            "text": "(1) antagonists was developed using Catalyst/HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 12.625,
            "text": "1) antagonists was developed using Catalyst/HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 12.625,
            "text": "pharmacophore model (Hypo1) with a well prediction capacity for CysLT(1) antagonists was developed using Catalyst/HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -4.76953125,
            "end_logit": -0.560546875,
            "text": "Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -4.76953125,
            "end_logit": -4.84375,
            "text": "Catalyst/HypoG",
            "probability": 0.0
        },
        {
            "start_logit": -9.8515625,
            "end_logit": -0.560546875,
            "text": "CysLT(1) antagonists was developed using Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": -0.560546875,
            "text": "Hypo1) with a well prediction capacity for CysLT(1) antagonists was developed using Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": -0.560546875,
            "text": "LT(1) antagonists was developed using Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": -0.560546875,
            "text": "(1) antagonists was developed using Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -4.76953125,
            "end_logit": -6.33203125,
            "text": "Catalyst/HypoGen program",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_12": [
        {
            "start_logit": 7.76171875,
            "end_logit": 11.5,
            "text": "HypoGen",
            "probability": 1.0
        },
        {
            "start_logit": -2.66015625,
            "end_logit": 11.5,
            "text": "Catalyst/HypoGen",
            "probability": 2.9802322387695312e-05
        },
        {
            "start_logit": -7.1953125,
            "end_logit": 11.5,
            "text": "en",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.76171875,
            "end_logit": -5.4765625,
            "text": "HypoGen program",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 11.5,
            "text": "opioid agonists were generated by the Catalyst/HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 11.5,
            "text": "/HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 11.5,
            "text": "pharmacophore models of opioid agonists were generated by the Catalyst/HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 11.5,
            "text": "agonists were generated by the Catalyst/HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": 7.76171875,
            "end_logit": -7.5390625,
            "text": "HypoG",
            "probability": 0.0
        },
        {
            "start_logit": -2.66015625,
            "end_logit": 0.1826171875,
            "text": "Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -2.66015625,
            "end_logit": -5.4765625,
            "text": "Catalyst/HypoGen program",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 0.1826171875,
            "text": "opioid agonists were generated by the Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -2.66015625,
            "end_logit": -7.5390625,
            "text": "Catalyst/HypoG",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 0.1826171875,
            "text": "pharmacophore models of opioid agonists were generated by the Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 0.1826171875,
            "text": "agonists were generated by the Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -2.66015625,
            "end_logit": -8.125,
            "text": "Catalyst/",
            "probability": 0.0
        },
        {
            "start_logit": -7.1953125,
            "end_logit": -5.4765625,
            "text": "en program",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": -5.4765625,
            "text": "opioid agonists were generated by the Catalyst/HypoGen program",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": -5.4765625,
            "text": "/HypoGen program",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": -5.4765625,
            "text": "pharmacophore models of opioid agonists were generated by the Catalyst/HypoGen program",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_13": [
        {
            "start_logit": 12.9375,
            "end_logit": 13.328125,
            "text": "MOE-package",
            "probability": 1.0
        },
        {
            "start_logit": -5.234375,
            "end_logit": 13.328125,
            "text": "package",
            "probability": 0.0
        },
        {
            "start_logit": 12.9375,
            "end_logit": -4.8515625,
            "text": "MOE",
            "probability": 0.0
        },
        {
            "start_logit": 12.9375,
            "end_logit": -5.015625,
            "text": "MO",
            "probability": 0.0
        },
        {
            "start_logit": 12.9375,
            "end_logit": -7.80859375,
            "text": "MOE-",
            "probability": 0.0
        },
        {
            "start_logit": -8.953125,
            "end_logit": 13.328125,
            "text": "Pharmacophore Elucidation (MOE-package",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 13.328125,
            "text": "E-package",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 13.328125,
            "text": "with the tool Pharmacophore Elucidation (MOE-package",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 13.328125,
            "text": "superposition of the ligands was performed with the tool Pharmacophore Elucidation (MOE-package",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 13.328125,
            "text": "(MOE-package",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": 13.328125,
            "text": "-package",
            "probability": 0.0
        },
        {
            "start_logit": -8.953125,
            "end_logit": -4.8515625,
            "text": "Pharmacophore Elucidation (MOE",
            "probability": 0.0
        },
        {
            "start_logit": -8.953125,
            "end_logit": -5.015625,
            "text": "Pharmacophore Elucidation (MO",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": -4.8515625,
            "text": "E",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": -4.8515625,
            "text": "with the tool Pharmacophore Elucidation (MOE",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": -5.015625,
            "text": "with the tool Pharmacophore Elucidation (MO",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": -4.8515625,
            "text": "superposition of the ligands was performed with the tool Pharmacophore Elucidation (MOE",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": -4.8515625,
            "text": "(MOE",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": -5.015625,
            "text": "superposition of the ligands was performed with the tool Pharmacophore Elucidation (MO",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": -5.015625,
            "text": "(MO",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_14": [
        {
            "start_logit": 12.4140625,
            "end_logit": 8.1484375,
            "text": "Catalyst/HipHop",
            "probability": 0.9990234375
        },
        {
            "start_logit": 12.4140625,
            "end_logit": 0.578125,
            "text": "Catalyst",
            "probability": 0.000514984130859375
        },
        {
            "start_logit": 12.4140625,
            "end_logit": -6.4921875,
            "text": "Catalyst/HipHo",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 12.4140625,
            "end_logit": -6.91796875,
            "text": "Catalyst/Hip",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 12.4140625,
            "end_logit": -9.46875,
            "text": "Catalyst/",
            "probability": 0.0
        },
        {
            "start_logit": -8.5546875,
            "end_logit": 8.1484375,
            "text": "HipHop",
            "probability": 0.0
        },
        {
            "start_logit": -8.609375,
            "end_logit": 8.1484375,
            "text": "p",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": 8.1484375,
            "text": "/HipHop",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": 8.1484375,
            "text": "Hop",
            "probability": 0.0
        },
        {
            "start_logit": -9.9296875,
            "end_logit": 8.1484375,
            "text": "AT1 and ET(A) receptors based on highly selective AT1 and ET(A) antagonists using the program Catalyst/HipHop",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": 8.1484375,
            "text": "AT1 and ET(A) antagonists using the program Catalyst/HipHop",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 8.1484375,
            "text": "ET(A) receptors based on highly selective AT1 and ET(A) antagonists using the program Catalyst/HipHop",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 8.1484375,
            "text": "ET(A) antagonists using the program Catalyst/HipHop",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 8.1484375,
            "text": "A) antagonists using the program Catalyst/HipHop",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 8.1484375,
            "text": "A) receptors based on highly selective AT1 and ET(A) antagonists using the program Catalyst/HipHop",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 8.1484375,
            "text": "program Catalyst/HipHop",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 8.1484375,
            "text": "receptors based on highly selective AT1 and ET(A) antagonists using the program Catalyst/HipHop",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 8.1484375,
            "text": "and ET(A) antagonists using the program Catalyst/HipHop",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 8.1484375,
            "text": "and ET(A) receptors based on highly selective AT1 and ET(A) antagonists using the program Catalyst/HipHop",
            "probability": 0.0
        },
        {
            "start_logit": -9.9296875,
            "end_logit": 0.578125,
            "text": "AT1 and ET(A) receptors based on highly selective AT1 and ET(A) antagonists using the program Catalyst",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_15": [
        {
            "start_logit": 9.1953125,
            "end_logit": 11.8515625,
            "text": "Catalyst",
            "probability": 0.994140625
        },
        {
            "start_logit": 4.01953125,
            "end_logit": 11.8515625,
            "text": "HipHop and HypoGen modules within Catalyst",
            "probability": 0.00563812255859375
        },
        {
            "start_logit": 0.150634765625,
            "end_logit": 11.8515625,
            "text": "HypoGen modules within Catalyst",
            "probability": 0.00011706352233886719
        },
        {
            "start_logit": 4.01953125,
            "end_logit": 5.40234375,
            "text": "HipHop",
            "probability": 8.881092071533203e-06
        },
        {
            "start_logit": 4.01953125,
            "end_logit": 0.5546875,
            "text": "HipHop and HypoGen",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.9921875,
            "end_logit": 11.8515625,
            "text": "en modules within Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -9.5390625,
            "end_logit": 11.8515625,
            "text": "p and HypoGen modules within Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.27734375,
            "text": "Catalyst program",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 11.8515625,
            "text": "within Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 11.8515625,
            "text": "5-LOX have been developed with the aid of HipHop and HypoGen modules within Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 11.8515625,
            "text": "modules within Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -8.140625,
            "text": "Catalyst program package",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 11.8515625,
            "text": "pharmacophore models of inhibitors of 5-LOX have been developed with the aid of HipHop and HypoGen modules within Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 11.8515625,
            "text": "Hop and HypoGen modules within Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 11.8515625,
            "text": "of 5-LOX have been developed with the aid of HipHop and HypoGen modules within Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": 0.150634765625,
            "end_logit": 0.5546875,
            "text": "HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": 4.01953125,
            "end_logit": -6.3046875,
            "text": "HipHo",
            "probability": 0.0
        },
        {
            "start_logit": 4.01953125,
            "end_logit": -7.27734375,
            "text": "HipHop and HypoGen modules within Catalyst program",
            "probability": 0.0
        },
        {
            "start_logit": 4.01953125,
            "end_logit": -7.4765625,
            "text": "HipHop and HypoG",
            "probability": 0.0
        },
        {
            "start_logit": 4.01953125,
            "end_logit": -8.140625,
            "text": "HipHop and HypoGen modules within Catalyst program package",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_16": [
        {
            "start_logit": 10.4609375,
            "end_logit": 12.4453125,
            "text": "HypoGen",
            "probability": 1.0
        },
        {
            "start_logit": -3.498046875,
            "end_logit": 12.4453125,
            "text": "Catalyst/HypoGen",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -5.484375,
            "end_logit": 12.4453125,
            "text": "as required by the Catalyst/HypoGen",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.22265625,
            "end_logit": 12.4453125,
            "text": "en",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.4609375,
            "end_logit": -6.69921875,
            "text": "HypoG",
            "probability": 0.0
        },
        {
            "start_logit": 10.4609375,
            "end_logit": -7.03125,
            "text": "HypoGen program",
            "probability": 0.0
        },
        {
            "start_logit": -9.359375,
            "end_logit": 12.4453125,
            "text": "/HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 12.4453125,
            "text": "data set consisting of 24 inhibitors was selected on the basis of the information content of the structures and activity data as required by the Catalyst/HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 12.4453125,
            "text": "activity data as required by the Catalyst/HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 12.4453125,
            "text": "24 inhibitors was selected on the basis of the information content of the structures and activity data as required by the Catalyst/HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 12.4453125,
            "text": "and activity data as required by the Catalyst/HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 12.4453125,
            "text": "of the structures and activity data as required by the Catalyst/HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": 10.4609375,
            "end_logit": -8.9296875,
            "text": "HypoGen program.",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 12.4453125,
            "text": "content of the structures and activity data as required by the Catalyst/HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 12.4453125,
            "text": "selected on the basis of the information content of the structures and activity data as required by the Catalyst/HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -11.0234375,
            "end_logit": 12.4453125,
            "text": "by the Catalyst/HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -3.498046875,
            "end_logit": 0.25732421875,
            "text": "Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -5.484375,
            "end_logit": 0.25732421875,
            "text": "as required by the Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 0.25732421875,
            "text": "data set consisting of 24 inhibitors was selected on the basis of the information content of the structures and activity data as required by the Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -5.484375,
            "end_logit": -4.6796875,
            "text": "as",
            "probability": 0.0
        }
    ],
    "58962ed178275d0c4a000006_1": [
        {
            "start_logit": 14.3046875,
            "end_logit": 14.0078125,
            "text": "sacubitril",
            "probability": 1.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -3.291015625,
            "text": "sac",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.06640625,
            "end_logit": 14.0078125,
            "text": "il",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -5.04296875,
            "text": "sacubitril/valsartan",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -7.19140625,
            "text": "sacub",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -7.8984375,
            "text": "sacubitr",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -7.921875,
            "text": "sacubitril/vals",
            "probability": 0.0
        },
        {
            "start_logit": -7.67578125,
            "end_logit": 14.0078125,
            "text": "itril",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -8.2578125,
            "text": "sacubitril/valsartan (Entresto\u00ae, Novartis), still commonly referred to as LCZ",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -8.3125,
            "text": "sacubitril/valsartan (Entresto\u00ae, Novartis), still commonly referred to as LC",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -8.5,
            "text": "sacubitril/valsartan (Entresto\u00ae, Novartis), still commonly referred to as LCZ696",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -9.015625,
            "text": "sacubitril/valsartan (Entresto\u00ae, Novartis",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -9.3359375,
            "text": "sacubitril/",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -9.3515625,
            "text": "sacubitril/valsartan (Entresto\u00ae, Novartis)",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -9.3984375,
            "text": "sacubitril/valsartan (Entresto\u00ae, Novartis), still commonly referred to as LCZ69",
            "probability": 0.0
        },
        {
            "start_logit": -9.109375,
            "end_logit": 14.0078125,
            "text": "ubitril",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -9.4375,
            "text": "sacubitril/valsartan (Entresto\u00ae, Novartis), still commonly referred to as LCZ696, compared",
            "probability": 0.0
        },
        {
            "start_logit": -9.4140625,
            "end_logit": 14.0078125,
            "text": "HFrEF), has recently shown improved cardiovascular outcomes with sacubitril",
            "probability": 0.0
        },
        {
            "start_logit": -9.4375,
            "end_logit": 14.0078125,
            "text": "heart failure and reduced ejection fraction (HFrEF), has recently shown improved cardiovascular outcomes with sacubitril",
            "probability": 0.0
        },
        {
            "start_logit": -9.796875,
            "end_logit": 14.0078125,
            "text": "reduced ejection fraction (HFrEF), has recently shown improved cardiovascular outcomes with sacubitril",
            "probability": 0.0
        }
    ],
    "58962ed178275d0c4a000006_2": [
        {
            "start_logit": 14.28125,
            "end_logit": 13.9140625,
            "text": "sacubitril",
            "probability": 1.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -3.3203125,
            "text": "sac",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.203125,
            "end_logit": 13.9140625,
            "text": "il",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -7.0703125,
            "text": "sacub",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -7.26171875,
            "text": "sacubitril/valsartan",
            "probability": 0.0
        },
        {
            "start_logit": -7.4453125,
            "end_logit": 13.9140625,
            "text": "itril",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -7.84375,
            "text": "sacubitr",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -8.9375,
            "text": "sacubitril/vals",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -9.328125,
            "text": "sacubitril/valsartan (Entresto(\u00ae) ), the newly FDA-approved medication that dually inhibits angiotensin and nep",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -9.390625,
            "text": "sacubitril/",
            "probability": 0.0
        },
        {
            "start_logit": -9.2109375,
            "end_logit": 13.9140625,
            "text": "ubitril",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -9.6015625,
            "text": "sacubitril/valsartan (Entresto(\u00ae) )",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -9.6484375,
            "text": "sacubitril/valsartan (Entresto(\u00ae) ), the newly FDA-approved medication that dually inhibits angiotensin and",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -9.796875,
            "text": "sacubitril/valsartan (Entresto(\u00ae)",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -9.859375,
            "text": "sacubitril/valsartan (Entresto(\u00ae) ), the newly FDA-approved medication that dually inhibits",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -9.859375,
            "text": "sacubitril/valsartan (Entresto(\u00ae) ), the newly FDA-approved",
            "probability": 0.0
        },
        {
            "start_logit": -4.203125,
            "end_logit": -7.26171875,
            "text": "il/valsartan",
            "probability": 0.0
        },
        {
            "start_logit": -4.203125,
            "end_logit": -8.9375,
            "text": "il/vals",
            "probability": 0.0
        },
        {
            "start_logit": -4.203125,
            "end_logit": -9.0234375,
            "text": "il/valsartan (Entresto(\u00ae) ), the newly FDA-approved medication that dually inhibits angiotensin and neprilysin,",
            "probability": 0.0
        },
        {
            "start_logit": -4.203125,
            "end_logit": -9.2421875,
            "text": "il/valsartan (Entresto(\u00ae) ), the newly FDA-approved medication that dually inhibits angiotensin and neprilysin",
            "probability": 0.0
        }
    ],
    "58962ed178275d0c4a000006_3": [
        {
            "start_logit": 14.0859375,
            "end_logit": 13.9921875,
            "text": "Sacubitril",
            "probability": 1.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -3.650390625,
            "text": "Sac",
            "probability": 0.0
        },
        {
            "start_logit": -4.07421875,
            "end_logit": 13.9921875,
            "text": "il",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -5.62890625,
            "text": "Sacubitril valsartan",
            "probability": 0.0
        },
        {
            "start_logit": -7.05078125,
            "end_logit": 13.9921875,
            "text": "itril",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -7.52734375,
            "text": "Sacub",
            "probability": 0.0
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 13.9921875,
            "text": "\u25bc Sacubitril",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -8.09375,
            "text": "Sacubitr",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -8.6015625,
            "text": "Sacubitril vals",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -8.671875,
            "text": "Sacubitril valsartan (Entresto-Novartis)",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -8.890625,
            "text": "Sacubitril valsartan (Entresto-Novartis",
            "probability": 0.0
        },
        {
            "start_logit": -8.9375,
            "end_logit": 13.9921875,
            "text": "ubitril",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.3359375,
            "text": "Sacubitril valsartan (",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.46875,
            "text": "Sacubitril valsartan (Entresto-Novartis) is a new oral drug licensed",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.5390625,
            "text": "Sacubitril valsartan (Entresto-Novartis) is",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.59375,
            "text": "Sacubitril valsartan (Entresto-Novartis) is a new oral drug licensed for the treatment of symptomatic chronic heart failure",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.609375,
            "text": "Sacubitril valsartan (Entresto-Novartis) is a new oral drug",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.6953125,
            "text": "Sacubitril valsartan (Entresto-Novartis) is a new oral",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.8515625,
            "text": "Sacubitril valsartan (Entresto-Nov",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.9765625,
            "text": "Sacubitril valsartan (Entresto-Novartis) is a new",
            "probability": 0.0
        }
    ],
    "58962ed178275d0c4a000006_4": [
        {
            "start_logit": 14.109375,
            "end_logit": 13.546875,
            "text": "Sacubitril",
            "probability": 1.0
        },
        {
            "start_logit": 14.109375,
            "end_logit": -3.587890625,
            "text": "Sac",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.109375,
            "end_logit": -4.1796875,
            "text": "Sacubitril/Valsartan",
            "probability": 0.0
        },
        {
            "start_logit": -4.8203125,
            "end_logit": 13.546875,
            "text": "il",
            "probability": 0.0
        },
        {
            "start_logit": 14.109375,
            "end_logit": -6.24609375,
            "text": "Sacub",
            "probability": 0.0
        },
        {
            "start_logit": 14.109375,
            "end_logit": -7.28515625,
            "text": "Sacubitr",
            "probability": 0.0
        },
        {
            "start_logit": 14.109375,
            "end_logit": -7.5234375,
            "text": "Sacubitril/Vals",
            "probability": 0.0
        },
        {
            "start_logit": 14.109375,
            "end_logit": -8.3984375,
            "text": "Sacubitril/",
            "probability": 0.0
        },
        {
            "start_logit": -7.90625,
            "end_logit": 13.546875,
            "text": "itril",
            "probability": 0.0
        },
        {
            "start_logit": 14.109375,
            "end_logit": -8.546875,
            "text": "Sacubitril/Valsartan (Entresto\u2122)",
            "probability": 0.0
        },
        {
            "start_logit": 14.109375,
            "end_logit": -8.8203125,
            "text": "Sacubitril/Valsartan (Entresto\u2122",
            "probability": 0.0
        },
        {
            "start_logit": 14.109375,
            "end_logit": -8.90625,
            "text": "Sacubitril/Valsartan (Entresto\u2122) in a 63-Year-Old Woman",
            "probability": 0.0
        },
        {
            "start_logit": 14.109375,
            "end_logit": -9.1953125,
            "text": "Sacubitril/Valsartan (Entresto\u2122) in a",
            "probability": 0.0
        },
        {
            "start_logit": 14.109375,
            "end_logit": -9.2421875,
            "text": "Sacubitril/Valsartan (",
            "probability": 0.0
        },
        {
            "start_logit": 14.109375,
            "end_logit": -9.265625,
            "text": "Sacubitril/Valsartan (Entresto\u2122) in a 63-Year-Old Woman.",
            "probability": 0.0
        },
        {
            "start_logit": 14.109375,
            "end_logit": -9.4609375,
            "text": "Sacubitril/Valsartan (Entresto\u2122) in a 63-Year-",
            "probability": 0.0
        },
        {
            "start_logit": 14.109375,
            "end_logit": -9.4609375,
            "text": "Sacubitril/Valsartan (Entresto\u2122) in a 63-",
            "probability": 0.0
        },
        {
            "start_logit": -9.5625,
            "end_logit": 13.546875,
            "text": "ubitril",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": 13.546875,
            "text": "Atorvastatin and Sacubitril",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 13.546875,
            "text": "Rhabdomyolysis After Coadministration of Atorvastatin and Sacubitril",
            "probability": 0.0
        }
    ],
    "58962ed178275d0c4a000006_5": [
        {
            "start_logit": 14.265625,
            "end_logit": 13.6796875,
            "text": "sacubitril",
            "probability": 1.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -3.34375,
            "text": "sac",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.265625,
            "end_logit": -4.37109375,
            "text": "sacubitril/valsartan",
            "probability": 0.0
        },
        {
            "start_logit": -4.59375,
            "end_logit": 13.6796875,
            "text": "il",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -6.92578125,
            "text": "sacub",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -7.26953125,
            "text": "sacubitr",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -7.9140625,
            "text": "sacubitril/vals",
            "probability": 0.0
        },
        {
            "start_logit": -7.74609375,
            "end_logit": 13.6796875,
            "text": "itril",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -8.5703125,
            "text": "sacubitril/valsartan (Entresto\u2122",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -8.8984375,
            "text": "sacubitril/",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 13.6796875,
            "text": "enalapril 20 mg twice daily for heart failure developed rhabdomyolysis 26 days after enalapril was stopped and sacubitril",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.0,
            "text": "sacubitril/valsartan (Entresto\u2122)",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.0859375,
            "text": "sacubitril/valsartan (Entresto\u2122) started",
            "probability": 0.0
        },
        {
            "start_logit": -9.1171875,
            "end_logit": 13.6796875,
            "text": "rivaroxaban 15 mg daily, and enalapril 20 mg twice daily for heart failure developed rhabdomyolysis 26 days after enalapril was stopped and sacubitril",
            "probability": 0.0
        },
        {
            "start_logit": -9.390625,
            "end_logit": 13.6796875,
            "text": "heart failure developed rhabdomyolysis 26 days after enalapril was stopped and sacubitril",
            "probability": 0.0
        },
        {
            "start_logit": -9.4140625,
            "end_logit": 13.6796875,
            "text": "ubitril",
            "probability": 0.0
        },
        {
            "start_logit": -4.59375,
            "end_logit": -4.37109375,
            "text": "il/valsartan",
            "probability": 0.0
        },
        {
            "start_logit": -5.8515625,
            "end_logit": -4.37109375,
            "text": "valsartan",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": -3.34375,
            "text": "enalapril 20 mg twice daily for heart failure developed rhabdomyolysis 26 days after enalapril was stopped and sac",
            "probability": 0.0
        },
        {
            "start_logit": -7.74609375,
            "end_logit": -4.37109375,
            "text": "itril/valsartan",
            "probability": 0.0
        }
    ],
    "58962ed178275d0c4a000006_6": [
        {
            "start_logit": 14.265625,
            "end_logit": 13.921875,
            "text": "Sacubitril",
            "probability": 1.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -3.220703125,
            "text": "Sac",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.16796875,
            "end_logit": 13.921875,
            "text": "il",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -5.15234375,
            "text": "Sacubitril/valsartan",
            "probability": 0.0
        },
        {
            "start_logit": -6.9296875,
            "end_logit": 13.921875,
            "text": "itril",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -7.578125,
            "text": "Sacub",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -8.1640625,
            "text": "Sacubitr",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -8.296875,
            "text": "Sacubitril/valsartan [LCZ696 (Entresto), Novartis Pharmaceuticals Corp.] is the first",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -8.65625,
            "text": "Sacubitril/vals",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.0078125,
            "text": "Sacubitril/valsartan [LCZ696 (Entresto), Novartis Pharmaceuticals Corp.] is",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.28125,
            "text": "Sacubitril/valsartan [LCZ696 (Entresto), Novartis Pharmaceuticals Corp.]",
            "probability": 0.0
        },
        {
            "start_logit": -9.0,
            "end_logit": 13.921875,
            "text": "ubitril",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.4296875,
            "text": "Sacubitril/",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.6171875,
            "text": "Sacubitril/valsartan [LCZ696 (Entresto)",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.640625,
            "text": "Sacubitril/valsartan [LCZ",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.796875,
            "text": "Sacubitril/valsartan [LCZ696 (Entresto), Novartis Pharmaceuticals Corp.] is the",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.796875,
            "text": "Sacubitril/valsartan [LC",
            "probability": 0.0
        },
        {
            "start_logit": -4.16796875,
            "end_logit": -5.15234375,
            "text": "il/valsartan",
            "probability": 0.0
        },
        {
            "start_logit": -6.9296875,
            "end_logit": -5.15234375,
            "text": "itril/valsartan",
            "probability": 0.0
        },
        {
            "start_logit": -7.03125,
            "end_logit": -5.15234375,
            "text": "valsartan",
            "probability": 0.0
        }
    ],
    "58962ed178275d0c4a000006_7": [
        {
            "start_logit": 13.59375,
            "end_logit": 13.609375,
            "text": "sacubitril",
            "probability": 1.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -4.2890625,
            "text": "sac",
            "probability": 0.0
        },
        {
            "start_logit": -4.74609375,
            "end_logit": 13.609375,
            "text": "il",
            "probability": 0.0
        },
        {
            "start_logit": -6.05859375,
            "end_logit": 13.609375,
            "text": "Valsartan/sacubitril",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -6.80859375,
            "text": "sacub",
            "probability": 0.0
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 13.609375,
            "text": "itril",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -7.859375,
            "text": "sacubitr",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -8.4375,
            "text": "sacubitril (formerly known as LC",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -8.5234375,
            "text": "sacubitril (formerly known as LCZ696",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -8.578125,
            "text": "sacubitril (formerly known as LCZ",
            "probability": 0.0
        },
        {
            "start_logit": -8.671875,
            "end_logit": 13.609375,
            "text": "/sacubitril",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -8.84375,
            "text": "sacubitril (formerly known as LCZ696 and currently marketed by Novartis as Entresto) combines the angiotensin receptor blocker",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.28125,
            "text": "sacubitril (formerly known as LCZ696 and currently marketed by Novartis",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.34375,
            "text": "sacubitril (formerly known as LCZ696 and currently marketed by Novartis as Entresto) combines the angiotensin receptor blocker vals",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": 13.609375,
            "text": "artan/sacubitril",
            "probability": 0.0
        },
        {
            "start_logit": -9.7265625,
            "end_logit": 13.609375,
            "text": "ubitril",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 13.609375,
            "text": "heart failure: Valsartan/sacubitril",
            "probability": 0.0
        },
        {
            "start_logit": -6.05859375,
            "end_logit": -4.2890625,
            "text": "Valsartan/sac",
            "probability": 0.0
        },
        {
            "start_logit": -6.05859375,
            "end_logit": -5.671875,
            "text": "Valsartan",
            "probability": 0.0
        },
        {
            "start_logit": -4.74609375,
            "end_logit": -7.5625,
            "text": "il (formerly known as LCZ696 and currently marketed by Novartis as Entresto) combines the angiotensin receptor blocker valsartan",
            "probability": 0.0
        }
    ],
    "58962ed178275d0c4a000006_8": [
        {
            "start_logit": 13.890625,
            "end_logit": 13.59375,
            "text": "Sacubitril",
            "probability": 1.0
        },
        {
            "start_logit": 13.890625,
            "end_logit": -3.64453125,
            "text": "Sac",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.609375,
            "end_logit": 13.59375,
            "text": "il",
            "probability": 0.0
        },
        {
            "start_logit": 13.890625,
            "end_logit": -7.30078125,
            "text": "Sacubitril/valsartan",
            "probability": 0.0
        },
        {
            "start_logit": 13.890625,
            "end_logit": -7.546875,
            "text": "Sacub",
            "probability": 0.0
        },
        {
            "start_logit": -7.2890625,
            "end_logit": 13.59375,
            "text": "itril",
            "probability": 0.0
        },
        {
            "start_logit": 13.890625,
            "end_logit": -7.82421875,
            "text": "Sacubitr",
            "probability": 0.0
        },
        {
            "start_logit": 13.890625,
            "end_logit": -8.8203125,
            "text": "Sacubitril/valsartan (Entresto) for chronic heart failure",
            "probability": 0.0
        },
        {
            "start_logit": 13.890625,
            "end_logit": -8.90625,
            "text": "Sacubitril/",
            "probability": 0.0
        },
        {
            "start_logit": -8.9296875,
            "end_logit": 13.59375,
            "text": "ubitril",
            "probability": 0.0
        },
        {
            "start_logit": 13.890625,
            "end_logit": -9.25,
            "text": "Sacubitril/valsartan (Entresto)",
            "probability": 0.0
        },
        {
            "start_logit": 13.890625,
            "end_logit": -9.3203125,
            "text": "Sacubitril/vals",
            "probability": 0.0
        },
        {
            "start_logit": 13.890625,
            "end_logit": -9.3984375,
            "text": "Sacubitril/valsartan (Entresto",
            "probability": 0.0
        },
        {
            "start_logit": -4.609375,
            "end_logit": -7.30078125,
            "text": "il/valsartan",
            "probability": 0.0
        },
        {
            "start_logit": -4.609375,
            "end_logit": -8.8203125,
            "text": "il/valsartan (Entresto) for chronic heart failure",
            "probability": 0.0
        },
        {
            "start_logit": -4.609375,
            "end_logit": -8.90625,
            "text": "il/",
            "probability": 0.0
        },
        {
            "start_logit": -4.609375,
            "end_logit": -9.25,
            "text": "il/valsartan (Entresto)",
            "probability": 0.0
        },
        {
            "start_logit": -4.609375,
            "end_logit": -9.3203125,
            "text": "il/vals",
            "probability": 0.0
        },
        {
            "start_logit": -4.609375,
            "end_logit": -9.3984375,
            "text": "il/valsartan (Entresto",
            "probability": 0.0
        },
        {
            "start_logit": -7.2890625,
            "end_logit": -7.30078125,
            "text": "itril/valsartan",
            "probability": 0.0
        }
    ],
    "58962ed178275d0c4a000006_9": [
        {
            "start_logit": 14.3203125,
            "end_logit": 14.125,
            "text": "sacubitril",
            "probability": 1.0
        },
        {
            "start_logit": 14.3203125,
            "end_logit": -3.283203125,
            "text": "sac",
            "probability": 0.0
        },
        {
            "start_logit": -3.85546875,
            "end_logit": 14.125,
            "text": "il",
            "probability": 0.0
        },
        {
            "start_logit": 14.3203125,
            "end_logit": -6.66015625,
            "text": "sacubitril and valsartan",
            "probability": 0.0
        },
        {
            "start_logit": 14.3203125,
            "end_logit": -7.6171875,
            "text": "sacub",
            "probability": 0.0
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 14.125,
            "text": "itril",
            "probability": 0.0
        },
        {
            "start_logit": 14.3203125,
            "end_logit": -7.71875,
            "text": "sacubitr",
            "probability": 0.0
        },
        {
            "start_logit": 14.3203125,
            "end_logit": -8.9140625,
            "text": "sacubitril and vals",
            "probability": 0.0
        },
        {
            "start_logit": -8.9921875,
            "end_logit": 14.125,
            "text": "ubitril",
            "probability": 0.0
        },
        {
            "start_logit": 14.3203125,
            "end_logit": -9.2265625,
            "text": "sacubitril and",
            "probability": 0.0
        },
        {
            "start_logit": -9.1796875,
            "end_logit": 14.125,
            "text": "molecular combination of sacubitril",
            "probability": 0.0
        },
        {
            "start_logit": 14.3203125,
            "end_logit": -9.4296875,
            "text": "sacubitril and valsartan (Entresto)",
            "probability": 0.0
        },
        {
            "start_logit": 14.3203125,
            "end_logit": -9.5078125,
            "text": "sacubitril and valsartan (Entresto) is",
            "probability": 0.0
        },
        {
            "start_logit": 14.3203125,
            "end_logit": -9.7109375,
            "text": "sacubitril and valsartan (Entresto) is a new drug for reducing the risk of cardiovascular death and hospitalization for heart failure",
            "probability": 0.0
        },
        {
            "start_logit": 14.3203125,
            "end_logit": -9.90625,
            "text": "sacubitril and valsartan (Entresto) is a new drug",
            "probability": 0.0
        },
        {
            "start_logit": 14.3203125,
            "end_logit": -9.953125,
            "text": "sacubitril and valsartan (Entresto",
            "probability": 0.0
        },
        {
            "start_logit": -3.85546875,
            "end_logit": -6.66015625,
            "text": "il and valsartan",
            "probability": 0.0
        },
        {
            "start_logit": -9.1796875,
            "end_logit": -3.283203125,
            "text": "molecular combination of sac",
            "probability": 0.0
        },
        {
            "start_logit": -3.85546875,
            "end_logit": -8.9140625,
            "text": "il and vals",
            "probability": 0.0
        },
        {
            "start_logit": -3.85546875,
            "end_logit": -9.2265625,
            "text": "il and",
            "probability": 0.0
        }
    ],
    "58962ed178275d0c4a000006_10": [
        {
            "start_logit": 13.5703125,
            "end_logit": 13.1796875,
            "text": "Sacubitril",
            "probability": 1.0
        },
        {
            "start_logit": 13.5703125,
            "end_logit": -2.494140625,
            "text": "Sacubitril valsartan",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.5703125,
            "end_logit": -4.3828125,
            "text": "Sac",
            "probability": 0.0
        },
        {
            "start_logit": -5.453125,
            "end_logit": 13.1796875,
            "text": "il",
            "probability": 0.0
        },
        {
            "start_logit": 13.5703125,
            "end_logit": -7.76171875,
            "text": "Sacubitril valsartan (Entresto-Novartis",
            "probability": 0.0
        },
        {
            "start_logit": 13.5703125,
            "end_logit": -7.76953125,
            "text": "Sacub",
            "probability": 0.0
        },
        {
            "start_logit": 13.5703125,
            "end_logit": -8.0625,
            "text": "Sacubitr",
            "probability": 0.0
        },
        {
            "start_logit": -7.80078125,
            "end_logit": 13.1796875,
            "text": "itril",
            "probability": 0.0
        },
        {
            "start_logit": -7.80078125,
            "end_logit": 13.1796875,
            "text": "\u25bc Sacubitril",
            "probability": 0.0
        },
        {
            "start_logit": 13.5703125,
            "end_logit": -8.5390625,
            "text": "Sacubitril valsartan (Entresto-Novartis)",
            "probability": 0.0
        },
        {
            "start_logit": 13.5703125,
            "end_logit": -8.6953125,
            "text": "Sacubitril vals",
            "probability": 0.0
        },
        {
            "start_logit": 13.5703125,
            "end_logit": -8.703125,
            "text": "Sacubitril valsartan (Entresto-Novartis) is",
            "probability": 0.0
        },
        {
            "start_logit": 13.5703125,
            "end_logit": -9.125,
            "text": "Sacubitril valsartan (Entresto",
            "probability": 0.0
        },
        {
            "start_logit": 13.5703125,
            "end_logit": -9.1796875,
            "text": "Sacubitril valsartan (",
            "probability": 0.0
        },
        {
            "start_logit": 13.5703125,
            "end_logit": -9.1875,
            "text": "Sacubitril valsartan (Entresto-Novartis) is a new oral drug",
            "probability": 0.0
        },
        {
            "start_logit": -9.0234375,
            "end_logit": 13.1796875,
            "text": "ubitril",
            "probability": 0.0
        },
        {
            "start_logit": -4.96875,
            "end_logit": -2.494140625,
            "text": "valsartan",
            "probability": 0.0
        },
        {
            "start_logit": -5.453125,
            "end_logit": -2.494140625,
            "text": "il valsartan",
            "probability": 0.0
        },
        {
            "start_logit": -6.140625,
            "end_logit": -2.494140625,
            "text": "artan",
            "probability": 0.0
        },
        {
            "start_logit": -7.80078125,
            "end_logit": -2.494140625,
            "text": "itril valsartan",
            "probability": 0.0
        }
    ],
    "5e92015b2d3121100d000004_1": [
        {
            "start_logit": 14.09375,
            "end_logit": 13.828125,
            "text": "chronic lymphocytic leukemia",
            "probability": 1.0
        },
        {
            "start_logit": 14.09375,
            "end_logit": -3.1328125,
            "text": "chronic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.939453125,
            "end_logit": 13.828125,
            "text": "leukemia",
            "probability": 0.0
        },
        {
            "start_logit": 14.09375,
            "end_logit": -6.953125,
            "text": "chronic lymphocytic",
            "probability": 0.0
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 13.828125,
            "text": "lymphocytic leukemia",
            "probability": 0.0
        },
        {
            "start_logit": -7.80078125,
            "end_logit": 13.828125,
            "text": "B-cell activating factor levels may denote nascent chronic lymphocytic leukemia",
            "probability": 0.0
        },
        {
            "start_logit": 14.09375,
            "end_logit": -9.265625,
            "text": "chronic lymphocytic leukemia many years pre",
            "probability": 0.0
        },
        {
            "start_logit": 14.09375,
            "end_logit": -9.6953125,
            "text": "chronic lymphocytic leukemia many years pre-diagnosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.09375,
            "end_logit": -9.8515625,
            "text": "chronic lymphocytic leukemia many years pre-diagnosis.",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": 13.828125,
            "text": "activating factor levels may denote nascent chronic lymphocytic leukemia",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 13.828125,
            "text": "Decreased B-cell activating factor levels may denote nascent chronic lymphocytic leukemia",
            "probability": 0.0
        },
        {
            "start_logit": -10.234375,
            "end_logit": 13.828125,
            "text": "immune activation precedes non-Hodgkin lymphoma diagnosis by several years. Decreased B-cell activating factor levels may denote nascent chronic lymphocytic leukemia",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 13.828125,
            "text": "nascent chronic lymphocytic leukemia",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 13.828125,
            "text": "Hodgkin lymphoma diagnosis by several years. Decreased B-cell activating factor levels may denote nascent chronic lymphocytic leukemia",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 13.828125,
            "text": "non-Hodgkin lymphoma diagnosis by several years. Decreased B-cell activating factor levels may denote nascent chronic lymphocytic leukemia",
            "probability": 0.0
        },
        {
            "start_logit": -7.80078125,
            "end_logit": -3.1328125,
            "text": "B-cell activating factor levels may denote nascent chronic",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": -3.1328125,
            "text": "activating factor levels may denote nascent chronic",
            "probability": 0.0
        },
        {
            "start_logit": -3.939453125,
            "end_logit": -9.265625,
            "text": "leukemia many years pre",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": -3.1328125,
            "text": "Decreased B-cell activating factor levels may denote nascent chronic",
            "probability": 0.0
        },
        {
            "start_logit": -10.234375,
            "end_logit": -3.1328125,
            "text": "immune activation precedes non-Hodgkin lymphoma diagnosis by several years. Decreased B-cell activating factor levels may denote nascent chronic",
            "probability": 0.0
        }
    ],
    "5e92015b2d3121100d000004_2": [
        {
            "start_logit": 12.3203125,
            "end_logit": 9.8828125,
            "text": "soluble CD30",
            "probability": 1.0
        },
        {
            "start_logit": -1.4794921875,
            "end_logit": 9.8828125,
            "text": "CD30",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 12.3203125,
            "end_logit": -5.5703125,
            "text": "soluble",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 12.3203125,
            "end_logit": -6.03515625,
            "text": "soluble CD30, and soluble tumor necrosis factor receptor-2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.3203125,
            "end_logit": -7.8046875,
            "text": "soluble CD30, and soluble tumor necrosis factor",
            "probability": 0.0
        },
        {
            "start_logit": 12.3203125,
            "end_logit": -7.8515625,
            "text": "soluble CD30, and soluble tumor necrosis factor receptor-2 were individually positively associated, and B-cell activating factor of the tumor necrosis factor family",
            "probability": 0.0
        },
        {
            "start_logit": 12.3203125,
            "end_logit": -8.5078125,
            "text": "soluble CD3",
            "probability": 0.0
        },
        {
            "start_logit": 12.3203125,
            "end_logit": -8.9140625,
            "text": "soluble CD30, and soluble tumor necrosis factor receptor-2 were individually positively associated, and B-cell activating factor of the tumor necrosis factor",
            "probability": 0.0
        },
        {
            "start_logit": 12.3203125,
            "end_logit": -9.140625,
            "text": "soluble CD30, and soluble tumor necrosis factor receptor",
            "probability": 0.0
        },
        {
            "start_logit": 12.3203125,
            "end_logit": -9.171875,
            "text": "soluble CD30, and soluble tumor necrosis factor receptor-2 were individually positively associated, and B",
            "probability": 0.0
        },
        {
            "start_logit": 12.3203125,
            "end_logit": -9.171875,
            "text": "soluble CD30, and soluble tumor necrosis factor receptor-2 were individually positively associated, and B-cell activating factor",
            "probability": 0.0
        },
        {
            "start_logit": 12.3203125,
            "end_logit": -9.2109375,
            "text": "soluble CD30, and soluble tumor necrosis factor receptor-2 were individually positively associated, and B-",
            "probability": 0.0
        },
        {
            "start_logit": 12.3203125,
            "end_logit": -9.2109375,
            "text": "soluble CD30, and",
            "probability": 0.0
        },
        {
            "start_logit": -7.14453125,
            "end_logit": 9.8828125,
            "text": "interleukin-2 receptor-\u03b1, CXC chemokine ligand 13, soluble CD30",
            "probability": 0.0
        },
        {
            "start_logit": -7.31640625,
            "end_logit": 9.8828125,
            "text": "Soluble interleukin-2 receptor-\u03b1, CXC chemokine ligand 13, soluble CD30",
            "probability": 0.0
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 9.8828125,
            "text": "0",
            "probability": 0.0
        },
        {
            "start_logit": -9.578125,
            "end_logit": 9.8828125,
            "text": "CXC chemokine ligand 13, soluble CD30",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": 9.8828125,
            "text": "\u03b1, CXC chemokine ligand 13, soluble CD30",
            "probability": 0.0
        },
        {
            "start_logit": -1.4794921875,
            "end_logit": -6.03515625,
            "text": "CD30, and soluble tumor necrosis factor receptor-2",
            "probability": 0.0
        },
        {
            "start_logit": -1.4794921875,
            "end_logit": -7.8046875,
            "text": "CD30, and soluble tumor necrosis factor",
            "probability": 0.0
        }
    ],
    "5e92015b2d3121100d000004_3": [
        {
            "start_logit": 13.5,
            "end_logit": 13.0859375,
            "text": "GALECTIN-3",
            "probability": 1.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -3.783203125,
            "text": "GALECTIN",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.51171875,
            "end_logit": 13.0859375,
            "text": "3",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -6.94921875,
            "text": "GALECTIN-",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -9.8359375,
            "text": "GALECTIN-3 AS A",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -9.890625,
            "text": "GALECTIN-3 AS A PROGNOSTIC BIOMARKER",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -9.9140625,
            "text": "GALECTIN-3 AS A PROGNOSTIC BIOMARKER IN PATIENTS WITH NON-HODGKIN LYMPHOMA.",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -10.203125,
            "text": "GALECTIN-3 AS A PROGNOSTIC BIOMARKER IN PATIENTS WITH NON-HODGKIN LYMPHOMA",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -10.28125,
            "text": "GALECTIN-3 AS A PROGNOSTIC",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -10.3125,
            "text": "GALECTIN-3 AS",
            "probability": 0.0
        },
        {
            "start_logit": -4.51171875,
            "end_logit": -9.8359375,
            "text": "3 AS A",
            "probability": 0.0
        },
        {
            "start_logit": -4.51171875,
            "end_logit": -9.890625,
            "text": "3 AS A PROGNOSTIC BIOMARKER",
            "probability": 0.0
        },
        {
            "start_logit": -4.51171875,
            "end_logit": -9.9140625,
            "text": "3 AS A PROGNOSTIC BIOMARKER IN PATIENTS WITH NON-HODGKIN LYMPHOMA.",
            "probability": 0.0
        },
        {
            "start_logit": -4.51171875,
            "end_logit": -10.203125,
            "text": "3 AS A PROGNOSTIC BIOMARKER IN PATIENTS WITH NON-HODGKIN LYMPHOMA",
            "probability": 0.0
        },
        {
            "start_logit": -4.51171875,
            "end_logit": -10.28125,
            "text": "3 AS A PROGNOSTIC",
            "probability": 0.0
        },
        {
            "start_logit": -4.51171875,
            "end_logit": -10.3125,
            "text": "3 AS",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": -9.9140625,
            "text": "HODGKIN LYMPHOMA.",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": -9.9140625,
            "text": "NON-HODGKIN LYMPHOMA.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": -9.8359375,
            "text": "A",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": -9.890625,
            "text": "A PROGNOSTIC BIOMARKER",
            "probability": 0.0
        }
    ],
    "5333f728d6d3ac6a34000041_1": [
        {
            "start_logit": 11.4921875,
            "end_logit": 12.515625,
            "text": "na\u00efve Bayes classifier",
            "probability": 1.0
        },
        {
            "start_logit": -6.21875,
            "end_logit": 12.515625,
            "text": "classifier",
            "probability": 0.0
        },
        {
            "start_logit": 11.4921875,
            "end_logit": -6.5546875,
            "text": "na\u00efve Bayes",
            "probability": 0.0
        },
        {
            "start_logit": 11.4921875,
            "end_logit": -6.609375,
            "text": "na\u00efve",
            "probability": 0.0
        },
        {
            "start_logit": -9.375,
            "end_logit": 12.515625,
            "text": "Bayes classifier",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 12.515625,
            "text": "learning method for the prediction of heterodimeric protein complexes. This method learns the parameters of the features, which are embedded in the na\u00efve Bayes classifier",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 12.515625,
            "text": "This method learns the parameters of the features, which are embedded in the na\u00efve Bayes classifier",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 12.515625,
            "text": "-learning method for the prediction of heterodimeric protein complexes. This method learns the parameters of the features, which are embedded in the na\u00efve Bayes classifier",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": 12.515625,
            "text": "of the features, which are embedded in the na\u00efve Bayes classifier",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 12.515625,
            "text": "protein complexes. This method learns the parameters of the features, which are embedded in the na\u00efve Bayes classifier",
            "probability": 0.0
        },
        {
            "start_logit": -9.375,
            "end_logit": -6.5546875,
            "text": "Bayes",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": -6.5546875,
            "text": "learning method for the prediction of heterodimeric protein complexes. This method learns the parameters of the features, which are embedded in the na\u00efve Bayes",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": -6.609375,
            "text": "learning method for the prediction of heterodimeric protein complexes. This method learns the parameters of the features, which are embedded in the na\u00efve",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": -6.5546875,
            "text": "This method learns the parameters of the features, which are embedded in the na\u00efve Bayes",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": -6.609375,
            "text": "This method learns the parameters of the features, which are embedded in the na\u00efve",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": -6.5546875,
            "text": "supervised-learning method for the prediction of heterodimeric protein complexes. This method learns the parameters of the features, which are embedded in the na\u00efve Bayes",
            "probability": 0.0
        },
        {
            "start_logit": -9.8671875,
            "end_logit": -7.20703125,
            "text": "genomic data sets, and proposed a supervised-learning method",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": -6.609375,
            "text": "supervised-learning method for the prediction of heterodimeric protein complexes. This method learns the parameters of the features, which are embedded in the na\u00efve",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -6.5546875,
            "text": "-learning method for the prediction of heterodimeric protein complexes. This method learns the parameters of the features, which are embedded in the na\u00efve Bayes",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": -6.5546875,
            "text": "of the features, which are embedded in the na\u00efve Bayes",
            "probability": 0.0
        }
    ],
    "5333f728d6d3ac6a34000041_2": [
        {
            "start_logit": 13.71875,
            "end_logit": 13.4765625,
            "text": "Negatome",
            "probability": 1.0
        },
        {
            "start_logit": 13.71875,
            "end_logit": -4.421875,
            "text": "Neg",
            "probability": 0.0
        },
        {
            "start_logit": -4.68359375,
            "end_logit": 13.4765625,
            "text": "me",
            "probability": 0.0
        },
        {
            "start_logit": 13.71875,
            "end_logit": -6.95703125,
            "text": "Negato",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 13.4765625,
            "text": "atome",
            "probability": 0.0
        },
        {
            "start_logit": 13.71875,
            "end_logit": -8.6953125,
            "text": "Negatome,",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": 13.4765625,
            "text": "PPIs) and for assessing the false positive rates of PPI detection efforts. We present the second version of Negatome",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": 13.4765625,
            "text": "false positive rates of PPI detection efforts. We present the second version of Negatome",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": 13.4765625,
            "text": "present the second version of Negatome",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 13.4765625,
            "text": "version of Negatome",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 13.4765625,
            "text": "second version of Negatome",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 13.4765625,
            "text": "PPI detection efforts. We present the second version of Negatome",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 13.4765625,
            "text": "assessing the false positive rates of PPI detection efforts. We present the second version of Negatome",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 13.4765625,
            "text": "protein-protein interactions (PPIs) and for assessing the false positive rates of PPI detection efforts. We present the second version of Negatome",
            "probability": 0.0
        },
        {
            "start_logit": -4.68359375,
            "end_logit": -8.6953125,
            "text": "me,",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": -4.421875,
            "text": "PPIs) and for assessing the false positive rates of PPI detection efforts. We present the second version of Neg",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": -4.421875,
            "text": "false positive rates of PPI detection efforts. We present the second version of Neg",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": -4.421875,
            "text": "present the second version of Neg",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": -4.421875,
            "text": "version of Neg",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": -4.421875,
            "text": "second version of Neg",
            "probability": 0.0
        }
    ],
    "5333f728d6d3ac6a34000041_3": [
        {
            "start_logit": 12.8125,
            "end_logit": 12.21875,
            "text": "Negatome",
            "probability": 1.0
        },
        {
            "start_logit": 12.8125,
            "end_logit": -5.1328125,
            "text": "Neg",
            "probability": 0.0
        },
        {
            "start_logit": 12.8125,
            "end_logit": -5.890625,
            "text": "Negato",
            "probability": 0.0
        },
        {
            "start_logit": -5.57421875,
            "end_logit": 12.21875,
            "text": "me",
            "probability": 0.0
        },
        {
            "start_logit": 12.8125,
            "end_logit": -8.25,
            "text": "Negatome is derived by manual curation of literature and by analyzing three-dimensional structures of protein complexes",
            "probability": 0.0
        },
        {
            "start_logit": 12.8125,
            "end_logit": -8.859375,
            "text": "Negatome is derived by manual curation of literature and by analyzing three-dimensional structures of protein complexes.",
            "probability": 0.0
        },
        {
            "start_logit": 12.8125,
            "end_logit": -8.90625,
            "text": "Negatome is",
            "probability": 0.0
        },
        {
            "start_logit": 12.8125,
            "end_logit": -8.9140625,
            "text": "Negatome is derived by manual curation of literature and by analyzing three-dimensional structures",
            "probability": 0.0
        },
        {
            "start_logit": -8.71875,
            "end_logit": 12.21875,
            "text": "atome",
            "probability": 0.0
        },
        {
            "start_logit": 12.8125,
            "end_logit": -9.4453125,
            "text": "Negatome is derived by manual curation of literature",
            "probability": 0.0
        },
        {
            "start_logit": 12.8125,
            "end_logit": -9.4453125,
            "text": "Negatome is derived by manual curation of literature and by analyzing three-dimensional structures of",
            "probability": 0.0
        },
        {
            "start_logit": 12.8125,
            "end_logit": -9.453125,
            "text": "Negatome is derived by manual curation of",
            "probability": 0.0
        },
        {
            "start_logit": 12.8125,
            "end_logit": -9.5,
            "text": "Negatome is derived by manual curation of literature and by analyzing three-",
            "probability": 0.0
        },
        {
            "start_logit": 12.8125,
            "end_logit": -9.53125,
            "text": "Negatome is derived",
            "probability": 0.0
        },
        {
            "start_logit": 12.8125,
            "end_logit": -9.59375,
            "text": "Negatome is derived by manual curation of literature and by analyzing three-dimensional structures of protein",
            "probability": 0.0
        },
        {
            "start_logit": 12.8125,
            "end_logit": -9.8125,
            "text": "Negatome is derived by manual curation of literature and",
            "probability": 0.0
        },
        {
            "start_logit": 12.8125,
            "end_logit": -9.859375,
            "text": "Negatome is derived by manual curation of literature and by analyzing three-dimensional",
            "probability": 0.0
        },
        {
            "start_logit": 12.8125,
            "end_logit": -9.9296875,
            "text": "Negatome is derived by manual curation of literature and by analyzing three",
            "probability": 0.0
        },
        {
            "start_logit": -5.57421875,
            "end_logit": -8.25,
            "text": "me is derived by manual curation of literature and by analyzing three-dimensional structures of protein complexes",
            "probability": 0.0
        },
        {
            "start_logit": -5.57421875,
            "end_logit": -8.859375,
            "text": "me is derived by manual curation of literature and by analyzing three-dimensional structures of protein complexes.",
            "probability": 0.0
        }
    ],
    "5333f728d6d3ac6a34000041_4": [
        {
            "start_logit": 13.515625,
            "end_logit": 12.8515625,
            "text": "Support Vector Machine",
            "probability": 0.99609375
        },
        {
            "start_logit": 13.515625,
            "end_logit": 7.2265625,
            "text": "Support Vector Machine (SVM",
            "probability": 0.00359344482421875
        },
        {
            "start_logit": 6.6171875,
            "end_logit": 7.2265625,
            "text": "SVM",
            "probability": 3.635883331298828e-06
        },
        {
            "start_logit": 13.515625,
            "end_logit": -3.955078125,
            "text": "Support",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.515625,
            "end_logit": -4.51171875,
            "text": "Support Vector Machine (SVM) is used to cluster the pockets that are most likely to bind ligands with the attributes of geometric characteristics, interaction potential",
            "probability": 0.0
        },
        {
            "start_logit": -5.52734375,
            "end_logit": 12.8515625,
            "text": "Machine",
            "probability": 0.0
        },
        {
            "start_logit": 13.515625,
            "end_logit": -7.87890625,
            "text": "Support Vector Machine (",
            "probability": 0.0
        },
        {
            "start_logit": 13.515625,
            "end_logit": -7.9765625,
            "text": "Support Vector Machine (SVM)",
            "probability": 0.0
        },
        {
            "start_logit": 13.515625,
            "end_logit": -8.234375,
            "text": "Support Vector",
            "probability": 0.0
        },
        {
            "start_logit": 13.515625,
            "end_logit": -8.3046875,
            "text": "Support Vector Machine (SVM) is used to cluster the pockets that are most likely to bind ligands with the attributes of geometric characteristics",
            "probability": 0.0
        },
        {
            "start_logit": 13.515625,
            "end_logit": -8.4609375,
            "text": "Support Vector Machine (SVM) is used to cluster the pockets that are most likely to bind ligands with the attributes of geometric characteristics, interaction potential, offset",
            "probability": 0.0
        },
        {
            "start_logit": 13.515625,
            "end_logit": -9.125,
            "text": "Support Vector Machine (SVM) is used to cluster the pockets",
            "probability": 0.0
        },
        {
            "start_logit": 13.515625,
            "end_logit": -9.3046875,
            "text": "Support Vector Machine (SVM) is",
            "probability": 0.0
        },
        {
            "start_logit": 13.515625,
            "end_logit": -9.6171875,
            "text": "Support Vector Machine (SVM) is used to cluster the",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 12.8515625,
            "text": "Vector Machine",
            "probability": 0.0
        },
        {
            "start_logit": 6.6171875,
            "end_logit": -4.51171875,
            "text": "SVM) is used to cluster the pockets that are most likely to bind ligands with the attributes of geometric characteristics, interaction potential",
            "probability": 0.0
        },
        {
            "start_logit": -5.52734375,
            "end_logit": 7.2265625,
            "text": "Machine (SVM",
            "probability": 0.0
        },
        {
            "start_logit": 6.6171875,
            "end_logit": -6.3828125,
            "text": "SVM) is used to cluster the pockets that are most likely to bind ligands with the attributes of geometric characteristics, interaction potential, offset from protein",
            "probability": 0.0
        },
        {
            "start_logit": 6.6171875,
            "end_logit": -7.9765625,
            "text": "SVM)",
            "probability": 0.0
        },
        {
            "start_logit": 6.6171875,
            "end_logit": -8.3046875,
            "text": "SVM) is used to cluster the pockets that are most likely to bind ligands with the attributes of geometric characteristics",
            "probability": 0.0
        }
    ],
    "5333f728d6d3ac6a34000041_5": [
        {
            "start_logit": 13.859375,
            "end_logit": 13.9609375,
            "text": "PEWCC",
            "probability": 1.0
        },
        {
            "start_logit": 13.859375,
            "end_logit": -3.9296875,
            "text": "PE",
            "probability": 0.0
        },
        {
            "start_logit": -4.05859375,
            "end_logit": 13.9609375,
            "text": "CC",
            "probability": 0.0
        },
        {
            "start_logit": -6.63671875,
            "end_logit": 13.9609375,
            "text": "graph mining algorithm (PEWCC",
            "probability": 0.0
        },
        {
            "start_logit": 13.859375,
            "end_logit": -6.578125,
            "text": "PEWCC) to identify such protein complexes. Firstly, the algorithm assesses the reliability of the interaction data",
            "probability": 0.0
        },
        {
            "start_logit": 13.859375,
            "end_logit": -7.26171875,
            "text": "PEW",
            "probability": 0.0
        },
        {
            "start_logit": 13.859375,
            "end_logit": -8.1640625,
            "text": "PEWCC)",
            "probability": 0.0
        },
        {
            "start_logit": 13.859375,
            "end_logit": -8.5234375,
            "text": "PEWCC) to identify such protein complexes. Firstly, the algorithm",
            "probability": 0.0
        },
        {
            "start_logit": 13.859375,
            "end_logit": -8.828125,
            "text": "PEWCC) to identify such protein complexes. Firstly, the algorithm assesses the reliability of the interaction",
            "probability": 0.0
        },
        {
            "start_logit": 13.859375,
            "end_logit": -8.890625,
            "text": "PEWCC) to identify such protein complexes. Firstly, the algorithm assesses the reliability of the interaction data, then predicts protein complexes",
            "probability": 0.0
        },
        {
            "start_logit": -9.2265625,
            "end_logit": 13.9609375,
            "text": "WCC",
            "probability": 0.0
        },
        {
            "start_logit": -9.515625,
            "end_logit": 13.9609375,
            "text": "algorithm (PEWCC",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": 13.9609375,
            "text": "mining algorithm (PEWCC",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 13.9609375,
            "text": "(PEWCC",
            "probability": 0.0
        },
        {
            "start_logit": -6.63671875,
            "end_logit": -3.9296875,
            "text": "graph mining algorithm (PE",
            "probability": 0.0
        },
        {
            "start_logit": -6.63671875,
            "end_logit": -3.98828125,
            "text": "graph mining",
            "probability": 0.0
        },
        {
            "start_logit": -4.05859375,
            "end_logit": -6.578125,
            "text": "CC) to identify such protein complexes. Firstly, the algorithm assesses the reliability of the interaction data",
            "probability": 0.0
        },
        {
            "start_logit": -6.63671875,
            "end_logit": -5.0859375,
            "text": "graph mining algorithm",
            "probability": 0.0
        },
        {
            "start_logit": -4.05859375,
            "end_logit": -8.1640625,
            "text": "CC)",
            "probability": 0.0
        },
        {
            "start_logit": -4.05859375,
            "end_logit": -8.5234375,
            "text": "CC) to identify such protein complexes. Firstly, the algorithm",
            "probability": 0.0
        }
    ],
    "5333f728d6d3ac6a34000041_6": [
        {
            "start_logit": 11.203125,
            "end_logit": 12.4140625,
            "text": "iPTMClust",
            "probability": 0.95166015625
        },
        {
            "start_logit": 11.203125,
            "end_logit": 9.40625,
            "text": "iPTMClust, which extends a recently introduced PTM refinement algorithm PTMClust",
            "probability": 0.046630859375
        },
        {
            "start_logit": 7.76171875,
            "end_logit": 9.40625,
            "text": "PTMClust",
            "probability": 0.001499176025390625
        },
        {
            "start_logit": -6.23046875,
            "end_logit": 12.4140625,
            "text": "st",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -6.38671875,
            "text": "iPTMC",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -6.41015625,
            "text": "iPT",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -7.1015625,
            "text": "iPTMClust, which extends a recently introduced PTM refinement algorithm PTMC",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -7.24609375,
            "text": "iPTMClust, which extends a recently introduced PTM refinement algorithm PTMClust and uses a non-parametric Bayesian model",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -7.29296875,
            "text": "iPTMClu",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -7.296875,
            "text": "iPTMClust, which extends a recently introduced PTM refinement algorithm PTMClu",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -7.859375,
            "text": "iPTMClust, which extends a recently introduced PTM refinement algorithm PT",
            "probability": 0.0
        },
        {
            "start_logit": -6.23046875,
            "end_logit": 9.40625,
            "text": "st, which extends a recently introduced PTM refinement algorithm PTMClust",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -8.2578125,
            "text": "iPTMClust, which extends a recently introduced PTM",
            "probability": 0.0
        },
        {
            "start_logit": -9.5,
            "end_logit": 12.4140625,
            "text": "MClust",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -8.4765625,
            "text": "iPTMClust, which extends a recently introduced PTM refinement algorithm",
            "probability": 0.0
        },
        {
            "start_logit": -9.859375,
            "end_logit": 12.4140625,
            "text": "lust",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 12.4140625,
            "text": "PTM refinement algorithm, iPTMClust",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.40625,
            "text": "st",
            "probability": 0.0
        },
        {
            "start_logit": 7.76171875,
            "end_logit": -7.1015625,
            "text": "PTMC",
            "probability": 0.0
        },
        {
            "start_logit": 7.76171875,
            "end_logit": -7.24609375,
            "text": "PTMClust and uses a non-parametric Bayesian model",
            "probability": 0.0
        }
    ],
    "5333f728d6d3ac6a34000041_7": [
        {
            "start_logit": 13.1953125,
            "end_logit": 13.4296875,
            "text": "NDComplex",
            "probability": 1.0
        },
        {
            "start_logit": 13.1953125,
            "end_logit": -4.88671875,
            "text": "ND",
            "probability": 0.0
        },
        {
            "start_logit": -5.33984375,
            "end_logit": 13.4296875,
            "text": "plex",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 13.4296875,
            "text": "Complex",
            "probability": 0.0
        },
        {
            "start_logit": 13.1953125,
            "end_logit": -8.5078125,
            "text": "NDCom",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 13.4296875,
            "text": "software program NDComplex",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 13.4296875,
            "text": "yeast protein interaction networks, and show that our algorithm is able to identify complexes more accurately than existing algorithms. A software program NDComplex",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": 13.4296875,
            "text": "A software program NDComplex",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 13.4296875,
            "text": "our algorithm is able to identify complexes more accurately than existing algorithms. A software program NDComplex",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 13.4296875,
            "text": "program NDComplex",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": -4.88671875,
            "text": "software program ND",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": -4.88671875,
            "text": "our algorithm on a few yeast protein interaction networks, and show that our algorithm is able to identify complexes more accurately than existing algorithms. A software program ND",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -4.88671875,
            "text": "yeast protein interaction networks, and show that our algorithm is able to identify complexes more accurately than existing algorithms. A software program ND",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": -4.88671875,
            "text": "A software program ND",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": -4.88671875,
            "text": "our algorithm is able to identify complexes more accurately than existing algorithms. A software program ND",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": -4.88671875,
            "text": "program ND",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -8.5078125,
            "text": "Com",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": -7.62890625,
            "text": "test our algorithm on a few yeast protein interaction networks",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": -7.62890625,
            "text": "our algorithm on a few yeast protein interaction networks",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -7.62890625,
            "text": "yeast protein interaction networks",
            "probability": 0.0
        }
    ],
    "5333f728d6d3ac6a34000041_8": [
        {
            "start_logit": 14.0078125,
            "end_logit": 14.09375,
            "text": "PROCOMOSS",
            "probability": 1.0
        },
        {
            "start_logit": -3.3046875,
            "end_logit": 14.09375,
            "text": "OSS",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.0078125,
            "end_logit": -3.978515625,
            "text": "PROC",
            "probability": 0.0
        },
        {
            "start_logit": 14.0078125,
            "end_logit": -5.42578125,
            "text": "PROCOM",
            "probability": 0.0
        },
        {
            "start_logit": 14.0078125,
            "end_logit": -5.77734375,
            "text": "PROCOMOSS (Protein Complex Detection using Multi-objective Evolutionary Approach",
            "probability": 0.0
        },
        {
            "start_logit": 14.0078125,
            "end_logit": -6.26171875,
            "text": "PROCOMOSS (Protein Complex Detection using Multi-objective Evolutionary Approach based on Semantic Similarity",
            "probability": 0.0
        },
        {
            "start_logit": 14.0078125,
            "end_logit": -6.98046875,
            "text": "PROCOMOSS (Protein Complex Detection using Multi-objective Evolutionary Approach based on Semantic Similarity) for partitioning the whole PPI network",
            "probability": 0.0
        },
        {
            "start_logit": 14.0078125,
            "end_logit": -7.9921875,
            "text": "PROCOMOSS (Protein Complex Detection using Multi-objective Evolutionary",
            "probability": 0.0
        },
        {
            "start_logit": 14.0078125,
            "end_logit": -8.546875,
            "text": "PROCOMOSS (Protein Complex Detection using Multi-objective Evolutionary Approach based on Semantic",
            "probability": 0.0
        },
        {
            "start_logit": 14.0078125,
            "end_logit": -8.5625,
            "text": "PROCOMOSS (Protein Complex",
            "probability": 0.0
        },
        {
            "start_logit": 14.0078125,
            "end_logit": -8.890625,
            "text": "PROCOMOSS (Protein Complex Detection using Multi-objective Evolutionary Approach based on Semantic Similarity)",
            "probability": 0.0
        },
        {
            "start_logit": 14.0078125,
            "end_logit": -8.9296875,
            "text": "PROCOMOSS (Protein Complex Detection using Multi-objective",
            "probability": 0.0
        },
        {
            "start_logit": 14.0078125,
            "end_logit": -9.2578125,
            "text": "PROCOMOSS (Protein Complex Detection using Multi-objective Evolutionary Approach based",
            "probability": 0.0
        },
        {
            "start_logit": 14.0078125,
            "end_logit": -9.359375,
            "text": "PROCOMOSS (",
            "probability": 0.0
        },
        {
            "start_logit": 14.0078125,
            "end_logit": -9.3828125,
            "text": "PROCOMOSS (Protein Complex Detection using Multi-objective Evolutionary Approach based on Semantic Similarity) for partitioning the whole PPI",
            "probability": 0.0
        },
        {
            "start_logit": 14.0078125,
            "end_logit": -9.390625,
            "text": "PROCOMOSS (Protein Complex Detection using Multi-objective Evolutionary Approach based on",
            "probability": 0.0
        },
        {
            "start_logit": 14.0078125,
            "end_logit": -9.4765625,
            "text": "PROCOMOSS (Protein Complex Detection",
            "probability": 0.0
        },
        {
            "start_logit": -9.578125,
            "end_logit": 14.09375,
            "text": "OMOSS",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 14.09375,
            "text": "developed an algorithm PROCOMOSS",
            "probability": 0.0
        },
        {
            "start_logit": -3.3046875,
            "end_logit": -5.77734375,
            "text": "OSS (Protein Complex Detection using Multi-objective Evolutionary Approach",
            "probability": 0.0
        }
    ],
    "5333f728d6d3ac6a34000041_9": [
        {
            "start_logit": 13.2890625,
            "end_logit": 13.4765625,
            "text": "metaPIS",
            "probability": 1.0
        },
        {
            "start_logit": -4.59375,
            "end_logit": 13.4765625,
            "text": "IS",
            "probability": 0.0
        },
        {
            "start_logit": 13.2890625,
            "end_logit": -4.43359375,
            "text": "metaP",
            "probability": 0.0
        },
        {
            "start_logit": 13.2890625,
            "end_logit": -6.41796875,
            "text": "metaPIS' web-server",
            "probability": 0.0
        },
        {
            "start_logit": 13.2890625,
            "end_logit": -7.93359375,
            "text": "metaPIS' web-server was implemented for meta-prediction",
            "probability": 0.0
        },
        {
            "start_logit": 13.2890625,
            "end_logit": -8.9921875,
            "text": "metaPIS' web-server was implemented",
            "probability": 0.0
        },
        {
            "start_logit": 13.2890625,
            "end_logit": -9.1640625,
            "text": "metaPIS' web-server was implemented for meta",
            "probability": 0.0
        },
        {
            "start_logit": 13.2890625,
            "end_logit": -9.1953125,
            "text": "metaPIS' web",
            "probability": 0.0
        },
        {
            "start_logit": 13.2890625,
            "end_logit": -9.2890625,
            "text": "metaPIS' web-server was implemented for meta-prediction.",
            "probability": 0.0
        },
        {
            "start_logit": 13.2890625,
            "end_logit": -9.53125,
            "text": "metaPIS' web-server was",
            "probability": 0.0
        },
        {
            "start_logit": 13.2890625,
            "end_logit": -9.53125,
            "text": "metaPIS' web-server was implemented for",
            "probability": 0.0
        },
        {
            "start_logit": -9.7265625,
            "end_logit": 13.4765625,
            "text": "'metaPIS",
            "probability": 0.0
        },
        {
            "start_logit": 13.2890625,
            "end_logit": -9.71875,
            "text": "metaPIS' web-server was implemented for meta-",
            "probability": 0.0
        },
        {
            "start_logit": 13.2890625,
            "end_logit": -9.71875,
            "text": "metaPIS'",
            "probability": 0.0
        },
        {
            "start_logit": 13.2890625,
            "end_logit": -10.078125,
            "text": "metaPIS' web-",
            "probability": 0.0
        },
        {
            "start_logit": -4.59375,
            "end_logit": -6.41796875,
            "text": "IS' web-server",
            "probability": 0.0
        },
        {
            "start_logit": -4.59375,
            "end_logit": -7.93359375,
            "text": "IS' web-server was implemented for meta-prediction",
            "probability": 0.0
        },
        {
            "start_logit": -4.59375,
            "end_logit": -8.9921875,
            "text": "IS' web-server was implemented",
            "probability": 0.0
        },
        {
            "start_logit": -4.59375,
            "end_logit": -9.1640625,
            "text": "IS' web-server was implemented for meta",
            "probability": 0.0
        },
        {
            "start_logit": -4.59375,
            "end_logit": -9.1953125,
            "text": "IS' web",
            "probability": 0.0
        }
    ],
    "5333f728d6d3ac6a34000041_10": [
        {
            "start_logit": 13.5546875,
            "end_logit": 13.890625,
            "text": "EPOF",
            "probability": 1.0
        },
        {
            "start_logit": -4.11328125,
            "end_logit": 13.890625,
            "text": "F",
            "probability": 0.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -4.41015625,
            "text": "EPO",
            "probability": 0.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -5.93359375,
            "text": "EPOF, is proposed, using essential proteins and the local metric of vertex fitness",
            "probability": 0.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -7.9140625,
            "text": "EPOF, is proposed, using essential proteins",
            "probability": 0.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -8.5859375,
            "text": "EPOF, is proposed, using essential proteins and the local metric of vertex",
            "probability": 0.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -8.6015625,
            "text": "EPOF, is proposed, using essential proteins and the local metric",
            "probability": 0.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -8.640625,
            "text": "EPOF, is proposed, using essential",
            "probability": 0.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -9.046875,
            "text": "EPOF,",
            "probability": 0.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -9.53125,
            "text": "EPOF, is proposed, using essential proteins and",
            "probability": 0.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -9.59375,
            "text": "EPOF, is proposed, using essential proteins and the",
            "probability": 0.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -9.6015625,
            "text": "EPOF, is proposed",
            "probability": 0.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -9.7109375,
            "text": "EPOF, is",
            "probability": 0.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -9.9140625,
            "text": "EPOF, is proposed, using",
            "probability": 0.0
        },
        {
            "start_logit": -10.328125,
            "end_logit": 13.890625,
            "text": "named EPOF",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 13.890625,
            "text": "protein complex identifying method, named EPOF",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 13.890625,
            "text": "identifying method, named EPOF",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 13.890625,
            "text": "novel protein complex identifying method, named EPOF",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 13.890625,
            "text": "complex identifying method, named EPOF",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 13.890625,
            "text": "this paper, a novel protein complex identifying method, named EPOF",
            "probability": 0.0
        }
    ],
    "5333f728d6d3ac6a34000041_11": [
        {
            "start_logit": 12.703125,
            "end_logit": 12.96875,
            "text": "EAGLE",
            "probability": 1.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": -1.658203125,
            "text": "EAGLE, NFC, MCODE",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 12.703125,
            "end_logit": -4.03515625,
            "text": "EAGLE, NFC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.453125,
            "end_logit": 12.96875,
            "text": "E",
            "probability": 0.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": -5.4921875,
            "text": "EA",
            "probability": 0.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": -5.93359375,
            "text": "EAGLE, NFC, MCODE, DPClus, IPCA, CPM, MCL, CMC, SPICi, and Core-Attachment",
            "probability": 0.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": -6.0703125,
            "text": "EAGLE, NFC, MCODE, DPClus",
            "probability": 0.0
        },
        {
            "start_logit": -6.4765625,
            "end_logit": 12.96875,
            "text": "EPOF to other ten previous algorithms, including EAGLE",
            "probability": 0.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": -6.65234375,
            "text": "EAGLE, NF",
            "probability": 0.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": -6.8125,
            "text": "EAGLE, NFC, MC",
            "probability": 0.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": -7.16015625,
            "text": "EAGL",
            "probability": 0.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": -7.21484375,
            "text": "EAGLE, NFC, MCODE, DPClus, IPCA, CPM, MCL, CMC",
            "probability": 0.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": -7.59765625,
            "text": "EAGLE, NFC, MCODE, DPClus, IPCA, CPM, MCL, CMC, SPICi",
            "probability": 0.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": -7.83984375,
            "text": "EAGLE, NFC, MCODE, DPClus, IPCA, CPM",
            "probability": 0.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": -8.125,
            "text": "EAGLE, NFC, MCODE, DPClus, IPCA, CPM, MCL",
            "probability": 0.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": -8.2734375,
            "text": "EAGLE, NFC, MCODE, DPClus, IPCA",
            "probability": 0.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": -8.71875,
            "text": "EAGLE, NFC, MCODE, DPC",
            "probability": 0.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": -8.8984375,
            "text": "EAGLE, NFC, MCODE, DPClus, IPCA, CPM, MCL, CMC, SPICi, and Core",
            "probability": 0.0
        },
        {
            "start_logit": -9.2421875,
            "end_logit": 12.96875,
            "text": "GLE",
            "probability": 0.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": -9.40625,
            "text": "EAGLE, NFC, MCODE, DPClus, IPCA, CPM, MCL, CMC, SPICi, and Core-",
            "probability": 0.0
        }
    ],
    "5333f728d6d3ac6a34000041_12": [
        {
            "start_logit": 9.328125,
            "end_logit": 10.3046875,
            "text": "ClusterONE",
            "probability": 0.9990234375
        },
        {
            "start_logit": 9.328125,
            "end_logit": 3.23828125,
            "text": "ClusterONE, CMC, CFinder",
            "probability": 0.0008554458618164062
        },
        {
            "start_logit": 9.328125,
            "end_logit": 0.6435546875,
            "text": "ClusterONE, CMC",
            "probability": 6.395578384399414e-05
        },
        {
            "start_logit": 9.328125,
            "end_logit": -4.109375,
            "text": "ClusterONE, CMC, CFinder, MCL",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 0.0980224609375,
            "end_logit": 3.23828125,
            "text": "CFinder",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -6.1875,
            "text": "ClusterONE, CMC, CFinder, MCL, MCode",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 10.3046875,
            "text": "ONE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -6.67578125,
            "text": "ClusterONE, CMC, CF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.00390625,
            "text": "ClusterONE, CMC, CFinder, MCL, MCode and Core",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.1689453125,
            "end_logit": 3.23828125,
            "text": "CMC, CFinder",
            "probability": 0.0
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.89453125,
            "text": "Cluster",
            "probability": 0.0
        },
        {
            "start_logit": 9.328125,
            "end_logit": -8.5078125,
            "text": "ClusterONE, CMC, CFinder, MCL, MCode and",
            "probability": 0.0
        },
        {
            "start_logit": 9.328125,
            "end_logit": -8.8515625,
            "text": "ClusterONE, CMC, CFinder, MCL, MCode and Core) in terms of precision and recall",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": 10.3046875,
            "text": "ProRank to some of the well known protein complex prediction methods (ClusterONE",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 10.3046875,
            "text": "of the well known protein complex prediction methods (ClusterONE",
            "probability": 0.0
        },
        {
            "start_logit": 9.328125,
            "end_logit": -9.2734375,
            "text": "ClusterONE, CMC, CFinder, MCL, MCode and Core)",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 10.3046875,
            "text": "compare the performance of ProRank to some of the well known protein complex prediction methods (ClusterONE",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 10.3046875,
            "text": "performance of ProRank to some of the well known protein complex prediction methods (ClusterONE",
            "probability": 0.0
        },
        {
            "start_logit": -1.1689453125,
            "end_logit": 0.6435546875,
            "text": "CMC",
            "probability": 0.0
        },
        {
            "start_logit": 0.0980224609375,
            "end_logit": -4.109375,
            "text": "CFinder, MCL",
            "probability": 0.0
        }
    ],
    "5333f728d6d3ac6a34000041_13": [
        {
            "start_logit": 12.0859375,
            "end_logit": 11.2421875,
            "text": "MCL",
            "probability": 1.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -5.671875,
            "text": "MCL, Spectral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -6.03515625,
            "text": "MCL, Spectral, RNSC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -7.05078125,
            "text": "MCL, Spectral, RNSC and Affinity Propagation",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -7.12890625,
            "text": "MCL, Spectral, RNSC and Affinity Propagation algorithms",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -7.484375,
            "text": "MCL, Spectral, RNSC and Affinity",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -8.296875,
            "text": "MCL, Spectral, RNSC and Affinity Propagation algorithms and applied them to six PPI datasets produced experimentally by Yeast 2 Hybrid (Y2H",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -8.96875,
            "text": "MCL, Spectral, RNSC and Affinity Propagation algorithms and applied them to six PPI",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -8.9921875,
            "text": "MCL, Spectral, RNSC and",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -9.0625,
            "text": "MCL, Spectral, RNSC and Affinity Propagation algorithms and applied them",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -9.40625,
            "text": "MCL, Spectral, RNS",
            "probability": 0.0
        },
        {
            "start_logit": 12.0859375,
            "end_logit": -9.4921875,
            "text": "MCL, Spectral, RNSC and Affinity Propagation algorithms and applied them to six PPI datasets produced experimentally by Yeast 2 Hybrid (Y2",
            "probability": 0.0
        },
        {
            "start_logit": -9.8359375,
            "end_logit": 11.2421875,
            "text": "clustering algorithms using six different interaction datasets. We parameterized the MCL",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 11.2421875,
            "text": "parameterized the MCL",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 11.2421875,
            "text": "different interaction datasets. We parameterized the MCL",
            "probability": 0.0
        },
        {
            "start_logit": -7.1015625,
            "end_logit": -5.671875,
            "text": "Spectral",
            "probability": 0.0
        },
        {
            "start_logit": -7.1015625,
            "end_logit": -6.03515625,
            "text": "Spectral, RNSC",
            "probability": 0.0
        },
        {
            "start_logit": -7.1015625,
            "end_logit": -7.05078125,
            "text": "Spectral, RNSC and Affinity Propagation",
            "probability": 0.0
        },
        {
            "start_logit": -7.1015625,
            "end_logit": -7.12890625,
            "text": "Spectral, RNSC and Affinity Propagation algorithms",
            "probability": 0.0
        },
        {
            "start_logit": -7.1015625,
            "end_logit": -7.484375,
            "text": "Spectral, RNSC and Affinity",
            "probability": 0.0
        }
    ],
    "5333f728d6d3ac6a34000041_14": [
        {
            "start_logit": 14.0,
            "end_logit": 14.3125,
            "text": "HKC",
            "probability": 1.0
        },
        {
            "start_logit": -3.3359375,
            "end_logit": 14.3125,
            "text": "C",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -3.02734375,
            "text": "HKC, to detect protein complexes in genome-scale PPI networks. HKC mainly uses the concepts of highest k-core",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -3.82421875,
            "text": "HK",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -6.28515625,
            "text": "HKC, to detect protein complexes in genome-scale PPI networks. HKC mainly uses the concepts of highest k-core and cohesion",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -6.81640625,
            "text": "HKC, to detect protein complexes in genome-scale PPI networks. HKC mainly uses the concepts of highest",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -7.21875,
            "text": "HKC, to detect protein complexes in genome-scale PPI networks. HKC mainly uses the concepts of highest k",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -7.3515625,
            "text": "HKC,",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -7.81640625,
            "text": "HKC, to detect protein complexes in genome-scale PPI networks",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -8.1171875,
            "text": "HKC, to detect protein complexes in genome-scale PPI networks. HKC mainly uses the concepts of highest k-",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -8.2421875,
            "text": "HKC, to detect protein complexes in genome-scale PPI networks. HKC",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -8.3359375,
            "text": "HKC, to detect protein complexes in genome-scale PPI networks. HKC mainly uses the concepts of highest k-core and",
            "probability": 0.0
        },
        {
            "start_logit": -8.8828125,
            "end_logit": 14.3125,
            "text": "topology-based algorithm, HKC",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -9.0078125,
            "text": "HKC, to detect protein complexes",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -9.1796875,
            "text": "HKC, to detect protein complexes in genome-scale PPI",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 14.3125,
            "text": "algorithm, HKC",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 14.3125,
            "text": "new topology-based algorithm, HKC",
            "probability": 0.0
        },
        {
            "start_logit": -3.3359375,
            "end_logit": -3.02734375,
            "text": "C, to detect protein complexes in genome-scale PPI networks. HKC mainly uses the concepts of highest k-core",
            "probability": 0.0
        },
        {
            "start_logit": -3.3359375,
            "end_logit": -6.28515625,
            "text": "C, to detect protein complexes in genome-scale PPI networks. HKC mainly uses the concepts of highest k-core and cohesion",
            "probability": 0.0
        },
        {
            "start_logit": -6.62109375,
            "end_logit": -3.02734375,
            "text": "k-core",
            "probability": 0.0
        }
    ],
    "5333f728d6d3ac6a34000041_15": [
        {
            "start_logit": 13.6015625,
            "end_logit": 14.078125,
            "text": "RRW",
            "probability": 1.0
        },
        {
            "start_logit": -3.75390625,
            "end_logit": 14.078125,
            "text": "W",
            "probability": 0.0
        },
        {
            "start_logit": 13.6015625,
            "end_logit": -4.421875,
            "text": "RR",
            "probability": 0.0
        },
        {
            "start_logit": -7.80078125,
            "end_logit": 14.078125,
            "text": "Macropol et al. proposed a protein complex prediction algorithm, called RRW",
            "probability": 0.0
        },
        {
            "start_logit": 13.6015625,
            "end_logit": -8.25,
            "text": "RRW, which repeatedly expands a current cluster of proteins according to the stationary vector of a random walk",
            "probability": 0.0
        },
        {
            "start_logit": 13.6015625,
            "end_logit": -8.6875,
            "text": "RRW, which repeatedly expands a current cluster of proteins",
            "probability": 0.0
        },
        {
            "start_logit": -9.9921875,
            "end_logit": 14.078125,
            "text": "called RRW",
            "probability": 0.0
        },
        {
            "start_logit": -2.873046875,
            "end_logit": -1.8466796875,
            "text": "NWE",
            "probability": 0.0
        },
        {
            "start_logit": -2.873046875,
            "end_logit": -5.01171875,
            "text": "NW",
            "probability": 0.0
        },
        {
            "start_logit": -7.76171875,
            "end_logit": -1.8466796875,
            "text": "E",
            "probability": 0.0
        },
        {
            "start_logit": -2.873046875,
            "end_logit": -6.75,
            "text": "NWE (Node",
            "probability": 0.0
        },
        {
            "start_logit": -2.873046875,
            "end_logit": -7.18359375,
            "text": "NWE (Node-Weighted Expansion of clusters of proteins)",
            "probability": 0.0
        },
        {
            "start_logit": -2.873046875,
            "end_logit": -8.203125,
            "text": "NWE (Node-Weighted Expansion of clusters of proteins",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": -1.8466796875,
            "text": "resulting algorithm is called NWE",
            "probability": 0.0
        },
        {
            "start_logit": -10.0234375,
            "end_logit": -1.8466796875,
            "text": "of which is weighted by the sum of the strengths of supporting evidence for the direct physical interactions involving the protein. The resulting algorithm is called NWE",
            "probability": 0.0
        },
        {
            "start_logit": -3.75390625,
            "end_logit": -8.25,
            "text": "W, which repeatedly expands a current cluster of proteins according to the stationary vector of a random walk",
            "probability": 0.0
        },
        {
            "start_logit": -7.80078125,
            "end_logit": -4.421875,
            "text": "Macropol et al. proposed a protein complex prediction algorithm, called RR",
            "probability": 0.0
        },
        {
            "start_logit": -3.75390625,
            "end_logit": -8.6875,
            "text": "W, which repeatedly expands a current cluster of proteins",
            "probability": 0.0
        },
        {
            "start_logit": -7.55078125,
            "end_logit": -5.26171875,
            "text": "RRW",
            "probability": 0.0
        },
        {
            "start_logit": -7.80078125,
            "end_logit": -5.51171875,
            "text": "Macropol",
            "probability": 0.0
        }
    ],
    "5333f728d6d3ac6a34000041_16": [
        {
            "start_logit": 10.9296875,
            "end_logit": 10.8515625,
            "text": "CPM",
            "probability": 1.0
        },
        {
            "start_logit": 10.9296875,
            "end_logit": 1.4794921875,
            "text": "CPM and introduced distance restriction, and develop a novel algorithm called CP-DR",
            "probability": 8.481740951538086e-05
        },
        {
            "start_logit": 10.9296875,
            "end_logit": -2.787109375,
            "text": "CPM and introduced distance restriction, and develop a novel algorithm called CP",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -3.892578125,
            "end_logit": 10.8515625,
            "text": "algorithm CPM",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.85546875,
            "end_logit": 10.8515625,
            "text": "k-clique community of algorithm CPM",
            "probability": 0.0
        },
        {
            "start_logit": 10.9296875,
            "end_logit": -7.41796875,
            "text": "CPM and introduced distance restriction",
            "probability": 0.0
        },
        {
            "start_logit": 1.7958984375,
            "end_logit": 1.4794921875,
            "text": "CP-DR",
            "probability": 0.0
        },
        {
            "start_logit": 10.9296875,
            "end_logit": -7.91015625,
            "text": "CPM and introduced distance restriction, and develop a novel algorithm called CP-",
            "probability": 0.0
        },
        {
            "start_logit": 10.9296875,
            "end_logit": -8.109375,
            "text": "CPM and introduced distance restriction, and develop a novel algorithm called CP-DR based on the new topological model",
            "probability": 0.0
        },
        {
            "start_logit": 10.9296875,
            "end_logit": -9.3984375,
            "text": "CPM and introduced distance restriction,",
            "probability": 0.0
        },
        {
            "start_logit": 10.9296875,
            "end_logit": -9.3984375,
            "text": "CPM and introduced distance restriction, and develop a novel algorithm called CP-DR based on the new topological model for identifying protein complexes",
            "probability": 0.0
        },
        {
            "start_logit": -9.9296875,
            "end_logit": 10.8515625,
            "text": "community of algorithm CPM",
            "probability": 0.0
        },
        {
            "start_logit": -10.0859375,
            "end_logit": 10.8515625,
            "text": "topological model by extending the definition of k-clique community of algorithm CPM",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 10.8515625,
            "text": "extending the definition of k-clique community of algorithm CPM",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 10.8515625,
            "text": "new topological model by extending the definition of k-clique community of algorithm CPM",
            "probability": 0.0
        },
        {
            "start_logit": 1.7958984375,
            "end_logit": -2.787109375,
            "text": "CP",
            "probability": 0.0
        },
        {
            "start_logit": -3.892578125,
            "end_logit": 1.4794921875,
            "text": "algorithm CPM and introduced distance restriction, and develop a novel algorithm called CP-DR",
            "probability": 0.0
        },
        {
            "start_logit": -6.85546875,
            "end_logit": 1.4794921875,
            "text": "k-clique community of algorithm CPM and introduced distance restriction, and develop a novel algorithm called CP-DR",
            "probability": 0.0
        },
        {
            "start_logit": 1.7958984375,
            "end_logit": -7.91015625,
            "text": "CP-",
            "probability": 0.0
        },
        {
            "start_logit": 1.7958984375,
            "end_logit": -8.109375,
            "text": "CP-DR based on the new topological model",
            "probability": 0.0
        }
    ],
    "5333f728d6d3ac6a34000041_17": [
        {
            "start_logit": 13.75,
            "end_logit": 14.25,
            "text": "PIPE",
            "probability": 1.0
        },
        {
            "start_logit": -3.48046875,
            "end_logit": 14.25,
            "text": "E",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.75,
            "end_logit": -4.21875,
            "text": "PIP",
            "probability": 0.0
        },
        {
            "start_logit": 13.75,
            "end_logit": -7.98046875,
            "text": "PIPE. This tool is capable of predicting protein-protein interactions for any target pair of the yeast Saccharomyces cerevisiae proteins",
            "probability": 0.0
        },
        {
            "start_logit": 13.75,
            "end_logit": -8.0,
            "text": "PIPE. This tool is capable of predicting protein-protein interactions for any target pair",
            "probability": 0.0
        },
        {
            "start_logit": 13.75,
            "end_logit": -8.140625,
            "text": "PIPE. This tool is capable of predicting protein-protein interactions for any target",
            "probability": 0.0
        },
        {
            "start_logit": 13.75,
            "end_logit": -8.59375,
            "text": "PIPE. This tool is capable of predicting protein-protein interactions for any target pair of the yeast Saccharomyces cerevisiae",
            "probability": 0.0
        },
        {
            "start_logit": 13.75,
            "end_logit": -8.6171875,
            "text": "PIPE. This tool is capable of predicting protein-protein interactions for any target pair of the yeast Saccharomyces cerevisiae proteins from their primary structure",
            "probability": 0.0
        },
        {
            "start_logit": 13.75,
            "end_logit": -8.921875,
            "text": "PIPE. This tool",
            "probability": 0.0
        },
        {
            "start_logit": 13.75,
            "end_logit": -9.1640625,
            "text": "PIPE. This tool is capable of predicting protein-protein interactions",
            "probability": 0.0
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 14.25,
            "text": "Engine termed PIPE",
            "probability": 0.0
        },
        {
            "start_logit": 13.75,
            "end_logit": -9.40625,
            "text": "PIPE. This tool is capable of predicting protein-protein interactions for any target pair of the yeast Saccharomyces cerevisiae proteins from their",
            "probability": 0.0
        },
        {
            "start_logit": 13.75,
            "end_logit": -9.484375,
            "text": "PIPE. This tool is capable of predicting protein-protein interactions for any target pair of the yeast",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 14.25,
            "text": "termed PIPE",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 14.25,
            "text": "Protein-Protein Interaction Prediction Engine termed PIPE",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 14.25,
            "text": "implementation of a novel Protein-Protein Interaction Prediction Engine termed PIPE",
            "probability": 0.0
        },
        {
            "start_logit": -3.48046875,
            "end_logit": -7.98046875,
            "text": "E. This tool is capable of predicting protein-protein interactions for any target pair of the yeast Saccharomyces cerevisiae proteins",
            "probability": 0.0
        },
        {
            "start_logit": -3.48046875,
            "end_logit": -8.0,
            "text": "E. This tool is capable of predicting protein-protein interactions for any target pair",
            "probability": 0.0
        },
        {
            "start_logit": -3.48046875,
            "end_logit": -8.140625,
            "text": "E. This tool is capable of predicting protein-protein interactions for any target",
            "probability": 0.0
        },
        {
            "start_logit": -3.48046875,
            "end_logit": -8.59375,
            "text": "E. This tool is capable of predicting protein-protein interactions for any target pair of the yeast Saccharomyces cerevisiae",
            "probability": 0.0
        }
    ],
    "60321aad1cb411341a000134_1": [
        {
            "start_logit": 9.234375,
            "end_logit": 6.0546875,
            "text": "cytolysin A",
            "probability": 0.94921875
        },
        {
            "start_logit": 9.234375,
            "end_logit": 2.970703125,
            "text": "cytolysin A) and \u03b2-PFT (\u03b1-hemolysin",
            "probability": 0.043365478515625
        },
        {
            "start_logit": 9.234375,
            "end_logit": 1.197265625,
            "text": "cytolysin",
            "probability": 0.007358551025390625
        },
        {
            "start_logit": 9.234375,
            "end_logit": -3.30078125,
            "text": "cytolysin A) and \u03b2-PFT (\u03b1-hemolysin)",
            "probability": 8.171796798706055e-05
        },
        {
            "start_logit": 9.234375,
            "end_logit": -4.34375,
            "text": "cytolysin A)",
            "probability": 2.8908252716064453e-05
        },
        {
            "start_logit": 9.234375,
            "end_logit": -5.4609375,
            "text": "cytolysin A) and \u03b2-PFT (\u03b1-hem",
            "probability": 9.417533874511719e-06
        },
        {
            "start_logit": 0.388916015625,
            "end_logit": 2.970703125,
            "text": "\u03b1-hemolysin",
            "probability": 6.258487701416016e-06
        },
        {
            "start_logit": 9.234375,
            "end_logit": -6.1875,
            "text": "cytolysin A) and \u03b2-PFT (\u03b1",
            "probability": 4.589557647705078e-06
        },
        {
            "start_logit": 9.234375,
            "end_logit": -6.97265625,
            "text": "cytolysin A) and \u03b2-PFT (\u03b1-",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.65625,
            "text": "cytolys",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.66015625,
            "text": "cyto",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.8125,
            "text": "cytolysin A) and \u03b2",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -8.90625,
            "text": "cytolysin A) and \u03b2-PFT (",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.54296875,
            "end_logit": 6.0546875,
            "text": "A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.8828125,
            "end_logit": 6.0546875,
            "text": "lysin A",
            "probability": 0.0
        },
        {
            "start_logit": 0.388916015625,
            "end_logit": -3.30078125,
            "text": "\u03b1-hemolysin)",
            "probability": 0.0
        },
        {
            "start_logit": -6.54296875,
            "end_logit": 2.970703125,
            "text": "A) and \u03b2-PFT (\u03b1-hemolysin",
            "probability": 0.0
        },
        {
            "start_logit": -6.5625,
            "end_logit": 2.970703125,
            "text": "olysin",
            "probability": 0.0
        },
        {
            "start_logit": -9.859375,
            "end_logit": 6.0546875,
            "text": "\u03b1-PFT (cytolysin A",
            "probability": 0.0
        },
        {
            "start_logit": -9.8828125,
            "end_logit": 6.0546875,
            "text": "PFT (cytolysin A",
            "probability": 0.0
        }
    ],
    "60321aad1cb411341a000134_2": [
        {
            "start_logit": 14.0,
            "end_logit": 14.3125,
            "text": "Streptolysin O",
            "probability": 1.0
        },
        {
            "start_logit": -2.91015625,
            "end_logit": 14.3125,
            "text": "O",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.0,
            "end_logit": -3.828125,
            "text": "Strept",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -5.0703125,
            "text": "Streptolysin O (SLO",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -5.65234375,
            "text": "Streptolysin O (SLO)",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -6.9453125,
            "text": "Streptolysin O (",
            "probability": 0.0
        },
        {
            "start_logit": -7.2890625,
            "end_logit": 14.3125,
            "text": "olysin O",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -7.41796875,
            "text": "Streptolysin O (SL",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -8.2578125,
            "text": "Streptolysin O (SLO) is a",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -8.375,
            "text": "Streptolysin",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -8.640625,
            "text": "Streptolysin O (SLO) is a bacterial pore-forming toxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -8.9609375,
            "text": "Streptolysin O (SLO) is",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -9.140625,
            "text": "Streptolysin O (SLO) is a bacterial",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -9.671875,
            "text": "Streptolysin O (SLO) is a bacterial pore-forming toxin that is employed to permeabilize cell membranes in some biological experiments",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -9.7421875,
            "text": "Streptolysin O (SLO) is a bacterial pore-forming toxin that is employed to permeabilize cell membranes",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -9.78125,
            "text": "Streptolysin O (SLO) is a bacterial pore-forming toxin that is",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -9.9765625,
            "text": "Streptolysin O (SLO) is a bacterial pore-forming toxin that is employed to",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -10.1171875,
            "text": "Streptolysin O (SLO) is a bacterial pore-forming toxin that is employed to permeabilize cell membranes in some biological experiments.",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -10.1640625,
            "text": "Streptolysin O (SLO) is a bacterial pore-forming toxin that is employed",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -10.1953125,
            "text": "Streptolysin O (SLO) is a bacterial pore-forming toxin that is employed to permeabil",
            "probability": 0.0
        }
    ],
    "60321aad1cb411341a000134_3": [
        {
            "start_logit": 11.2265625,
            "end_logit": 11.3515625,
            "text": "pneumolysin",
            "probability": 1.0
        },
        {
            "start_logit": 11.2265625,
            "end_logit": -6.80859375,
            "text": "pneum",
            "probability": 0.0
        },
        {
            "start_logit": -7.59375,
            "end_logit": 11.3515625,
            "text": "olysin",
            "probability": 0.0
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 11.3515625,
            "text": "S. pneumoniae pneumolysin",
            "probability": 0.0
        },
        {
            "start_logit": -7.85546875,
            "end_logit": -4.83203125,
            "text": "S. pneumoniae",
            "probability": 0.0
        },
        {
            "start_logit": -7.85546875,
            "end_logit": -6.80859375,
            "text": "S. pneumoniae pneum",
            "probability": 0.0
        },
        {
            "start_logit": -7.85546875,
            "end_logit": -9.3203125,
            "text": "S.",
            "probability": 0.0
        },
        {
            "start_logit": -7.85546875,
            "end_logit": -9.828125,
            "text": "S",
            "probability": 0.0
        }
    ],
    "60321aad1cb411341a000134_4": [
        {
            "start_logit": 12.5859375,
            "end_logit": 11.2578125,
            "text": "streptolysin O",
            "probability": 1.0
        },
        {
            "start_logit": 12.5859375,
            "end_logit": -0.427490234375,
            "text": "streptolysin O (SLO)-type and listeriolysin",
            "probability": 8.404254913330078e-06
        },
        {
            "start_logit": 12.5859375,
            "end_logit": -2.396484375,
            "text": "streptolysin",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 12.5859375,
            "end_logit": -4.5703125,
            "text": "streptolysin O (SLO)-type",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.5859375,
            "end_logit": -5.62890625,
            "text": "streptolysin O (SLO",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.5859375,
            "end_logit": -5.83203125,
            "text": "strept",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.5859375,
            "end_logit": -6.19921875,
            "text": "streptolysin O (SL",
            "probability": 0.0
        },
        {
            "start_logit": 12.5859375,
            "end_logit": -6.27734375,
            "text": "streptolysin O (SLO)",
            "probability": 0.0
        },
        {
            "start_logit": 12.5859375,
            "end_logit": -6.58203125,
            "text": "streptolysin O (",
            "probability": 0.0
        },
        {
            "start_logit": 12.5859375,
            "end_logit": -6.7734375,
            "text": "streptolysin O (SLO)-type and listeriol",
            "probability": 0.0
        },
        {
            "start_logit": 12.5859375,
            "end_logit": -7.30859375,
            "text": "streptolysin O (SLO)-type and listeriolys",
            "probability": 0.0
        },
        {
            "start_logit": 12.5859375,
            "end_logit": -7.33203125,
            "text": "streptolysin O (SLO)-type and lister",
            "probability": 0.0
        },
        {
            "start_logit": -6.2578125,
            "end_logit": 11.2578125,
            "text": "O",
            "probability": 0.0
        },
        {
            "start_logit": 12.5859375,
            "end_logit": -8.6640625,
            "text": "streptolysin O (SLO)-type and",
            "probability": 0.0
        },
        {
            "start_logit": 12.5859375,
            "end_logit": -9.75,
            "text": "streptolysin O (SLO)-",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 11.2578125,
            "text": "olysin O",
            "probability": 0.0
        },
        {
            "start_logit": -2.419921875,
            "end_logit": -0.427490234375,
            "text": "listeriolysin",
            "probability": 0.0
        },
        {
            "start_logit": -6.2578125,
            "end_logit": -0.427490234375,
            "text": "O (SLO)-type and listeriolysin",
            "probability": 0.0
        },
        {
            "start_logit": -6.3515625,
            "end_logit": -0.427490234375,
            "text": "and listeriolysin",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -0.427490234375,
            "text": "SLO)-type and listeriolysin",
            "probability": 0.0
        }
    ],
    "60321aad1cb411341a000134_5": [
        {
            "start_logit": 10.5078125,
            "end_logit": 10.921875,
            "text": "leukocidin",
            "probability": 1.0
        },
        {
            "start_logit": 10.5078125,
            "end_logit": -6.51171875,
            "text": "leuk",
            "probability": 0.0
        },
        {
            "start_logit": -7.0,
            "end_logit": 10.921875,
            "text": "din",
            "probability": 0.0
        },
        {
            "start_logit": -7.640625,
            "end_logit": 10.921875,
            "text": "staphylococcal pore-forming cytotoxin, leukocidin",
            "probability": 0.0
        },
        {
            "start_logit": -8.640625,
            "end_logit": 10.921875,
            "text": "cytotoxin, leukocidin",
            "probability": 0.0
        },
        {
            "start_logit": 10.5078125,
            "end_logit": -8.4453125,
            "text": "leukoci",
            "probability": 0.0
        },
        {
            "start_logit": -9.1171875,
            "end_logit": 10.921875,
            "text": "ocidin",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": 10.921875,
            "text": "ere we report the structures of a staphylococcal pore-forming cytotoxin, leukocidin",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 10.921875,
            "text": ", leukocidin",
            "probability": 0.0
        },
        {
            "start_logit": -7.640625,
            "end_logit": -6.51171875,
            "text": "staphylococcal pore-forming cytotoxin, leuk",
            "probability": 0.0
        },
        {
            "start_logit": -7.640625,
            "end_logit": -7.0859375,
            "text": "staphylococcal pore-forming cytotoxin",
            "probability": 0.0
        },
        {
            "start_logit": -8.640625,
            "end_logit": -6.51171875,
            "text": "cytotoxin, leuk",
            "probability": 0.0
        },
        {
            "start_logit": -8.640625,
            "end_logit": -7.0859375,
            "text": "cytotoxin",
            "probability": 0.0
        },
        {
            "start_logit": -7.640625,
            "end_logit": -8.4453125,
            "text": "staphylococcal pore-forming cytotoxin, leukoci",
            "probability": 0.0
        },
        {
            "start_logit": -7.640625,
            "end_logit": -8.7734375,
            "text": "staphylococcal",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": -6.51171875,
            "text": "ere we report the structures of a staphylococcal pore-forming cytotoxin, leuk",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": -6.51171875,
            "text": ", leuk",
            "probability": 0.0
        },
        {
            "start_logit": -8.640625,
            "end_logit": -8.4453125,
            "text": "cytotoxin, leukoci",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": -7.0859375,
            "text": "ere we report the structures of a staphylococcal pore-forming cytotoxin",
            "probability": 0.0
        },
        {
            "start_logit": -9.1171875,
            "end_logit": -8.4453125,
            "text": "oci",
            "probability": 0.0
        }
    ],
    "56cdf3745795f9a73e000039_1": [
        {
            "start_logit": 11.6796875,
            "end_logit": 11.59375,
            "text": "mTOR",
            "probability": 1.0
        },
        {
            "start_logit": -1.7744140625,
            "end_logit": 11.59375,
            "text": "mTOR kinase controls cell growth, proliferation, and survival through two distinct multiprotein complexes, mTORC1 and mTORC2. mTOR",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 11.6796875,
            "end_logit": -6.10546875,
            "text": "mTOR and mLST8 are in both complexes, while raptor",
            "probability": 0.0
        },
        {
            "start_logit": 11.6796875,
            "end_logit": -6.390625,
            "text": "mTOR and mLST8",
            "probability": 0.0
        },
        {
            "start_logit": 11.6796875,
            "end_logit": -6.43359375,
            "text": "mTOR and mLST8 are in both complexes, while raptor and rictor",
            "probability": 0.0
        },
        {
            "start_logit": 11.6796875,
            "end_logit": -7.4921875,
            "text": "mTOR and mL",
            "probability": 0.0
        },
        {
            "start_logit": 11.6796875,
            "end_logit": -7.8515625,
            "text": "mTOR and mLST8 are",
            "probability": 0.0
        },
        {
            "start_logit": 11.6796875,
            "end_logit": -8.1875,
            "text": "mTOR and mLST",
            "probability": 0.0
        },
        {
            "start_logit": 11.6796875,
            "end_logit": -8.6953125,
            "text": "mTOR and mLST8 are in both complexes, while rap",
            "probability": 0.0
        },
        {
            "start_logit": 11.6796875,
            "end_logit": -8.75,
            "text": "mTOR and mLST8 are in both complexes, while raptor and rict",
            "probability": 0.0
        },
        {
            "start_logit": 11.6796875,
            "end_logit": -8.9765625,
            "text": "mTOR and",
            "probability": 0.0
        },
        {
            "start_logit": 11.6796875,
            "end_logit": -9.4453125,
            "text": "mTOR and mLST8 are in both complexes, while raptor and ri",
            "probability": 0.0
        },
        {
            "start_logit": 11.6796875,
            "end_logit": -9.5,
            "text": "mTOR and mLST8 are in both complexes, while raptor and rictor are part of only mTORC1 and mTORC2",
            "probability": 0.0
        },
        {
            "start_logit": 11.6796875,
            "end_logit": -9.65625,
            "text": "mTOR and mLST8 are in both complexes, while raptor and rictor are part of only mTORC1 and mTORC2, respectively.",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": 11.59375,
            "text": "kinase controls cell growth, proliferation, and survival through two distinct multiprotein complexes, mTORC1 and mTORC2. mTOR",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 11.59375,
            "text": "mTORC2. mTOR",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": 11.59375,
            "text": "mTORC1 and mTORC2. mTOR",
            "probability": 0.0
        },
        {
            "start_logit": -1.7744140625,
            "end_logit": -1.1416015625,
            "text": "mTOR",
            "probability": 0.0
        },
        {
            "start_logit": -1.7744140625,
            "end_logit": -5.93359375,
            "text": "mTOR kinase",
            "probability": 0.0
        },
        {
            "start_logit": -1.7744140625,
            "end_logit": -6.390625,
            "text": "mTOR kinase controls cell growth, proliferation, and survival through two distinct multiprotein complexes, mTORC1 and mTORC2. mTOR and mLST8",
            "probability": 0.0
        }
    ],
    "56cdf3745795f9a73e000039_2": [
        {
            "start_logit": 9.3046875,
            "end_logit": 10.875,
            "text": "mTOR",
            "probability": 1.0
        },
        {
            "start_logit": 9.3046875,
            "end_logit": 0.90625,
            "text": "mTOR (mammalian target of rapamycin",
            "probability": 4.649162292480469e-05
        },
        {
            "start_logit": -0.42529296875,
            "end_logit": 9.9765625,
            "text": "mTOR",
            "probability": 2.4139881134033203e-05
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -3.5703125,
            "text": "mTOR (mammalian target of rapamycin)",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -4.1328125,
            "text": "mTOR (mammalian target of rapamycin) protein kinase is an important regulator of cell growth. Two complexes of mTOR",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -5.89453125,
            "text": "mTOR (mammalian target of rapamycin) protein kinase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.6328125,
            "end_logit": 9.9765625,
            "text": "mTOR-Raptor (regulatory associated protein of mTOR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.41796875,
            "end_logit": 9.9765625,
            "text": "regulatory associated protein of mTOR",
            "probability": 0.0
        },
        {
            "start_logit": -7.625,
            "end_logit": 9.9765625,
            "text": "mTOR have been identified: complex 1, consisting of mTOR-Raptor (regulatory associated protein of mTOR",
            "probability": 0.0
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.609375,
            "text": "mTOR (mammalian target",
            "probability": 0.0
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.69921875,
            "text": "mTOR (mammalian",
            "probability": 0.0
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.98828125,
            "text": "mTOR (mammalian target of rapamycin) protein",
            "probability": 0.0
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -8.1484375,
            "text": "mTOR (mammalian target of",
            "probability": 0.0
        },
        {
            "start_logit": -9.5390625,
            "end_logit": 9.9765625,
            "text": "of mTOR",
            "probability": 0.0
        },
        {
            "start_logit": -9.8515625,
            "end_logit": 9.9765625,
            "text": "Raptor (regulatory associated protein of mTOR",
            "probability": 0.0
        },
        {
            "start_logit": -6.453125,
            "end_logit": 0.90625,
            "text": "mammalian target of rapamycin",
            "probability": 0.0
        },
        {
            "start_logit": -0.42529296875,
            "end_logit": -5.1328125,
            "text": "mTOR)-mLST8 (termed mTORC1), and complex 2, comprising mTOR-Rictor (rapamycin",
            "probability": 0.0
        },
        {
            "start_logit": -0.42529296875,
            "end_logit": -6.51953125,
            "text": "mTOR)-mLST8 (termed mTORC1), and complex 2, comprising mTOR-Rictor (rapamycinins",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 0.90625,
            "text": "rapamycin",
            "probability": 0.0
        },
        {
            "start_logit": -0.42529296875,
            "end_logit": -7.953125,
            "text": "mTOR)-mLST8 (termed mTORC1), and complex 2, comprising mTOR-Rictor (rapamycininsensitive",
            "probability": 0.0
        }
    ],
    "56cdf3745795f9a73e000039_3": [
        {
            "start_logit": 11.8828125,
            "end_logit": 11.0703125,
            "text": "mTOR",
            "probability": 1.0
        },
        {
            "start_logit": 11.8828125,
            "end_logit": -6.7109375,
            "text": "mTOR, and GbetaL",
            "probability": 0.0
        },
        {
            "start_logit": -6.84765625,
            "end_logit": 11.0703125,
            "text": "raptor, mTOR",
            "probability": 0.0
        },
        {
            "start_logit": 11.8828125,
            "end_logit": -8.8828125,
            "text": "mTOR, and Gb",
            "probability": 0.0
        },
        {
            "start_logit": 11.8828125,
            "end_logit": -9.1328125,
            "text": "mTOR, and GbetaL)",
            "probability": 0.0
        },
        {
            "start_logit": 11.8828125,
            "end_logit": -9.1640625,
            "text": "mTOR, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.8828125,
            "end_logit": -9.96875,
            "text": "mTOR,",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": 11.0703125,
            "text": ", mTOR",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 11.0703125,
            "text": "tor, mTOR",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 11.0703125,
            "text": "mTORC1 (raptor, mTOR",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 11.0703125,
            "text": "of mTORC1 (raptor, mTOR",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 11.0703125,
            "text": "composition of mTORC1 (raptor, mTOR",
            "probability": 0.0
        },
        {
            "start_logit": -6.84765625,
            "end_logit": -4.81640625,
            "text": "raptor",
            "probability": 0.0
        },
        {
            "start_logit": -6.84765625,
            "end_logit": -6.7109375,
            "text": "raptor, mTOR, and GbetaL",
            "probability": 0.0
        },
        {
            "start_logit": -6.84765625,
            "end_logit": -7.9375,
            "text": "rap",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": -4.81640625,
            "text": "tor",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": -4.81640625,
            "text": "mTORC1 (raptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": -4.81640625,
            "text": "of mTORC1 (raptor",
            "probability": 0.0
        },
        {
            "start_logit": -8.9453125,
            "end_logit": -6.7109375,
            "text": "GbetaL",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": -4.81640625,
            "text": "composition of mTORC1 (raptor",
            "probability": 0.0
        }
    ],
    "56cdf3745795f9a73e000039_4": [
        {
            "start_logit": 10.078125,
            "end_logit": 12.34375,
            "text": "mTOR",
            "probability": 1.0
        },
        {
            "start_logit": -4.875,
            "end_logit": 12.34375,
            "text": "mammalian target of rapamycin (mTOR",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 10.078125,
            "end_logit": -4.7421875,
            "text": "mTOR)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.078125,
            "end_logit": -5.33984375,
            "text": "mTOR) is part of two distinct complexes, mTORC1, containing raptor",
            "probability": 0.0
        },
        {
            "start_logit": -8.4609375,
            "end_logit": 12.34375,
            "text": "rapamycin (mTOR",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -7.07421875,
            "text": "mTOR) is part of two distinct complexes, mTORC1, containing raptor and mLST8",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -7.83984375,
            "text": "mTOR) is part of two distinct complexes, mTORC1, containing raptor and mLST8, and mTORC2, containing rictor",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": 12.34375,
            "text": "target of rapamycin (mTOR",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 12.34375,
            "text": "(mTOR",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.515625,
            "text": "mTOR) is",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.53125,
            "text": "mTOR) is part of two distinct complexes, mTORC1, containing raptor and mLST8, and mTORC2",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.9140625,
            "text": "mTOR) is part",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -9.0078125,
            "text": "mTOR) is part of two distinct complexes",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -9.03125,
            "text": "mTOR) is part of two distinct complexes, mTORC1, containing raptor and",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -9.15625,
            "text": "mTOR) is part of two distinct complexes, mTORC1, containing rap",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -9.1953125,
            "text": "mTOR) is part of two distinct complexes, mTORC1, containing raptor and mL",
            "probability": 0.0
        },
        {
            "start_logit": -4.875,
            "end_logit": -1.36328125,
            "text": "mammalian target of rapamycin",
            "probability": 0.0
        },
        {
            "start_logit": -4.875,
            "end_logit": -4.7421875,
            "text": "mammalian target of rapamycin (mTOR)",
            "probability": 0.0
        },
        {
            "start_logit": -8.4609375,
            "end_logit": -1.36328125,
            "text": "rapamycin",
            "probability": 0.0
        },
        {
            "start_logit": -4.875,
            "end_logit": -5.33984375,
            "text": "mammalian target of rapamycin (mTOR) is part of two distinct complexes, mTORC1, containing raptor",
            "probability": 0.0
        }
    ],
    "56cdf3745795f9a73e000039_5": [
        {
            "start_logit": 11.34375,
            "end_logit": 12.0390625,
            "text": "mTOR",
            "probability": 1.0
        },
        {
            "start_logit": 11.34375,
            "end_logit": -6.37890625,
            "text": "mTOR, raptor",
            "probability": 0.0
        },
        {
            "start_logit": 11.34375,
            "end_logit": -6.73828125,
            "text": "mTOR, raptor, mLST8/GbetaL and PRAS40",
            "probability": 0.0
        },
        {
            "start_logit": 11.34375,
            "end_logit": -7.76171875,
            "text": "mTOR, raptor, mLST8/GbetaL",
            "probability": 0.0
        },
        {
            "start_logit": 11.34375,
            "end_logit": -8.3359375,
            "text": "mTOR, raptor, mLST8/GbetaL and PRAS",
            "probability": 0.0
        },
        {
            "start_logit": 11.34375,
            "end_logit": -8.4765625,
            "text": "mTOR, raptor, mLST8/Gb",
            "probability": 0.0
        },
        {
            "start_logit": 11.34375,
            "end_logit": -8.4765625,
            "text": "mTOR, raptor, mL",
            "probability": 0.0
        },
        {
            "start_logit": 11.34375,
            "end_logit": -8.484375,
            "text": "mTOR, raptor, mLST8",
            "probability": 0.0
        },
        {
            "start_logit": 11.34375,
            "end_logit": -8.7109375,
            "text": "mTOR, raptor, mLST8/GbetaL and",
            "probability": 0.0
        },
        {
            "start_logit": 11.34375,
            "end_logit": -8.7265625,
            "text": "mTOR, rap",
            "probability": 0.0
        },
        {
            "start_logit": 11.34375,
            "end_logit": -8.9375,
            "text": "mTOR, raptor, mLST",
            "probability": 0.0
        },
        {
            "start_logit": 11.34375,
            "end_logit": -9.078125,
            "text": "mTOR,",
            "probability": 0.0
        },
        {
            "start_logit": 11.34375,
            "end_logit": -9.15625,
            "text": "mTOR, raptor, mLST8/GbetaL and PRA",
            "probability": 0.0
        },
        {
            "start_logit": 11.34375,
            "end_logit": -9.46875,
            "text": "mTOR, raptor, mLST8/GbetaL and PRAS40.",
            "probability": 0.0
        },
        {
            "start_logit": 11.34375,
            "end_logit": -9.578125,
            "text": "mTOR, raptor,",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 12.0390625,
            "text": "mTORC1 protein kinase complex consists of mTOR",
            "probability": 0.0
        },
        {
            "start_logit": -7.94921875,
            "end_logit": -6.73828125,
            "text": "mLST8/GbetaL and PRAS40",
            "probability": 0.0
        },
        {
            "start_logit": -8.3671875,
            "end_logit": -6.37890625,
            "text": "raptor",
            "probability": 0.0
        },
        {
            "start_logit": -8.3671875,
            "end_logit": -6.73828125,
            "text": "raptor, mLST8/GbetaL and PRAS40",
            "probability": 0.0
        },
        {
            "start_logit": -7.94921875,
            "end_logit": -7.76171875,
            "text": "mLST8/GbetaL",
            "probability": 0.0
        }
    ],
    "56cdf3745795f9a73e000039_6": [
        {
            "start_logit": 11.1171875,
            "end_logit": 12.1796875,
            "text": "mTOR",
            "probability": 1.0
        },
        {
            "start_logit": 11.1171875,
            "end_logit": -4.55859375,
            "text": "mTOR, Raptor (regulatory associated protein of mTOR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.1171875,
            "end_logit": -7.21875,
            "text": "mTOR, Raptor",
            "probability": 0.0
        },
        {
            "start_logit": 11.1171875,
            "end_logit": -7.2890625,
            "text": "mTOR, Raptor (regulatory associated protein",
            "probability": 0.0
        },
        {
            "start_logit": 11.1171875,
            "end_logit": -7.51171875,
            "text": "mTOR, Raptor (regulatory associated protein of mTOR) and mLST8",
            "probability": 0.0
        },
        {
            "start_logit": -9.0078125,
            "end_logit": 12.1796875,
            "text": "complex 1 (mTORC1), consisting of mTOR",
            "probability": 0.0
        },
        {
            "start_logit": 11.1171875,
            "end_logit": -8.0546875,
            "text": "mTOR, Raptor (regulatory associated protein of mTOR)",
            "probability": 0.0
        },
        {
            "start_logit": 11.1171875,
            "end_logit": -8.3125,
            "text": "mTOR, Raptor (regulatory associated protein of mTOR) and",
            "probability": 0.0
        },
        {
            "start_logit": 11.1171875,
            "end_logit": -8.515625,
            "text": "mTOR, Raptor (regulatory associated protein of mTOR) and mLST8 (mammalian lethal with SEC13 protein",
            "probability": 0.0
        },
        {
            "start_logit": 11.1171875,
            "end_logit": -8.625,
            "text": "mTOR, Raptor (regulatory associated protein of mTOR) and mLST8 (mammalian lethal with SEC13 protein 8) and complex 2 (mTORC2",
            "probability": 0.0
        },
        {
            "start_logit": -4.55078125,
            "end_logit": -3.345703125,
            "text": "mTOR",
            "probability": 0.0
        },
        {
            "start_logit": -4.55078125,
            "end_logit": -6.54296875,
            "text": "mTOR (mammalian target of rapamycin",
            "probability": 0.0
        },
        {
            "start_logit": -4.55078125,
            "end_logit": -7.24609375,
            "text": "mTOR (mammalian target of rapamycin)",
            "probability": 0.0
        },
        {
            "start_logit": -7.37890625,
            "end_logit": -4.55859375,
            "text": "mTOR",
            "probability": 0.0
        },
        {
            "start_logit": -7.94921875,
            "end_logit": -4.55859375,
            "text": "regulatory associated protein of mTOR",
            "probability": 0.0
        },
        {
            "start_logit": -4.55078125,
            "end_logit": -8.015625,
            "text": "mTOR (mammalian target of rapamycin) protein kinase",
            "probability": 0.0
        },
        {
            "start_logit": -8.40625,
            "end_logit": -4.55859375,
            "text": "Raptor (regulatory associated protein of mTOR",
            "probability": 0.0
        },
        {
            "start_logit": -4.55078125,
            "end_logit": -8.6484375,
            "text": "mTOR (mammalian target of rapamycin) protein",
            "probability": 0.0
        },
        {
            "start_logit": -9.0078125,
            "end_logit": -4.55859375,
            "text": "complex 1 (mTORC1), consisting of mTOR, Raptor (regulatory associated protein of mTOR",
            "probability": 0.0
        },
        {
            "start_logit": -7.37890625,
            "end_logit": -7.51171875,
            "text": "mTOR) and mLST8",
            "probability": 0.0
        }
    ],
    "5e2f906ffbd6abf43b00002c_1": [
        {
            "start_logit": 12.8359375,
            "end_logit": 11.4609375,
            "text": "oral viscous lidocaine",
            "probability": 1.0
        },
        {
            "start_logit": 12.8359375,
            "end_logit": -0.0460205078125,
            "text": "oral viscous lidocaine/ antacid",
            "probability": 1.0073184967041016e-05
        },
        {
            "start_logit": -0.81103515625,
            "end_logit": 11.4609375,
            "text": "lidocaine",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 12.8359375,
            "end_logit": -2.513671875,
            "text": "oral",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 12.8359375,
            "end_logit": -2.59765625,
            "text": "oral viscous lidocaine/ antacid \u00b1 anticholinergic",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -3.619140625,
            "end_logit": 11.4609375,
            "text": "viscous lidocaine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.8359375,
            "end_logit": -5.52734375,
            "text": "oral viscous lidocaine/ ant",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.8359375,
            "end_logit": -6.93359375,
            "text": "oral viscous",
            "probability": 0.0
        },
        {
            "start_logit": 12.8359375,
            "end_logit": -8.4453125,
            "text": "oral viscous lidocaine/",
            "probability": 0.0
        },
        {
            "start_logit": 12.8359375,
            "end_logit": -8.625,
            "text": "oral viscous lidocaine/ antacid \u00b1 anticholinergic)",
            "probability": 0.0
        },
        {
            "start_logit": 12.8359375,
            "end_logit": -9.484375,
            "text": "oral viscous lidocaine/ antacid \u00b1",
            "probability": 0.0
        },
        {
            "start_logit": 12.8359375,
            "end_logit": -10.03125,
            "text": "oral viscous lidocaine/ antacid \u00b1 anticholinergic) to standard diagnostic protocols (serial electrocardiograms (ECGs)",
            "probability": 0.0
        },
        {
            "start_logit": 0.155029296875,
            "end_logit": -0.0460205078125,
            "text": "antacid",
            "probability": 0.0
        },
        {
            "start_logit": -0.81103515625,
            "end_logit": -0.0460205078125,
            "text": "lidocaine/ antacid",
            "probability": 0.0
        },
        {
            "start_logit": 0.155029296875,
            "end_logit": -2.59765625,
            "text": "antacid \u00b1 anticholinergic",
            "probability": 0.0
        },
        {
            "start_logit": -0.81103515625,
            "end_logit": -2.59765625,
            "text": "lidocaine/ antacid \u00b1 anticholinergic",
            "probability": 0.0
        },
        {
            "start_logit": -3.619140625,
            "end_logit": -0.0460205078125,
            "text": "viscous lidocaine/ antacid",
            "probability": 0.0
        },
        {
            "start_logit": 0.155029296875,
            "end_logit": -5.52734375,
            "text": "ant",
            "probability": 0.0
        },
        {
            "start_logit": -3.619140625,
            "end_logit": -2.59765625,
            "text": "viscous lidocaine/ antacid \u00b1 anticholinergic",
            "probability": 0.0
        },
        {
            "start_logit": -0.81103515625,
            "end_logit": -5.52734375,
            "text": "lidocaine/ ant",
            "probability": 0.0
        }
    ],
    "5e2f906ffbd6abf43b00002c_2": [
        {
            "start_logit": 12.484375,
            "end_logit": 12.2578125,
            "text": "Benzocaine",
            "probability": 1.0
        },
        {
            "start_logit": 12.484375,
            "end_logit": -1.365234375,
            "text": "Benzocaine or viscous Lidocaine",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 12.484375,
            "end_logit": -3.765625,
            "text": "Benzocaine or viscous Lidocaine in addition to 30 cc of Maalox",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.484375,
            "end_logit": -3.880859375,
            "text": "Benzo",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.484375,
            "end_logit": -5.4140625,
            "text": "Benzoca",
            "probability": 0.0
        },
        {
            "start_logit": -5.359375,
            "end_logit": 12.2578125,
            "text": "ine",
            "probability": 0.0
        },
        {
            "start_logit": 12.484375,
            "end_logit": -8.3203125,
            "text": "Benzocaine or viscous Lidocaine in addition to 30 cc of Maalo",
            "probability": 0.0
        },
        {
            "start_logit": 12.484375,
            "end_logit": -8.3515625,
            "text": "Benzocaine or viscous",
            "probability": 0.0
        },
        {
            "start_logit": 12.484375,
            "end_logit": -8.9296875,
            "text": "Benzocaine or viscous Lidocaine in addition to 30 cc of Maalox and 10 cc of Donnatal",
            "probability": 0.0
        },
        {
            "start_logit": 12.484375,
            "end_logit": -9.03125,
            "text": "Benzocaine or viscous Lidocaine in addition to 30 cc of Maalox and",
            "probability": 0.0
        },
        {
            "start_logit": 12.484375,
            "end_logit": -9.0625,
            "text": "Benzocaine or viscous Lidocaine in addition to 30 cc of Ma",
            "probability": 0.0
        },
        {
            "start_logit": 12.484375,
            "end_logit": -9.2265625,
            "text": "Benzocaine or viscous Lidocaine in addition to",
            "probability": 0.0
        },
        {
            "start_logit": 12.484375,
            "end_logit": -9.3046875,
            "text": "Benzocaine or viscous Lidocaine in addition to 30 cc of Maalox and 10 cc of Donnatal.",
            "probability": 0.0
        },
        {
            "start_logit": 12.484375,
            "end_logit": -9.40625,
            "text": "Benzocaine or viscous Lidocaine in addition to 30 cc of",
            "probability": 0.0
        },
        {
            "start_logit": 12.484375,
            "end_logit": -9.4296875,
            "text": "Benzocaine or",
            "probability": 0.0
        },
        {
            "start_logit": 12.484375,
            "end_logit": -9.6171875,
            "text": "Benzocaine or viscous Lidocaine in addition to 30 cc",
            "probability": 0.0
        },
        {
            "start_logit": 12.484375,
            "end_logit": -9.671875,
            "text": "Benzocaine or viscous Lidocaine in addition to 30",
            "probability": 0.0
        },
        {
            "start_logit": 12.484375,
            "end_logit": -9.703125,
            "text": "Benzocaine or viscous Lidocaine in addition",
            "probability": 0.0
        },
        {
            "start_logit": -10.1171875,
            "end_logit": 12.2578125,
            "text": "caine",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 12.2578125,
            "text": "either Benzocaine",
            "probability": 0.0
        }
    ],
    "5e2f906ffbd6abf43b00002c_3": [
        {
            "start_logit": 8.796875,
            "end_logit": 7.90234375,
            "text": "Donnatal",
            "probability": 0.60498046875
        },
        {
            "start_logit": 7.578125,
            "end_logit": 8.09375,
            "text": "antacid",
            "probability": 0.2156982421875
        },
        {
            "start_logit": 7.578125,
            "end_logit": 7.90234375,
            "text": "antacid (group 1); antacid + Donnatal",
            "probability": 0.178955078125
        },
        {
            "start_logit": 8.796875,
            "end_logit": -0.84765625,
            "text": "Donnatal (group 2); antacid + Donnatal + viscous lidocaine",
            "probability": 9.590387344360352e-05
        },
        {
            "start_logit": 7.578125,
            "end_logit": -0.84765625,
            "text": "antacid (group 1); antacid + Donnatal (group 2); antacid + Donnatal + viscous lidocaine",
            "probability": 2.8371810913085938e-05
        },
        {
            "start_logit": 8.796875,
            "end_logit": -4.71484375,
            "text": "Don",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -3.875,
            "end_logit": 7.90234375,
            "text": "; antacid + Donnatal",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 8.796875,
            "end_logit": -5.82421875,
            "text": "Donnat",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.578125,
            "end_logit": -4.71484375,
            "text": "antacid (group 1); antacid + Don",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.578125,
            "end_logit": -5.82421875,
            "text": "antacid (group 1); antacid + Donnat",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.796875,
            "end_logit": -7.3671875,
            "text": "Donnatal (group 2); antacid + Donnatal + viscous",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.796875,
            "end_logit": -7.45703125,
            "text": "Donnatal (group 2); antacid + Donnatal",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.7265625,
            "end_logit": 7.90234375,
            "text": "antacid + Donnatal",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.578125,
            "end_logit": -6.4453125,
            "text": "antacid (group 1); antacid",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.13671875,
            "end_logit": 7.90234375,
            "text": "al",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.578125,
            "end_logit": -7.16015625,
            "text": "ant",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.578125,
            "end_logit": -7.3671875,
            "text": "antacid (group 1); antacid + Donnatal (group 2); antacid + Donnatal + viscous",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.796875,
            "end_logit": -8.671875,
            "text": "Donnatal (group 2); antacid + Donnatal + viscous lidocaine (group 3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.578125,
            "end_logit": -7.45703125,
            "text": "antacid (group 1); antacid + Donnatal (group 2); antacid + Donnatal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.09375,
            "text": "acid",
            "probability": 5.960464477539063e-08
        }
    ],
    "5e2f906ffbd6abf43b00002c_4": [
        {
            "start_logit": 11.1953125,
            "end_logit": 9.671875,
            "text": "antacid",
            "probability": 1.0
        },
        {
            "start_logit": 11.1953125,
            "end_logit": 1.3427734375,
            "text": "antacid, viscous lidocaine",
            "probability": 0.0002397298812866211
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -4.58984375,
            "text": "antacid, viscous lidocaine, and an anticholinergic",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -6.51953125,
            "text": "ant",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -8.25,
            "text": "antacid, viscous",
            "probability": 0.0
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -8.625,
            "text": "antacid, viscous lidocaine, and",
            "probability": 0.0
        },
        {
            "start_logit": 0.50341796875,
            "end_logit": 1.3427734375,
            "text": "lidocaine",
            "probability": 0.0
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -9.4921875,
            "text": "antacid,",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.671875,
            "text": "liquid antacid",
            "probability": 0.0
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -9.609375,
            "text": "antacid, viscous lidocaine,",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.671875,
            "text": "acid",
            "probability": 0.0
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -9.8984375,
            "text": "antacid, viscous lidocaine, and an anticholinergic)",
            "probability": 0.0
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -9.984375,
            "text": "antacid, viscous lidocaine, and an",
            "probability": 0.0
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -10.0703125,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department",
            "probability": 0.0
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -10.1328125,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department in a single hospital",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": 9.671875,
            "text": "STUDY OBJECTIVE: To determine practice patterns regarding administration of the \"GI cocktail\" (a mixture of liquid antacid",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": 9.671875,
            "text": "mixture of liquid antacid",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 9.671875,
            "text": "administration of the \"GI cocktail\" (a mixture of liquid antacid",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 9.671875,
            "text": "To determine practice patterns regarding administration of the \"GI cocktail\" (a mixture of liquid antacid",
            "probability": 0.0
        },
        {
            "start_logit": 0.50341796875,
            "end_logit": -4.58984375,
            "text": "lidocaine, and an anticholinergic",
            "probability": 0.0
        }
    ],
    "5e2f906ffbd6abf43b00002c_5": [
        {
            "start_logit": 2.970703125,
            "end_logit": 7.390625,
            "text": "2% viscous lidocaine",
            "probability": 0.888671875
        },
        {
            "start_logit": 0.60791015625,
            "end_logit": 7.390625,
            "text": "antacid (Mylanta II), or 30 mL of antacid plus 15 mL of 2% viscous lidocaine",
            "probability": 0.083984375
        },
        {
            "start_logit": -0.52880859375,
            "end_logit": 7.390625,
            "text": "lidocaine",
            "probability": 0.026947021484375
        },
        {
            "start_logit": 0.60791015625,
            "end_logit": 0.7763671875,
            "text": "antacid",
            "probability": 0.00011229515075683594
        },
        {
            "start_logit": 2.970703125,
            "end_logit": -1.8017578125,
            "text": "2",
            "probability": 9.08970832824707e-05
        },
        {
            "start_logit": -6.4140625,
            "end_logit": 7.390625,
            "text": "viscous lidocaine",
            "probability": 7.480382919311523e-05
        },
        {
            "start_logit": 0.60791015625,
            "end_logit": -1.8017578125,
            "text": "antacid (Mylanta II), or 30 mL of antacid plus 15 mL of 2",
            "probability": 8.52346420288086e-06
        },
        {
            "start_logit": -8.9453125,
            "end_logit": 7.390625,
            "text": "% viscous lidocaine",
            "probability": 5.9604644775390625e-06
        },
        {
            "start_logit": -8.9609375,
            "end_logit": 7.390625,
            "text": "15 mL of 2% viscous lidocaine",
            "probability": 5.900859832763672e-06
        },
        {
            "start_logit": -9.015625,
            "end_logit": 7.390625,
            "text": "acid (Mylanta II), or 30 mL of antacid plus 15 mL of 2% viscous lidocaine",
            "probability": 5.543231964111328e-06
        },
        {
            "start_logit": -9.2109375,
            "end_logit": 7.390625,
            "text": "or 30 mL of antacid plus 15 mL of 2% viscous lidocaine",
            "probability": 4.5299530029296875e-06
        },
        {
            "start_logit": -9.46875,
            "end_logit": 7.390625,
            "text": "antacid plus 15 mL of 2% viscous lidocaine",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": -9.5078125,
            "end_logit": 7.390625,
            "text": "Mylanta II), or 30 mL of antacid plus 15 mL of 2% viscous lidocaine",
            "probability": 3.3974647521972656e-06
        },
        {
            "start_logit": 2.970703125,
            "end_logit": -5.140625,
            "text": "2%",
            "probability": 3.2186508178710938e-06
        },
        {
            "start_logit": -9.578125,
            "end_logit": 7.390625,
            "text": "of antacid (Mylanta II), or 30 mL of antacid plus 15 mL of 2% viscous lidocaine",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": -9.7578125,
            "end_logit": 7.390625,
            "text": "of antacid plus 15 mL of 2% viscous lidocaine",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": -10.015625,
            "end_logit": 7.390625,
            "text": "of 2% viscous lidocaine",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -10.0625,
            "end_logit": 7.390625,
            "text": "mL of 2% viscous lidocaine",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -10.2421875,
            "end_logit": 7.390625,
            "text": "receive 30 mL of antacid (Mylanta II), or 30 mL of antacid plus 15 mL of 2% viscous lidocaine",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 2.970703125,
            "end_logit": -5.90625,
            "text": "2% viscous",
            "probability": 1.4901161193847656e-06
        }
    ],
    "5e2f906ffbd6abf43b00002c_6": [
        {
            "start_logit": 10.7109375,
            "end_logit": 9.3203125,
            "text": "antacid",
            "probability": 0.9990234375
        },
        {
            "start_logit": 10.7109375,
            "end_logit": 1.9267578125,
            "text": "antacid, viscous lidocaine",
            "probability": 0.0006165504455566406
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -4.19921875,
            "text": "antacid, viscous lidocaine, and an anticholinergic",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -6.80078125,
            "text": "ant",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 1.9130859375,
            "end_logit": 1.9267578125,
            "text": "lidocaine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -8.296875,
            "text": "antacid, viscous",
            "probability": 0.0
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -8.6328125,
            "text": "antacid, viscous lidocaine, and",
            "probability": 0.0
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -9.5390625,
            "text": "antacid,",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.3203125,
            "text": "liquid antacid",
            "probability": 0.0
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -9.7265625,
            "text": "antacid, viscous lidocaine,",
            "probability": 0.0
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -9.796875,
            "text": "antacid, viscous lidocaine, and an anticholinergic)",
            "probability": 0.0
        },
        {
            "start_logit": -8.4375,
            "end_logit": 9.3203125,
            "text": "acid",
            "probability": 0.0
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -10.0703125,
            "text": "antacid, viscous lidocaine, and an",
            "probability": 0.0
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -10.125,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department",
            "probability": 0.0
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -10.203125,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department in a single hospital",
            "probability": 0.0
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -10.2578125,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department in a single hospital and the responses and final dispositions",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 9.3203125,
            "text": "administration of the \"GI cocktail\" (a mixture of liquid antacid",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 9.3203125,
            "text": "To determine practice patterns regarding administration of the \"GI cocktail\" (a mixture of liquid antacid",
            "probability": 0.0
        },
        {
            "start_logit": 1.9130859375,
            "end_logit": -4.19921875,
            "text": "lidocaine, and an anticholinergic",
            "probability": 0.0
        },
        {
            "start_logit": -5.51953125,
            "end_logit": 1.9267578125,
            "text": "viscous lidocaine",
            "probability": 0.0
        }
    ],
    "5e2f906ffbd6abf43b00002c_7": [
        {
            "start_logit": 10.7109375,
            "end_logit": 9.3203125,
            "text": "antacid",
            "probability": 0.9990234375
        },
        {
            "start_logit": 10.7109375,
            "end_logit": 1.9267578125,
            "text": "antacid, viscous lidocaine",
            "probability": 0.0006165504455566406
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -4.19921875,
            "text": "antacid, viscous lidocaine, and an anticholinergic",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -6.80078125,
            "text": "ant",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 1.9130859375,
            "end_logit": 1.9267578125,
            "text": "lidocaine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -8.296875,
            "text": "antacid, viscous",
            "probability": 0.0
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -8.6328125,
            "text": "antacid, viscous lidocaine, and",
            "probability": 0.0
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -9.5390625,
            "text": "antacid,",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.3203125,
            "text": "liquid antacid",
            "probability": 0.0
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -9.7265625,
            "text": "antacid, viscous lidocaine,",
            "probability": 0.0
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -9.796875,
            "text": "antacid, viscous lidocaine, and an anticholinergic)",
            "probability": 0.0
        },
        {
            "start_logit": -8.4375,
            "end_logit": 9.3203125,
            "text": "acid",
            "probability": 0.0
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -10.0703125,
            "text": "antacid, viscous lidocaine, and an",
            "probability": 0.0
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -10.125,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department",
            "probability": 0.0
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -10.203125,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department in a single hospital",
            "probability": 0.0
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -10.2578125,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department in a single hospital and the responses and final dispositions",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 9.3203125,
            "text": "administration of the \"GI cocktail\" (a mixture of liquid antacid",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 9.3203125,
            "text": "To determine practice patterns regarding administration of the \"GI cocktail\" (a mixture of liquid antacid",
            "probability": 0.0
        },
        {
            "start_logit": 1.9130859375,
            "end_logit": -4.19921875,
            "text": "lidocaine, and an anticholinergic",
            "probability": 0.0
        },
        {
            "start_logit": -5.51953125,
            "end_logit": 1.9267578125,
            "text": "viscous lidocaine",
            "probability": 0.0
        }
    ],
    "5e2f906ffbd6abf43b00002c_8": [
        {
            "start_logit": 10.90625,
            "end_logit": 9.4921875,
            "text": "antacid",
            "probability": 1.0
        },
        {
            "start_logit": 10.90625,
            "end_logit": 1.5908203125,
            "text": "antacid, viscous lidocaine",
            "probability": 0.00036835670471191406
        },
        {
            "start_logit": 10.90625,
            "end_logit": -4.375,
            "text": "antacid, viscous lidocaine, and an anticholinergic",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 10.90625,
            "end_logit": -6.6484375,
            "text": "ant",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 1.2958984375,
            "end_logit": 1.5908203125,
            "text": "lidocaine",
            "probability": 0.0
        },
        {
            "start_logit": 10.90625,
            "end_logit": -8.2421875,
            "text": "antacid, viscous",
            "probability": 0.0
        },
        {
            "start_logit": 10.90625,
            "end_logit": -8.5546875,
            "text": "antacid, viscous lidocaine, and",
            "probability": 0.0
        },
        {
            "start_logit": 10.90625,
            "end_logit": -9.4375,
            "text": "antacid,",
            "probability": 0.0
        },
        {
            "start_logit": 10.90625,
            "end_logit": -9.5859375,
            "text": "antacid, viscous lidocaine,",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.4921875,
            "text": "liquid antacid",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.4921875,
            "text": "acid",
            "probability": 0.0
        },
        {
            "start_logit": 10.90625,
            "end_logit": -9.9140625,
            "text": "antacid, viscous lidocaine, and an anticholinergic)",
            "probability": 0.0
        },
        {
            "start_logit": 10.90625,
            "end_logit": -10.0703125,
            "text": "antacid, viscous lidocaine, and an",
            "probability": 0.0
        },
        {
            "start_logit": 10.90625,
            "end_logit": -10.203125,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department",
            "probability": 0.0
        },
        {
            "start_logit": 10.90625,
            "end_logit": -10.25,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department in a single hospital",
            "probability": 0.0
        },
        {
            "start_logit": -10.234375,
            "end_logit": 9.4921875,
            "text": ": To determine practice patterns regarding administration of the \"GI cocktail\" (a mixture of liquid antacid",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 9.4921875,
            "text": "administration of the \"GI cocktail\" (a mixture of liquid antacid",
            "probability": 0.0
        },
        {
            "start_logit": 1.2958984375,
            "end_logit": -4.375,
            "text": "lidocaine, and an anticholinergic",
            "probability": 0.0
        },
        {
            "start_logit": -5.625,
            "end_logit": 1.5908203125,
            "text": "viscous lidocaine",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 1.5908203125,
            "text": "liquid antacid, viscous lidocaine",
            "probability": 0.0
        }
    ],
    "5895e9977d9090f353000013_1": [
        {
            "start_logit": 13.8984375,
            "end_logit": 13.40625,
            "text": "Hypotrichosis",
            "probability": 1.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -1.2734375,
            "text": "Hypotrichosis with juvenile macular dystrophy",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -3.27734375,
            "text": "Hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -3.9609375,
            "text": "Hypot",
            "probability": 0.0
        },
        {
            "start_logit": -4.88671875,
            "end_logit": 13.40625,
            "text": "osis",
            "probability": 0.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -5.40234375,
            "text": "Hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia, ectrodactyly",
            "probability": 0.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -5.9375,
            "text": "Hypotrich",
            "probability": 0.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -6.234375,
            "text": "Hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal",
            "probability": 0.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -6.49609375,
            "text": "Hypotrichosis with juvenile macular",
            "probability": 0.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -6.69140625,
            "text": "Hypotrichosis with juvenile macular dystrophy (HJMD) and ectoderm",
            "probability": 0.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -6.77734375,
            "text": "Hypotrichosis with juvenile macular dystrophy (HJMD",
            "probability": 0.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -6.7890625,
            "text": "Hypotrichosis with juvenile macular dystrophy (",
            "probability": 0.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -7.08203125,
            "text": "Hypotrichosis with juvenile macular dystrophy (HJMD)",
            "probability": 0.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -7.55078125,
            "text": "Hypotrichosis with juvenile macular dystrophy (H",
            "probability": 0.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -7.74609375,
            "text": "Hypotrichosis with juvenile",
            "probability": 0.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -7.75390625,
            "text": "Hypotrichosis with juvenile macular dystrophy (HJ",
            "probability": 0.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -7.84765625,
            "text": "Hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia, ectrodactyly and macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -8.0234375,
            "text": "Hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia, ectrod",
            "probability": 0.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -8.796875,
            "text": "Hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia, ectrodactyly and macular dystrophy (EEM)",
            "probability": 0.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -8.8359375,
            "text": "Hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia, ectrodactyly and macular dystrophy (",
            "probability": 0.0
        }
    ],
    "5895e9977d9090f353000013_2": [
        {
            "start_logit": 11.0625,
            "end_logit": 10.34375,
            "text": "hypotrichosis",
            "probability": 1.0
        },
        {
            "start_logit": 11.0625,
            "end_logit": 2.41015625,
            "text": "hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia",
            "probability": 0.0003571510314941406
        },
        {
            "start_logit": 11.0625,
            "end_logit": -1.359375,
            "text": "hypotrichosis with juvenile macular dystrophy",
            "probability": 8.285045623779297e-06
        },
        {
            "start_logit": 11.0625,
            "end_logit": -3.001953125,
            "text": "hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia, ectrodactyly",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": 11.0625,
            "end_logit": -5.22265625,
            "text": "hypotrich",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.0625,
            "end_logit": -5.6484375,
            "text": "hypotrichosis with juvenile macular dystrophy (HJMD",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.0625,
            "end_logit": -5.75,
            "text": "hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.0625,
            "end_logit": -5.9453125,
            "text": "hypot",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.0625,
            "end_logit": -6.1484375,
            "text": "hypotrichosis with juvenile macular dystrophy (HJ",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.0625,
            "end_logit": -6.63671875,
            "text": "hypotrichosis with juvenile macular",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.0625,
            "end_logit": -6.98046875,
            "text": "hypotrichosis with juvenile macular dystrophy (HJMD) and ectoderm",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.638671875,
            "end_logit": 2.41015625,
            "text": "ectodermal dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 11.0625,
            "end_logit": -7.0625,
            "text": "hypotrichosis with juvenile macular dystrophy (HJMD)",
            "probability": 0.0
        },
        {
            "start_logit": 11.0625,
            "end_logit": -7.234375,
            "text": "hypotrichosis with juvenile macular dystrophy (",
            "probability": 0.0
        },
        {
            "start_logit": 11.0625,
            "end_logit": -7.57421875,
            "text": "hypotrichosis with juvenile macular dystrophy (H",
            "probability": 0.0
        },
        {
            "start_logit": 11.0625,
            "end_logit": -7.6640625,
            "text": "hypotrichosis with juvenile",
            "probability": 0.0
        },
        {
            "start_logit": 11.0625,
            "end_logit": -7.69921875,
            "text": "hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia, ectrodactyly, and macular dystrophy (EEM)",
            "probability": 0.0
        },
        {
            "start_logit": 11.0625,
            "end_logit": -7.7109375,
            "text": "hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia, ectrod",
            "probability": 0.0
        },
        {
            "start_logit": -7.1015625,
            "end_logit": 10.34375,
            "text": "osis",
            "probability": 0.0
        },
        {
            "start_logit": 11.0625,
            "end_logit": -8.0625,
            "text": "hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia, ectrodactyly, and macular dystrophy",
            "probability": 0.0
        }
    ],
    "5895e9977d9090f353000013_3": [
        {
            "start_logit": 13.46875,
            "end_logit": 12.6640625,
            "text": "ectodermal dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -2.3828125,
            "text": "ectodermal dysplasia, ectrodactyly",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -2.9921875,
            "end_logit": 12.6640625,
            "text": "hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.46875,
            "end_logit": -4.15234375,
            "text": "ectoderm",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.46875,
            "end_logit": -6.203125,
            "text": "ectodermal dysplasia, ectrodactyly, macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -5.44140625,
            "end_logit": 12.6640625,
            "text": "dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -6.9765625,
            "text": "ectodermal dysplasia, ectrod",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -8.03125,
            "text": "ectodermal",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -8.703125,
            "text": "ectodermal dysplasia, ect",
            "probability": 0.0
        },
        {
            "start_logit": -8.5,
            "end_logit": 12.6640625,
            "text": "juvenile macular dystrophy (HJMD) and ectodermal dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -8.671875,
            "end_logit": 12.6640625,
            "text": "with juvenile macular dystrophy (HJMD) and ectodermal dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -9.0,
            "end_logit": 12.6640625,
            "text": "richosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -9.0234375,
            "end_logit": 12.6640625,
            "text": "HJMD) and ectodermal dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -9.21875,
            "end_logit": 12.6640625,
            "text": "osis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -9.296875,
            "end_logit": 12.6640625,
            "text": "macular dystrophy (HJMD) and ectodermal dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 12.6640625,
            "text": "dystrophy (HJMD) and ectodermal dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -9.8828125,
            "end_logit": 12.6640625,
            "text": "al dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 12.6640625,
            "text": "MD) and ectodermal dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -2.9921875,
            "end_logit": -2.3828125,
            "text": "hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia, ectrodactyly",
            "probability": 0.0
        },
        {
            "start_logit": -2.9921875,
            "end_logit": -2.900390625,
            "text": "hypotrichosis",
            "probability": 0.0
        }
    ],
    "5895e9977d9090f353000013_4": [
        {
            "start_logit": 13.8125,
            "end_logit": 12.953125,
            "text": "ectodermal dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -3.521484375,
            "text": "ectoderm",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.8125,
            "end_logit": -4.4140625,
            "text": "ectodermal dysplasia, ectrodactyly",
            "probability": 0.0
        },
        {
            "start_logit": -4.625,
            "end_logit": 12.953125,
            "text": "dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -6.51171875,
            "text": "ectodermal",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -7.20703125,
            "text": "ectodermal dysplasia, ectrodactyly and macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -7.703125,
            "text": "ectodermal dysplasia, ectrod",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -8.15625,
            "text": "ectodermal dysplasia, ect",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -8.5703125,
            "text": "ectodermal dysplasia, ectrodactyly and",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -9.234375,
            "text": "ectodermal dysplasia, ectrodactyly and macular",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -9.2421875,
            "text": "ectodermal dysplasia, ectrodactyly and macular dystrophy.",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 12.953125,
            "text": "al dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 12.953125,
            "text": "EEM syndrome is a rare condition characterised by ectodermal dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": 12.953125,
            "text": "rare condition characterised by ectodermal dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -11.1640625,
            "end_logit": 12.953125,
            "text": "syndrome is a rare condition characterised by ectodermal dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -11.171875,
            "end_logit": 12.953125,
            "text": "M syndrome is a rare condition characterised by ectodermal dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -4.625,
            "end_logit": -4.4140625,
            "text": "dysplasia, ectrodactyly",
            "probability": 0.0
        },
        {
            "start_logit": -5.86328125,
            "end_logit": -4.4140625,
            "text": "ectrodactyly",
            "probability": 0.0
        },
        {
            "start_logit": -4.625,
            "end_logit": -7.20703125,
            "text": "dysplasia, ectrodactyly and macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -4.625,
            "end_logit": -7.703125,
            "text": "dysplasia, ectrod",
            "probability": 0.0
        }
    ],
    "5895e9977d9090f353000013_5": [
        {
            "start_logit": 14.1484375,
            "end_logit": 13.28125,
            "text": "ectodermal dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -3.205078125,
            "text": "ectoderm",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -3.806640625,
            "text": "ectodermal dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.375,
            "end_logit": 13.28125,
            "text": "dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -6.80859375,
            "text": "ectodermal",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -7.0625,
            "text": "ectodermal dysplasia, ectrodactyly, and macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -7.42578125,
            "text": "ectodermal dysplasia, ectrod",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -7.7421875,
            "text": "ectodermal dysplasia, ect",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -8.6953125,
            "text": "ectodermal dysplasia, ectrodactyly, and",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -9.2734375,
            "text": "ectodermal dysplasia, ectrodactyly, and macular",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -9.3671875,
            "text": "ectodermal dysplasia,",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -9.640625,
            "text": "ectodermal dysplasia, ectrodactyly,",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -9.6484375,
            "text": "ectodermal dysplasia, ectrodactyly, and macular dystrophy.",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 13.28125,
            "text": "al dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 13.28125,
            "text": ": EEM syndrome is the rare association of ectodermal dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 13.28125,
            "text": "EEM syndrome is the rare association of ectodermal dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 13.28125,
            "text": "BACKGROUND: EEM syndrome is the rare association of ectodermal dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -4.375,
            "end_logit": -3.806640625,
            "text": "dysplasia, ectrodactyly",
            "probability": 0.0
        },
        {
            "start_logit": -5.70703125,
            "end_logit": -3.806640625,
            "text": "ectrodactyly",
            "probability": 0.0
        },
        {
            "start_logit": -4.375,
            "end_logit": -7.0625,
            "text": "dysplasia, ectrodactyly, and macular dystrophy",
            "probability": 0.0
        }
    ],
    "5895e9977d9090f353000013_6": [
        {
            "start_logit": 13.8359375,
            "end_logit": 13.1640625,
            "text": "ectodermal dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -3.154296875,
            "text": "ectodermal dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -3.7734375,
            "text": "ectoderm",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -5.30078125,
            "text": "ectodermal dysplasia, ectrodactyly, macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -4.75,
            "end_logit": 13.1640625,
            "text": "dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -6.22265625,
            "text": "ectodermal dysplasia, ectrod",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -7.125,
            "text": "ectodermal dysplasia, ect",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -7.578125,
            "text": "ectodermal",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -7.8828125,
            "text": "ectodermal dysplasia, ectrodactyly, macular",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -8.4765625,
            "text": "ectodermal dysplasia, ectrodactyly, macular dystrophy (EEM syndrome)",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -9.1796875,
            "text": "ectodermal dysplasia, ectrodactyly,",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -9.6015625,
            "text": "ectodermal dysplasia, ectrodactyly, macular dystrophy (EEM syndrome).",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -9.6171875,
            "text": "ectodermal dysplasia,",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": 13.1640625,
            "text": "CDH3 mutations cause ectodermal dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": 13.1640625,
            "text": "al dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -4.45703125,
            "end_logit": -3.154296875,
            "text": "ectrodactyly",
            "probability": 0.0
        },
        {
            "start_logit": -4.75,
            "end_logit": -3.154296875,
            "text": "dysplasia, ectrodactyly",
            "probability": 0.0
        },
        {
            "start_logit": -4.45703125,
            "end_logit": -5.30078125,
            "text": "ectrodactyly, macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -4.75,
            "end_logit": -5.30078125,
            "text": "dysplasia, ectrodactyly, macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -4.45703125,
            "end_logit": -6.22265625,
            "text": "ectrod",
            "probability": 0.0
        }
    ],
    "5895e9977d9090f353000013_7": [
        {
            "start_logit": 14.421875,
            "end_logit": 13.5234375,
            "text": "Ectodermal dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -2.953125,
            "text": "Ectoderm",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.421875,
            "end_logit": -3.9375,
            "text": "Ectodermal dysplasia, ectrodactyly",
            "probability": 0.0
        },
        {
            "start_logit": -4.03125,
            "end_logit": 13.5234375,
            "text": "dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -5.74609375,
            "text": "Ectodermal dysplasia, ectrodactyly and macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -6.953125,
            "text": "Ectodermal dysplasia, ectrod",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -7.3203125,
            "text": "Ectodermal",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -7.81640625,
            "text": "Ectodermal dysplasia, ect",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -8.328125,
            "text": "Ectodermal dysplasia, ectrodactyly and macular",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -8.4453125,
            "text": "Ectodermal dysplasia, ectrodactyly and macular dystrophy (EEM syndrome)",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -8.484375,
            "text": "Ectodermal dysplasia, ectrodactyly and macular dystrophy (EEM syndrome) in siblings",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -9.0234375,
            "text": "Ectodermal dysplasia, ectrodactyly and",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -9.2265625,
            "text": "Ectodermal dysplasia, ectrodactyly and macular dystrophy (EEM syndrome) in siblings.",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -9.5234375,
            "text": "Ectodermal dysplasia, ectrodactyly and macular dystrophy (EEM syndrome) in",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -9.8125,
            "text": "Ectodermal dysplasia,",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -9.875,
            "text": "Ectodermal dysplasia, ectrodactyly and macular dystrophy (EEM",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -9.9453125,
            "text": "Ectodermal dysplasia, ectrodactyly and macular dystrophy (EEM syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 13.5234375,
            "text": "al dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -4.03125,
            "end_logit": -3.9375,
            "text": "dysplasia, ectrodactyly",
            "probability": 0.0
        },
        {
            "start_logit": -5.13671875,
            "end_logit": -3.9375,
            "text": "ectrodactyly",
            "probability": 0.0
        }
    ],
    "5895e9977d9090f353000013_8": [
        {
            "start_logit": 14.5234375,
            "end_logit": 13.59375,
            "text": "ectodermal dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -2.65234375,
            "text": "ectoderm",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -4.58203125,
            "text": "ectodermal dysplasia, ectrodactyly",
            "probability": 0.0
        },
        {
            "start_logit": -3.984375,
            "end_logit": 13.59375,
            "text": "dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -6.453125,
            "text": "ectodermal dysplasia, ectrodactyly, and macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -6.87890625,
            "text": "ectodermal",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -7.48828125,
            "text": "ectodermal dysplasia, ectrod",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -8.328125,
            "text": "ectodermal dysplasia, ect",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -8.78125,
            "text": "ectodermal dysplasia, ectrodactyly, and macular",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -8.984375,
            "text": "ectodermal dysplasia, ectrodactyly, and",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -9.0234375,
            "text": "ectodermal dysplasia, ectrodactyly, and macular dystrophy: the EEM syndrome.",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -9.6484375,
            "text": "ectodermal dysplasia, ectrodactyly, and macular dystrophy: the EEM syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -9.78125,
            "text": "ectodermal dysplasia,",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -9.796875,
            "text": "ectodermal dysplasia, ectrodactyly, and macular dystrophy: the EEM",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 13.59375,
            "text": "al dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -3.984375,
            "end_logit": -4.58203125,
            "text": "dysplasia, ectrodactyly",
            "probability": 0.0
        },
        {
            "start_logit": -3.984375,
            "end_logit": -6.453125,
            "text": "dysplasia, ectrodactyly, and macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -6.625,
            "end_logit": -4.58203125,
            "text": "ectrodactyly",
            "probability": 0.0
        },
        {
            "start_logit": -3.984375,
            "end_logit": -7.48828125,
            "text": "dysplasia, ectrod",
            "probability": 0.0
        },
        {
            "start_logit": -3.984375,
            "end_logit": -8.328125,
            "text": "dysplasia, ect",
            "probability": 0.0
        }
    ],
    "5895e9977d9090f353000013_9": [
        {
            "start_logit": 14.5078125,
            "end_logit": 13.578125,
            "text": "ectodermal dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -2.662109375,
            "text": "ectoderm",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -4.84765625,
            "text": "ectodermal dysplasia, ectrodactyly",
            "probability": 0.0
        },
        {
            "start_logit": -3.947265625,
            "end_logit": 13.578125,
            "text": "dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -6.453125,
            "text": "ectodermal dysplasia, ectrodactyly and macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -6.85546875,
            "text": "ectodermal",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -7.42578125,
            "text": "ectodermal dysplasia, ectrod",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -8.203125,
            "text": "ectodermal dysplasia, ectrodactyly and macular dystrophy: EEM syndrome (case report",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -8.390625,
            "text": "ectodermal dysplasia, ect",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -8.8671875,
            "text": "ectodermal dysplasia, ectrodactyly and",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -8.9375,
            "text": "ectodermal dysplasia, ectrodactyly and macular",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -9.265625,
            "text": "ectodermal dysplasia, ectrodactyly and macular dystrophy: EEM syndrome (case report)",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -9.453125,
            "text": "ectodermal dysplasia, ectrodactyly and macular dystrophy: EEM syndrome (case report).",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -9.6484375,
            "text": "ectodermal dysplasia,",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 13.578125,
            "text": "al dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -3.947265625,
            "end_logit": -4.84765625,
            "text": "dysplasia, ectrodactyly",
            "probability": 0.0
        },
        {
            "start_logit": -3.947265625,
            "end_logit": -6.453125,
            "text": "dysplasia, ectrodactyly and macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -5.890625,
            "end_logit": -4.84765625,
            "text": "ectrodactyly",
            "probability": 0.0
        },
        {
            "start_logit": -3.947265625,
            "end_logit": -7.42578125,
            "text": "dysplasia, ectrod",
            "probability": 0.0
        },
        {
            "start_logit": -3.947265625,
            "end_logit": -8.203125,
            "text": "dysplasia, ectrodactyly and macular dystrophy: EEM syndrome (case report",
            "probability": 0.0
        }
    ],
    "5895e9977d9090f353000013_10": [
        {
            "start_logit": 14.078125,
            "end_logit": 13.2109375,
            "text": "ectodermal dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": 14.078125,
            "end_logit": -3.30078125,
            "text": "ectoderm",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.078125,
            "end_logit": -3.6953125,
            "text": "ectodermal dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.4375,
            "end_logit": 13.2109375,
            "text": "dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 14.078125,
            "end_logit": -6.65234375,
            "text": "ectodermal dysplasia, ectrodactyly, and macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": 14.078125,
            "end_logit": -6.7421875,
            "text": "ectodermal",
            "probability": 0.0
        },
        {
            "start_logit": 14.078125,
            "end_logit": -7.4453125,
            "text": "ectodermal dysplasia, ectrod",
            "probability": 0.0
        },
        {
            "start_logit": 14.078125,
            "end_logit": -7.7578125,
            "text": "ectodermal dysplasia, ect",
            "probability": 0.0
        },
        {
            "start_logit": 14.078125,
            "end_logit": -8.640625,
            "text": "ectodermal dysplasia, ectrodactyly, and",
            "probability": 0.0
        },
        {
            "start_logit": 14.078125,
            "end_logit": -8.90625,
            "text": "ectodermal dysplasia, ectrodactyly, and macular",
            "probability": 0.0
        },
        {
            "start_logit": 14.078125,
            "end_logit": -9.234375,
            "text": "ectodermal dysplasia, ectrodactyly, and macular dystrophy.",
            "probability": 0.0
        },
        {
            "start_logit": 14.078125,
            "end_logit": -9.34375,
            "text": "ectodermal dysplasia,",
            "probability": 0.0
        },
        {
            "start_logit": 14.078125,
            "end_logit": -9.5625,
            "text": "ectodermal dysplasia, ectrodactyly,",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 13.2109375,
            "text": "al dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 13.2109375,
            "text": "EEM syndrome is the rare association of ectodermal dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -11.140625,
            "end_logit": 13.2109375,
            "text": "syndrome is the rare association of ectodermal dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -4.4375,
            "end_logit": -3.6953125,
            "text": "dysplasia, ectrodactyly",
            "probability": 0.0
        },
        {
            "start_logit": -5.1796875,
            "end_logit": -3.6953125,
            "text": "ectrodactyly",
            "probability": 0.0
        },
        {
            "start_logit": -4.4375,
            "end_logit": -6.65234375,
            "text": "dysplasia, ectrodactyly, and macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -5.1796875,
            "end_logit": -6.65234375,
            "text": "ectrodactyly, and macular dystrophy",
            "probability": 0.0
        }
    ],
    "5895e9977d9090f353000013_11": [
        {
            "start_logit": 14.3046875,
            "end_logit": 13.3359375,
            "text": "ectodermal dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -3.07421875,
            "text": "ectoderm",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -4.5234375,
            "text": "ectodermal dysplasia, ectrodactyly",
            "probability": 0.0
        },
        {
            "start_logit": -4.38671875,
            "end_logit": 13.3359375,
            "text": "dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -6.46875,
            "text": "ectodermal dysplasia, ectrodactyly, and macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -7.39453125,
            "text": "ectodermal dysplasia, ectrod",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -7.55078125,
            "text": "ectodermal",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -8.0390625,
            "text": "ectodermal dysplasia, ect",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -8.625,
            "text": "ectodermal dysplasia, ectrodactyly, and macular dystrophy (the EEM syndrome)",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -8.78125,
            "text": "ectodermal dysplasia, ectrodactyly, and macular",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -8.890625,
            "text": "ectodermal dysplasia, ectrodactyly, and",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -9.546875,
            "text": "ectodermal dysplasia, ectrodactyly, and macular dystrophy (the EEM syndrome).",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -9.625,
            "text": "ectodermal dysplasia,",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -9.734375,
            "text": "ectodermal dysplasia, ectrodactyly,",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -9.875,
            "text": "ectodermal dysplasia, ectrodactyly, and macular dystrophy (the EEM syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 13.3359375,
            "text": "al dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 13.3359375,
            "text": "brother and sister with ectodermal dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -4.38671875,
            "end_logit": -4.5234375,
            "text": "dysplasia, ectrodactyly",
            "probability": 0.0
        },
        {
            "start_logit": -4.38671875,
            "end_logit": -6.46875,
            "text": "dysplasia, ectrodactyly, and macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -6.33203125,
            "end_logit": -4.5234375,
            "text": "ectrodactyly",
            "probability": 0.0
        }
    ],
    "5895e9977d9090f353000013_12": [
        {
            "start_logit": 14.421875,
            "end_logit": 13.5234375,
            "text": "Ectodermal dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -2.953125,
            "text": "Ectoderm",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.421875,
            "end_logit": -3.9375,
            "text": "Ectodermal dysplasia, ectrodactyly",
            "probability": 0.0
        },
        {
            "start_logit": -4.03125,
            "end_logit": 13.5234375,
            "text": "dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -5.74609375,
            "text": "Ectodermal dysplasia, ectrodactyly and macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -6.953125,
            "text": "Ectodermal dysplasia, ectrod",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -7.3203125,
            "text": "Ectodermal",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -7.81640625,
            "text": "Ectodermal dysplasia, ect",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -8.328125,
            "text": "Ectodermal dysplasia, ectrodactyly and macular",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -8.4453125,
            "text": "Ectodermal dysplasia, ectrodactyly and macular dystrophy (EEM syndrome)",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -8.484375,
            "text": "Ectodermal dysplasia, ectrodactyly and macular dystrophy (EEM syndrome) in siblings",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -9.0234375,
            "text": "Ectodermal dysplasia, ectrodactyly and",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -9.2265625,
            "text": "Ectodermal dysplasia, ectrodactyly and macular dystrophy (EEM syndrome) in siblings.",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -9.5234375,
            "text": "Ectodermal dysplasia, ectrodactyly and macular dystrophy (EEM syndrome) in",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -9.8125,
            "text": "Ectodermal dysplasia,",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -9.875,
            "text": "Ectodermal dysplasia, ectrodactyly and macular dystrophy (EEM",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -9.9453125,
            "text": "Ectodermal dysplasia, ectrodactyly and macular dystrophy (EEM syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 13.5234375,
            "text": "al dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -4.03125,
            "end_logit": -3.9375,
            "text": "dysplasia, ectrodactyly",
            "probability": 0.0
        },
        {
            "start_logit": -5.13671875,
            "end_logit": -3.9375,
            "text": "ectrodactyly",
            "probability": 0.0
        }
    ],
    "5895e9977d9090f353000013_13": [
        {
            "start_logit": 13.8359375,
            "end_logit": 13.1640625,
            "text": "ectodermal dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -3.154296875,
            "text": "ectodermal dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -3.7734375,
            "text": "ectoderm",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -5.30078125,
            "text": "ectodermal dysplasia, ectrodactyly, macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -4.75,
            "end_logit": 13.1640625,
            "text": "dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -6.22265625,
            "text": "ectodermal dysplasia, ectrod",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -7.125,
            "text": "ectodermal dysplasia, ect",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -7.578125,
            "text": "ectodermal",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -7.8828125,
            "text": "ectodermal dysplasia, ectrodactyly, macular",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -8.4765625,
            "text": "ectodermal dysplasia, ectrodactyly, macular dystrophy (EEM syndrome)",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -9.1796875,
            "text": "ectodermal dysplasia, ectrodactyly,",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -9.6015625,
            "text": "ectodermal dysplasia, ectrodactyly, macular dystrophy (EEM syndrome).",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -9.6171875,
            "text": "ectodermal dysplasia,",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": 13.1640625,
            "text": "CDH3 mutations cause ectodermal dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": 13.1640625,
            "text": "al dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -4.45703125,
            "end_logit": -3.154296875,
            "text": "ectrodactyly",
            "probability": 0.0
        },
        {
            "start_logit": -4.75,
            "end_logit": -3.154296875,
            "text": "dysplasia, ectrodactyly",
            "probability": 0.0
        },
        {
            "start_logit": -4.45703125,
            "end_logit": -5.30078125,
            "text": "ectrodactyly, macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -4.75,
            "end_logit": -5.30078125,
            "text": "dysplasia, ectrodactyly, macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -4.45703125,
            "end_logit": -6.22265625,
            "text": "ectrod",
            "probability": 0.0
        }
    ],
    "56e460d051531f7e33000019_1": [
        {
            "start_logit": -1.580078125,
            "end_logit": 9.515625,
            "text": "sleep",
            "probability": 0.84912109375
        },
        {
            "start_logit": -3.337890625,
            "end_logit": 9.515625,
            "text": "timing of sleep",
            "probability": 0.1463623046875
        },
        {
            "start_logit": -7.0859375,
            "end_logit": 9.515625,
            "text": "Csnk1e in regulating not only the timing of sleep",
            "probability": 0.0034427642822265625
        },
        {
            "start_logit": -9.1015625,
            "end_logit": 9.515625,
            "text": "the timing of sleep",
            "probability": 0.00045871734619140625
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 9.515625,
            "text": "nk1e in regulating not only the timing of sleep",
            "probability": 0.00022351741790771484
        },
        {
            "start_logit": -9.8359375,
            "end_logit": 9.515625,
            "text": "of sleep",
            "probability": 0.0002200603485107422
        },
        {
            "start_logit": -9.96875,
            "end_logit": 9.515625,
            "text": "regulating not only the timing of sleep",
            "probability": 0.00019276142120361328
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 9.515625,
            "text": "not only the timing of sleep",
            "probability": 0.00013780593872070312
        },
        {
            "start_logit": -1.580078125,
            "end_logit": -1.5390625,
            "text": "sleep, but also the REM sleep amount",
            "probability": 1.341104507446289e-05
        },
        {
            "start_logit": -3.337890625,
            "end_logit": -1.5390625,
            "text": "timing of sleep, but also the REM sleep amount",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": -1.580078125,
            "end_logit": -3.931640625,
            "text": "sleep, but also the REM sleep amount and NREM sleep architecture",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -1.580078125,
            "end_logit": -4.07421875,
            "text": "sleep, but also the REM sleep",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -3.337890625,
            "end_logit": -3.931640625,
            "text": "timing of sleep, but also the REM sleep amount and NREM sleep architecture",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -1.580078125,
            "end_logit": -5.703125,
            "text": "sleep, but also the REM sleep amount and NREM sleep architecture, and support Csnk1e as a causal gene in the sleep QTL",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.8359375,
            "end_logit": -1.5390625,
            "text": "REM sleep amount",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -1.580078125,
            "end_logit": -5.83203125,
            "text": "sleep, but also the REM",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -3.337890625,
            "end_logit": -4.07421875,
            "text": "timing of sleep, but also the REM sleep",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.0859375,
            "end_logit": -1.5390625,
            "text": "Csnk1e in regulating not only the timing of sleep, but also the REM sleep amount",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.337890625,
            "end_logit": -5.703125,
            "text": "timing of sleep, but also the REM sleep amount and NREM sleep architecture, and support Csnk1e as a causal gene in the sleep QTL",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.337890625,
            "end_logit": -5.83203125,
            "text": "timing of sleep, but also the REM",
            "probability": 5.960464477539063e-08
        }
    ],
    "56e460d051531f7e33000019_2": [
        {
            "start_logit": 0.97802734375,
            "end_logit": 4.00390625,
            "text": "breast cancer can suppress Wnt/beta-catenin as",
            "probability": 0.59619140625
        },
        {
            "start_logit": 0.57666015625,
            "end_logit": 4.00390625,
            "text": "as",
            "probability": 0.400390625
        },
        {
            "start_logit": 0.97802734375,
            "end_logit": -1.45703125,
            "text": "breast cancer",
            "probability": 0.0025348663330078125
        },
        {
            "start_logit": -4.82421875,
            "end_logit": 1.7890625,
            "text": "cell adhesion and migration",
            "probability": 0.00019693374633789062
        },
        {
            "start_logit": 0.97802734375,
            "end_logit": -4.45703125,
            "text": "breast cancer can suppress Wnt/beta-catenin",
            "probability": 0.00012624263763427734
        },
        {
            "start_logit": -8.234375,
            "end_logit": 4.00390625,
            "text": "Wnt/beta-catenin as",
            "probability": 5.9604644775390625e-05
        },
        {
            "start_logit": -8.40625,
            "end_logit": 4.00390625,
            "text": "suppress Wnt/beta-catenin as",
            "probability": 5.0187110900878906e-05
        },
        {
            "start_logit": 0.97802734375,
            "end_logit": -5.84375,
            "text": "breast cancer can suppress Wnt",
            "probability": 3.165006637573242e-05
        },
        {
            "start_logit": -9.5390625,
            "end_logit": 4.00390625,
            "text": "CK1epsilon found in breast cancer can suppress Wnt/beta-catenin as",
            "probability": 1.615285873413086e-05
        },
        {
            "start_logit": 0.97802734375,
            "end_logit": -7.09375,
            "text": "breast cancer can suppress Wnt/beta-catenin as well",
            "probability": 9.059906005859375e-06
        },
        {
            "start_logit": 0.97802734375,
            "end_logit": -7.10546875,
            "text": "breast cancer can suppress Wnt/beta-catenin as well as promote the Wnt/Rac-1/JNK and Wnt/NFAT",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 4.00390625,
            "text": "mutations of CK1epsilon found in breast cancer can suppress Wnt/beta-catenin as",
            "probability": 8.761882781982422e-06
        },
        {
            "start_logit": 0.97802734375,
            "end_logit": -7.296875,
            "text": "breast cancer can suppress Wnt/beta",
            "probability": 7.3909759521484375e-06
        },
        {
            "start_logit": 0.97802734375,
            "end_logit": -7.4453125,
            "text": "breast cancer can suppress Wnt/beta-catenin as well as promote the Wnt/Rac-1/JNK",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": 0.57666015625,
            "end_logit": -7.09375,
            "text": "as well",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": 0.57666015625,
            "end_logit": -7.10546875,
            "text": "as well as promote the Wnt/Rac-1/JNK and Wnt/NFAT",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": 0.57666015625,
            "end_logit": -7.22265625,
            "text": "as well as promote the Wnt/Rac-1/JNK and Wnt/NFAT pathways, thus contributing to breast cancer development via effects on cell adhesion",
            "probability": 5.304813385009766e-06
        },
        {
            "start_logit": 0.57666015625,
            "end_logit": -7.4453125,
            "text": "as well as promote the Wnt/Rac-1/JNK",
            "probability": 4.291534423828125e-06
        },
        {
            "start_logit": 0.97802734375,
            "end_logit": -8.125,
            "text": "breast cancer can suppress Wnt/beta-catenin as well as promote the Wnt/Rac-1/JNK and Wnt/NFAT pathways",
            "probability": 3.2186508178710938e-06
        },
        {
            "start_logit": 0.57666015625,
            "end_logit": -8.125,
            "text": "as well as promote the Wnt/Rac-1/JNK and Wnt/NFAT pathways",
            "probability": 2.1457672119140625e-06
        }
    ],
    "56e460d051531f7e33000019_3": [
        {
            "start_logit": 12.2421875,
            "end_logit": 12.984375,
            "text": "short circadian period",
            "probability": 1.0
        },
        {
            "start_logit": 12.2421875,
            "end_logit": 1.3408203125,
            "text": "short circadian period, abnormal entrainment",
            "probability": 8.881092071533203e-06
        },
        {
            "start_logit": -3.869140625,
            "end_logit": 12.984375,
            "text": "circadian period",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.09765625,
            "end_logit": 1.3408203125,
            "text": "abnormal entrainment",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.2421875,
            "end_logit": -4.1796875,
            "text": "short circadian period, abnormal entrainment to light cycles",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.14453125,
            "end_logit": 12.984375,
            "text": "period",
            "probability": 0.0
        },
        {
            "start_logit": 12.2421875,
            "end_logit": -4.5,
            "text": "short circadian period, abnormal",
            "probability": 0.0
        },
        {
            "start_logit": 12.2421875,
            "end_logit": -4.69140625,
            "text": "short",
            "probability": 0.0
        },
        {
            "start_logit": 12.2421875,
            "end_logit": -5.85546875,
            "text": "short circadian period, abnormal entrain",
            "probability": 0.0
        },
        {
            "start_logit": 12.2421875,
            "end_logit": -7.23828125,
            "text": "short circadian period, abnormal entrainment to",
            "probability": 0.0
        },
        {
            "start_logit": 12.2421875,
            "end_logit": -8.5,
            "text": "short circadian period, abnormal entrainment to light",
            "probability": 0.0
        },
        {
            "start_logit": 12.2421875,
            "end_logit": -9.0,
            "text": "short circadian period, abnormal entrainment to light cycles, and potentiated resetting responses to light",
            "probability": 0.0
        },
        {
            "start_logit": 12.2421875,
            "end_logit": -9.015625,
            "text": "short circadian",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": 12.984375,
            "text": "a short circadian period",
            "probability": 0.0
        },
        {
            "start_logit": 7.09765625,
            "end_logit": -4.1796875,
            "text": "abnormal entrainment to light cycles",
            "probability": 0.0
        },
        {
            "start_logit": 12.2421875,
            "end_logit": -9.5703125,
            "text": "short circadian period, abnormal entrainment to light cycles, and potentiated resetting responses",
            "probability": 0.0
        },
        {
            "start_logit": 7.09765625,
            "end_logit": -4.5,
            "text": "abnormal",
            "probability": 0.0
        },
        {
            "start_logit": 12.2421875,
            "end_logit": -9.6875,
            "text": "short circadian period, abnormal entrainment to light cycles, and potentiated resetting",
            "probability": 0.0
        },
        {
            "start_logit": 12.2421875,
            "end_logit": -9.921875,
            "text": "short circadian period, abnormal entrainment to light cycles, and potentiated resetting responses to light.",
            "probability": 0.0
        },
        {
            "start_logit": 12.2421875,
            "end_logit": -9.9609375,
            "text": "short circadian period, abnormal entrainment to light cycles, and",
            "probability": 0.0
        }
    ],
    "62008130c9dfcb9c0900001c_1": [
        {
            "start_logit": 11.171875,
            "end_logit": 11.15625,
            "text": "Leukocytosis (1 point), Tachycardia (1 point), and age",
            "probability": 0.74365234375
        },
        {
            "start_logit": 11.171875,
            "end_logit": 10.0625,
            "text": "Leukocytosis",
            "probability": 0.2491455078125
        },
        {
            "start_logit": 6.5703125,
            "end_logit": 11.15625,
            "text": "age",
            "probability": 0.007404327392578125
        },
        {
            "start_logit": 11.171875,
            "end_logit": -5.2109375,
            "text": "Leuk",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.39453125,
            "end_logit": 11.15625,
            "text": ", Leukocytosis (1 point), Tachycardia (1 point), and age",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.39453125,
            "end_logit": 10.0625,
            "text": ", Leukocytosis",
            "probability": 0.0
        },
        {
            "start_logit": -6.57421875,
            "end_logit": 11.15625,
            "text": "Asymmetry (3 points), Leukocytosis (1 point), Tachycardia (1 point), and age",
            "probability": 0.0
        },
        {
            "start_logit": 11.171875,
            "end_logit": -7.046875,
            "text": "Leukocytosis (1 point), Tachycardia (1 point), and age \u226570",
            "probability": 0.0
        },
        {
            "start_logit": 11.171875,
            "end_logit": -7.34375,
            "text": "Leukocytosis (1 point), Tachycardia",
            "probability": 0.0
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 11.15625,
            "text": "ocytosis (1 point), Tachycardia (1 point), and age",
            "probability": 0.0
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 11.15625,
            "text": "Tachycardia (1 point), and age",
            "probability": 0.0
        },
        {
            "start_logit": -6.57421875,
            "end_logit": 10.0625,
            "text": "Asymmetry (3 points), Leukocytosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 10.0625,
            "text": "ocytosis",
            "probability": 0.0
        },
        {
            "start_logit": 11.171875,
            "end_logit": -8.609375,
            "text": "Leukocytosis (1 point), Tachycardia (1 point), and age \u2265",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": 11.15625,
            "text": ", Tachycardia (1 point), and age",
            "probability": 0.0
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 11.15625,
            "text": "and age",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 11.15625,
            "text": "ALT-70 cellulitis score as follows: Asymmetry (3 points), Leukocytosis (1 point), Tachycardia (1 point), and age",
            "probability": 0.0
        },
        {
            "start_logit": 11.171875,
            "end_logit": -10.296875,
            "text": "Leukocytosis (1 point), Tachycardia (1 point), and",
            "probability": 0.0
        },
        {
            "start_logit": 11.171875,
            "end_logit": -10.328125,
            "text": "Leukocytosis (1 point)",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 11.15625,
            "text": "as follows: Asymmetry (3 points), Leukocytosis (1 point), Tachycardia (1 point), and age",
            "probability": 0.0
        }
    ],
    "5e493bc06d0a277941000003_1": [
        {
            "start_logit": 10.6484375,
            "end_logit": 12.4765625,
            "text": "glioblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 12.4765625,
            "text": "PINT suppresses oncogenic transcriptional elongation in glioblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 12.4765625,
            "text": "transcriptional elongation in glioblastoma",
            "probability": 0.0
        },
        {
            "start_logit": 10.6484375,
            "end_logit": -9.53125,
            "text": "glioblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": -9.4375,
            "text": "PINT suppresses oncogenic transcriptional elongation in",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": -9.4375,
            "text": "transcriptional elongation in",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": -9.53125,
            "text": "PINT suppresses oncogenic transcriptional elongation in glioblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": -9.53125,
            "text": "transcriptional elongation in glioblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": -9.9140625,
            "text": "PINT suppresses oncogenic transcriptional elongation",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": -9.9140625,
            "text": "transcriptional elongation",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": -9.984375,
            "text": "PINT suppresses oncogenic",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": -10.3828125,
            "text": "PINT",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": -10.4296875,
            "text": "PINT suppresses",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": -10.4453125,
            "text": "PINT suppresses oncogenic transcriptional",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": -10.4453125,
            "text": "transcriptional",
            "probability": 0.0
        }
    ],
    "5e493bc06d0a277941000003_2": [
        {
            "start_logit": 9.9921875,
            "end_logit": 13.015625,
            "text": "glioblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -9.734375,
            "end_logit": 13.015625,
            "text": "suppresses glioblastoma",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -7.98046875,
            "text": "glioblastoma cell proliferation in vitro and in vivo. This peptide directly interacts with polymerase associated factor complex (PAF1c",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -9.6640625,
            "text": "glioblastoma cell proliferation in vitro and in vivo. This peptide directly interacts with polymerase associated factor complex (PAF1c)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -9.6796875,
            "text": "glioblastoma cell proliferation",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -9.765625,
            "text": "glioblastoma cell",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -9.796875,
            "text": "glioblastoma cell proliferation in vitro and in vivo. This peptide directly interacts with polymerase associated factor complex (",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -9.8359375,
            "text": "glioblastoma cell proliferation in vitro and in vivo. This peptide directly interacts with polymerase associated factor complex",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -9.8515625,
            "text": "glioblastoma cell proliferation in vitro and in vivo. This peptide directly interacts with polymerase associated factor complex (PAF1c) and inhibits the",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -9.8828125,
            "text": "glioblastoma cell proliferation in vitro and in vivo. This peptide directly interacts with polymerase associated factor complex (PAF1c) and inhibits the transcriptional elongation of multiple oncogenes",
            "probability": 0.0
        },
        {
            "start_logit": -9.0078125,
            "end_logit": -7.9140625,
            "text": "tumorigenesis",
            "probability": 0.0
        },
        {
            "start_logit": -9.2421875,
            "end_logit": -7.9140625,
            "text": "glioblastoma tumorigenesis",
            "probability": 0.0
        },
        {
            "start_logit": -9.328125,
            "end_logit": -7.9140625,
            "text": "glioblastoma compared with the levels in normal tissues. Our results establish the existence of peptides encoded by circRNAs and demonstrate their potential functions in glioblastoma tumorigenesis",
            "probability": 0.0
        },
        {
            "start_logit": -9.3828125,
            "end_logit": -7.98046875,
            "text": "PAF1c",
            "probability": 0.0
        },
        {
            "start_logit": -9.609375,
            "end_logit": -7.98046875,
            "text": "This peptide directly interacts with polymerase associated factor complex (PAF1c",
            "probability": 0.0
        },
        {
            "start_logit": -9.734375,
            "end_logit": -7.98046875,
            "text": "suppresses glioblastoma cell proliferation in vitro and in vivo. This peptide directly interacts with polymerase associated factor complex (PAF1c",
            "probability": 0.0
        },
        {
            "start_logit": -9.328125,
            "end_logit": -8.6171875,
            "text": "glioblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -9.3828125,
            "end_logit": -8.6171875,
            "text": "PAF1c) and inhibits the transcriptional elongation of multiple oncogenes. The expression of this peptide and its corresponding circRNA are decreased in glioblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": -7.98046875,
            "text": "polymerase associated factor complex (PAF1c",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": -7.9140625,
            "text": "tissues. Our results establish the existence of peptides encoded by circRNAs and demonstrate their potential functions in glioblastoma tumorigenesis",
            "probability": 0.0
        }
    ],
    "5e493bc06d0a277941000003_3": [
        {
            "start_logit": 14.7421875,
            "end_logit": 14.78125,
            "text": "Breast cancer",
            "probability": 1.0
        },
        {
            "start_logit": -2.015625,
            "end_logit": 14.78125,
            "text": "cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.7421875,
            "end_logit": -2.146484375,
            "text": "Breast",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.7421875,
            "end_logit": -7.9296875,
            "text": "Breast cancer is a heterogeneous and polygenic disease",
            "probability": 0.0
        },
        {
            "start_logit": 14.7421875,
            "end_logit": -9.0390625,
            "text": "Breast cancer is",
            "probability": 0.0
        },
        {
            "start_logit": -1.6513671875,
            "end_logit": -1.484375,
            "text": "breast cancer",
            "probability": 0.0
        },
        {
            "start_logit": -4.16015625,
            "end_logit": -3.421875,
            "text": "Luminal A",
            "probability": 0.0
        },
        {
            "start_logit": -2.015625,
            "end_logit": -7.9296875,
            "text": "cancer is a heterogeneous and polygenic disease",
            "probability": 0.0
        },
        {
            "start_logit": -1.6513671875,
            "end_logit": -8.5,
            "text": "breast",
            "probability": 0.0
        },
        {
            "start_logit": -6.96875,
            "end_logit": -3.421875,
            "text": "A",
            "probability": 0.0
        },
        {
            "start_logit": -5.6796875,
            "end_logit": -4.76953125,
            "text": "breast cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.54296875,
            "end_logit": -3.421875,
            "text": "and 7q32.3/LINC-PINT (rs4593472) were associated with Luminal A",
            "probability": 0.0
        },
        {
            "start_logit": -2.015625,
            "end_logit": -9.0390625,
            "text": "cancer is",
            "probability": 0.0
        },
        {
            "start_logit": -4.16015625,
            "end_logit": -7.8984375,
            "text": "Luminal",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": -3.421875,
            "text": "with Luminal A",
            "probability": 0.0
        },
        {
            "start_logit": -4.16015625,
            "end_logit": -8.3671875,
            "text": "Luminal A, and 10q26.1/FGFR2 (rs35054928) was associated with Luminal B",
            "probability": 0.0
        },
        {
            "start_logit": -4.16015625,
            "end_logit": -8.421875,
            "text": "Luminal A, and 10q26.1/FGFR2",
            "probability": 0.0
        },
        {
            "start_logit": -5.6796875,
            "end_logit": -7.546875,
            "text": "breast cancer patients (2,935 samples matched molecular subtypes)",
            "probability": 0.0
        },
        {
            "start_logit": -8.6796875,
            "end_logit": -4.76953125,
            "text": "a female Chinese cohort of 3,036 breast cancer",
            "probability": 0.0
        },
        {
            "start_logit": -5.6796875,
            "end_logit": -8.2734375,
            "text": "breast cancer patients (2,935 samples matched",
            "probability": 0.0
        }
    ],
    "5e493bc06d0a277941000003_4": [
        {
            "start_logit": 14.3046875,
            "end_logit": 14.046875,
            "text": "pancreatic cancer",
            "probability": 1.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -3.0625,
            "text": "pancreatic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.701171875,
            "end_logit": 14.046875,
            "text": "cancer",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -9.390625,
            "text": "pancreatic cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 14.046875,
            "text": "pint are diagnostic and prognostic biomarkers for pancreatic cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 14.046875,
            "text": "Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer",
            "probability": 0.0
        },
        {
            "start_logit": -3.701171875,
            "end_logit": -9.390625,
            "text": "cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": -3.0625,
            "text": "pint are diagnostic and prognostic biomarkers for pancreatic",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": -3.0625,
            "text": "Linc-pint are diagnostic and prognostic biomarkers for pancreatic",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": -9.390625,
            "text": "pint are diagnostic and prognostic biomarkers for pancreatic cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": -9.546875,
            "text": "pint are diagnostic and prognostic biomarkers for",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": -9.390625,
            "text": "Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": -9.546875,
            "text": "Linc-pint are diagnostic and prognostic biomarkers for",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": -10.015625,
            "text": "pint are diagnostic and",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": -10.1953125,
            "text": "pint are diagnostic and prognostic biomarkers",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": -10.015625,
            "text": "Linc-pint are diagnostic and",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": -10.21875,
            "text": "pint are",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": -10.1953125,
            "text": "Linc-pint are diagnostic and prognostic biomarkers",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": -10.375,
            "text": "pint are diagnostic and prognostic",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": -10.21875,
            "text": "Linc-pint are",
            "probability": 0.0
        }
    ],
    "5e493bc06d0a277941000003_5": [
        {
            "start_logit": 14.828125,
            "end_logit": 14.8671875,
            "text": "pancreatic cancer",
            "probability": 1.0
        },
        {
            "start_logit": 14.828125,
            "end_logit": -1.76171875,
            "text": "pancreatic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.95703125,
            "end_logit": 14.8671875,
            "text": "cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.828125,
            "end_logit": -6.09765625,
            "text": "pancreatic cancer (PCa",
            "probability": 0.0
        },
        {
            "start_logit": 14.828125,
            "end_logit": -7.56640625,
            "text": "pancreatic cancer (PCa)",
            "probability": 0.0
        },
        {
            "start_logit": 14.828125,
            "end_logit": -7.7890625,
            "text": "pancreatic cancer (",
            "probability": 0.0
        },
        {
            "start_logit": -1.95703125,
            "end_logit": -6.09765625,
            "text": "cancer (PCa",
            "probability": 0.0
        },
        {
            "start_logit": -1.95703125,
            "end_logit": -7.56640625,
            "text": "cancer (PCa)",
            "probability": 0.0
        },
        {
            "start_logit": -1.95703125,
            "end_logit": -7.7890625,
            "text": "cancer (",
            "probability": 0.0
        },
        {
            "start_logit": -6.46484375,
            "end_logit": -5.0703125,
            "text": "cholangiocarcinoma",
            "probability": 0.0
        },
        {
            "start_logit": -7.3984375,
            "end_logit": -5.0703125,
            "text": "CAV) and cholangiocarcinoma",
            "probability": 0.0
        },
        {
            "start_logit": -7.91796875,
            "end_logit": -5.0703125,
            "text": "carcinoma of the ampulla of Vater (CAV) and cholangiocarcinoma",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": -5.0703125,
            "text": "and cholangiocarcinoma",
            "probability": 0.0
        },
        {
            "start_logit": -6.46484375,
            "end_logit": -7.0,
            "text": "cholangiocarcinoma (CCA), and suggest that Linc-pint could be used for distinguishing the cause of malignant obstructive jaundice",
            "probability": 0.0
        },
        {
            "start_logit": -7.578125,
            "end_logit": -6.09765625,
            "text": "PCa",
            "probability": 0.0
        },
        {
            "start_logit": -6.46484375,
            "end_logit": -7.37890625,
            "text": "cholangiocarcinoma (CCA",
            "probability": 0.0
        },
        {
            "start_logit": -8.8515625,
            "end_logit": -5.0703125,
            "text": "ampulla of Vater (CAV) and cholangiocarcinoma",
            "probability": 0.0
        },
        {
            "start_logit": -7.3984375,
            "end_logit": -6.78125,
            "text": "CAV",
            "probability": 0.0
        },
        {
            "start_logit": -9.1171875,
            "end_logit": -5.0703125,
            "text": ", carcinoma of the ampulla of Vater (CAV) and cholangiocarcinoma",
            "probability": 0.0
        },
        {
            "start_logit": -6.46484375,
            "end_logit": -7.81640625,
            "text": "cholangiocarcinoma (CCA)",
            "probability": 0.0
        }
    ],
    "601d31df1cb411341a00002e_1": [
        {
            "start_logit": 12.8359375,
            "end_logit": 13.25,
            "text": "THOC1",
            "probability": 1.0
        },
        {
            "start_logit": 12.8359375,
            "end_logit": -0.896484375,
            "text": "THOC1, THOC2",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -5.1328125,
            "end_logit": 13.25,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": 12.8359375,
            "end_logit": -5.171875,
            "text": "THOC1, THOC2, THOC5, THOC6, THOC7",
            "probability": 0.0
        },
        {
            "start_logit": 12.8359375,
            "end_logit": -5.30078125,
            "text": "TH",
            "probability": 0.0
        },
        {
            "start_logit": 12.8359375,
            "end_logit": -5.9375,
            "text": "THOC1, THOC",
            "probability": 0.0
        },
        {
            "start_logit": 12.8359375,
            "end_logit": -6.38671875,
            "text": "THOC",
            "probability": 0.0
        },
        {
            "start_logit": 12.8359375,
            "end_logit": -7.87890625,
            "text": "THOC1, TH",
            "probability": 0.0
        },
        {
            "start_logit": -3.064453125,
            "end_logit": -0.896484375,
            "text": "THOC2",
            "probability": 0.0
        },
        {
            "start_logit": -5.1328125,
            "end_logit": -0.896484375,
            "text": "1, THOC2",
            "probability": 0.0
        },
        {
            "start_logit": -3.515625,
            "end_logit": -3.84765625,
            "text": "ID",
            "probability": 0.0
        },
        {
            "start_logit": -3.064453125,
            "end_logit": -5.171875,
            "text": "THOC2, THOC5, THOC6, THOC7",
            "probability": 0.0
        },
        {
            "start_logit": -3.064453125,
            "end_logit": -5.9375,
            "text": "THOC",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -0.896484375,
            "text": "2",
            "probability": 0.0
        },
        {
            "start_logit": -9.0703125,
            "end_logit": -0.896484375,
            "text": ", THOC2",
            "probability": 0.0
        },
        {
            "start_logit": -5.1328125,
            "end_logit": -5.171875,
            "text": "1, THOC2, THOC5, THOC6, THOC7",
            "probability": 0.0
        },
        {
            "start_logit": -3.515625,
            "end_logit": -6.84765625,
            "text": "ID, with a variable severity, and disorders of growth. A subset of affected individuals' has",
            "probability": 0.0
        },
        {
            "start_logit": -3.515625,
            "end_logit": -7.1015625,
            "text": "ID, with a variable severity, and disorders of growth. A subset of affected individuals' has severe-profound ID, persistent hypotonia and respiratory abnormalities",
            "probability": 0.0
        },
        {
            "start_logit": -3.515625,
            "end_logit": -7.1171875,
            "text": "ID, with a variable severity, and disorders of growth. A subset of affected individuals'",
            "probability": 0.0
        },
        {
            "start_logit": -3.515625,
            "end_logit": -7.19921875,
            "text": "ID, with a variable severity, and disorders of growth. A subset of affected individuals' has severe-profound ID, persistent hypotonia",
            "probability": 0.0
        }
    ],
    "6238a32a3a8413c6530000b9_1": [
        {
            "start_logit": 10.296875,
            "end_logit": 9.1796875,
            "text": "nausea",
            "probability": 1.0
        },
        {
            "start_logit": 10.296875,
            "end_logit": -4.60546875,
            "text": "nausea, vomiting, dizziness, photophobia, tinnitus",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -4.01953125,
            "end_logit": 9.1796875,
            "text": "headaches, nausea",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 10.296875,
            "end_logit": -5.58984375,
            "text": "nausea, vomiting, dizziness, photophobia",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 10.296875,
            "end_logit": -5.7578125,
            "text": "nausea, vomiting",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 10.296875,
            "end_logit": -6.828125,
            "text": "nausea, vomiting, dizziness, photophobia, tinnitus, and vertigo",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.296875,
            "end_logit": -7.20703125,
            "text": "nausea, vomiting, dizziness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 9.1796875,
            "text": "postural headaches, nausea",
            "probability": 0.0
        },
        {
            "start_logit": 10.296875,
            "end_logit": -8.546875,
            "text": "nausea, vomiting, dizziness, photop",
            "probability": 0.0
        },
        {
            "start_logit": 10.296875,
            "end_logit": -8.609375,
            "text": "nausea, vomiting, dizziness, photophobia, tinnitus, and",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 9.1796875,
            "text": "cause postural headaches, nausea",
            "probability": 0.0
        },
        {
            "start_logit": 10.296875,
            "end_logit": -8.9453125,
            "text": "nausea, vomiting, dizziness, photopho",
            "probability": 0.0
        },
        {
            "start_logit": 10.296875,
            "end_logit": -9.796875,
            "text": "nausea,",
            "probability": 0.0
        },
        {
            "start_logit": 10.296875,
            "end_logit": -10.3203125,
            "text": "nausea, vomiting, dizziness, photophobia,",
            "probability": 0.0
        },
        {
            "start_logit": 10.296875,
            "end_logit": -10.3984375,
            "text": "nausea, vomiting,",
            "probability": 0.0
        },
        {
            "start_logit": 10.296875,
            "end_logit": -10.40625,
            "text": "nausea, vomiting, dizziness,",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": 9.1796875,
            "text": ", nausea",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": 9.1796875,
            "text": "Incidental durotomy can cause postural headaches, nausea",
            "probability": 0.0
        },
        {
            "start_logit": -4.01953125,
            "end_logit": -1.853515625,
            "text": "headaches",
            "probability": 0.0
        },
        {
            "start_logit": -4.01953125,
            "end_logit": -4.60546875,
            "text": "headaches, nausea, vomiting, dizziness, photophobia, tinnitus",
            "probability": 0.0
        }
    ],
    "6238a32a3a8413c6530000b9_2": [
        {
            "start_logit": 11.4140625,
            "end_logit": 10.6484375,
            "text": "nausea",
            "probability": 1.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -4.96484375,
            "text": "nausea, vomiting, dizziness, photophobia, tinnitus",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -5.5859375,
            "text": "nausea, vomiting",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -5.75390625,
            "text": "nausea, vomiting, dizziness, photophobia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.9296875,
            "end_logit": 10.6484375,
            "text": "headaches, nausea",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -6.8125,
            "text": "nausea, vomiting, dizziness",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -7.640625,
            "text": "nausea, vomiting, dizziness, photophobia, tinnitus, and vertigo",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -8.5703125,
            "text": "nausea, vomiting, dizziness, photopho",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -8.6171875,
            "text": "nausea, vomiting, dizziness, photop",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -8.796875,
            "text": "nausea, vomiting, dizziness, photophobia, tinnitus, and",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 10.6484375,
            "text": "cause postural headaches, nausea",
            "probability": 0.0
        },
        {
            "start_logit": -8.515625,
            "end_logit": 10.6484375,
            "text": "postural headaches, nausea",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -9.8125,
            "text": "nausea,",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -10.0703125,
            "text": "nausea, vomiting,",
            "probability": 0.0
        },
        {
            "start_logit": -9.359375,
            "end_logit": 10.6484375,
            "text": ", nausea",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -10.15625,
            "text": "nausea, vomiting, dizziness, photophobia, tinnitus, and vertigo. These symptoms are believed to",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -10.1875,
            "text": "nausea, vomiting, dizziness, photophobia,",
            "probability": 0.0
        },
        {
            "start_logit": -9.609375,
            "end_logit": 10.6484375,
            "text": "ATA: Incidental durotomy can cause postural headaches, nausea",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": 10.6484375,
            "text": "Incidental durotomy can cause postural headaches, nausea",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": 10.6484375,
            "text": ": Incidental durotomy can cause postural headaches, nausea",
            "probability": 0.0
        }
    ],
    "5c928958ecadf2e73f000017_1": [
        {
            "start_logit": 6.96484375,
            "end_logit": 9.734375,
            "text": "four-channel single-reaction multiplexing",
            "probability": 1.0
        },
        {
            "start_logit": -4.1328125,
            "end_logit": 9.734375,
            "text": "(i) four-channel single-reaction multiplexing",
            "probability": 1.5079975128173828e-05
        },
        {
            "start_logit": -4.7734375,
            "end_logit": 9.734375,
            "text": "single-reaction multiplexing",
            "probability": 7.927417755126953e-06
        },
        {
            "start_logit": 6.96484375,
            "end_logit": -3.32421875,
            "text": "four-channel single-reaction multiplexing with orthogonal CRISPR enzymes;",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 6.96484375,
            "end_logit": -3.99609375,
            "text": "four-channel single-reaction multiplexing with orthogonal",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -7.16796875,
            "end_logit": 9.734375,
            "text": "i) four-channel single-reaction multiplexing",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.20703125,
            "end_logit": 9.734375,
            "text": "ing",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 9.734375,
            "text": ") four-channel single-reaction multiplexing",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 9.734375,
            "text": "multiplexing",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 6.96484375,
            "end_logit": -5.94921875,
            "text": "four-channel single-reaction",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 6.96484375,
            "end_logit": -6.59375,
            "text": "four-channel single-reaction multiplexing with orthogonal CRISPR enzymes; (ii) quantitative measurement of input as low as 2 attomol",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.96484375,
            "end_logit": -6.859375,
            "text": "four-channel single-reaction multiplex",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.96484375,
            "end_logit": -6.94921875,
            "text": "four-channel single-reaction multiplexing with orthogonal CRISPR enzymes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.96484375,
            "end_logit": -7.29296875,
            "text": "four-channel single-reaction multiplexing with orthogonal CRISPR enzymes; (ii) quantitative measurement of input as low as 2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.96484375,
            "end_logit": -7.8359375,
            "text": "four-channel single-reaction multiplexing with orthogonal CRISPR",
            "probability": 0.0
        },
        {
            "start_logit": 6.96484375,
            "end_logit": -8.0703125,
            "text": "four-channel single-reaction multiplexing with orthogonal CRISPR enzymes; (ii) quantitative measurement of input as low as 2 attomolar",
            "probability": 0.0
        },
        {
            "start_logit": 6.96484375,
            "end_logit": -8.3203125,
            "text": "four-channel",
            "probability": 0.0
        },
        {
            "start_logit": 6.96484375,
            "end_logit": -8.6484375,
            "text": "four-channel single-reaction multiplexing with orthogonal CRISPR enzymes; (ii) quantitative measurement of input as low as 2 att",
            "probability": 0.0
        },
        {
            "start_logit": 6.96484375,
            "end_logit": -8.6953125,
            "text": "four-channel single-reaction multiplexing with orthogonal CRISPR enzymes; (ii) quantitative measurement of input as low as",
            "probability": 0.0
        },
        {
            "start_logit": 1.62109375,
            "end_logit": -6.82421875,
            "text": "CRISPR enzymology",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_1": [
        {
            "start_logit": 11.328125,
            "end_logit": 11.8671875,
            "text": "thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": 3.73046875,
            "text": "thrombocytopenia, anasarca, fever",
            "probability": 0.0002961158752441406
        },
        {
            "start_logit": 11.328125,
            "end_logit": -4.1875,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.328125,
            "end_logit": -4.40625,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 2.025390625,
            "end_logit": 3.73046875,
            "text": "fever",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -7.78125,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly (TAFRO) syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -8.046875,
            "text": "thrombocytopenia, anasarca",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -8.1484375,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly (TAFRO)",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -8.15625,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly (",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -8.484375,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -8.5234375,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly (TAFRO",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -8.71875,
            "text": "thrombocytopenia, anasarca, fever, reticulin",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -9.203125,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organ",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -9.2109375,
            "text": "thrombocytopenia, ana",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": 11.8671875,
            "text": "Although thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -9.5078125,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly (TAFRO) syndrome was",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -9.5078125,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly (TAFRO) syndrome was first described as a",
            "probability": 0.0
        },
        {
            "start_logit": 2.025390625,
            "end_logit": -4.1875,
            "text": "fever, reticulin fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 2.025390625,
            "end_logit": -4.40625,
            "text": "fever, reticulin fibrosis and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -7.7421875,
            "end_logit": 3.73046875,
            "text": "anasarca, fever",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_2": [
        {
            "start_logit": 11.4765625,
            "end_logit": 11.828125,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -5.1015625,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -6.1796875,
            "text": "Thrombocytopenia, anasarca, myelofibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -7.62109375,
            "text": "Thrombocytopenia, anasarca, myel",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -8.015625,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -8.375,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly (TAFRO)",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -8.4609375,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -8.609375,
            "text": "Thrombocytopenia, anasarca",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -8.7109375,
            "text": "Thrombocytopenia, anasarca, myelofib",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -8.9765625,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly (TAFRO",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -9.2265625,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly (",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -9.3125,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is",
            "probability": 0.0
        },
        {
            "start_logit": -1.63671875,
            "end_logit": 0.474609375,
            "text": "fever",
            "probability": 0.0
        },
        {
            "start_logit": -8.53125,
            "end_logit": 0.474609375,
            "text": "thrombocytopenia, anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -9.421875,
            "end_logit": 0.474609375,
            "text": "multicentric Castleman's disease, characterized by thrombocytopenia, anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -9.578125,
            "end_logit": 0.474609375,
            "text": "idiopathic multicentric Castleman's disease, characterized by thrombocytopenia, anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -9.8359375,
            "end_logit": 0.474609375,
            "text": "anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -1.63671875,
            "end_logit": -7.875,
            "text": "fever, reticulin myelofibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.0,
            "end_logit": 0.474609375,
            "text": "TAFRO) syndrome is a severe subtype of idiopathic multicentric Castleman's disease, characterized by thrombocytopenia, anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -1.63671875,
            "end_logit": -8.5625,
            "text": "fever, reticulin",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_3": [
        {
            "start_logit": 11.1328125,
            "end_logit": 12.1875,
            "text": "thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 11.1328125,
            "end_logit": -5.0625,
            "text": "thrombocytopenia, anasarca, myelofibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.1328125,
            "end_logit": -7.1484375,
            "text": "thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": 11.1328125,
            "end_logit": -8.109375,
            "text": "thrombocytopenia, anasarca",
            "probability": 0.0
        },
        {
            "start_logit": 11.1328125,
            "end_logit": -8.3046875,
            "text": "thrombocytopenia, anasarca, myel",
            "probability": 0.0
        },
        {
            "start_logit": 11.1328125,
            "end_logit": -8.34375,
            "text": "thrombocytopenia, anasarca, myelofibrosis, renal dysfunction",
            "probability": 0.0
        },
        {
            "start_logit": 11.1328125,
            "end_logit": -8.5390625,
            "text": "thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly)",
            "probability": 0.0
        },
        {
            "start_logit": 11.1328125,
            "end_logit": -8.6171875,
            "text": "thrombocytopenia, anasarca, myelofib",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": 12.1875,
            "text": "TAFRO syndrome (thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": 11.1328125,
            "end_logit": -9.1875,
            "text": "thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.1328125,
            "end_logit": -9.1953125,
            "text": "thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organ",
            "probability": 0.0
        },
        {
            "start_logit": 11.1328125,
            "end_logit": -9.5,
            "text": "thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly) is an atypical manifestation of multicentric Castleman's disease",
            "probability": 0.0
        },
        {
            "start_logit": 11.1328125,
            "end_logit": -9.515625,
            "text": "thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly) is",
            "probability": 0.0
        },
        {
            "start_logit": 11.1328125,
            "end_logit": -9.5234375,
            "text": "thrombocytopenia,",
            "probability": 0.0
        },
        {
            "start_logit": 11.1328125,
            "end_logit": -9.546875,
            "text": "thrombocytopenia, ana",
            "probability": 0.0
        },
        {
            "start_logit": -6.29296875,
            "end_logit": -5.0625,
            "text": "myelofibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -6.29296875,
            "end_logit": -7.1484375,
            "text": "myelofibrosis, renal dysfunction, and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -8.46875,
            "end_logit": -5.0625,
            "text": "anasarca, myelofibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -6.29296875,
            "end_logit": -8.3046875,
            "text": "myel",
            "probability": 0.0
        },
        {
            "start_logit": -6.29296875,
            "end_logit": -8.34375,
            "text": "myelofibrosis, renal dysfunction",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_4": [
        {
            "start_logit": 11.0859375,
            "end_logit": 10.609375,
            "text": "ascites",
            "probability": 0.9921875
        },
        {
            "start_logit": 6.20703125,
            "end_logit": 10.609375,
            "text": "thrombocytopenia, ascites",
            "probability": 0.007572174072265625
        },
        {
            "start_logit": 6.20703125,
            "end_logit": 6.05859375,
            "text": "thrombocytopenia",
            "probability": 8.028745651245117e-05
        },
        {
            "start_logit": -1.6337890625,
            "end_logit": 10.609375,
            "text": "TAFRO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": 11.0859375,
            "end_logit": -6.5078125,
            "text": "ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.6337890625,
            "end_logit": 6.05859375,
            "text": "TAFRO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.0859375,
            "end_logit": -6.9140625,
            "text": "ascites (anasarca), microcytic anemia, myelofibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 11.0859375,
            "end_logit": -8.4609375,
            "text": "ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly : a status report",
            "probability": 0.0
        },
        {
            "start_logit": 11.0859375,
            "end_logit": -8.4609375,
            "text": "ascites (anasarca",
            "probability": 0.0
        },
        {
            "start_logit": 11.0859375,
            "end_logit": -9.203125,
            "text": "ascites (anasarca), microcytic anemia, myelofib",
            "probability": 0.0
        },
        {
            "start_logit": 11.0859375,
            "end_logit": -9.375,
            "text": "ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly :",
            "probability": 0.0
        },
        {
            "start_logit": 11.0859375,
            "end_logit": -9.4375,
            "text": "ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.0859375,
            "end_logit": -9.5625,
            "text": "ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction",
            "probability": 0.0
        },
        {
            "start_logit": -9.734375,
            "end_logit": 10.609375,
            "text": ", ascites",
            "probability": 0.0
        },
        {
            "start_logit": -9.9453125,
            "end_logit": 10.609375,
            "text": "ma disease (TAFRO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites",
            "probability": 0.0
        },
        {
            "start_logit": -9.9921875,
            "end_logit": 10.609375,
            "text": "Kojima disease (TAFRO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 10.609375,
            "text": "jima disease (TAFRO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites",
            "probability": 0.0
        },
        {
            "start_logit": 6.20703125,
            "end_logit": -6.5078125,
            "text": "thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": 6.20703125,
            "end_logit": -6.9140625,
            "text": "thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 6.20703125,
            "end_logit": -8.4609375,
            "text": "thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly : a status report",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_5": [
        {
            "start_logit": 11.5625,
            "end_logit": 11.484375,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 11.5625,
            "end_logit": -2.353515625,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy and histopathology pattern of atypical Castleman's disease",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 11.5625,
            "end_logit": -5.8671875,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy",
            "probability": 0.0
        },
        {
            "start_logit": 11.5625,
            "end_logit": -6.98046875,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 11.5625,
            "end_logit": -7.90234375,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": 11.5625,
            "end_logit": -7.91015625,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy and histopathology pattern of atypical",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 11.484375,
            "text": "TAFRO Syndrome) is characterized by Thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": 11.5625,
            "end_logit": -8.890625,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy and histopathology pattern of",
            "probability": 0.0
        },
        {
            "start_logit": 11.5625,
            "end_logit": -9.0625,
            "text": "Thrombocytopenia, Anasarca, myel",
            "probability": 0.0
        },
        {
            "start_logit": 11.5625,
            "end_logit": -9.1484375,
            "text": "Thrombocytopenia, Anasarca, myeloFib",
            "probability": 0.0
        },
        {
            "start_logit": 11.5625,
            "end_logit": -9.2109375,
            "text": "Thrombocytopenia, Anasarca",
            "probability": 0.0
        },
        {
            "start_logit": 11.5625,
            "end_logit": -9.3828125,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy and",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 11.484375,
            "text": "Castleman-Kojima disease (TAFRO Syndrome) is characterized by Thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 11.484375,
            "text": "Kojima disease (TAFRO Syndrome) is characterized by Thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": -7.12890625,
            "end_logit": -2.353515625,
            "text": "Castleman's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.1796875,
            "end_logit": -2.353515625,
            "text": "myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy and histopathology pattern of atypical Castleman's disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -2.353515625,
            "text": "disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -2.353515625,
            "text": "histopathology pattern of atypical Castleman's disease",
            "probability": 0.0
        },
        {
            "start_logit": -9.1171875,
            "end_logit": -2.353515625,
            "text": "lymphadenopathy and histopathology pattern of atypical Castleman's disease",
            "probability": 0.0
        },
        {
            "start_logit": -9.578125,
            "end_logit": -2.353515625,
            "text": "atypical Castleman's disease",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_6": [
        {
            "start_logit": 11.171875,
            "end_logit": 12.109375,
            "text": "thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 11.171875,
            "end_logit": -2.4609375,
            "text": "thrombocytopenia, anasarca, fever",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 11.171875,
            "end_logit": -5.3671875,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis, and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": 11.171875,
            "end_logit": -5.765625,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 11.171875,
            "end_logit": -7.625,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis, and organomegaly)",
            "probability": 0.0
        },
        {
            "start_logit": 11.171875,
            "end_logit": -8.1484375,
            "text": "thrombocytopenia, anasarca",
            "probability": 0.0
        },
        {
            "start_logit": -9.8046875,
            "end_logit": 12.109375,
            "text": "TAFRO (i.e., thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": -9.8359375,
            "end_logit": 12.109375,
            "text": "i.e., thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": 11.171875,
            "end_logit": -8.953125,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis, and organ",
            "probability": 0.0
        },
        {
            "start_logit": 11.171875,
            "end_logit": -9.0234375,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.171875,
            "end_logit": -9.0703125,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis, and organomegaly) syndrome,",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 12.109375,
            "text": "multicentric Castleman's disease, TAFRO (i.e., thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": 11.171875,
            "end_logit": -9.1015625,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis, and organomegaly) syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 11.171875,
            "end_logit": -9.1875,
            "text": "thrombocytopenia, anasarca, fever, renal failure",
            "probability": 0.0
        },
        {
            "start_logit": 11.171875,
            "end_logit": -9.265625,
            "text": "thrombocytopenia, ana",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 12.109375,
            "text": "Castleman's disease, TAFRO (i.e., thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": 11.171875,
            "end_logit": -9.3984375,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis, and organomegaly) syndrome, was recently proposed",
            "probability": 0.0
        },
        {
            "start_logit": 11.171875,
            "end_logit": -9.4296875,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis,",
            "probability": 0.0
        },
        {
            "start_logit": -4.33203125,
            "end_logit": -2.4609375,
            "text": "fever",
            "probability": 0.0
        },
        {
            "start_logit": -4.33203125,
            "end_logit": -5.3671875,
            "text": "fever, renal failure or reticulin fibrosis, and organomegaly",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_7": [
        {
            "start_logit": 11.6328125,
            "end_logit": 11.21875,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 11.6328125,
            "end_logit": -6.12890625,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -5.953125,
            "end_logit": 11.21875,
            "text": "TAFRO syndrome is a novel disease concept characterized by Thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": 11.6328125,
            "end_logit": -7.02734375,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy",
            "probability": 0.0
        },
        {
            "start_logit": 11.6328125,
            "end_logit": -8.0625,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": 11.6328125,
            "end_logit": -8.46875,
            "text": "Thrombocytopenia, Anasarca, myel",
            "probability": 0.0
        },
        {
            "start_logit": 11.6328125,
            "end_logit": -8.6328125,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy and a histopathological pattern of atypical",
            "probability": 0.0
        },
        {
            "start_logit": 11.6328125,
            "end_logit": -8.6953125,
            "text": "Thrombocytopenia, Anasarca",
            "probability": 0.0
        },
        {
            "start_logit": 11.6328125,
            "end_logit": -8.921875,
            "text": "Thrombocytopenia, Anasarca, myeloFib",
            "probability": 0.0
        },
        {
            "start_logit": 11.6328125,
            "end_logit": -9.5625,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction",
            "probability": 0.0
        },
        {
            "start_logit": 11.6328125,
            "end_logit": -9.5625,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy and a histopathological pattern",
            "probability": 0.0
        },
        {
            "start_logit": -5.953125,
            "end_logit": -6.12890625,
            "text": "TAFRO syndrome is a novel disease concept characterized by Thrombocytopenia, Anasarca, myeloFibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -6.02734375,
            "end_logit": -6.12890625,
            "text": "myeloFibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -5.953125,
            "end_logit": -7.02734375,
            "text": "TAFRO syndrome is a novel disease concept characterized by Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy",
            "probability": 0.0
        },
        {
            "start_logit": -6.02734375,
            "end_logit": -7.02734375,
            "text": "myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy",
            "probability": 0.0
        },
        {
            "start_logit": -6.02734375,
            "end_logit": -7.12890625,
            "text": "myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy and a histopathological pattern of atypical Castleman's disease",
            "probability": 0.0
        },
        {
            "start_logit": -5.953125,
            "end_logit": -7.66015625,
            "text": "TAFRO",
            "probability": 0.0
        },
        {
            "start_logit": -5.953125,
            "end_logit": -7.890625,
            "text": "TAFRO syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -5.953125,
            "end_logit": -8.0625,
            "text": "TAFRO syndrome is a novel disease concept characterized by Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -6.02734375,
            "end_logit": -8.0625,
            "text": "myeloFibrosis, Renal dysfunction, Organomegaly",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_8": [
        {
            "start_logit": 11.6015625,
            "end_logit": 11.6640625,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 11.6015625,
            "end_logit": -3.900390625,
            "text": "Thrombocytopenia (T), anasarca (A), myelofibrosis",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.6015625,
            "end_logit": -5.44140625,
            "text": "Thrombocytopenia (T), anasarca (A), myelofibrosis (F), renal dysfunction (R), and organomegaly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.6015625,
            "end_logit": -7.4609375,
            "text": "Thrombocytopenia (T), anasarca (A), myel",
            "probability": 0.0
        },
        {
            "start_logit": 11.6015625,
            "end_logit": -7.515625,
            "text": "Thrombocytopenia (T)",
            "probability": 0.0
        },
        {
            "start_logit": 11.6015625,
            "end_logit": -8.1484375,
            "text": "Thrombocytopenia (T), anasarca (A), myelofib",
            "probability": 0.0
        },
        {
            "start_logit": 11.6015625,
            "end_logit": -8.2265625,
            "text": "Thrombocytopenia (T), anasarca",
            "probability": 0.0
        },
        {
            "start_logit": 11.6015625,
            "end_logit": -8.5234375,
            "text": "Thrombocytopenia (T), anasarca (A), myelofibrosis (F), renal dysfunction",
            "probability": 0.0
        },
        {
            "start_logit": 11.6015625,
            "end_logit": -8.75,
            "text": "Thrombocytopenia (T), anasarca (A), myelofibrosis (F",
            "probability": 0.0
        },
        {
            "start_logit": 11.6015625,
            "end_logit": -8.859375,
            "text": "Thrombocytopenia (T",
            "probability": 0.0
        },
        {
            "start_logit": 11.6015625,
            "end_logit": -8.9140625,
            "text": "Thrombocytopenia (T), ana",
            "probability": 0.0
        },
        {
            "start_logit": 11.6015625,
            "end_logit": -9.2109375,
            "text": "Thrombocytopenia (T), anasarca (A), myelofibrosis (F), renal dysfunction (R), and",
            "probability": 0.0
        },
        {
            "start_logit": 11.6015625,
            "end_logit": -9.234375,
            "text": "Thrombocytopenia (T), anasarca (A), myelofibrosis (F), renal dysfunction (R), and organ",
            "probability": 0.0
        },
        {
            "start_logit": -5.09375,
            "end_logit": -3.900390625,
            "text": "myelofibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -5.09375,
            "end_logit": -5.44140625,
            "text": "myelofibrosis (F), renal dysfunction (R), and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -7.44140625,
            "end_logit": -3.900390625,
            "text": "anasarca (A), myelofibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -5.09375,
            "end_logit": -7.4609375,
            "text": "myel",
            "probability": 0.0
        },
        {
            "start_logit": -7.44140625,
            "end_logit": -5.44140625,
            "text": "anasarca (A), myelofibrosis (F), renal dysfunction (R), and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -9.2265625,
            "end_logit": -3.900390625,
            "text": "T), anasarca (A), myelofibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -9.28125,
            "end_logit": -3.900390625,
            "text": "ofibrosis",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_9": [
        {
            "start_logit": 11.3125,
            "end_logit": 12.0,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -5.63671875,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -6.81640625,
            "text": "Thrombocytopenia, anasarca, myelofibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -7.53125,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction",
            "probability": 0.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -8.078125,
            "text": "Thrombocytopenia, anasarca, myel",
            "probability": 0.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -8.3984375,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly (TAFRO)",
            "probability": 0.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -8.40625,
            "text": "Thrombocytopenia, anasarca",
            "probability": 0.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -8.4375,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -8.640625,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal",
            "probability": 0.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -8.8671875,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly (TAFRO",
            "probability": 0.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -9.015625,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -9.171875,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly (",
            "probability": 0.0
        },
        {
            "start_logit": -4.390625,
            "end_logit": -1.9990234375,
            "text": "fever",
            "probability": 0.0
        },
        {
            "start_logit": -9.359375,
            "end_logit": -1.9990234375,
            "text": "thrombocytopenia, anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -9.8203125,
            "end_logit": -1.9990234375,
            "text": "multicentric Castleman's disease, characterized by thrombocytopenia, anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -9.9296875,
            "end_logit": -1.9990234375,
            "text": "anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": -1.9990234375,
            "text": "TAFRO) syndrome is a severe subtype of idiopathic multicentric Castleman's disease, characterized by thrombocytopenia, anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -6.7265625,
            "end_logit": -5.63671875,
            "text": "myelofibrosis, renal dysfunction, and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -4.390625,
            "end_logit": -8.3515625,
            "text": "fever, reticulin",
            "probability": 0.0
        },
        {
            "start_logit": -4.390625,
            "end_logit": -8.8828125,
            "text": "fever, reticulin myelofibrosis",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_10": [
        {
            "start_logit": 11.1875,
            "end_logit": 12.03125,
            "text": "thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -1.0380859375,
            "text": "thrombocytopenia, anasarca, fever",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 11.1875,
            "end_logit": -2.783203125,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis and organomegaly",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 11.1875,
            "end_logit": -5.1796875,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.1875,
            "end_logit": -5.89453125,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis and organomegaly)",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -6.390625,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis and organomegaly) syndrome, has been identified in Japan. Previo",
            "probability": 0.0
        },
        {
            "start_logit": -8.953125,
            "end_logit": 12.03125,
            "text": "TAFRO (i.e. thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -8.34375,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -8.46875,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis and organomegaly) syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -8.546875,
            "text": "thrombocytopenia, anasarca",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -8.671875,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis and organomegaly) syndrome,",
            "probability": 0.0
        },
        {
            "start_logit": -9.640625,
            "end_logit": 12.03125,
            "text": "multicentric Castleman disease, TAFRO (i.e. thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -8.8984375,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis and organ",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -9.1875,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis and",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": 12.03125,
            "text": "Castleman disease, TAFRO (i.e. thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 12.03125,
            "text": ". thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -9.5625,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis and organomegaly) syndrome, has",
            "probability": 0.0
        },
        {
            "start_logit": -3.076171875,
            "end_logit": -1.0380859375,
            "text": "fever",
            "probability": 0.0
        },
        {
            "start_logit": -3.076171875,
            "end_logit": -2.783203125,
            "text": "fever, renal failure or reticulin fibrosis and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -3.076171875,
            "end_logit": -5.1796875,
            "text": "fever, renal failure or reticulin fibrosis",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_11": [
        {
            "start_logit": 11.46875,
            "end_logit": 11.53125,
            "text": "thrombocytopenia",
            "probability": 0.9912109375
        },
        {
            "start_logit": 11.46875,
            "end_logit": 6.78515625,
            "text": "thrombocytopenia, anasarca, fever",
            "probability": 0.008575439453125
        },
        {
            "start_logit": 5.921875,
            "end_logit": 6.78515625,
            "text": "fever",
            "probability": 3.343820571899414e-05
        },
        {
            "start_logit": 11.46875,
            "end_logit": -4.234375,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.46875,
            "end_logit": -4.25,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.46875,
            "end_logit": -7.921875,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly (TAFRO",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -8.2109375,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly (TAFRO) syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -8.4453125,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly (TAFRO)",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -8.6171875,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -8.625,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly (",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -8.84375,
            "text": "thrombocytopenia, anasarca",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -9.0625,
            "text": "thrombocytopenia, anasarca, fever, reticulin",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -9.21875,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organ",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -9.5078125,
            "text": "thrombocytopenia, ana",
            "probability": 0.0
        },
        {
            "start_logit": 5.921875,
            "end_logit": -4.234375,
            "text": "fever, reticulin fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 5.921875,
            "end_logit": -4.25,
            "text": "fever, reticulin fibrosis and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 11.53125,
            "text": "Although thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": -8.609375,
            "end_logit": 6.78515625,
            "text": "anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": 5.921875,
            "end_logit": -7.921875,
            "text": "fever, reticulin fibrosis and organomegaly (TAFRO",
            "probability": 0.0
        },
        {
            "start_logit": 5.921875,
            "end_logit": -8.2109375,
            "text": "fever, reticulin fibrosis and organomegaly (TAFRO) syndrome",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_12": [
        {
            "start_logit": 11.5859375,
            "end_logit": 11.6484375,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -1.421875,
            "text": "Thrombocytopenia, anasarca, fever",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -4.66796875,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -5.10546875,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -7.66796875,
            "text": "Thrombocytopenia, anasarca",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -7.91015625,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly (TAFRO)",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -8.09375,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly (TAFRO) syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -8.2265625,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly (TAFRO",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -8.3984375,
            "text": "Thrombocytopenia, ana",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -8.625,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, organ",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -8.6953125,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly (TAFRO) syndrome is",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -8.8203125,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis,",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -8.890625,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly (",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -8.953125,
            "text": "Thrombocytopenia, anasarca, fever, reticulin",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -9.1015625,
            "text": "Thrombocytopenia, anasarca,",
            "probability": 0.0
        },
        {
            "start_logit": -3.384765625,
            "end_logit": -1.421875,
            "text": "fever",
            "probability": 0.0
        },
        {
            "start_logit": -3.384765625,
            "end_logit": -4.66796875,
            "text": "fever, reticulin fibrosis, organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -3.384765625,
            "end_logit": -5.10546875,
            "text": "fever, reticulin fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": -1.421875,
            "text": "anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -3.384765625,
            "end_logit": -7.91015625,
            "text": "fever, reticulin fibrosis, organomegaly (TAFRO)",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_13": [
        {
            "start_logit": 11.5859375,
            "end_logit": 11.640625,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": 0.06195068359375,
            "text": "Thrombocytopenia, anasarca, fever",
            "probability": 9.417533874511719e-06
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -4.56640625,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -4.7734375,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -7.5859375,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO)",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -7.83203125,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -7.953125,
            "text": "Thrombocytopenia, anasarca",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -7.984375,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -8.140625,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -8.28125,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -8.6171875,
            "text": "Thrombocytopenia, ana",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -8.7421875,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome is",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -8.8515625,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis,",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -8.953125,
            "text": "Thrombocytopenia, anasarca, fever, reticulin",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -9.1796875,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organ",
            "probability": 0.0
        },
        {
            "start_logit": -1.80078125,
            "end_logit": 0.06195068359375,
            "text": "fever",
            "probability": 0.0
        },
        {
            "start_logit": -1.80078125,
            "end_logit": -4.56640625,
            "text": "fever, reticulin fibrosis, and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -1.80078125,
            "end_logit": -4.7734375,
            "text": "fever, reticulin fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.7578125,
            "end_logit": 0.06195068359375,
            "text": "anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -1.80078125,
            "end_logit": -7.5859375,
            "text": "fever, reticulin fibrosis, and organomegaly (TAFRO)",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_14": [
        {
            "start_logit": 11.1953125,
            "end_logit": 12.1171875,
            "text": "thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -5.046875,
            "text": "thrombocytopenia (T), anasarca (A), fever",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -7.58984375,
            "text": "thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -7.74609375,
            "text": "thrombocytopenia (T)",
            "probability": 0.0
        },
        {
            "start_logit": -9.46875,
            "end_logit": 12.1171875,
            "text": "iMCD) that involves a constellation of syndromes: thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -8.609375,
            "text": "thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis (R), and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -8.890625,
            "text": "thrombocytopenia (T), anasarca",
            "probability": 0.0
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -8.9921875,
            "text": "thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis (R), and",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 12.1171875,
            "text": "idiopathic multicentric Castleman disease (iMCD) that involves a constellation of syndromes: thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": 12.1171875,
            "text": "TAFRO syndrome is a newly recognized variant of idiopathic multicentric Castleman disease (iMCD) that involves a constellation of syndromes: thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -9.4609375,
            "text": "thrombocytopenia (T",
            "probability": 0.0
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -9.578125,
            "text": "thrombocytopenia (T), ana",
            "probability": 0.0
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -9.5859375,
            "text": "thrombocytopenia (T), anasarca (A), fever (F), reticulin",
            "probability": 0.0
        },
        {
            "start_logit": -6.58984375,
            "end_logit": -5.046875,
            "text": "fever",
            "probability": 0.0
        },
        {
            "start_logit": -6.58984375,
            "end_logit": -7.36328125,
            "text": "fever (F), reticulin fibrosis (R), and organomegaly (O). Thromboc",
            "probability": 0.0
        },
        {
            "start_logit": -8.90625,
            "end_logit": -5.046875,
            "text": "anasarca (A), fever",
            "probability": 0.0
        },
        {
            "start_logit": -9.0390625,
            "end_logit": -5.046875,
            "text": ", anasarca (A), fever",
            "probability": 0.0
        },
        {
            "start_logit": -6.80078125,
            "end_logit": -7.36328125,
            "text": "Thromboc",
            "probability": 0.0
        },
        {
            "start_logit": -6.58984375,
            "end_logit": -7.58984375,
            "text": "fever (F), reticulin fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -9.375,
            "end_logit": -5.046875,
            "text": "T), anasarca (A), fever",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_15": [
        {
            "start_logit": 11.734375,
            "end_logit": 11.53125,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 11.734375,
            "end_logit": -4.9375,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction and organomegaly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.734375,
            "end_logit": -6.0859375,
            "text": "Thrombocytopenia, anasarca, myelofibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 11.734375,
            "end_logit": -7.15625,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction",
            "probability": 0.0
        },
        {
            "start_logit": 11.734375,
            "end_logit": -7.73828125,
            "text": "Thrombocytopenia, anasarca",
            "probability": 0.0
        },
        {
            "start_logit": 11.734375,
            "end_logit": -8.1953125,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction and organomegaly (TAFRO) syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 11.734375,
            "end_logit": -8.484375,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction and organomegaly (TAFRO)",
            "probability": 0.0
        },
        {
            "start_logit": 11.734375,
            "end_logit": -8.6796875,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction and",
            "probability": 0.0
        },
        {
            "start_logit": 11.734375,
            "end_logit": -8.7890625,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction and organomegaly (TAFRO",
            "probability": 0.0
        },
        {
            "start_logit": 11.734375,
            "end_logit": -8.7890625,
            "text": "Thrombocytopenia, anasarca, myel",
            "probability": 0.0
        },
        {
            "start_logit": 11.734375,
            "end_logit": -8.9375,
            "text": "Thrombocytopenia, ana",
            "probability": 0.0
        },
        {
            "start_logit": 11.734375,
            "end_logit": -8.953125,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction and organomegaly (",
            "probability": 0.0
        },
        {
            "start_logit": 11.734375,
            "end_logit": -9.0234375,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal",
            "probability": 0.0
        },
        {
            "start_logit": 11.734375,
            "end_logit": -9.140625,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction and organomegaly (TAFRO) syndrome is",
            "probability": 0.0
        },
        {
            "start_logit": 11.734375,
            "end_logit": -9.1484375,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction and organ",
            "probability": 0.0
        },
        {
            "start_logit": -6.78125,
            "end_logit": -4.9375,
            "text": "myelofibrosis, renal dysfunction and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -4.9375,
            "text": "anasarca, myelofibrosis, renal dysfunction and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -7.8046875,
            "end_logit": -4.9375,
            "text": "organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -6.78125,
            "end_logit": -6.0859375,
            "text": "myelofibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.546875,
            "end_logit": -4.9375,
            "text": "renal dysfunction and organomegaly",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_16": [
        {
            "start_logit": 11.828125,
            "end_logit": 11.28125,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 11.828125,
            "end_logit": 2.158203125,
            "text": "Thrombocytopenia, anasarca, fever",
            "probability": 0.00010889768600463867
        },
        {
            "start_logit": 11.828125,
            "end_logit": -6.3203125,
            "text": "Thrombocytopenia, anasarca, fever, renal insufficiency, and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": 11.828125,
            "end_logit": -8.2734375,
            "text": "Thrombocytopenia, anasarca, fever, renal insufficiency",
            "probability": 0.0
        },
        {
            "start_logit": 11.828125,
            "end_logit": -8.4140625,
            "text": "Thrombocytopenia, anasarca, fever, renal insufficiency, and organomegaly constitute",
            "probability": 0.0
        },
        {
            "start_logit": 11.828125,
            "end_logit": -8.765625,
            "text": "Thrombocytopenia, anasarca",
            "probability": 0.0
        },
        {
            "start_logit": 11.828125,
            "end_logit": -8.796875,
            "text": "Thrombocytopenia, anasarca, fever, renal insufficiency, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.828125,
            "end_logit": -9.1484375,
            "text": "Thrombocytopenia, anasarca, fever, renal insufficiency, and organomegaly constitute TAFRO syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 11.828125,
            "end_logit": -9.2578125,
            "text": "Thrombocytopenia, anasarca, fever, renal insufficiency, and organomegaly constitute TAFRO",
            "probability": 0.0
        },
        {
            "start_logit": 11.828125,
            "end_logit": -9.390625,
            "text": "Thrombocytopenia, anasarca, fever, renal insufficiency, and organomegaly constitute TAFRO syndrome, a variant of Castleman disease.",
            "probability": 0.0
        },
        {
            "start_logit": 11.828125,
            "end_logit": -9.5234375,
            "text": "Thrombocytopenia, anasarca, fever, renal insufficiency, and organ",
            "probability": 0.0
        },
        {
            "start_logit": 11.828125,
            "end_logit": -9.5234375,
            "text": "Thrombocytopenia,",
            "probability": 0.0
        },
        {
            "start_logit": 0.08599853515625,
            "end_logit": 2.158203125,
            "text": "fever",
            "probability": 0.0
        },
        {
            "start_logit": 11.828125,
            "end_logit": -9.625,
            "text": "Thrombocytopenia, ana",
            "probability": 0.0
        },
        {
            "start_logit": 11.828125,
            "end_logit": -9.6796875,
            "text": "Thrombocytopenia, anasarca, fever, renal",
            "probability": 0.0
        },
        {
            "start_logit": 11.828125,
            "end_logit": -9.703125,
            "text": "Thrombocytopenia, anasarca, fever, renal insufficiency, and organomegaly constitute TAFRO syndrome, a variant of Castleman disease. We",
            "probability": 0.0
        },
        {
            "start_logit": 0.08599853515625,
            "end_logit": -6.3203125,
            "text": "fever, renal insufficiency, and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -8.578125,
            "end_logit": 2.158203125,
            "text": "anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 2.158203125,
            "text": ", anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 2.158203125,
            "text": ", fever",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_17": [
        {
            "start_logit": 11.4609375,
            "end_logit": 11.8046875,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 11.4609375,
            "end_logit": -1.0537109375,
            "text": "Thrombocytopenia, anasarca, fever",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": 11.4609375,
            "end_logit": -5.03515625,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.4609375,
            "end_logit": -5.11328125,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.4609375,
            "end_logit": -7.78515625,
            "text": "Thrombocytopenia, anasarca",
            "probability": 0.0
        },
        {
            "start_logit": 11.4609375,
            "end_logit": -7.87890625,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO)",
            "probability": 0.0
        },
        {
            "start_logit": 11.4609375,
            "end_logit": -7.97265625,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 11.4609375,
            "end_logit": -7.9921875,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO",
            "probability": 0.0
        },
        {
            "start_logit": 11.4609375,
            "end_logit": -8.3046875,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.4609375,
            "end_logit": -8.3125,
            "text": "Thrombocytopenia, ana",
            "probability": 0.0
        },
        {
            "start_logit": 11.4609375,
            "end_logit": -8.5,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (",
            "probability": 0.0
        },
        {
            "start_logit": 11.4609375,
            "end_logit": -8.6796875,
            "text": "Thrombocytopenia, anasarca, fever, reticulin",
            "probability": 0.0
        },
        {
            "start_logit": 11.4609375,
            "end_logit": -8.6953125,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome is considered as a",
            "probability": 0.0
        },
        {
            "start_logit": 11.4609375,
            "end_logit": -8.8515625,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis,",
            "probability": 0.0
        },
        {
            "start_logit": 11.4609375,
            "end_logit": -8.953125,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome is",
            "probability": 0.0
        },
        {
            "start_logit": 11.4609375,
            "end_logit": -8.9765625,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organ",
            "probability": 0.0
        },
        {
            "start_logit": -2.935546875,
            "end_logit": -1.0537109375,
            "text": "fever",
            "probability": 0.0
        },
        {
            "start_logit": -2.935546875,
            "end_logit": -5.03515625,
            "text": "fever, reticulin fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -2.935546875,
            "end_logit": -5.11328125,
            "text": "fever, reticulin fibrosis, and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -7.765625,
            "end_logit": -1.0537109375,
            "text": "anasarca, fever",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_18": [
        {
            "start_logit": 11.40625,
            "end_logit": 11.8515625,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -0.306640625,
            "text": "Thrombocytopenia, ascites",
            "probability": 5.304813385009766e-06
        },
        {
            "start_logit": 11.40625,
            "end_logit": -5.5078125,
            "text": "Thrombocytopenia, ascites, myelofibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -5.71875,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -7.703125,
            "text": "Thrombocytopenia, ascites, myel",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -7.96875,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -8.3515625,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -8.40625,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (TAFRO)",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -8.7109375,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (TAFRO",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -8.859375,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -9.0390625,
            "text": "Thrombocytopenia, ascites, myelofib",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -9.0703125,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -9.21875,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -9.4921875,
            "text": "Thrombocytopenia, ascites,",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -9.4921875,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is a",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 11.8515625,
            "text": ": Thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": 0.6123046875,
            "end_logit": -0.306640625,
            "text": "ascites",
            "probability": 0.0
        },
        {
            "start_logit": 0.6123046875,
            "end_logit": -5.5078125,
            "text": "ascites, myelofibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 0.6123046875,
            "end_logit": -5.71875,
            "text": "ascites, myelofibrosis, renal dysfunction, and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": 0.6123046875,
            "end_logit": -7.703125,
            "text": "ascites, myel",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_19": [
        {
            "start_logit": 11.3828125,
            "end_logit": 11.9140625,
            "text": "thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -1.5322265625,
            "text": "thrombocytopenia, anasarca, fever",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -6.30078125,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -6.6640625,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -7.41015625,
            "text": "thrombocytopenia, anasarca",
            "probability": 0.0
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -8.265625,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis, and",
            "probability": 0.0
        },
        {
            "start_logit": -9.015625,
            "end_logit": 11.9140625,
            "text": "TAFRO syndrome (thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -8.7421875,
            "text": "thrombocytopenia, ana",
            "probability": 0.0
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -8.75,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly)",
            "probability": 0.0
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -9.0703125,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis, and organ",
            "probability": 0.0
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -9.1328125,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly), which is thought to be a variant",
            "probability": 0.0
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -9.2578125,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly), which is thought to be",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 11.9140625,
            "text": "pathophysiology and comorbidities of TAFRO syndrome (thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": -3.3984375,
            "end_logit": -1.5322265625,
            "text": "fever",
            "probability": 0.0
        },
        {
            "start_logit": -3.3984375,
            "end_logit": -6.30078125,
            "text": "fever, reticulin fibrosis, and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -3.3984375,
            "end_logit": -6.40625,
            "text": "fever, reticulin fibrosis, and organomegaly), which is thought to be a variant of multicentric Castleman's disease",
            "probability": 0.0
        },
        {
            "start_logit": -3.3984375,
            "end_logit": -6.6640625,
            "text": "fever, reticulin fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.59375,
            "end_logit": -1.5322265625,
            "text": "anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -9.015625,
            "end_logit": -1.5322265625,
            "text": "TAFRO syndrome (thrombocytopenia, anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -3.3984375,
            "end_logit": -8.265625,
            "text": "fever, reticulin fibrosis, and",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_20": [
        {
            "start_logit": 11.4765625,
            "end_logit": 11.7890625,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -0.6796875,
            "text": "Thrombocytopenia, anasarca, fever",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -4.9140625,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -4.98046875,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -7.83203125,
            "text": "Thrombocytopenia, anasarca",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -7.8671875,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO)",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -8.0078125,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -8.109375,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -8.2734375,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -8.296875,
            "text": "Thrombocytopenia, ana",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -8.359375,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -8.625,
            "text": "Thrombocytopenia, anasarca, fever, reticulin",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -8.6484375,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome is considered as a",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -8.7734375,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis,",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -9.0,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome is",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -9.0078125,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organ",
            "probability": 0.0
        },
        {
            "start_logit": -2.4765625,
            "end_logit": -0.6796875,
            "text": "fever",
            "probability": 0.0
        },
        {
            "start_logit": -2.4765625,
            "end_logit": -4.9140625,
            "text": "fever, reticulin fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -2.4765625,
            "end_logit": -4.98046875,
            "text": "fever, reticulin fibrosis, and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -7.58203125,
            "end_logit": -0.6796875,
            "text": "anasarca, fever",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_21": [
        {
            "start_logit": 11.546875,
            "end_logit": 11.703125,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -1.337890625,
            "text": "Thrombocytopenia, anasarca, fever",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 11.546875,
            "end_logit": -4.51953125,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.546875,
            "end_logit": -5.08984375,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.546875,
            "end_logit": -7.8203125,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly (TAFRO) syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -7.82421875,
            "text": "Thrombocytopenia, anasarca",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -7.9765625,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly (TAFRO)",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -8.203125,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly (TAFRO",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -8.25,
            "text": "Thrombocytopenia, ana",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -8.7421875,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, organ",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -8.78125,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly (",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -8.78125,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis,",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -8.7890625,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly (TAFRO) syndrome is",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -8.828125,
            "text": "Thrombocytopenia, anasarca, fever, reticulin",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -9.1328125,
            "text": "Thrombocytopenia, anasarca,",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -9.3671875,
            "text": "Thrombocytopenia, anasarca, fever,",
            "probability": 0.0
        },
        {
            "start_logit": -3.2265625,
            "end_logit": -1.337890625,
            "text": "fever",
            "probability": 0.0
        },
        {
            "start_logit": -3.2265625,
            "end_logit": -4.51953125,
            "text": "fever, reticulin fibrosis, organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -3.2265625,
            "end_logit": -5.08984375,
            "text": "fever, reticulin fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": -1.337890625,
            "text": "anasarca, fever",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_22": [
        {
            "start_logit": 11.5546875,
            "end_logit": 11.6953125,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -0.459228515625,
            "text": "Thrombocytopenia, anasarca, fever",
            "probability": 5.245208740234375e-06
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -4.7578125,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -5.04296875,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -7.71484375,
            "text": "Thrombocytopenia, anasarca",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -7.8125,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO)",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -7.96484375,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -8.0390625,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -8.3984375,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -8.40625,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -8.5,
            "text": "Thrombocytopenia, ana",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -8.671875,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome is",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -8.859375,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis,",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -8.9375,
            "text": "Thrombocytopenia, anasarca, fever, reticulin",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -9.171875,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organ",
            "probability": 0.0
        },
        {
            "start_logit": -2.30859375,
            "end_logit": -0.459228515625,
            "text": "fever",
            "probability": 0.0
        },
        {
            "start_logit": -2.30859375,
            "end_logit": -4.7578125,
            "text": "fever, reticulin fibrosis, and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -2.30859375,
            "end_logit": -5.04296875,
            "text": "fever, reticulin fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": -0.459228515625,
            "text": "anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -2.30859375,
            "end_logit": -7.8125,
            "text": "fever, reticulin fibrosis, and organomegaly (TAFRO)",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_23": [
        {
            "start_logit": 11.3984375,
            "end_logit": 11.8828125,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 11.3984375,
            "end_logit": 0.0352783203125,
            "text": "Thrombocytopenia, ascites",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": 11.3984375,
            "end_logit": -5.47265625,
            "text": "Thrombocytopenia, ascites, myelofibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 11.3984375,
            "end_logit": -5.87109375,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": 11.3984375,
            "end_logit": -7.51171875,
            "text": "Thrombocytopenia, ascites, myel",
            "probability": 0.0
        },
        {
            "start_logit": 11.3984375,
            "end_logit": -8.1953125,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 11.3984375,
            "end_logit": -8.2734375,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction",
            "probability": 0.0
        },
        {
            "start_logit": 11.3984375,
            "end_logit": -8.5859375,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (TAFRO)",
            "probability": 0.0
        },
        {
            "start_logit": 11.3984375,
            "end_logit": -9.015625,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.3984375,
            "end_logit": -9.046875,
            "text": "Thrombocytopenia, ascites, myelofib",
            "probability": 0.0
        },
        {
            "start_logit": 11.3984375,
            "end_logit": -9.1953125,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is",
            "probability": 0.0
        },
        {
            "start_logit": 11.3984375,
            "end_logit": -9.1953125,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (TAFRO",
            "probability": 0.0
        },
        {
            "start_logit": 11.3984375,
            "end_logit": -9.3125,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (",
            "probability": 0.0
        },
        {
            "start_logit": 11.3984375,
            "end_logit": -9.328125,
            "text": "Thrombocytopenia, ascites,",
            "probability": 0.0
        },
        {
            "start_logit": 11.3984375,
            "end_logit": -9.484375,
            "text": "Thrombocytopenia,",
            "probability": 0.0
        },
        {
            "start_logit": 11.3984375,
            "end_logit": -9.546875,
            "text": "Thrombocytopenia, ascites, myelofibrosis,",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": 11.8828125,
            "text": ": Thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": 1.1064453125,
            "end_logit": 0.0352783203125,
            "text": "ascites",
            "probability": 0.0
        },
        {
            "start_logit": 1.1064453125,
            "end_logit": -5.47265625,
            "text": "ascites, myelofibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 1.1064453125,
            "end_logit": -5.87109375,
            "text": "ascites, myelofibrosis, renal dysfunction, and organomegaly",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_24": [
        {
            "start_logit": 11.2734375,
            "end_logit": 12.0078125,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -6.33984375,
            "text": "Thrombocytopenia, Anasarca, MyeloFibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -6.65234375,
            "text": "Thrombocytopenia, Anasarca, MyeloFibrosis, Renal failure, Organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -8.03125,
            "text": "Thrombocytopenia, Anasarca",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -8.6796875,
            "text": "Thrombocytopenia, Anasarca, MyeloFibrosis, Renal failure, Organomegaly)",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -8.9921875,
            "text": "Thrombocytopenia, Anasarca, Myel",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -9.015625,
            "text": "Thrombocytopenia, Anasarca, MyeloFib",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -9.046875,
            "text": "Thrombocytopenia, Anasarca, MyeloFibrosis, Renal failure, Organ",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -9.0625,
            "text": "Thrombocytopenia,",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -9.140625,
            "text": "Thrombocytopenia, Anasarca, MyeloFibrosis, Renal failure",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -9.53125,
            "text": "Thrombocytopenia, Ana",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -9.5703125,
            "text": "Thrombocytopenia, Anasarca, MyeloFibrosis, Renal failure, Organomegaly).",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -9.5859375,
            "text": "Thrombocytopenia, Anasarca,",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 12.0078125,
            "text": "TAFRO represents the constellation of symptoms (Thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": -7.109375,
            "end_logit": -6.33984375,
            "text": "MyeloFibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.109375,
            "end_logit": -6.65234375,
            "text": "MyeloFibrosis, Renal failure, Organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -6.65234375,
            "text": "Organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -8.578125,
            "end_logit": -6.33984375,
            "text": "Anasarca, MyeloFibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.578125,
            "end_logit": -6.65234375,
            "text": "Anasarca, MyeloFibrosis, Renal failure, Organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -7.109375,
            "end_logit": -8.6796875,
            "text": "MyeloFibrosis, Renal failure, Organomegaly)",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_25": [
        {
            "start_logit": 11.140625,
            "end_logit": 12.15625,
            "text": "thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -3.81640625,
            "text": "thrombocytopenia (T), anasarca (A), fever",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.140625,
            "end_logit": -7.1875,
            "text": "thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -7.54296875,
            "text": "thrombocytopenia (T)",
            "probability": 0.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -8.2265625,
            "text": "thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis (R), and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": 12.15625,
            "text": "iMCD) that involves a constellation of syndromes: thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -8.59375,
            "text": "thrombocytopenia (T), anasarca",
            "probability": 0.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -8.828125,
            "text": "thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis (R), and",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": 12.15625,
            "text": "idiopathic multicentric Castleman disease (iMCD) that involves a constellation of syndromes: thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -9.359375,
            "text": "thrombocytopenia (T",
            "probability": 0.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -9.421875,
            "text": "thrombocytopenia (T), ana",
            "probability": 0.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -9.4453125,
            "text": "thrombocytopenia (T), anasarca (A",
            "probability": 0.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -9.5,
            "text": "thrombocytopenia (T), anasarca (A), fever (F",
            "probability": 0.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -9.5625,
            "text": "thrombocytopenia (T), anasarca (A), fever (F), reticulin",
            "probability": 0.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -9.5703125,
            "text": "thrombocytopenia (T), anasarca (A), fever (F)",
            "probability": 0.0
        },
        {
            "start_logit": -5.4453125,
            "end_logit": -3.81640625,
            "text": "fever",
            "probability": 0.0
        },
        {
            "start_logit": -5.4453125,
            "end_logit": -7.1875,
            "text": "fever (F), reticulin fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.984375,
            "end_logit": -3.81640625,
            "text": "anasarca (A), fever",
            "probability": 0.0
        },
        {
            "start_logit": -9.140625,
            "end_logit": -3.81640625,
            "text": ", anasarca (A), fever",
            "probability": 0.0
        },
        {
            "start_logit": -9.3671875,
            "end_logit": -3.81640625,
            "text": "T), anasarca (A), fever",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_26": [
        {
            "start_logit": 11.25,
            "end_logit": 12.0234375,
            "text": "thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -2.04296875,
            "text": "thrombocytopenia, anasarca, fever",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.9765625,
            "end_logit": 12.0234375,
            "text": "TAFRO syndrome is a newly identified disorder of unknown etiology characterized by thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -7.65234375,
            "text": "thrombocytopenia, anasarca, fever, reticulin myelofibrosis, renal dysfunction, and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -7.9375,
            "text": "thrombocytopenia, anasarca, fever, reticulin myelofibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -8.3671875,
            "text": "thrombocytopenia, anasarca, fever, reticulin myelofibrosis, renal dysfunction, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -8.7578125,
            "text": "thrombocytopenia, anasarca, fever, reticulin myelofibrosis, renal dysfunction, and organomegaly.",
            "probability": 0.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -8.90625,
            "text": "thrombocytopenia, anasarca",
            "probability": 0.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -9.2734375,
            "text": "thrombocytopenia, anasarca, fever, reticulin myelofibrosis, renal dysfunction",
            "probability": 0.0
        },
        {
            "start_logit": -3.86328125,
            "end_logit": -2.04296875,
            "text": "fever",
            "probability": 0.0
        },
        {
            "start_logit": -6.9765625,
            "end_logit": -2.04296875,
            "text": "TAFRO syndrome is a newly identified disorder of unknown etiology characterized by thrombocytopenia, anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -9.0703125,
            "end_logit": -2.04296875,
            "text": "anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -3.86328125,
            "end_logit": -7.65234375,
            "text": "fever, reticulin myelofibrosis, renal dysfunction, and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -3.86328125,
            "end_logit": -7.9375,
            "text": "fever, reticulin myelofibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -3.86328125,
            "end_logit": -8.3671875,
            "text": "fever, reticulin myelofibrosis, renal dysfunction, and",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -2.04296875,
            "text": "ca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -3.86328125,
            "end_logit": -8.7578125,
            "text": "fever, reticulin myelofibrosis, renal dysfunction, and organomegaly.",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": -2.04296875,
            "text": ", fever",
            "probability": 0.0
        },
        {
            "start_logit": -3.86328125,
            "end_logit": -9.2734375,
            "text": "fever, reticulin myelofibrosis, renal dysfunction",
            "probability": 0.0
        },
        {
            "start_logit": -6.9765625,
            "end_logit": -6.87890625,
            "text": "TAFRO",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_27": [
        {
            "start_logit": 11.1171875,
            "end_logit": 12.046875,
            "text": "thrombocytopenia",
            "probability": 0.98193359375
        },
        {
            "start_logit": 11.1171875,
            "end_logit": 7.98828125,
            "text": "thrombocytopenia, ascites",
            "probability": 0.01715087890625
        },
        {
            "start_logit": 8.203125,
            "end_logit": 7.98828125,
            "text": "ascites",
            "probability": 0.0009236335754394531
        },
        {
            "start_logit": -7.59375,
            "end_logit": 12.046875,
            "text": "TAFRO syndrome, an acronym for thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": 11.1171875,
            "end_logit": -7.296875,
            "text": "thrombocytopenia, ascites, myelofibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 11.1171875,
            "end_logit": -7.51953125,
            "text": "thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": 11.1171875,
            "end_logit": -8.9140625,
            "text": "thrombocytopenia, ascites, myelofibrosis, renal dysfunction",
            "probability": 0.0
        },
        {
            "start_logit": 11.1171875,
            "end_logit": -9.0625,
            "text": "thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.1171875,
            "end_logit": -9.3828125,
            "text": "thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly.",
            "probability": 0.0
        },
        {
            "start_logit": 11.1171875,
            "end_logit": -9.3984375,
            "text": "thrombocytopenia,",
            "probability": 0.0
        },
        {
            "start_logit": 11.1171875,
            "end_logit": -9.5390625,
            "text": "thrombocytopenia, ascites, myel",
            "probability": 0.0
        },
        {
            "start_logit": 8.203125,
            "end_logit": -7.296875,
            "text": "ascites, myelofibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 8.203125,
            "end_logit": -7.51953125,
            "text": "ascites, myelofibrosis, renal dysfunction, and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -7.59375,
            "end_logit": 7.98828125,
            "text": "TAFRO syndrome, an acronym for thrombocytopenia, ascites",
            "probability": 0.0
        },
        {
            "start_logit": 8.203125,
            "end_logit": -8.9140625,
            "text": "ascites, myelofibrosis, renal dysfunction",
            "probability": 0.0
        },
        {
            "start_logit": 8.203125,
            "end_logit": -9.0625,
            "text": "ascites, myelofibrosis, renal dysfunction, and",
            "probability": 0.0
        },
        {
            "start_logit": 8.203125,
            "end_logit": -9.3828125,
            "text": "ascites, myelofibrosis, renal dysfunction, and organomegaly.",
            "probability": 0.0
        },
        {
            "start_logit": 8.203125,
            "end_logit": -9.5390625,
            "text": "ascites, myel",
            "probability": 0.0
        },
        {
            "start_logit": -7.59375,
            "end_logit": -7.296875,
            "text": "TAFRO syndrome, an acronym for thrombocytopenia, ascites, myelofibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.59375,
            "end_logit": -7.51953125,
            "text": "TAFRO syndrome, an acronym for thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_28": [
        {
            "start_logit": 11.296875,
            "end_logit": 11.9765625,
            "text": "thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 11.296875,
            "end_logit": -0.85791015625,
            "text": "thrombocytopenia (T), anasarca (A), fever",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": 11.296875,
            "end_logit": -4.30078125,
            "text": "thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.72265625,
            "end_logit": 11.9765625,
            "text": "iMCD cases in Japan sharing a constellation of clinical features, including thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": 11.296875,
            "end_logit": -7.6640625,
            "text": "thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis (R), and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": 11.296875,
            "end_logit": -8.2109375,
            "text": "thrombocytopenia (T)",
            "probability": 0.0
        },
        {
            "start_logit": 11.296875,
            "end_logit": -9.0625,
            "text": "thrombocytopenia (T), anasarca (A), fever (F), reticulin",
            "probability": 0.0
        },
        {
            "start_logit": 11.296875,
            "end_logit": -9.125,
            "text": "thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis (R), and",
            "probability": 0.0
        },
        {
            "start_logit": 11.296875,
            "end_logit": -9.2265625,
            "text": "thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis (R), and organomegaly (O",
            "probability": 0.0
        },
        {
            "start_logit": 11.296875,
            "end_logit": -9.5,
            "text": "thrombocytopenia (T),",
            "probability": 0.0
        },
        {
            "start_logit": -2.3125,
            "end_logit": -0.85791015625,
            "text": "fever",
            "probability": 0.0
        },
        {
            "start_logit": -2.3125,
            "end_logit": -4.30078125,
            "text": "fever (F), reticulin fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.72265625,
            "end_logit": -0.85791015625,
            "text": "iMCD cases in Japan sharing a constellation of clinical features, including thrombocytopenia (T), anasarca (A), fever",
            "probability": 0.0
        },
        {
            "start_logit": -2.3125,
            "end_logit": -7.6640625,
            "text": "fever (F), reticulin fibrosis (R), and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": -0.85791015625,
            "text": "T), anasarca (A), fever",
            "probability": 0.0
        },
        {
            "start_logit": -2.3125,
            "end_logit": -8.0546875,
            "text": "fever (F), reticulin fibrosis (R), and organomegaly (O) has been described as TAFRO",
            "probability": 0.0
        },
        {
            "start_logit": -9.640625,
            "end_logit": -0.85791015625,
            "text": "anasarca (A), fever",
            "probability": 0.0
        },
        {
            "start_logit": -2.3125,
            "end_logit": -8.265625,
            "text": "fever (F), reticulin fibrosis (R), and organomegaly (O) has been described as TAFRO syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.90625,
            "end_logit": -0.85791015625,
            "text": "A), fever",
            "probability": 0.0
        },
        {
            "start_logit": -6.578125,
            "end_logit": -4.30078125,
            "text": "fibrosis",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_29": [
        {
            "start_logit": 11.140625,
            "end_logit": 12.1328125,
            "text": "thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -2.607421875,
            "text": "thrombocytopenia, anasarca, fever",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 11.140625,
            "end_logit": -6.94921875,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -7.328125,
            "text": "thrombocytopenia, anasarca",
            "probability": 0.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -7.5546875,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -7.97265625,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis, and",
            "probability": 0.0
        },
        {
            "start_logit": -8.96875,
            "end_logit": 12.1328125,
            "text": "TAFRO syndrome, named from thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -8.8125,
            "text": "thrombocytopenia,",
            "probability": 0.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -8.921875,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly.",
            "probability": 0.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -9.0234375,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis, and organ",
            "probability": 0.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -9.0390625,
            "text": "thrombocytopenia, ana",
            "probability": 0.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -9.1796875,
            "text": "thrombocytopenia, anasa",
            "probability": 0.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -9.234375,
            "text": "thrombocytopenia, anasarca,",
            "probability": 0.0
        },
        {
            "start_logit": -4.4921875,
            "end_logit": -2.607421875,
            "text": "fever",
            "probability": 0.0
        },
        {
            "start_logit": -4.4921875,
            "end_logit": -6.94921875,
            "text": "fever, reticulin fibrosis, and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -8.859375,
            "end_logit": -2.607421875,
            "text": "anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -8.96875,
            "end_logit": -2.607421875,
            "text": "TAFRO syndrome, named from thrombocytopenia, anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -4.4921875,
            "end_logit": -7.5546875,
            "text": "fever, reticulin fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -4.4921875,
            "end_logit": -7.97265625,
            "text": "fever, reticulin fibrosis, and",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": -2.607421875,
            "text": "ca, fever",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_30": [
        {
            "start_logit": 7.625,
            "end_logit": 3.9140625,
            "text": "idiopathic multicentric Castleman disease with TAFRO syndrome",
            "probability": 0.77734375
        },
        {
            "start_logit": 7.625,
            "end_logit": 2.6328125,
            "text": "idiopathic multicentric Castleman disease with TAFRO",
            "probability": 0.2158203125
        },
        {
            "start_logit": 2.607421875,
            "end_logit": 3.189453125,
            "text": "thrombocytopenia (T), anasarca (A), fever",
            "probability": 0.00249481201171875
        },
        {
            "start_logit": 2.607421875,
            "end_logit": 2.896484375,
            "text": "thrombocytopenia",
            "probability": 0.001861572265625
        },
        {
            "start_logit": 7.625,
            "end_logit": -2.44140625,
            "text": "idiopathic multicentric Castleman disease with TAFRO syndrome (iMCD-TAFRO),",
            "probability": 0.0013513565063476562
        },
        {
            "start_logit": 7.625,
            "end_logit": -3.6796875,
            "text": "idiopathic multicentric Castleman disease with TAFRO syndrome (iMCD-TAFRO)",
            "probability": 0.0003914833068847656
        },
        {
            "start_logit": 0.296630859375,
            "end_logit": 3.189453125,
            "text": "fever",
            "probability": 0.00024700164794921875
        },
        {
            "start_logit": 7.625,
            "end_logit": -5.0078125,
            "text": "idiopathic multicentric Castleman disease",
            "probability": 0.00010371208190917969
        },
        {
            "start_logit": 7.625,
            "end_logit": -7.5859375,
            "text": "idiopathic multicentric Castleman disease with TAFRO syndrome (iMCD-TAFRO",
            "probability": 7.867813110351562e-06
        },
        {
            "start_logit": 7.625,
            "end_logit": -7.6796875,
            "text": "idiopathic multicentric Castleman disease with TAFRO syndrome (iMCD",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": 7.625,
            "end_logit": -7.90625,
            "text": "idiopathic multicentric Cast",
            "probability": 5.7220458984375e-06
        },
        {
            "start_logit": 7.625,
            "end_logit": -8.0625,
            "text": "idiopathic multicentric Castlem",
            "probability": 4.887580871582031e-06
        },
        {
            "start_logit": 7.625,
            "end_logit": -8.140625,
            "text": "idiopathic multicentric Castleman disease with",
            "probability": 4.5299530029296875e-06
        },
        {
            "start_logit": 7.625,
            "end_logit": -8.296875,
            "text": "idiopathic multicentric",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": 7.625,
            "end_logit": -8.4765625,
            "text": "idiopathic",
            "probability": 3.2186508178710938e-06
        },
        {
            "start_logit": 7.625,
            "end_logit": -8.484375,
            "text": "idiopathic multicentric Castleman disease with TAFRO syndrome (",
            "probability": 3.2186508178710938e-06
        },
        {
            "start_logit": 7.625,
            "end_logit": -8.6171875,
            "text": "idiopathic multicentric Castleman",
            "probability": 2.8014183044433594e-06
        },
        {
            "start_logit": 7.625,
            "end_logit": -9.0390625,
            "text": "idiopathic multicentric Castleman disease with TAFRO syndrome (iMCD-TAF",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": -6.6796875,
            "end_logit": 3.9140625,
            "text": "TAFRO syndrome",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.6796875,
            "end_logit": 2.896484375,
            "text": "TAFRO syndrome (iMCD-TAFRO), is a recently recognized systemic inflammatory disorder with a characteristic series of clinical symptoms, including thrombocytopenia",
            "probability": 1.7881393432617188e-07
        }
    ],
    "60322b501cb411341a000137_1": [
        {
            "start_logit": 9.359375,
            "end_logit": 9.1640625,
            "text": "LGALS7",
            "probability": 1.0
        },
        {
            "start_logit": 9.359375,
            "end_logit": 0.22705078125,
            "text": "LGALS7, ASPN",
            "probability": 0.0001302957534790039
        },
        {
            "start_logit": 9.359375,
            "end_logit": 0.09039306640625,
            "text": "LGALS7, ASPN, HSP90",
            "probability": 0.00011414289474487305
        },
        {
            "start_logit": 9.359375,
            "end_logit": -0.1728515625,
            "text": "LGALS7, ASPN, HSP90AA1",
            "probability": 8.749961853027344e-05
        },
        {
            "start_logit": 9.359375,
            "end_logit": -2.294921875,
            "text": "LGALS7, ASPN, HSP90AA1 and HSP90AB1",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": 9.359375,
            "end_logit": -4.32421875,
            "text": "LGALS7, ASPN, HSP90AA1 and HSP90",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 9.359375,
            "end_logit": -5.98046875,
            "text": "LGALS",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.359375,
            "end_logit": -6.4296875,
            "text": "LGALS7, ASP",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.359375,
            "end_logit": -6.58203125,
            "text": "LG",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.359375,
            "end_logit": -7.08203125,
            "text": "LGALS7, ASPN, HSP90AA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.17578125,
            "end_logit": 9.1640625,
            "text": "7",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.359375,
            "end_logit": -7.44921875,
            "text": "LGALS7, ASPN, HSP90AA1 and HSP90AB",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.359375,
            "end_logit": -7.890625,
            "text": "LGALS7, ASPN, HSP90AA1 and HSP90AB1.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 0.42822265625,
            "end_logit": 0.09039306640625,
            "text": "HSP90",
            "probability": 0.0
        },
        {
            "start_logit": 0.42822265625,
            "end_logit": -0.1728515625,
            "text": "HSP90AA1",
            "probability": 0.0
        },
        {
            "start_logit": 9.359375,
            "end_logit": -9.1640625,
            "text": "LGALS7, ASPN, HSP90AA1 and",
            "probability": 0.0
        },
        {
            "start_logit": 9.359375,
            "end_logit": -9.40625,
            "text": "LGALS7,",
            "probability": 0.0
        },
        {
            "start_logit": 9.359375,
            "end_logit": -9.8515625,
            "text": "LGALS7, ASPN,",
            "probability": 0.0
        },
        {
            "start_logit": -9.703125,
            "end_logit": 9.1640625,
            "text": "ALS7",
            "probability": 0.0
        },
        {
            "start_logit": -1.6826171875,
            "end_logit": 0.22705078125,
            "text": "ASPN",
            "probability": 0.0
        }
    ],
    "60322b501cb411341a000137_2": [
        {
            "start_logit": 5.58984375,
            "end_logit": 6.46484375,
            "text": "COL1A1, SCGB1A1, TAGLN",
            "probability": 0.420654296875
        },
        {
            "start_logit": 5.26953125,
            "end_logit": 6.46484375,
            "text": "TAGLN",
            "probability": 0.305419921875
        },
        {
            "start_logit": 5.58984375,
            "end_logit": 6.0390625,
            "text": "COL1A1",
            "probability": 0.27392578125
        },
        {
            "start_logit": -4.6015625,
            "end_logit": 6.46484375,
            "text": "SCGB1A1, TAGLN",
            "probability": 1.5795230865478516e-05
        },
        {
            "start_logit": 5.26953125,
            "end_logit": -4.90234375,
            "text": "TAGLN, PSEN2, TSPAN1, CTSB, AGR2, CSPG2, and SERPINB3",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": 5.58984375,
            "end_logit": -5.6953125,
            "text": "COL1A1, SCGB1A1, TAGLN, PSEN2, TSPAN1, CTSB, AGR2",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": 5.26953125,
            "end_logit": -5.6953125,
            "text": "TAGLN, PSEN2, TSPAN1, CTSB, AGR2",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": 5.58984375,
            "end_logit": -6.05859375,
            "text": "COL1A1, SCG",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 5.58984375,
            "end_logit": -6.484375,
            "text": "COL1A1, SCGB1",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 5.58984375,
            "end_logit": -6.609375,
            "text": "COL1A1, SCGB1A1, TAGL",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 5.26953125,
            "end_logit": -6.609375,
            "text": "TAGL",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 5.26953125,
            "end_logit": -7.05078125,
            "text": "TAGLN, PSEN2, TSPAN1, CTSB, AGR2, CSPG2, and SERPIN",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 6.46484375,
            "text": "1A1, SCGB1A1, TAGLN",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 5.58984375,
            "end_logit": -7.54296875,
            "text": "COL",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 6.0390625,
            "text": "1A1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 5.58984375,
            "end_logit": -7.87890625,
            "text": "COL1A1, SCGB1A1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 5.58984375,
            "end_logit": -7.91796875,
            "text": "COL1A1, SCGB1A1, TAGLN, PSEN2, TSPAN1, CTSB, AGR2, CSPG2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 5.26953125,
            "end_logit": -7.91796875,
            "text": "TAGLN, PSEN2, TSPAN1, CTSB, AGR2, CSPG2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 5.58984375,
            "end_logit": -8.28125,
            "text": "COL1A1, SCGB1A1, TAGLN, PSEN2, TSPAN1, CTSB",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -9.171875,
            "end_logit": 6.46484375,
            "text": "N",
            "probability": 1.7881393432617188e-07
        }
    ],
    "60322b501cb411341a000137_3": [
        {
            "start_logit": 9.875,
            "end_logit": 10.2265625,
            "text": "fibronectin",
            "probability": 1.0
        },
        {
            "start_logit": -6.33203125,
            "end_logit": 10.2265625,
            "text": "cell adhesion proteins such as emilin-1 and fibronectin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 10.2265625,
            "text": "emilin-1 and fibronectin",
            "probability": 0.0
        },
        {
            "start_logit": -9.140625,
            "end_logit": 10.2265625,
            "text": "phase with cell proliferation and high production of cell adhesion proteins such as emilin-1 and fibronectin",
            "probability": 0.0
        },
        {
            "start_logit": -9.4765625,
            "end_logit": 10.2265625,
            "text": "with cell proliferation and high production of cell adhesion proteins such as emilin-1 and fibronectin",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": 10.2265625,
            "text": "initial phase with cell proliferation and high production of cell adhesion proteins such as emilin-1 and fibronectin",
            "probability": 0.0
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 10.2265625,
            "text": "an initial phase with cell proliferation and high production of cell adhesion proteins such as emilin-1 and fibronectin",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -10.0390625,
            "text": "fibronectin.",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 10.2265625,
            "text": "remodeling of the scaffold was characterized by an initial phase with cell proliferation and high production of cell adhesion proteins such as emilin-1 and fibronectin",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 10.2265625,
            "text": "high production of cell adhesion proteins such as emilin-1 and fibronectin",
            "probability": 0.0
        },
        {
            "start_logit": -6.33203125,
            "end_logit": -3.888671875,
            "text": "cell adhesion proteins",
            "probability": 0.0
        },
        {
            "start_logit": -9.140625,
            "end_logit": -3.888671875,
            "text": "phase with cell proliferation and high production of cell adhesion proteins",
            "probability": 0.0
        },
        {
            "start_logit": -6.33203125,
            "end_logit": -6.89453125,
            "text": "cell adhesion proteins such as emilin-1",
            "probability": 0.0
        },
        {
            "start_logit": -9.4765625,
            "end_logit": -3.888671875,
            "text": "with cell proliferation and high production of cell adhesion proteins",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": -3.888671875,
            "text": "initial phase with cell proliferation and high production of cell adhesion proteins",
            "probability": 0.0
        },
        {
            "start_logit": -6.33203125,
            "end_logit": -7.55859375,
            "text": "cell adhesion",
            "probability": 0.0
        },
        {
            "start_logit": -10.0390625,
            "end_logit": -3.888671875,
            "text": "an initial phase with cell proliferation and high production of cell adhesion proteins",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": -3.888671875,
            "text": "remodeling of the scaffold was characterized by an initial phase with cell proliferation and high production of cell adhesion proteins",
            "probability": 0.0
        },
        {
            "start_logit": -7.6640625,
            "end_logit": -6.89453125,
            "text": "emilin-1",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": -3.888671875,
            "text": "high production of cell adhesion proteins",
            "probability": 0.0
        }
    ],
    "60322b501cb411341a000137_4": [
        {
            "start_logit": 9.15625,
            "end_logit": 8.390625,
            "text": "versican",
            "probability": 0.99609375
        },
        {
            "start_logit": 3.109375,
            "end_logit": 8.390625,
            "text": "f proteoglycans, such as versican",
            "probability": 0.0023555755615234375
        },
        {
            "start_logit": 9.15625,
            "end_logit": 2.076171875,
            "text": "versican and decorin",
            "probability": 0.0018072128295898438
        },
        {
            "start_logit": 3.109375,
            "end_logit": 3.29296875,
            "text": "f proteoglycans",
            "probability": 1.4424324035644531e-05
        },
        {
            "start_logit": 3.109375,
            "end_logit": 2.076171875,
            "text": "f proteoglycans, such as versican and decorin",
            "probability": 4.291534423828125e-06
        },
        {
            "start_logit": 9.15625,
            "end_logit": -6.671875,
            "text": "versican and",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.15625,
            "end_logit": -7.2734375,
            "text": "vers",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.15625,
            "end_logit": -9.1953125,
            "text": "versican and dec",
            "probability": 0.0
        },
        {
            "start_logit": -8.640625,
            "end_logit": 8.390625,
            "text": "ican",
            "probability": 0.0
        },
        {
            "start_logit": -9.9296875,
            "end_logit": 8.390625,
            "text": "proteoglycans, such as versican",
            "probability": 0.0
        },
        {
            "start_logit": -5.4453125,
            "end_logit": 2.076171875,
            "text": "decorin",
            "probability": 0.0
        },
        {
            "start_logit": 3.109375,
            "end_logit": -6.671875,
            "text": "f proteoglycans, such as versican and",
            "probability": 0.0
        },
        {
            "start_logit": 3.109375,
            "end_logit": -7.2734375,
            "text": "f proteoglycans, such as vers",
            "probability": 0.0
        },
        {
            "start_logit": 3.109375,
            "end_logit": -8.3359375,
            "text": "f proteoglycans, such as",
            "probability": 0.0
        },
        {
            "start_logit": 3.109375,
            "end_logit": -9.1953125,
            "text": "f proteoglycans, such as versican and dec",
            "probability": 0.0
        },
        {
            "start_logit": 3.109375,
            "end_logit": -9.28125,
            "text": "f",
            "probability": 0.0
        },
        {
            "start_logit": 3.109375,
            "end_logit": -9.515625,
            "text": "f proteoglycans, such",
            "probability": 0.0
        },
        {
            "start_logit": -8.640625,
            "end_logit": 2.076171875,
            "text": "ican and decorin",
            "probability": 0.0
        },
        {
            "start_logit": 3.109375,
            "end_logit": -9.6953125,
            "text": "f proteoglycans,",
            "probability": 0.0
        },
        {
            "start_logit": -9.9296875,
            "end_logit": 3.29296875,
            "text": "proteoglycans",
            "probability": 0.0
        }
    ],
    "601ec1fb1cb411341a000061_1": [
        {
            "start_logit": 12.203125,
            "end_logit": 12.5859375,
            "text": "Alobar",
            "probability": 1.0
        },
        {
            "start_logit": 12.203125,
            "end_logit": -1.5712890625,
            "text": "Alobar, Semilobar, Lobar and Middle interhemispheric fusion",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 12.203125,
            "end_logit": -4.52734375,
            "text": "Alobar, Semilobar, Lobar and Middle interhemispheric fusion variant",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.203125,
            "end_logit": -5.05859375,
            "text": "Al",
            "probability": 0.0
        },
        {
            "start_logit": -5.4765625,
            "end_logit": 12.5859375,
            "text": "r",
            "probability": 0.0
        },
        {
            "start_logit": 12.203125,
            "end_logit": -5.2265625,
            "text": "Alobar, Semilobar, Lobar and Middle interhemispheric",
            "probability": 0.0
        },
        {
            "start_logit": 12.203125,
            "end_logit": -5.40234375,
            "text": "Aloba",
            "probability": 0.0
        },
        {
            "start_logit": 12.203125,
            "end_logit": -6.24609375,
            "text": "Alobar, Semilobar",
            "probability": 0.0
        },
        {
            "start_logit": 12.203125,
            "end_logit": -6.7109375,
            "text": "Alobar, Semilobar, Lobar",
            "probability": 0.0
        },
        {
            "start_logit": 12.203125,
            "end_logit": -6.8359375,
            "text": "Alobar, Semilobar, Lobar and Middle",
            "probability": 0.0
        },
        {
            "start_logit": 12.203125,
            "end_logit": -7.859375,
            "text": "Alobar, Semilobar, Lobar and Middle inter",
            "probability": 0.0
        },
        {
            "start_logit": 12.203125,
            "end_logit": -8.078125,
            "text": "Alobar,",
            "probability": 0.0
        },
        {
            "start_logit": 12.203125,
            "end_logit": -8.1015625,
            "text": "Alobar, Semi",
            "probability": 0.0
        },
        {
            "start_logit": 12.203125,
            "end_logit": -8.2890625,
            "text": "Alobar, Semilo",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": 12.5859375,
            "text": "types: Alobar",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 12.5859375,
            "text": "classified into 4 types: Alobar",
            "probability": 0.0
        },
        {
            "start_logit": -5.4765625,
            "end_logit": -1.5712890625,
            "text": "r, Semilobar, Lobar and Middle interhemispheric fusion",
            "probability": 0.0
        },
        {
            "start_logit": -7.2578125,
            "end_logit": -1.5712890625,
            "text": "interhemispheric fusion",
            "probability": 0.0
        },
        {
            "start_logit": -5.4765625,
            "end_logit": -4.52734375,
            "text": "r, Semilobar, Lobar and Middle interhemispheric fusion variant",
            "probability": 0.0
        },
        {
            "start_logit": -8.5,
            "end_logit": -1.5712890625,
            "text": "Lobar and Middle interhemispheric fusion",
            "probability": 0.0
        }
    ],
    "5166f41a298dcd4e5100005b_1": [
        {
            "start_logit": 13.8828125,
            "end_logit": 13.1953125,
            "text": "BIX-01294",
            "probability": 1.0
        },
        {
            "start_logit": 13.8828125,
            "end_logit": -3.3671875,
            "text": "BIX-01294) of the human G9a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.8828125,
            "end_logit": -3.517578125,
            "text": "BI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.8828125,
            "end_logit": -5.27734375,
            "text": "BIX-01294) of the human G9a histone methyltransferase. Two compounds, BIX-01294 and its derivative TM2",
            "probability": 0.0
        },
        {
            "start_logit": 13.8828125,
            "end_logit": -5.35546875,
            "text": "BIX-012",
            "probability": 0.0
        },
        {
            "start_logit": -4.9140625,
            "end_logit": 13.1953125,
            "text": "94",
            "probability": 0.0
        },
        {
            "start_logit": 13.8828125,
            "end_logit": -6.078125,
            "text": "BIX-01294) of the human G9a histone methyltransferase. Two compounds, BIX-01294 and its derivative TM2-115",
            "probability": 0.0
        },
        {
            "start_logit": 13.8828125,
            "end_logit": -6.3515625,
            "text": "BIX-01294) of the human G9a histone methyltransferase. Two compounds, BIX-01294 and its derivative TM",
            "probability": 0.0
        },
        {
            "start_logit": 13.8828125,
            "end_logit": -6.453125,
            "text": "BIX-01294) of the human G9",
            "probability": 0.0
        },
        {
            "start_logit": 13.8828125,
            "end_logit": -6.55859375,
            "text": "BIX-01294) of the human G9a histone methyltransferase. Two compounds, BIX-01294",
            "probability": 0.0
        },
        {
            "start_logit": 13.8828125,
            "end_logit": -7.109375,
            "text": "BIX-",
            "probability": 0.0
        },
        {
            "start_logit": 13.8828125,
            "end_logit": -7.66015625,
            "text": "BIX",
            "probability": 0.0
        },
        {
            "start_logit": 13.8828125,
            "end_logit": -8.0625,
            "text": "BIX-01294) of the human G9a histone methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": 13.8828125,
            "end_logit": -8.140625,
            "text": "BIX-01294) of the human G9a histone methyltransferase. Two compounds, BIX-01294 and its derivative",
            "probability": 0.0
        },
        {
            "start_logit": 13.8828125,
            "end_logit": -8.359375,
            "text": "BIX-01294) of the human G9a histone methyltransferase. Two compounds, BIX-012",
            "probability": 0.0
        },
        {
            "start_logit": 13.8828125,
            "end_logit": -8.5078125,
            "text": "BIX-01294) of the human G9a histone methyltransferase. Two compounds, BIX-01294 and its",
            "probability": 0.0
        },
        {
            "start_logit": 13.8828125,
            "end_logit": -8.6796875,
            "text": "BIX-01294) of the human G9a histone methyltransferase. Two compounds, BI",
            "probability": 0.0
        },
        {
            "start_logit": 13.8828125,
            "end_logit": -8.875,
            "text": "BIX-01294) of the human G9a histone methyltransferase. Two compounds, BIX-01294 and its derivative TM2-",
            "probability": 0.0
        },
        {
            "start_logit": -9.140625,
            "end_logit": 13.1953125,
            "text": "01294",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 13.1953125,
            "text": "X-01294",
            "probability": 0.0
        }
    ],
    "5166f41a298dcd4e5100005b_2": [
        {
            "start_logit": 13.9609375,
            "end_logit": 13.453125,
            "text": "BIX-01294",
            "probability": 1.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -3.451171875,
            "text": "BIX-012",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -3.482421875,
            "text": "BI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.29296875,
            "end_logit": 13.453125,
            "text": "94",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -4.8203125,
            "text": "BIX-",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -5.54296875,
            "text": "BIX",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -5.54296875,
            "text": "BIX-01294 and TM2-115",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -6.421875,
            "text": "BIX-01294 and TM2",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -7.02734375,
            "text": "BIX-01294 and TM",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -8.078125,
            "text": "BIX-01294 and TM2-",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -8.59375,
            "text": "BIX-01294 and",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -9.1171875,
            "text": "BIX-01294 and TM2-115 inhibit malaria parasite",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -9.1484375,
            "text": "BIX-01294 and TM2-115 inhibit malaria parasite histone methyltransferases, resulting in rapid and irreversible parasite death",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -9.34375,
            "text": "BIX-01294 and TM2-115 inhibit malaria parasite histone methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -9.3671875,
            "text": "BIX-01294 and TM2-115 inhibit malaria parasite histone methyltransferases,",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -9.4375,
            "text": "BIX-01294 and TM2-115 inhibit malaria parasite histone methyltransferases",
            "probability": 0.0
        },
        {
            "start_logit": -9.1015625,
            "end_logit": 13.453125,
            "text": "01294",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -9.671875,
            "text": "BIX-01294 and TM2-115 inhibit malaria parasite histone",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -9.7109375,
            "text": "BIX-01294 and TM2-115 inhibit malaria parasite histone methyltransferases, resulting in rapid and irreversible parasite death.",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -9.7109375,
            "text": "BIX-01294 and TM2-115 inhibit malaria",
            "probability": 0.0
        }
    ],
    "5166f41a298dcd4e5100005b_3": [
        {
            "start_logit": 12.84375,
            "end_logit": 12.1484375,
            "text": "BIX-01294",
            "probability": 1.0
        },
        {
            "start_logit": 12.84375,
            "end_logit": -4.125,
            "text": "BIX-012",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.84375,
            "end_logit": -4.51171875,
            "text": "BI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.51953125,
            "end_logit": 12.1484375,
            "text": "G9a) has been shown to be a primary mediator of H3K9 dimethylation; BIX-01294",
            "probability": 0.0
        },
        {
            "start_logit": -5.578125,
            "end_logit": 12.1484375,
            "text": "94",
            "probability": 0.0
        },
        {
            "start_logit": 12.84375,
            "end_logit": -6.33203125,
            "text": "BIX-",
            "probability": 0.0
        },
        {
            "start_logit": -5.96484375,
            "end_logit": 12.1484375,
            "text": "EHMT2; also known as G9a) has been shown to be a primary mediator of H3K9 dimethylation; BIX-01294",
            "probability": 0.0
        },
        {
            "start_logit": 12.84375,
            "end_logit": -7.30078125,
            "text": "BIX",
            "probability": 0.0
        },
        {
            "start_logit": -6.8046875,
            "end_logit": 12.1484375,
            "text": "2; also known as G9a) has been shown to be a primary mediator of H3K9 dimethylation; BIX-01294",
            "probability": 0.0
        },
        {
            "start_logit": 12.84375,
            "end_logit": -8.5625,
            "text": "BIX-01294 has been shown to be a specific inhibitor of EHMT2",
            "probability": 0.0
        },
        {
            "start_logit": -9.15625,
            "end_logit": 12.1484375,
            "text": "01294",
            "probability": 0.0
        },
        {
            "start_logit": -9.828125,
            "end_logit": 12.1484375,
            "text": "MT2; also known as G9a) has been shown to be a primary mediator of H3K9 dimethylation; BIX-01294",
            "probability": 0.0
        },
        {
            "start_logit": -9.9921875,
            "end_logit": 12.1484375,
            "text": "a) has been shown to be a primary mediator of H3K9 dimethylation; BIX-01294",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": 12.1484375,
            "text": "X-01294",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 12.1484375,
            "text": "H3K9 dimethylation; BIX-01294",
            "probability": 0.0
        },
        {
            "start_logit": -5.96484375,
            "end_logit": -0.52490234375,
            "text": "EHMT2",
            "probability": 0.0
        },
        {
            "start_logit": -6.3984375,
            "end_logit": -0.52490234375,
            "text": "euchromatic histone-lysine N-methyltransferase 2 (EHMT2",
            "probability": 0.0
        },
        {
            "start_logit": -5.51953125,
            "end_logit": -1.80078125,
            "text": "G9a",
            "probability": 0.0
        },
        {
            "start_logit": -6.8046875,
            "end_logit": -0.52490234375,
            "text": "2",
            "probability": 0.0
        },
        {
            "start_logit": -7.0625,
            "end_logit": -0.52490234375,
            "text": "2 (EHMT2",
            "probability": 0.0
        }
    ],
    "5166f41a298dcd4e5100005b_4": [
        {
            "start_logit": 13.6796875,
            "end_logit": 13.0703125,
            "text": "BIX-01294",
            "probability": 1.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -3.771484375,
            "text": "BI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -4.17578125,
            "text": "BIX-012",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.80078125,
            "end_logit": 13.0703125,
            "text": "94",
            "probability": 0.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -5.7890625,
            "text": "BIX",
            "probability": 0.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -5.796875,
            "text": "BIX-",
            "probability": 0.0
        },
        {
            "start_logit": -6.81640625,
            "end_logit": 13.0703125,
            "text": "EHMT2 by BIX-01294",
            "probability": 0.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -9.0234375,
            "text": "BIX-01294 would result in reduced levels of H3K9 dimethyl",
            "probability": 0.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -9.0859375,
            "text": "BIX-01294 would result in reduced levels of H3K9 dimethylation",
            "probability": 0.0
        },
        {
            "start_logit": -8.625,
            "end_logit": 13.0703125,
            "text": "01294",
            "probability": 0.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -9.2734375,
            "text": "BIX-01294 would result in reduced levels of H3K9",
            "probability": 0.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -9.4375,
            "text": "BIX-01294 would",
            "probability": 0.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -9.453125,
            "text": "BIX-01294 would result in reduced levels of H3K9 dimethylation and compromised embryo development",
            "probability": 0.0
        },
        {
            "start_logit": -9.234375,
            "end_logit": 13.0703125,
            "text": "2 by BIX-01294",
            "probability": 0.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -9.859375,
            "text": "BIX-01294 would result in reduced levels of H3K9 dimethylation and compromised embryo development.",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": 13.0703125,
            "text": "X-01294",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": 13.0703125,
            "text": "MT2 by BIX-01294",
            "probability": 0.0
        },
        {
            "start_logit": -6.81640625,
            "end_logit": -3.712890625,
            "text": "EHMT2",
            "probability": 0.0
        },
        {
            "start_logit": -6.81640625,
            "end_logit": -3.771484375,
            "text": "EHMT2 by BI",
            "probability": 0.0
        },
        {
            "start_logit": -6.81640625,
            "end_logit": -4.17578125,
            "text": "EHMT2 by BIX-012",
            "probability": 0.0
        }
    ],
    "5166f41a298dcd4e5100005b_5": [
        {
            "start_logit": 11.9140625,
            "end_logit": 9.0234375,
            "text": "2,4-pyridinedicarboxylic acid",
            "probability": 1.0
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -4.08203125,
            "text": "2",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -4.37890625,
            "text": "2,4-pyridinedicarboxylic acid (2,4-PDCA",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -4.94140625,
            "text": "2,4-pyridinedicarboxylic acid (2",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -5.8828125,
            "text": "2,4-pyridinedi",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -6.8203125,
            "text": "2,4-pyridinedicarboxylic acid (2,4-PDC",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -7.47265625,
            "text": "2,4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -7.5390625,
            "text": "2,4-pyridine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -7.74609375,
            "text": "2,4-pyridinedicarb",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -7.8828125,
            "text": "2,4-pyridinedicarboxylic acid (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -7.92578125,
            "text": "2,4-pyridinedicarboxyl",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -7.92578125,
            "text": "2,4-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -8.1015625,
            "text": "2,4-pyridinedicarboxylic acid (2,4-PDCA) with a potency similar to that reported for the HDM",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -8.234375,
            "text": "2,4-pyridinedicarboxylic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -8.2734375,
            "text": "2,4-pyridinedicarboxylic acid (2,4-PDCA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -8.8671875,
            "text": "2,4-pyridinedicarboxylic acid (2,4-PDCA) with a potency similar to that reported for the HDM KD",
            "probability": 0.0
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -8.9921875,
            "text": "2,4-pyridinedicarboxylic acid (2,4",
            "probability": 0.0
        },
        {
            "start_logit": -7.0078125,
            "end_logit": 9.0234375,
            "text": "ccKDM5B showed both in vitro and in cell inhibition of ccKDM5B by 2,4-pyridinedicarboxylic acid",
            "probability": 0.0
        },
        {
            "start_logit": -8.7734375,
            "end_logit": 9.0234375,
            "text": "acid",
            "probability": 0.0
        },
        {
            "start_logit": -9.15625,
            "end_logit": 9.0234375,
            "text": "ccKDM5B by 2,4-pyridinedicarboxylic acid",
            "probability": 0.0
        }
    ],
    "5166f41a298dcd4e5100005b_6": [
        {
            "start_logit": 13.796875,
            "end_logit": 13.1484375,
            "text": "DZNep",
            "probability": 1.0
        },
        {
            "start_logit": 13.796875,
            "end_logit": -0.42919921875,
            "text": "DZNep), an inhibitor of H3K27me3",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 13.796875,
            "end_logit": -3.556640625,
            "text": "DZ",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.796875,
            "end_logit": -3.767578125,
            "text": "DZNep), an inhibitor of H3K27me3 and H4K20me3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.25,
            "end_logit": 13.1484375,
            "text": "3-deazaneplanocin A (DZNep",
            "probability": 0.0
        },
        {
            "start_logit": 13.796875,
            "end_logit": -5.44140625,
            "text": "DZNep), an inhibitor of H3K27me3 and H4K20",
            "probability": 0.0
        },
        {
            "start_logit": -5.09375,
            "end_logit": 13.1484375,
            "text": "p",
            "probability": 0.0
        },
        {
            "start_logit": 13.796875,
            "end_logit": -6.734375,
            "text": "DZNep), an inhibitor of H3K27me3 and H4K2",
            "probability": 0.0
        },
        {
            "start_logit": 13.796875,
            "end_logit": -6.93359375,
            "text": "DZNep)",
            "probability": 0.0
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 13.1484375,
            "text": "cin A (DZNep",
            "probability": 0.0
        },
        {
            "start_logit": -8.5078125,
            "end_logit": 13.1484375,
            "text": "Nep",
            "probability": 0.0
        },
        {
            "start_logit": -9.1484375,
            "end_logit": 13.1484375,
            "text": "A (DZNep",
            "probability": 0.0
        },
        {
            "start_logit": -9.5859375,
            "end_logit": 13.1484375,
            "text": "anocin A (DZNep",
            "probability": 0.0
        },
        {
            "start_logit": -9.703125,
            "end_logit": 13.1484375,
            "text": "azaneplanocin A (DZNep",
            "probability": 0.0
        },
        {
            "start_logit": -9.7578125,
            "end_logit": 13.1484375,
            "text": "aneplanocin A (DZNep",
            "probability": 0.0
        },
        {
            "start_logit": -4.078125,
            "end_logit": -0.42919921875,
            "text": "H3K27me3",
            "probability": 0.0
        },
        {
            "start_logit": -4.25,
            "end_logit": -0.42919921875,
            "text": "3-deazaneplanocin A (DZNep), an inhibitor of H3K27me3",
            "probability": 0.0
        },
        {
            "start_logit": -4.25,
            "end_logit": -0.474365234375,
            "text": "3-deazaneplanocin A",
            "probability": 0.0
        },
        {
            "start_logit": -5.09375,
            "end_logit": -0.42919921875,
            "text": "p), an inhibitor of H3K27me3",
            "probability": 0.0
        },
        {
            "start_logit": -4.25,
            "end_logit": -3.556640625,
            "text": "3-deazaneplanocin A (DZ",
            "probability": 0.0
        }
    ],
    "5166f41a298dcd4e5100005b_7": [
        {
            "start_logit": 14.2890625,
            "end_logit": 14.125,
            "text": "DZNep",
            "probability": 1.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -3.19921875,
            "text": "DZ",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.556640625,
            "end_logit": 14.125,
            "text": "p",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -5.86328125,
            "text": "DZNep, a pharmacologic inhibitor of KMT6",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -7.71484375,
            "text": "DZNe",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -7.96875,
            "text": "DZNep, a pharmacologic inhibitor of KM",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -8.109375,
            "text": "DZNep, a pharmacologic inhibitor of KMT6 expression, recapitulated the effects of KMT6 knockdown",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": 14.125,
            "text": "Nep",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -8.4375,
            "text": "DZNep, a",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -8.4765625,
            "text": "DZNep,",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -8.5078125,
            "text": "DZNep, a pharmacologic inhibitor of KMT6 expression,",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -8.5625,
            "text": "DZNep, a pharmacologic inhibitor of KMT6 expression",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -8.71875,
            "text": "DZNep, a pharmacologic inhibitor of KMT",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -9.1328125,
            "text": "DZNep, a pharmacologic",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -9.1953125,
            "text": "DZNep, a pharmacologic inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -9.21875,
            "text": "DZNep, a pharmacologic inhibitor of KMT6 expression, recapitulated the effects of KMT6",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -9.2421875,
            "text": "DZNep, a pharmacologic inhibitor of",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -9.3203125,
            "text": "DZNep, a pharmacologic inhibitor of KMT6 expression, recapitulated the effects of KMT6 knockdown.",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -9.46875,
            "text": "DZNep, a pharmacologic inhibitor of KMT6 expression, recapitulated the effects of",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -9.5703125,
            "text": "DZNep, a pharmacologic inhibitor of KMT6 expression, recapitulated the effects of KM",
            "probability": 0.0
        }
    ],
    "5166f41a298dcd4e5100005b_8": [
        {
            "start_logit": 13.625,
            "end_logit": 12.96875,
            "text": "DZNep",
            "probability": 1.0
        },
        {
            "start_logit": 13.625,
            "end_logit": -3.130859375,
            "text": "DZNep) modulate chromatin through indirect inhibition of histone methyltransferases including EZH2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.625,
            "end_logit": -3.751953125,
            "text": "DZ",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.6328125,
            "end_logit": 12.96875,
            "text": "3-deazaneplanocin A (DZNep",
            "probability": 0.0
        },
        {
            "start_logit": -5.4453125,
            "end_logit": 12.96875,
            "text": "p",
            "probability": 0.0
        },
        {
            "start_logit": 13.625,
            "end_logit": -6.91015625,
            "text": "DZNep) modulate chromatin through indirect inhibition of histone methyltransferases including EZH2. We investigated the biological effects of AdoHcy hydrolase inhibition using DZ",
            "probability": 0.0
        },
        {
            "start_logit": 13.625,
            "end_logit": -7.34375,
            "text": "DZNe",
            "probability": 0.0
        },
        {
            "start_logit": -7.328125,
            "end_logit": 12.96875,
            "text": "AHI) such as 3-deazaneplanocin A (DZNep",
            "probability": 0.0
        },
        {
            "start_logit": -7.5,
            "end_logit": 12.96875,
            "text": "cin A (DZNep",
            "probability": 0.0
        },
        {
            "start_logit": -8.8046875,
            "end_logit": 12.96875,
            "text": "A (DZNep",
            "probability": 0.0
        },
        {
            "start_logit": -8.984375,
            "end_logit": 12.96875,
            "text": "Nep",
            "probability": 0.0
        },
        {
            "start_logit": -4.6328125,
            "end_logit": -3.130859375,
            "text": "3-deazaneplanocin A (DZNep) modulate chromatin through indirect inhibition of histone methyltransferases including EZH2",
            "probability": 0.0
        },
        {
            "start_logit": -4.6328125,
            "end_logit": -3.751953125,
            "text": "3-deazaneplanocin A (DZ",
            "probability": 0.0
        },
        {
            "start_logit": -4.6328125,
            "end_logit": -3.818359375,
            "text": "3-deazaneplanocin A",
            "probability": 0.0
        },
        {
            "start_logit": -5.4453125,
            "end_logit": -3.130859375,
            "text": "p) modulate chromatin through indirect inhibition of histone methyltransferases including EZH2",
            "probability": 0.0
        },
        {
            "start_logit": -6.75,
            "end_logit": -3.130859375,
            "text": "EZH2",
            "probability": 0.0
        },
        {
            "start_logit": -5.4453125,
            "end_logit": -4.796875,
            "text": "p) modulate chromatin through indirect inhibition of histone methyltransferases including EZH2. We investigated the biological effects of AdoHcy hydrolase inhibition using DZNep",
            "probability": 0.0
        },
        {
            "start_logit": -4.6328125,
            "end_logit": -5.7421875,
            "text": "3",
            "probability": 0.0
        },
        {
            "start_logit": -7.328125,
            "end_logit": -3.130859375,
            "text": "AHI) such as 3-deazaneplanocin A (DZNep) modulate chromatin through indirect inhibition of histone methyltransferases including EZH2",
            "probability": 0.0
        },
        {
            "start_logit": -7.5,
            "end_logit": -3.130859375,
            "text": "cin A (DZNep) modulate chromatin through indirect inhibition of histone methyltransferases including EZH2",
            "probability": 0.0
        }
    ],
    "5166f41a298dcd4e5100005b_9": [
        {
            "start_logit": 13.546875,
            "end_logit": 13.6171875,
            "text": "psammaplin A",
            "probability": 1.0
        },
        {
            "start_logit": 13.546875,
            "end_logit": -4.1015625,
            "text": "psa",
            "probability": 0.0
        },
        {
            "start_logit": 13.546875,
            "end_logit": -4.56640625,
            "text": "psammaplin A (PsA",
            "probability": 0.0
        },
        {
            "start_logit": -4.62890625,
            "end_logit": 13.6171875,
            "text": "A",
            "probability": 0.0
        },
        {
            "start_logit": 13.546875,
            "end_logit": -5.9765625,
            "text": "psammapl",
            "probability": 0.0
        },
        {
            "start_logit": 13.546875,
            "end_logit": -6.0,
            "text": "psammaplin A (",
            "probability": 0.0
        },
        {
            "start_logit": 13.546875,
            "end_logit": -6.34375,
            "text": "psammaplin",
            "probability": 0.0
        },
        {
            "start_logit": -6.84375,
            "end_logit": 13.6171875,
            "text": "histone deacetylase and DNA methyltransferase inhibitor, psammaplin A",
            "probability": 0.0
        },
        {
            "start_logit": -7.00390625,
            "end_logit": 13.6171875,
            "text": "mmaplin A",
            "probability": 0.0
        },
        {
            "start_logit": 13.546875,
            "end_logit": -7.71484375,
            "text": "psammaplin A (PsA)",
            "probability": 0.0
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 13.6171875,
            "text": "in A",
            "probability": 0.0
        },
        {
            "start_logit": 13.546875,
            "end_logit": -8.671875,
            "text": "psammaplin A (PsA),",
            "probability": 0.0
        },
        {
            "start_logit": 13.546875,
            "end_logit": -8.9375,
            "text": "psammaplin A (PsA), in mice.",
            "probability": 0.0
        },
        {
            "start_logit": 13.546875,
            "end_logit": -9.109375,
            "text": "psammaplin A (PsA), in",
            "probability": 0.0
        },
        {
            "start_logit": 13.546875,
            "end_logit": -9.171875,
            "text": "psammaplin A (PsA), in mice",
            "probability": 0.0
        },
        {
            "start_logit": -9.734375,
            "end_logit": 13.6171875,
            "text": "aplin A",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": 13.6171875,
            "text": "DNA methyltransferase inhibitor, psammaplin A",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 13.6171875,
            "text": "pharmacokinetics and tissue distribution of a novel histone deacetylase and DNA methyltransferase inhibitor, psammaplin A",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 13.6171875,
            "text": "tissue distribution of a novel histone deacetylase and DNA methyltransferase inhibitor, psammaplin A",
            "probability": 0.0
        },
        {
            "start_logit": -4.62890625,
            "end_logit": -4.56640625,
            "text": "A (PsA",
            "probability": 0.0
        }
    ],
    "5166f41a298dcd4e5100005b_10": [
        {
            "start_logit": 13.3359375,
            "end_logit": 13.7109375,
            "text": "sulforaphane",
            "probability": 1.0
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -1.7705078125,
            "text": "sulforaphane (SFN",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -4.03125,
            "text": "sulforaphane (SF",
            "probability": 0.0
        },
        {
            "start_logit": -4.57421875,
            "end_logit": 13.7109375,
            "text": "ne",
            "probability": 0.0
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -4.80078125,
            "text": "sulfo",
            "probability": 0.0
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -5.4453125,
            "text": "sulforaphane (",
            "probability": 0.0
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -6.3671875,
            "text": "sulforaphane (SFN)",
            "probability": 0.0
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -6.8515625,
            "text": "sulforapha",
            "probability": 0.0
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 13.7109375,
            "text": "bioactive component sulforaphane",
            "probability": 0.0
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -8.0546875,
            "text": "sulfora",
            "probability": 0.0
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -8.125,
            "text": "sulforaphane (SFN),",
            "probability": 0.0
        },
        {
            "start_logit": -9.0,
            "end_logit": 13.7109375,
            "text": "histone deacetylase (HDAC) inhibitors, such as the bioactive component sulforaphane",
            "probability": 0.0
        },
        {
            "start_logit": -9.609375,
            "end_logit": 13.7109375,
            "text": "phane",
            "probability": 0.0
        },
        {
            "start_logit": -9.65625,
            "end_logit": 13.7109375,
            "text": "HDAC) inhibitors, such as the bioactive component sulforaphane",
            "probability": 0.0
        },
        {
            "start_logit": -9.8515625,
            "end_logit": 13.7109375,
            "text": "Human diet contains many histone deacetylase (HDAC) inhibitors, such as the bioactive component sulforaphane",
            "probability": 0.0
        },
        {
            "start_logit": -9.9453125,
            "end_logit": 13.7109375,
            "text": "raphane",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 13.7109375,
            "text": "component sulforaphane",
            "probability": 0.0
        },
        {
            "start_logit": -4.57421875,
            "end_logit": -1.7705078125,
            "text": "ne (SFN",
            "probability": 0.0
        },
        {
            "start_logit": -5.01171875,
            "end_logit": -1.7705078125,
            "text": "SFN",
            "probability": 0.0
        },
        {
            "start_logit": -4.57421875,
            "end_logit": -4.03125,
            "text": "ne (SF",
            "probability": 0.0
        }
    ],
    "5166f41a298dcd4e5100005b_11": [
        {
            "start_logit": 14.6640625,
            "end_logit": 13.6875,
            "text": "5-Aza-2'-deoxycytidine",
            "probability": 1.0
        },
        {
            "start_logit": 14.6640625,
            "end_logit": -2.17578125,
            "text": "5",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.6640625,
            "end_logit": -4.30078125,
            "text": "5-Aza-2'-deoxycytidine) and histone deacetylase inhibitor (trichostatin A",
            "probability": 0.0
        },
        {
            "start_logit": 14.6640625,
            "end_logit": -4.71484375,
            "text": "5-Aza-2'-deoxy",
            "probability": 0.0
        },
        {
            "start_logit": 14.6640625,
            "end_logit": -4.8203125,
            "text": "5-Aza",
            "probability": 0.0
        },
        {
            "start_logit": -4.265625,
            "end_logit": 13.6875,
            "text": "cytidine",
            "probability": 0.0
        },
        {
            "start_logit": 14.6640625,
            "end_logit": -5.890625,
            "text": "5-Aza-2",
            "probability": 0.0
        },
        {
            "start_logit": 14.6640625,
            "end_logit": -6.44921875,
            "text": "5-Aza-2'-",
            "probability": 0.0
        },
        {
            "start_logit": 14.6640625,
            "end_logit": -6.921875,
            "text": "5-Aza-",
            "probability": 0.0
        },
        {
            "start_logit": 14.6640625,
            "end_logit": -7.0546875,
            "text": "5-Aza-2'-deoxycytidine)",
            "probability": 0.0
        },
        {
            "start_logit": 14.6640625,
            "end_logit": -7.765625,
            "text": "5-Aza-2'-deoxycytidine) and histone deacetylase",
            "probability": 0.0
        },
        {
            "start_logit": 14.6640625,
            "end_logit": -8.015625,
            "text": "5-Aza-2'",
            "probability": 0.0
        },
        {
            "start_logit": -7.1484375,
            "end_logit": 13.6875,
            "text": "DNA methyltransferase inhibitor (5-Aza-2'-deoxycytidine",
            "probability": 0.0
        },
        {
            "start_logit": 14.6640625,
            "end_logit": -8.2265625,
            "text": "5-",
            "probability": 0.0
        },
        {
            "start_logit": 14.6640625,
            "end_logit": -8.375,
            "text": "5-Aza-2'-deoxycytidine) and histone deacetylase inhibitor (trich",
            "probability": 0.0
        },
        {
            "start_logit": 14.6640625,
            "end_logit": -8.5546875,
            "text": "5-Aza-2'-deoxycytidine) and histone deacetylase inhibitor (trichostatin A) reduced leptin receptor",
            "probability": 0.0
        },
        {
            "start_logit": 14.6640625,
            "end_logit": -8.5625,
            "text": "5-Aza-2'-deoxycytidine) and histone deacetylase inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": 14.6640625,
            "end_logit": -8.7265625,
            "text": "5-Aza-2'-deoxycytidine) and histone deacetylase inhibitor (trichostatin A) reduced leptin",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": 13.6875,
            "text": "deoxycytidine",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": 13.6875,
            "text": "(5-Aza-2'-deoxycytidine",
            "probability": 0.0
        }
    ],
    "5166f41a298dcd4e5100005b_12": [
        {
            "start_logit": 14.1796875,
            "end_logit": 14.421875,
            "text": "trichostatin A",
            "probability": 1.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -1.78125,
            "text": "trichostatin A (TSA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.982421875,
            "end_logit": 14.421875,
            "text": "A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -3.197265625,
            "text": "trichostatin A (TSA) and sodium butyrate",
            "probability": 0.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -3.357421875,
            "text": "trich",
            "probability": 0.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -3.876953125,
            "text": "trichostatin A (",
            "probability": 0.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -3.994140625,
            "text": "trichostatin A (TSA) and sodium butyrate (NaBt",
            "probability": 0.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -5.4140625,
            "text": "trichostatin A (TSA)",
            "probability": 0.0
        },
        {
            "start_logit": -6.1015625,
            "end_logit": 14.421875,
            "text": "histone deacetylase (HDAC) inhibitors trichostatin A",
            "probability": 0.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -6.71875,
            "text": "trichostatin",
            "probability": 0.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -6.8203125,
            "text": "trichostatin A (TSA) and sodium butyrate (NaBt) significantly increased Wnt5a",
            "probability": 0.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -7.1640625,
            "text": "trichostatin A (TSA) and sodium butyrate (NaB",
            "probability": 0.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -7.90234375,
            "text": "trichostatin A (TSA) and sodium",
            "probability": 0.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -7.90625,
            "text": "trichostatin A (TSA) and sodium butyrate (",
            "probability": 0.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -8.640625,
            "text": "trichostatin A (TSA) and",
            "probability": 0.0
        },
        {
            "start_logit": -9.1015625,
            "end_logit": 14.421875,
            "text": "HDAC) inhibitors trichostatin A",
            "probability": 0.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -8.9921875,
            "text": "trichostatin A (TSA) and sodium butyrate (NaBt) significantly increased Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -9.3984375,
            "end_logit": 14.421875,
            "text": "inhibitors trichostatin A",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": 14.421875,
            "text": "ostatin A",
            "probability": 0.0
        },
        {
            "start_logit": -2.982421875,
            "end_logit": -1.78125,
            "text": "A (TSA",
            "probability": 0.0
        }
    ],
    "5162c8a8298dcd4e51000047_1": [
        {
            "start_logit": 12.1640625,
            "end_logit": 12.5390625,
            "text": "PARN",
            "probability": 1.0
        },
        {
            "start_logit": -6.09375,
            "end_logit": 12.5390625,
            "text": "N",
            "probability": 0.0
        },
        {
            "start_logit": 12.1640625,
            "end_logit": -6.02734375,
            "text": "PAR",
            "probability": 0.0
        },
        {
            "start_logit": 12.1640625,
            "end_logit": -6.6171875,
            "text": "PARN) is unique in its domain composition, which contains three potential RNA-binding domains: the catalytic nuclease",
            "probability": 0.0
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 12.5390625,
            "text": "poly(A)-specific ribonuclease (PARN",
            "probability": 0.0
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 12.5390625,
            "text": "ribonuclease (PARN",
            "probability": 0.0
        },
        {
            "start_logit": 12.1640625,
            "end_logit": -7.33984375,
            "text": "PARN)",
            "probability": 0.0
        },
        {
            "start_logit": 12.1640625,
            "end_logit": -7.5390625,
            "text": "PARN) is unique in its domain composition, which contains three potential RNA-binding domains: the catalytic nuclease domain",
            "probability": 0.0
        },
        {
            "start_logit": 12.1640625,
            "end_logit": -7.81640625,
            "text": "PARN) is unique in its domain composition, which contains three potential RNA-binding domains: the catalytic nuclease domain, the R3H",
            "probability": 0.0
        },
        {
            "start_logit": -8.75,
            "end_logit": 12.5390625,
            "text": "(PARN",
            "probability": 0.0
        },
        {
            "start_logit": -8.796875,
            "end_logit": 12.5390625,
            "text": ", poly(A)-specific ribonuclease (PARN",
            "probability": 0.0
        },
        {
            "start_logit": 12.1640625,
            "end_logit": -8.484375,
            "text": "PARN) is unique in its domain composition, which contains three potential RNA-binding domains: the catalytic nuclease domain, the R3H domain and",
            "probability": 0.0
        },
        {
            "start_logit": 12.1640625,
            "end_logit": -8.53125,
            "text": "PARN) is unique",
            "probability": 0.0
        },
        {
            "start_logit": 12.1640625,
            "end_logit": -8.75,
            "text": "PARN) is unique in its domain composition, which contains three potential RNA-binding domains: the catalytic nuclease domain, the R3H domain",
            "probability": 0.0
        },
        {
            "start_logit": 12.1640625,
            "end_logit": -8.859375,
            "text": "PARN) is unique in its domain composition, which contains three potential RNA-binding domains",
            "probability": 0.0
        },
        {
            "start_logit": 12.1640625,
            "end_logit": -9.0234375,
            "text": "PARN) is unique in its domain composition, which contains three potential RNA-binding domains: the catalytic nuclease domain, the R3",
            "probability": 0.0
        },
        {
            "start_logit": -9.859375,
            "end_logit": 12.5390625,
            "text": "deadenylase family, poly(A)-specific ribonuclease (PARN",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": 12.5390625,
            "text": "specific ribonuclease (PARN",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": 12.5390625,
            "text": "(A)-specific ribonuclease (PARN",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 12.5390625,
            "text": "A)-specific ribonuclease (PARN",
            "probability": 0.0
        }
    ],
    "5162c8a8298dcd4e51000047_2": [
        {
            "start_logit": 13.640625,
            "end_logit": 13.03125,
            "text": "CCR4",
            "probability": 1.0
        },
        {
            "start_logit": 13.640625,
            "end_logit": -3.322265625,
            "text": "CCR4 family",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.640625,
            "end_logit": -4.4453125,
            "text": "CCR",
            "probability": 0.0
        },
        {
            "start_logit": 13.640625,
            "end_logit": -5.66015625,
            "text": "CCR4 family proteins",
            "probability": 0.0
        },
        {
            "start_logit": -5.41796875,
            "end_logit": 13.03125,
            "text": "4",
            "probability": 0.0
        },
        {
            "start_logit": 13.640625,
            "end_logit": -7.296875,
            "text": "CCR4 family proteins are",
            "probability": 0.0
        },
        {
            "start_logit": 13.640625,
            "end_logit": -8.34375,
            "text": "CCR4 family proteins are 3'-5'-deadenylases",
            "probability": 0.0
        },
        {
            "start_logit": 13.640625,
            "end_logit": -9.3125,
            "text": "CCR4 family proteins are 3'-5'-deadenylases that function in the first step of the degradation of poly(A) mRNA",
            "probability": 0.0
        },
        {
            "start_logit": 13.640625,
            "end_logit": -9.453125,
            "text": "CCR4 family proteins are 3'-5'-deadenylases that function in the",
            "probability": 0.0
        },
        {
            "start_logit": 13.640625,
            "end_logit": -9.5234375,
            "text": "CCR4 family proteins are 3'-5'-deadenylases that function",
            "probability": 0.0
        },
        {
            "start_logit": 13.640625,
            "end_logit": -9.7265625,
            "text": "CCR4 family proteins are 3'-5'-deadenylases that function in the first step",
            "probability": 0.0
        },
        {
            "start_logit": 13.640625,
            "end_logit": -9.8515625,
            "text": "CCR4 family proteins are 3'-5'-deadenylases that",
            "probability": 0.0
        },
        {
            "start_logit": 13.640625,
            "end_logit": -9.859375,
            "text": "CCR4 family proteins are 3'-5'-deadenylases that function in the first step of the degradation of poly(A) mRNA.",
            "probability": 0.0
        },
        {
            "start_logit": 13.640625,
            "end_logit": -9.859375,
            "text": "CCR4 family proteins are 3'-5'-",
            "probability": 0.0
        },
        {
            "start_logit": 13.640625,
            "end_logit": -9.90625,
            "text": "CCR4 family proteins are 3'-5'-deadenylases that function in",
            "probability": 0.0
        },
        {
            "start_logit": 13.640625,
            "end_logit": -9.96875,
            "text": "CCR4 family proteins are 3'-5'-deadenylases that function in the first",
            "probability": 0.0
        },
        {
            "start_logit": -5.41796875,
            "end_logit": -3.322265625,
            "text": "4 family",
            "probability": 0.0
        },
        {
            "start_logit": -5.41796875,
            "end_logit": -5.66015625,
            "text": "4 family proteins",
            "probability": 0.0
        },
        {
            "start_logit": -5.41796875,
            "end_logit": -7.296875,
            "text": "4 family proteins are",
            "probability": 0.0
        },
        {
            "start_logit": -5.41796875,
            "end_logit": -8.34375,
            "text": "4 family proteins are 3'-5'-deadenylases",
            "probability": 0.0
        }
    ],
    "5162c8a8298dcd4e51000047_3": [
        {
            "start_logit": 13.8515625,
            "end_logit": 13.8984375,
            "text": "CCR4",
            "probability": 1.0
        },
        {
            "start_logit": -3.794921875,
            "end_logit": 13.8984375,
            "text": "4",
            "probability": 0.0
        },
        {
            "start_logit": 13.8515625,
            "end_logit": -3.837890625,
            "text": "CCR4, an evolutionarily conserved member of the CCR4-NOT complex",
            "probability": 0.0
        },
        {
            "start_logit": 13.8515625,
            "end_logit": -3.966796875,
            "text": "CCR",
            "probability": 0.0
        },
        {
            "start_logit": 13.8515625,
            "end_logit": -4.3828125,
            "text": "CCR4, an evolutionarily conserved member of the CCR4-NOT",
            "probability": 0.0
        },
        {
            "start_logit": 13.8515625,
            "end_logit": -6.6875,
            "text": "CCR4, an evolutionarily conserved member of the CCR4",
            "probability": 0.0
        },
        {
            "start_logit": 13.8515625,
            "end_logit": -7.12890625,
            "text": "CCR4, an evolutionarily conserved member",
            "probability": 0.0
        },
        {
            "start_logit": 13.8515625,
            "end_logit": -7.34375,
            "text": "CCR4, an evolutionarily conserved member of the CCR4-NOT complex,",
            "probability": 0.0
        },
        {
            "start_logit": 13.8515625,
            "end_logit": -7.4609375,
            "text": "CCR4, an evolutionarily conserved member of",
            "probability": 0.0
        },
        {
            "start_logit": 13.8515625,
            "end_logit": -7.49609375,
            "text": "CCR4, an evolutionarily conserved member of the",
            "probability": 0.0
        },
        {
            "start_logit": 13.8515625,
            "end_logit": -7.76171875,
            "text": "CCR4, an evolutionarily conserved member of the CCR4-",
            "probability": 0.0
        },
        {
            "start_logit": 13.8515625,
            "end_logit": -7.84375,
            "text": "CCR4,",
            "probability": 0.0
        },
        {
            "start_logit": 13.8515625,
            "end_logit": -7.9296875,
            "text": "CCR4, an evolutionarily conserved",
            "probability": 0.0
        },
        {
            "start_logit": 13.8515625,
            "end_logit": -8.2109375,
            "text": "CCR4, an",
            "probability": 0.0
        },
        {
            "start_logit": -3.794921875,
            "end_logit": -3.837890625,
            "text": "4, an evolutionarily conserved member of the CCR4-NOT complex",
            "probability": 0.0
        },
        {
            "start_logit": -4.1796875,
            "end_logit": -3.837890625,
            "text": "CCR4-NOT complex",
            "probability": 0.0
        },
        {
            "start_logit": -3.794921875,
            "end_logit": -4.3828125,
            "text": "4, an evolutionarily conserved member of the CCR4-NOT",
            "probability": 0.0
        },
        {
            "start_logit": -4.1796875,
            "end_logit": -4.3828125,
            "text": "CCR4-NOT",
            "probability": 0.0
        },
        {
            "start_logit": -3.794921875,
            "end_logit": -6.6875,
            "text": "4, an evolutionarily conserved member of the CCR4",
            "probability": 0.0
        },
        {
            "start_logit": -4.1796875,
            "end_logit": -6.6875,
            "text": "CCR4",
            "probability": 0.0
        }
    ],
    "5162c8a8298dcd4e51000047_4": [
        {
            "start_logit": 13.03125,
            "end_logit": 12.625,
            "text": "Pop2",
            "probability": 0.9970703125
        },
        {
            "start_logit": 13.03125,
            "end_logit": 6.84375,
            "text": "Pop2 protein, belonging to the eukaryotic Caf1",
            "probability": 0.00307464599609375
        },
        {
            "start_logit": 5.15625,
            "end_logit": 6.84375,
            "text": "Caf1",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 13.03125,
            "end_logit": -4.72265625,
            "text": "Pop",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -5.34765625,
            "text": "Pop2 protein, belonging to the eukaryotic Caf1 family",
            "probability": 0.0
        },
        {
            "start_logit": -5.65234375,
            "end_logit": 12.625,
            "text": "2",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -6.51953125,
            "text": "Pop2 protein, belonging to the eukaryotic Caf",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -8.0,
            "text": "Pop2 protein, belonging to the",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -8.0546875,
            "text": "Pop2 protein",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -8.109375,
            "text": "Pop2 protein, belonging to the eukaryotic",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -8.2578125,
            "text": "Pop2 protein, belonging to the eukaryotic Caf1 family, is required",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -8.265625,
            "text": "Pop2 protein, belonging to the eukaryotic Caf1 family,",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -8.3046875,
            "text": "Pop2 protein, belonging to",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -8.921875,
            "text": "Pop2 protein,",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -9.03125,
            "text": "Pop2 protein, belonging",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -9.265625,
            "text": "Pop2 protein, belonging to the eukaryotic Caf1 family, is",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -9.625,
            "text": "Pop2 protein, belonging to the eukaryotic Caf1 family, is required for mRNA deadenylation in vivo.",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -9.9140625,
            "text": "Pop2 protein, belonging to the eukaryotic Caf1 family, is required for mRNA deadenylation in vivo",
            "probability": 0.0
        },
        {
            "start_logit": -9.875,
            "end_logit": 12.625,
            "text": "yeast Pop2",
            "probability": 0.0
        },
        {
            "start_logit": -5.65234375,
            "end_logit": 6.84375,
            "text": "2 protein, belonging to the eukaryotic Caf1",
            "probability": 0.0
        }
    ],
    "5162c8a8298dcd4e51000047_5": [
        {
            "start_logit": 13.9453125,
            "end_logit": 13.984375,
            "text": "CCR4",
            "probability": 1.0
        },
        {
            "start_logit": -3.62890625,
            "end_logit": 13.984375,
            "text": "4",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -3.83203125,
            "text": "CCR",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -5.859375,
            "text": "CCR4 appears to be the principle deadenylase of the CCR4-NOT complex",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -6.35546875,
            "text": "CCR4 appears to be the principle deadenylase of the CCR4-NOT",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -7.98828125,
            "text": "CCR4 appears",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -8.0078125,
            "text": "CCR4 appears to be the principle deadenylase of the CCR4",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 13.984375,
            "text": "RNases, CCR4",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -8.4296875,
            "text": "CCR4 appears to be",
            "probability": 0.0
        },
        {
            "start_logit": -8.546875,
            "end_logit": 13.984375,
            "text": "CAF1 protein belongs to the DEDDh family of RNases, CCR4",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -9.03125,
            "text": "CCR4 appears to be the principle deadenylase",
            "probability": 0.0
        },
        {
            "start_logit": -9.109375,
            "end_logit": 13.984375,
            "text": "DEDDh family of RNases, CCR4",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -9.0859375,
            "text": "CCR4 appears to be the principle deadenylase of the CCR4-",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 13.984375,
            "text": "Although CAF1 protein belongs to the DEDDh family of RNases, CCR4",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 13.984375,
            "text": "Dh family of RNases, CCR4",
            "probability": 0.0
        },
        {
            "start_logit": -3.62890625,
            "end_logit": -5.859375,
            "text": "4 appears to be the principle deadenylase of the CCR4-NOT complex",
            "probability": 0.0
        },
        {
            "start_logit": -3.62890625,
            "end_logit": -6.35546875,
            "text": "4 appears to be the principle deadenylase of the CCR4-NOT",
            "probability": 0.0
        },
        {
            "start_logit": -3.62890625,
            "end_logit": -7.98828125,
            "text": "4 appears",
            "probability": 0.0
        },
        {
            "start_logit": -3.62890625,
            "end_logit": -8.0078125,
            "text": "4 appears to be the principle deadenylase of the CCR4",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -3.83203125,
            "text": "RNases, CCR",
            "probability": 0.0
        }
    ],
    "5162c8a8298dcd4e51000047_6": [
        {
            "start_logit": 12.5234375,
            "end_logit": 12.2109375,
            "text": "DEDD",
            "probability": 1.0
        },
        {
            "start_logit": 3.650390625,
            "end_logit": 12.2109375,
            "text": "CCR4, increased length of RNA substrates converted mCAF1 into a processive enzyme. In contrast to two other DEDD",
            "probability": 0.0001398324966430664
        },
        {
            "start_logit": 12.5234375,
            "end_logit": 1.1875,
            "text": "DEDD family",
            "probability": 1.633167266845703e-05
        },
        {
            "start_logit": 12.5234375,
            "end_logit": -1.4892578125,
            "text": "DEDD family members, PAN2 and PARN",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 3.650390625,
            "end_logit": 5.26953125,
            "text": "CCR4",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.5234375,
            "end_logit": -5.4375,
            "text": "DED",
            "probability": 0.0
        },
        {
            "start_logit": 12.5234375,
            "end_logit": -6.359375,
            "text": "DEDD family members, PAN2",
            "probability": 0.0
        },
        {
            "start_logit": -6.42578125,
            "end_logit": 12.2109375,
            "text": "D",
            "probability": 0.0
        },
        {
            "start_logit": 12.5234375,
            "end_logit": -6.80078125,
            "text": "DEDD family members, PAN2 and PAR",
            "probability": 0.0
        },
        {
            "start_logit": 3.650390625,
            "end_logit": 1.1875,
            "text": "CCR4, increased length of RNA substrates converted mCAF1 into a processive enzyme. In contrast to two other DEDD family",
            "probability": 0.0
        },
        {
            "start_logit": 12.5234375,
            "end_logit": -7.6953125,
            "text": "DEDD family members, PAN",
            "probability": 0.0
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 12.2109375,
            "text": "mCAF1 into a processive enzyme. In contrast to two other DEDD",
            "probability": 0.0
        },
        {
            "start_logit": -7.81640625,
            "end_logit": 12.2109375,
            "text": "4, increased length of RNA substrates converted mCAF1 into a processive enzyme. In contrast to two other DEDD",
            "probability": 0.0
        },
        {
            "start_logit": 12.5234375,
            "end_logit": -8.5390625,
            "text": "DEDD family members, PAN2 and PARN,",
            "probability": 0.0
        },
        {
            "start_logit": 12.5234375,
            "end_logit": -8.7265625,
            "text": "DEDD family members, PAN2 and PARN, mCAF1 was not activated either by PAB1",
            "probability": 0.0
        },
        {
            "start_logit": 12.5234375,
            "end_logit": -9.0859375,
            "text": "DEDD family members, PAN2 and PARN, mCAF1 was not activated either by PAB1 or capped",
            "probability": 0.0
        },
        {
            "start_logit": 12.5234375,
            "end_logit": -9.109375,
            "text": "DEDD family members",
            "probability": 0.0
        },
        {
            "start_logit": 12.5234375,
            "end_logit": -9.3359375,
            "text": "DEDD family members, PAN2 and PARN, mCAF1",
            "probability": 0.0
        },
        {
            "start_logit": 3.650390625,
            "end_logit": -5.4375,
            "text": "CCR4, increased length of RNA substrates converted mCAF1 into a processive enzyme. In contrast to two other DED",
            "probability": 0.0
        },
        {
            "start_logit": -7.81640625,
            "end_logit": 5.26953125,
            "text": "4",
            "probability": 0.0
        }
    ],
    "5162c8a8298dcd4e51000047_7": [
        {
            "start_logit": 14.125,
            "end_logit": 14.0859375,
            "text": "CCR4",
            "probability": 1.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -3.5234375,
            "text": "CCR",
            "probability": 0.0
        },
        {
            "start_logit": -3.57421875,
            "end_logit": 14.0859375,
            "text": "4",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -7.24609375,
            "text": "CCR4 protein, which is part of the cytoplasmic deadenylase,",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -7.30078125,
            "text": "CCR4 protein",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -8.0859375,
            "text": "CCR4 protein, which is part of the cytoplasmic",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -8.1015625,
            "text": "CCR4 protein, which is part of the cytoplasmic deadenylase",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -8.1171875,
            "text": "CCR4 protein, which is",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -8.484375,
            "text": "CCR4 protein, which is part",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -8.515625,
            "text": "CCR4 protein, which is part of",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -8.609375,
            "text": "CCR4 protein,",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -8.640625,
            "text": "CCR4 protein, which is part of the",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -8.65625,
            "text": "CCR4 protein, which is part of the cytoplasmic deadenylase, contains a C-terminal domain",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -8.703125,
            "text": "CCR4 protein, which is part of the cytoplasmic deadenylase, contains a C-terminal domain that displays homology",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -8.9375,
            "text": "CCR4 protein, which is part of the cytoplasmic deadenylase, contains a C-terminal domain that displays homology to an Mg2+-dependent DNase",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": 14.0859375,
            "text": "evolutionarily conserved CCR4",
            "probability": 0.0
        },
        {
            "start_logit": -3.57421875,
            "end_logit": -7.24609375,
            "text": "4 protein, which is part of the cytoplasmic deadenylase,",
            "probability": 0.0
        },
        {
            "start_logit": -3.57421875,
            "end_logit": -7.30078125,
            "text": "4 protein",
            "probability": 0.0
        },
        {
            "start_logit": -3.57421875,
            "end_logit": -8.0859375,
            "text": "4 protein, which is part of the cytoplasmic",
            "probability": 0.0
        },
        {
            "start_logit": -3.57421875,
            "end_logit": -8.1015625,
            "text": "4 protein, which is part of the cytoplasmic deadenylase",
            "probability": 0.0
        }
    ],
    "5162c8a8298dcd4e51000047_8": [
        {
            "start_logit": 14.2578125,
            "end_logit": 14.40625,
            "text": "CCR4",
            "probability": 1.0
        },
        {
            "start_logit": -2.962890625,
            "end_logit": 14.40625,
            "text": "4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -3.248046875,
            "text": "CCR",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -6.18359375,
            "text": "CCR4 and most probably other members of a widely distributed CCR4",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -6.73046875,
            "text": "CCR4 and most probably other members of a widely distributed CCR4-like family of proteins constitute",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -6.734375,
            "text": "CCR4 and most probably other members of a widely distributed CCR4-like",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -6.765625,
            "text": "CCR4 and most probably other members of a widely distributed CCR4-like family of proteins",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -7.4453125,
            "text": "CCR4 and most probably other members of a widely distributed CCR4-like family",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -7.5859375,
            "text": "CCR4 and most probably other members of a widely distributed CCR",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -8.5703125,
            "text": "CCR4 and most probably other members of a",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -8.6171875,
            "text": "CCR4 and most probably other members of a widely distributed CCR4-like family of",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -8.9375,
            "text": "CCR4 and most probably other members of a widely distributed CCR4-",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.3359375,
            "text": "CCR4 and most probably other members of",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.34375,
            "text": "CCR4 and most probably other members of a widely distributed CCR4-like family of proteins constitute a novel class of RNA-DNA exonucleases",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.3984375,
            "text": "CCR4 and",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.3984375,
            "text": "CCR4 and most probably other",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.484375,
            "text": "CCR4 and most probably other members",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.4921875,
            "text": "CCR4 and most probably other members of a widely distributed CCR4-like family of proteins constitute a novel",
            "probability": 0.0
        },
        {
            "start_logit": -2.962890625,
            "end_logit": -6.18359375,
            "text": "4 and most probably other members of a widely distributed CCR4",
            "probability": 0.0
        },
        {
            "start_logit": -2.962890625,
            "end_logit": -6.73046875,
            "text": "4 and most probably other members of a widely distributed CCR4-like family of proteins constitute",
            "probability": 0.0
        }
    ],
    "5162c8a8298dcd4e51000047_9": [
        {
            "start_logit": 13.25,
            "end_logit": 13.5078125,
            "text": "PARN",
            "probability": 1.0
        },
        {
            "start_logit": 13.25,
            "end_logit": -1.240234375,
            "text": "PARN, Nocturnin and Angel",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 13.25,
            "end_logit": -3.203125,
            "text": "PARN, Nocturnin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.66015625,
            "end_logit": 13.5078125,
            "text": "N",
            "probability": 0.0
        },
        {
            "start_logit": 13.25,
            "end_logit": -4.79296875,
            "text": "PAR",
            "probability": 0.0
        },
        {
            "start_logit": 13.25,
            "end_logit": -7.8203125,
            "text": "PARN, Nocturnin and",
            "probability": 0.0
        },
        {
            "start_logit": 13.25,
            "end_logit": -7.96875,
            "text": "PARN, Nocturnin and Ang",
            "probability": 0.0
        },
        {
            "start_logit": 13.25,
            "end_logit": -8.0859375,
            "text": "PARN, Noct",
            "probability": 0.0
        },
        {
            "start_logit": 13.25,
            "end_logit": -8.2578125,
            "text": "PARN, Nocturnin and Angel are three of the multiple deadenylases",
            "probability": 0.0
        },
        {
            "start_logit": 13.25,
            "end_logit": -8.5703125,
            "text": "PARN, Nocturnin and Angel are",
            "probability": 0.0
        },
        {
            "start_logit": 13.25,
            "end_logit": -8.5859375,
            "text": "PARN, Nocturn",
            "probability": 0.0
        },
        {
            "start_logit": 13.25,
            "end_logit": -8.6953125,
            "text": "PARN,",
            "probability": 0.0
        },
        {
            "start_logit": 13.25,
            "end_logit": -8.9765625,
            "text": "PARN, Nocturnin and Angel are three of the multiple deadenylases that have been described",
            "probability": 0.0
        },
        {
            "start_logit": 13.25,
            "end_logit": -9.1015625,
            "text": "PARN, Nocturnin and Angel are three of the multiple deadenylases that have been described in eukaryotic cells",
            "probability": 0.0
        },
        {
            "start_logit": 13.25,
            "end_logit": -9.28125,
            "text": "PARN, Nocturnin and Angel are three",
            "probability": 0.0
        },
        {
            "start_logit": 13.25,
            "end_logit": -9.3046875,
            "text": "PARN, Nocturnin and Angel are three of the multiple deadenylases that have been described in eukaryotic cells.",
            "probability": 0.0
        },
        {
            "start_logit": 13.25,
            "end_logit": -9.5859375,
            "text": "PARN, Nocturnin and Angel are three of the multiple deadenylases that have been described in",
            "probability": 0.0
        },
        {
            "start_logit": 13.25,
            "end_logit": -9.7109375,
            "text": "PARN, Nocturnin and Angel are three of the multiple deadenylases that have been",
            "probability": 0.0
        },
        {
            "start_logit": 13.25,
            "end_logit": -9.7421875,
            "text": "PARN, Nocturnin and Angel are three of the multiple deadenylases that have",
            "probability": 0.0
        },
        {
            "start_logit": -4.66015625,
            "end_logit": -1.240234375,
            "text": "N, Nocturnin and Angel",
            "probability": 0.0
        }
    ],
    "515db20e298dcd4e51000014_1": [
        {
            "start_logit": 6.08984375,
            "end_logit": 13.3515625,
            "text": "CBT",
            "probability": 1.0
        },
        {
            "start_logit": -8.875,
            "end_logit": 13.3515625,
            "text": "group cognitive-behavioral treatment (CBT",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -9.3203125,
            "end_logit": 13.3515625,
            "text": "school-based group cognitive-behavioral treatment (CBT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -9.5390625,
            "end_logit": 13.3515625,
            "text": "(CBT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.125,
            "end_logit": 13.3515625,
            "text": "a school-based group cognitive-behavioral treatment (CBT",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.08984375,
            "end_logit": -9.4921875,
            "text": "CBT)",
            "probability": 0.0
        },
        {
            "start_logit": 6.08984375,
            "end_logit": -9.6484375,
            "text": "CBT) for anxiety disorders with African-American adolescents. METHODS: Twelve adolescents (mean age = 15.6 years) with anxiety disorders were randomly assigned",
            "probability": 0.0
        },
        {
            "start_logit": 6.08984375,
            "end_logit": -9.8671875,
            "text": "CBT) for anxiety disorders with African-American adolescents. METHODS: Twelve adolescents (mean age = 15",
            "probability": 0.0
        },
        {
            "start_logit": -6.77734375,
            "end_logit": -5.9375,
            "text": "n",
            "probability": 0.0
        },
        {
            "start_logit": -6.77734375,
            "end_logit": -6.88671875,
            "text": "n = 6",
            "probability": 0.0
        },
        {
            "start_logit": -7.734375,
            "end_logit": -5.9375,
            "text": "(n",
            "probability": 0.0
        },
        {
            "start_logit": -6.77734375,
            "end_logit": -6.9453125,
            "text": "n = 6) or a group attention-support control condition",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -5.9375,
            "text": "to CBT (n",
            "probability": 0.0
        },
        {
            "start_logit": -6.77734375,
            "end_logit": -7.4609375,
            "text": "n =",
            "probability": 0.0
        },
        {
            "start_logit": -7.734375,
            "end_logit": -6.88671875,
            "text": "(n = 6",
            "probability": 0.0
        },
        {
            "start_logit": -7.734375,
            "end_logit": -6.9453125,
            "text": "(n = 6) or a group attention-support control condition",
            "probability": 0.0
        },
        {
            "start_logit": -6.77734375,
            "end_logit": -8.2265625,
            "text": "n = 6)",
            "probability": 0.0
        },
        {
            "start_logit": -6.77734375,
            "end_logit": -8.2734375,
            "text": "n = 6) or a group attention-support control",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -6.88671875,
            "text": "to CBT (n = 6",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -6.9453125,
            "text": "to CBT (n = 6) or a group attention-support control condition",
            "probability": 0.0
        }
    ],
    "515db20e298dcd4e51000014_2": [
        {
            "start_logit": 9.4609375,
            "end_logit": 12.8671875,
            "text": "CBT",
            "probability": 1.0
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -5.12890625,
            "text": "CBT no longer met diagnostic criteria for their primary anxiety disorder, compared with 1/5 in AS-Control",
            "probability": 0.0
        },
        {
            "start_logit": -9.421875,
            "end_logit": 12.8671875,
            "text": "in CBT",
            "probability": 0.0
        },
        {
            "start_logit": -9.578125,
            "end_logit": 12.8671875,
            "text": "adolescents in CBT",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 12.8671875,
            "text": "among those who attended more than one treatment session, 3/4 adolescents in CBT",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": 12.8671875,
            "text": "3/4 adolescents in CBT",
            "probability": 0.0
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -9.953125,
            "text": "CBT no longer met diagnostic criteria for their primary anxiety disorder,",
            "probability": 0.0
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -9.9609375,
            "text": "CBT no longer met diagnostic criteria for their primary anxiety disorder, compared with 1/5 in AS-Control. Clinician ratings of impairment and self-report",
            "probability": 0.0
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -9.96875,
            "text": "CBT no longer met diagnostic criteria for their primary anxiety disorder, compared with 1/5 in AS",
            "probability": 0.0
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -10.046875,
            "text": "CBT no longer met diagnostic criteria for their primary anxiety disorder, compared",
            "probability": 0.0
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -10.0546875,
            "text": "CBT no longer met diagnostic criteria for their primary anxiety disorder, compared with 1/5 in AS-Control.",
            "probability": 0.0
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -10.171875,
            "text": "CBT no longer met diagnostic criteria for their primary anxiety disorder, compared with 1/5 in",
            "probability": 0.0
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -10.234375,
            "text": "CBT no longer met diagnostic criteria",
            "probability": 0.0
        },
        {
            "start_logit": -8.3984375,
            "end_logit": -5.12890625,
            "text": "AS-Control",
            "probability": 0.0
        },
        {
            "start_logit": -9.015625,
            "end_logit": -5.12890625,
            "text": "compared with 1/5 in AS-Control",
            "probability": 0.0
        },
        {
            "start_logit": -9.421875,
            "end_logit": -5.12890625,
            "text": "in CBT no longer met diagnostic criteria for their primary anxiety disorder, compared with 1/5 in AS-Control",
            "probability": 0.0
        },
        {
            "start_logit": -9.578125,
            "end_logit": -5.12890625,
            "text": "adolescents in CBT no longer met diagnostic criteria for their primary anxiety disorder, compared with 1/5 in AS-Control",
            "probability": 0.0
        },
        {
            "start_logit": -9.8828125,
            "end_logit": -5.12890625,
            "text": "with 1/5 in AS-Control",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": -5.12890625,
            "text": "no longer met diagnostic criteria for their primary anxiety disorder, compared with 1/5 in AS-Control",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": -5.12890625,
            "text": "3/4 adolescents in CBT no longer met diagnostic criteria for their primary anxiety disorder, compared with 1/5 in AS-Control",
            "probability": 0.0
        }
    ],
    "515db20e298dcd4e51000014_3": [
        {
            "start_logit": 8.3125,
            "end_logit": 2.14453125,
            "text": "individual",
            "probability": 0.61669921875
        },
        {
            "start_logit": 8.3125,
            "end_logit": 1.6533203125,
            "text": "individual versus 41% in the group treatment",
            "probability": 0.3798828125
        },
        {
            "start_logit": 8.3125,
            "end_logit": -3.076171875,
            "text": "individual versus 41% in the group",
            "probability": 0.003337860107421875
        },
        {
            "start_logit": 8.3125,
            "end_logit": -9.0390625,
            "text": "individual versus 41% in the group treatment were free of any anxiety disorder",
            "probability": 8.58306884765625e-06
        },
        {
            "start_logit": 8.3125,
            "end_logit": -9.1875,
            "text": "individual versus 41% in the group treatment were free of any",
            "probability": 7.450580596923828e-06
        },
        {
            "start_logit": 8.3125,
            "end_logit": -9.3828125,
            "text": "individual versus 41% in the group treatment were free of any anxiety disorder at post-treatment; 62% versus 54% were free of their primary",
            "probability": 6.079673767089844e-06
        },
        {
            "start_logit": 8.3125,
            "end_logit": -9.9140625,
            "text": "individual versus 41% in the group treatment were",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": 8.3125,
            "end_logit": -9.9453125,
            "text": "individual versus 41% in the",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": 8.3125,
            "end_logit": -9.984375,
            "text": "individual versus 41% in the group treatment were free of any anxiety disorder at post-treatment",
            "probability": 3.337860107421875e-06
        },
        {
            "start_logit": -6.08984375,
            "end_logit": 1.6533203125,
            "text": "group treatment",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.1171875,
            "end_logit": 1.6533203125,
            "text": "versus 41% in the group treatment",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.4921875,
            "end_logit": 2.14453125,
            "text": "children in the individual",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": 2.14453125,
            "text": "Forty-eight percent of the children in the individual",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": 1.6533203125,
            "text": "children in the individual versus 41% in the group treatment",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": 1.6533203125,
            "text": "Forty-eight percent of the children in the individual versus 41% in the group treatment",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": 1.6533203125,
            "text": "41% in the group treatment",
            "probability": 0.0
        },
        {
            "start_logit": -6.08984375,
            "end_logit": -3.076171875,
            "text": "group",
            "probability": 0.0
        },
        {
            "start_logit": -7.1171875,
            "end_logit": -3.076171875,
            "text": "versus 41% in the group",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": -3.076171875,
            "text": "children in the individual versus 41% in the group",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": -3.076171875,
            "text": "Forty-eight percent of the children in the individual versus 41% in the group",
            "probability": 0.0
        }
    ],
    "5e3c841148dab47f26000002_1": [
        {
            "start_logit": 14.359375,
            "end_logit": 14.4921875,
            "text": "multiple sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": -2.8046875,
            "end_logit": 14.4921875,
            "text": "sclerosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.359375,
            "end_logit": -3.0,
            "text": "multiple",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -8.578125,
            "text": "multiple sclerosis by induction of inflammation and aggregation of tau protein: A commentary",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -8.921875,
            "text": "multiple sclerosis by induction of inflammation and aggregation of tau protein: A",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.25,
            "text": "multiple sclerosis by induction of inflammation",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.4609375,
            "text": "multiple sclerosis by induction of",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.4765625,
            "text": "multiple sclerosis by induction of inflammation and aggregation of tau protein:",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.859375,
            "text": "multiple sclerosis by induction of inflammation and aggregation of",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.9765625,
            "text": "multiple sclerosis by induction of inflammation and aggregation of tau",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.9765625,
            "text": "multiple sclerosis by",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -10.125,
            "text": "multiple sclerosis by induction of inflammation and",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -10.1328125,
            "text": "multiple sclerosis by induction",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 14.4921875,
            "text": "arsenic in multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 14.4921875,
            "text": "hypothetical roles of arsenic in multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 14.4921875,
            "text": "roles of arsenic in multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -2.8046875,
            "end_logit": -8.578125,
            "text": "sclerosis by induction of inflammation and aggregation of tau protein: A commentary",
            "probability": 0.0
        },
        {
            "start_logit": -2.8046875,
            "end_logit": -8.921875,
            "text": "sclerosis by induction of inflammation and aggregation of tau protein: A",
            "probability": 0.0
        },
        {
            "start_logit": -2.8046875,
            "end_logit": -9.25,
            "text": "sclerosis by induction of inflammation",
            "probability": 0.0
        },
        {
            "start_logit": -2.8046875,
            "end_logit": -9.4609375,
            "text": "sclerosis by induction of",
            "probability": 0.0
        }
    ],
    "5e3c841148dab47f26000002_2": [
        {
            "start_logit": 13.6484375,
            "end_logit": 13.296875,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": 13.6484375,
            "end_logit": -2.48828125,
            "text": "Alzheimer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.6484375,
            "end_logit": -2.61328125,
            "text": "Alzheimer's disease (AD",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.6484375,
            "end_logit": -5.0859375,
            "text": "Alzheimer's disease (",
            "probability": 0.0
        },
        {
            "start_logit": -4.99609375,
            "end_logit": 13.296875,
            "text": "disease",
            "probability": 0.0
        },
        {
            "start_logit": 13.6484375,
            "end_logit": -6.19140625,
            "text": "Alzheimer's disease (AD) is the most common cause of progressive dementia",
            "probability": 0.0
        },
        {
            "start_logit": 13.6484375,
            "end_logit": -6.96484375,
            "text": "Alzheimer's disease (AD)",
            "probability": 0.0
        },
        {
            "start_logit": 13.6484375,
            "end_logit": -7.953125,
            "text": "Alzheimer'",
            "probability": 0.0
        },
        {
            "start_logit": 13.6484375,
            "end_logit": -8.1875,
            "text": "Alzheimer's disease (AD) is the most common",
            "probability": 0.0
        },
        {
            "start_logit": 13.6484375,
            "end_logit": -8.3359375,
            "text": "Alzheimer's disease (AD) is",
            "probability": 0.0
        },
        {
            "start_logit": 13.6484375,
            "end_logit": -8.515625,
            "text": "Alzheimer's disease (AD) is the most",
            "probability": 0.0
        },
        {
            "start_logit": 13.6484375,
            "end_logit": -8.59375,
            "text": "Alzheimer's disease (AD) is the",
            "probability": 0.0
        },
        {
            "start_logit": 13.6484375,
            "end_logit": -8.9296875,
            "text": "Alzheimer's",
            "probability": 0.0
        },
        {
            "start_logit": -9.3515625,
            "end_logit": 13.296875,
            "text": "s disease",
            "probability": 0.0
        },
        {
            "start_logit": -4.99609375,
            "end_logit": -2.61328125,
            "text": "disease (AD",
            "probability": 0.0
        },
        {
            "start_logit": -5.8359375,
            "end_logit": -2.61328125,
            "text": "AD",
            "probability": 0.0
        },
        {
            "start_logit": -4.99609375,
            "end_logit": -5.0859375,
            "text": "disease (",
            "probability": 0.0
        },
        {
            "start_logit": -4.99609375,
            "end_logit": -6.19140625,
            "text": "disease (AD) is the most common cause of progressive dementia",
            "probability": 0.0
        },
        {
            "start_logit": -6.10546875,
            "end_logit": -5.52734375,
            "text": "NFTs",
            "probability": 0.0
        },
        {
            "start_logit": -4.99609375,
            "end_logit": -6.96484375,
            "text": "disease (AD)",
            "probability": 0.0
        }
    ],
    "5e3c841148dab47f26000002_3": [
        {
            "start_logit": 14.2734375,
            "end_logit": 14.03125,
            "text": "multiple sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -3.1796875,
            "text": "multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -3.5234375,
            "text": "multiple sclerosis (MS",
            "probability": 0.0
        },
        {
            "start_logit": -3.857421875,
            "end_logit": 14.03125,
            "text": "sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -7.64453125,
            "text": "multiple sclerosis (",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -7.8671875,
            "text": "multiple sclerosis (MS)",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -9.78125,
            "text": "multiple sclerosis (MS).",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 14.03125,
            "text": "\u03b1B crystallin, and amyloid P protein are all found in lesions of multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": 14.03125,
            "text": "amyloid P protein are all found in lesions of multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 14.03125,
            "text": "P protein are all found in lesions of multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 14.03125,
            "text": "lesions of multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -3.857421875,
            "end_logit": -3.5234375,
            "text": "sclerosis (MS",
            "probability": 0.0
        },
        {
            "start_logit": -5.66796875,
            "end_logit": -3.5234375,
            "text": "MS",
            "probability": 0.0
        },
        {
            "start_logit": -3.857421875,
            "end_logit": -7.64453125,
            "text": "sclerosis (",
            "probability": 0.0
        },
        {
            "start_logit": -3.857421875,
            "end_logit": -7.8671875,
            "text": "sclerosis (MS)",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": -3.1796875,
            "text": "\u03b1B crystallin, and amyloid P protein are all found in lesions of multiple",
            "probability": 0.0
        },
        {
            "start_logit": -5.66796875,
            "end_logit": -7.8671875,
            "text": "MS)",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": -3.1796875,
            "text": "amyloid P protein are all found in lesions of multiple",
            "probability": 0.0
        },
        {
            "start_logit": -3.857421875,
            "end_logit": -9.78125,
            "text": "sclerosis (MS).",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": -3.5234375,
            "text": "\u03b1B crystallin, and amyloid P protein are all found in lesions of multiple sclerosis (MS",
            "probability": 0.0
        }
    ],
    "5e3c841148dab47f26000002_4": [
        {
            "start_logit": 13.8125,
            "end_logit": 14.2734375,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": -3.26171875,
            "end_logit": 14.2734375,
            "text": "disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.8125,
            "end_logit": -2.86328125,
            "text": "Alzheimer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.8125,
            "end_logit": -3.216796875,
            "text": "Alzheimer's disease (AD",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -5.28515625,
            "text": "Alzheimer's disease (",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -6.5078125,
            "text": "Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia and parkinsonism",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -6.515625,
            "text": "Alzheimer's disease (AD)",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -6.625,
            "text": "Alzheimer's disease (AD), progressive supranuclear palsy",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -6.76171875,
            "text": "Alzheimer's disease (AD), progressive supranuclear palsy (PSP",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -6.7734375,
            "text": "Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -6.828125,
            "text": "Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia and parkinsonism linked",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -7.09375,
            "text": "Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia and parkinsonism linked to chromosome 17",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -8.1015625,
            "text": "Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -8.53125,
            "text": "Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia and parkinsonism linked to chromosome",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -8.53125,
            "text": "Alzheimer's disease (AD), progressive supranuclear palsy (",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -8.59375,
            "text": "Alzheimer'",
            "probability": 0.0
        },
        {
            "start_logit": -9.125,
            "end_logit": 14.2734375,
            "text": "s disease",
            "probability": 0.0
        },
        {
            "start_logit": -3.26171875,
            "end_logit": -3.216796875,
            "text": "disease (AD",
            "probability": 0.0
        },
        {
            "start_logit": -1.1064453125,
            "end_logit": -6.5078125,
            "text": ", progressive supranuclear palsy (PSP), frontotemporal dementia and parkinsonism",
            "probability": 0.0
        },
        {
            "start_logit": -1.1064453125,
            "end_logit": -6.625,
            "text": ", progressive supranuclear palsy",
            "probability": 0.0
        }
    ],
    "5e3c841148dab47f26000002_5": [
        {
            "start_logit": 12.4140625,
            "end_logit": 12.5390625,
            "text": "Alzheimer's and Parkinson's diseases",
            "probability": 1.0
        },
        {
            "start_logit": 12.4140625,
            "end_logit": -2.54296875,
            "text": "Alzheimer",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.3046875,
            "end_logit": 12.5390625,
            "text": "diseases",
            "probability": 0.0
        },
        {
            "start_logit": 12.4140625,
            "end_logit": -5.91015625,
            "text": "Alzheimer's and Parkinson",
            "probability": 0.0
        },
        {
            "start_logit": 12.4140625,
            "end_logit": -6.734375,
            "text": "Alzheimer's and Parkinson's diseases, there is a hyperphosphorylation",
            "probability": 0.0
        },
        {
            "start_logit": -7.1953125,
            "end_logit": 12.5390625,
            "text": "Parkinson's diseases",
            "probability": 0.0
        },
        {
            "start_logit": 12.4140625,
            "end_logit": -7.97265625,
            "text": "Alzheimer's",
            "probability": 0.0
        },
        {
            "start_logit": 12.4140625,
            "end_logit": -8.0,
            "text": "Alzheimer's and Parkinson'",
            "probability": 0.0
        },
        {
            "start_logit": 12.4140625,
            "end_logit": -8.125,
            "text": "Alzheimer'",
            "probability": 0.0
        },
        {
            "start_logit": 12.4140625,
            "end_logit": -8.140625,
            "text": "Alzheimer's and Parkinson's",
            "probability": 0.0
        },
        {
            "start_logit": 12.4140625,
            "end_logit": -8.8125,
            "text": "Alzheimer's and Parkinson's diseases, there is a hyperphosph",
            "probability": 0.0
        },
        {
            "start_logit": 12.4140625,
            "end_logit": -9.0546875,
            "text": "Alzheimer's and Parkinson's diseases, there is a hyperphosphorylation of tau",
            "probability": 0.0
        },
        {
            "start_logit": 12.4140625,
            "end_logit": -9.421875,
            "text": "Alzheimer's and Parkinson's diseases, there is a hyperphosphorylation of tau that leads",
            "probability": 0.0
        },
        {
            "start_logit": 12.4140625,
            "end_logit": -9.5,
            "text": "Alzheimer's and Parkinson's diseases, there is a hyperphosphorylation of tau that leads to the intracellular accumulation",
            "probability": 0.0
        },
        {
            "start_logit": 12.4140625,
            "end_logit": -9.515625,
            "text": "Alzheimer's and Parkinson's diseases, there is",
            "probability": 0.0
        },
        {
            "start_logit": 12.4140625,
            "end_logit": -9.5234375,
            "text": "Alzheimer's and",
            "probability": 0.0
        },
        {
            "start_logit": 12.4140625,
            "end_logit": -9.5234375,
            "text": "Alzheimer's and Parkinson's diseases, there is a",
            "probability": 0.0
        },
        {
            "start_logit": -9.7578125,
            "end_logit": 12.5390625,
            "text": "s and Parkinson's diseases",
            "probability": 0.0
        },
        {
            "start_logit": 12.4140625,
            "end_logit": -9.828125,
            "text": "Alzheimer's and Parkinson's diseases, there is a hyperphosphorylation of tau that leads to the intracellular accumulation of tau in the form",
            "probability": 0.0
        },
        {
            "start_logit": 12.4140625,
            "end_logit": -9.890625,
            "text": "Alzheimer's and Parkinson's diseases, there is a hyperphosphorylation of tau that leads to the intracellular accumulation of tau",
            "probability": 0.0
        }
    ],
    "58da5dc58acda34529000016_1": [
        {
            "start_logit": 6.328125,
            "end_logit": 4.91015625,
            "text": "acute heart failure",
            "probability": 0.94970703125
        },
        {
            "start_logit": 2.8515625,
            "end_logit": 4.91015625,
            "text": "heart failure",
            "probability": 0.02947998046875
        },
        {
            "start_logit": 6.328125,
            "end_logit": 0.98583984375,
            "text": "acute heart failure-acute coronary syndrome",
            "probability": 0.0188140869140625
        },
        {
            "start_logit": -0.89697265625,
            "end_logit": 4.91015625,
            "text": "CRS type 1 = acute worsening of heart function (acute heart failure",
            "probability": 0.0006933212280273438
        },
        {
            "start_logit": 2.8515625,
            "end_logit": 0.98583984375,
            "text": "heart failure-acute coronary syndrome",
            "probability": 0.0005817413330078125
        },
        {
            "start_logit": -0.89697265625,
            "end_logit": 3.173828125,
            "text": "CRS type 1",
            "probability": 0.00012290477752685547
        },
        {
            "start_logit": -0.89697265625,
            "end_logit": 0.98583984375,
            "text": "CRS type 1 = acute worsening of heart function (acute heart failure-acute coronary syndrome",
            "probability": 1.3709068298339844e-05
        },
        {
            "start_logit": 6.328125,
            "end_logit": -7.51171875,
            "text": "acute heart failure-acute coronary",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": 6.328125,
            "end_logit": -7.625,
            "text": "acute",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": -6.42578125,
            "end_logit": 4.91015625,
            "text": "type 1 = acute worsening of heart function (acute heart failure",
            "probability": 2.8014183044433594e-06
        },
        {
            "start_logit": 6.328125,
            "end_logit": -7.8671875,
            "text": "acute heart failure-acute",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": 6.328125,
            "end_logit": -7.87109375,
            "text": "acute heart failure-acute coronary syndrome) leading to kidney injury and/or dysfunction",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": -7.125,
            "end_logit": 4.91015625,
            "text": "acute worsening of heart function (acute heart failure",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 6.328125,
            "end_logit": -8.8359375,
            "text": "acute heart failure-acute coronary syndrome) leading to kidney injury and/or dysfunction; CRS type 2 = chronic abnormalities in heart function (chronic heart failure",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 6.328125,
            "end_logit": -9.1953125,
            "text": "acute heart failure-acute coronary syndrome) leading to kidney injury and/or",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 6.328125,
            "end_logit": -9.453125,
            "text": "acute heart failure-acute coronary syndrome) leading to kidney injury and/or dysfunction; CRS type 2 = chronic abnormalities in heart function (chronic",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.42578125,
            "end_logit": 3.173828125,
            "text": "type 1",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 4.91015625,
            "text": "= acute worsening of heart function (acute heart failure",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -8.8671875,
            "end_logit": 4.91015625,
            "text": "expanded into five subtypes: CRS type 1 = acute worsening of heart function (acute heart failure",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -9.0,
            "end_logit": 4.91015625,
            "text": "(acute heart failure",
            "probability": 2.384185791015625e-07
        }
    ],
    "58da5dc58acda34529000016_2": [
        {
            "start_logit": 14.5390625,
            "end_logit": 13.65625,
            "text": "heart failure",
            "probability": 1.0
        },
        {
            "start_logit": 14.5390625,
            "end_logit": -2.3671875,
            "text": "heart",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.1875,
            "end_logit": 13.65625,
            "text": "failure",
            "probability": 0.0
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 13.65625,
            "text": "CRS type 1 most commonly occurs in the setting of acutely decompensated heart failure",
            "probability": 0.0
        },
        {
            "start_logit": 14.5390625,
            "end_logit": -9.3828125,
            "text": "heart failure where approximately 25% of patients develop a rise in serum creatinine and a reduction of urine output after the first several doses of intravenous diuretics",
            "probability": 0.0
        },
        {
            "start_logit": -8.59375,
            "end_logit": 13.65625,
            "text": "type 1 most commonly occurs in the setting of acutely decompensated heart failure",
            "probability": 0.0
        },
        {
            "start_logit": 14.5390625,
            "end_logit": -9.734375,
            "text": "heart failure where",
            "probability": 0.0
        },
        {
            "start_logit": 14.5390625,
            "end_logit": -9.84375,
            "text": "heart failure where approximately 25% of patients develop a rise in serum creatinine and a reduction of urine output",
            "probability": 0.0
        },
        {
            "start_logit": -9.9453125,
            "end_logit": 13.65625,
            "text": "1 most commonly occurs in the setting of acutely decompensated heart failure",
            "probability": 0.0
        },
        {
            "start_logit": -7.84765625,
            "end_logit": -0.7841796875,
            "text": "CRS type 1",
            "probability": 0.0
        },
        {
            "start_logit": -8.59375,
            "end_logit": -0.7841796875,
            "text": "type 1",
            "probability": 0.0
        },
        {
            "start_logit": -7.84765625,
            "end_logit": -2.3671875,
            "text": "CRS type 1 most commonly occurs in the setting of acutely decompensated heart",
            "probability": 0.0
        },
        {
            "start_logit": -9.9453125,
            "end_logit": -0.7841796875,
            "text": "Cardiorenal syndromes (CRS) have been recently classified into five distinct entities, each with different major pathophysiologic mechanisms. CRS type 1",
            "probability": 0.0
        },
        {
            "start_logit": -9.9453125,
            "end_logit": -0.7841796875,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": -8.59375,
            "end_logit": -2.3671875,
            "text": "type 1 most commonly occurs in the setting of acutely decompensated heart",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": -0.7841796875,
            "text": "syndromes (CRS) have been recently classified into five distinct entities, each with different major pathophysiologic mechanisms. CRS type 1",
            "probability": 0.0
        },
        {
            "start_logit": -9.9453125,
            "end_logit": -2.3671875,
            "text": "1 most commonly occurs in the setting of acutely decompensated heart",
            "probability": 0.0
        },
        {
            "start_logit": -4.1875,
            "end_logit": -9.3828125,
            "text": "failure where approximately 25% of patients develop a rise in serum creatinine and a reduction of urine output after the first several doses of intravenous diuretics",
            "probability": 0.0
        },
        {
            "start_logit": -4.1875,
            "end_logit": -9.734375,
            "text": "failure where",
            "probability": 0.0
        },
        {
            "start_logit": -4.1875,
            "end_logit": -9.84375,
            "text": "failure where approximately 25% of patients develop a rise in serum creatinine and a reduction of urine output",
            "probability": 0.0
        }
    ],
    "58da5dc58acda34529000016_3": [
        {
            "start_logit": 14.6953125,
            "end_logit": 14.34375,
            "text": "heart failure",
            "probability": 1.0
        },
        {
            "start_logit": 14.6953125,
            "end_logit": -2.150390625,
            "text": "heart",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.1640625,
            "end_logit": 14.34375,
            "text": "failure",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 14.34375,
            "text": "CKD) in the setting of chronic heart failure",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 14.34375,
            "text": "chronic kidney disease (CKD) in the setting of chronic heart failure",
            "probability": 0.0
        },
        {
            "start_logit": -9.4296875,
            "end_logit": 14.34375,
            "text": "kidney disease (CKD) in the setting of chronic heart failure",
            "probability": 0.0
        },
        {
            "start_logit": -9.453125,
            "end_logit": 14.34375,
            "text": "CRS type 2 is the hastened progression of chronic kidney disease (CKD) in the setting of chronic heart failure",
            "probability": 0.0
        },
        {
            "start_logit": 14.6953125,
            "end_logit": -9.8984375,
            "text": "heart failure.",
            "probability": 0.0
        },
        {
            "start_logit": -9.9921875,
            "end_logit": 14.34375,
            "text": "type 2 is the hastened progression of chronic kidney disease (CKD) in the setting of chronic heart failure",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 14.34375,
            "text": "hastened progression of chronic kidney disease (CKD) in the setting of chronic heart failure",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 14.34375,
            "text": "tened progression of chronic kidney disease (CKD) in the setting of chronic heart failure",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": 14.34375,
            "text": "of chronic kidney disease (CKD) in the setting of chronic heart failure",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -2.150390625,
            "text": "CKD) in the setting of chronic heart",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": -2.150390625,
            "text": "chronic kidney disease (CKD) in the setting of chronic heart",
            "probability": 0.0
        },
        {
            "start_logit": -9.4296875,
            "end_logit": -2.150390625,
            "text": "kidney disease (CKD) in the setting of chronic heart",
            "probability": 0.0
        },
        {
            "start_logit": -9.453125,
            "end_logit": -2.150390625,
            "text": "CRS type 2 is the hastened progression of chronic kidney disease (CKD) in the setting of chronic heart",
            "probability": 0.0
        },
        {
            "start_logit": -9.9921875,
            "end_logit": -2.150390625,
            "text": "type 2 is the hastened progression of chronic kidney disease (CKD) in the setting of chronic heart",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": -2.150390625,
            "text": "hastened progression of chronic kidney disease (CKD) in the setting of chronic heart",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": -2.150390625,
            "text": "tened progression of chronic kidney disease (CKD) in the setting of chronic heart",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": -2.150390625,
            "text": "of chronic kidney disease (CKD) in the setting of chronic heart",
            "probability": 0.0
        }
    ],
    "58da5dc58acda34529000016_4": [
        {
            "start_logit": 14.4765625,
            "end_logit": 14.2265625,
            "text": "heart failure",
            "probability": 1.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -2.70703125,
            "text": "heart",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.30859375,
            "end_logit": 14.2265625,
            "text": "failure",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -7.37890625,
            "text": "heart failure after acute kidney injury",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -8.453125,
            "text": "heart failure after acute kidney injury from inflammatory, toxic, or ischemic insults",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 14.2265625,
            "text": "3 is acutely decompensated heart failure",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -8.703125,
            "text": "heart failure after acute kidney injury from inflammatory, toxic, or ischemic",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -9.3828125,
            "text": "heart failure after",
            "probability": 0.0
        },
        {
            "start_logit": -9.1328125,
            "end_logit": 14.2265625,
            "text": "CRS type 3 is acutely decompensated heart failure",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -9.625,
            "text": "heart failure after acute kidney",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -9.6875,
            "text": "heart failure after acute kidney injury from inflammatory, toxic, or ischemic insults.",
            "probability": 0.0
        },
        {
            "start_logit": -9.578125,
            "end_logit": 14.2265625,
            "text": "type 3 is acutely decompensated heart failure",
            "probability": 0.0
        },
        {
            "start_logit": -9.6953125,
            "end_logit": 14.2265625,
            "text": "acutely decompensated heart failure",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -9.9921875,
            "text": "heart failure after acute kidney injury from inflammatory, toxic, or",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -10.0625,
            "text": "heart failure after acute kidney injury from inflammatory, toxic",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 14.2265625,
            "text": "decompensated heart failure",
            "probability": 0.0
        },
        {
            "start_logit": -3.30859375,
            "end_logit": -7.37890625,
            "text": "failure after acute kidney injury",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": -2.70703125,
            "text": "3 is acutely decompensated heart",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": -2.734375,
            "text": "3",
            "probability": 0.0
        },
        {
            "start_logit": -3.30859375,
            "end_logit": -8.453125,
            "text": "failure after acute kidney injury from inflammatory, toxic, or ischemic insults",
            "probability": 0.0
        }
    ],
    "58da5dc58acda34529000016_5": [
        {
            "start_logit": 14.4921875,
            "end_logit": 13.3359375,
            "text": "heart failure",
            "probability": 1.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -2.431640625,
            "text": "heart",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -3.501953125,
            "text": "heart failure in the setting of CKD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.59375,
            "end_logit": 13.3359375,
            "text": "failure",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -9.0078125,
            "text": "heart failure in the setting of CKD. Cardiac myocyte dysfunction and fibrosis, so-called 'CKD",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": 13.3359375,
            "text": "type 4 is manifested by the acceleration of the progression of chronic heart failure",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -9.1640625,
            "text": "heart failure in the setting of CKD. Cardiac myocyte dysfunction and fibrosis, so-called 'CKD cardiomyopathy'",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -9.3671875,
            "text": "heart failure in the setting of CKD. Cardiac myocyte dysfunction and fibrosis, so-called 'CKD cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -9.71875,
            "text": "heart failure in the setting of CKD. Cardiac myocyte dysfunction and fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.796875,
            "end_logit": 13.3359375,
            "text": "CRS type 4 is manifested by the acceleration of the progression of chronic heart failure",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": 13.3359375,
            "text": "4 is manifested by the acceleration of the progression of chronic heart failure",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": 0.1820068359375,
            "text": "type 4",
            "probability": 0.0
        },
        {
            "start_logit": -4.59375,
            "end_logit": -3.501953125,
            "text": "failure in the setting of CKD",
            "probability": 0.0
        },
        {
            "start_logit": -8.796875,
            "end_logit": 0.1820068359375,
            "text": "CRS type 4",
            "probability": 0.0
        },
        {
            "start_logit": -6.1171875,
            "end_logit": -3.501953125,
            "text": "CKD",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": 0.1820068359375,
            "text": "4",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": -2.431640625,
            "text": "type 4 is manifested by the acceleration of the progression of chronic heart",
            "probability": 0.0
        },
        {
            "start_logit": -8.796875,
            "end_logit": -2.431640625,
            "text": "CRS type 4 is manifested by the acceleration of the progression of chronic heart",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": -3.501953125,
            "text": "type 4 is manifested by the acceleration of the progression of chronic heart failure in the setting of CKD",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": -2.431640625,
            "text": "4 is manifested by the acceleration of the progression of chronic heart",
            "probability": 0.0
        }
    ],
    "58da5dc58acda34529000016_6": [
        {
            "start_logit": 9.9375,
            "end_logit": 10.8984375,
            "text": "type 1",
            "probability": 1.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -3.515625,
            "text": "type 1 (acute cardiorenal syndrome) and type 3",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -5.3515625,
            "end_logit": 10.8984375,
            "text": "1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.9375,
            "end_logit": -5.1875,
            "text": "type 1 (acute cardiorenal syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.9375,
            "end_logit": -6.21875,
            "text": "type 1 (acute cardiorenal syndrome)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9375,
            "end_logit": -6.43359375,
            "text": "type 1 (acute cardiorenal syndrome) and type 3 (acute renocardiac syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 10.8984375,
            "text": "CRS type 1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -7.03125,
            "text": "type 1 (acute cardiorenal syndrome) and type 3 (acute renocardiac",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -7.47265625,
            "text": "type",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.28125,
            "text": "type 1 (",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.6484375,
            "text": "type 1 (acute cardiorenal",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -9.2421875,
            "text": "type 1 (acute cardiorenal syndrome) and type 3 (acute renocardiac syndrome).",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -9.28125,
            "text": "type 1 (acute",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -9.46875,
            "text": "type 1 (acute cardiorenal syndrome) and type 3 (",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -9.6484375,
            "text": "type 1 (acute cardiorenal syndrome) and type 3 (acute",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -9.6484375,
            "text": "type 1 (acute cardiorenal syndrome) and type 3 (acute renocardi",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -9.65625,
            "text": "type 1 (acute cardiorenal syndrome) and type 3 (acute ren",
            "probability": 0.0
        },
        {
            "start_logit": -5.3515625,
            "end_logit": -3.515625,
            "text": "1 (acute cardiorenal syndrome) and type 3",
            "probability": 0.0
        },
        {
            "start_logit": -5.3515625,
            "end_logit": -5.1875,
            "text": "1 (acute cardiorenal syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.30078125,
            "end_logit": -3.515625,
            "text": "cardiorenal syndrome) and type 3",
            "probability": 0.0
        }
    ],
    "58da5dc58acda34529000016_7": [
        {
            "start_logit": 6.328125,
            "end_logit": 4.91015625,
            "text": "acute heart failure",
            "probability": 0.94970703125
        },
        {
            "start_logit": 2.8515625,
            "end_logit": 4.91015625,
            "text": "heart failure",
            "probability": 0.02947998046875
        },
        {
            "start_logit": 6.328125,
            "end_logit": 0.98583984375,
            "text": "acute heart failure-acute coronary syndrome",
            "probability": 0.0188140869140625
        },
        {
            "start_logit": -0.89697265625,
            "end_logit": 4.91015625,
            "text": "CRS type 1 = acute worsening of heart function (acute heart failure",
            "probability": 0.0006933212280273438
        },
        {
            "start_logit": 2.8515625,
            "end_logit": 0.98583984375,
            "text": "heart failure-acute coronary syndrome",
            "probability": 0.0005817413330078125
        },
        {
            "start_logit": -0.89697265625,
            "end_logit": 3.173828125,
            "text": "CRS type 1",
            "probability": 0.00012290477752685547
        },
        {
            "start_logit": -0.89697265625,
            "end_logit": 0.98583984375,
            "text": "CRS type 1 = acute worsening of heart function (acute heart failure-acute coronary syndrome",
            "probability": 1.3709068298339844e-05
        },
        {
            "start_logit": 6.328125,
            "end_logit": -7.51171875,
            "text": "acute heart failure-acute coronary",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": 6.328125,
            "end_logit": -7.625,
            "text": "acute",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": -6.42578125,
            "end_logit": 4.91015625,
            "text": "type 1 = acute worsening of heart function (acute heart failure",
            "probability": 2.8014183044433594e-06
        },
        {
            "start_logit": 6.328125,
            "end_logit": -7.8671875,
            "text": "acute heart failure-acute",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": 6.328125,
            "end_logit": -7.87109375,
            "text": "acute heart failure-acute coronary syndrome) leading to kidney injury and/or dysfunction",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": -7.125,
            "end_logit": 4.91015625,
            "text": "acute worsening of heart function (acute heart failure",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 6.328125,
            "end_logit": -8.8359375,
            "text": "acute heart failure-acute coronary syndrome) leading to kidney injury and/or dysfunction; CRS type 2 = chronic abnormalities in heart function (chronic heart failure",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 6.328125,
            "end_logit": -9.1953125,
            "text": "acute heart failure-acute coronary syndrome) leading to kidney injury and/or",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 6.328125,
            "end_logit": -9.453125,
            "text": "acute heart failure-acute coronary syndrome) leading to kidney injury and/or dysfunction; CRS type 2 = chronic abnormalities in heart function (chronic",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.42578125,
            "end_logit": 3.173828125,
            "text": "type 1",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 4.91015625,
            "text": "= acute worsening of heart function (acute heart failure",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -8.8671875,
            "end_logit": 4.91015625,
            "text": "expanded into five subtypes: CRS type 1 = acute worsening of heart function (acute heart failure",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -9.0,
            "end_logit": 4.91015625,
            "text": "(acute heart failure",
            "probability": 2.384185791015625e-07
        }
    ],
    "58da5dc58acda34529000016_8": [
        {
            "start_logit": 6.58984375,
            "end_logit": 8.0703125,
            "text": "CRS type 1",
            "probability": 1.0
        },
        {
            "start_logit": -4.1328125,
            "end_logit": 8.0703125,
            "text": "type 1",
            "probability": 2.2113323211669922e-05
        },
        {
            "start_logit": 6.58984375,
            "end_logit": -3.677734375,
            "text": "CRS type 1 = acute worsening of heart",
            "probability": 7.927417755126953e-06
        },
        {
            "start_logit": 6.58984375,
            "end_logit": -4.0859375,
            "text": "CRS type 1 =",
            "probability": 5.245208740234375e-06
        },
        {
            "start_logit": 6.58984375,
            "end_logit": -4.7890625,
            "text": "CRS type 1 = acute worsening of heart function leading to kidney injury and/or dysfunction",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": 6.58984375,
            "end_logit": -5.68359375,
            "text": "CRS type 1 = acute worsening of heart function leading to kidney injury and/or",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 6.58984375,
            "end_logit": -6.359375,
            "text": "CRS",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -8.3125,
            "end_logit": 8.0703125,
            "text": "1",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -8.453125,
            "end_logit": 8.0703125,
            "text": "expanded into five subtypes reflecting the primacy of organ dysfunction and the time-frame of the syndrome: CRS type 1",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -9.09375,
            "end_logit": 8.0703125,
            "text": "subtypes reflecting the primacy of organ dysfunction and the time-frame of the syndrome: CRS type 1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -9.234375,
            "end_logit": 8.0703125,
            "text": ": CRS type 1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.58984375,
            "end_logit": -7.921875,
            "text": "CRS type 1 = acute worsening of heart function leading to kidney",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.58984375,
            "end_logit": -8.1015625,
            "text": "CRS type 1 = acute worsening of heart function leading to kidney injury",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.58984375,
            "end_logit": -9.515625,
            "text": "CRS type 1 = acute worsening of heart function",
            "probability": 0.0
        },
        {
            "start_logit": 6.58984375,
            "end_logit": -9.578125,
            "text": "CRS type 1 = acute worsening of heart function leading to kidney injury and/or dysfunction; CRS type 2 = chronic",
            "probability": 0.0
        },
        {
            "start_logit": 6.58984375,
            "end_logit": -9.59375,
            "text": "CRS type 1 = acute",
            "probability": 0.0
        },
        {
            "start_logit": 6.58984375,
            "end_logit": -9.6171875,
            "text": "CRS type 1 = acute worsening of heart function leading to kidney injury and",
            "probability": 0.0
        },
        {
            "start_logit": -3.357421875,
            "end_logit": -3.677734375,
            "text": "heart",
            "probability": 0.0
        },
        {
            "start_logit": -4.1328125,
            "end_logit": -3.677734375,
            "text": "type 1 = acute worsening of heart",
            "probability": 0.0
        },
        {
            "start_logit": -3.357421875,
            "end_logit": -4.7890625,
            "text": "heart function leading to kidney injury and/or dysfunction",
            "probability": 0.0
        }
    ],
    "5523e47f7b523f2123000004_1": [
        {
            "start_logit": 13.3515625,
            "end_logit": 13.1796875,
            "text": "dsRed",
            "probability": 1.0
        },
        {
            "start_logit": 13.3515625,
            "end_logit": -4.55078125,
            "text": "ds",
            "probability": 0.0
        },
        {
            "start_logit": -5.28515625,
            "end_logit": 13.1796875,
            "text": "Red",
            "probability": 0.0
        },
        {
            "start_logit": -6.9921875,
            "end_logit": 13.1796875,
            "text": "red fluorescent protein, dsRed",
            "probability": 0.0
        },
        {
            "start_logit": -7.17578125,
            "end_logit": 13.1796875,
            "text": "DsRed1-E5, is a mutant of the red fluorescent protein, dsRed",
            "probability": 0.0
        },
        {
            "start_logit": 13.3515625,
            "end_logit": -9.484375,
            "text": "dsRed, in which fluorescence shifts over time from green to red as the protein",
            "probability": 0.0
        },
        {
            "start_logit": 13.3515625,
            "end_logit": -9.6484375,
            "text": "dsRed, in which fluorescence shifts over time from green to red",
            "probability": 0.0
        },
        {
            "start_logit": 13.3515625,
            "end_logit": -9.75,
            "text": "dsRed, in which fluorescence shifts over time from green to red as the protein mature",
            "probability": 0.0
        },
        {
            "start_logit": 13.3515625,
            "end_logit": -9.859375,
            "text": "dsRed, in which fluorescence shifts over time from green",
            "probability": 0.0
        },
        {
            "start_logit": 13.3515625,
            "end_logit": -9.9140625,
            "text": "dsRed, in which fluorescence shifts over time from green to red as the",
            "probability": 0.0
        },
        {
            "start_logit": -9.7890625,
            "end_logit": 13.1796875,
            "text": "fluorescent protein, dsRed",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 13.1796875,
            "text": "Timer, or DsRed1-E5, is a mutant of the red fluorescent protein, dsRed",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": 13.1796875,
            "text": "Fluorescent Timer, or DsRed1-E5, is a mutant of the red fluorescent protein, dsRed",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 13.1796875,
            "text": "E5, is a mutant of the red fluorescent protein, dsRed",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 13.1796875,
            "text": "protein, dsRed",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 13.1796875,
            "text": "or DsRed1-E5, is a mutant of the red fluorescent protein, dsRed",
            "probability": 0.0
        },
        {
            "start_logit": -6.9921875,
            "end_logit": -3.4765625,
            "text": "red fluorescent protein",
            "probability": 0.0
        },
        {
            "start_logit": -7.17578125,
            "end_logit": -3.4765625,
            "text": "DsRed1-E5, is a mutant of the red fluorescent protein",
            "probability": 0.0
        },
        {
            "start_logit": -6.9921875,
            "end_logit": -4.55078125,
            "text": "red fluorescent protein, ds",
            "probability": 0.0
        },
        {
            "start_logit": -7.17578125,
            "end_logit": -4.55078125,
            "text": "DsRed1-E5, is a mutant of the red fluorescent protein, ds",
            "probability": 0.0
        }
    ],
    "5523e47f7b523f2123000004_2": [
        {
            "start_logit": 8.4375,
            "end_logit": 10.8046875,
            "text": "green fluorescent protein",
            "probability": 0.93017578125
        },
        {
            "start_logit": 8.4375,
            "end_logit": 8.2265625,
            "text": "green fluorescent protein (Gfp",
            "probability": 0.06951904296875
        },
        {
            "start_logit": 0.434326171875,
            "end_logit": 8.2265625,
            "text": "Gfp",
            "probability": 2.3484230041503906e-05
        },
        {
            "start_logit": 8.4375,
            "end_logit": -5.125,
            "text": "green fluorescent protein (Gfp)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 10.8046875,
            "text": "protein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.5546875,
            "end_logit": 10.8046875,
            "text": "fluorescent protein",
            "probability": 0.0
        },
        {
            "start_logit": 8.4375,
            "end_logit": -7.45703125,
            "text": "green fluorescent protein (",
            "probability": 0.0
        },
        {
            "start_logit": 8.4375,
            "end_logit": -7.53125,
            "text": "green",
            "probability": 0.0
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 8.2265625,
            "text": "protein (Gfp",
            "probability": 0.0
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.40625,
            "text": "green fluorescent",
            "probability": 0.0
        },
        {
            "start_logit": -9.5546875,
            "end_logit": 8.2265625,
            "text": "fluorescent protein (Gfp",
            "probability": 0.0
        },
        {
            "start_logit": 0.434326171875,
            "end_logit": -5.125,
            "text": "Gfp)",
            "probability": 0.0
        },
        {
            "start_logit": -7.5546875,
            "end_logit": -5.125,
            "text": "protein (Gfp)",
            "probability": 0.0
        },
        {
            "start_logit": -9.5546875,
            "end_logit": -5.125,
            "text": "fluorescent protein (Gfp)",
            "probability": 0.0
        },
        {
            "start_logit": -7.5546875,
            "end_logit": -7.45703125,
            "text": "protein (",
            "probability": 0.0
        },
        {
            "start_logit": -9.5546875,
            "end_logit": -7.45703125,
            "text": "fluorescent protein (",
            "probability": 0.0
        },
        {
            "start_logit": -9.5546875,
            "end_logit": -8.40625,
            "text": "fluorescent",
            "probability": 0.0
        }
    ],
    "5523e47f7b523f2123000004_3": [
        {
            "start_logit": 13.4921875,
            "end_logit": 13.46875,
            "text": "mCherry",
            "probability": 1.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -4.44921875,
            "text": "mCh",
            "probability": 0.0
        },
        {
            "start_logit": -4.9375,
            "end_logit": 13.46875,
            "text": "erry",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -8.3515625,
            "text": "mCherry was employed as a reporter protein",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -9.5625,
            "text": "mCherry was employed as a",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -10.0234375,
            "text": "mCherry was",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -10.1953125,
            "text": "mCherry was employed",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -10.25,
            "text": "mCherry was employed as",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -10.3125,
            "text": "mCherry was employed as a reporter",
            "probability": 0.0
        },
        {
            "start_logit": -4.9375,
            "end_logit": -8.3515625,
            "text": "erry was employed as a reporter protein",
            "probability": 0.0
        },
        {
            "start_logit": -4.9375,
            "end_logit": -9.5625,
            "text": "erry was employed as a",
            "probability": 0.0
        },
        {
            "start_logit": -4.9375,
            "end_logit": -10.0234375,
            "text": "erry was",
            "probability": 0.0
        },
        {
            "start_logit": -4.9375,
            "end_logit": -10.1953125,
            "text": "erry was employed",
            "probability": 0.0
        },
        {
            "start_logit": -4.9375,
            "end_logit": -10.25,
            "text": "erry was employed as",
            "probability": 0.0
        },
        {
            "start_logit": -4.9375,
            "end_logit": -10.3125,
            "text": "erry was employed as a reporter",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": -8.3515625,
            "text": "reporter protein",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": -10.3125,
            "text": "reporter",
            "probability": 0.0
        }
    ],
    "5523e47f7b523f2123000004_4": [
        {
            "start_logit": 11.7265625,
            "end_logit": 11.4765625,
            "text": "yellow fluorescent protein",
            "probability": 1.0
        },
        {
            "start_logit": 11.7265625,
            "end_logit": -5.3203125,
            "text": "yellow",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.66796875,
            "end_logit": 11.4765625,
            "text": "protein",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 11.4765625,
            "text": "fluorescent protein",
            "probability": 0.0
        },
        {
            "start_logit": 11.7265625,
            "end_logit": -8.84375,
            "text": "yellow fluorescent",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -8.84375,
            "text": "fluorescent",
            "probability": 0.0
        }
    ],
    "5523e47f7b523f2123000004_5": [
        {
            "start_logit": 10.3671875,
            "end_logit": 0.515625,
            "text": "green fluorescent reporter protein",
            "probability": 0.666015625
        },
        {
            "start_logit": 10.3671875,
            "end_logit": -0.22900390625,
            "text": "green",
            "probability": 0.31689453125
        },
        {
            "start_logit": 10.3671875,
            "end_logit": -3.138671875,
            "text": "green fluorescent",
            "probability": 0.0171966552734375
        },
        {
            "start_logit": 10.3671875,
            "end_logit": -9.484375,
            "text": "green fluorescent reporter",
            "probability": 3.0219554901123047e-05
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 0.515625,
            "text": "enhanced green fluorescent reporter protein",
            "probability": 0.0
        },
        {
            "start_logit": -7.60546875,
            "end_logit": -0.22900390625,
            "text": "enhanced green",
            "probability": 0.0
        },
        {
            "start_logit": -9.578125,
            "end_logit": 0.515625,
            "text": "reporter protein",
            "probability": 0.0
        },
        {
            "start_logit": -7.60546875,
            "end_logit": -3.138671875,
            "text": "enhanced green fluorescent",
            "probability": 0.0
        },
        {
            "start_logit": -7.60546875,
            "end_logit": -9.484375,
            "text": "enhanced green fluorescent reporter",
            "probability": 0.0
        },
        {
            "start_logit": -7.60546875,
            "end_logit": -10.1875,
            "text": "enhanced",
            "probability": 0.0
        },
        {
            "start_logit": -9.578125,
            "end_logit": -9.484375,
            "text": "reporter",
            "probability": 0.0
        }
    ],
    "5523e47f7b523f2123000004_6": [
        {
            "start_logit": 13.875,
            "end_logit": 14.578125,
            "text": "green fluorescent protein",
            "probability": 1.0
        },
        {
            "start_logit": 13.875,
            "end_logit": 2.46484375,
            "text": "green fluorescent protein (GFP",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": 13.875,
            "end_logit": -1.8828125,
            "text": "green fluorescent protein (GFP) and DsRed2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.85546875,
            "end_logit": 14.578125,
            "text": "protein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.875,
            "end_logit": -3.78515625,
            "text": "green",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -5.8828125,
            "text": "green fluorescent protein (GFP) and DsRed",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -6.6953125,
            "text": "green fluorescent",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -7.67578125,
            "text": "green fluorescent protein (",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -8.09375,
            "text": "green fluorescent protein (GFP)",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -8.859375,
            "text": "green fluorescent protein (GFP) and Ds",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -8.8984375,
            "text": "green fluorescent protein (GFP) and DsRed2]",
            "probability": 0.0
        },
        {
            "start_logit": -9.75,
            "end_logit": 14.578125,
            "text": "[green fluorescent protein",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": 14.578125,
            "text": "fluorescent protein",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 14.578125,
            "text": "reporter protein [green fluorescent protein",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -9.84375,
            "text": "green fluorescent protein (GFP) and",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 14.578125,
            "text": "fluorescent reporter protein [green fluorescent protein",
            "probability": 0.0
        },
        {
            "start_logit": -1.6201171875,
            "end_logit": 2.46484375,
            "text": "GFP",
            "probability": 0.0
        },
        {
            "start_logit": -2.85546875,
            "end_logit": 2.46484375,
            "text": "protein (GFP",
            "probability": 0.0
        },
        {
            "start_logit": -1.6201171875,
            "end_logit": -1.8828125,
            "text": "GFP) and DsRed2",
            "probability": 0.0
        },
        {
            "start_logit": -2.85546875,
            "end_logit": -1.8828125,
            "text": "protein (GFP) and DsRed2",
            "probability": 0.0
        }
    ],
    "5523e47f7b523f2123000004_7": [
        {
            "start_logit": 10.578125,
            "end_logit": 6.26171875,
            "text": "coral",
            "probability": 0.97705078125
        },
        {
            "start_logit": 10.578125,
            "end_logit": 2.521484375,
            "text": "coral fluorescent reporter protein",
            "probability": 0.0231475830078125
        },
        {
            "start_logit": 10.578125,
            "end_logit": -8.734375,
            "text": "coral fluorescent",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 10.578125,
            "end_logit": -8.9296875,
            "text": "coral fluorescent reporter",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -10.421875,
            "end_logit": 2.521484375,
            "text": "fluorescent reporter protein",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": -8.734375,
            "text": "fluorescent",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": -8.9296875,
            "text": "fluorescent reporter",
            "probability": 0.0
        }
    ],
    "5523e47f7b523f2123000004_8": [
        {
            "start_logit": 10.96875,
            "end_logit": 12.1328125,
            "text": "GFP",
            "probability": 1.0
        },
        {
            "start_logit": 10.96875,
            "end_logit": -7.92578125,
            "text": "GFP as a fluorescent reporter protein",
            "probability": 0.0
        },
        {
            "start_logit": 10.96875,
            "end_logit": -9.6640625,
            "text": "GFP as a",
            "probability": 0.0
        },
        {
            "start_logit": 10.96875,
            "end_logit": -9.953125,
            "text": "GFP as",
            "probability": 0.0
        },
        {
            "start_logit": 10.96875,
            "end_logit": -10.109375,
            "text": "GFP as a fluorescent",
            "probability": 0.0
        },
        {
            "start_logit": 10.96875,
            "end_logit": -10.203125,
            "text": "GFP as a fluorescent reporter",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": -7.92578125,
            "text": "as a fluorescent reporter protein",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": -9.6640625,
            "text": "as a",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": -9.953125,
            "text": "as",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": -10.109375,
            "text": "as a fluorescent",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": -10.203125,
            "text": "as a fluorescent reporter",
            "probability": 0.0
        }
    ],
    "5523e47f7b523f2123000004_9": [
        {
            "start_logit": 12.6640625,
            "end_logit": 12.1953125,
            "text": "eqFP611",
            "probability": 1.0
        },
        {
            "start_logit": 12.6640625,
            "end_logit": -5.625,
            "text": "eq",
            "probability": 0.0
        },
        {
            "start_logit": -7.12890625,
            "end_logit": 12.1953125,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": -7.390625,
            "end_logit": 12.1953125,
            "text": "red fluorescent protein eqFP611",
            "probability": 0.0
        },
        {
            "start_logit": 12.6640625,
            "end_logit": -7.8671875,
            "text": "eqFP61",
            "probability": 0.0
        },
        {
            "start_logit": 12.6640625,
            "end_logit": -8.0859375,
            "text": "eqFP",
            "probability": 0.0
        },
        {
            "start_logit": -9.3046875,
            "end_logit": 12.1953125,
            "text": "611",
            "probability": 0.0
        },
        {
            "start_logit": -9.6953125,
            "end_logit": 12.1953125,
            "text": "FP611",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": 12.1953125,
            "text": "fluorescent protein eqFP611",
            "probability": 0.0
        },
        {
            "start_logit": -7.390625,
            "end_logit": -4.453125,
            "text": "red fluorescent protein",
            "probability": 0.0
        },
        {
            "start_logit": -7.390625,
            "end_logit": -5.625,
            "text": "red fluorescent protein eq",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": -4.453125,
            "text": "fluorescent protein",
            "probability": 0.0
        },
        {
            "start_logit": -7.390625,
            "end_logit": -7.53125,
            "text": "red",
            "probability": 0.0
        },
        {
            "start_logit": -7.390625,
            "end_logit": -7.7734375,
            "text": "red fluorescent",
            "probability": 0.0
        },
        {
            "start_logit": -7.390625,
            "end_logit": -7.8671875,
            "text": "red fluorescent protein eqFP61",
            "probability": 0.0
        },
        {
            "start_logit": -7.390625,
            "end_logit": -8.0859375,
            "text": "red fluorescent protein eqFP",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": -5.625,
            "text": "fluorescent protein eq",
            "probability": 0.0
        },
        {
            "start_logit": -9.3046875,
            "end_logit": -7.8671875,
            "text": "61",
            "probability": 0.0
        },
        {
            "start_logit": -9.6953125,
            "end_logit": -7.8671875,
            "text": "FP61",
            "probability": 0.0
        },
        {
            "start_logit": -9.6953125,
            "end_logit": -8.0859375,
            "text": "FP",
            "probability": 0.0
        }
    ],
    "5523e47f7b523f2123000004_10": [
        {
            "start_logit": 13.9453125,
            "end_logit": 12.6015625,
            "text": "beta-phycoerythrin",
            "probability": 1.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -3.25,
            "text": "beta",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -5.51953125,
            "text": "beta-phycoerythrin, a fluorescent reporter protein derived from algae",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -5.83203125,
            "text": "beta-phycoerythr",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -6.01171875,
            "text": "beta-phycoe",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -6.91796875,
            "text": "beta-",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -6.98046875,
            "text": "beta-phyc",
            "probability": 0.0
        },
        {
            "start_logit": -5.734375,
            "end_logit": 12.6015625,
            "text": "in",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -7.6015625,
            "text": "beta-ph",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -7.62109375,
            "text": "beta-phycoery",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -7.83203125,
            "text": "beta-phycoerythrin, a fluorescent reporter protein derived from",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -8.7578125,
            "text": "beta-phycoerythrin, a",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -9.1171875,
            "text": "beta-phycoerythrin, a fluorescent reporter protein",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -9.5703125,
            "text": "beta-phycoerythrin,",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -9.78125,
            "text": "beta-phycoerythrin, a fluorescent reporter protein derived",
            "probability": 0.0
        },
        {
            "start_logit": -8.515625,
            "end_logit": 12.6015625,
            "text": "thrin",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -9.8984375,
            "text": "beta-phycoerythrin, a fluorescent",
            "probability": 0.0
        },
        {
            "start_logit": -9.4375,
            "end_logit": 12.6015625,
            "text": "rythrin",
            "probability": 0.0
        },
        {
            "start_logit": -9.671875,
            "end_logit": 12.6015625,
            "text": "phycoerythrin",
            "probability": 0.0
        },
        {
            "start_logit": -9.703125,
            "end_logit": 12.6015625,
            "text": "ycoerythrin",
            "probability": 0.0
        }
    ],
    "5523e47f7b523f2123000004_11": [
        {
            "start_logit": 12.3984375,
            "end_logit": 13.328125,
            "text": "Timer",
            "probability": 1.0
        },
        {
            "start_logit": -5.41796875,
            "end_logit": 13.328125,
            "text": "r",
            "probability": 0.0
        },
        {
            "start_logit": 12.3984375,
            "end_logit": -5.83203125,
            "text": "Time",
            "probability": 0.0
        },
        {
            "start_logit": -9.546875,
            "end_logit": 13.328125,
            "text": "live-cell fluorescent reporter protein, Timer",
            "probability": 0.0
        },
        {
            "start_logit": -9.546875,
            "end_logit": -5.83203125,
            "text": "live-cell fluorescent reporter protein, Time",
            "probability": 0.0
        },
        {
            "start_logit": -9.546875,
            "end_logit": -8.96875,
            "text": "live-cell",
            "probability": 0.0
        },
        {
            "start_logit": -9.546875,
            "end_logit": -9.1875,
            "text": "live-cell fluorescent reporter protein",
            "probability": 0.0
        },
        {
            "start_logit": -9.546875,
            "end_logit": -9.4765625,
            "text": "live-cell fluorescent reporter protein,",
            "probability": 0.0
        },
        {
            "start_logit": -9.546875,
            "end_logit": -9.5546875,
            "text": "live-cell fluorescent",
            "probability": 0.0
        },
        {
            "start_logit": -9.546875,
            "end_logit": -10.1640625,
            "text": "live",
            "probability": 0.0
        },
        {
            "start_logit": -9.546875,
            "end_logit": -10.21875,
            "text": "live-",
            "probability": 0.0
        },
        {
            "start_logit": -9.546875,
            "end_logit": -10.4140625,
            "text": "live-cell fluorescent reporter",
            "probability": 0.0
        }
    ],
    "602823e61cb411341a0000f9_1": [
        {
            "start_logit": 11.796875,
            "end_logit": 10.859375,
            "text": "irinotecan",
            "probability": 1.0
        },
        {
            "start_logit": 11.796875,
            "end_logit": -0.59912109375,
            "text": "irinotecan and oxaliplatin",
            "probability": 1.055002212524414e-05
        },
        {
            "start_logit": -9.140625,
            "end_logit": 10.859375,
            "text": "bevacizumab (FOLFOX/Bev) than those with high TS (TS-H) expression and that combined irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": 10.859375,
            "text": "with high TS (TS-H) expression and that combined irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": -9.7890625,
            "end_logit": 10.859375,
            "text": "combined irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 10.859375,
            "text": "H) expression and that combined irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": 0.33154296875,
            "end_logit": -0.59912109375,
            "text": "oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -1.404296875,
            "end_logit": -0.90478515625,
            "text": "oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -1.404296875,
            "end_logit": -6.7421875,
            "text": "oxaliplatin (FOLFOX) plus bevacizumab",
            "probability": 0.0
        },
        {
            "start_logit": -9.140625,
            "end_logit": -0.59912109375,
            "text": "bevacizumab (FOLFOX/Bev) than those with high TS (TS-H) expression and that combined irinotecan and oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -9.421875,
            "end_logit": -0.90478515625,
            "text": "leucovorin, and oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": -0.59912109375,
            "text": "with high TS (TS-H) expression and that combined irinotecan and oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -9.7890625,
            "end_logit": -0.59912109375,
            "text": "combined irinotecan and oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": -0.90478515625,
            "text": "5-fluorouracil, leucovorin, and oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -1.404296875,
            "end_logit": -9.078125,
            "text": "oxaliplatin (FOLFOX) plus bevacizumab (FOLFOX/Bev) than those with high TS (TS-H",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": -0.59912109375,
            "text": "H) expression and that combined irinotecan and oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": -0.90478515625,
            "text": "fluorouracil, leucovorin, and oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -1.404296875,
            "end_logit": -9.5,
            "text": "oxaliplatin (FOLFOX",
            "probability": 0.0
        },
        {
            "start_logit": -10.0,
            "end_logit": -0.90478515625,
            "text": "L) expression would have a higher response rate to combined 5-fluorouracil, leucovorin, and oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": -0.90478515625,
            "text": "low thymidylate synthase (TS-L) expression would have a higher response rate to combined 5-fluorouracil, leucovorin, and oxaliplatin",
            "probability": 0.0
        }
    ],
    "602823e61cb411341a0000f9_2": [
        {
            "start_logit": 7.40625,
            "end_logit": 8.8046875,
            "text": "capecitabine",
            "probability": 1.0
        },
        {
            "start_logit": 2.671875,
            "end_logit": -0.0148773193359375,
            "text": "irinotecan",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -8.5078125,
            "end_logit": 8.8046875,
            "text": "and capecitabine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 2.671875,
            "end_logit": -8.8359375,
            "text": "irinotecan + oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -4.22265625,
            "end_logit": -2.947265625,
            "text": "oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -5.62890625,
            "end_logit": -1.755859375,
            "text": "gemcitabine",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -0.0148773193359375,
            "text": ", irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": -6.05859375,
            "end_logit": -2.947265625,
            "text": "folinic acid + 5-fluorouracil + oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -6.05859375,
            "end_logit": -3.134765625,
            "text": "folinic acid + 5-fluorouracil",
            "probability": 0.0
        },
        {
            "start_logit": -9.8515625,
            "end_logit": -0.0148773193359375,
            "text": "fluorouracil (FF), irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": -9.859375,
            "end_logit": -0.0148773193359375,
            "text": "folinic acid + 5-fluorouracil + trimetrexate (FFT), folinic acid + 5-fluorouracil (FF), irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": -9.890625,
            "end_logit": -0.0148773193359375,
            "text": "FF), irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": -9.609375,
            "end_logit": -1.755859375,
            "text": "X), folinic acid + 5-fluorouracil + irinotecan (FOLFIRI), folinic acid + 5-fluorouracil + gemcitabine",
            "probability": 0.0
        },
        {
            "start_logit": -9.8671875,
            "end_logit": -1.755859375,
            "text": "irinotecan (FOLFIRI), folinic acid + 5-fluorouracil + gemcitabine",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": -2.947265625,
            "text": "5-fluorouracil + oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": -3.134765625,
            "text": "5-fluorouracil",
            "probability": 0.0
        },
        {
            "start_logit": -4.22265625,
            "end_logit": -8.453125,
            "text": "oxaliplatin (FOLFOX",
            "probability": 0.0
        },
        {
            "start_logit": -9.8515625,
            "end_logit": -2.947265625,
            "text": "+ oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -6.05859375,
            "end_logit": -6.984375,
            "text": "folinic acid",
            "probability": 0.0
        },
        {
            "start_logit": -5.62890625,
            "end_logit": -7.78515625,
            "text": "gemcitabine (FFG), folinic acid + 5-fluorouracil + trimetrexate",
            "probability": 0.0
        }
    ],
    "602823e61cb411341a0000f9_3": [
        {
            "start_logit": 11.25,
            "end_logit": 10.1328125,
            "text": "irinotecan",
            "probability": 0.62158203125
        },
        {
            "start_logit": 9.7421875,
            "end_logit": 10.6796875,
            "text": "fluorouracil",
            "probability": 0.2396240234375
        },
        {
            "start_logit": 9.7421875,
            "end_logit": 10.1328125,
            "text": "fluorouracil [FU] + irinotecan",
            "probability": 0.1387939453125
        },
        {
            "start_logit": 11.25,
            "end_logit": -7.640625,
            "text": "irinotecan [IRN]), FOLFOX (FU + oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -8.5078125,
            "text": "irinotecan [IRN",
            "probability": 0.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -8.6015625,
            "text": "irinotecan [IR",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -7.640625,
            "text": "fluorouracil [FU] + irinotecan [IRN]), FOLFOX (FU + oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -9.3828125,
            "text": "irinotecan [",
            "probability": 0.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -9.484375,
            "text": "irinotecan [IRN]), FOLFOX (FU + oxaliplatin), and IROX (IRN + oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -9.609375,
            "text": "irinotecan [IRN]), FOLFOX (FU",
            "probability": 0.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -9.6640625,
            "text": "irinotecan [IRN]), FOLFOX",
            "probability": 0.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -9.7109375,
            "text": "irinotecan [IRN])",
            "probability": 0.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -9.78125,
            "text": "irinotecan [IRN]), FOLFOX (FU + oxaliplatin), and IROX (IRN",
            "probability": 0.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -9.8671875,
            "text": "irinotecan [IRN]",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -8.5078125,
            "text": "fluorouracil [FU] + irinotecan [IRN",
            "probability": 0.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -10.0390625,
            "text": "irinotecan [IRN]), FOL",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -8.6015625,
            "text": "fluorouracil [FU] + irinotecan [IR",
            "probability": 0.0
        },
        {
            "start_logit": 9.7421875,
            "end_logit": -8.6796875,
            "text": "fluorouracil [FU",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": 10.6796875,
            "text": "IFL (fluorouracil",
            "probability": 0.0
        },
        {
            "start_logit": -9.375,
            "end_logit": 10.1328125,
            "text": "FU] + irinotecan",
            "probability": 0.0
        }
    ],
    "602823e61cb411341a0000f9_4": [
        {
            "start_logit": 9.5,
            "end_logit": 11.203125,
            "text": "capecitabine",
            "probability": 0.9990234375
        },
        {
            "start_logit": 2.96875,
            "end_logit": 11.203125,
            "text": "gemcitabine/capecitabine",
            "probability": 0.0014562606811523438
        },
        {
            "start_logit": 2.96875,
            "end_logit": 5.44921875,
            "text": "gemcitabine",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": 9.5,
            "end_logit": -4.94140625,
            "text": "capecitabine and developed HFS",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.83984375,
            "end_logit": 11.203125,
            "text": "oxaliplatin) and irinotecan/cetuximab regimens. He was started on gemcitabine/capecitabine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5,
            "end_logit": 11.203125,
            "text": "irinotecan/oxaliplatin) and irinotecan/cetuximab regimens. He was started on gemcitabine/capecitabine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.328125,
            "end_logit": 11.203125,
            "text": "cetuximab regimens. He was started on gemcitabine/capecitabine",
            "probability": 0.0
        },
        {
            "start_logit": 9.5,
            "end_logit": -8.0859375,
            "text": "capecitabine and developed HFS again, which was controlled with aggressive skin care and vitamin B6",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 11.203125,
            "text": "started on gemcitabine/capecitabine",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 11.203125,
            "text": "irinotecan/cetuximab regimens. He was started on gemcitabine/capecitabine",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 11.203125,
            "text": "IROX (irinotecan/oxaliplatin) and irinotecan/cetuximab regimens. He was started on gemcitabine/capecitabine",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 11.203125,
            "text": "/capecitabine",
            "probability": 0.0
        },
        {
            "start_logit": 9.5,
            "end_logit": -8.921875,
            "text": "capecitabine and developed HFS again, which was controlled with aggressive skin care and vitamin B6 treatment",
            "probability": 0.0
        },
        {
            "start_logit": 9.5,
            "end_logit": -9.0234375,
            "text": "capecitabine and developed HFS again, which was controlled with aggressive skin",
            "probability": 0.0
        },
        {
            "start_logit": 9.5,
            "end_logit": -9.2421875,
            "text": "capecitabine and developed HFS again, which was controlled with aggressive skin care and",
            "probability": 0.0
        },
        {
            "start_logit": 9.5,
            "end_logit": -9.59375,
            "text": "capecitabine and developed HFS again, which was controlled with aggressive skin care",
            "probability": 0.0
        },
        {
            "start_logit": 9.5,
            "end_logit": -9.6953125,
            "text": "capecitabine and",
            "probability": 0.0
        },
        {
            "start_logit": 9.5,
            "end_logit": -9.75,
            "text": "capecitabine and developed HFS again,",
            "probability": 0.0
        },
        {
            "start_logit": 9.5,
            "end_logit": -9.765625,
            "text": "capecitabine and developed HFS again, which was controlled",
            "probability": 0.0
        },
        {
            "start_logit": -6.83984375,
            "end_logit": 5.44921875,
            "text": "oxaliplatin) and irinotecan/cetuximab regimens. He was started on gemcitabine",
            "probability": 0.0
        }
    ],
    "602823e61cb411341a0000f9_5": [
        {
            "start_logit": 11.5078125,
            "end_logit": 11.765625,
            "text": "irinotecan",
            "probability": 1.0
        },
        {
            "start_logit": 11.5078125,
            "end_logit": -3.751953125,
            "text": "irinotecan plus oxaliplatin",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.5078125,
            "end_logit": -7.95703125,
            "text": "irinotecan plus oxaliplatin (IROX) is more efficacious than irinotecan alone after fluoropyrimidine",
            "probability": 0.0
        },
        {
            "start_logit": -8.84375,
            "end_logit": 11.765625,
            "text": "Haller et al. demonstrated that irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": 11.5078125,
            "end_logit": -8.9609375,
            "text": "irinotecan plus oxaliplatin (IROX) is more efficacious than irinotecan alone after fluoropyrimidine failure",
            "probability": 0.0
        },
        {
            "start_logit": 11.5078125,
            "end_logit": -9.15625,
            "text": "irinotecan plus oxaliplatin (IROX) is more efficacious than irinotecan alone",
            "probability": 0.0
        },
        {
            "start_logit": 11.5078125,
            "end_logit": -9.2421875,
            "text": "irinotecan plus oxaliplatin (IROX)",
            "probability": 0.0
        },
        {
            "start_logit": 11.5078125,
            "end_logit": -9.3046875,
            "text": "irinotecan plus",
            "probability": 0.0
        },
        {
            "start_logit": 11.5078125,
            "end_logit": -9.40625,
            "text": "irinotecan plus oxaliplatin (IROX) is more efficacious than irinotecan alone after fluoro",
            "probability": 0.0
        },
        {
            "start_logit": 11.5078125,
            "end_logit": -9.78125,
            "text": "irinotecan plus oxaliplatin (IROX) is",
            "probability": 0.0
        },
        {
            "start_logit": 11.5078125,
            "end_logit": -9.9765625,
            "text": "irinotecan plus oxaliplatin (IROX) is more efficacious",
            "probability": 0.0
        },
        {
            "start_logit": 11.5078125,
            "end_logit": -9.9921875,
            "text": "irinotecan plus oxaliplatin (IROX) is more efficacious than irinotecan alone after fluoropyr",
            "probability": 0.0
        },
        {
            "start_logit": 11.5078125,
            "end_logit": -10.0078125,
            "text": "irinotecan plus oxaliplatin (IROX) is more efficacious than irinotecan alone after fluoropyrimidine failure in",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 11.765625,
            "text": "that irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": 11.5078125,
            "end_logit": -10.0390625,
            "text": "irinotecan plus oxaliplatin (IROX",
            "probability": 0.0
        },
        {
            "start_logit": 11.5078125,
            "end_logit": -10.1328125,
            "text": "irinotecan plus oxaliplatin (IROX) is more efficacious than irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": 11.5078125,
            "end_logit": -10.2109375,
            "text": "irinotecan plus oxaliplatin (IROX) is more efficacious than irinotecan alone after fluoropyrimidine failure in advanced colorectal cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -4.07421875,
            "end_logit": -3.751953125,
            "text": "oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -4.07421875,
            "end_logit": -7.95703125,
            "text": "oxaliplatin (IROX) is more efficacious than irinotecan alone after fluoropyrimidine",
            "probability": 0.0
        },
        {
            "start_logit": -8.84375,
            "end_logit": -3.751953125,
            "text": "Haller et al. demonstrated that irinotecan plus oxaliplatin",
            "probability": 0.0
        }
    ],
    "602823e61cb411341a0000f9_6": [
        {
            "start_logit": 11.578125,
            "end_logit": 11.6796875,
            "text": "irinotecan",
            "probability": 1.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -3.142578125,
            "text": "irinotecan plus oxaliplatin",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 11.578125,
            "end_logit": -9.078125,
            "text": "irinotecan plus oxaliplatin (IROX)",
            "probability": 0.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -9.2578125,
            "text": "irinotecan plus",
            "probability": 0.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -9.296875,
            "text": "irinotecan plus oxaliplatin (IROX) is superior to irinotecan alone",
            "probability": 0.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -9.390625,
            "text": "irinotecan plus oxaliplatin (IROX) is superior to irinotecan alone in patients with metastatic colorectal cancer (CRC) previously treated with single-agent fluoropyrimidine",
            "probability": 0.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -9.453125,
            "text": "irinotecan plus oxaliplatin (IROX) is superior to irinotecan alone in patients with metastatic colorectal cancer (CRC) previously treated with single-agent fluoro",
            "probability": 0.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -9.453125,
            "text": "irinotecan plus oxaliplatin (IROX) is superior to irinotecan alone in patients with metastatic colorectal cancer (CRC",
            "probability": 0.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -9.546875,
            "text": "irinotecan plus oxaliplatin (IROX) is superior",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": 11.6796875,
            "text": "whether irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -9.6796875,
            "text": "irinotecan plus oxaliplatin (IROX) is superior to irinotecan alone in patients with metastatic",
            "probability": 0.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -9.7265625,
            "text": "irinotecan plus oxaliplatin (IROX) is",
            "probability": 0.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -9.734375,
            "text": "irinotecan plus oxaliplatin (IROX) is superior to irinotecan alone in",
            "probability": 0.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -9.875,
            "text": "irinotecan plus oxaliplatin (IROX) is superior to irinotecan alone in patients with metastatic colorectal cancer (CRC) previously",
            "probability": 0.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -9.890625,
            "text": "irinotecan plus oxaliplatin (IROX) is superior to irinotecan alone in patients with metastatic colorectal cancer (CRC)",
            "probability": 0.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -9.8984375,
            "text": "irinotecan plus oxaliplatin (IROX) is superior to irinotecan alone in patients with metastatic colorectal cancer (CRC) previously treated",
            "probability": 0.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -9.921875,
            "text": "irinotecan plus oxaliplatin (IROX) is superior to irinotecan alone in patients with metastatic colorectal cancer (",
            "probability": 0.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -10.0234375,
            "text": "irinotecan plus oxaliplatin (IROX) is superior to irinotecan alone in patients with metastatic colorectal cancer (CRC) previously treated with single-agent fluoropyr",
            "probability": 0.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -10.078125,
            "text": "irinotecan plus oxaliplatin (IROX) is superior to irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": 11.6796875,
            "text": "UNLABELLED: PURPOSE To determine whether irinotecan",
            "probability": 0.0
        }
    ],
    "602823e61cb411341a0000f9_7": [
        {
            "start_logit": 7.40625,
            "end_logit": 8.8046875,
            "text": "capecitabine",
            "probability": 1.0
        },
        {
            "start_logit": 2.671875,
            "end_logit": -0.0148773193359375,
            "text": "irinotecan",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -8.5078125,
            "end_logit": 8.8046875,
            "text": "and capecitabine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 2.671875,
            "end_logit": -8.8359375,
            "text": "irinotecan + oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -4.22265625,
            "end_logit": -2.947265625,
            "text": "oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -5.62890625,
            "end_logit": -1.755859375,
            "text": "gemcitabine",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -0.0148773193359375,
            "text": ", irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": -6.05859375,
            "end_logit": -2.947265625,
            "text": "folinic acid + 5-fluorouracil + oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -6.05859375,
            "end_logit": -3.134765625,
            "text": "folinic acid + 5-fluorouracil",
            "probability": 0.0
        },
        {
            "start_logit": -9.8515625,
            "end_logit": -0.0148773193359375,
            "text": "fluorouracil (FF), irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": -9.859375,
            "end_logit": -0.0148773193359375,
            "text": "folinic acid + 5-fluorouracil + trimetrexate (FFT), folinic acid + 5-fluorouracil (FF), irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": -9.890625,
            "end_logit": -0.0148773193359375,
            "text": "FF), irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": -9.609375,
            "end_logit": -1.755859375,
            "text": "X), folinic acid + 5-fluorouracil + irinotecan (FOLFIRI), folinic acid + 5-fluorouracil + gemcitabine",
            "probability": 0.0
        },
        {
            "start_logit": -9.8671875,
            "end_logit": -1.755859375,
            "text": "irinotecan (FOLFIRI), folinic acid + 5-fluorouracil + gemcitabine",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": -2.947265625,
            "text": "5-fluorouracil + oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": -3.134765625,
            "text": "5-fluorouracil",
            "probability": 0.0
        },
        {
            "start_logit": -4.22265625,
            "end_logit": -8.453125,
            "text": "oxaliplatin (FOLFOX",
            "probability": 0.0
        },
        {
            "start_logit": -9.8515625,
            "end_logit": -2.947265625,
            "text": "+ oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -6.05859375,
            "end_logit": -6.984375,
            "text": "folinic acid",
            "probability": 0.0
        },
        {
            "start_logit": -5.62890625,
            "end_logit": -7.78515625,
            "text": "gemcitabine (FFG), folinic acid + 5-fluorouracil + trimetrexate",
            "probability": 0.0
        }
    ],
    "602823e61cb411341a0000f9_8": [
        {
            "start_logit": 11.8828125,
            "end_logit": 11.125,
            "text": "irinotecan",
            "probability": 1.0
        },
        {
            "start_logit": 11.8828125,
            "end_logit": 3.19140625,
            "text": "irinotecan and oxaliplatin",
            "probability": 0.00036263465881347656
        },
        {
            "start_logit": 4.12109375,
            "end_logit": 3.19140625,
            "text": "oxaliplatin",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.8828125,
            "end_logit": -7.234375,
            "text": "irinotecan and oxaliplatin (IROX) : intergroup trial N9741",
            "probability": 0.0
        },
        {
            "start_logit": 11.8828125,
            "end_logit": -7.97265625,
            "text": "irinotecan and oxaliplatin (IROX)",
            "probability": 0.0
        },
        {
            "start_logit": 11.8828125,
            "end_logit": -8.7734375,
            "text": "irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in",
            "probability": 0.0
        },
        {
            "start_logit": 11.8828125,
            "end_logit": -8.921875,
            "text": "irinotecan and",
            "probability": 0.0
        },
        {
            "start_logit": 11.8828125,
            "end_logit": -9.2890625,
            "text": "irinotecan and oxaliplatin (IROX) : intergroup trial N",
            "probability": 0.0
        },
        {
            "start_logit": 11.8828125,
            "end_logit": -9.3515625,
            "text": "irinotecan and oxaliplatin (IROX) : intergroup trial",
            "probability": 0.0
        },
        {
            "start_logit": 11.8828125,
            "end_logit": -9.6484375,
            "text": "irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment",
            "probability": 0.0
        },
        {
            "start_logit": 11.8828125,
            "end_logit": -9.65625,
            "text": "irinotecan and oxaliplatin (",
            "probability": 0.0
        },
        {
            "start_logit": 11.8828125,
            "end_logit": -9.703125,
            "text": "irinotecan and oxaliplatin (IROX) : intergroup trial N97",
            "probability": 0.0
        },
        {
            "start_logit": 11.8828125,
            "end_logit": -9.7109375,
            "text": "irinotecan and oxaliplatin (IROX) :",
            "probability": 0.0
        },
        {
            "start_logit": 11.8828125,
            "end_logit": -9.7890625,
            "text": "irinotecan and oxaliplatin (IROX",
            "probability": 0.0
        },
        {
            "start_logit": 11.8828125,
            "end_logit": -9.9140625,
            "text": "irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer",
            "probability": 0.0
        },
        {
            "start_logit": 11.8828125,
            "end_logit": -9.9921875,
            "text": "irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 11.125,
            "text": "of irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 11.125,
            "text": "efficacy and toxicity analysis of irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": 4.12109375,
            "end_logit": -7.234375,
            "text": "oxaliplatin (IROX) : intergroup trial N9741",
            "probability": 0.0
        },
        {
            "start_logit": 4.12109375,
            "end_logit": -7.97265625,
            "text": "oxaliplatin (IROX)",
            "probability": 0.0
        }
    ],
    "602823e61cb411341a0000f9_9": [
        {
            "start_logit": 11.9375,
            "end_logit": 11.0703125,
            "text": "irinotecan",
            "probability": 1.0
        },
        {
            "start_logit": 11.9375,
            "end_logit": -0.03173828125,
            "text": "irinotecan and oxaliplatin",
            "probability": 1.519918441772461e-05
        },
        {
            "start_logit": 11.9375,
            "end_logit": -6.609375,
            "text": "irinotecan and oxaliplatin (IROX) as a salvage treatment for patients with gemcitabine- and 5-FU- refractory pancreatic",
            "probability": 0.0
        },
        {
            "start_logit": 11.9375,
            "end_logit": -8.1484375,
            "text": "irinotecan and oxaliplatin (IROX) as a salvage treatment for patients with gemcitabine",
            "probability": 0.0
        },
        {
            "start_logit": 11.9375,
            "end_logit": -8.1796875,
            "text": "irinotecan and oxaliplatin (IROX) as",
            "probability": 0.0
        },
        {
            "start_logit": 11.9375,
            "end_logit": -8.2578125,
            "text": "irinotecan and oxaliplatin (IROX) as a salvage treatment for patients with gemcitabine- and 5-FU",
            "probability": 0.0
        },
        {
            "start_logit": 11.9375,
            "end_logit": -8.4296875,
            "text": "irinotecan and oxaliplatin (IROX) as a",
            "probability": 0.0
        },
        {
            "start_logit": 11.9375,
            "end_logit": -8.5625,
            "text": "irinotecan and",
            "probability": 0.0
        },
        {
            "start_logit": 11.9375,
            "end_logit": -8.671875,
            "text": "irinotecan and oxaliplatin (IROX)",
            "probability": 0.0
        },
        {
            "start_logit": 11.9375,
            "end_logit": -8.9375,
            "text": "irinotecan and oxaliplatin (IROX) as a salvage treatment for",
            "probability": 0.0
        },
        {
            "start_logit": 11.9375,
            "end_logit": -9.046875,
            "text": "irinotecan and oxaliplatin (IROX) as a salvage treatment",
            "probability": 0.0
        },
        {
            "start_logit": 11.9375,
            "end_logit": -9.1640625,
            "text": "irinotecan and oxaliplatin (IROX) as a salvage treatment for patients with gemcitabine- and 5-FU- refractory pancreatic cancer",
            "probability": 0.0
        },
        {
            "start_logit": 11.9375,
            "end_logit": -9.5,
            "text": "irinotecan and oxaliplatin (IROX) as a salvage treatment for patients with gemcitabine- and 5-FU-",
            "probability": 0.0
        },
        {
            "start_logit": 11.9375,
            "end_logit": -9.6328125,
            "text": "irinotecan and oxaliplatin (IROX) as a salvage treatment for patients with gemcitabine- and 5-",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 11.0703125,
            "text": "of irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": 0.0943603515625,
            "end_logit": -0.03173828125,
            "text": "oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": 0.0943603515625,
            "end_logit": -6.609375,
            "text": "oxaliplatin (IROX) as a salvage treatment for patients with gemcitabine- and 5-FU- refractory pancreatic",
            "probability": 0.0
        },
        {
            "start_logit": 0.0943603515625,
            "end_logit": -8.1484375,
            "text": "oxaliplatin (IROX) as a salvage treatment for patients with gemcitabine",
            "probability": 0.0
        },
        {
            "start_logit": 0.0943603515625,
            "end_logit": -8.1796875,
            "text": "oxaliplatin (IROX) as",
            "probability": 0.0
        },
        {
            "start_logit": 0.0943603515625,
            "end_logit": -8.2578125,
            "text": "oxaliplatin (IROX) as a salvage treatment for patients with gemcitabine- and 5-FU",
            "probability": 0.0
        }
    ],
    "602823e61cb411341a0000f9_10": [
        {
            "start_logit": 8.171875,
            "end_logit": 11.8125,
            "text": "gemcitabine",
            "probability": 1.0
        },
        {
            "start_logit": -2.220703125,
            "end_logit": 11.8125,
            "text": "oxaliplatin) and irinotecan/cetuximab regimens. He was started on gemcitabine",
            "probability": 3.069639205932617e-05
        },
        {
            "start_logit": -4.35546875,
            "end_logit": 11.8125,
            "text": "irinotecan/oxaliplatin) and irinotecan/cetuximab regimens. He was started on gemcitabine",
            "probability": 3.635883331298828e-06
        },
        {
            "start_logit": 8.171875,
            "end_logit": -3.673828125,
            "text": "gemcitabine/ca",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -9.53125,
            "end_logit": 11.8125,
            "text": "cetuximab regimens. He was started on gemcitabine",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": 11.8125,
            "text": "isease on IROX (irinotecan/oxaliplatin) and irinotecan/cetuximab regimens. He was started on gemcitabine",
            "probability": 0.0
        },
        {
            "start_logit": -10.328125,
            "end_logit": 11.8125,
            "text": "ease on IROX (irinotecan/oxaliplatin) and irinotecan/cetuximab regimens. He was started on gemcitabine",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 11.8125,
            "text": "IROX (irinotecan/oxaliplatin) and irinotecan/cetuximab regimens. He was started on gemcitabine",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 11.8125,
            "text": "irinotecan/cetuximab regimens. He was started on gemcitabine",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 11.8125,
            "text": "/cetuximab regimens. He was started on gemcitabine",
            "probability": 0.0
        },
        {
            "start_logit": 8.171875,
            "end_logit": -9.1484375,
            "text": "gemcitabine/",
            "probability": 0.0
        },
        {
            "start_logit": -2.220703125,
            "end_logit": -0.006011962890625,
            "text": "oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -4.35546875,
            "end_logit": -0.006011962890625,
            "text": "irinotecan/oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -2.220703125,
            "end_logit": -3.673828125,
            "text": "oxaliplatin) and irinotecan/cetuximab regimens. He was started on gemcitabine/ca",
            "probability": 0.0
        },
        {
            "start_logit": -4.35546875,
            "end_logit": -3.21484375,
            "text": "irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": -2.220703125,
            "end_logit": -5.47265625,
            "text": "oxaliplatin) and irinotecan/cetuximab",
            "probability": 0.0
        },
        {
            "start_logit": -4.35546875,
            "end_logit": -3.673828125,
            "text": "irinotecan/oxaliplatin) and irinotecan/cetuximab regimens. He was started on gemcitabine/ca",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": -0.006011962890625,
            "text": "isease on IROX (irinotecan/oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -4.35546875,
            "end_logit": -5.47265625,
            "text": "irinotecan/oxaliplatin) and irinotecan/cetuximab",
            "probability": 0.0
        },
        {
            "start_logit": -10.328125,
            "end_logit": -0.006011962890625,
            "text": "ease on IROX (irinotecan/oxaliplatin",
            "probability": 0.0
        }
    ],
    "602823e61cb411341a0000f9_11": [
        {
            "start_logit": 9.2734375,
            "end_logit": 6.0234375,
            "text": "irinotecan",
            "probability": 0.99609375
        },
        {
            "start_logit": 3.4765625,
            "end_logit": 6.0234375,
            "text": "fluorouracil, leucovorin, and oxaliplatin (FOLFOX) of 9.8% was better than with irinotecan",
            "probability": 0.003025054931640625
        },
        {
            "start_logit": 1.71875,
            "end_logit": 6.0234375,
            "text": "oxaliplatin (FOLFOX) of 9.8% was better than with irinotecan",
            "probability": 0.0005216598510742188
        },
        {
            "start_logit": 3.4765625,
            "end_logit": 2.8671875,
            "text": "fluorouracil",
            "probability": 0.00012886524200439453
        },
        {
            "start_logit": 3.4765625,
            "end_logit": 2.234375,
            "text": "fluorouracil, leucovorin, and oxaliplatin",
            "probability": 6.842613220214844e-05
        },
        {
            "start_logit": 1.71875,
            "end_logit": 2.234375,
            "text": "oxaliplatin",
            "probability": 1.1801719665527344e-05
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -9.6171875,
            "text": "irinotecan plus bolus fluorouracil and leucovorin (IFL; 3",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -9.8671875,
            "text": "irinotecan plus bolus fluorouracil and leucovorin (IFL",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -10.109375,
            "text": "irinotecan plus bolus fluorouracil and leucovorin (IFL; 3.7%; P = .04) or",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -10.4921875,
            "text": "irinotecan plus bolus fluorouracil and leucovorin (IFL; 3.7%; P = .04",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -10.5859375,
            "text": "irinotecan plus bolus fluorouracil and leucovorin (IFL; 3.7%; P = .04) or with bolus irinotecan/oxaliplatin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -10.6015625,
            "text": "irinotecan plus bolus fluorouracil and leucovorin (IFL; 3.7%; P = .04) or with bolus irinotecan",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.046875,
            "end_logit": 6.0234375,
            "text": "with irinotecan",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.8671875,
            "end_logit": 6.0234375,
            "text": "infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) of 9.8% was better than with irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": 6.0234375,
            "text": "with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) of 9.8% was better than with irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": -9.4453125,
            "end_logit": 6.0234375,
            "text": "leucovorin, and oxaliplatin (FOLFOX) of 9.8% was better than with irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": 3.4765625,
            "end_logit": -8.4609375,
            "text": "fluorouracil, leucovorin",
            "probability": 0.0
        },
        {
            "start_logit": -8.8671875,
            "end_logit": 2.8671875,
            "text": "infusional fluorouracil",
            "probability": 0.0
        },
        {
            "start_logit": 3.4765625,
            "end_logit": -9.75,
            "text": "fluorouracil, leucovorin, and oxaliplatin (FOLFOX) of 9.8%",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": 2.8671875,
            "text": "with infusional fluorouracil",
            "probability": 0.0
        }
    ],
    "602823e61cb411341a0000f9_12": [
        {
            "start_logit": 10.1015625,
            "end_logit": 11.4609375,
            "text": "fluorouracil",
            "probability": 1.0
        },
        {
            "start_logit": -5.21875,
            "end_logit": 11.4609375,
            "text": "bolus fluorouracil",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -5.04296875,
            "text": "fluorouracil plus leucovorin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 11.4609375,
            "text": "irinotecan and bolus fluorouracil",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -7.87109375,
            "text": "fluorouracil plus leucovorin (IFL",
            "probability": 0.0
        },
        {
            "start_logit": -9.90625,
            "end_logit": 11.4609375,
            "text": "receive irinotecan and bolus fluorouracil",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -9.765625,
            "text": "fluorouracil plus leucovorin (IFL, control",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -9.796875,
            "text": "fluorouracil plus leucovorin (IFL, control combination), oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -9.9453125,
            "text": "fluorouracil plus leucov",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -10.109375,
            "text": "fluorouracil plus",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -10.1171875,
            "text": "fluorouracil plus leucovorin (IFL, control combination), oxaliplatin and infused fluorouracil plus leucovorin (FOLFOX",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -10.15625,
            "text": "fluorouracil plus leucovorin (IFL, control combination), oxaliplatin and infused fluorouracil plus leucovorin",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -10.203125,
            "text": "fluorouracil plus leucovorin (IFL, control combination",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -10.25,
            "text": "fluorouracil plus leucovorin (IF",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -10.359375,
            "text": "fluorouracil plus leucovorin (",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -10.3828125,
            "text": "fluorouracil plus leuc",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -10.4375,
            "text": "fluorouracil plus leucovorin (IFL, control combination), oxaliplatin and infused fluorouracil plus leucovorin (FOL",
            "probability": 0.0
        },
        {
            "start_logit": -1.41796875,
            "end_logit": -2.208984375,
            "text": "oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -5.21875,
            "end_logit": -5.04296875,
            "text": "bolus fluorouracil plus leucovorin",
            "probability": 0.0
        },
        {
            "start_logit": -8.9765625,
            "end_logit": -2.208984375,
            "text": "irinotecan and oxaliplatin",
            "probability": 0.0
        }
    ],
    "602823e61cb411341a0000f9_13": [
        {
            "start_logit": 11.9296875,
            "end_logit": 11.296875,
            "text": "irinotecan",
            "probability": 1.0
        },
        {
            "start_logit": 11.9296875,
            "end_logit": -5.15625,
            "text": "irinotecan/oxalipltin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.9296875,
            "end_logit": -6.37109375,
            "text": "irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic",
            "probability": 0.0
        },
        {
            "start_logit": 11.9296875,
            "end_logit": -7.74609375,
            "text": "irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil",
            "probability": 0.0
        },
        {
            "start_logit": 11.9296875,
            "end_logit": -8.34375,
            "text": "irinotecan/oxalipltin (IROX) combination chemotherapy",
            "probability": 0.0
        },
        {
            "start_logit": 11.9296875,
            "end_logit": -8.3515625,
            "text": "irinotecan/oxal",
            "probability": 0.0
        },
        {
            "start_logit": 11.9296875,
            "end_logit": -8.3828125,
            "text": "irinotecan/oxalipltin (IROX)",
            "probability": 0.0
        },
        {
            "start_logit": 11.9296875,
            "end_logit": -8.4296875,
            "text": "irinotecan/oxalipltin (IROX) combination chemotherapy for",
            "probability": 0.0
        },
        {
            "start_logit": 11.9296875,
            "end_logit": -8.4765625,
            "text": "irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer",
            "probability": 0.0
        },
        {
            "start_logit": 11.9296875,
            "end_logit": -8.6328125,
            "text": "irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine",
            "probability": 0.0
        },
        {
            "start_logit": 11.9296875,
            "end_logit": -8.8203125,
            "text": "irinotecan/oxalipl",
            "probability": 0.0
        },
        {
            "start_logit": 11.9296875,
            "end_logit": -9.0,
            "text": "irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil-",
            "probability": 0.0
        },
        {
            "start_logit": 11.9296875,
            "end_logit": -9.125,
            "text": "irinotecan/",
            "probability": 0.0
        },
        {
            "start_logit": 11.9296875,
            "end_logit": -9.15625,
            "text": "irinotecan/oxalipltin (IROX) combination",
            "probability": 0.0
        },
        {
            "start_logit": 11.9296875,
            "end_logit": -9.2890625,
            "text": "irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-",
            "probability": 0.0
        },
        {
            "start_logit": 11.9296875,
            "end_logit": -9.5078125,
            "text": "irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory",
            "probability": 0.0
        },
        {
            "start_logit": 11.9296875,
            "end_logit": -9.5234375,
            "text": "irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine-",
            "probability": 0.0
        },
        {
            "start_logit": 11.9296875,
            "end_logit": -9.7734375,
            "text": "irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -6.671875,
            "end_logit": -5.15625,
            "text": "oxalipltin",
            "probability": 0.0
        },
        {
            "start_logit": -6.671875,
            "end_logit": -6.37109375,
            "text": "oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic",
            "probability": 0.0
        }
    ],
    "602823e61cb411341a0000f9_14": [
        {
            "start_logit": 10.53125,
            "end_logit": 10.0234375,
            "text": "irinotecan",
            "probability": 1.0
        },
        {
            "start_logit": 10.53125,
            "end_logit": -2.638671875,
            "text": "irinotecan + FU/LV), FOLFOX4 (oxaliplatin + FU/LV), and IROX (irinotecan + oxaliplatin",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": 10.53125,
            "end_logit": -6.98828125,
            "text": "irinotecan + FU/LV",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.53125,
            "end_logit": -7.2421875,
            "text": "irinotecan + FU",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.53125,
            "end_logit": -7.8203125,
            "text": "irinotecan + FU/LV), FOLFOX4",
            "probability": 0.0
        },
        {
            "start_logit": 10.53125,
            "end_logit": -8.2890625,
            "text": "irinotecan + FU/LV), FOLFOX4 (oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": 10.53125,
            "end_logit": -9.0859375,
            "text": "irinotecan + FU/LV), FOL",
            "probability": 0.0
        },
        {
            "start_logit": 10.53125,
            "end_logit": -9.328125,
            "text": "irinotecan +",
            "probability": 0.0
        },
        {
            "start_logit": 10.53125,
            "end_logit": -9.5625,
            "text": "irinotecan + FU/LV), FOLFOX",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": 10.0234375,
            "text": "IFL (irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": 10.53125,
            "end_logit": -9.5859375,
            "text": "irinotecan + FU/",
            "probability": 0.0
        },
        {
            "start_logit": 10.53125,
            "end_logit": -9.59375,
            "text": "irinotecan + FU/LV), FOLFOX4 (oxaliplatin + FU/LV), and IROX (irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": 10.53125,
            "end_logit": -9.671875,
            "text": "irinotecan + FU/LV), FOLFOX4 (oxaliplatin + FU",
            "probability": 0.0
        },
        {
            "start_logit": 10.53125,
            "end_logit": -9.8046875,
            "text": "irinotecan + FU/LV), FOLFOX4 (oxaliplatin + FU/LV",
            "probability": 0.0
        },
        {
            "start_logit": 10.53125,
            "end_logit": -9.875,
            "text": "irinotecan + FU/LV), FOLFOX4 (oxaliplatin + FU/LV), and IROX (irinotecan +",
            "probability": 0.0
        },
        {
            "start_logit": 10.53125,
            "end_logit": -10.0078125,
            "text": "irinotecan + FU/LV), FOLFO",
            "probability": 0.0
        },
        {
            "start_logit": 10.53125,
            "end_logit": -10.046875,
            "text": "irinotecan + FU/LV)",
            "probability": 0.0
        },
        {
            "start_logit": -9.7578125,
            "end_logit": 10.0234375,
            "text": "of IFL (irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 10.0234375,
            "text": "L (irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": -3.341796875,
            "end_logit": -2.638671875,
            "text": "oxaliplatin",
            "probability": 0.0
        }
    ],
    "602823e61cb411341a0000f9_15": [
        {
            "start_logit": 10.015625,
            "end_logit": 10.4140625,
            "text": "irinotecan",
            "probability": 1.0
        },
        {
            "start_logit": -3.66015625,
            "end_logit": 10.4140625,
            "text": ") irinotecan",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 10.015625,
            "end_logit": -4.58203125,
            "text": "irinotecan/5-FU/leucovorin (LV) (IFL, n = 264), (F) oxaliplatin",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 10.015625,
            "end_logit": -6.578125,
            "text": "irinotecan/5-FU/leucovorin (LV) (IFL",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 10.4140625,
            "text": "A) irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -7.84765625,
            "text": "irinotecan/5-FU",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -7.859375,
            "text": "irinotecan/5-FU/leucovorin",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.6953125,
            "text": "irinotecan/5-FU/leucovorin (LV",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -9.0,
            "text": "irinotecan/5",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": 10.4140625,
            "text": "arms (A) irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -9.1796875,
            "text": "irinotecan/5-FU/leucovorin (LV) (IF",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -9.421875,
            "text": "irinotecan/5-FU/leucovorin (",
            "probability": 0.0
        },
        {
            "start_logit": -3.66015625,
            "end_logit": -4.58203125,
            "text": ") irinotecan/5-FU/leucovorin (LV) (IFL, n = 264), (F) oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -3.66015625,
            "end_logit": -6.578125,
            "text": ") irinotecan/5-FU/leucovorin (LV) (IFL",
            "probability": 0.0
        },
        {
            "start_logit": -5.3359375,
            "end_logit": -5.32421875,
            "text": "irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": -3.66015625,
            "end_logit": -7.84765625,
            "text": ") irinotecan/5-FU",
            "probability": 0.0
        },
        {
            "start_logit": -3.66015625,
            "end_logit": -7.859375,
            "text": ") irinotecan/5-FU/leucovorin",
            "probability": 0.0
        },
        {
            "start_logit": -7.06640625,
            "end_logit": -4.58203125,
            "text": "oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -7.66015625,
            "end_logit": -4.58203125,
            "text": "A) irinotecan/5-FU/leucovorin (LV) (IFL, n = 264), (F) oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -3.66015625,
            "end_logit": -8.6953125,
            "text": ") irinotecan/5-FU/leucovorin (LV",
            "probability": 0.0
        }
    ],
    "52ecf2dd98d023950500002e_1": [
        {
            "start_logit": 9.9453125,
            "end_logit": 10.96875,
            "text": "rs7140952",
            "probability": 0.99609375
        },
        {
            "start_logit": 9.9453125,
            "end_logit": 5.3828125,
            "text": "rs7140952 polymorphism is associated with components of metabolic syndrome including blood pressure and central obesity",
            "probability": 0.003765106201171875
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -2.01953125,
            "text": "rs7140",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -3.46484375,
            "text": "rs714095",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -1.0419921875,
            "end_logit": 5.3828125,
            "text": "obesity",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.65625,
            "end_logit": 10.96875,
            "text": "2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -6.22265625,
            "text": "rs",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.59375,
            "end_logit": 10.96875,
            "text": "7140952",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -7.80859375,
            "text": "rs7140952 polymorphism is associated with components of metabolic syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.25,
            "text": "rs71",
            "probability": 0.0
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 10.96875,
            "text": "952",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.953125,
            "text": "rs7140952 polymorphism",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -9.5078125,
            "text": "rs7140952 polymorphism is associated with components of metabolic syndrome including blood pressure and central obesity.",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -9.703125,
            "text": "rs7140952 polymorphism is",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -9.8359375,
            "text": "rs7140952 polymorphism is associated",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -10.1796875,
            "text": "rs7140952 polymorphism is associated with components of metabolic syndrome including blood pressure and central",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -10.265625,
            "text": "rs7140952 polymorphism is associated with components of metabolic syndrome including",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -10.328125,
            "text": "rs7140952 polymorphism is associated with components of metabolic",
            "probability": 0.0
        },
        {
            "start_logit": -6.65625,
            "end_logit": 5.3828125,
            "text": "2 polymorphism is associated with components of metabolic syndrome including blood pressure and central obesity",
            "probability": 0.0
        },
        {
            "start_logit": -8.59375,
            "end_logit": 5.3828125,
            "text": "7140952 polymorphism is associated with components of metabolic syndrome including blood pressure and central obesity",
            "probability": 0.0
        }
    ],
    "52ecf2dd98d023950500002e_2": [
        {
            "start_logit": 12.53125,
            "end_logit": 10.109375,
            "text": "Ala92",
            "probability": 1.0
        },
        {
            "start_logit": 12.53125,
            "end_logit": -1.6357421875,
            "text": "Ala92 type 2",
            "probability": 7.927417755126953e-06
        },
        {
            "start_logit": 12.53125,
            "end_logit": -3.40234375,
            "text": "Ala92 type 2 deiodinase",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 12.53125,
            "end_logit": -5.17578125,
            "text": "Ala",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 12.53125,
            "end_logit": -7.90234375,
            "text": "Ala92 type 2 deiodinase allele",
            "probability": 0.0
        },
        {
            "start_logit": 12.53125,
            "end_logit": -8.3125,
            "text": "Ala92 type 2 deiod",
            "probability": 0.0
        },
        {
            "start_logit": 12.53125,
            "end_logit": -8.421875,
            "text": "Ala92 type",
            "probability": 0.0
        },
        {
            "start_logit": 12.53125,
            "end_logit": -9.03125,
            "text": "Ala92 type 2 de",
            "probability": 0.0
        },
        {
            "start_logit": 12.53125,
            "end_logit": -9.2421875,
            "text": "Ala92 type 2 deiodinase allele increases risk for the development of hypertension.",
            "probability": 0.0
        },
        {
            "start_logit": 12.53125,
            "end_logit": -9.421875,
            "text": "Ala92 type 2 deiodinase allele increases",
            "probability": 0.0
        },
        {
            "start_logit": 12.53125,
            "end_logit": -9.96875,
            "text": "Ala92 type 2 deiodinase allele increases risk for the development of hypertension",
            "probability": 0.0
        },
        {
            "start_logit": 12.53125,
            "end_logit": -10.0859375,
            "text": "Ala92 type 2 deiodinase allele increases risk for the",
            "probability": 0.0
        },
        {
            "start_logit": -8.390625,
            "end_logit": 10.109375,
            "text": "92",
            "probability": 0.0
        },
        {
            "start_logit": -5.1796875,
            "end_logit": -1.6357421875,
            "text": "type 2",
            "probability": 0.0
        },
        {
            "start_logit": -5.1796875,
            "end_logit": -3.40234375,
            "text": "type 2 deiodinase",
            "probability": 0.0
        },
        {
            "start_logit": -8.390625,
            "end_logit": -1.6357421875,
            "text": "92 type 2",
            "probability": 0.0
        },
        {
            "start_logit": -8.390625,
            "end_logit": -3.40234375,
            "text": "92 type 2 deiodinase",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": -1.6357421875,
            "text": "2",
            "probability": 0.0
        },
        {
            "start_logit": -5.1796875,
            "end_logit": -7.90234375,
            "text": "type 2 deiodinase allele",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": -3.40234375,
            "text": "deiodinase",
            "probability": 0.0
        }
    ],
    "54fe09036ad7dcbc12000009_1": [
        {
            "start_logit": 8.5,
            "end_logit": 11.703125,
            "text": "notothenoids",
            "probability": 1.0
        },
        {
            "start_logit": -6.5234375,
            "end_logit": 11.703125,
            "text": "enoids",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.5,
            "end_logit": -4.40234375,
            "text": "notothenoids,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.0234375,
            "end_logit": 11.703125,
            "text": "othenoids",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 11.703125,
            "text": "of Antarctic and Arctic notothenoids",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 11.703125,
            "text": "anti-freeze glycoprotein of Antarctic and Arctic notothenoids",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 11.703125,
            "text": "Antarctic and Arctic notothenoids",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 11.703125,
            "text": "freeze glycoprotein of Antarctic and Arctic notothenoids",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 11.703125,
            "text": "Arctic notothenoids",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 11.703125,
            "text": "-freeze glycoprotein of Antarctic and Arctic notothenoids",
            "probability": 0.0
        },
        {
            "start_logit": 8.5,
            "end_logit": -8.53125,
            "text": "nototh",
            "probability": 0.0
        },
        {
            "start_logit": 8.5,
            "end_logit": -8.765625,
            "text": "not",
            "probability": 0.0
        },
        {
            "start_logit": -6.5234375,
            "end_logit": -4.40234375,
            "text": "enoids,",
            "probability": 0.0
        },
        {
            "start_logit": -10.0234375,
            "end_logit": -4.40234375,
            "text": "othenoids,",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": -4.40234375,
            "text": "of Antarctic and Arctic notothenoids,",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": -4.40234375,
            "text": "anti-freeze glycoprotein of Antarctic and Arctic notothenoids,",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": -4.40234375,
            "text": "Antarctic and Arctic notothenoids,",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": -4.40234375,
            "text": "freeze glycoprotein of Antarctic and Arctic notothenoids,",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": -4.40234375,
            "text": "Arctic notothenoids,",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": -4.40234375,
            "text": ",",
            "probability": 0.0
        }
    ],
    "54fe09036ad7dcbc12000009_2": [
        {
            "start_logit": 13.453125,
            "end_logit": 9.5078125,
            "text": "AFP I",
            "probability": 1.0
        },
        {
            "start_logit": 13.453125,
            "end_logit": 0.787109375,
            "text": "AFP I or AFP III",
            "probability": 0.00016224384307861328
        },
        {
            "start_logit": 13.453125,
            "end_logit": -2.716796875,
            "text": "AFP",
            "probability": 4.887580871582031e-06
        },
        {
            "start_logit": 13.453125,
            "end_logit": -3.669921875,
            "text": "AFP I or AFP",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": 13.453125,
            "end_logit": -8.0234375,
            "text": "AFP I or",
            "probability": 0.0
        },
        {
            "start_logit": -8.484375,
            "end_logit": 9.5078125,
            "text": "I",
            "probability": 0.0
        },
        {
            "start_logit": -4.0546875,
            "end_logit": 0.787109375,
            "text": "AFP III",
            "probability": 0.0
        },
        {
            "start_logit": -8.484375,
            "end_logit": 0.787109375,
            "text": "I or AFP III",
            "probability": 0.0
        },
        {
            "start_logit": -4.0546875,
            "end_logit": -3.669921875,
            "text": "AFP",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 0.787109375,
            "text": "III",
            "probability": 0.0
        },
        {
            "start_logit": -8.484375,
            "end_logit": -3.669921875,
            "text": "I or AFP",
            "probability": 0.0
        },
        {
            "start_logit": -8.484375,
            "end_logit": -8.0234375,
            "text": "I or",
            "probability": 0.0
        }
    ],
    "54fe09036ad7dcbc12000009_3": [
        {
            "start_logit": 7.87109375,
            "end_logit": 9.421875,
            "text": "wild type III thermal hysteresis protein",
            "probability": 0.896484375
        },
        {
            "start_logit": 5.70703125,
            "end_logit": 9.421875,
            "text": "thermal hysteresis protein",
            "probability": 0.1021728515625
        },
        {
            "start_logit": 7.87109375,
            "end_logit": 2.443359375,
            "text": "wild type III",
            "probability": 0.0008301734924316406
        },
        {
            "start_logit": 7.87109375,
            "end_logit": 1.1787109375,
            "text": "wild type III thermal hysteresis",
            "probability": 0.00023436546325683594
        },
        {
            "start_logit": 5.70703125,
            "end_logit": 1.1787109375,
            "text": "thermal hysteresis",
            "probability": 2.7120113372802734e-05
        },
        {
            "start_logit": -3.6171875,
            "end_logit": 9.421875,
            "text": "III thermal hysteresis protein",
            "probability": 9.119510650634766e-06
        },
        {
            "start_logit": 7.87109375,
            "end_logit": -7.50390625,
            "text": "wild",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.375,
            "end_logit": 9.421875,
            "text": "protein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.87109375,
            "end_logit": -8.28125,
            "text": "wild type",
            "probability": 0.0
        },
        {
            "start_logit": 7.87109375,
            "end_logit": -8.90625,
            "text": "wild type III thermal",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 9.421875,
            "text": "hysteresis protein",
            "probability": 0.0
        },
        {
            "start_logit": -3.6171875,
            "end_logit": 2.443359375,
            "text": "III",
            "probability": 0.0
        },
        {
            "start_logit": -3.6171875,
            "end_logit": 1.1787109375,
            "text": "III thermal hysteresis",
            "probability": 0.0
        },
        {
            "start_logit": 5.70703125,
            "end_logit": -8.90625,
            "text": "thermal",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 1.1787109375,
            "text": "hysteresis",
            "probability": 0.0
        },
        {
            "start_logit": -3.6171875,
            "end_logit": -8.90625,
            "text": "III thermal",
            "probability": 0.0
        }
    ],
    "54fe09036ad7dcbc12000009_4": [
        {
            "start_logit": -2.662109375,
            "end_logit": 10.078125,
            "text": "-3",
            "probability": 0.7900390625
        },
        {
            "start_logit": -4.04296875,
            "end_logit": 10.078125,
            "text": "skin-type anti-freeze protein-3",
            "probability": 0.1990966796875
        },
        {
            "start_logit": -7.828125,
            "end_logit": 10.078125,
            "text": "anti-freeze protein-3",
            "probability": 0.0045166015625
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 10.078125,
            "text": "3",
            "probability": 0.004230499267578125
        },
        {
            "start_logit": -9.15625,
            "end_logit": 10.078125,
            "text": "protein-3",
            "probability": 0.00119781494140625
        },
        {
            "start_logit": -10.25,
            "end_logit": 10.078125,
            "text": "type anti-freeze protein-3",
            "probability": 0.00040078163146972656
        },
        {
            "start_logit": -10.421875,
            "end_logit": 10.078125,
            "text": "freeze protein-3",
            "probability": 0.00033783912658691406
        },
        {
            "start_logit": -4.04296875,
            "end_logit": -3.71484375,
            "text": "skin-type anti-freeze protein",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -4.04296875,
            "end_logit": -6.9765625,
            "text": "skin",
            "probability": 0.0
        },
        {
            "start_logit": -7.828125,
            "end_logit": -3.71484375,
            "text": "anti-freeze protein",
            "probability": 0.0
        },
        {
            "start_logit": -4.04296875,
            "end_logit": -8.3515625,
            "text": "skin-type",
            "probability": 0.0
        },
        {
            "start_logit": -9.15625,
            "end_logit": -3.71484375,
            "text": "protein",
            "probability": 0.0
        },
        {
            "start_logit": -4.04296875,
            "end_logit": -9.25,
            "text": "skin-",
            "probability": 0.0
        },
        {
            "start_logit": -4.04296875,
            "end_logit": -9.328125,
            "text": "skin-type anti-freeze",
            "probability": 0.0
        },
        {
            "start_logit": -4.04296875,
            "end_logit": -9.59375,
            "text": "skin-type anti-",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": -3.71484375,
            "text": "type anti-freeze protein",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": -3.71484375,
            "text": "freeze protein",
            "probability": 0.0
        },
        {
            "start_logit": -7.828125,
            "end_logit": -9.328125,
            "text": "anti-freeze",
            "probability": 0.0
        },
        {
            "start_logit": -7.828125,
            "end_logit": -9.59375,
            "text": "anti-",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": -8.3515625,
            "text": "type",
            "probability": 0.0
        }
    ],
    "60274ec61cb411341a0000e5_1": [
        {
            "start_logit": 11.2578125,
            "end_logit": 11.328125,
            "text": "vincristine",
            "probability": 1.0
        },
        {
            "start_logit": 11.2578125,
            "end_logit": 2.19140625,
            "text": "vincristine, adriamycin",
            "probability": 0.00010722875595092773
        },
        {
            "start_logit": 11.2578125,
            "end_logit": -1.8359375,
            "text": "vincristine, adriamycin and cyclophosphamide",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 11.2578125,
            "end_logit": -3.16015625,
            "text": "vincristine, adriamycin and cyclophosphamide) alternating with ICE (ifosphamide, cisplatin",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 3.509765625,
            "end_logit": 2.19140625,
            "text": "adriamycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.2578125,
            "end_logit": -7.37109375,
            "text": "vincristine, adriamycin and cyclophosphamide) alternating with ICE (ifosphamide, cisplatin and etoposide",
            "probability": 0.0
        },
        {
            "start_logit": 11.2578125,
            "end_logit": -8.515625,
            "text": "vincristine, adriamycin and cyclophosphamide) alternating with ICE",
            "probability": 0.0
        },
        {
            "start_logit": -8.671875,
            "end_logit": 11.328125,
            "text": "radiotherapy to a dose of 46-50 Gy and chemotherapy with VAC (vincristine",
            "probability": 0.0
        },
        {
            "start_logit": 11.2578125,
            "end_logit": -8.7578125,
            "text": "vincristine, adriamycin and",
            "probability": 0.0
        },
        {
            "start_logit": -8.90625,
            "end_logit": 11.328125,
            "text": "chemotherapy with VAC (vincristine",
            "probability": 0.0
        },
        {
            "start_logit": 11.2578125,
            "end_logit": -9.203125,
            "text": "vincristine, adriamycin and cyclophosphamide) alternating with ICE (ifosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": 11.328125,
            "text": "with VAC (vincristine",
            "probability": 0.0
        },
        {
            "start_logit": -9.625,
            "end_logit": 11.328125,
            "text": "adjuvant radiotherapy to a dose of 46-50 Gy and chemotherapy with VAC (vincristine",
            "probability": 0.0
        },
        {
            "start_logit": 3.509765625,
            "end_logit": -1.8359375,
            "text": "adriamycin and cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": 11.328125,
            "text": "surgical exploration with a laminectomy and partial resection followed by adjuvant radiotherapy to a dose of 46-50 Gy and chemotherapy with VAC (vincristine",
            "probability": 0.0
        },
        {
            "start_logit": -9.8046875,
            "end_logit": 11.328125,
            "text": "with a laminectomy and partial resection followed by adjuvant radiotherapy to a dose of 46-50 Gy and chemotherapy with VAC (vincristine",
            "probability": 0.0
        },
        {
            "start_logit": 11.2578125,
            "end_logit": -9.8359375,
            "text": "vincristine, adriamycin and cyclophosphamide)",
            "probability": 0.0
        },
        {
            "start_logit": -9.9453125,
            "end_logit": 11.328125,
            "text": "resection followed by adjuvant radiotherapy to a dose of 46-50 Gy and chemotherapy with VAC (vincristine",
            "probability": 0.0
        },
        {
            "start_logit": 11.2578125,
            "end_logit": -9.96875,
            "text": "vincristine, adriamycin and cyclophosphamide) alternating with ICE (ifosphamide, cisplatin and etoposide) for",
            "probability": 0.0
        },
        {
            "start_logit": 11.2578125,
            "end_logit": -10.125,
            "text": "vincristine,",
            "probability": 0.0
        }
    ],
    "60274ec61cb411341a0000e5_2": [
        {
            "start_logit": 10.6328125,
            "end_logit": 12.3125,
            "text": "vincristine",
            "probability": 1.0
        },
        {
            "start_logit": 10.6328125,
            "end_logit": 3.87890625,
            "text": "vincristine, dactinomycin",
            "probability": 0.0002200603485107422
        },
        {
            "start_logit": -4.578125,
            "end_logit": 12.3125,
            "text": "doxorubicin (DOX) to the combination of vincristine",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 1.7509765625,
            "end_logit": 3.87890625,
            "text": "dactinomycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.6328125,
            "end_logit": -6.22265625,
            "text": "vincristine, dactinomycin, cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 12.3125,
            "text": "DOX) to the combination of vincristine",
            "probability": 0.0
        },
        {
            "start_logit": 10.6328125,
            "end_logit": -6.42578125,
            "text": "vincristine, dac",
            "probability": 0.0
        },
        {
            "start_logit": 10.6328125,
            "end_logit": -6.640625,
            "text": "vincristine, dactin",
            "probability": 0.0
        },
        {
            "start_logit": 10.6328125,
            "end_logit": -7.546875,
            "text": "vincristine, dactinomycin, cyclophosphamide (VAC), and XRT",
            "probability": 0.0
        },
        {
            "start_logit": -9.734375,
            "end_logit": 12.3125,
            "text": "patients with localized, gross residual tumor, adding doxorubicin (DOX) to the combination of vincristine",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": 12.3125,
            "text": "of vincristine",
            "probability": 0.0
        },
        {
            "start_logit": 10.6328125,
            "end_logit": -9.140625,
            "text": "vincristine, dactinomycin, cyclophosphamide (VAC), and XR",
            "probability": 0.0
        },
        {
            "start_logit": 10.6328125,
            "end_logit": -9.5,
            "text": "vincristine, dactinomycin, cyclophosphamide (VAC",
            "probability": 0.0
        },
        {
            "start_logit": 10.6328125,
            "end_logit": -9.5,
            "text": "vincristine, dactinomycin, cyclophosphamide (VAC)",
            "probability": 0.0
        },
        {
            "start_logit": 10.6328125,
            "end_logit": -9.71875,
            "text": "vincristine, dactinomycin, cyclophosphamide (",
            "probability": 0.0
        },
        {
            "start_logit": 10.6328125,
            "end_logit": -9.796875,
            "text": "vincristine, dactinomycin, cyclophosphamide (VAC), and",
            "probability": 0.0
        },
        {
            "start_logit": -4.578125,
            "end_logit": 3.87890625,
            "text": "doxorubicin (DOX) to the combination of vincristine, dactinomycin",
            "probability": 0.0
        },
        {
            "start_logit": -5.3125,
            "end_logit": 3.87890625,
            "text": "omycin",
            "probability": 0.0
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 3.87890625,
            "text": "DOX) to the combination of vincristine, dactinomycin",
            "probability": 0.0
        },
        {
            "start_logit": 1.7509765625,
            "end_logit": -6.22265625,
            "text": "dactinomycin, cyclophosphamide",
            "probability": 0.0
        }
    ],
    "60274ec61cb411341a0000e5_3": [
        {
            "start_logit": 9.3984375,
            "end_logit": 12.015625,
            "text": "cyclophosphamide",
            "probability": 1.0
        },
        {
            "start_logit": -4.0703125,
            "end_logit": 12.015625,
            "text": "vincristine-dactinomycin (VA) or VA plus cyclophosphamide",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -4.765625,
            "end_logit": 12.015625,
            "text": "omycin (VA) or VA plus cyclophosphamide",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -5.90625,
            "end_logit": 12.015625,
            "text": "dactinomycin (VA) or VA plus cyclophosphamide",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.3984375,
            "end_logit": -5.38671875,
            "text": "cyclophosphamide (VAC) +/- doxorubicin",
            "probability": 0.0
        },
        {
            "start_logit": -8.8359375,
            "end_logit": 12.015625,
            "text": "tinomycin (VA) or VA plus cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -8.9765625,
            "end_logit": 12.015625,
            "text": "radiotherapy (XRT) and vincristine-dactinomycin (VA) or VA plus cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": 12.015625,
            "text": "or VA plus cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -9.6796875,
            "end_logit": 12.015625,
            "text": "with radiotherapy (XRT) and vincristine-dactinomycin (VA) or VA plus cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": 9.3984375,
            "end_logit": -7.30078125,
            "text": "cyclophosphamide (VAC) +",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": 12.015625,
            "text": "XRT) and vincristine-dactinomycin (VA) or VA plus cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 12.015625,
            "text": "and vincristine-dactinomycin (VA) or VA plus cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": 12.015625,
            "text": "plus cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": 12.015625,
            "text": "VA plus cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 12.015625,
            "text": "VA) or VA plus cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": 9.3984375,
            "end_logit": -9.3359375,
            "text": "cyclophosphamide (VAC)",
            "probability": 0.0
        },
        {
            "start_logit": 9.3984375,
            "end_logit": -9.4375,
            "text": "cyclophosphamide (VAC) +/-",
            "probability": 0.0
        },
        {
            "start_logit": -4.0703125,
            "end_logit": 1.173828125,
            "text": "vincristine-dactinomycin",
            "probability": 0.0
        },
        {
            "start_logit": -4.765625,
            "end_logit": 1.173828125,
            "text": "omycin",
            "probability": 0.0
        },
        {
            "start_logit": -5.90625,
            "end_logit": 1.173828125,
            "text": "dactinomycin",
            "probability": 0.0
        }
    ],
    "60274ec61cb411341a0000e5_4": [
        {
            "start_logit": 11.5859375,
            "end_logit": 11.625,
            "text": "vincristine",
            "probability": 1.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -4.375,
            "text": "vincristine, actinomycin, cyclophosphamide",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -4.82421875,
            "text": "vincristine, actinomycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -8.7890625,
            "text": "vincristine, actinomycin, cyclophosphamide (VAC)",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -9.2109375,
            "text": "vincristine, actinomycin,",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -9.296875,
            "text": "vincristine, actinomycin, cyclophosphamide (VAC) regime, described in Kilman, et al. (1973) and Koop",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -9.3984375,
            "text": "vincristine, actinomycin, cyclophosphamide (VAC) regime, described in Kilman, et al. (1973) and Koop, et al.",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -9.75,
            "text": "vincristine, actinomycin, cyclophosphamide (VAC) regime,",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -9.8984375,
            "text": "vincristine, actinomycin, cyclophosphamide (VAC) regime, described in Kilman, et al. (1973) and Koop, et al. (196",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -10.0078125,
            "text": "vincristine, actinomycin, cyclophosphamide (VAC) regime, described in",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -10.0546875,
            "text": "vincristine, actinomycin, cyclophosphamide (VAC) regime, described in Kilman, et al. (1973)",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -10.0625,
            "text": "vincristine, actinomycin, cyclophosphamide (VAC",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -10.09375,
            "text": "vincristine, actinomycin, cyclophosphamide (VAC) regime, described in Kilman, et al.",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 11.625,
            "text": "chemotherapeutic regimen remains unchanged. This vincristine",
            "probability": 0.0
        },
        {
            "start_logit": -5.484375,
            "end_logit": -4.375,
            "text": "actinomycin, cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -5.484375,
            "end_logit": -4.82421875,
            "text": "actinomycin",
            "probability": 0.0
        },
        {
            "start_logit": -6.88671875,
            "end_logit": -4.375,
            "text": "cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -5.484375,
            "end_logit": -8.7890625,
            "text": "actinomycin, cyclophosphamide (VAC)",
            "probability": 0.0
        },
        {
            "start_logit": -9.9296875,
            "end_logit": -4.375,
            "text": ", cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -9.9921875,
            "end_logit": -4.375,
            "text": ", actinomycin, cyclophosphamide",
            "probability": 0.0
        }
    ],
    "60274ec61cb411341a0000e5_5": [
        {
            "start_logit": 13.828125,
            "end_logit": 13.671875,
            "text": "mesna",
            "probability": 1.0
        },
        {
            "start_logit": 13.828125,
            "end_logit": -3.85546875,
            "text": "mes",
            "probability": 0.0
        },
        {
            "start_logit": -4.62890625,
            "end_logit": 13.671875,
            "text": "na",
            "probability": 0.0
        },
        {
            "start_logit": -5.59765625,
            "end_logit": 13.671875,
            "text": "vincristine, adriablastin, cyclophosphamide (VAC) and etoposide, ifosfamide with mesna",
            "probability": 0.0
        },
        {
            "start_logit": -6.15234375,
            "end_logit": 13.671875,
            "text": "ifosfamide with mesna",
            "probability": 0.0
        },
        {
            "start_logit": -6.8359375,
            "end_logit": 13.671875,
            "text": "cyclophosphamide (VAC) and etoposide, ifosfamide with mesna",
            "probability": 0.0
        },
        {
            "start_logit": -7.0859375,
            "end_logit": 13.671875,
            "text": "etoposide, ifosfamide with mesna",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 13.671875,
            "text": "adriablastin, cyclophosphamide (VAC) and etoposide, ifosfamide with mesna",
            "probability": 0.0
        },
        {
            "start_logit": 13.828125,
            "end_logit": -8.265625,
            "text": "mesna protection",
            "probability": 0.0
        },
        {
            "start_logit": -8.4609375,
            "end_logit": 13.671875,
            "text": "osfamide with mesna",
            "probability": 0.0
        },
        {
            "start_logit": -8.734375,
            "end_logit": 13.671875,
            "text": "alternating vincristine, adriablastin, cyclophosphamide (VAC) and etoposide, ifosfamide with mesna",
            "probability": 0.0
        },
        {
            "start_logit": -9.21875,
            "end_logit": 13.671875,
            "text": "induction chemotherapy consisting of alternating vincristine, adriablastin, cyclophosphamide (VAC) and etoposide, ifosfamide with mesna",
            "probability": 0.0
        },
        {
            "start_logit": -9.375,
            "end_logit": 13.671875,
            "text": "and etoposide, ifosfamide with mesna",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": 13.671875,
            "text": ", ifosfamide with mesna",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": 13.671875,
            "text": "chemotherapy consisting of alternating vincristine, adriablastin, cyclophosphamide (VAC) and etoposide, ifosfamide with mesna",
            "probability": 0.0
        },
        {
            "start_logit": 13.828125,
            "end_logit": -9.9375,
            "text": "mesna protection (IE), a local treatment modality was chosen based on tumor and patient characteristics",
            "probability": 0.0
        },
        {
            "start_logit": 13.828125,
            "end_logit": -9.9453125,
            "text": "mesna protection (IE",
            "probability": 0.0
        },
        {
            "start_logit": 13.828125,
            "end_logit": -10.046875,
            "text": "mesna protection (",
            "probability": 0.0
        },
        {
            "start_logit": -9.9140625,
            "end_logit": 13.671875,
            "text": ", cyclophosphamide (VAC) and etoposide, ifosfamide with mesna",
            "probability": 0.0
        },
        {
            "start_logit": 13.828125,
            "end_logit": -10.1953125,
            "text": "mesna protection (IE), a local treatment modality",
            "probability": 0.0
        }
    ],
    "60274ec61cb411341a0000e5_6": [
        {
            "start_logit": 11.6640625,
            "end_logit": 11.3046875,
            "text": "vincristine",
            "probability": 1.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -3.642578125,
            "text": "vincristine (V), doxorubicin",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -4.12109375,
            "text": "vincristine (V), doxorubicin (A), cyclophosphamide (C) alternated with one cycle of 'VIAc': V, ifosfamide",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -6.50390625,
            "text": "vincristine (V)",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -6.91015625,
            "text": "vincristine (V), doxorubicin (A), cyclophosphamide (C) alternated with one cycle of 'VIAc': V, if",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -7.48828125,
            "text": "vincristine (V), doxorubicin (A), cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -9.1015625,
            "text": "vincristine (V",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -9.2265625,
            "text": "vincristine (V), doxorubicin (A)",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -9.2734375,
            "text": "vincristine (V), doxorubicin (A), cyclophosphamide (C) alternated with one cycle of 'VIAc",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -9.390625,
            "text": "vincristine (V), doxorubicin (A",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -9.4453125,
            "text": "vincristine (V), doxorubicin (A), cyclophosphamide (C) alternated with one cycle of 'VIAc': V, ifosfamide (",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -9.484375,
            "text": "vincristine (",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -9.5078125,
            "text": "vincristine (V), doxorubicin (",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -9.53125,
            "text": "vincristine (V), doxorubicin (A), cyclophosphamide (C",
            "probability": 0.0
        },
        {
            "start_logit": -2.78125,
            "end_logit": -3.642578125,
            "text": "doxorubicin",
            "probability": 0.0
        },
        {
            "start_logit": -2.78125,
            "end_logit": -4.12109375,
            "text": "doxorubicin (A), cyclophosphamide (C) alternated with one cycle of 'VIAc': V, ifosfamide",
            "probability": 0.0
        },
        {
            "start_logit": -4.84375,
            "end_logit": -4.12109375,
            "text": "ifosfamide",
            "probability": 0.0
        },
        {
            "start_logit": -2.78125,
            "end_logit": -6.91015625,
            "text": "doxorubicin (A), cyclophosphamide (C) alternated with one cycle of 'VIAc': V, if",
            "probability": 0.0
        },
        {
            "start_logit": -2.78125,
            "end_logit": -7.48828125,
            "text": "doxorubicin (A), cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -2.78125,
            "end_logit": -7.6171875,
            "text": "doxorubicin (A), cyclophosphamide (C) alternated with one cycle of 'VIAc': V, ifosfamide (I), actinomycin",
            "probability": 0.0
        }
    ],
    "60274ec61cb411341a0000e5_7": [
        {
            "start_logit": 11.3828125,
            "end_logit": 10.9921875,
            "text": "vindesine",
            "probability": 0.95166015625
        },
        {
            "start_logit": 11.3828125,
            "end_logit": 7.84375,
            "text": "vindesine and cisplatin have shown the effectiveness of this drug in patients with Ewing's sarcoma (ES) who had relapsed during VAC (vincristine",
            "probability": 0.04052734375
        },
        {
            "start_logit": 9.6953125,
            "end_logit": 7.84375,
            "text": "vincristine",
            "probability": 0.00749969482421875
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -3.06640625,
            "text": "vindesine and cisplatin",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -5.24609375,
            "end_logit": 10.9921875,
            "text": "ifosfamide both alone and combined with vindesine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -5.80859375,
            "text": "vin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6953125,
            "end_logit": -4.63671875,
            "text": "vincristine, actinomycin, cyclosphosphamide)/VAd (vincristine, Adriamycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.40234375,
            "end_logit": 10.9921875,
            "text": "ine",
            "probability": 0.0
        },
        {
            "start_logit": -3.8203125,
            "end_logit": 7.84375,
            "text": "cisplatin have shown the effectiveness of this drug in patients with Ewing's sarcoma (ES) who had relapsed during VAC (vincristine",
            "probability": 0.0
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -7.47265625,
            "text": "vindes",
            "probability": 0.0
        },
        {
            "start_logit": 9.6953125,
            "end_logit": -7.16015625,
            "text": "vincristine, actinomycin, cyclosphosphamide",
            "probability": 0.0
        },
        {
            "start_logit": 9.6953125,
            "end_logit": -7.87109375,
            "text": "vincristine, actinomycin",
            "probability": 0.0
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -9.5625,
            "text": "vindesine and",
            "probability": 0.0
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -9.8203125,
            "text": "vindesine and cisplatin have shown the effectiveness of this drug in patients with Ewing's sarcoma (ES) who had relapsed",
            "probability": 0.0
        },
        {
            "start_logit": -6.40234375,
            "end_logit": 7.84375,
            "text": "ine and cisplatin have shown the effectiveness of this drug in patients with Ewing's sarcoma (ES) who had relapsed during VAC (vincristine",
            "probability": 0.0
        },
        {
            "start_logit": -9.75,
            "end_logit": 10.9921875,
            "text": "desine",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 10.9921875,
            "text": "osfamide both alone and combined with vindesine",
            "probability": 0.0
        },
        {
            "start_logit": 9.6953125,
            "end_logit": -9.5078125,
            "text": "vincristine, actinomycin, cyclo",
            "probability": 0.0
        },
        {
            "start_logit": 9.6953125,
            "end_logit": -9.6796875,
            "text": "vincristine, actinomycin, cyclosphospham",
            "probability": 0.0
        },
        {
            "start_logit": 9.6953125,
            "end_logit": -9.8046875,
            "text": "vincristine, actinomycin, cyclosphosphamide)/VAd (vincristine, Adriamycin)",
            "probability": 0.0
        }
    ],
    "60274ec61cb411341a0000e5_8": [
        {
            "start_logit": 11.234375,
            "end_logit": 10.7109375,
            "text": "vindesine",
            "probability": 0.9326171875
        },
        {
            "start_logit": 11.234375,
            "end_logit": 7.85546875,
            "text": "vindesine and cisplatin have shown the effectiveness of this drug in patients with Ewing's sarcoma (ES) who had relapsed during VAC (vincristine",
            "probability": 0.05426025390625
        },
        {
            "start_logit": 9.8125,
            "end_logit": 7.85546875,
            "text": "vincristine",
            "probability": 0.01309967041015625
        },
        {
            "start_logit": 11.234375,
            "end_logit": -2.69921875,
            "text": "vindesine and cisplatin",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -5.17578125,
            "end_logit": 10.7109375,
            "text": "ifosfamide both alone and combined with vindesine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.234375,
            "end_logit": -5.921875,
            "text": "vin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8125,
            "end_logit": -4.62890625,
            "text": "vincristine, actinomycin, cyclosphosphamide)/VAd (vincristine, Adriamycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.392578125,
            "end_logit": 7.85546875,
            "text": "cisplatin have shown the effectiveness of this drug in patients with Ewing's sarcoma (ES) who had relapsed during VAC (vincristine",
            "probability": 0.0
        },
        {
            "start_logit": -6.609375,
            "end_logit": 10.7109375,
            "text": "ine",
            "probability": 0.0
        },
        {
            "start_logit": 11.234375,
            "end_logit": -7.5234375,
            "text": "vindes",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.4609375,
            "text": "vincristine, actinomycin, cyclosphosphamide",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.7578125,
            "text": "vincristine, actinomycin",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -7.89453125,
            "text": "vincristine, actinomycin, cyclosphosphamide)/VAd (vincristine, Adriamycin) therapy. In Novembe",
            "probability": 0.0
        },
        {
            "start_logit": 11.234375,
            "end_logit": -9.5546875,
            "text": "vindesine and",
            "probability": 0.0
        },
        {
            "start_logit": 11.234375,
            "end_logit": -9.6015625,
            "text": "vindesine and cisplatin have shown the effectiveness of this drug in patients with Ewing's sarcoma (ES) who had relapsed",
            "probability": 0.0
        },
        {
            "start_logit": 11.234375,
            "end_logit": -9.6640625,
            "text": "vindesine and cisplatin have shown the effectiveness of this drug in patients with Ewing's sarcoma (ES) who had relapsed during VAC",
            "probability": 0.0
        },
        {
            "start_logit": 11.234375,
            "end_logit": -9.765625,
            "text": "vindesine and cisplatin have shown the effectiveness of this drug in patients with Ewing's sarcoma (ES)",
            "probability": 0.0
        },
        {
            "start_logit": -6.609375,
            "end_logit": 7.85546875,
            "text": "ine and cisplatin have shown the effectiveness of this drug in patients with Ewing's sarcoma (ES) who had relapsed during VAC (vincristine",
            "probability": 0.0
        },
        {
            "start_logit": -9.7578125,
            "end_logit": 10.7109375,
            "text": "desine",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -9.59375,
            "text": "vincristine, actinomycin, cyclosphosphamide)/VAd",
            "probability": 0.0
        }
    ],
    "60274ec61cb411341a0000e5_9": [
        {
            "start_logit": 11.0,
            "end_logit": 10.5390625,
            "text": "vincristine",
            "probability": 0.99609375
        },
        {
            "start_logit": 11.0,
            "end_logit": 5.046875,
            "text": "vincristine, adriamycin, cyclophosphamide (VAC) may be able to replace vincristine, adriamycin, ifosfamide",
            "probability": 0.0041351318359375
        },
        {
            "start_logit": 11.0,
            "end_logit": -0.97216796875,
            "text": "vincristine, adriamycin",
            "probability": 1.0073184967041016e-05
        },
        {
            "start_logit": 3.138671875,
            "end_logit": 5.046875,
            "text": "ifosfamide",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": 11.0,
            "end_logit": -5.27734375,
            "text": "vincristine, adriamycin, cyclophosphamide",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.0,
            "end_logit": -6.4921875,
            "text": "vincristine, adriamycin, cyclophosphamide (VAC) may be able to replace vincristine, adriamycin, if",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.6337890625,
            "end_logit": 5.046875,
            "text": "adriamycin, cyclophosphamide (VAC) may be able to replace vincristine, adriamycin, ifosfamide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.0,
            "end_logit": -9.15625,
            "text": "vincristine, adriamycin, cyclophosphamide (VAC) may be able to replace vincristine, adriamycin",
            "probability": 0.0
        },
        {
            "start_logit": 11.0,
            "end_logit": -9.4296875,
            "text": "vincristine, adriamycin, cyclophosphamide (VAC) may be able",
            "probability": 0.0
        },
        {
            "start_logit": 11.0,
            "end_logit": -9.7890625,
            "text": "vincristine, adriamycin, cyclophosphamide (VAC) may",
            "probability": 0.0
        },
        {
            "start_logit": 11.0,
            "end_logit": -10.1640625,
            "text": "vincristine, adriamycin, cyclophosphamide (VAC)",
            "probability": 0.0
        },
        {
            "start_logit": 11.0,
            "end_logit": -10.1796875,
            "text": "vincristine, adriamycin, cyclophosphamide (VAC) may be able to replace vincristine, adriamycin, ifosfamide (VAI)",
            "probability": 0.0
        },
        {
            "start_logit": 11.0,
            "end_logit": -10.25,
            "text": "vincristine, adriamycin, cyclophosphamide (VAC) may be able to replace",
            "probability": 0.0
        },
        {
            "start_logit": -9.8515625,
            "end_logit": 10.5390625,
            "text": ", vincristine",
            "probability": 0.0
        },
        {
            "start_logit": 11.0,
            "end_logit": -10.546875,
            "text": "vincristine, adriamycin, cyclophosphamide (VAC) may be able to replace vincristine, adriamycin, ifosfamide (VAI) in",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": 10.5390625,
            "text": "randomised Euro-EWING99-R1 trial, vincristine",
            "probability": 0.0
        },
        {
            "start_logit": -10.1171875,
            "end_logit": 10.5390625,
            "text": "R1 trial, vincristine",
            "probability": 0.0
        },
        {
            "start_logit": 11.0,
            "end_logit": -10.6484375,
            "text": "vincristine, adriamycin, cyclophosphamide (VAC) may be able to replace vincristine, adriamycin, ifosfamide (VAI",
            "probability": 0.0
        },
        {
            "start_logit": 11.0,
            "end_logit": -10.65625,
            "text": "vincristine, adriamycin, cyclophosphamide (VAC) may be able to replace vincristine, adriamycin, ifosfamide (VAI) in the",
            "probability": 0.0
        },
        {
            "start_logit": 11.0,
            "end_logit": -10.6796875,
            "text": "vincristine, adriamycin, cyclophosphamide (VAC) may be able to",
            "probability": 0.0
        }
    ],
    "60274ec61cb411341a0000e5_10": [
        {
            "start_logit": 11.453125,
            "end_logit": 11.7109375,
            "text": "Vincristine",
            "probability": 1.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": 0.6904296875,
            "text": "Vincristine, actinomycin D",
            "probability": 1.6450881958007812e-05
        },
        {
            "start_logit": 11.453125,
            "end_logit": -3.90234375,
            "text": "Vincristine, actinomycin D, and cyclophosphamide",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.453125,
            "end_logit": -5.74609375,
            "text": "Vincristine, actinomycin D, and cyclophosphamide (VAC) were administered to 14 patients with Ewing's sarcoma. The pr",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -7.8671875,
            "text": "Vincristine, actinomycin",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -8.7421875,
            "text": "Vincristine, actinomycin D, and cyclophosphamide (VAC)",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -8.84375,
            "text": "Vincristine, actinomycin D, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -9.09375,
            "text": "Vincristine, actinomycin D,",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -9.2734375,
            "text": "Vincristine, actinomycin D, and cyclophosphamide (VAC) were",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -9.765625,
            "text": "Vincristine, actinomycin D, and cyclophosphamide (VAC) were administered to 14 patients with Ewing's sarcoma. The",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -9.8125,
            "text": "Vincristine, actinomycin D, and cyclophosphamide (",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -9.9140625,
            "text": "Vincristine,",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -9.9375,
            "text": "Vincristine, actinomycin D, and cyclophosphamide (VAC) were administered",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -9.9453125,
            "text": "Vincristine, actinomycin D, and cyclophosphamide (VAC",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -10.078125,
            "text": "Vincristine, actinomycin D, and cyclophosphamide (VAC) were administered to 14 patients with Ewing's sarcoma.",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -10.265625,
            "text": "Vincristine, actinomycin D, and cyclophosphamide (VAC) were administered to",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -10.2890625,
            "text": "Vincristine, actinomycin D, and cyclophosphamide (VAC) were administered to 14 patients with",
            "probability": 0.0
        },
        {
            "start_logit": -0.1502685546875,
            "end_logit": 0.6904296875,
            "text": "actinomycin D",
            "probability": 0.0
        },
        {
            "start_logit": -0.1502685546875,
            "end_logit": -3.90234375,
            "text": "actinomycin D, and cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -0.1502685546875,
            "end_logit": -5.74609375,
            "text": "actinomycin D, and cyclophosphamide (VAC) were administered to 14 patients with Ewing's sarcoma. The pr",
            "probability": 0.0
        }
    ],
    "60274ec61cb411341a0000e5_11": [
        {
            "start_logit": 3.109375,
            "end_logit": 4.35546875,
            "text": "vincristine, ifosfamide",
            "probability": 0.5400390625
        },
        {
            "start_logit": 2.73046875,
            "end_logit": 4.35546875,
            "text": "ifosfamide",
            "probability": 0.36962890625
        },
        {
            "start_logit": 3.109375,
            "end_logit": 2.47265625,
            "text": "vincristine",
            "probability": 0.0821533203125
        },
        {
            "start_logit": 3.109375,
            "end_logit": -0.459228515625,
            "text": "vincristine, ifosfamide, doxorubicin",
            "probability": 0.00438690185546875
        },
        {
            "start_logit": 2.73046875,
            "end_logit": -0.459228515625,
            "text": "ifosfamide, doxorubicin",
            "probability": 0.0029926300048828125
        },
        {
            "start_logit": 1.1435546875,
            "end_logit": -0.459228515625,
            "text": "doxorubicin",
            "probability": 0.0006127357482910156
        },
        {
            "start_logit": 3.109375,
            "end_logit": -3.423828125,
            "text": "vincristine, ifosfamide, doxorubicin, and etoposide",
            "probability": 0.00022530555725097656
        },
        {
            "start_logit": 1.1435546875,
            "end_logit": -1.6875,
            "text": "doxorubicin, and etoposide (VIDE); vincristine, actinomycin D, and ifosfamide (VAI); or vincristine, actinomycin D, and cyclophosphamide",
            "probability": 0.00017964839935302734
        },
        {
            "start_logit": 2.73046875,
            "end_logit": -3.423828125,
            "text": "ifosfamide, doxorubicin, and etoposide",
            "probability": 0.00015485286712646484
        },
        {
            "start_logit": 1.1435546875,
            "end_logit": -3.423828125,
            "text": "doxorubicin, and etoposide",
            "probability": 3.147125244140625e-05
        },
        {
            "start_logit": 3.109375,
            "end_logit": -7.07421875,
            "text": "vincristine, ifosfamide, doxorubicin, and etoposide (VIDE); vincristine, actinomycin D",
            "probability": 5.841255187988281e-06
        },
        {
            "start_logit": -2.439453125,
            "end_logit": -1.6875,
            "text": "etoposide (VIDE); vincristine, actinomycin D, and ifosfamide (VAI); or vincristine, actinomycin D, and cyclophosphamide",
            "probability": 5.0067901611328125e-06
        },
        {
            "start_logit": 2.73046875,
            "end_logit": -7.07421875,
            "text": "ifosfamide, doxorubicin, and etoposide (VIDE); vincristine, actinomycin D",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": 3.109375,
            "end_logit": -7.49609375,
            "text": "vincristine, ifosfamide, doxorubicin, and etoposide (VIDE); vincristine, actinomycin D, and ifosfamide",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": 3.109375,
            "end_logit": -7.5546875,
            "text": "vincristine, if",
            "probability": 3.635883331298828e-06
        },
        {
            "start_logit": -8.8359375,
            "end_logit": 4.35546875,
            "text": "osfamide",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": 2.73046875,
            "end_logit": -7.49609375,
            "text": "ifosfamide, doxorubicin, and etoposide (VIDE); vincristine, actinomycin D, and ifosfamide",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": 2.73046875,
            "end_logit": -7.5546875,
            "text": "if",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": -9.515625,
            "end_logit": 4.35546875,
            "text": "G-CSF in different treatment courses of chemotherapy, which consisted of vincristine, ifosfamide",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -9.8359375,
            "end_logit": 4.35546875,
            "text": ", ifosfamide",
            "probability": 1.3113021850585938e-06
        }
    ],
    "60274ec61cb411341a0000e5_12": [
        {
            "start_logit": 11.578125,
            "end_logit": 11.2890625,
            "text": "vincristine",
            "probability": 1.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -1.572265625,
            "text": "vincristine, actinomycin D, and cyclophosphamide",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": 11.578125,
            "end_logit": -1.7666015625,
            "text": "vincristine, actinomycin D",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 11.578125,
            "end_logit": -3.0,
            "text": "vincristine, actinomycin D, and cyclophosphamide) regimens with anthracyclines",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 11.578125,
            "end_logit": -7.01171875,
            "text": "vincristine, actinomycin D, and cyclophosphamide) regimens with anthracyclines resulted in better survival. Presence of distant metastases",
            "probability": 0.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -7.06640625,
            "text": "vincristine, actinomycin D, and cyclophosphamide) regimens with anthracycline",
            "probability": 0.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -7.3203125,
            "text": "vincristine, actinomycin D, and cyclophosphamide) regimens with anthracyclines resulted in better survival. Presence of distant metastases, large primary tumors",
            "probability": 0.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -7.46484375,
            "text": "vincristine, actinomycin D, and cyclophosphamide) regimens with anthracyclines resulted in better survival. Presence of distant metastases, large primary tumors, and pelvic localization",
            "probability": 0.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -8.25,
            "text": "vincristine, actinomycin",
            "probability": 0.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -8.65625,
            "text": "vincristine, actinomycin D, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -8.78125,
            "text": "vincristine, actinomycin D, and cyclophosphamide) regimens with anthracyclines resulted in better survival. Presence of distant metastases, large primary tumors, and pelvic",
            "probability": 0.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -9.046875,
            "text": "vincristine, actinomycin D, and cyclophosphamide) regimens with anthracyclines resulted in better survival. Presence of distant metastases, large primary",
            "probability": 0.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -9.3203125,
            "text": "vincristine, actinomycin D, and cyclophosphamide) regimens with anthracyclines resulted in better survival. Presence of distant",
            "probability": 0.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -9.4296875,
            "text": "vincristine, actinomycin D,",
            "probability": 0.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -9.4453125,
            "text": "vincristine,",
            "probability": 0.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -9.4609375,
            "text": "vincristine, actinomycin D, and cyclophosphamide)",
            "probability": 0.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -9.5078125,
            "text": "vincristine, actinomycin D, and cyclophosphamide) regimens with anthracyclines resulted in better survival. Presence of distant metastases, large primary tumors, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -9.8515625,
            "text": "vincristine, actinomycin D, and cyclophosphamide) regimens with anthracyclines resulted in better survival. Presence of",
            "probability": 0.0
        },
        {
            "start_logit": 11.578125,
            "end_logit": -9.9140625,
            "text": "vincristine, actinomycin D, and cyclophosphamide) regimens with anthracyclines resulted in better survival. Presence of distant metastases, large",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 11.2890625,
            "text": "VAC (vincristine",
            "probability": 0.0
        }
    ],
    "60274ec61cb411341a0000e5_13": [
        {
            "start_logit": 12.9296875,
            "end_logit": 12.0703125,
            "text": "actinomycin D",
            "probability": 0.8896484375
        },
        {
            "start_logit": 10.75,
            "end_logit": 12.0703125,
            "text": "vincristine, actinomycin D",
            "probability": 0.09979248046875
        },
        {
            "start_logit": 10.75,
            "end_logit": 9.828125,
            "text": "vincristine",
            "probability": 0.01068115234375
        },
        {
            "start_logit": 12.9296875,
            "end_logit": -3.90625,
            "text": "actinomycin D, and cyclophosphamide",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.9296875,
            "end_logit": -4.75390625,
            "text": "actinomycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.75,
            "end_logit": -3.90625,
            "text": "vincristine, actinomycin D, and cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": 10.75,
            "end_logit": -4.75390625,
            "text": "vincristine, actinomycin",
            "probability": 0.0
        },
        {
            "start_logit": -6.140625,
            "end_logit": 12.0703125,
            "text": "D",
            "probability": 0.0
        },
        {
            "start_logit": 12.9296875,
            "end_logit": -8.6640625,
            "text": "actinomycin D, and",
            "probability": 0.0
        },
        {
            "start_logit": 12.9296875,
            "end_logit": -8.9921875,
            "text": "actinomycin D, and cyclophosphamide (VAC) regiment as an adjuvant chemotherapy",
            "probability": 0.0
        },
        {
            "start_logit": 12.9296875,
            "end_logit": -9.3984375,
            "text": "actinomycin D, and cyclophosphamide (VAC)",
            "probability": 0.0
        },
        {
            "start_logit": 12.9296875,
            "end_logit": -9.90625,
            "text": "actinomycin D,",
            "probability": 0.0
        },
        {
            "start_logit": 12.9296875,
            "end_logit": -10.109375,
            "text": "actinomycin D, and cyclophosphamide (VAC) regiment as an",
            "probability": 0.0
        },
        {
            "start_logit": -9.296875,
            "end_logit": 12.0703125,
            "text": "wide excision with safe margin of 1-2 cm, followed by 6-12 cycles of vincristine, actinomycin D",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": 12.0703125,
            "text": ", actinomycin D",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": 12.0703125,
            "text": "of vincristine, actinomycin D",
            "probability": 0.0
        },
        {
            "start_logit": -9.875,
            "end_logit": 12.0703125,
            "text": "excision with safe margin of 1-2 cm, followed by 6-12 cycles of vincristine, actinomycin D",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 12.0703125,
            "text": "safe margin of 1-2 cm, followed by 6-12 cycles of vincristine, actinomycin D",
            "probability": 0.0
        },
        {
            "start_logit": 10.75,
            "end_logit": -8.6640625,
            "text": "vincristine, actinomycin D, and",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 12.0703125,
            "text": "6-12 cycles of vincristine, actinomycin D",
            "probability": 0.0
        }
    ],
    "60274ec61cb411341a0000e5_14": [
        {
            "start_logit": 11.9921875,
            "end_logit": 10.59375,
            "text": "Cyclophosphamide",
            "probability": 1.0
        },
        {
            "start_logit": 11.9921875,
            "end_logit": 1.1552734375,
            "text": "Cyclophosphamide dose escalation in combination with vincristine",
            "probability": 7.903575897216797e-05
        },
        {
            "start_logit": 11.9921875,
            "end_logit": -3.767578125,
            "text": "Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 11.9921875,
            "end_logit": -6.4140625,
            "text": "Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.9921875,
            "end_logit": -6.7890625,
            "text": "Cyclophosphamide dose escalation",
            "probability": 0.0
        },
        {
            "start_logit": 3.728515625,
            "end_logit": 1.1552734375,
            "text": "vincristine",
            "probability": 0.0
        },
        {
            "start_logit": 11.9921875,
            "end_logit": -7.94921875,
            "text": "Cyclophosphamide dose escalation in combination with vincristine and actinomycin",
            "probability": 0.0
        },
        {
            "start_logit": 11.9921875,
            "end_logit": -8.2734375,
            "text": "Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support",
            "probability": 0.0
        },
        {
            "start_logit": 11.9921875,
            "end_logit": -8.765625,
            "text": "Cyclophosphamide dose escalation in combination with vincristine and",
            "probability": 0.0
        },
        {
            "start_logit": 11.9921875,
            "end_logit": -8.8828125,
            "text": "Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study",
            "probability": 0.0
        },
        {
            "start_logit": 11.9921875,
            "end_logit": -8.9921875,
            "text": "Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC)",
            "probability": 0.0
        },
        {
            "start_logit": 11.9921875,
            "end_logit": -9.203125,
            "text": "Cyclophosphamide dose escalation in combination with vincristine and actinomycin-",
            "probability": 0.0
        },
        {
            "start_logit": 11.9921875,
            "end_logit": -9.28125,
            "text": "Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A",
            "probability": 0.0
        },
        {
            "start_logit": 11.9921875,
            "end_logit": -9.3125,
            "text": "Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual",
            "probability": 0.0
        },
        {
            "start_logit": 11.9921875,
            "end_logit": -9.3359375,
            "text": "Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity",
            "probability": 0.0
        },
        {
            "start_logit": 11.9921875,
            "end_logit": -9.5078125,
            "text": "Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma.",
            "probability": 0.0
        },
        {
            "start_logit": 11.9921875,
            "end_logit": -9.5234375,
            "text": "Cyclophosphamide dose escalation in combination with",
            "probability": 0.0
        },
        {
            "start_logit": 11.9921875,
            "end_logit": -9.5859375,
            "text": "Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and",
            "probability": 0.0
        },
        {
            "start_logit": 11.9921875,
            "end_logit": -9.609375,
            "text": "Cyclophosphamide dose escalation in",
            "probability": 0.0
        },
        {
            "start_logit": 3.728515625,
            "end_logit": -3.767578125,
            "text": "vincristine and actinomycin-D",
            "probability": 0.0
        }
    ],
    "60274ec61cb411341a0000e5_15": [
        {
            "start_logit": 12.3203125,
            "end_logit": 10.21875,
            "text": "vincristine",
            "probability": 1.0
        },
        {
            "start_logit": 12.3203125,
            "end_logit": -5.3359375,
            "text": "vincristine (Vcr)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 12.3203125,
            "end_logit": -6.40234375,
            "text": "vincristine (Vcr",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.3203125,
            "end_logit": -6.54296875,
            "text": "vincristine (Vcr) and actinomycin-D",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.3203125,
            "end_logit": -8.1484375,
            "text": "vincristine (Vcr) and actinomycin-D (Amd), known as VAC, to establish a Cyc dose with myelotoxicity comparable to an if",
            "probability": 0.0
        },
        {
            "start_logit": 12.3203125,
            "end_logit": -8.296875,
            "text": "vincristine (Vcr) and actinomycin-D (Amd",
            "probability": 0.0
        },
        {
            "start_logit": 12.3203125,
            "end_logit": -8.4375,
            "text": "vincristine (Vcr) and actinomycin",
            "probability": 0.0
        },
        {
            "start_logit": 12.3203125,
            "end_logit": -8.6640625,
            "text": "vincristine (",
            "probability": 0.0
        },
        {
            "start_logit": 12.3203125,
            "end_logit": -8.90625,
            "text": "vincristine (Vcr) and actinomycin-D (",
            "probability": 0.0
        },
        {
            "start_logit": -8.59375,
            "end_logit": 10.21875,
            "text": "cyclophosphamide (Cyc) pilot without hematopoietic growth factor (HGF) support in combination with vincristine",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": 10.21875,
            "text": "escalating-dose cyclophosphamide (Cyc) pilot without hematopoietic growth factor (HGF) support in combination with vincristine",
            "probability": 0.0
        },
        {
            "start_logit": -9.90625,
            "end_logit": 10.21875,
            "text": "with vincristine",
            "probability": 0.0
        },
        {
            "start_logit": -9.9453125,
            "end_logit": 10.21875,
            "text": "hematopoietic growth factor (HGF) support in combination with vincristine",
            "probability": 0.0
        },
        {
            "start_logit": -9.9453125,
            "end_logit": 10.21875,
            "text": "Cyc) pilot without hematopoietic growth factor (HGF) support in combination with vincristine",
            "probability": 0.0
        },
        {
            "start_logit": -5.66796875,
            "end_logit": -6.3984375,
            "text": "ifosfamide",
            "probability": 0.0
        },
        {
            "start_logit": -6.2578125,
            "end_logit": -6.3984375,
            "text": "actinomycin-D (Amd), known as VAC, to establish a Cyc dose with myelotoxicity comparable to an ifosfamide",
            "probability": 0.0
        },
        {
            "start_logit": -6.2578125,
            "end_logit": -6.54296875,
            "text": "actinomycin-D",
            "probability": 0.0
        },
        {
            "start_logit": -5.66796875,
            "end_logit": -7.71484375,
            "text": "ifosfamide (Ifos",
            "probability": 0.0
        },
        {
            "start_logit": -5.66796875,
            "end_logit": -8.1484375,
            "text": "if",
            "probability": 0.0
        },
        {
            "start_logit": -8.59375,
            "end_logit": -5.3359375,
            "text": "cyclophosphamide (Cyc) pilot without hematopoietic growth factor (HGF) support in combination with vincristine (Vcr)",
            "probability": 0.0
        }
    ],
    "60274ec61cb411341a0000e5_16": [
        {
            "start_logit": 8.9140625,
            "end_logit": 10.1171875,
            "text": "dactinomycin",
            "probability": 0.62841796875
        },
        {
            "start_logit": 8.359375,
            "end_logit": 10.1171875,
            "text": "vincristine/dactinomycin",
            "probability": 0.358154296875
        },
        {
            "start_logit": 8.359375,
            "end_logit": 6.8203125,
            "text": "vincristine",
            "probability": 0.0133514404296875
        },
        {
            "start_logit": -2.8984375,
            "end_logit": 10.1171875,
            "text": "etoposide/ifosfamide (VP16/IFOS) cycles, alternating with vincristine/dactinomycin",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -2.09375,
            "text": "dactinomycin/cyclophosphamide",
            "probability": 3.0994415283203125e-06
        },
        {
            "start_logit": 8.359375,
            "end_logit": -2.09375,
            "text": "vincristine/dactinomycin/cyclophosphamide",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -4.2578125,
            "end_logit": 10.1171875,
            "text": "ifosfamide (VP16/IFOS) cycles, alternating with vincristine/dactinomycin",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -5.56640625,
            "end_logit": 10.1171875,
            "text": "omycin",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -2.8984375,
            "end_logit": 6.8203125,
            "text": "etoposide/ifosfamide (VP16/IFOS) cycles, alternating with vincristine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -5.26953125,
            "text": "dac",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -5.703125,
            "text": "dactin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.359375,
            "end_logit": -5.26953125,
            "text": "vincristine/dac",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.359375,
            "end_logit": -5.703125,
            "text": "vincristine/dactin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.2578125,
            "end_logit": 6.8203125,
            "text": "ifosfamide (VP16/IFOS) cycles, alternating with vincristine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.1171875,
            "end_logit": 10.1171875,
            "text": "osfamide (VP16/IFOS) cycles, alternating with vincristine/dactinomycin",
            "probability": 0.0
        },
        {
            "start_logit": -9.578125,
            "end_logit": 10.1171875,
            "text": "tinomycin",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 10.1171875,
            "text": "with vincristine/dactinomycin",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 10.1171875,
            "text": ": Standard chemotherapy consisted of etoposide/ifosfamide (VP16/IFOS) cycles, alternating with vincristine/dactinomycin",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 10.1171875,
            "text": "IFOS) cycles, alternating with vincristine/dactinomycin",
            "probability": 0.0
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -9.2421875,
            "text": "dactinomycin/",
            "probability": 0.0
        }
    ],
    "60274ec61cb411341a0000e5_17": [
        {
            "start_logit": 10.5390625,
            "end_logit": 11.7734375,
            "text": "dactinomycin",
            "probability": 0.96142578125
        },
        {
            "start_logit": 7.328125,
            "end_logit": 11.7734375,
            "text": "vincristine, dactinomycin",
            "probability": 0.038482666015625
        },
        {
            "start_logit": 7.328125,
            "end_logit": 5.12890625,
            "text": "vincristine",
            "probability": 5.02467155456543e-05
        },
        {
            "start_logit": -5.12109375,
            "end_logit": 11.7734375,
            "text": "adriamycin (ADR) or bilateral pulmonary radiotherapy (RT) to vincristine, dactinomycin",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.44921875,
            "end_logit": 11.7734375,
            "text": "omycin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.5390625,
            "end_logit": -5.03125,
            "text": "dactinomycin, and cyclophosphamide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.5390625,
            "end_logit": -6.1015625,
            "text": "dac",
            "probability": 0.0
        },
        {
            "start_logit": -8.5703125,
            "end_logit": 11.7734375,
            "text": "radiotherapy (RT) to vincristine, dactinomycin",
            "probability": 0.0
        },
        {
            "start_logit": 10.5390625,
            "end_logit": -7.44921875,
            "text": "dactin",
            "probability": 0.0
        },
        {
            "start_logit": -9.453125,
            "end_logit": 11.7734375,
            "text": "tinomycin",
            "probability": 0.0
        },
        {
            "start_logit": 7.328125,
            "end_logit": -5.03125,
            "text": "vincristine, dactinomycin, and cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -9.71875,
            "end_logit": 11.7734375,
            "text": "RT) to vincristine, dactinomycin",
            "probability": 0.0
        },
        {
            "start_logit": -9.75,
            "end_logit": 11.7734375,
            "text": "bilateral pulmonary radiotherapy (RT) to vincristine, dactinomycin",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": 11.7734375,
            "text": "ADR) or bilateral pulmonary radiotherapy (RT) to vincristine, dactinomycin",
            "probability": 0.0
        },
        {
            "start_logit": 10.5390625,
            "end_logit": -8.625,
            "text": "dactinomycin, and",
            "probability": 0.0
        },
        {
            "start_logit": -9.8828125,
            "end_logit": 11.7734375,
            "text": "pulmonary radiotherapy (RT) to vincristine, dactinomycin",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 11.7734375,
            "text": ", dactinomycin",
            "probability": 0.0
        },
        {
            "start_logit": 10.5390625,
            "end_logit": -9.2265625,
            "text": "dactinomycin, and cyclophosphamide (VAC therapy)",
            "probability": 0.0
        },
        {
            "start_logit": 7.328125,
            "end_logit": -6.1015625,
            "text": "vincristine, dac",
            "probability": 0.0
        },
        {
            "start_logit": 10.5390625,
            "end_logit": -9.59375,
            "text": "dactinomycin, and cyclophosphamide (VAC therapy) would",
            "probability": 0.0
        }
    ],
    "60274ec61cb411341a0000e5_18": [
        {
            "start_logit": 11.140625,
            "end_logit": 11.96875,
            "text": "vincristine",
            "probability": 1.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -5.234375,
            "text": "vincristine, actinomycin-D, and cyclophosphamide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.140625,
            "end_logit": -5.41796875,
            "text": "vincristine, actinomycin-D",
            "probability": 0.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -7.8359375,
            "text": "vincristine, actinomycin",
            "probability": 0.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -8.8984375,
            "text": "vincristine, actinomycin-D, and",
            "probability": 0.0
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 11.96875,
            "text": "Taking the lead from the use of vincristine",
            "probability": 0.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -9.2421875,
            "text": "vincristine, actinomycin-D, and cyclophosphamide (VAC) by Dr. Ruth Heyn",
            "probability": 0.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -9.7265625,
            "text": "vincristine, actinomycin-",
            "probability": 0.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -9.796875,
            "text": "vincristine, actinomycin-D, and cyclophosphamide (VAC) by Dr. Ruth Heyn, Dr. Harold Mauer",
            "probability": 0.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -9.796875,
            "text": "vincristine, actinomycin-D, and cyclophosphamide (VAC)",
            "probability": 0.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -10.0859375,
            "text": "vincristine, actinomycin-D, and cyclophosphamide (VAC) by Dr. Ruth He",
            "probability": 0.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -10.0859375,
            "text": "vincristine, actinomycin-D, and cyclophosphamide (",
            "probability": 0.0
        },
        {
            "start_logit": -5.890625,
            "end_logit": -5.234375,
            "text": "actinomycin-D, and cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -5.890625,
            "end_logit": -5.41796875,
            "text": "actinomycin-D",
            "probability": 0.0
        },
        {
            "start_logit": -6.40625,
            "end_logit": -5.234375,
            "text": "cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -5.890625,
            "end_logit": -7.8359375,
            "text": "actinomycin",
            "probability": 0.0
        },
        {
            "start_logit": -5.890625,
            "end_logit": -8.8984375,
            "text": "actinomycin-D, and",
            "probability": 0.0
        },
        {
            "start_logit": -9.6171875,
            "end_logit": -5.234375,
            "text": ", actinomycin-D, and cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -9.6171875,
            "end_logit": -5.41796875,
            "text": ", actinomycin-D",
            "probability": 0.0
        },
        {
            "start_logit": -9.8203125,
            "end_logit": -5.234375,
            "text": "Taking the lead from the use of vincristine, actinomycin-D, and cyclophosphamide",
            "probability": 0.0
        }
    ],
    "5c851c2675a4a5d219000006_1": [
        {
            "start_logit": 14.2421875,
            "end_logit": 14.125,
            "text": "actoxumab",
            "probability": 1.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -3.296875,
            "text": "act",
            "probability": 0.0
        },
        {
            "start_logit": -3.599609375,
            "end_logit": 14.125,
            "text": "umab",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -5.73828125,
            "text": "actox",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -6.9921875,
            "text": "actoxumab and bezlotoxumab",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -8.1953125,
            "text": "actoxumab and bez",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -8.4140625,
            "text": "actoxumab and be",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -8.75,
            "text": "actoxumab and bezlot",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -9.078125,
            "text": "actoxumab and bezlotox",
            "probability": 0.0
        },
        {
            "start_logit": -3.599609375,
            "end_logit": -6.9921875,
            "text": "umab and bezlotoxumab",
            "probability": 0.0
        },
        {
            "start_logit": -5.37890625,
            "end_logit": -6.12890625,
            "text": "toxin A (TcdA)",
            "probability": 0.0
        },
        {
            "start_logit": -3.599609375,
            "end_logit": -8.1953125,
            "text": "umab and bez",
            "probability": 0.0
        },
        {
            "start_logit": -3.599609375,
            "end_logit": -8.4140625,
            "text": "umab and be",
            "probability": 0.0
        },
        {
            "start_logit": -3.599609375,
            "end_logit": -8.75,
            "text": "umab and bezlot",
            "probability": 0.0
        },
        {
            "start_logit": -3.599609375,
            "end_logit": -9.078125,
            "text": "umab and bezlotox",
            "probability": 0.0
        },
        {
            "start_logit": -5.37890625,
            "end_logit": -7.6484375,
            "text": "toxin",
            "probability": 0.0
        },
        {
            "start_logit": -5.37890625,
            "end_logit": -8.6640625,
            "text": "toxin A (TcdA) and toxin B (TcdB",
            "probability": 0.0
        },
        {
            "start_logit": -5.37890625,
            "end_logit": -8.71875,
            "text": "toxin A (",
            "probability": 0.0
        },
        {
            "start_logit": -5.37890625,
            "end_logit": -8.734375,
            "text": "toxin A",
            "probability": 0.0
        },
        {
            "start_logit": -5.37890625,
            "end_logit": -8.84375,
            "text": "toxin A (TcdA) and toxin B (",
            "probability": 0.0
        }
    ],
    "5c851c2675a4a5d219000006_2": [
        {
            "start_logit": 12.8515625,
            "end_logit": 12.5234375,
            "text": "Bezlotoxumab",
            "probability": 1.0
        },
        {
            "start_logit": 12.8515625,
            "end_logit": -4.5703125,
            "text": "Be",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.8515625,
            "end_logit": -5.171875,
            "text": "Bez",
            "probability": 0.0
        },
        {
            "start_logit": 12.8515625,
            "end_logit": -5.34765625,
            "text": "Bezlotox",
            "probability": 0.0
        },
        {
            "start_logit": -6.171875,
            "end_logit": 12.5234375,
            "text": "umab",
            "probability": 0.0
        },
        {
            "start_logit": 12.8515625,
            "end_logit": -6.57421875,
            "text": "Bezlot",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 12.5234375,
            "text": "lotoxumab",
            "probability": 0.0
        },
        {
            "start_logit": -9.0390625,
            "end_logit": 12.5234375,
            "text": "oxumab",
            "probability": 0.0
        },
        {
            "start_logit": 12.8515625,
            "end_logit": -9.4140625,
            "text": "Bezlotoxumab was recently",
            "probability": 0.0
        },
        {
            "start_logit": 12.8515625,
            "end_logit": -9.421875,
            "text": "Bezlotoxumab was",
            "probability": 0.0
        },
        {
            "start_logit": 12.8515625,
            "end_logit": -10.0,
            "text": "Bezlotoxumab was recently approved by the FDA for reducing the recurrence of CDI",
            "probability": 0.0
        },
        {
            "start_logit": 12.8515625,
            "end_logit": -10.0078125,
            "text": "Bezlotoxumab was recently approved by the FDA for reducing the recurrence of CDI.",
            "probability": 0.0
        },
        {
            "start_logit": 12.8515625,
            "end_logit": -10.1640625,
            "text": "Bezlotoxumab was recently approved",
            "probability": 0.0
        },
        {
            "start_logit": 12.8515625,
            "end_logit": -10.1953125,
            "text": "Bezlotoxumab was recently approved by the FDA",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": 12.5234375,
            "text": "zlotoxumab",
            "probability": 0.0
        },
        {
            "start_logit": 12.8515625,
            "end_logit": -10.3125,
            "text": "Bezlotoxumab was recently approved by the FDA for reducing the",
            "probability": 0.0
        },
        {
            "start_logit": 12.8515625,
            "end_logit": -10.375,
            "text": "Bezlotoxumab was recently approved by the",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -5.34765625,
            "text": "lotox",
            "probability": 0.0
        },
        {
            "start_logit": -9.0390625,
            "end_logit": -5.34765625,
            "text": "ox",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -6.57421875,
            "text": "lot",
            "probability": 0.0
        }
    ],
    "5c851c2675a4a5d219000006_3": [
        {
            "start_logit": 14.0859375,
            "end_logit": 13.953125,
            "text": "actoxumab",
            "probability": 1.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -3.591796875,
            "text": "act",
            "probability": 0.0
        },
        {
            "start_logit": -3.90234375,
            "end_logit": 13.953125,
            "text": "umab",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -5.72265625,
            "text": "actox",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -7.0390625,
            "text": "actoxumab and bezlotoxumab",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -8.3203125,
            "text": "actoxumab and bez",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -8.5625,
            "text": "actoxumab and bezlotoxumab bind to and neutralize TcdA and TcdB",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -8.7109375,
            "text": "actoxumab and be",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -8.796875,
            "text": "actoxumab and bezlot",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.125,
            "text": "actoxumab and bezlotox",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.4765625,
            "text": "actoxumab and bezlotoxumab bind to and neutralize TcdA",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.53125,
            "text": "actoxumab and bezlotoxumab bind",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.6875,
            "text": "actoxumab and bezlotoxumab bind to and neutralize TcdA and",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.7734375,
            "text": "actoxumab and",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.8515625,
            "text": "actoxumab and bezlotoxumab bind to and neutralize TcdA and TcdB, respectively.",
            "probability": 0.0
        },
        {
            "start_logit": -9.890625,
            "end_logit": 13.953125,
            "text": "antitoxin antibodies actoxumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 13.953125,
            "text": "oxumab",
            "probability": 0.0
        },
        {
            "start_logit": -3.90234375,
            "end_logit": -7.0390625,
            "text": "umab and bezlotoxumab",
            "probability": 0.0
        },
        {
            "start_logit": -3.90234375,
            "end_logit": -8.3203125,
            "text": "umab and bez",
            "probability": 0.0
        },
        {
            "start_logit": -3.90234375,
            "end_logit": -8.5625,
            "text": "umab and bezlotoxumab bind to and neutralize TcdA and TcdB",
            "probability": 0.0
        }
    ],
    "5c851c2675a4a5d219000006_4": [
        {
            "start_logit": 14.03125,
            "end_logit": 14.0703125,
            "text": "actoxumab",
            "probability": 1.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -3.6015625,
            "text": "act",
            "probability": 0.0
        },
        {
            "start_logit": -3.833984375,
            "end_logit": 14.0703125,
            "text": "umab",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -5.328125,
            "text": "actox",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -5.41015625,
            "text": "actoxumab and bezlotoxumab",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -7.85546875,
            "text": "actoxumab and bez",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -7.859375,
            "text": "actoxumab and bezlot",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -8.09375,
            "text": "actoxumab and bezlotox",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -8.4921875,
            "text": "actoxumab and be",
            "probability": 0.0
        },
        {
            "start_logit": -9.28125,
            "end_logit": 14.0703125,
            "text": "monoclonal antitoxin antibodies actoxumab",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.28125,
            "text": "actoxumab and",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.3359375,
            "text": "actoxumab and bezlotoxumab.",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": 14.0703125,
            "text": "antitoxin antibodies actoxumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 14.0703125,
            "text": "of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 14.0703125,
            "text": "Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 14.0703125,
            "text": "oxumab",
            "probability": 0.0
        },
        {
            "start_logit": -3.833984375,
            "end_logit": -5.41015625,
            "text": "umab and bezlotoxumab",
            "probability": 0.0
        },
        {
            "start_logit": -3.833984375,
            "end_logit": -7.85546875,
            "text": "umab and bez",
            "probability": 0.0
        },
        {
            "start_logit": -3.833984375,
            "end_logit": -7.859375,
            "text": "umab and bezlot",
            "probability": 0.0
        },
        {
            "start_logit": -3.833984375,
            "end_logit": -8.09375,
            "text": "umab and bezlotox",
            "probability": 0.0
        }
    ],
    "5c851c2675a4a5d219000006_5": [
        {
            "start_logit": 12.15625,
            "end_logit": 12.6484375,
            "text": "Bezlotoxumab",
            "probability": 1.0
        },
        {
            "start_logit": 12.15625,
            "end_logit": -4.25,
            "text": "Bezlotoxumab: anti-toxin B monoclonal antibody",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.15625,
            "end_logit": -5.03125,
            "text": "Bez",
            "probability": 0.0
        },
        {
            "start_logit": 12.15625,
            "end_logit": -5.1015625,
            "text": "Be",
            "probability": 0.0
        },
        {
            "start_logit": -6.01171875,
            "end_logit": 12.6484375,
            "text": "umab",
            "probability": 0.0
        },
        {
            "start_logit": 12.15625,
            "end_logit": -6.49609375,
            "text": "Bezlotoxumab: anti-toxin B",
            "probability": 0.0
        },
        {
            "start_logit": 12.15625,
            "end_logit": -6.84765625,
            "text": "Bezlot",
            "probability": 0.0
        },
        {
            "start_logit": 12.15625,
            "end_logit": -6.89453125,
            "text": "Bezlotox",
            "probability": 0.0
        },
        {
            "start_logit": 12.15625,
            "end_logit": -7.1875,
            "text": "Bezlotoxumab: anti-toxin B monoclonal",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 12.6484375,
            "text": "lotoxumab",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 12.6484375,
            "text": "oxumab",
            "probability": 0.0
        },
        {
            "start_logit": 12.15625,
            "end_logit": -8.5,
            "text": "Bezlotoxumab: anti-toxin",
            "probability": 0.0
        },
        {
            "start_logit": 12.15625,
            "end_logit": -9.4609375,
            "text": "Bezlotoxumab: anti-",
            "probability": 0.0
        },
        {
            "start_logit": 12.15625,
            "end_logit": -9.5625,
            "text": "Bezlotoxumab: anti",
            "probability": 0.0
        },
        {
            "start_logit": -10.140625,
            "end_logit": 12.6484375,
            "text": "zlotoxumab",
            "probability": 0.0
        },
        {
            "start_logit": 12.15625,
            "end_logit": -9.9921875,
            "text": "Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence of Clostridium difficile infection.",
            "probability": 0.0
        },
        {
            "start_logit": 12.15625,
            "end_logit": -10.1328125,
            "text": "Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence of Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 12.15625,
            "end_logit": -10.3828125,
            "text": "Bezlotoxumab:",
            "probability": 0.0
        },
        {
            "start_logit": -5.41796875,
            "end_logit": -4.25,
            "text": "anti-toxin B monoclonal antibody",
            "probability": 0.0
        },
        {
            "start_logit": -6.01171875,
            "end_logit": -4.25,
            "text": "umab: anti-toxin B monoclonal antibody",
            "probability": 0.0
        }
    ],
    "5c851c2675a4a5d219000006_6": [
        {
            "start_logit": 10.9296875,
            "end_logit": 11.8671875,
            "text": "Bezlotoxumab",
            "probability": 1.0
        },
        {
            "start_logit": -6.578125,
            "end_logit": 11.8671875,
            "text": "umab",
            "probability": 0.0
        },
        {
            "start_logit": 10.9296875,
            "end_logit": -5.921875,
            "text": "Bez",
            "probability": 0.0
        },
        {
            "start_logit": 10.9296875,
            "end_logit": -5.93359375,
            "text": "Be",
            "probability": 0.0
        },
        {
            "start_logit": 10.9296875,
            "end_logit": -6.62890625,
            "text": "Bezlotox",
            "probability": 0.0
        },
        {
            "start_logit": 10.9296875,
            "end_logit": -6.6328125,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin B developed by Merck & Co",
            "probability": 0.0
        },
        {
            "start_logit": 10.9296875,
            "end_logit": -6.8515625,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody",
            "probability": 0.0
        },
        {
            "start_logit": 10.9296875,
            "end_logit": -6.8515625,
            "text": "Bezlot",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": 11.8671875,
            "text": "lotoxumab",
            "probability": 0.0
        },
        {
            "start_logit": -8.46875,
            "end_logit": 11.8671875,
            "text": "oxumab",
            "probability": 0.0
        },
        {
            "start_logit": 10.9296875,
            "end_logit": -8.09375,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin B developed by Merck & Co.",
            "probability": 0.0
        },
        {
            "start_logit": 10.9296875,
            "end_logit": -8.09375,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin B developed by Merck",
            "probability": 0.0
        },
        {
            "start_logit": 10.9296875,
            "end_logit": -8.21875,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin B",
            "probability": 0.0
        },
        {
            "start_logit": 10.9296875,
            "end_logit": -8.2734375,
            "text": "Bezlotoxumab (Zinplava\u2122",
            "probability": 0.0
        },
        {
            "start_logit": 10.9296875,
            "end_logit": -8.4296875,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal",
            "probability": 0.0
        },
        {
            "start_logit": -9.875,
            "end_logit": 11.8671875,
            "text": "zlotoxumab",
            "probability": 0.0
        },
        {
            "start_logit": 10.9296875,
            "end_logit": -9.2265625,
            "text": "Bezlotoxumab (Z",
            "probability": 0.0
        },
        {
            "start_logit": 10.9296875,
            "end_logit": -9.234375,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin B developed",
            "probability": 0.0
        },
        {
            "start_logit": 10.9296875,
            "end_logit": -9.28125,
            "text": "Bezlotoxumab (Zinplava\u2122)",
            "probability": 0.0
        },
        {
            "start_logit": 10.9296875,
            "end_logit": -9.3671875,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin B developed by",
            "probability": 0.0
        }
    ],
    "5c851c2675a4a5d219000006_7": [
        {
            "start_logit": 11.671875,
            "end_logit": 12.3125,
            "text": "Bezlotoxumab",
            "probability": 1.0
        },
        {
            "start_logit": -6.1640625,
            "end_logit": 12.3125,
            "text": "umab",
            "probability": 0.0
        },
        {
            "start_logit": 11.671875,
            "end_logit": -5.65234375,
            "text": "Be",
            "probability": 0.0
        },
        {
            "start_logit": 11.671875,
            "end_logit": -5.87109375,
            "text": "Bez",
            "probability": 0.0
        },
        {
            "start_logit": 11.671875,
            "end_logit": -6.9453125,
            "text": "Bezlot",
            "probability": 0.0
        },
        {
            "start_logit": 11.671875,
            "end_logit": -7.0625,
            "text": "Bezlotox",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 12.3125,
            "text": "oxumab",
            "probability": 0.0
        },
        {
            "start_logit": -8.40625,
            "end_logit": 12.3125,
            "text": "lotoxumab",
            "probability": 0.0
        },
        {
            "start_logit": 11.671875,
            "end_logit": -7.81640625,
            "text": "Bezlotoxumab (Zinplava\u2122) is a fully human monoclonal antibody",
            "probability": 0.0
        },
        {
            "start_logit": 11.671875,
            "end_logit": -7.859375,
            "text": "Bezlotoxumab (Zinplava\u2122) is",
            "probability": 0.0
        },
        {
            "start_logit": 11.671875,
            "end_logit": -8.421875,
            "text": "Bezlotoxumab (Zinplava\u2122",
            "probability": 0.0
        },
        {
            "start_logit": 11.671875,
            "end_logit": -8.84375,
            "text": "Bezlotoxumab (Zinplava\u2122) is a fully human monoclonal antibody against Clostridium difficile toxin B",
            "probability": 0.0
        },
        {
            "start_logit": 11.671875,
            "end_logit": -8.859375,
            "text": "Bezlotoxumab (Z",
            "probability": 0.0
        },
        {
            "start_logit": 11.671875,
            "end_logit": -8.8671875,
            "text": "Bezlotoxumab (Zin",
            "probability": 0.0
        },
        {
            "start_logit": 11.671875,
            "end_logit": -8.8828125,
            "text": "Bezlotoxumab (Zinplava\u2122) is a fully human monoclonal",
            "probability": 0.0
        },
        {
            "start_logit": -9.578125,
            "end_logit": 12.3125,
            "text": "zlotoxumab",
            "probability": 0.0
        },
        {
            "start_logit": 11.671875,
            "end_logit": -8.984375,
            "text": "Bezlotoxumab (",
            "probability": 0.0
        },
        {
            "start_logit": 11.671875,
            "end_logit": -9.140625,
            "text": "Bezlotoxumab (Zinplava\u2122) is a fully human monoclonal antibody against Clostridium difficile toxin B indicated",
            "probability": 0.0
        },
        {
            "start_logit": 11.671875,
            "end_logit": -9.2890625,
            "text": "Bezlotoxumab (Zinplava\u2122) is a fully human",
            "probability": 0.0
        },
        {
            "start_logit": 11.671875,
            "end_logit": -9.3359375,
            "text": "Bezlotoxumab (Zinplava",
            "probability": 0.0
        }
    ],
    "5c851c2675a4a5d219000006_8": [
        {
            "start_logit": 10.9609375,
            "end_logit": 11.875,
            "text": "Bezlotoxumab",
            "probability": 1.0
        },
        {
            "start_logit": -6.58984375,
            "end_logit": 11.875,
            "text": "umab",
            "probability": 0.0
        },
        {
            "start_logit": 10.9609375,
            "end_logit": -5.94921875,
            "text": "Be",
            "probability": 0.0
        },
        {
            "start_logit": 10.9609375,
            "end_logit": -6.125,
            "text": "Bez",
            "probability": 0.0
        },
        {
            "start_logit": 10.9609375,
            "end_logit": -6.77734375,
            "text": "Bezlotox",
            "probability": 0.0
        },
        {
            "start_logit": 10.9609375,
            "end_logit": -6.92578125,
            "text": "Bezlot",
            "probability": 0.0
        },
        {
            "start_logit": 10.9609375,
            "end_logit": -7.0859375,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin B developed by Merck &amp; Co",
            "probability": 0.0
        },
        {
            "start_logit": 10.9609375,
            "end_logit": -7.36328125,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 11.875,
            "text": "lotoxumab",
            "probability": 0.0
        },
        {
            "start_logit": -8.3984375,
            "end_logit": 11.875,
            "text": "oxumab",
            "probability": 0.0
        },
        {
            "start_logit": 10.9609375,
            "end_logit": -8.2578125,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin B",
            "probability": 0.0
        },
        {
            "start_logit": 10.9609375,
            "end_logit": -8.3515625,
            "text": "Bezlotoxumab (Zinplava\u2122",
            "probability": 0.0
        },
        {
            "start_logit": 10.9609375,
            "end_logit": -8.5703125,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin B developed by Merck",
            "probability": 0.0
        },
        {
            "start_logit": 10.9609375,
            "end_logit": -8.640625,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal",
            "probability": 0.0
        },
        {
            "start_logit": 10.9609375,
            "end_logit": -8.7578125,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin B developed by Merck &amp;",
            "probability": 0.0
        },
        {
            "start_logit": -9.890625,
            "end_logit": 11.875,
            "text": "zlotoxumab",
            "probability": 0.0
        },
        {
            "start_logit": 10.9609375,
            "end_logit": -9.15625,
            "text": "Bezlotoxumab (Z",
            "probability": 0.0
        },
        {
            "start_logit": 10.9609375,
            "end_logit": -9.265625,
            "text": "Bezlotoxumab (Zinplava\u2122) is",
            "probability": 0.0
        },
        {
            "start_logit": 10.9609375,
            "end_logit": -9.3203125,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin B developed",
            "probability": 0.0
        },
        {
            "start_logit": 10.9609375,
            "end_logit": -9.328125,
            "text": "Bezlotoxumab (Zinplava\u2122)",
            "probability": 0.0
        }
    ],
    "58bc666702b8c60953000004_1": [
        {
            "start_logit": 9.3671875,
            "end_logit": 10.1484375,
            "text": "amyotrophic lateral sclerosis",
            "probability": 0.70947265625
        },
        {
            "start_logit": 9.3671875,
            "end_logit": 9.1328125,
            "text": "amyotrophic lateral sclerosis (ALS",
            "probability": 0.2568359375
        },
        {
            "start_logit": 7.32421875,
            "end_logit": 9.1328125,
            "text": "ALS",
            "probability": 0.033203125
        },
        {
            "start_logit": 9.3671875,
            "end_logit": -4.5703125,
            "text": "amyotrophic lateral sclerosis (ALS)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.390625,
            "end_logit": 10.1484375,
            "text": "neurodegenerative disorders caused by protein misfolding and aggregation, including amyotrophic lateral sclerosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3671875,
            "end_logit": -6.08203125,
            "text": "amyotrophic lateral sclerosis (ALS), Parkinson's disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.32421875,
            "end_logit": -4.5703125,
            "text": "ALS)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.390625,
            "end_logit": 9.1328125,
            "text": "neurodegenerative disorders caused by protein misfolding and aggregation, including amyotrophic lateral sclerosis (ALS",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3671875,
            "end_logit": -6.81640625,
            "text": "amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.875,
            "end_logit": 10.1484375,
            "text": "sclerosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3671875,
            "end_logit": -7.23828125,
            "text": "amyotrophic",
            "probability": 0.0
        },
        {
            "start_logit": 9.3671875,
            "end_logit": -7.64453125,
            "text": "amyotrophic lateral sclerosis (",
            "probability": 0.0
        },
        {
            "start_logit": 9.3671875,
            "end_logit": -8.09375,
            "text": "amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": 9.1328125,
            "text": "sclerosis (ALS",
            "probability": 0.0
        },
        {
            "start_logit": 7.32421875,
            "end_logit": -6.08203125,
            "text": "ALS), Parkinson's disease",
            "probability": 0.0
        },
        {
            "start_logit": -9.0,
            "end_logit": 10.1484375,
            "text": "disorders caused by protein misfolding and aggregation, including amyotrophic lateral sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.3671875,
            "end_logit": -8.3671875,
            "text": "amyotrophic lateral sclerosis (ALS), Parkinson",
            "probability": 0.0
        },
        {
            "start_logit": -9.3125,
            "end_logit": 10.1484375,
            "text": "lateral sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.3671875,
            "end_logit": -8.6015625,
            "text": "amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and Alzheimer's disease (AD",
            "probability": 0.0
        },
        {
            "start_logit": 7.32421875,
            "end_logit": -6.81640625,
            "text": "ALS), Parkinson's disease (PD",
            "probability": 0.0
        }
    ],
    "58bc666702b8c60953000004_2": [
        {
            "start_logit": 13.5859375,
            "end_logit": 13.40625,
            "text": "prions",
            "probability": 1.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -2.431640625,
            "text": "prion",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.4453125,
            "end_logit": 13.40625,
            "text": "s",
            "probability": 0.0
        },
        {
            "start_logit": -6.1484375,
            "end_logit": 13.40625,
            "text": "Hsp104 dissolves disordered aggregates and prions",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -8.2890625,
            "text": "prions is unknown",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -9.53125,
            "text": "prions is unknown.",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -10.0859375,
            "text": "prions is",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 13.40625,
            "text": "dissolves disordered aggregates and prions",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 13.40625,
            "text": "aggregates and prions",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 13.40625,
            "text": "which Hsp104 dissolves disordered aggregates and prions",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 13.40625,
            "text": "disordered aggregates and prions",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 13.40625,
            "text": "ves disordered aggregates and prions",
            "probability": 0.0
        },
        {
            "start_logit": -6.1484375,
            "end_logit": -2.431640625,
            "text": "Hsp104 dissolves disordered aggregates and prion",
            "probability": 0.0
        },
        {
            "start_logit": -6.1484375,
            "end_logit": -5.296875,
            "text": "Hsp104",
            "probability": 0.0
        },
        {
            "start_logit": -4.4453125,
            "end_logit": -8.2890625,
            "text": "s is unknown",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": -2.431640625,
            "text": "dissolves disordered aggregates and prion",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": -2.431640625,
            "text": "aggregates and prion",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": -2.431640625,
            "text": "which Hsp104 dissolves disordered aggregates and prion",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": -2.431640625,
            "text": "disordered aggregates and prion",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": -2.431640625,
            "text": "ves disordered aggregates and prion",
            "probability": 0.0
        }
    ],
    "52e0141498d023950500000e_1": [
        {
            "start_logit": 10.515625,
            "end_logit": 11.09375,
            "text": "growth rate deficit",
            "probability": 1.0
        },
        {
            "start_logit": 0.8935546875,
            "end_logit": 11.09375,
            "text": "significant growth rate deficit",
            "probability": 6.604194641113281e-05
        },
        {
            "start_logit": 10.515625,
            "end_logit": -3.607421875,
            "text": "growth rate",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.15234375,
            "end_logit": 11.09375,
            "text": "deficit",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.515625,
            "end_logit": -6.1484375,
            "text": "growth",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.515625,
            "end_logit": -7.640625,
            "text": "growth rate deficit in both roots and shoots and lowered activity of specific mitochondrial enzymes associated with respiratory metabolism",
            "probability": 0.0
        },
        {
            "start_logit": 10.515625,
            "end_logit": -8.5625,
            "text": "growth rate deficit in both roots and shoots and lowered activity of specific mitochondrial enzymes",
            "probability": 0.0
        },
        {
            "start_logit": 10.515625,
            "end_logit": -8.7578125,
            "text": "growth rate deficit in",
            "probability": 0.0
        },
        {
            "start_logit": 10.515625,
            "end_logit": -8.8203125,
            "text": "growth rate deficit in both roots and shoots and lowered activity",
            "probability": 0.0
        },
        {
            "start_logit": -9.4453125,
            "end_logit": 11.09375,
            "text": "rate deficit",
            "probability": 0.0
        },
        {
            "start_logit": 10.515625,
            "end_logit": -8.921875,
            "text": "growth rate deficit in both roots and shoots and lowered activity of",
            "probability": 0.0
        },
        {
            "start_logit": 10.515625,
            "end_logit": -8.953125,
            "text": "growth rate deficit in both roots and shoots and lowered activity of specific mitochondrial enzymes associated",
            "probability": 0.0
        },
        {
            "start_logit": 10.515625,
            "end_logit": -9.09375,
            "text": "growth rate deficit in both roots and shoots and",
            "probability": 0.0
        },
        {
            "start_logit": 10.515625,
            "end_logit": -9.3046875,
            "text": "growth rate deficit in both roots and shoots and lowered activity of specific mitochondrial",
            "probability": 0.0
        },
        {
            "start_logit": -9.9921875,
            "end_logit": 11.09375,
            "text": "Arabidopsis thaliana) leads to a significant growth rate deficit",
            "probability": 0.0
        },
        {
            "start_logit": 10.515625,
            "end_logit": -9.5078125,
            "text": "growth rate deficit in both roots and shoots and lowered activity of specific mitochondrial enzymes associated with respiratory",
            "probability": 0.0
        },
        {
            "start_logit": 10.515625,
            "end_logit": -9.515625,
            "text": "growth rate deficit in both roots and",
            "probability": 0.0
        },
        {
            "start_logit": 10.515625,
            "end_logit": -9.515625,
            "text": "growth rate deficit in both roots and shoots and lowered activity of specific",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 11.09375,
            "text": "Arabidopsis (Arabidopsis thaliana) leads to a significant growth rate deficit",
            "probability": 0.0
        },
        {
            "start_logit": 10.515625,
            "end_logit": -9.7578125,
            "text": "growth rate deficit in both roots and shoots and lowered activity of specific mitochondrial enzymes associated with",
            "probability": 0.0
        }
    ],
    "52e0141498d023950500000e_2": [
        {
            "start_logit": 14.15625,
            "end_logit": 14.3125,
            "text": "growth retardation",
            "probability": 1.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": 1.333984375,
            "text": "growth retardation and impaired seedling establishment",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": -3.1796875,
            "end_logit": 14.3125,
            "text": "retardation",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -3.134765625,
            "text": "growth",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -6.078125,
            "text": "growth retardation and impaired",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -6.5078125,
            "text": "growth retardation and impaired seedling",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -7.95703125,
            "text": "growth retardation and impaired seedling establishment can",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -8.109375,
            "text": "growth retardation and impaired seedling establishment can be attributed to defects in the oil",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -8.6875,
            "text": "growth retardation and impaired seedling establishment can be attributed to defects in the oil reserve",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -8.71875,
            "text": "growth retardation and",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -8.7734375,
            "text": "growth retardation and impaired seedling establishment can be attributed to defects in the oil reserve mobilization pathway",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -8.9453125,
            "text": "growth retardation and impaired seedling establishment can be attributed to defects in the oil reserve mobilization",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -9.265625,
            "text": "growth retardation and impaired seedling establishment can be attributed to defects in the",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -9.3984375,
            "text": "growth retardation and impaired seedling establishment can be attributed",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -9.421875,
            "text": "growth retardation and impaired seedling establishment can be attributed to defects",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -9.4921875,
            "text": "growth retardation and impaired seedling establishment can be",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -9.515625,
            "text": "growth retardation and impaired seedling establishment can be attributed to",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 14.3125,
            "text": "Lon selective proteolysis leading to growth retardation",
            "probability": 0.0
        },
        {
            "start_logit": -3.1796875,
            "end_logit": 1.333984375,
            "text": "retardation and impaired seedling establishment",
            "probability": 0.0
        },
        {
            "start_logit": -3.244140625,
            "end_logit": 1.333984375,
            "text": "impaired seedling establishment",
            "probability": 0.0
        }
    ],
    "52fa73e82059c6d71c000059_1": [
        {
            "start_logit": 12.765625,
            "end_logit": 9.421875,
            "text": "Agrobacterium-mediated",
            "probability": 0.93115234375
        },
        {
            "start_logit": 12.765625,
            "end_logit": 6.71875,
            "text": "Agrobacterium-mediated as",
            "probability": 0.0623779296875
        },
        {
            "start_logit": 12.765625,
            "end_logit": 4.4296875,
            "text": "Agrobacterium-mediated as well as direct delivery methods",
            "probability": 0.0062713623046875
        },
        {
            "start_logit": 4.34765625,
            "end_logit": 6.71875,
            "text": "as",
            "probability": 1.3709068298339844e-05
        },
        {
            "start_logit": 12.765625,
            "end_logit": -2.828125,
            "text": "Agrobacterium-mediated as well",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": 4.34765625,
            "end_logit": 4.4296875,
            "text": "as well as direct delivery methods",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 12.765625,
            "end_logit": -4.26171875,
            "text": "Agrobacterium",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 12.765625,
            "end_logit": -7.109375,
            "text": "Agrobacterium-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.765625,
            "end_logit": -7.328125,
            "text": "Agrobacterium-mediated as well as",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.765625,
            "end_logit": -8.15625,
            "text": "Agrobacterium-mediated as well as direct delivery",
            "probability": 0.0
        },
        {
            "start_logit": 12.765625,
            "end_logit": -8.21875,
            "text": "Agrobacterium-mediated as well as direct",
            "probability": 0.0
        },
        {
            "start_logit": 12.765625,
            "end_logit": -8.796875,
            "text": "Agrobacterium-mediated as well as direct delivery methods have",
            "probability": 0.0
        },
        {
            "start_logit": 12.765625,
            "end_logit": -9.5234375,
            "text": "Agrobacterium-mediated as well as direct delivery methods have been used",
            "probability": 0.0
        },
        {
            "start_logit": -6.60546875,
            "end_logit": 9.421875,
            "text": "genetic transformation, Agrobacterium-mediated",
            "probability": 0.0
        },
        {
            "start_logit": 4.34765625,
            "end_logit": -2.828125,
            "text": "as well",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.421875,
            "text": "mediated",
            "probability": 0.0
        },
        {
            "start_logit": -3.548828125,
            "end_logit": 4.4296875,
            "text": "direct delivery methods",
            "probability": 0.0
        },
        {
            "start_logit": -8.984375,
            "end_logit": 9.421875,
            "text": "efficient genetic transformation, Agrobacterium-mediated",
            "probability": 0.0
        },
        {
            "start_logit": -6.60546875,
            "end_logit": 6.71875,
            "text": "genetic transformation, Agrobacterium-mediated as",
            "probability": 0.0
        },
        {
            "start_logit": -9.7890625,
            "end_logit": 9.421875,
            "text": "transformation, Agrobacterium-mediated",
            "probability": 0.0
        }
    ],
    "52fa73e82059c6d71c000059_2": [
        {
            "start_logit": 11.5,
            "end_logit": 11.0078125,
            "text": "Red/ET recombination",
            "probability": 0.9990234375
        },
        {
            "start_logit": 11.5,
            "end_logit": 4.125,
            "text": "Red/ET recombination and unique restriction site elimination",
            "probability": 0.0010318756103515625
        },
        {
            "start_logit": 11.5,
            "end_logit": 3.212890625,
            "text": "Red",
            "probability": 0.00041365623474121094
        },
        {
            "start_logit": 4.3125,
            "end_logit": 5.3515625,
            "text": "site-directed plasmid mutagenesis",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": 11.5,
            "end_logit": -3.451171875,
            "text": "Red/ET",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 11.5,
            "end_logit": -4.1875,
            "text": "Red/ET recombination and unique restriction site",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.1875,
            "end_logit": 11.0078125,
            "text": "recombination",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -7.98828125,
            "text": "Red/ET recombination and unique restriction site elimination enables extensive manipulation regardless of plasmid size and DNA sequence elements",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -8.5546875,
            "text": "Red/",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 11.0078125,
            "text": "combined use of Red/ET recombination",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -9.234375,
            "text": "Red/ET recombination and unique restriction site elimination enables extensive manipulation regardless of plasmid size and DNA sequence",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -9.3359375,
            "text": "Red/ET recombination and unique restriction site elimination enables",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -9.3359375,
            "text": "Red/ET recombination and unique restriction",
            "probability": 0.0
        },
        {
            "start_logit": -8.96875,
            "end_logit": 11.0078125,
            "text": "ET recombination",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -9.5234375,
            "text": "Red/ET recombination and",
            "probability": 0.0
        },
        {
            "start_logit": -2.17578125,
            "end_logit": 4.125,
            "text": "unique restriction site elimination",
            "probability": 0.0
        },
        {
            "start_logit": -9.3046875,
            "end_logit": 11.0078125,
            "text": "in vitro DNA synthesis. As demonstrated here, the combined use of Red/ET recombination",
            "probability": 0.0
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 11.0078125,
            "text": "use of Red/ET recombination",
            "probability": 0.0
        },
        {
            "start_logit": -5.23828125,
            "end_logit": 5.3515625,
            "text": "mutagenesis",
            "probability": 0.0
        },
        {
            "start_logit": -4.86328125,
            "end_logit": 4.125,
            "text": "restriction site elimination",
            "probability": 0.0
        }
    ],
    "52fa73e82059c6d71c000059_3": [
        {
            "start_logit": 12.5703125,
            "end_logit": 12.6171875,
            "text": "Bacterial artificial chromosomes",
            "probability": 1.0
        },
        {
            "start_logit": 12.5703125,
            "end_logit": -1.5205078125,
            "text": "Bacterial artificial chromosomes (BACs",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 12.5703125,
            "end_logit": -3.109375,
            "text": "Bacterial artificial chromosomes (BAC",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.5703125,
            "end_logit": -5.16015625,
            "text": "Bacterial",
            "probability": 0.0
        },
        {
            "start_logit": -5.37890625,
            "end_logit": 12.6171875,
            "text": "chromosomes",
            "probability": 0.0
        },
        {
            "start_logit": 12.5703125,
            "end_logit": -5.4140625,
            "text": "Bacterial artificial chromosomes (BACs)",
            "probability": 0.0
        },
        {
            "start_logit": 12.5703125,
            "end_logit": -6.58984375,
            "text": "Bacterial artificial chromosomes (",
            "probability": 0.0
        },
        {
            "start_logit": 12.5703125,
            "end_logit": -7.73828125,
            "text": "Bacterial artificial chromosomes (BACs) derived from genomes of large DNA viruses are powerful tools",
            "probability": 0.0
        },
        {
            "start_logit": 12.5703125,
            "end_logit": -7.7578125,
            "text": "Bacterial artificial chromosomes (BACs) derived from genomes of large DNA viruses are",
            "probability": 0.0
        },
        {
            "start_logit": 12.5703125,
            "end_logit": -8.1875,
            "text": "Bacterial artificial chromosomes (BACs) derived from genomes of large DNA viruses",
            "probability": 0.0
        },
        {
            "start_logit": 12.5703125,
            "end_logit": -8.3984375,
            "text": "Bacterial artificial",
            "probability": 0.0
        },
        {
            "start_logit": 12.5703125,
            "end_logit": -8.46875,
            "text": "Bacterial artificial chromosomes (BACs) derived",
            "probability": 0.0
        },
        {
            "start_logit": 12.5703125,
            "end_logit": -8.6640625,
            "text": "Bacterial artificial chromosomes (BACs) derived from",
            "probability": 0.0
        },
        {
            "start_logit": 12.5703125,
            "end_logit": -9.453125,
            "text": "Bacterial artificial chromosomes (BACs) derived from genomes of large DNA viruses are powerful",
            "probability": 0.0
        },
        {
            "start_logit": 12.5703125,
            "end_logit": -9.5546875,
            "text": "Bacterial artificial chromosomes (BACs) derived from genomes of large DNA viruses are powerful tools for",
            "probability": 0.0
        },
        {
            "start_logit": 12.5703125,
            "end_logit": -9.625,
            "text": "Bacterial artificial chromosomes (BACs) derived from genomes of large DNA viruses are powerful tools for functional delineation of viral genes",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": 12.6171875,
            "text": "artificial chromosomes",
            "probability": 0.0
        },
        {
            "start_logit": 12.5703125,
            "end_logit": -10.0078125,
            "text": "Bacterial artificial chromosomes (BACs) derived from genomes of large DNA viruses are powerful tools for functional delineation of viral genes.",
            "probability": 0.0
        },
        {
            "start_logit": 12.5703125,
            "end_logit": -10.1171875,
            "text": "Bacterial artificial chromosomes (BACs) derived from genomes of",
            "probability": 0.0
        },
        {
            "start_logit": 12.5703125,
            "end_logit": -10.140625,
            "text": "Bacterial artificial chromosomes (BACs) derived from genomes of large",
            "probability": 0.0
        }
    ],
    "52fa73e82059c6d71c000059_4": [
        {
            "start_logit": 5.92578125,
            "end_logit": 7.3984375,
            "text": "cloning the genomes of large DNA viruses as BACs",
            "probability": 0.984375
        },
        {
            "start_logit": 1.75,
            "end_logit": 7.3984375,
            "text": "BACs",
            "probability": 0.01506805419921875
        },
        {
            "start_logit": -2.896484375,
            "end_logit": 7.3984375,
            "text": "as BACs",
            "probability": 0.0001442432403564453
        },
        {
            "start_logit": 5.92578125,
            "end_logit": -4.2265625,
            "text": "cloning the genomes of large DNA viruses as BAC",
            "probability": 8.821487426757812e-06
        },
        {
            "start_logit": -6.79296875,
            "end_logit": 7.3984375,
            "text": "genomes of large DNA viruses as BACs",
            "probability": 2.9206275939941406e-06
        },
        {
            "start_logit": 5.92578125,
            "end_logit": -5.42578125,
            "text": "cloning the genomes of large DNA viruses as BACs, which entails direct in vitro transposition of viral genomes with a BAC cassette",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": 5.92578125,
            "end_logit": -6.3671875,
            "text": "cloning the genomes of large DNA viruses",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 5.92578125,
            "end_logit": -7.125,
            "text": "cloning the genomes of large DNA viruses as BACs, which entails direct in vitro transposition of viral genomes with a BAC",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 5.92578125,
            "end_logit": -7.19921875,
            "text": "cloning the genomes of large DNA viruses as",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 5.92578125,
            "end_logit": -8.203125,
            "text": "cloning the genomes of large DNA viruses as BACs, which entails direct in vitro transposition of viral genomes with a",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -9.84375,
            "end_logit": 7.3984375,
            "text": "large DNA viruses as BACs",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.8515625,
            "end_logit": 7.3984375,
            "text": "s",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 1.75,
            "end_logit": -4.2265625,
            "text": "BAC",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.92578125,
            "end_logit": -8.7421875,
            "text": "cloning the genomes of large DNA viruses as BACs, which entails direct in vitro transposition",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.92578125,
            "end_logit": -8.875,
            "text": "cloning the genomes of large DNA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.92578125,
            "end_logit": -8.9140625,
            "text": "cloning",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.92578125,
            "end_logit": -9.53125,
            "text": "cloning the genomes of large DNA viruses as BACs, which entails direct in vitro",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.75,
            "end_logit": -5.42578125,
            "text": "BACs, which entails direct in vitro transposition of viral genomes with a BAC cassette",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.75,
            "end_logit": -7.125,
            "text": "BACs, which entails direct in vitro transposition of viral genomes with a BAC",
            "probability": 0.0
        },
        {
            "start_logit": 1.75,
            "end_logit": -8.203125,
            "text": "BACs, which entails direct in vitro transposition of viral genomes with a",
            "probability": 0.0
        }
    ],
    "530cefaaad0bf1360c000002_1": [
        {
            "start_logit": 7.5859375,
            "end_logit": 9.65625,
            "text": "subgenual cingulate gyrus",
            "probability": 0.9990234375
        },
        {
            "start_logit": 7.5859375,
            "end_logit": 3.0859375,
            "text": "subgenual cingulate gyrus (Cg25/24), the anterior limb of the capsula interna (ALIC), and the nucleus accumbens",
            "probability": 0.0013895034790039062
        },
        {
            "start_logit": -3.48828125,
            "end_logit": 9.65625,
            "text": "cingulate gyrus",
            "probability": 1.5437602996826172e-05
        },
        {
            "start_logit": 2.48828125,
            "end_logit": 3.0859375,
            "text": "nucleus accumbens",
            "probability": 8.52346420288086e-06
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -3.4296875,
            "text": "subgenual cingulate gyrus (Cg25/24",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -5.390625,
            "text": "subgenual cingulate gyrus (Cg25",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 9.65625,
            "text": "gyrus",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 9.65625,
            "text": "at the subgenual cingulate gyrus",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -5.8984375,
            "text": "subgenual cingulate gyrus (Cg25/24), the anterior limb of the capsula interna (ALIC), and the nucleus",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -6.66015625,
            "text": "subgenual cingulate gyrus (Cg25/24), the anterior limb of the capsula interna",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -6.78515625,
            "text": "subgenual cingulate gyrus (Cg",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -6.89453125,
            "text": "subgenual cingulate gyrus (Cg25/24), the anterior limb of the capsul",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.28125,
            "end_logit": 9.65625,
            "text": "ual cingulate gyrus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.421875,
            "end_logit": 9.65625,
            "text": "stimulated at the subgenual cingulate gyrus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -7.53125,
            "text": "subgenual cingulate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -7.625,
            "text": "subgenual cingulate gyrus (Cg25/24)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -7.703125,
            "text": "subgenual cingulate gyrus (Cg25/24), the anterior limb of the capsula interna (ALIC",
            "probability": 0.0
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -7.7734375,
            "text": "subgenual cingulate gyrus (Cg25/24), the anterior limb of the capsula intern",
            "probability": 0.0
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -7.98046875,
            "text": "subgenual cingulate gyrus (Cg25/",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 9.65625,
            "text": "scientific evaluation as a new treatment option for these treatment-resistant patients. First clinical studies with small samples have been stimulated at the subgenual cingulate gyrus",
            "probability": 0.0
        }
    ],
    "530cefaaad0bf1360c000002_2": [
        {
            "start_logit": 10.03125,
            "end_logit": 10.9609375,
            "text": "medial forebrain bundle",
            "probability": 1.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": 1.7294921875,
            "text": "medial forebrain bundle, habenula",
            "probability": 9.685754776000977e-05
        },
        {
            "start_logit": -6.12890625,
            "end_logit": 10.9609375,
            "text": "bundle",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.03125,
            "end_logit": -6.15625,
            "text": "medial forebrain bundle, haben",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.03125,
            "end_logit": -6.25,
            "text": "medial",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.03125,
            "end_logit": -7.24609375,
            "text": "medial forebrain bundle, hab",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -7.6015625,
            "text": "medial forebrain bundle,",
            "probability": 0.0
        },
        {
            "start_logit": 0.50341796875,
            "end_logit": 1.7294921875,
            "text": "habenula",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.0,
            "text": "medial forebrain",
            "probability": 0.0
        },
        {
            "start_logit": -8.9765625,
            "end_logit": 10.9609375,
            "text": "forebrain bundle",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 10.9609375,
            "text": ".g., medial forebrain bundle",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 10.9609375,
            "text": "hypothesis-guided targets (e.g., medial forebrain bundle",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 10.9609375,
            "text": "e.g., medial forebrain bundle",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -9.625,
            "text": "medial forebrain bundle, habenula) are about",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -9.75,
            "text": "medial forebrain bundle, habenula)",
            "probability": 0.0
        },
        {
            "start_logit": -6.12890625,
            "end_logit": 1.7294921875,
            "text": "bundle, habenula",
            "probability": 0.0
        },
        {
            "start_logit": -7.234375,
            "end_logit": 1.7294921875,
            "text": ", habenula",
            "probability": 0.0
        },
        {
            "start_logit": 0.50341796875,
            "end_logit": -6.15625,
            "text": "haben",
            "probability": 0.0
        },
        {
            "start_logit": -7.7578125,
            "end_logit": 1.7294921875,
            "text": "ula",
            "probability": 0.0
        },
        {
            "start_logit": 0.50341796875,
            "end_logit": -7.24609375,
            "text": "hab",
            "probability": 0.0
        }
    ],
    "530cefaaad0bf1360c000002_3": [
        {
            "start_logit": 12.796875,
            "end_logit": 11.9296875,
            "text": "nucleus accumbens",
            "probability": 1.0
        },
        {
            "start_logit": 12.796875,
            "end_logit": -4.32421875,
            "text": "nucleus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.95703125,
            "end_logit": 11.9296875,
            "text": "accumbens",
            "probability": 0.0
        },
        {
            "start_logit": 12.796875,
            "end_logit": -6.94140625,
            "text": "nucleus accumbens (",
            "probability": 0.0
        },
        {
            "start_logit": 12.796875,
            "end_logit": -7.14453125,
            "text": "nucleus accumbens (NAcc",
            "probability": 0.0
        },
        {
            "start_logit": 12.796875,
            "end_logit": -7.85546875,
            "text": "nucleus accumbens (NAcc-DBS",
            "probability": 0.0
        },
        {
            "start_logit": 12.796875,
            "end_logit": -8.6328125,
            "text": "nucleus accumbens (NAc",
            "probability": 0.0
        },
        {
            "start_logit": 12.796875,
            "end_logit": -8.9609375,
            "text": "nucleus accumbens (NAcc-DBS) has",
            "probability": 0.0
        },
        {
            "start_logit": 12.796875,
            "end_logit": -9.1328125,
            "text": "nucleus accumbens (NAcc-DBS)",
            "probability": 0.0
        },
        {
            "start_logit": 12.796875,
            "end_logit": -9.2890625,
            "text": "nucleus accumbens (NAcc-DBS) has antidepressant effects in patients suffering from treatment-resistant depression (TRD",
            "probability": 0.0
        },
        {
            "start_logit": 12.796875,
            "end_logit": -9.421875,
            "text": "nucleus accumbens (NAcc-DBS) has antidepressant effects",
            "probability": 0.0
        },
        {
            "start_logit": 12.796875,
            "end_logit": -9.7734375,
            "text": "nucleus accumbens (NAcc-DBS) has antidepressant effects in patients suffering from treatment-resistant depression (TRD)",
            "probability": 0.0
        },
        {
            "start_logit": 12.796875,
            "end_logit": -9.8046875,
            "text": "nucleus accumbens (NAcc-DBS) has antidepressant effects in patients suffering from treatment-resistant depression (",
            "probability": 0.0
        },
        {
            "start_logit": 12.796875,
            "end_logit": -10.03125,
            "text": "nucleus accumbens (NAcc-",
            "probability": 0.0
        },
        {
            "start_logit": 12.796875,
            "end_logit": -10.03125,
            "text": "nucleus accumbens (NAcc-DBS) has antidepressant",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": 11.9296875,
            "text": "to the nucleus accumbens",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 11.9296875,
            "text": "Deep brain stimulation (DBS) to the nucleus accumbens",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 11.9296875,
            "text": "brain stimulation (DBS) to the nucleus accumbens",
            "probability": 0.0
        },
        {
            "start_logit": -5.95703125,
            "end_logit": -6.94140625,
            "text": "accumbens (",
            "probability": 0.0
        },
        {
            "start_logit": -5.95703125,
            "end_logit": -7.14453125,
            "text": "accumbens (NAcc",
            "probability": 0.0
        }
    ],
    "530cefaaad0bf1360c000002_4": [
        {
            "start_logit": 6.265625,
            "end_logit": 9.265625,
            "text": "ventral striatum",
            "probability": 0.82568359375
        },
        {
            "start_logit": 6.72265625,
            "end_logit": 6.76171875,
            "text": "nucleus accumbens",
            "probability": 0.10662841796875
        },
        {
            "start_logit": 6.265625,
            "end_logit": 6.76171875,
            "text": "ventral striatum, including the head of the caudate nucleus and the nucleus accumbens",
            "probability": 0.06781005859375
        },
        {
            "start_logit": 6.265625,
            "end_logit": -1.1728515625,
            "text": "ventral striatum, including the head of the caudate nucleus",
            "probability": 2.4199485778808594e-05
        },
        {
            "start_logit": -5.18359375,
            "end_logit": 9.265625,
            "text": "striatum",
            "probability": 8.761882781982422e-06
        },
        {
            "start_logit": -3.6484375,
            "end_logit": 6.76171875,
            "text": "caudate nucleus and the nucleus accumbens",
            "probability": 3.337860107421875e-06
        },
        {
            "start_logit": 6.265625,
            "end_logit": -3.974609375,
            "text": "ventral striatum, including the head of the caudate",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": -5.18359375,
            "end_logit": 6.76171875,
            "text": "striatum, including the head of the caudate nucleus and the nucleus accumbens",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 6.72265625,
            "end_logit": -5.68359375,
            "text": "nucleus",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 6.265625,
            "end_logit": -5.296875,
            "text": "ventral striatum, including the head of the caudate nucleus and",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 6.265625,
            "end_logit": -5.68359375,
            "text": "ventral striatum, including the head of the caudate nucleus and the nucleus",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 6.265625,
            "end_logit": -5.91796875,
            "text": "ventral striatum, including the head of the caudate nucleus and the",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 6.72265625,
            "end_logit": -6.921875,
            "text": "nucleus accumbens,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.265625,
            "end_logit": -6.921875,
            "text": "ventral striatum, including the head of the caudate nucleus and the nucleus accumbens,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.265625,
            "end_logit": -6.9375,
            "text": "ventral striatum,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.72265625,
            "end_logit": -8.1875,
            "text": "nucleus accumbens, is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.4375,
            "end_logit": 6.76171875,
            "text": "head of the caudate nucleus and the nucleus accumbens",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.265625,
            "end_logit": -8.1875,
            "text": "ventral striatum, including the head of the caudate nucleus and the nucleus accumbens, is",
            "probability": 0.0
        },
        {
            "start_logit": 6.265625,
            "end_logit": -8.3828125,
            "text": "ventral striatum, including the",
            "probability": 0.0
        },
        {
            "start_logit": 6.72265625,
            "end_logit": -8.90625,
            "text": "nucleus accumbens, is a putative target for deep brain stimulation (DBS) in the treatment of obsessive-compulsive disorder (OCD",
            "probability": 0.0
        }
    ],
    "530cefaaad0bf1360c000002_5": [
        {
            "start_logit": 12.703125,
            "end_logit": 12.578125,
            "text": "nucleus accumbens",
            "probability": 1.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": 4.89453125,
            "text": "nucleus accumbens, the lateral habenula",
            "probability": 0.0004584789276123047
        },
        {
            "start_logit": 12.703125,
            "end_logit": -4.6796875,
            "text": "nucleus accumbens, the lateral haben",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.703125,
            "end_logit": -4.91796875,
            "text": "nucleus",
            "probability": 0.0
        },
        {
            "start_logit": -5.6484375,
            "end_logit": 12.578125,
            "text": "accumbens",
            "probability": 0.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": -6.4296875,
            "text": "nucleus accumbens, the lateral",
            "probability": 0.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": -6.6171875,
            "text": "nucleus accumbens, the lateral hab",
            "probability": 0.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": -7.59765625,
            "text": "nucleus accumbens, the lateral habenula or",
            "probability": 0.0
        },
        {
            "start_logit": -0.28271484375,
            "end_logit": 4.89453125,
            "text": "lateral habenula",
            "probability": 0.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": -8.1484375,
            "text": "nucleus accumbens, the lateral habenula or cortical areas",
            "probability": 0.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": -8.4140625,
            "text": "nucleus accumbens, the",
            "probability": 0.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": -9.203125,
            "text": "nucleus accumbens, the lateral habenula or cortical",
            "probability": 0.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": -9.2890625,
            "text": "nucleus accumbens,",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 12.578125,
            "text": ".g., nucleus accumbens",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 12.578125,
            "text": "applied in several small samples of patients with treatment-resistant depression when the stimulation focused on different areas, e.g., nucleus accumbens",
            "probability": 0.0
        },
        {
            "start_logit": -5.6484375,
            "end_logit": 4.89453125,
            "text": "accumbens, the lateral habenula",
            "probability": 0.0
        },
        {
            "start_logit": -6.04296875,
            "end_logit": 4.89453125,
            "text": "habenula",
            "probability": 0.0
        },
        {
            "start_logit": -7.10546875,
            "end_logit": 4.89453125,
            "text": "ula",
            "probability": 0.0
        },
        {
            "start_logit": -9.421875,
            "end_logit": 4.89453125,
            "text": "enula",
            "probability": 0.0
        },
        {
            "start_logit": -9.546875,
            "end_logit": 4.89453125,
            "text": ", the lateral habenula",
            "probability": 0.0
        }
    ],
    "530cefaaad0bf1360c000002_6": [
        {
            "start_logit": 13.21875,
            "end_logit": 12.1640625,
            "text": "nucleus accumbens",
            "probability": 1.0
        },
        {
            "start_logit": 13.21875,
            "end_logit": -3.943359375,
            "text": "nucleus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.84375,
            "end_logit": 12.1640625,
            "text": "accumbens",
            "probability": 0.0
        },
        {
            "start_logit": 13.21875,
            "end_logit": -9.2890625,
            "text": "nucleus accumbens of",
            "probability": 0.0
        },
        {
            "start_logit": 13.21875,
            "end_logit": -9.859375,
            "text": "nucleus accumbens of five patients undergoing deep brain stimulation for treatment of refractory major depression.",
            "probability": 0.0
        },
        {
            "start_logit": 13.21875,
            "end_logit": -9.9375,
            "text": "nucleus accumbens of five patients undergoing deep brain stimulation for",
            "probability": 0.0
        },
        {
            "start_logit": 13.21875,
            "end_logit": -9.96875,
            "text": "nucleus accumbens of five patients undergoing deep brain stimulation",
            "probability": 0.0
        },
        {
            "start_logit": 13.21875,
            "end_logit": -10.125,
            "text": "nucleus accumbens of five patients undergoing deep brain stimulation for treatment of refractory major depression",
            "probability": 0.0
        },
        {
            "start_logit": 13.21875,
            "end_logit": -10.2109375,
            "text": "nucleus accumbens of five patients undergoing deep brain stimulation for treatment of",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 12.1640625,
            "text": "recorded electrophysiological activity directly from the nucleus accumbens",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": 12.1640625,
            "text": "directly from the nucleus accumbens",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": -3.943359375,
            "text": "recorded electrophysiological activity directly from the nucleus",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": -3.943359375,
            "text": "directly from the nucleus",
            "probability": 0.0
        },
        {
            "start_logit": -5.84375,
            "end_logit": -9.2890625,
            "text": "accumbens of",
            "probability": 0.0
        },
        {
            "start_logit": -5.84375,
            "end_logit": -9.859375,
            "text": "accumbens of five patients undergoing deep brain stimulation for treatment of refractory major depression.",
            "probability": 0.0
        },
        {
            "start_logit": -5.84375,
            "end_logit": -9.9375,
            "text": "accumbens of five patients undergoing deep brain stimulation for",
            "probability": 0.0
        },
        {
            "start_logit": -5.84375,
            "end_logit": -9.96875,
            "text": "accumbens of five patients undergoing deep brain stimulation",
            "probability": 0.0
        },
        {
            "start_logit": -5.84375,
            "end_logit": -10.125,
            "text": "accumbens of five patients undergoing deep brain stimulation for treatment of refractory major depression",
            "probability": 0.0
        },
        {
            "start_logit": -5.84375,
            "end_logit": -10.2109375,
            "text": "accumbens of five patients undergoing deep brain stimulation for treatment of",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": -8.265625,
            "text": "recorded electrophysiological activity directly from the",
            "probability": 0.0
        }
    ],
    "530cefaaad0bf1360c000002_7": [
        {
            "start_logit": 12.8828125,
            "end_logit": 12.765625,
            "text": "lateral habenula",
            "probability": 1.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -4.515625,
            "text": "lateral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -5.12890625,
            "text": "lateral haben",
            "probability": 0.0
        },
        {
            "start_logit": -5.94140625,
            "end_logit": 12.765625,
            "text": "ula",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -6.06640625,
            "text": "lateral hab",
            "probability": 0.0
        },
        {
            "start_logit": -6.47265625,
            "end_logit": 12.765625,
            "text": "habenula",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -8.8671875,
            "text": "lateral habenula via deep brain stimulation (DBS)",
            "probability": 0.0
        },
        {
            "start_logit": -9.7265625,
            "end_logit": 12.765625,
            "text": "enula",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -10.0078125,
            "text": "lateral habenula via deep brain stimulation (DBS) has",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -10.15625,
            "text": "lateral habenula via deep brain stimulation (DBS",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -10.1875,
            "text": "lateral habenula via deep brain stimulation (DBS) has antidepressive properties.",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -10.3125,
            "text": "lateral habenula via deep brain stimulation (DBS) has antidepressive properties",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -10.4765625,
            "text": "lateral habenula via deep brain stimulation (",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -10.4921875,
            "text": "lateral habenula via",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -10.5625,
            "text": "lateral habenula via deep brain stimulation (DBS) has antidepressive",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 12.765625,
            "text": "inhibition of the lateral habenula",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 12.765625,
            "text": "Functional inhibition of the lateral habenula",
            "probability": 0.0
        },
        {
            "start_logit": -6.47265625,
            "end_logit": -5.12890625,
            "text": "haben",
            "probability": 0.0
        },
        {
            "start_logit": -6.47265625,
            "end_logit": -6.06640625,
            "text": "hab",
            "probability": 0.0
        },
        {
            "start_logit": -5.94140625,
            "end_logit": -8.8671875,
            "text": "ula via deep brain stimulation (DBS)",
            "probability": 0.0
        }
    ],
    "530cefaaad0bf1360c000002_8": [
        {
            "start_logit": 13.0078125,
            "end_logit": 11.8671875,
            "text": "nucleus accumbens",
            "probability": 1.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -4.28125,
            "text": "nucleus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.0625,
            "end_logit": 11.8671875,
            "text": "accumbens",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -9.140625,
            "text": "nucleus accumbens might offer",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -9.515625,
            "text": "nucleus accumbens might offer a",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -9.703125,
            "text": "nucleus accumbens might",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 11.8671875,
            "text": "reward system in depression, DBS to the nucleus accumbens",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 11.8671875,
            "text": "pleasure from previously pleasurable activities--and because there is clear evidence of dysfunctions of the reward system in depression, DBS to the nucleus accumbens",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 11.8671875,
            "text": "dysfunctions of the reward system in depression, DBS to the nucleus accumbens",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 11.8671875,
            "text": "pleasurable activities--and because there is clear evidence of dysfunctions of the reward system in depression, DBS to the nucleus accumbens",
            "probability": 0.0
        },
        {
            "start_logit": -6.26171875,
            "end_logit": -7.9921875,
            "text": "Because",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": -4.28125,
            "text": "reward system in depression, DBS to the nucleus",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -4.28125,
            "text": "pleasure from previously pleasurable activities--and because there is clear evidence of dysfunctions of the reward system in depression, DBS to the nucleus",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": -4.28125,
            "text": "dysfunctions of the reward system in depression, DBS to the nucleus",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": -4.28125,
            "text": "pleasurable activities--and because there is clear evidence of dysfunctions of the reward system in depression, DBS to the nucleus",
            "probability": 0.0
        },
        {
            "start_logit": -6.26171875,
            "end_logit": -8.8515625,
            "text": "Because a prominent clinical feature of depression is anhedonia",
            "probability": 0.0
        },
        {
            "start_logit": -6.0625,
            "end_logit": -9.140625,
            "text": "accumbens might offer",
            "probability": 0.0
        },
        {
            "start_logit": -6.26171875,
            "end_logit": -9.171875,
            "text": "Because a prominent clinical feature of depression is anhedonia--the inability to experience pleasure from previously pleasurable activities-",
            "probability": 0.0
        },
        {
            "start_logit": -6.0625,
            "end_logit": -9.515625,
            "text": "accumbens might offer a",
            "probability": 0.0
        },
        {
            "start_logit": -6.26171875,
            "end_logit": -9.390625,
            "text": "Because a prominent clinical feature of depression is anhedonia--the inability to experience pleasure from previously pleasurable activities",
            "probability": 0.0
        }
    ],
    "530cefaaad0bf1360c000002_9": [
        {
            "start_logit": 12.78125,
            "end_logit": 12.0234375,
            "text": "nucleus accumbens",
            "probability": 1.0
        },
        {
            "start_logit": 12.78125,
            "end_logit": -4.2734375,
            "text": "nucleus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.86328125,
            "end_logit": 12.0234375,
            "text": "accumbens",
            "probability": 0.0
        },
        {
            "start_logit": 12.78125,
            "end_logit": -8.359375,
            "text": "nucleus accumbens might be a hypothesis",
            "probability": 0.0
        },
        {
            "start_logit": 12.78125,
            "end_logit": -8.84375,
            "text": "nucleus accumbens might",
            "probability": 0.0
        },
        {
            "start_logit": 12.78125,
            "end_logit": -9.4921875,
            "text": "nucleus accumbens might be a hypothesis-guided approach",
            "probability": 0.0
        },
        {
            "start_logit": 12.78125,
            "end_logit": -9.625,
            "text": "nucleus accumbens might be a",
            "probability": 0.0
        },
        {
            "start_logit": 12.78125,
            "end_logit": -9.8828125,
            "text": "nucleus accumbens might be",
            "probability": 0.0
        },
        {
            "start_logit": 12.78125,
            "end_logit": -9.96875,
            "text": "nucleus accumbens might be a hypothesis-guided approach for",
            "probability": 0.0
        },
        {
            "start_logit": 12.78125,
            "end_logit": -10.0,
            "text": "nucleus accumbens might be a hypothesis-guided approach for refractory major depression.",
            "probability": 0.0
        },
        {
            "start_logit": 12.78125,
            "end_logit": -10.1171875,
            "text": "nucleus accumbens might be a hypothesis-",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 12.0234375,
            "text": "that DBS to the nucleus accumbens",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 12.0234375,
            "text": "to the nucleus accumbens",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 12.0234375,
            "text": "DBS to the nucleus accumbens",
            "probability": 0.0
        },
        {
            "start_logit": -5.86328125,
            "end_logit": -8.359375,
            "text": "accumbens might be a hypothesis",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": -4.2734375,
            "text": "that DBS to the nucleus",
            "probability": 0.0
        },
        {
            "start_logit": -5.86328125,
            "end_logit": -8.84375,
            "text": "accumbens might",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": -4.2734375,
            "text": "to the nucleus",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": -4.2734375,
            "text": "DBS to the nucleus",
            "probability": 0.0
        },
        {
            "start_logit": -5.86328125,
            "end_logit": -9.4921875,
            "text": "accumbens might be a hypothesis-guided approach",
            "probability": 0.0
        }
    ],
    "530cefaaad0bf1360c000002_10": [
        {
            "start_logit": 6.6328125,
            "end_logit": 11.4765625,
            "text": "ventral caudate nucleus",
            "probability": 0.63330078125
        },
        {
            "start_logit": 6.078125,
            "end_logit": 11.4765625,
            "text": "caudate nucleus",
            "probability": 0.366455078125
        },
        {
            "start_logit": -7.05859375,
            "end_logit": 11.4765625,
            "text": "nucleus",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 11.4765625,
            "text": "of the ventral caudate nucleus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.4375,
            "end_logit": 11.4765625,
            "text": "Deep brain stimulation of the ventral caudate nucleus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.671875,
            "end_logit": 11.4765625,
            "text": "brain stimulation of the ventral caudate nucleus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.6328125,
            "end_logit": -7.4765625,
            "text": "ventral caudate",
            "probability": 0.0
        },
        {
            "start_logit": 6.6328125,
            "end_logit": -7.70703125,
            "text": "ventral",
            "probability": 0.0
        },
        {
            "start_logit": 6.078125,
            "end_logit": -7.4765625,
            "text": "caudate",
            "probability": 0.0
        },
        {
            "start_logit": 6.6328125,
            "end_logit": -9.09375,
            "text": "ventral caudate nucleus markedly improved symptoms of depression and anxiety until",
            "probability": 0.0
        },
        {
            "start_logit": 6.6328125,
            "end_logit": -9.546875,
            "text": "ventral caudate nucleus markedly improved symptoms of depression and anxiety until their remission",
            "probability": 0.0
        },
        {
            "start_logit": 6.078125,
            "end_logit": -9.09375,
            "text": "caudate nucleus markedly improved symptoms of depression and anxiety until",
            "probability": 0.0
        },
        {
            "start_logit": 6.6328125,
            "end_logit": -9.7734375,
            "text": "ventral caudate nucleus markedly improved symptoms of depression and anxiety",
            "probability": 0.0
        },
        {
            "start_logit": 6.6328125,
            "end_logit": -9.7734375,
            "text": "ventral caudate nucleus markedly improved symptoms of depression and anxiety until their remission, which was achieved",
            "probability": 0.0
        },
        {
            "start_logit": 6.6328125,
            "end_logit": -9.875,
            "text": "ventral caudate nucleus markedly improved symptoms of depression and anxiety until their remission, which was achieved at 6 months after the start of stimulation (HDRS",
            "probability": 0.0
        },
        {
            "start_logit": 6.6328125,
            "end_logit": -10.0546875,
            "text": "ventral caudate nucleus markedly improved symptoms of depression",
            "probability": 0.0
        },
        {
            "start_logit": 6.078125,
            "end_logit": -9.546875,
            "text": "caudate nucleus markedly improved symptoms of depression and anxiety until their remission",
            "probability": 0.0
        },
        {
            "start_logit": 6.078125,
            "end_logit": -9.7734375,
            "text": "caudate nucleus markedly improved symptoms of depression and anxiety",
            "probability": 0.0
        },
        {
            "start_logit": 6.078125,
            "end_logit": -9.7734375,
            "text": "caudate nucleus markedly improved symptoms of depression and anxiety until their remission, which was achieved",
            "probability": 0.0
        },
        {
            "start_logit": 6.078125,
            "end_logit": -9.875,
            "text": "caudate nucleus markedly improved symptoms of depression and anxiety until their remission, which was achieved at 6 months after the start of stimulation (HDRS",
            "probability": 0.0
        }
    ],
    "530cefaaad0bf1360c000002_11": [
        {
            "start_logit": 5.95703125,
            "end_logit": 11.3671875,
            "text": "ventral caudate nucleus",
            "probability": 0.5849609375
        },
        {
            "start_logit": 5.61328125,
            "end_logit": 11.3671875,
            "text": "caudate nucleus",
            "probability": 0.414794921875
        },
        {
            "start_logit": -6.9765625,
            "end_logit": 11.3671875,
            "text": "nucleus",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -10.1796875,
            "end_logit": 11.3671875,
            "text": "of the ventral caudate nucleus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 11.3671875,
            "text": "that DBS of the ventral caudate nucleus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.453125,
            "end_logit": 11.3671875,
            "text": "neuropsychological deterioration was observed, indicating that DBS of the ventral caudate nucleus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 11.3671875,
            "text": "DBS of the ventral caudate nucleus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.95703125,
            "end_logit": -6.703125,
            "text": "ventral caudate",
            "probability": 0.0
        },
        {
            "start_logit": 5.61328125,
            "end_logit": -6.703125,
            "text": "caudate",
            "probability": 0.0
        },
        {
            "start_logit": 5.95703125,
            "end_logit": -7.1328125,
            "text": "ventral",
            "probability": 0.0
        },
        {
            "start_logit": 5.95703125,
            "end_logit": -7.69921875,
            "text": "ventral caudate nucleus could be a promising strategy in the treatment of refractory cases of both OCD",
            "probability": 0.0
        },
        {
            "start_logit": 5.61328125,
            "end_logit": -7.69921875,
            "text": "caudate nucleus could be a promising strategy in the treatment of refractory cases of both OCD",
            "probability": 0.0
        },
        {
            "start_logit": 5.95703125,
            "end_logit": -8.8515625,
            "text": "ventral caudate nucleus could",
            "probability": 0.0
        },
        {
            "start_logit": 5.61328125,
            "end_logit": -8.8515625,
            "text": "caudate nucleus could",
            "probability": 0.0
        },
        {
            "start_logit": 5.95703125,
            "end_logit": -9.7890625,
            "text": "ventral caudate nucleus could be a",
            "probability": 0.0
        },
        {
            "start_logit": 5.95703125,
            "end_logit": -9.8359375,
            "text": "ventral caudate nucleus could be",
            "probability": 0.0
        },
        {
            "start_logit": 5.95703125,
            "end_logit": -10.1328125,
            "text": "ventral caudate nucleus could be a promising",
            "probability": 0.0
        },
        {
            "start_logit": 5.61328125,
            "end_logit": -9.7890625,
            "text": "caudate nucleus could be a",
            "probability": 0.0
        },
        {
            "start_logit": 5.61328125,
            "end_logit": -9.8359375,
            "text": "caudate nucleus could be",
            "probability": 0.0
        },
        {
            "start_logit": 5.95703125,
            "end_logit": -10.2890625,
            "text": "ventral caudate nucleus could be a promising strategy",
            "probability": 0.0
        }
    ],
    "530cefaaad0bf1360c000002_12": [
        {
            "start_logit": 9.59375,
            "end_logit": 9.828125,
            "text": "nucleus accumbens",
            "probability": 0.990234375
        },
        {
            "start_logit": 4.9296875,
            "end_logit": 9.828125,
            "text": "caudate nucleus stimulation preferentially alleviated OCD manifestations, whereas nucleus accumbens",
            "probability": 0.00933837890625
        },
        {
            "start_logit": 4.9296875,
            "end_logit": 6.7890625,
            "text": "caudate nucleus",
            "probability": 0.0004470348358154297
        },
        {
            "start_logit": 9.59375,
            "end_logit": -3.748046875,
            "text": "nucleus",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -6.2890625,
            "end_logit": 9.828125,
            "text": "accumbens",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.375,
            "end_logit": 9.828125,
            "text": "nucleus stimulation preferentially alleviated OCD manifestations, whereas nucleus accumbens",
            "probability": 0.0
        },
        {
            "start_logit": 4.9296875,
            "end_logit": -3.748046875,
            "text": "caudate nucleus stimulation preferentially alleviated OCD manifestations, whereas nucleus",
            "probability": 0.0
        },
        {
            "start_logit": 4.9296875,
            "end_logit": -4.09765625,
            "text": "caudate",
            "probability": 0.0
        },
        {
            "start_logit": 4.9296875,
            "end_logit": -4.8359375,
            "text": "caudate nucleus stimulation preferentially alleviated OCD",
            "probability": 0.0
        },
        {
            "start_logit": -9.75,
            "end_logit": 9.828125,
            "text": "OCD manifestations, whereas nucleus accumbens",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": 9.828125,
            "text": "Comparisons of clinical outcomes and anatomical data on electrode positioning showed that caudate nucleus stimulation preferentially alleviated OCD manifestations, whereas nucleus accumbens",
            "probability": 0.0
        },
        {
            "start_logit": 9.59375,
            "end_logit": -9.875,
            "text": "nucleus accumbens stimulation improved depressive symptoms.",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": 9.828125,
            "text": "whereas nucleus accumbens",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 9.828125,
            "text": "that caudate nucleus stimulation preferentially alleviated OCD manifestations, whereas nucleus accumbens",
            "probability": 0.0
        },
        {
            "start_logit": -8.375,
            "end_logit": 6.7890625,
            "text": "nucleus",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": 6.7890625,
            "text": "Comparisons of clinical outcomes and anatomical data on electrode positioning showed that caudate nucleus",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 6.7890625,
            "text": "that caudate nucleus",
            "probability": 0.0
        },
        {
            "start_logit": 4.9296875,
            "end_logit": -9.0859375,
            "text": "caudate nucleus stimulation preferentially",
            "probability": 0.0
        },
        {
            "start_logit": 4.9296875,
            "end_logit": -9.1796875,
            "text": "caudate nucleus stimulation preferentially alleviated OCD manifestations,",
            "probability": 0.0
        },
        {
            "start_logit": 4.9296875,
            "end_logit": -9.5390625,
            "text": "caudate nucleus stimulation preferentially alleviated OCD manifestations",
            "probability": 0.0
        }
    ],
    "58da2a348acda34529000014_1": [
        {
            "start_logit": 11.21875,
            "end_logit": 12.0078125,
            "text": "AFP",
            "probability": 1.0
        },
        {
            "start_logit": -8.6015625,
            "end_logit": 12.0078125,
            "text": "\u03b1-fetoprotein (AFP",
            "probability": 0.0
        },
        {
            "start_logit": -9.15625,
            "end_logit": 12.0078125,
            "text": ", \u03b1-fetoprotein (AFP",
            "probability": 0.0
        },
        {
            "start_logit": 11.21875,
            "end_logit": -8.5390625,
            "text": "AFP)",
            "probability": 0.0
        },
        {
            "start_logit": 11.21875,
            "end_logit": -9.2890625,
            "text": "AFP) and unconjugated oestriol",
            "probability": 0.0
        },
        {
            "start_logit": -10.0859375,
            "end_logit": 12.0078125,
            "text": "fetoprotein (AFP",
            "probability": 0.0
        },
        {
            "start_logit": 11.21875,
            "end_logit": -9.3203125,
            "text": "AFP) and unconjugated oestriol (uE3",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": 12.0078125,
            "text": "(AFP",
            "probability": 0.0
        },
        {
            "start_logit": 11.21875,
            "end_logit": -10.2421875,
            "text": "AFP) and unconjugated oestriol (u",
            "probability": 0.0
        },
        {
            "start_logit": 11.21875,
            "end_logit": -10.2578125,
            "text": "AFP) and unconjugated oestriol (uE",
            "probability": 0.0
        },
        {
            "start_logit": 11.21875,
            "end_logit": -10.2578125,
            "text": "AFP) and unconjugated",
            "probability": 0.0
        },
        {
            "start_logit": 11.21875,
            "end_logit": -10.3046875,
            "text": "AFP) and unconjugated oestriol (",
            "probability": 0.0
        },
        {
            "start_logit": -8.6015625,
            "end_logit": -8.0703125,
            "text": "\u03b1-fetoprotein",
            "probability": 0.0
        },
        {
            "start_logit": -8.6015625,
            "end_logit": -8.5390625,
            "text": "\u03b1-fetoprotein (AFP)",
            "probability": 0.0
        },
        {
            "start_logit": -9.15625,
            "end_logit": -8.0703125,
            "text": ", \u03b1-fetoprotein",
            "probability": 0.0
        },
        {
            "start_logit": -8.6015625,
            "end_logit": -8.921875,
            "text": "\u03b1-fetoprotein (",
            "probability": 0.0
        },
        {
            "start_logit": -9.15625,
            "end_logit": -8.5390625,
            "text": ", \u03b1-fetoprotein (AFP)",
            "probability": 0.0
        },
        {
            "start_logit": -8.6015625,
            "end_logit": -9.2890625,
            "text": "\u03b1-fetoprotein (AFP) and unconjugated oestriol",
            "probability": 0.0
        },
        {
            "start_logit": -8.6015625,
            "end_logit": -9.3203125,
            "text": "\u03b1-fetoprotein (AFP) and unconjugated oestriol (uE3",
            "probability": 0.0
        },
        {
            "start_logit": -9.15625,
            "end_logit": -8.921875,
            "text": ", \u03b1-fetoprotein (",
            "probability": 0.0
        }
    ],
    "58da2a348acda34529000014_2": [
        {
            "start_logit": 11.546875,
            "end_logit": 10.734375,
            "text": "estriol",
            "probability": 1.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": 2.20703125,
            "text": "estriol for the prenatal diagnosis of fetal chromosomal abnormalities",
            "probability": 0.0001971721649169922
        },
        {
            "start_logit": 0.175537109375,
            "end_logit": 10.734375,
            "text": "alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol",
            "probability": 1.150369644165039e-05
        },
        {
            "start_logit": -0.6875,
            "end_logit": 10.734375,
            "text": "human chorionic gonadotropin, and unconjugated estriol",
            "probability": 4.887580871582031e-06
        },
        {
            "start_logit": 11.546875,
            "end_logit": -5.76953125,
            "text": "estr",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.98046875,
            "end_logit": 10.734375,
            "text": "maternal serum triple marker screening of alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol",
            "probability": 0.0
        },
        {
            "start_logit": -6.79296875,
            "end_logit": 10.734375,
            "text": "unconjugated estriol",
            "probability": 0.0
        },
        {
            "start_logit": -7.00390625,
            "end_logit": 10.734375,
            "text": "iol",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -8.84375,
            "text": "estriol for the prenatal diagnosis of fetal chromosomal abnormalities in Turkish pregnant women",
            "probability": 0.0
        },
        {
            "start_logit": 0.175537109375,
            "end_logit": 2.20703125,
            "text": "alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol for the prenatal diagnosis of fetal chromosomal abnormalities",
            "probability": 0.0
        },
        {
            "start_logit": -8.5,
            "end_logit": 10.734375,
            "text": ", human chorionic gonadotropin, and unconjugated estriol",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -9.59375,
            "text": "estriol for the prenatal diagnosis of fetal chromosomal",
            "probability": 0.0
        },
        {
            "start_logit": -8.890625,
            "end_logit": 10.734375,
            "text": "fetoprotein, human chorionic gonadotropin, and unconjugated estriol",
            "probability": 0.0
        },
        {
            "start_logit": -9.0078125,
            "end_logit": 10.734375,
            "text": "chorionic gonadotropin, and unconjugated estriol",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -9.875,
            "text": "estriol for",
            "probability": 0.0
        },
        {
            "start_logit": -9.0625,
            "end_logit": 10.734375,
            "text": "and unconjugated estriol",
            "probability": 0.0
        },
        {
            "start_logit": -0.6875,
            "end_logit": 2.20703125,
            "text": "human chorionic gonadotropin, and unconjugated estriol for the prenatal diagnosis of fetal chromosomal abnormalities",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -10.1875,
            "text": "estriol for the prenatal diagnosis of fetal chromosomal abnormalities in",
            "probability": 0.0
        },
        {
            "start_logit": -9.734375,
            "end_logit": 10.734375,
            "text": "of alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 10.734375,
            "text": "screening of alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol",
            "probability": 0.0
        }
    ],
    "58da2a348acda34529000014_3": [
        {
            "start_logit": 13.7109375,
            "end_logit": 13.609375,
            "text": "Down's syndrome",
            "probability": 1.0
        },
        {
            "start_logit": -3.298828125,
            "end_logit": 13.609375,
            "text": "alpha-fetoprotein, beta-chorionic gonadotrophin and unconjugated oestriol) with amniocentesis in the detection of fetuses with Down's syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.7109375,
            "end_logit": -3.8984375,
            "text": "Down",
            "probability": 0.0
        },
        {
            "start_logit": -4.6640625,
            "end_logit": 13.609375,
            "text": "syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -5.27734375,
            "end_logit": 13.609375,
            "text": "oestriol) with amniocentesis in the detection of fetuses with Down's syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 13.7109375,
            "end_logit": -6.25390625,
            "text": "Down'",
            "probability": 0.0
        },
        {
            "start_logit": -6.87109375,
            "end_logit": 13.609375,
            "text": "beta-chorionic gonadotrophin and unconjugated oestriol) with amniocentesis in the detection of fetuses with Down's syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 13.7109375,
            "end_logit": -7.58203125,
            "text": "Down's",
            "probability": 0.0
        },
        {
            "start_logit": 13.7109375,
            "end_logit": -8.0625,
            "text": "Down's syndrome in women of 35 years of age",
            "probability": 0.0
        },
        {
            "start_logit": -8.859375,
            "end_logit": 13.609375,
            "text": ", beta-chorionic gonadotrophin and unconjugated oestriol) with amniocentesis in the detection of fetuses with Down's syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.8671875,
            "end_logit": 13.609375,
            "text": "unconjugated oestriol) with amniocentesis in the detection of fetuses with Down's syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.0234375,
            "end_logit": 13.609375,
            "text": "amniocentesis in the detection of fetuses with Down's syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 13.7109375,
            "end_logit": -9.2265625,
            "text": "Down's syndrome in women of 35 years of age or more",
            "probability": 0.0
        },
        {
            "start_logit": -9.3984375,
            "end_logit": 13.609375,
            "text": "s syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.453125,
            "end_logit": 13.609375,
            "text": "fetoprotein, beta-chorionic gonadotrophin and unconjugated oestriol) with amniocentesis in the detection of fetuses with Down's syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": 13.609375,
            "text": "fetuses with Down's syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.5859375,
            "end_logit": 13.609375,
            "text": "and unconjugated oestriol) with amniocentesis in the detection of fetuses with Down's syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.609375,
            "end_logit": 13.609375,
            "text": "screening (alpha-fetoprotein, beta-chorionic gonadotrophin and unconjugated oestriol) with amniocentesis in the detection of fetuses with Down's syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": 13.609375,
            "text": "the detection of fetuses with Down's syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.875,
            "end_logit": 13.609375,
            "text": "of fetuses with Down's syndrome",
            "probability": 0.0
        }
    ],
    "58da2a348acda34529000014_4": [
        {
            "start_logit": 13.7109375,
            "end_logit": 13.609375,
            "text": "Down's syndrome",
            "probability": 1.0
        },
        {
            "start_logit": -3.298828125,
            "end_logit": 13.609375,
            "text": "alpha-fetoprotein, beta-chorionic gonadotrophin and unconjugated oestriol) with amniocentesis in the detection of fetuses with Down's syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.7109375,
            "end_logit": -3.8984375,
            "text": "Down",
            "probability": 0.0
        },
        {
            "start_logit": -4.6640625,
            "end_logit": 13.609375,
            "text": "syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -5.27734375,
            "end_logit": 13.609375,
            "text": "oestriol) with amniocentesis in the detection of fetuses with Down's syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 13.7109375,
            "end_logit": -6.25390625,
            "text": "Down'",
            "probability": 0.0
        },
        {
            "start_logit": -6.87109375,
            "end_logit": 13.609375,
            "text": "beta-chorionic gonadotrophin and unconjugated oestriol) with amniocentesis in the detection of fetuses with Down's syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 13.7109375,
            "end_logit": -7.58203125,
            "text": "Down's",
            "probability": 0.0
        },
        {
            "start_logit": 13.7109375,
            "end_logit": -8.0625,
            "text": "Down's syndrome in women of 35 years of age",
            "probability": 0.0
        },
        {
            "start_logit": -8.859375,
            "end_logit": 13.609375,
            "text": ", beta-chorionic gonadotrophin and unconjugated oestriol) with amniocentesis in the detection of fetuses with Down's syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.8671875,
            "end_logit": 13.609375,
            "text": "unconjugated oestriol) with amniocentesis in the detection of fetuses with Down's syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.0234375,
            "end_logit": 13.609375,
            "text": "amniocentesis in the detection of fetuses with Down's syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 13.7109375,
            "end_logit": -9.2265625,
            "text": "Down's syndrome in women of 35 years of age or more",
            "probability": 0.0
        },
        {
            "start_logit": -9.3984375,
            "end_logit": 13.609375,
            "text": "s syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.453125,
            "end_logit": 13.609375,
            "text": "fetoprotein, beta-chorionic gonadotrophin and unconjugated oestriol) with amniocentesis in the detection of fetuses with Down's syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": 13.609375,
            "text": "fetuses with Down's syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.5859375,
            "end_logit": 13.609375,
            "text": "and unconjugated oestriol) with amniocentesis in the detection of fetuses with Down's syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.609375,
            "end_logit": 13.609375,
            "text": "screening (alpha-fetoprotein, beta-chorionic gonadotrophin and unconjugated oestriol) with amniocentesis in the detection of fetuses with Down's syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": 13.609375,
            "text": "the detection of fetuses with Down's syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.875,
            "end_logit": 13.609375,
            "text": "of fetuses with Down's syndrome",
            "probability": 0.0
        }
    ],
    "58da2a348acda34529000014_5": [
        {
            "start_logit": 10.5546875,
            "end_logit": 8.140625,
            "text": "oestriol",
            "probability": 1.0
        },
        {
            "start_logit": 5.20703125,
            "end_logit": 4.53515625,
            "text": "PAPP-A",
            "probability": 0.0001302957534790039
        },
        {
            "start_logit": 10.5546875,
            "end_logit": -6.9296875,
            "text": "oestr",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -0.95703125,
            "end_logit": 4.53515625,
            "text": "maternal age and serum-free beta-hCG and PAPP-A",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -2.02734375,
            "end_logit": 4.53515625,
            "text": "beta-hCG and PAPP-A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.20703125,
            "end_logit": -3.345703125,
            "text": "PAPP-A at 10 weeks of pregnancy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.20703125,
            "end_logit": -3.935546875,
            "text": "PAPP",
            "probability": 0.0
        },
        {
            "start_logit": -8.5390625,
            "end_logit": 8.140625,
            "text": "iol",
            "probability": 0.0
        },
        {
            "start_logit": -8.90625,
            "end_logit": 8.140625,
            "text": "unconjugated oestriol",
            "probability": 0.0
        },
        {
            "start_logit": -0.95703125,
            "end_logit": -0.11431884765625,
            "text": "maternal age",
            "probability": 0.0
        },
        {
            "start_logit": -9.359375,
            "end_logit": 8.140625,
            "text": "with maternal age) and similar to the triple test (alpha-fetoprotein, unconjugated oestriol",
            "probability": 0.0
        },
        {
            "start_logit": -9.4453125,
            "end_logit": 8.140625,
            "text": "fetoprotein and hCG with maternal age) and similar to the triple test (alpha-fetoprotein, unconjugated oestriol",
            "probability": 0.0
        },
        {
            "start_logit": 5.20703125,
            "end_logit": -6.78125,
            "text": "PAPP-",
            "probability": 0.0
        },
        {
            "start_logit": -0.95703125,
            "end_logit": -0.63232421875,
            "text": "maternal age and serum-free beta-hCG",
            "probability": 0.0
        },
        {
            "start_logit": -6.3203125,
            "end_logit": 4.53515625,
            "text": "A",
            "probability": 0.0
        },
        {
            "start_logit": 5.20703125,
            "end_logit": -7.5234375,
            "text": "PAPP-A at 10 weeks of pregnancy was better than the double test (alpha-fetoprotein",
            "probability": 0.0
        },
        {
            "start_logit": -7.05859375,
            "end_logit": 4.53515625,
            "text": "hCG and PAPP-A",
            "probability": 0.0
        },
        {
            "start_logit": -2.02734375,
            "end_logit": -0.63232421875,
            "text": "beta-hCG",
            "probability": 0.0
        },
        {
            "start_logit": 5.20703125,
            "end_logit": -8.578125,
            "text": "PAPP-A at 10 weeks of pregnancy was better than the double test (alpha",
            "probability": 0.0
        },
        {
            "start_logit": 5.20703125,
            "end_logit": -8.7265625,
            "text": "PAPP-A at 10 weeks",
            "probability": 0.0
        }
    ],
    "58da2a348acda34529000014_6": [
        {
            "start_logit": 14.0,
            "end_logit": 14.421875,
            "text": "Down syndrome",
            "probability": 1.0
        },
        {
            "start_logit": -3.33984375,
            "end_logit": 14.421875,
            "text": "syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -3.740234375,
            "text": "Down",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -6.10546875,
            "text": "Down syndrome (DS",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -6.7578125,
            "text": "Down syndrome (DS) is advisable and (2) alternative screening and diagnosis manoeuvres.\"Triple-marker\" screening of maternal serum",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -7.36328125,
            "text": "Down syndrome (",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -7.91796875,
            "text": "Down syndrome (DS) is advisable and (2) alternative screening and diagnosis manoeuvres.\"Triple-marker\" screening of maternal",
            "probability": 0.0
        },
        {
            "start_logit": -9.4296875,
            "end_logit": 14.421875,
            "text": "prenatal screening for and diagnosis of Down syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -2.876953125,
            "end_logit": -4.55859375,
            "text": "maternal serum levels of alpha-fetoprotein, human chorionic gonadotropin and unconjugated estriol",
            "probability": 0.0
        },
        {
            "start_logit": -2.876953125,
            "end_logit": -5.7734375,
            "text": "maternal serum levels of alpha-fetoprotein",
            "probability": 0.0
        },
        {
            "start_logit": -2.876953125,
            "end_logit": -6.46484375,
            "text": "maternal serum levels of alpha-fetoprotein, human chorionic gonadotropin",
            "probability": 0.0
        },
        {
            "start_logit": -3.33984375,
            "end_logit": -6.10546875,
            "text": "syndrome (DS",
            "probability": 0.0
        },
        {
            "start_logit": -2.876953125,
            "end_logit": -6.7578125,
            "text": "maternal serum",
            "probability": 0.0
        },
        {
            "start_logit": -5.12890625,
            "end_logit": -4.55859375,
            "text": "human chorionic gonadotropin and unconjugated estriol",
            "probability": 0.0
        },
        {
            "start_logit": -5.3203125,
            "end_logit": -4.55859375,
            "text": "alpha-fetoprotein, human chorionic gonadotropin and unconjugated estriol",
            "probability": 0.0
        },
        {
            "start_logit": -3.33984375,
            "end_logit": -6.7578125,
            "text": "syndrome (DS) is advisable and (2) alternative screening and diagnosis manoeuvres.\"Triple-marker\" screening of maternal serum",
            "probability": 0.0
        },
        {
            "start_logit": -3.33984375,
            "end_logit": -7.36328125,
            "text": "syndrome (",
            "probability": 0.0
        },
        {
            "start_logit": -2.876953125,
            "end_logit": -7.91796875,
            "text": "maternal",
            "probability": 0.0
        },
        {
            "start_logit": -5.3203125,
            "end_logit": -5.7734375,
            "text": "alpha-fetoprotein",
            "probability": 0.0
        },
        {
            "start_logit": -2.876953125,
            "end_logit": -8.375,
            "text": "maternal serum levels of alpha-fetoprotein, human chorionic gonadotropin and unconjugated",
            "probability": 0.0
        }
    ],
    "58da2a348acda34529000014_7": [
        {
            "start_logit": 10.7109375,
            "end_logit": 9.4453125,
            "text": "DS",
            "probability": 0.87744140625
        },
        {
            "start_logit": 10.7109375,
            "end_logit": 6.9140625,
            "text": "DS fetus due to either advanced maternal age",
            "probability": 0.06982421875
        },
        {
            "start_logit": 10.7109375,
            "end_logit": 6.23046875,
            "text": "DS fetus due to either advanced maternal age (AMA) or a positive expanded maternal serum alpha fetoprotein",
            "probability": 0.03509521484375
        },
        {
            "start_logit": 10.03125,
            "end_logit": 6.23046875,
            "text": "maternal serum alpha fetoprotein",
            "probability": 0.0179290771484375
        },
        {
            "start_logit": 1.916015625,
            "end_logit": 6.9140625,
            "text": "advanced maternal age",
            "probability": 1.055002212524414e-05
        },
        {
            "start_logit": 1.916015625,
            "end_logit": 6.23046875,
            "text": "advanced maternal age (AMA) or a positive expanded maternal serum alpha fetoprotein",
            "probability": 5.364418029785156e-06
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -4.02734375,
            "text": "DS fetus due to either advanced maternal age (AMA) or a positive expanded maternal serum alpha fetoprotein (MSAFP",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 10.03125,
            "end_logit": -4.02734375,
            "text": "maternal serum alpha fetoprotein (MSAFP",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -5.4921875,
            "text": "DS fetus due to either advanced maternal age (AMA) or a positive expanded maternal serum",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 10.03125,
            "end_logit": -5.4921875,
            "text": "maternal serum",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -2.56640625,
            "end_logit": 6.9140625,
            "text": "maternal age",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -6.57421875,
            "text": "DS fetus due to either advanced maternal age (AMA) or a positive expanded maternal",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.56640625,
            "end_logit": 6.23046875,
            "text": "maternal age (AMA) or a positive expanded maternal serum alpha fetoprotein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.03125,
            "end_logit": -6.57421875,
            "text": "maternal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.115234375,
            "end_logit": 6.23046875,
            "text": "alpha fetoprotein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -8.0078125,
            "text": "DS fetus due to either advanced maternal age (AMA",
            "probability": 0.0
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -8.4765625,
            "text": "DS fetus due to either advanced maternal age (AMA)",
            "probability": 0.0
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -8.4921875,
            "text": "DS fetus due to either advanced maternal age (AMA) or a positive expanded maternal serum alpha fetoprotein (MSA",
            "probability": 0.0
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -8.7109375,
            "text": "DS fetus due to either advanced maternal age (AMA) or a",
            "probability": 0.0
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -8.7578125,
            "text": "DS fetus due to either advanced maternal age (AMA) or a positive expanded maternal serum alpha fetoprotein (MSAFP)",
            "probability": 0.0
        }
    ],
    "58da2a348acda34529000014_8": [
        {
            "start_logit": 13.6640625,
            "end_logit": 13.7421875,
            "text": "Down syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 4.703125,
            "end_logit": 13.7421875,
            "text": "estriol and alpha-fetoprotein in the triple screen test, and with the addition of inhibin-A in the quadruple marker test for detecting Down syndrome",
            "probability": 0.00012731552124023438
        },
        {
            "start_logit": 13.6640625,
            "end_logit": -4.3046875,
            "text": "Down",
            "probability": 0.0
        },
        {
            "start_logit": -4.59765625,
            "end_logit": 13.7421875,
            "text": "syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 4.703125,
            "end_logit": 3.982421875,
            "text": "estriol",
            "probability": 0.0
        },
        {
            "start_logit": -6.51171875,
            "end_logit": 13.7421875,
            "text": "alpha-fetoprotein in the triple screen test, and with the addition of inhibin-A in the quadruple marker test for detecting Down syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.4296875,
            "end_logit": 13.7421875,
            "text": "inhibin-A in the quadruple marker test for detecting Down syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.4296875,
            "end_logit": 13.7421875,
            "text": "iol and alpha-fetoprotein in the triple screen test, and with the addition of inhibin-A in the quadruple marker test for detecting Down syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 13.6640625,
            "end_logit": -8.3671875,
            "text": "Down syndrome in the second trimester of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -9.171875,
            "end_logit": 13.7421875,
            "text": "fetoprotein in the triple screen test, and with the addition of inhibin-A in the quadruple marker test for detecting Down syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.234375,
            "end_logit": 13.7421875,
            "text": "detecting Down syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 13.6640625,
            "end_logit": -9.4921875,
            "text": "Down syndrome in the second trimester",
            "probability": 0.0
        },
        {
            "start_logit": -10.0,
            "end_logit": 13.7421875,
            "text": "with the addition of inhibin-A in the quadruple marker test for detecting Down syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 4.703125,
            "end_logit": -4.3046875,
            "text": "estriol and alpha-fetoprotein in the triple screen test, and with the addition of inhibin-A in the quadruple marker test for detecting Down",
            "probability": 0.0
        },
        {
            "start_logit": 4.703125,
            "end_logit": -6.31640625,
            "text": "estriol and alpha-fetoprotein",
            "probability": 0.0
        },
        {
            "start_logit": 4.703125,
            "end_logit": -6.54296875,
            "text": "estr",
            "probability": 0.0
        },
        {
            "start_logit": 4.703125,
            "end_logit": -8.453125,
            "text": "estriol and alpha",
            "probability": 0.0
        },
        {
            "start_logit": 4.703125,
            "end_logit": -9.0390625,
            "text": "estriol and alpha-fetoprotein in the triple screen test, and with the addition of inhibin-A",
            "probability": 0.0
        },
        {
            "start_logit": -8.4296875,
            "end_logit": 3.982421875,
            "text": "iol",
            "probability": 0.0
        },
        {
            "start_logit": 4.703125,
            "end_logit": -9.34375,
            "text": "estriol and",
            "probability": 0.0
        }
    ],
    "58da2a348acda34529000014_9": [
        {
            "start_logit": 11.875,
            "end_logit": 10.1328125,
            "text": "alpha-fetoprotein",
            "probability": 0.998046875
        },
        {
            "start_logit": 11.875,
            "end_logit": 3.30078125,
            "text": "alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol",
            "probability": 0.0010805130004882812
        },
        {
            "start_logit": 4.45703125,
            "end_logit": 10.1328125,
            "text": "maternal serum alpha-fetoprotein",
            "probability": 0.000606536865234375
        },
        {
            "start_logit": 11.875,
            "end_logit": -0.50341796875,
            "text": "alpha-fetoprotein, human chorionic gonadotropin",
            "probability": 2.4259090423583984e-05
        },
        {
            "start_logit": 4.45703125,
            "end_logit": 3.30078125,
            "text": "maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 4.44921875,
            "end_logit": 3.30078125,
            "text": "estriol",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 11.875,
            "end_logit": -5.1015625,
            "text": "alpha",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 1.376953125,
            "end_logit": 3.30078125,
            "text": "human chorionic gonadotropin, and unconjugated estriol",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.45703125,
            "end_logit": -0.50341796875,
            "text": "maternal serum alpha-fetoprotein, human chorionic gonadotropin",
            "probability": 0.0
        },
        {
            "start_logit": 11.875,
            "end_logit": -8.0625,
            "text": "alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estr",
            "probability": 0.0
        },
        {
            "start_logit": 11.875,
            "end_logit": -8.1640625,
            "text": "alpha-fetoprotein, human chorionic gonadotropin, and unconjugated",
            "probability": 0.0
        },
        {
            "start_logit": -6.64453125,
            "end_logit": 10.1328125,
            "text": "fetoprotein",
            "probability": 0.0
        },
        {
            "start_logit": 11.875,
            "end_logit": -8.7578125,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": 11.875,
            "end_logit": -9.3125,
            "text": "alpha-fetoprotein, human chorionic",
            "probability": 0.0
        },
        {
            "start_logit": 11.875,
            "end_logit": -9.484375,
            "text": "alpha-fetoprotein, human chorionic gonadotropin, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.875,
            "end_logit": -9.6171875,
            "text": "alpha-fetoprotein, human chorionic gonadotropin, and uncon",
            "probability": 0.0
        },
        {
            "start_logit": 11.875,
            "end_logit": -9.640625,
            "text": "alpha-fetoprotein, human",
            "probability": 0.0
        },
        {
            "start_logit": 11.875,
            "end_logit": -9.953125,
            "text": "alpha-fetoprotein,",
            "probability": 0.0
        },
        {
            "start_logit": 11.875,
            "end_logit": -9.984375,
            "text": "alpha-fetoprotein, human chorionic gonadotropin,",
            "probability": 0.0
        },
        {
            "start_logit": 11.875,
            "end_logit": -10.0,
            "text": "alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol)",
            "probability": 0.0
        }
    ],
    "61f52fca882a024a10000003_1": [
        {
            "start_logit": 13.203125,
            "end_logit": 12.6171875,
            "text": "Joubert syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -4.171875,
            "text": "Jo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.203125,
            "end_logit": -6.171875,
            "text": "Joubert",
            "probability": 0.0
        },
        {
            "start_logit": -5.90234375,
            "end_logit": 12.6171875,
            "text": "syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -6.56640625,
            "text": "Jouber",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 12.6171875,
            "text": "t syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.8984375,
            "end_logit": 12.6171875,
            "text": "ubert syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -9.6015625,
            "text": "Joubert syndrome.",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 12.6171875,
            "text": "odyssey and has prognostic implications for patients with presumed Joubert syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 12.6171875,
            "text": "LAMA1 mutations ends diagnostic odyssey and has prognostic implications for patients with presumed Joubert syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 12.6171875,
            "text": "diagnostic odyssey and has prognostic implications for patients with presumed Joubert syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 12.6171875,
            "text": "Identification of LAMA1 mutations ends diagnostic odyssey and has prognostic implications for patients with presumed Joubert syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": 12.6171875,
            "text": "of LAMA1 mutations ends diagnostic odyssey and has prognostic implications for patients with presumed Joubert syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": 12.6171875,
            "text": "mutations ends diagnostic odyssey and has prognostic implications for patients with presumed Joubert syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -11.0859375,
            "end_logit": 12.6171875,
            "text": "has prognostic implications for patients with presumed Joubert syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": -6.171875,
            "text": "t",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": -4.171875,
            "text": "odyssey and has prognostic implications for patients with presumed Jo",
            "probability": 0.0
        },
        {
            "start_logit": -8.8984375,
            "end_logit": -6.171875,
            "text": "ubert",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": -4.171875,
            "text": "LAMA1 mutations ends diagnostic odyssey and has prognostic implications for patients with presumed Jo",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": -4.171875,
            "text": "diagnostic odyssey and has prognostic implications for patients with presumed Jo",
            "probability": 0.0
        }
    ],
    "61f52fca882a024a10000003_2": [
        {
            "start_logit": 13.7578125,
            "end_logit": 14.1640625,
            "text": "Joubert syndrome",
            "probability": 1.0
        },
        {
            "start_logit": -3.84375,
            "end_logit": 14.1640625,
            "text": "syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 13.7578125,
            "end_logit": -3.88671875,
            "text": "Jo",
            "probability": 0.0
        },
        {
            "start_logit": -7.265625,
            "end_logit": 14.1640625,
            "text": "neurology syndromes are a broad and complex group of conditions with a large spectrum of clinical phenotypes. Joubert syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 13.7578125,
            "end_logit": -6.94921875,
            "text": "Joubert",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 14.1640625,
            "text": "Paediatric neurology syndromes are a broad and complex group of conditions with a large spectrum of clinical phenotypes. Joubert syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 13.7578125,
            "end_logit": -8.3046875,
            "text": "Joubert syndrome is a genetically heterogeneous neurological ciliopathy",
            "probability": 0.0
        },
        {
            "start_logit": 13.7578125,
            "end_logit": -8.3359375,
            "text": "Jouber",
            "probability": 0.0
        },
        {
            "start_logit": -8.875,
            "end_logit": 14.1640625,
            "text": "t syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 13.7578125,
            "end_logit": -8.8203125,
            "text": "Joubert syndrome is",
            "probability": 0.0
        },
        {
            "start_logit": -1.1435546875,
            "end_logit": -5.85546875,
            "text": "Poretti-Boltshauser syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -1.1435546875,
            "end_logit": -6.01171875,
            "text": "Pore",
            "probability": 0.0
        },
        {
            "start_logit": -1.1435546875,
            "end_logit": -6.6328125,
            "text": "Poretti-Boltshauser syndrome. Analysis of brain MRI revealed cerebellar dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -1.1435546875,
            "end_logit": -7.890625,
            "text": "Poretti",
            "probability": 0.0
        },
        {
            "start_logit": -1.1435546875,
            "end_logit": -8.03125,
            "text": "Poretti-Boltshauser syndrome. Analysis of brain MRI revealed cerebellar dysplasia and cerebellar cysts",
            "probability": 0.0
        },
        {
            "start_logit": -1.1435546875,
            "end_logit": -8.046875,
            "text": "Poretti-Boltshauser",
            "probability": 0.0
        },
        {
            "start_logit": -1.1435546875,
            "end_logit": -8.3125,
            "text": "Poretti-Boltshause",
            "probability": 0.0
        },
        {
            "start_logit": -1.1435546875,
            "end_logit": -8.8984375,
            "text": "Poretti-Boltshauser syndrome. Analysis of brain MRI revealed cerebellar",
            "probability": 0.0
        },
        {
            "start_logit": -1.1435546875,
            "end_logit": -8.921875,
            "text": "Poretti-Boltsha",
            "probability": 0.0
        },
        {
            "start_logit": -7.265625,
            "end_logit": -3.88671875,
            "text": "neurology syndromes are a broad and complex group of conditions with a large spectrum of clinical phenotypes. Jo",
            "probability": 0.0
        }
    ],
    "61f52fca882a024a10000003_3": [
        {
            "start_logit": 7.61328125,
            "end_logit": 8.875,
            "text": "Knobloch syndrome",
            "probability": 0.82763671875
        },
        {
            "start_logit": 7.61328125,
            "end_logit": 6.6171875,
            "text": "Knobloch syndrome, and the patients with LAMA1 mutations had Poretti-Boltshauser syndrome",
            "probability": 0.0872802734375
        },
        {
            "start_logit": 7.58984375,
            "end_logit": 6.6171875,
            "text": "Poretti-Boltshauser syndrome",
            "probability": 0.0845947265625
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -3.390625,
            "text": "Knobloch syndrome, and the patients with LAMA1 mutations had Poretti-Boltshauser",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -3.390625,
            "text": "Poretti-Boltshauser",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -3.46484375,
            "text": "Knoblo",
            "probability": 3.635883331298828e-06
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -3.509765625,
            "text": "Knobloch syndrome, and the patients with LAMA1 mutations had Poretti",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -3.509765625,
            "text": "Poretti",
            "probability": 3.3974647521972656e-06
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -3.974609375,
            "text": "Knob",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -4.6640625,
            "text": "Knobloch",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -4.91015625,
            "text": "Knobloch syndrome, and the patients with LAMA1 mutations had Poretti-Boltshause",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -4.91015625,
            "text": "Poretti-Boltshause",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -4.9765625,
            "text": "Knobloch syndrome, and the patients with LAMA1 mutations had Poretti-Boltsha",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -4.9765625,
            "text": "Poretti-Boltsha",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -5.30078125,
            "text": "Knobloch syndrome, and the patients with LAMA1 mutations had Porett",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -5.30078125,
            "text": "Porett",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -5.89453125,
            "text": "Knobloch syndrome, and the patients with LAMA1 mutations had Poretti-Bolts",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -5.89453125,
            "text": "Poretti-Bolts",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -6.11328125,
            "text": "Knobloch syndrome, and the patients with LAMA1 mutations had Pore",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -6.11328125,
            "text": "Pore",
            "probability": 2.384185791015625e-07
        }
    ],
    "6027505c1cb411341a0000e6_1": [
        {
            "start_logit": 13.0546875,
            "end_logit": 10.9921875,
            "text": "Thulium laser",
            "probability": 1.0
        },
        {
            "start_logit": 13.0546875,
            "end_logit": 0.2158203125,
            "text": "Thulium laser transurethral vaporesection of the prostate versus transurethral resection of the prostate",
            "probability": 2.092123031616211e-05
        },
        {
            "start_logit": 13.0546875,
            "end_logit": -1.068359375,
            "text": "Thulium laser transurethral vaporesection of the prostate",
            "probability": 5.781650543212891e-06
        },
        {
            "start_logit": 13.0546875,
            "end_logit": -4.7890625,
            "text": "Th",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.0546875,
            "end_logit": -5.61328125,
            "text": "Thulium laser transurethral vaporesection of the prostate versus transurethral resection of the prostate for men with lower urinary tract symptoms or urinary retention",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.0546875,
            "end_logit": -5.84375,
            "text": "Thulium",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.0546875,
            "end_logit": -6.62109375,
            "text": "Thulium laser transurethral vaporesection of the prostate versus transurethral",
            "probability": 0.0
        },
        {
            "start_logit": 13.0546875,
            "end_logit": -6.65234375,
            "text": "Thulium laser transurethral vaporesection of the prostate versus transurethral resection",
            "probability": 0.0
        },
        {
            "start_logit": 13.0546875,
            "end_logit": -7.0078125,
            "text": "Thulium laser transurethral vaporesection",
            "probability": 0.0
        },
        {
            "start_logit": 13.0546875,
            "end_logit": -7.1328125,
            "text": "Thulium laser transurethral vaporesection of the prostate versus",
            "probability": 0.0
        },
        {
            "start_logit": -5.1015625,
            "end_logit": 10.9921875,
            "text": "laser",
            "probability": 0.0
        },
        {
            "start_logit": 13.0546875,
            "end_logit": -7.3515625,
            "text": "Thulium laser transurethral vaporesection of the prostate versus transurethral resection of the",
            "probability": 0.0
        },
        {
            "start_logit": 13.0546875,
            "end_logit": -7.62109375,
            "text": "Thulium laser transurethral vaporesection of the prostate versus transurethral resection of the prostate for men with lower urinary tract symptoms",
            "probability": 0.0
        },
        {
            "start_logit": 13.0546875,
            "end_logit": -8.109375,
            "text": "Thulium laser transurethral vapor",
            "probability": 0.0
        },
        {
            "start_logit": 13.0546875,
            "end_logit": -8.3125,
            "text": "Thulium laser transurethral vaporesection of the",
            "probability": 0.0
        },
        {
            "start_logit": 13.0546875,
            "end_logit": -8.6171875,
            "text": "Thulium laser transurethral vaporesection of the prostate versus transurethral resection of",
            "probability": 0.0
        },
        {
            "start_logit": 13.0546875,
            "end_logit": -8.765625,
            "text": "Thulium laser transurethral vaporesection of the prostate versus transurethral resection of the prostate for men with lower urinary tract symptoms or urinary",
            "probability": 0.0
        },
        {
            "start_logit": -6.73046875,
            "end_logit": 10.9921875,
            "text": "ulium laser",
            "probability": 0.0
        },
        {
            "start_logit": 13.0546875,
            "end_logit": -8.8125,
            "text": "Thulium laser transurethral vaporese",
            "probability": 0.0
        },
        {
            "start_logit": 13.0546875,
            "end_logit": -9.015625,
            "text": "Thulium laser transurethral vaporesect",
            "probability": 0.0
        }
    ],
    "6027505c1cb411341a0000e6_2": [
        {
            "start_logit": 5.578125,
            "end_logit": 7.8515625,
            "text": "Transurethral resection of the prostate (TURP",
            "probability": 0.5302734375
        },
        {
            "start_logit": 5.578125,
            "end_logit": 7.71484375,
            "text": "Transurethral resection of the prostate (TURP)",
            "probability": 0.46435546875
        },
        {
            "start_logit": 0.376953125,
            "end_logit": 7.8515625,
            "text": "TURP",
            "probability": 0.0029163360595703125
        },
        {
            "start_logit": 0.376953125,
            "end_logit": 7.71484375,
            "text": "TURP)",
            "probability": 0.002552032470703125
        },
        {
            "start_logit": 5.578125,
            "end_logit": -0.78662109375,
            "text": "Transurethral resection of the prostate",
            "probability": 9.375810623168945e-05
        },
        {
            "start_logit": 5.578125,
            "end_logit": -3.962890625,
            "text": "Transurethral resection of the prostate (TURP) is the standard operation for benign prostatic obstruction. Thulium laser",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": 5.578125,
            "end_logit": -4.21875,
            "text": "Transurethral",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": -7.0546875,
            "end_logit": 7.8515625,
            "text": "(TURP",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": 5.578125,
            "end_logit": -4.8203125,
            "text": "Transurethral resection of the prostate (",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": -7.0546875,
            "end_logit": 7.71484375,
            "text": "(TURP)",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 7.71484375,
            "text": ")",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -8.640625,
            "end_logit": 7.8515625,
            "text": "resection of the prostate (TURP",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -8.640625,
            "end_logit": 7.71484375,
            "text": "resection of the prostate (TURP)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 5.578125,
            "end_logit": -7.0390625,
            "text": "Transurethral resection of the prostate (TURP) is the standard operation for benign prostatic obstruction",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 5.578125,
            "end_logit": -7.9765625,
            "text": "Transurethral resection of the prostate (TURP) is the standard operation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.578125,
            "end_logit": -8.203125,
            "text": "Transurethral resection of the prostate (TURP) is the standard operation for benign prostatic obstruction. Thulium",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.578125,
            "end_logit": -8.5,
            "text": "Transurethral resection of the prostate (TURP) is the standard operation for benign prostatic obstruction. Thulium laser transurethral vaporesection of the prostate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.578125,
            "end_logit": -8.875,
            "text": "Transurethral resection of the prostate (TURP) is the standard operation for benign prostatic obstruction. Th",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 0.376953125,
            "end_logit": -3.962890625,
            "text": "TURP) is the standard operation for benign prostatic obstruction. Thulium laser",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.5087890625,
            "end_logit": -3.962890625,
            "text": "Thulium laser",
            "probability": 0.0
        }
    ],
    "6027505c1cb411341a0000e6_3": [
        {
            "start_logit": 11.203125,
            "end_logit": 9.546875,
            "text": "transurethral resection of the prostate",
            "probability": 1.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -2.732421875,
            "text": "transurethral resection of the prostate vs thulium laser",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": 11.203125,
            "end_logit": -2.845703125,
            "text": "transurethral resection of the prostate vs thulium laser transurethral vaporesection of the prostate in the UNBLOCS randomised controlled trial for benign prostatic obstruction",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": 11.203125,
            "end_logit": -5.37890625,
            "text": "transurethral resection of the prostate vs thulium laser transurethral vaporesection",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 11.203125,
            "end_logit": -5.5078125,
            "text": "transurethral resection of the prostate vs thulium laser transurethral vaporesection of the prostate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 11.203125,
            "end_logit": -5.7890625,
            "text": "transurethral",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 11.203125,
            "end_logit": -5.7890625,
            "text": "transurethral resection of the prostate vs thulium",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 11.203125,
            "end_logit": -6.50390625,
            "text": "transurethral resection of the prostate vs thulium laser transurethral vapor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.109375,
            "end_logit": 9.546875,
            "text": "prostate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.203125,
            "end_logit": -6.859375,
            "text": "transurethral resection of the prostate vs th",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.203125,
            "end_logit": -6.95703125,
            "text": "transurethral resection of the prostate vs thuli",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.203125,
            "end_logit": -7.51171875,
            "text": "transurethral resection of the prostate vs thulium laser transurethral vaporese",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.203125,
            "end_logit": -7.64453125,
            "text": "transurethral resection of the prostate vs thulium laser transurethral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.203125,
            "end_logit": -7.69921875,
            "text": "transurethral resection of the prostate vs thulium laser transurethral vaporesection of the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.09765625,
            "end_logit": 9.546875,
            "text": "cost-effectiveness of transurethral resection of the prostate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.203125,
            "end_logit": -8.125,
            "text": "transurethral resection",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -8.1484375,
            "text": "transurethral resection of the prostate vs thulium laser transurethral vaporesection of the prostate in the UNBLOCS randomised controlled trial for benign prostatic",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -8.515625,
            "text": "transurethral resection of the prostate vs thulium laser transurethral vaporesection of",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -8.53125,
            "text": "transurethral resection of the prostate vs",
            "probability": 0.0
        },
        {
            "start_logit": -8.7421875,
            "end_logit": 9.546875,
            "text": "resection of the prostate",
            "probability": 0.0
        }
    ],
    "6027505c1cb411341a0000e6_4": [
        {
            "start_logit": 5.30078125,
            "end_logit": 6.82421875,
            "text": "transurethral resection of the prostate (TURP",
            "probability": 0.98388671875
        },
        {
            "start_logit": 1.138671875,
            "end_logit": 6.82421875,
            "text": "TURP",
            "probability": 0.015289306640625
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -0.077880859375,
            "text": "transurethral resection of the prostate",
            "probability": 0.0009889602661132812
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -3.291015625,
            "text": "transurethral resection of the prostate (TURP) compared to the new laser technique of thulium laser",
            "probability": 3.9696693420410156e-05
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -4.83984375,
            "text": "transurethral resection of the prostate (",
            "probability": 8.463859558105469e-06
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -5.375,
            "text": "transurethral resection of the prostate (TURP) compared",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -6.1484375,
            "text": "transurethral",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 6.82421875,
            "text": "of transurethral resection of the prostate (TURP",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": -8.5625,
            "end_logit": 6.82421875,
            "text": "cost-effectiveness of the current 'gold standard' operation of transurethral resection of the prostate (TURP",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -7.07421875,
            "text": "transurethral resection of the prostate (TURP) compared to the new laser technique of thulium",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 1.138671875,
            "end_logit": -3.291015625,
            "text": "TURP) compared to the new laser technique of thulium laser",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -9.09375,
            "end_logit": 6.82421875,
            "text": "of the prostate (TURP",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -9.25,
            "end_logit": 6.82421875,
            "text": "operation of transurethral resection of the prostate (TURP",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -7.8515625,
            "text": "transurethral resection of the prostate (TURP) compared to the new laser technique of thulium laser transurethral vaporesection of the prostate",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -9.3984375,
            "end_logit": 6.82421875,
            "text": "the prostate (TURP",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -7.9296875,
            "text": "transurethral resection of the prostate (TURP) compared to the new laser",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -9.484375,
            "end_logit": 6.82421875,
            "text": "resection of the prostate (TURP",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -8.1015625,
            "text": "transurethral resection of the prostate (TURP) compared to the new laser technique of thulium laser transurethral vaporesection of the prostate (",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -8.125,
            "text": "transurethral resection of the prostate (TURP) compared to the new laser technique of th",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -8.2109375,
            "text": "transurethral resection of the prostate (TURP) compared to the new laser technique of thulium laser transurethral vapor",
            "probability": 2.980232238769531e-07
        }
    ],
    "6027505c1cb411341a0000e6_5": [
        {
            "start_logit": 11.9140625,
            "end_logit": 8.9296875,
            "text": "Thulium laser",
            "probability": 0.9892578125
        },
        {
            "start_logit": 11.9140625,
            "end_logit": 3.923828125,
            "text": "Thulium laser transurethral vaporesection versus transurethral resection of the prostate",
            "probability": 0.00661468505859375
        },
        {
            "start_logit": 11.9140625,
            "end_logit": 3.52734375,
            "text": "Thulium laser transurethral vaporesection",
            "probability": 0.0044403076171875
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -1.298828125,
            "text": "Thulium laser transurethral vaporesection versus transurethral resection of the prostate for benign prostatic obstruction",
            "probability": 3.5822391510009766e-05
        },
        {
            "start_logit": 4.11328125,
            "end_logit": 3.923828125,
            "text": "transurethral resection of the prostate",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -5.3203125,
            "text": "Thulium",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -5.765625,
            "text": "Th",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -6.2890625,
            "text": "Thulium laser transurethral vaporesection versus transurethral",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -6.640625,
            "text": "Thulium laser transurethral vaporesection versus transurethral resection",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -7.12890625,
            "text": "Thulium laser transurethral vaporesection versus transurethral resection of the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -7.2734375,
            "text": "Thulium laser transurethral vapor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -7.77734375,
            "text": "Thulium laser transurethral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -7.98828125,
            "text": "Thulium laser transurethral vaporesection versus transurethral resection of the prostate for benign prostatic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -8.0234375,
            "text": "Thulium laser transurethral vaporese",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -8.0859375,
            "text": "Thulium laser transurethral vaporesection versus transurethral resection of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -8.2109375,
            "text": "Thulium laser transurethral vaporesection versus transurethral resection of the prostate for",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -8.390625,
            "text": "Thulium laser transurethral vaporesection versus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -8.640625,
            "text": "Thuli",
            "probability": 0.0
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -8.6796875,
            "text": "Thulium laser transurethral vaporesect",
            "probability": 0.0
        },
        {
            "start_logit": 4.11328125,
            "end_logit": -1.298828125,
            "text": "transurethral resection of the prostate for benign prostatic obstruction",
            "probability": 0.0
        }
    ],
    "6027505c1cb411341a0000e6_6": [
        {
            "start_logit": 7.79296875,
            "end_logit": 1.35546875,
            "text": "thulium laser transurethral vaporesection of the prostate (ThuVARP) versus transurethral resection of the prostate (TURP",
            "probability": 0.88671875
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -1.4609375,
            "text": "thulium laser",
            "probability": 0.05303955078125
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -1.607421875,
            "text": "thulium laser transurethral vaporesection of the prostate (ThuVARP) versus transurethral resection of the prostate",
            "probability": 0.0458984375
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -3.21875,
            "text": "thulium laser transurethral vaporesection of the prostate",
            "probability": 0.00914764404296875
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -4.31640625,
            "text": "thulium laser transurethral vaporesection of the prostate (ThuVARP",
            "probability": 0.0030498504638671875
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -6.3671875,
            "text": "thulium laser transurethral vaporesection of the prostate (ThuVARP) versus transurethral",
            "probability": 0.0003924369812011719
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -6.6171875,
            "text": "thulium laser transurethral vaporesection of the prostate (ThuVARP) versus transurethral resection",
            "probability": 0.0003056526184082031
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -6.625,
            "text": "thulium laser transurethral vaporesection of the prostate (",
            "probability": 0.0003032684326171875
        },
        {
            "start_logit": -0.7099609375,
            "end_logit": 1.35546875,
            "text": "transurethral resection of the prostate (TURP",
            "probability": 0.00018036365509033203
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.19140625,
            "text": "thulium",
            "probability": 0.00017213821411132812
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.32421875,
            "text": "thulium laser transurethral vapor",
            "probability": 0.0001506805419921875
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.484375,
            "text": "thulium laser transurethral vaporesection of the prostate (ThuVARP) versus transurethral resection of the prostate (",
            "probability": 0.00012791156768798828
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.4921875,
            "text": "thulium laser transurethral vaporesection of the prostate (Th",
            "probability": 0.00012791156768798828
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.55078125,
            "text": "th",
            "probability": 0.0001201629638671875
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -8.1484375,
            "text": "thulium laser transurethral vaporesection",
            "probability": 6.639957427978516e-05
        },
        {
            "start_logit": -3.27734375,
            "end_logit": 1.35546875,
            "text": "TURP",
            "probability": 1.3768672943115234e-05
        },
        {
            "start_logit": -0.7099609375,
            "end_logit": -1.607421875,
            "text": "transurethral resection of the prostate",
            "probability": 9.238719940185547e-06
        },
        {
            "start_logit": -6.6015625,
            "end_logit": 1.35546875,
            "text": "versus transurethral resection of the prostate (TURP",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.08203125,
            "end_logit": 1.35546875,
            "text": "transurethral vaporesection of the prostate (ThuVARP) versus transurethral resection of the prostate (TURP",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.4453125,
            "end_logit": 1.35546875,
            "text": "ThuVARP) versus transurethral resection of the prostate (TURP",
            "probability": 2.384185791015625e-07
        }
    ],
    "6027505c1cb411341a0000e6_7": [
        {
            "start_logit": 10.8515625,
            "end_logit": 8.9609375,
            "text": "transurethral resection of the prostate",
            "probability": 1.0
        },
        {
            "start_logit": 10.8515625,
            "end_logit": -2.71875,
            "text": "transurethral resection of the prostate vs thulium laser",
            "probability": 8.463859558105469e-06
        },
        {
            "start_logit": 10.8515625,
            "end_logit": -2.734375,
            "text": "transurethral resection of the prostate vs thulium laser transurethral vaporesection of the prostate in the UNBLOCS randomised controlled trial for benign prostatic obstruction",
            "probability": 8.344650268554688e-06
        },
        {
            "start_logit": 10.8515625,
            "end_logit": -5.48828125,
            "text": "transurethral resection of the prostate vs thulium laser transurethral vaporesection",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 10.8515625,
            "end_logit": -5.69140625,
            "text": "transurethral resection of the prostate vs thulium laser transurethral vaporesection of the prostate",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 10.8515625,
            "end_logit": -5.86328125,
            "text": "transurethral resection of the prostate vs thulium",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 10.8515625,
            "end_logit": -5.91015625,
            "text": "transurethral",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 10.8515625,
            "end_logit": -6.6484375,
            "text": "transurethral resection of the prostate vs thulium laser transurethral vapor",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 10.8515625,
            "end_logit": -6.96875,
            "text": "transurethral resection of the prostate vs th",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.8515625,
            "end_logit": -7.0859375,
            "text": "transurethral resection of the prostate vs thuli",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.30078125,
            "end_logit": 8.9609375,
            "text": "prostate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.8515625,
            "end_logit": -7.44140625,
            "text": "transurethral resection of the prostate vs thulium laser transurethral vaporese",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.8515625,
            "end_logit": -7.671875,
            "text": "transurethral resection of the prostate vs thulium laser transurethral vaporesection of the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.8515625,
            "end_logit": -7.8125,
            "text": "transurethral resection of the prostate vs thulium laser transurethral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.8515625,
            "end_logit": -8.1640625,
            "text": "transurethral resection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.8515625,
            "end_logit": -8.1875,
            "text": "transurethral resection of the prostate vs thulium laser transurethral vaporesection of the prostate in the UNBLOCS randomised controlled trial for benign prostatic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.37109375,
            "end_logit": 8.9609375,
            "text": "cost-effectiveness of transurethral resection of the prostate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.8515625,
            "end_logit": -8.4609375,
            "text": "transurethral resection of the prostate vs",
            "probability": 0.0
        },
        {
            "start_logit": 10.8515625,
            "end_logit": -8.484375,
            "text": "transurethral resection of the prostate vs thulium laser transurethral vaporesection of the prostate in",
            "probability": 0.0
        },
        {
            "start_logit": -8.7421875,
            "end_logit": 8.9609375,
            "text": "resection of the prostate",
            "probability": 0.0
        }
    ],
    "55031270e9bde6963400001a_1": [
        {
            "start_logit": 13.3515625,
            "end_logit": 13.7578125,
            "text": "Fanconi anemia",
            "probability": 1.0
        },
        {
            "start_logit": -4.41015625,
            "end_logit": 13.7578125,
            "text": "anemia",
            "probability": 0.0
        },
        {
            "start_logit": 13.3515625,
            "end_logit": -4.0234375,
            "text": "Fanconi anemia and dyskeratosis congenita",
            "probability": 0.0
        },
        {
            "start_logit": 13.3515625,
            "end_logit": -4.40234375,
            "text": "Fa",
            "probability": 0.0
        },
        {
            "start_logit": 13.3515625,
            "end_logit": -5.83984375,
            "text": "Fanconi",
            "probability": 0.0
        },
        {
            "start_logit": 13.3515625,
            "end_logit": -5.87890625,
            "text": "Fanc",
            "probability": 0.0
        },
        {
            "start_logit": 13.3515625,
            "end_logit": -7.578125,
            "text": "Fanconi anemia and dyskeratosis",
            "probability": 0.0
        },
        {
            "start_logit": 13.3515625,
            "end_logit": -8.2578125,
            "text": "Fanconi anemia and dyskera",
            "probability": 0.0
        },
        {
            "start_logit": 13.3515625,
            "end_logit": -8.421875,
            "text": "Fanconi anemia and dyskeratosis congen",
            "probability": 0.0
        },
        {
            "start_logit": 13.3515625,
            "end_logit": -8.8046875,
            "text": "Fanconi anemia and dyskerato",
            "probability": 0.0
        },
        {
            "start_logit": -9.3515625,
            "end_logit": 13.7578125,
            "text": "nconi anemia",
            "probability": 0.0
        },
        {
            "start_logit": 13.3515625,
            "end_logit": -9.0,
            "text": "Fanconi anemia and dysk",
            "probability": 0.0
        },
        {
            "start_logit": 13.3515625,
            "end_logit": -9.1171875,
            "text": "Fanconi anemia and",
            "probability": 0.0
        },
        {
            "start_logit": -9.6171875,
            "end_logit": 13.7578125,
            "text": "oni anemia",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 13.7578125,
            "text": "orbital manifestations of the inherited bone marrow failure syndromes: Fanconi anemia",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 13.7578125,
            "text": ": Fanconi anemia",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 13.7578125,
            "text": "Ocular and orbital manifestations of the inherited bone marrow failure syndromes: Fanconi anemia",
            "probability": 0.0
        },
        {
            "start_logit": -4.41015625,
            "end_logit": -4.0234375,
            "text": "anemia and dyskeratosis congenita",
            "probability": 0.0
        },
        {
            "start_logit": -5.17578125,
            "end_logit": -4.0234375,
            "text": "dyskeratosis congenita",
            "probability": 0.0
        },
        {
            "start_logit": -4.41015625,
            "end_logit": -7.578125,
            "text": "anemia and dyskeratosis",
            "probability": 0.0
        }
    ],
    "55031270e9bde6963400001a_2": [
        {
            "start_logit": 12.53125,
            "end_logit": 13.875,
            "text": "Fanconi anemia",
            "probability": 1.0
        },
        {
            "start_logit": -4.05078125,
            "end_logit": 13.875,
            "text": "anemia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.34375,
            "end_logit": 13.875,
            "text": "are Fanconi anemia",
            "probability": 0.0
        },
        {
            "start_logit": 12.53125,
            "end_logit": -5.14453125,
            "text": "Fa",
            "probability": 0.0
        },
        {
            "start_logit": 12.53125,
            "end_logit": -6.18359375,
            "text": "Fanconi anemia (FA",
            "probability": 0.0
        },
        {
            "start_logit": 12.53125,
            "end_logit": -6.33203125,
            "text": "Fanconi",
            "probability": 0.0
        },
        {
            "start_logit": 12.53125,
            "end_logit": -6.85546875,
            "text": "Fanconi anemia (FA)",
            "probability": 0.0
        },
        {
            "start_logit": 12.53125,
            "end_logit": -6.97265625,
            "text": "Fanc",
            "probability": 0.0
        },
        {
            "start_logit": 12.53125,
            "end_logit": -7.296875,
            "text": "Fanconi anemia (",
            "probability": 0.0
        },
        {
            "start_logit": 12.53125,
            "end_logit": -7.91796875,
            "text": "Fanconi anemia (FA), dyskeratosis congenita (DC",
            "probability": 0.0
        },
        {
            "start_logit": 12.53125,
            "end_logit": -8.1015625,
            "text": "Fanconi anemia (FA), dyskeratosis congenita",
            "probability": 0.0
        },
        {
            "start_logit": -9.5625,
            "end_logit": 13.875,
            "text": "nconi anemia",
            "probability": 0.0
        },
        {
            "start_logit": -9.859375,
            "end_logit": 13.875,
            "text": "oni anemia",
            "probability": 0.0
        },
        {
            "start_logit": 12.53125,
            "end_logit": -9.3671875,
            "text": "Fanconi anemia (FA), dyskeratosis",
            "probability": 0.0
        },
        {
            "start_logit": -4.05078125,
            "end_logit": -6.18359375,
            "text": "anemia (FA",
            "probability": 0.0
        },
        {
            "start_logit": -2.451171875,
            "end_logit": -7.91796875,
            "text": ", dyskeratosis congenita (DC",
            "probability": 0.0
        },
        {
            "start_logit": -5.34375,
            "end_logit": -5.14453125,
            "text": "are Fa",
            "probability": 0.0
        },
        {
            "start_logit": -2.451171875,
            "end_logit": -8.1015625,
            "text": ", dyskeratosis congenita",
            "probability": 0.0
        },
        {
            "start_logit": -2.451171875,
            "end_logit": -8.328125,
            "text": ", dyskeratosis congenita (DC), Diamond-Blackfan anemia (DBA), and Shwachman-Diamond syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -4.05078125,
            "end_logit": -6.85546875,
            "text": "anemia (FA)",
            "probability": 0.0
        }
    ],
    "55031270e9bde6963400001a_3": [
        {
            "start_logit": 13.2421875,
            "end_logit": 13.8203125,
            "text": "Fanconi anemia",
            "probability": 1.0
        },
        {
            "start_logit": -4.16796875,
            "end_logit": 13.8203125,
            "text": "anemia",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -4.5546875,
            "text": "Fa",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -5.8203125,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -5.8515625,
            "text": "Fanconi",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -5.96875,
            "text": "Fanc",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -6.20703125,
            "text": "Fanconi anemia, dyskeratosis congenita",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -7.1796875,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -7.85546875,
            "text": "Fanconi anemia, dyskeratosis",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -8.1875,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome, and amegakaryocytic thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -8.3515625,
            "text": "Fanconi anemia, dyskera",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -8.515625,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwachman",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -8.5234375,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwa",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -8.75,
            "text": "Fanconi anemia, dyskeratosis congen",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -8.7578125,
            "text": "Fanconi anemia, dyskeratosis congenita, Sh",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -8.7890625,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwach",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -8.8984375,
            "text": "Fanconi anemia, dysk",
            "probability": 0.0
        },
        {
            "start_logit": -9.5390625,
            "end_logit": 13.8203125,
            "text": "nconi anemia",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -9.0859375,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome, and",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -9.125,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwachman-",
            "probability": 0.0
        }
    ],
    "55031270e9bde6963400001a_4": [
        {
            "start_logit": 13.0859375,
            "end_logit": 13.65625,
            "text": "Fanconi anemia",
            "probability": 1.0
        },
        {
            "start_logit": -4.40625,
            "end_logit": 13.65625,
            "text": "anemia",
            "probability": 0.0
        },
        {
            "start_logit": 13.0859375,
            "end_logit": -4.65625,
            "text": "Fa",
            "probability": 0.0
        },
        {
            "start_logit": 13.0859375,
            "end_logit": -5.9375,
            "text": "Fanc",
            "probability": 0.0
        },
        {
            "start_logit": 13.0859375,
            "end_logit": -5.984375,
            "text": "Fanconi",
            "probability": 0.0
        },
        {
            "start_logit": 13.0859375,
            "end_logit": -6.14453125,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 13.0859375,
            "end_logit": -6.609375,
            "text": "Fanconi anemia, dyskeratosis congenita",
            "probability": 0.0
        },
        {
            "start_logit": 13.0859375,
            "end_logit": -6.73046875,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome, and amegakaryocytic thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": 13.0859375,
            "end_logit": -7.49609375,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond",
            "probability": 0.0
        },
        {
            "start_logit": 13.0859375,
            "end_logit": -8.0703125,
            "text": "Fanconi anemia, dyskeratosis",
            "probability": 0.0
        },
        {
            "start_logit": 13.0859375,
            "end_logit": -8.4765625,
            "text": "Fanconi anemia, dyskera",
            "probability": 0.0
        },
        {
            "start_logit": 13.0859375,
            "end_logit": -8.6484375,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwa",
            "probability": 0.0
        },
        {
            "start_logit": 13.0859375,
            "end_logit": -8.7578125,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwachman",
            "probability": 0.0
        },
        {
            "start_logit": 13.0859375,
            "end_logit": -8.828125,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwach",
            "probability": 0.0
        },
        {
            "start_logit": 13.0859375,
            "end_logit": -8.953125,
            "text": "Fanconi anemia, dyskeratosis congen",
            "probability": 0.0
        },
        {
            "start_logit": 13.0859375,
            "end_logit": -8.9765625,
            "text": "Fanconi anemia, dyskeratosis congenita, Sh",
            "probability": 0.0
        },
        {
            "start_logit": 13.0859375,
            "end_logit": -9.0234375,
            "text": "Fanconi anemia, dysk",
            "probability": 0.0
        },
        {
            "start_logit": -9.59375,
            "end_logit": 13.65625,
            "text": "nconi anemia",
            "probability": 0.0
        },
        {
            "start_logit": 13.0859375,
            "end_logit": -9.09375,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome, and",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": 13.65625,
            "text": "oni anemia",
            "probability": 0.0
        }
    ],
    "58839d892305cd7e21000006_1": [
        {
            "start_logit": 9.4453125,
            "end_logit": 7.37890625,
            "text": "growth hormone",
            "probability": 0.99609375
        },
        {
            "start_logit": 9.4453125,
            "end_logit": 1.73828125,
            "text": "growth hormone/insulin-like growth factor genes",
            "probability": 0.0035381317138671875
        },
        {
            "start_logit": 9.4453125,
            "end_logit": -3.15625,
            "text": "growth hormone/insulin-like growth factor genes (growth pathways), respiratory complex I",
            "probability": 2.6345252990722656e-05
        },
        {
            "start_logit": 9.4453125,
            "end_logit": -3.798828125,
            "text": "growth hormone/insulin-like growth factor genes (growth pathways",
            "probability": 1.3887882232666016e-05
        },
        {
            "start_logit": 9.4453125,
            "end_logit": -6.0546875,
            "text": "growth hormone/insulin-like growth factor genes (growth pathways), respiratory complex",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 9.4453125,
            "end_logit": -6.453125,
            "text": "growth hormone/insulin-like growth factor",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 9.4453125,
            "end_logit": -7.7109375,
            "text": "growth hormone/insulin-like growth factor genes (growth pathways), respiratory complex I genes (metabolic pathways",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.4453125,
            "end_logit": -7.74609375,
            "text": "growth hormone/insulin-like growth factor genes (growth pathways), respiratory complex I genes",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.4453125,
            "end_logit": -7.78515625,
            "text": "growth hormone/insulin-like growth factor genes (growth pathways)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.4453125,
            "end_logit": -8.234375,
            "text": "growth hormone/insulin-like growth factor genes (growth pathways), respiratory",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.4453125,
            "end_logit": -8.4453125,
            "text": "growth",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.4453125,
            "end_logit": -8.96875,
            "text": "growth hormone/insulin-like growth factor genes (growth",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4453125,
            "end_logit": -9.171875,
            "text": "growth hormone/insulin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4453125,
            "end_logit": -9.3671875,
            "text": "growth hormone/insulin-like growth",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.4453125,
            "end_logit": -9.3984375,
            "text": "growth hormone/insulin-like growth factor genes (growth pathways), respiratory complex I genes (metabolic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.453125,
            "end_logit": 7.37890625,
            "text": "positive selection in growth hormone",
            "probability": 0.0
        },
        {
            "start_logit": -9.21875,
            "end_logit": 7.37890625,
            "text": "hormone",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 1.73828125,
            "text": "genes",
            "probability": 0.0
        },
        {
            "start_logit": -8.453125,
            "end_logit": 1.73828125,
            "text": "positive selection in growth hormone/insulin-like growth factor genes",
            "probability": 0.0
        },
        {
            "start_logit": -8.6640625,
            "end_logit": 1.73828125,
            "text": "insulin-like growth factor genes",
            "probability": 0.0
        }
    ],
    "58839d892305cd7e21000006_2": [
        {
            "start_logit": -4.90625,
            "end_logit": -2.458984375,
            "text": "microRNA genes",
            "probability": 0.93505859375
        },
        {
            "start_logit": -8.7890625,
            "end_logit": -2.458984375,
            "text": "protein-coding and microRNA genes",
            "probability": 0.019256591796875
        },
        {
            "start_logit": -4.90625,
            "end_logit": -6.65234375,
            "text": "microRNA",
            "probability": 0.01409149169921875
        },
        {
            "start_logit": -9.1015625,
            "end_logit": -2.458984375,
            "text": "both protein-coding and microRNA genes",
            "probability": 0.01409149169921875
        },
        {
            "start_logit": -4.90625,
            "end_logit": -7.3046875,
            "text": "microRNA genes related to reproduction",
            "probability": 0.0073699951171875
        },
        {
            "start_logit": -10.40625,
            "end_logit": -2.458984375,
            "text": "and microRNA genes",
            "probability": 0.0038204193115234375
        },
        {
            "start_logit": -4.90625,
            "end_logit": -8.515625,
            "text": "microRNA genes related",
            "probability": 0.002193450927734375
        },
        {
            "start_logit": -4.90625,
            "end_logit": -9.0625,
            "text": "microRNA genes related to",
            "probability": 0.001270294189453125
        },
        {
            "start_logit": -4.90625,
            "end_logit": -9.6328125,
            "text": "microRNA genes related to reproduction exhibited",
            "probability": 0.0007181167602539062
        },
        {
            "start_logit": -4.90625,
            "end_logit": -9.859375,
            "text": "microRNA genes related to reproduction exhibited evidence",
            "probability": 0.0005726814270019531
        },
        {
            "start_logit": -4.90625,
            "end_logit": -10.0078125,
            "text": "microRNA genes related to reproduction exhibited evidence of rapid sequence evolution.",
            "probability": 0.0004935264587402344
        },
        {
            "start_logit": -4.90625,
            "end_logit": -10.1171875,
            "text": "microRNA genes related to reproduction exhibited evidence of rapid sequence evolution",
            "probability": 0.00044226646423339844
        },
        {
            "start_logit": -8.7890625,
            "end_logit": -6.65234375,
            "text": "protein-coding and microRNA",
            "probability": 0.0002923011779785156
        },
        {
            "start_logit": -9.1015625,
            "end_logit": -6.65234375,
            "text": "both protein-coding and microRNA",
            "probability": 0.00021398067474365234
        },
        {
            "start_logit": -8.7890625,
            "end_logit": -7.3046875,
            "text": "protein-coding and microRNA genes related to reproduction",
            "probability": 0.00015175342559814453
        },
        {
            "start_logit": -9.1015625,
            "end_logit": -7.3046875,
            "text": "both protein-coding and microRNA genes related to reproduction",
            "probability": 0.00011098384857177734
        },
        {
            "start_logit": -10.40625,
            "end_logit": -6.65234375,
            "text": "and microRNA",
            "probability": 5.7578086853027344e-05
        },
        {
            "start_logit": -8.7890625,
            "end_logit": -8.515625,
            "text": "protein-coding and microRNA genes related",
            "probability": 4.482269287109375e-05
        },
        {
            "start_logit": -9.1015625,
            "end_logit": -8.515625,
            "text": "both protein-coding and microRNA genes related",
            "probability": 3.2842159271240234e-05
        },
        {
            "start_logit": -10.40625,
            "end_logit": -7.3046875,
            "text": "and microRNA genes related to reproduction",
            "probability": 2.9861927032470703e-05
        }
    ],
    "58839d892305cd7e21000006_3": [
        {
            "start_logit": -4.90625,
            "end_logit": -2.458984375,
            "text": "microRNA genes",
            "probability": 0.93505859375
        },
        {
            "start_logit": -8.7890625,
            "end_logit": -2.458984375,
            "text": "protein-coding and microRNA genes",
            "probability": 0.019256591796875
        },
        {
            "start_logit": -4.90625,
            "end_logit": -6.65234375,
            "text": "microRNA",
            "probability": 0.01409149169921875
        },
        {
            "start_logit": -9.1015625,
            "end_logit": -2.458984375,
            "text": "both protein-coding and microRNA genes",
            "probability": 0.01409149169921875
        },
        {
            "start_logit": -4.90625,
            "end_logit": -7.3046875,
            "text": "microRNA genes related to reproduction",
            "probability": 0.0073699951171875
        },
        {
            "start_logit": -10.40625,
            "end_logit": -2.458984375,
            "text": "and microRNA genes",
            "probability": 0.0038204193115234375
        },
        {
            "start_logit": -4.90625,
            "end_logit": -8.515625,
            "text": "microRNA genes related",
            "probability": 0.002193450927734375
        },
        {
            "start_logit": -4.90625,
            "end_logit": -9.0625,
            "text": "microRNA genes related to",
            "probability": 0.001270294189453125
        },
        {
            "start_logit": -4.90625,
            "end_logit": -9.6328125,
            "text": "microRNA genes related to reproduction exhibited",
            "probability": 0.0007181167602539062
        },
        {
            "start_logit": -4.90625,
            "end_logit": -9.859375,
            "text": "microRNA genes related to reproduction exhibited evidence",
            "probability": 0.0005726814270019531
        },
        {
            "start_logit": -4.90625,
            "end_logit": -10.0078125,
            "text": "microRNA genes related to reproduction exhibited evidence of rapid sequence evolution.",
            "probability": 0.0004935264587402344
        },
        {
            "start_logit": -4.90625,
            "end_logit": -10.1171875,
            "text": "microRNA genes related to reproduction exhibited evidence of rapid sequence evolution",
            "probability": 0.00044226646423339844
        },
        {
            "start_logit": -8.7890625,
            "end_logit": -6.65234375,
            "text": "protein-coding and microRNA",
            "probability": 0.0002923011779785156
        },
        {
            "start_logit": -9.1015625,
            "end_logit": -6.65234375,
            "text": "both protein-coding and microRNA",
            "probability": 0.00021398067474365234
        },
        {
            "start_logit": -8.7890625,
            "end_logit": -7.3046875,
            "text": "protein-coding and microRNA genes related to reproduction",
            "probability": 0.00015175342559814453
        },
        {
            "start_logit": -9.1015625,
            "end_logit": -7.3046875,
            "text": "both protein-coding and microRNA genes related to reproduction",
            "probability": 0.00011098384857177734
        },
        {
            "start_logit": -10.40625,
            "end_logit": -6.65234375,
            "text": "and microRNA",
            "probability": 5.7578086853027344e-05
        },
        {
            "start_logit": -8.7890625,
            "end_logit": -8.515625,
            "text": "protein-coding and microRNA genes related",
            "probability": 4.482269287109375e-05
        },
        {
            "start_logit": -9.1015625,
            "end_logit": -8.515625,
            "text": "both protein-coding and microRNA genes related",
            "probability": 3.2842159271240234e-05
        },
        {
            "start_logit": -10.40625,
            "end_logit": -7.3046875,
            "text": "and microRNA genes related to reproduction",
            "probability": 2.9861927032470703e-05
        }
    ],
    "54cf705ff693c3b16b000014_1": [
        {
            "start_logit": 7.81640625,
            "end_logit": 10.7734375,
            "text": "\u03b1v\u03b23",
            "probability": 0.97607421875
        },
        {
            "start_logit": 4.109375,
            "end_logit": 10.7734375,
            "text": "integrins \u03b1v\u03b23",
            "probability": 0.0238800048828125
        },
        {
            "start_logit": -5.65234375,
            "end_logit": 10.7734375,
            "text": "3",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 7.81640625,
            "end_logit": -3.326171875,
            "text": "\u03b1v",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -9.0390625,
            "end_logit": 10.7734375,
            "text": "pleural mesothelioma cells through antagonism of integrins \u03b1v\u03b23",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.81640625,
            "end_logit": -6.08984375,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.81640625,
            "end_logit": -6.1171875,
            "text": "\u03b1v\u03b2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 10.7734375,
            "text": "malignant pleural mesothelioma cells through antagonism of integrins \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": 10.7734375,
            "text": "mesothelioma cells through antagonism of integrins \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": 4.109375,
            "end_logit": -3.326171875,
            "text": "integrins \u03b1v",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 10.7734375,
            "text": "\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": 7.81640625,
            "end_logit": -7.921875,
            "text": "\u03b1v\u03b23 and",
            "probability": 0.0
        },
        {
            "start_logit": 7.81640625,
            "end_logit": -7.98046875,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -10.953125,
            "end_logit": 10.7734375,
            "text": "engitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -11.0,
            "end_logit": 10.7734375,
            "text": "itide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": 10.7734375,
            "text": "Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": 7.81640625,
            "end_logit": -8.3359375,
            "text": "\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": 7.81640625,
            "end_logit": -9.1484375,
            "text": "\u03b1v\u03b23 and \u03b1v",
            "probability": 0.0
        },
        {
            "start_logit": 4.109375,
            "end_logit": -5.60546875,
            "text": "integrins",
            "probability": 0.0
        },
        {
            "start_logit": 7.81640625,
            "end_logit": -9.46875,
            "text": "\u03b1v\u03b23 and \u03b1",
            "probability": 0.0
        }
    ],
    "54cf705ff693c3b16b000014_2": [
        {
            "start_logit": 6.8671875,
            "end_logit": 10.484375,
            "text": "\u03b1v\u03b23",
            "probability": 0.86865234375
        },
        {
            "start_logit": 4.96484375,
            "end_logit": 10.484375,
            "text": "integrins \u03b1v\u03b23",
            "probability": 0.131103515625
        },
        {
            "start_logit": -5.72265625,
            "end_logit": 10.484375,
            "text": "3",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": 6.8671875,
            "end_logit": -4.28515625,
            "text": "\u03b1v",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -9.0546875,
            "end_logit": 10.484375,
            "text": "As there is evidence for expression of the integrins \u03b1v\u03b23",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 4.96484375,
            "end_logit": -4.28515625,
            "text": "integrins \u03b1v",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.84375,
            "end_logit": 10.484375,
            "text": "\u03b23",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.8671875,
            "end_logit": -6.640625,
            "text": "\u03b1v\u03b2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.8671875,
            "end_logit": -6.98828125,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25",
            "probability": 0.0
        },
        {
            "start_logit": 6.8671875,
            "end_logit": -8.421875,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 4.96484375,
            "end_logit": -6.640625,
            "text": "integrins \u03b1v\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 6.8671875,
            "end_logit": -8.65625,
            "text": "\u03b1v\u03b23 and",
            "probability": 0.0
        },
        {
            "start_logit": 4.96484375,
            "end_logit": -6.80859375,
            "text": "integrins",
            "probability": 0.0
        },
        {
            "start_logit": 6.8671875,
            "end_logit": -8.8359375,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 in MPM, there is a rationale",
            "probability": 0.0
        },
        {
            "start_logit": 4.96484375,
            "end_logit": -6.98828125,
            "text": "integrins \u03b1v\u03b23 and \u03b1v\u03b25",
            "probability": 0.0
        },
        {
            "start_logit": 6.8671875,
            "end_logit": -8.953125,
            "text": "\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": 6.8671875,
            "end_logit": -9.1484375,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 in MPM, there is a rationale for investigating the effects on MPM of cilengitide, a",
            "probability": 0.0
        },
        {
            "start_logit": 4.96484375,
            "end_logit": -8.421875,
            "text": "integrins \u03b1v\u03b23 and \u03b1v\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 4.96484375,
            "end_logit": -8.65625,
            "text": "integrins \u03b1v\u03b23 and",
            "probability": 0.0
        },
        {
            "start_logit": 4.96484375,
            "end_logit": -8.8359375,
            "text": "integrins \u03b1v\u03b23 and \u03b1v\u03b25 in MPM, there is a rationale",
            "probability": 0.0
        }
    ],
    "54cf705ff693c3b16b000014_3": [
        {
            "start_logit": 12.5859375,
            "end_logit": 11.7578125,
            "text": "\u03b1v\u03b23",
            "probability": 1.0
        },
        {
            "start_logit": 12.5859375,
            "end_logit": -2.900390625,
            "text": "\u03b1v",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 12.5859375,
            "end_logit": -5.390625,
            "text": "\u03b1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.6640625,
            "end_logit": 11.7578125,
            "text": "3",
            "probability": 0.0
        },
        {
            "start_logit": 12.5859375,
            "end_logit": -7.1328125,
            "text": "\u03b1v\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 12.5859375,
            "end_logit": -7.24609375,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25",
            "probability": 0.0
        },
        {
            "start_logit": 12.5859375,
            "end_logit": -8.34375,
            "text": "\u03b1v\u03b23 and",
            "probability": 0.0
        },
        {
            "start_logit": 12.5859375,
            "end_logit": -9.3046875,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 12.5859375,
            "end_logit": -9.8828125,
            "text": "\u03b1v\u03b23 and \u03b1v",
            "probability": 0.0
        },
        {
            "start_logit": -9.078125,
            "end_logit": 11.7578125,
            "text": "\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -9.5078125,
            "end_logit": 11.7578125,
            "text": "these effects of cilengitide were, at least partly, due to antagonism of \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -9.5078125,
            "end_logit": -2.900390625,
            "text": "these effects of cilengitide were, at least partly, due to antagonism of \u03b1v",
            "probability": 0.0
        },
        {
            "start_logit": -5.6640625,
            "end_logit": -7.24609375,
            "text": "3 and \u03b1v\u03b25",
            "probability": 0.0
        },
        {
            "start_logit": -5.6640625,
            "end_logit": -8.34375,
            "text": "3 and",
            "probability": 0.0
        },
        {
            "start_logit": -9.5078125,
            "end_logit": -5.390625,
            "text": "these effects of cilengitide were, at least partly, due to antagonism of \u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -5.6640625,
            "end_logit": -9.3046875,
            "text": "3 and \u03b1v\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -5.6640625,
            "end_logit": -9.8828125,
            "text": "3 and \u03b1v",
            "probability": 0.0
        },
        {
            "start_logit": -9.078125,
            "end_logit": -7.1328125,
            "text": "\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -9.078125,
            "end_logit": -7.24609375,
            "text": "\u03b23 and \u03b1v\u03b25",
            "probability": 0.0
        },
        {
            "start_logit": -9.5078125,
            "end_logit": -7.1328125,
            "text": "these effects of cilengitide were, at least partly, due to antagonism of \u03b1v\u03b2",
            "probability": 0.0
        }
    ],
    "54cf705ff693c3b16b000014_4": [
        {
            "start_logit": 13.28125,
            "end_logit": 11.953125,
            "text": "\u03b1v\u03b23",
            "probability": 1.0
        },
        {
            "start_logit": 13.28125,
            "end_logit": -3.3359375,
            "text": "\u03b1v",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 13.28125,
            "end_logit": -4.703125,
            "text": "\u03b1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.28125,
            "end_logit": -6.48046875,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins",
            "probability": 0.0
        },
        {
            "start_logit": -5.48046875,
            "end_logit": 11.953125,
            "text": "3",
            "probability": 0.0
        },
        {
            "start_logit": 13.28125,
            "end_logit": -6.90234375,
            "text": "\u03b1v\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 13.28125,
            "end_logit": -7.60546875,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25",
            "probability": 0.0
        },
        {
            "start_logit": 13.28125,
            "end_logit": -8.859375,
            "text": "\u03b1v\u03b23 and",
            "probability": 0.0
        },
        {
            "start_logit": 13.28125,
            "end_logit": -9.3515625,
            "text": "\u03b1v\u03b23 and \u03b1v",
            "probability": 0.0
        },
        {
            "start_logit": 13.28125,
            "end_logit": -9.359375,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins and was developed for antiangiogenic",
            "probability": 0.0
        },
        {
            "start_logit": 13.28125,
            "end_logit": -9.3984375,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 13.28125,
            "end_logit": -9.7734375,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins and",
            "probability": 0.0
        },
        {
            "start_logit": 13.28125,
            "end_logit": -9.9375,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins and was developed for antiangiogenic therapy.",
            "probability": 0.0
        },
        {
            "start_logit": -8.96875,
            "end_logit": 11.953125,
            "text": "\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -10.1171875,
            "end_logit": 11.953125,
            "text": "Abstract The RGD cyclic pentapetide, cilengitide, is a selective inhibitor of \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 11.953125,
            "text": "RGD cyclic pentapetide, cilengitide, is a selective inhibitor of \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 11.953125,
            "text": "engitide, is a selective inhibitor of \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 11.953125,
            "text": "pentapetide, cilengitide, is a selective inhibitor of \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -10.953125,
            "end_logit": 11.953125,
            "text": "cilengitide, is a selective inhibitor of \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -5.48046875,
            "end_logit": -6.48046875,
            "text": "3 and \u03b1v\u03b25 integrins",
            "probability": 0.0
        }
    ],
    "54cf705ff693c3b16b000014_5": [
        {
            "start_logit": 13.4921875,
            "end_logit": 12.09375,
            "text": "\u03b1v\u03b23",
            "probability": 1.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -3.875,
            "text": "\u03b1v",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -4.54296875,
            "text": "\u03b1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.33984375,
            "end_logit": 12.09375,
            "text": "3",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -7.07421875,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -7.1015625,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrin",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -7.30859375,
            "text": "\u03b1v\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -8.6484375,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrin receptors",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -9.4765625,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -9.5625,
            "text": "\u03b1v\u03b23 and \u03b1v",
            "probability": 0.0
        },
        {
            "start_logit": -8.953125,
            "end_logit": 12.09375,
            "text": "RGD-peptide of sequence cyclo[RGDfNMeV] that was was developed as a highly active and selective ligand for the \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -9.0234375,
            "end_logit": 12.09375,
            "text": "\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 12.09375,
            "text": "cyclo[RGDfNMeV] that was was developed as a highly active and selective ligand for the \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 12.09375,
            "text": "RGDfNMeV] that was was developed as a highly active and selective ligand for the \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 12.09375,
            "text": "was developed as a highly active and selective ligand for the \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -5.33984375,
            "end_logit": -7.07421875,
            "text": "3 and \u03b1v\u03b25",
            "probability": 0.0
        },
        {
            "start_logit": -5.33984375,
            "end_logit": -7.1015625,
            "text": "3 and \u03b1v\u03b25 integrin",
            "probability": 0.0
        },
        {
            "start_logit": -8.953125,
            "end_logit": -3.875,
            "text": "RGD-peptide of sequence cyclo[RGDfNMeV] that was was developed as a highly active and selective ligand for the \u03b1v",
            "probability": 0.0
        },
        {
            "start_logit": -8.953125,
            "end_logit": -4.54296875,
            "text": "RGD-peptide of sequence cyclo[RGDfNMeV] that was was developed as a highly active and selective ligand for the \u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -5.33984375,
            "end_logit": -8.6484375,
            "text": "3 and \u03b1v\u03b25 integrin receptors",
            "probability": 0.0
        }
    ],
    "54cf705ff693c3b16b000014_6": [
        {
            "start_logit": 12.8984375,
            "end_logit": 10.5390625,
            "text": "\u03b1v\u03b25",
            "probability": 1.0
        },
        {
            "start_logit": 12.8984375,
            "end_logit": 1.455078125,
            "text": "\u03b1v\u03b25 was the predominantly expressed integrin heterodimer in meningiomas, whereas \u03b1v\u03b23",
            "probability": 0.00011324882507324219
        },
        {
            "start_logit": 12.8984375,
            "end_logit": -3.041015625,
            "text": "\u03b1v",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 12.8984375,
            "end_logit": -4.984375,
            "text": "\u03b1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 12.8984375,
            "end_logit": -5.875,
            "text": "\u03b1v\u03b25 was the predominantly expressed integrin heterodimer in meningiomas, whereas \u03b1v",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.8984375,
            "end_logit": -6.1875,
            "text": "\u03b1v\u03b25 was the predominantly expressed integrin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.8984375,
            "end_logit": -6.78125,
            "text": "\u03b1v\u03b25 was the predominantly expressed integrin heterodimer in meningiomas, whereas \u03b1v\u03b23 was mainly detected in tumor blood vessels",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.8984375,
            "end_logit": -6.80859375,
            "text": "\u03b1v\u03b25 was the predominantly expressed integrin heterodimer in meningiomas, whereas \u03b1v\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 12.8984375,
            "end_logit": -7.5703125,
            "text": "\u03b1v\u03b25 was the predominantly expressed integrin heterodimer in meningiomas, whereas \u03b1v\u03b23 was",
            "probability": 0.0
        },
        {
            "start_logit": 12.8984375,
            "end_logit": -7.6796875,
            "text": "\u03b1v\u03b25 was the predominantly expressed integrin heterodimer",
            "probability": 0.0
        },
        {
            "start_logit": 12.8984375,
            "end_logit": -7.953125,
            "text": "\u03b1v\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 12.8984375,
            "end_logit": -7.9921875,
            "text": "\u03b1v\u03b25 was",
            "probability": 0.0
        },
        {
            "start_logit": 12.8984375,
            "end_logit": -8.53125,
            "text": "\u03b1v\u03b25 was the predominantly expressed integrin heterodimer in meningiomas, whereas \u03b1",
            "probability": 0.0
        },
        {
            "start_logit": 12.8984375,
            "end_logit": -8.9765625,
            "text": "\u03b1v\u03b25 was the predominantly expressed integrin heterodimer in meningiomas, whereas \u03b1v\u03b23 was mainly detected in",
            "probability": 0.0
        },
        {
            "start_logit": 12.8984375,
            "end_logit": -9.234375,
            "text": "\u03b1v\u03b25 was the predominantly expressed integrin heterodimer in meningiomas,",
            "probability": 0.0
        },
        {
            "start_logit": 12.8984375,
            "end_logit": -9.609375,
            "text": "\u03b1v\u03b25 was the predominantly expressed integrin heterodimer in meningiomas, whereas \u03b1v\u03b23 was mainly detected in tumor blood",
            "probability": 0.0
        },
        {
            "start_logit": 12.8984375,
            "end_logit": -9.6328125,
            "text": "\u03b1v\u03b25 was the",
            "probability": 0.0
        },
        {
            "start_logit": 12.8984375,
            "end_logit": -9.6484375,
            "text": "\u03b1v\u03b25 was the predominantly expressed integrin heterodimer in meningiomas, whereas \u03b1v\u03b23 was mainly detected",
            "probability": 0.0
        },
        {
            "start_logit": -7.65625,
            "end_logit": 10.5390625,
            "text": "5",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 10.5390625,
            "text": "\u03b25",
            "probability": 0.0
        }
    ],
    "54cf705ff693c3b16b000014_7": [
        {
            "start_logit": 9.671875,
            "end_logit": 4.125,
            "text": "\u03b1v\u03b25",
            "probability": 0.9921875
        },
        {
            "start_logit": 9.671875,
            "end_logit": -0.9755859375,
            "text": "\u03b1v\u03b25 integrin",
            "probability": 0.00604248046875
        },
        {
            "start_logit": 2.3828125,
            "end_logit": 4.71875,
            "text": "\u03b1v\u03b23",
            "probability": 0.0012273788452148438
        },
        {
            "start_logit": 9.671875,
            "end_logit": -3.89453125,
            "text": "\u03b1v",
            "probability": 0.0003275871276855469
        },
        {
            "start_logit": 9.671875,
            "end_logit": -5.4140625,
            "text": "\u03b1v\u03b25 integrin and were not sensitive to cilengitide, suggesting that cilengitide's action largely depends on \u03b1v\u03b2",
            "probability": 7.146596908569336e-05
        },
        {
            "start_logit": 9.671875,
            "end_logit": -5.4375,
            "text": "\u03b1v\u03b25 integrin and were not sensitive to cilengitide, suggesting that cilengitide's action largely depends on \u03b1v",
            "probability": 6.979703903198242e-05
        },
        {
            "start_logit": 9.671875,
            "end_logit": -5.7890625,
            "text": "\u03b1v\u03b2",
            "probability": 4.9114227294921875e-05
        },
        {
            "start_logit": 9.671875,
            "end_logit": -7.49609375,
            "text": "\u03b1",
            "probability": 8.881092071533203e-06
        },
        {
            "start_logit": 9.671875,
            "end_logit": -7.96484375,
            "text": "\u03b1v\u03b25 integrin and were not sensitive to cilengitide, suggesting that cilengitide's action largely depends on \u03b1",
            "probability": 5.543231964111328e-06
        },
        {
            "start_logit": 9.671875,
            "end_logit": -9.8125,
            "text": "\u03b1v\u03b25 integrin and were not sensitive to cilengitide, suggesting",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 9.671875,
            "end_logit": -9.828125,
            "text": "\u03b1v\u03b25 integrin and were not sensitive",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 9.671875,
            "end_logit": -9.9296875,
            "text": "\u03b1v\u03b25 integrin and were not sensitive to cilengitide, suggesting that cilengitide's action largely depends on",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 9.671875,
            "end_logit": -10.0078125,
            "text": "\u03b1v\u03b25 integrin and were not sensitive to cilengitide, suggesting that cilengitide's action largely depends",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 9.671875,
            "end_logit": -10.234375,
            "text": "\u03b1v\u03b25 integrin and",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 9.671875,
            "end_logit": -10.3359375,
            "text": "\u03b1v\u03b25 integrin and were not sensitive to",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.19921875,
            "end_logit": 4.71875,
            "text": "3",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.2421875,
            "end_logit": 4.71875,
            "text": "integrin and were not sensitive to cilengitide, suggesting that cilengitide's action largely depends on \u03b1v\u03b23",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 2.3828125,
            "end_logit": -5.4140625,
            "text": "\u03b1v\u03b2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 2.3828125,
            "end_logit": -5.4375,
            "text": "\u03b1v",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.03125,
            "end_logit": 4.71875,
            "text": "\u03b23",
            "probability": 0.0
        }
    ],
    "54cf705ff693c3b16b000014_8": [
        {
            "start_logit": 13.34375,
            "end_logit": 11.7265625,
            "text": "\u03b1v\u03b23",
            "probability": 1.0
        },
        {
            "start_logit": 13.34375,
            "end_logit": -2.115234375,
            "text": "\u03b1v",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 13.34375,
            "end_logit": -4.58203125,
            "text": "\u03b1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.34375,
            "end_logit": -5.06640625,
            "text": "\u03b1v\u03b2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.34375,
            "end_logit": -7.68359375,
            "text": "\u03b1v\u03b23 expression and sensitivity to anoikis",
            "probability": 0.0
        },
        {
            "start_logit": -6.2109375,
            "end_logit": 11.7265625,
            "text": "3",
            "probability": 0.0
        },
        {
            "start_logit": 13.34375,
            "end_logit": -8.65625,
            "text": "\u03b1v\u03b23 expression",
            "probability": 0.0
        },
        {
            "start_logit": 13.34375,
            "end_logit": -9.421875,
            "text": "\u03b1v\u03b23 expression and sensitivity to anoi",
            "probability": 0.0
        },
        {
            "start_logit": 13.34375,
            "end_logit": -9.4453125,
            "text": "\u03b1v\u03b23 expression and sensitivity to anoiki",
            "probability": 0.0
        },
        {
            "start_logit": 13.34375,
            "end_logit": -9.7734375,
            "text": "\u03b1v\u03b23 expression and sensitivity to",
            "probability": 0.0
        },
        {
            "start_logit": 13.34375,
            "end_logit": -10.140625,
            "text": "\u03b1v\u03b23 expression and sensitivity to anoikis.",
            "probability": 0.0
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 11.7265625,
            "text": "\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 11.7265625,
            "text": "neuroblastoma cells appears to be dependent on \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 11.7265625,
            "text": "glioma and neuroblastoma cells appears to be dependent on \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 11.7265625,
            "text": "engitide's action on glioma and neuroblastoma cells appears to be dependent on \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 11.7265625,
            "text": "itide's action on glioma and neuroblastoma cells appears to be dependent on \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 11.7265625,
            "text": "Cilengitide's action on glioma and neuroblastoma cells appears to be dependent on \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": -2.115234375,
            "text": "neuroblastoma cells appears to be dependent on \u03b1v",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": -2.115234375,
            "text": "glioma and neuroblastoma cells appears to be dependent on \u03b1v",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": -2.115234375,
            "text": "engitide's action on glioma and neuroblastoma cells appears to be dependent on \u03b1v",
            "probability": 0.0
        }
    ],
    "54cf705ff693c3b16b000014_9": [
        {
            "start_logit": 13.4375,
            "end_logit": 11.90625,
            "text": "\u03b1v\u03b23",
            "probability": 1.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -4.12109375,
            "text": "\u03b1v",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.4375,
            "end_logit": -4.76953125,
            "text": "\u03b1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.4375,
            "end_logit": -6.55078125,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -7.10546875,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25",
            "probability": 0.0
        },
        {
            "start_logit": -5.84375,
            "end_logit": 11.90625,
            "text": "3",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -7.90234375,
            "text": "\u03b1v\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -9.15625,
            "text": "\u03b1v\u03b23 and",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -9.1875,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -9.234375,
            "text": "\u03b1v\u03b23 and \u03b1v",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -9.3671875,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins, from day 30 to 55 after tumor cell inoculation of MDA-MB-231 breast cancer",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -9.59375,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins,",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -9.71875,
            "text": "\u03b1v\u03b23 and \u03b1",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -9.8359375,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins, from day 30",
            "probability": 0.0
        },
        {
            "start_logit": -8.8984375,
            "end_logit": 11.90625,
            "text": "\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -9.1015625,
            "end_logit": 11.90625,
            "text": "nude rats bearing bone metastases were treated with cilengitide, a small molecule inhibitor of \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -9.390625,
            "end_logit": 11.90625,
            "text": "bone metastases were treated with cilengitide, a small molecule inhibitor of \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -9.90625,
            "end_logit": 11.90625,
            "text": ": For this purpose, nude rats bearing bone metastases were treated with cilengitide, a small molecule inhibitor of \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -5.84375,
            "end_logit": -6.55078125,
            "text": "3 and \u03b1v\u03b25 integrins",
            "probability": 0.0
        },
        {
            "start_logit": -5.84375,
            "end_logit": -7.10546875,
            "text": "3 and \u03b1v\u03b25",
            "probability": 0.0
        }
    ],
    "54cf705ff693c3b16b000014_10": [
        {
            "start_logit": 13.6796875,
            "end_logit": 11.6484375,
            "text": "\u03b1V\u03b23",
            "probability": 1.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -2.1640625,
            "text": "\u03b1V\u03b23/\u03b1V\u03b25 integrin",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -3.755859375,
            "text": "\u03b1V\u03b23/\u03b1V\u03b25",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -4.01171875,
            "text": "\u03b1V",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -4.12109375,
            "text": "\u03b1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -6.26171875,
            "text": "\u03b1V\u03b23/\u03b1V\u03b25 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion",
            "probability": 0.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -6.984375,
            "text": "\u03b1V\u03b23/\u03b1V\u03b25 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a",
            "probability": 0.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -7.01171875,
            "text": "\u03b1V\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -7.69921875,
            "text": "\u03b1V\u03b23/\u03b1V\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -7.84375,
            "text": "\u03b1V\u03b23/\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -7.984375,
            "text": "\u03b1V\u03b23/\u03b1V\u03b25 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model",
            "probability": 0.0
        },
        {
            "start_logit": -6.015625,
            "end_logit": 11.6484375,
            "text": "3",
            "probability": 0.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -8.0859375,
            "text": "\u03b1V\u03b23/\u03b1V\u03b25 integrin inhibitor cilengitide augments tumor response to melphalan",
            "probability": 0.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -8.3359375,
            "text": "\u03b1V\u03b23/\u03b1V",
            "probability": 0.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -9.40625,
            "text": "\u03b1V\u03b23/\u03b1V\u03b25 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in",
            "probability": 0.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -9.703125,
            "text": "\u03b1V\u03b23/\u03b1V\u03b25 integrin inhibitor cilengitide augments tumor",
            "probability": 0.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -9.8203125,
            "text": "\u03b1V\u03b23/\u03b1V\u03b25 integrin inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -9.8203125,
            "text": "\u03b1V\u03b23/",
            "probability": 0.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -9.8515625,
            "text": "\u03b1V\u03b23/\u03b1V\u03b25 integrin inhibitor cilengitide augments tumor response",
            "probability": 0.0
        },
        {
            "start_logit": -9.5234375,
            "end_logit": 11.6484375,
            "text": "\u03b23",
            "probability": 0.0
        }
    ],
    "54cf705ff693c3b16b000014_11": [
        {
            "start_logit": 12.0,
            "end_logit": 10.078125,
            "text": "\u03b1v\u03b23",
            "probability": 1.0
        },
        {
            "start_logit": 12.0,
            "end_logit": -4.4140625,
            "text": "\u03b1v",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 12.0,
            "end_logit": -5.07421875,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 12.0,
            "end_logit": -6.0703125,
            "text": "\u03b1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.0,
            "end_logit": -6.2890625,
            "text": "\u03b1v\u03b2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.0,
            "end_logit": -6.5078125,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.11328125,
            "end_logit": 10.078125,
            "text": "3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.0,
            "end_logit": -7.80859375,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins has shown encouraging activity in patients with glioblastoma as single agent, and in association with standard RT",
            "probability": 0.0
        },
        {
            "start_logit": 12.0,
            "end_logit": -8.0703125,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins has shown encouraging activity in patients with glioblastoma",
            "probability": 0.0
        },
        {
            "start_logit": 12.0,
            "end_logit": -8.28125,
            "text": "\u03b1v\u03b23 and",
            "probability": 0.0
        },
        {
            "start_logit": 12.0,
            "end_logit": -9.2265625,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins has shown encouraging activity in patients with glioblastoma as single agent, and in association with standard RT and",
            "probability": 0.0
        },
        {
            "start_logit": 12.0,
            "end_logit": -9.390625,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins has shown encouraging activity in patients with glioblastoma as single agent, and in",
            "probability": 0.0
        },
        {
            "start_logit": 12.0,
            "end_logit": -9.3984375,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins has shown encouraging activity in",
            "probability": 0.0
        },
        {
            "start_logit": 12.0,
            "end_logit": -9.40625,
            "text": "\u03b1v\u03b23 and \u03b1v",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": 10.078125,
            "text": "\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 10.078125,
            "text": "Arg-Gly-Glu(RGD)-containing pentapeptide that selectively blocks activation of the \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 10.078125,
            "text": "itide, a cyclized Arg-Gly-Glu(RGD)-containing pentapeptide that selectively blocks activation of the \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -5.11328125,
            "end_logit": -5.07421875,
            "text": "3 and \u03b1v\u03b25 integrins",
            "probability": 0.0
        },
        {
            "start_logit": -5.11328125,
            "end_logit": -6.5078125,
            "text": "3 and \u03b1v\u03b25",
            "probability": 0.0
        },
        {
            "start_logit": -6.73046875,
            "end_logit": -5.07421875,
            "text": "integrins",
            "probability": 0.0
        }
    ],
    "54cf705ff693c3b16b000014_12": [
        {
            "start_logit": 12.609375,
            "end_logit": 11.8671875,
            "text": "\u03b1v\u03b23",
            "probability": 1.0
        },
        {
            "start_logit": 12.609375,
            "end_logit": -3.130859375,
            "text": "\u03b1v\u03b23, \u03b1v\u03b25, and \u03b15\u03b21",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 12.609375,
            "end_logit": -3.93359375,
            "text": "\u03b1v",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.609375,
            "end_logit": -5.0859375,
            "text": "\u03b1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.03515625,
            "end_logit": 11.8671875,
            "text": "3",
            "probability": 0.0
        },
        {
            "start_logit": 12.609375,
            "end_logit": -6.76171875,
            "text": "\u03b1v\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 12.609375,
            "end_logit": -7.0078125,
            "text": "\u03b1v\u03b23, \u03b1v\u03b25",
            "probability": 0.0
        },
        {
            "start_logit": 12.609375,
            "end_logit": -7.2890625,
            "text": "\u03b1v\u03b23, \u03b1v\u03b25, and \u03b15\u03b21 integrin",
            "probability": 0.0
        },
        {
            "start_logit": 12.609375,
            "end_logit": -8.1328125,
            "text": "\u03b1v\u03b23, \u03b1v\u03b25, and \u03b15\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 12.609375,
            "end_logit": -8.1640625,
            "text": "\u03b1v\u03b23, \u03b1v\u03b25, and \u03b1",
            "probability": 0.0
        },
        {
            "start_logit": 12.609375,
            "end_logit": -8.40625,
            "text": "\u03b1v\u03b23, \u03b1v\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 12.609375,
            "end_logit": -8.5234375,
            "text": "\u03b1v\u03b23, \u03b1v\u03b25, and \u03b15",
            "probability": 0.0
        },
        {
            "start_logit": 12.609375,
            "end_logit": -8.7109375,
            "text": "\u03b1v\u03b23, \u03b1v\u03b25, and \u03b15\u03b21 integrin receptors",
            "probability": 0.0
        },
        {
            "start_logit": 12.609375,
            "end_logit": -8.859375,
            "text": "\u03b1v\u03b23, \u03b1v\u03b25, and \u03b15\u03b21 integrin receptors,",
            "probability": 0.0
        },
        {
            "start_logit": 12.609375,
            "end_logit": -9.0078125,
            "text": "\u03b1v\u03b23, \u03b1v\u03b25, and",
            "probability": 0.0
        },
        {
            "start_logit": 12.609375,
            "end_logit": -9.0234375,
            "text": "\u03b1v\u03b23, \u03b1v",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 11.8671875,
            "text": "\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 11.8671875,
            "text": "of the \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 11.8671875,
            "text": "R-G-D-f-V) 2, potent antagonists of the \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 11.8671875,
            "text": "V] 1, and its parent peptide cyclo(R-G-D-f-V) 2, potent antagonists of the \u03b1v\u03b23",
            "probability": 0.0
        }
    ],
    "54cf705ff693c3b16b000014_13": [
        {
            "start_logit": 12.8515625,
            "end_logit": 11.171875,
            "text": "\u03b1v\u03b23",
            "probability": 1.0
        },
        {
            "start_logit": 12.8515625,
            "end_logit": -3.12890625,
            "text": "\u03b1v",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 12.8515625,
            "end_logit": -5.08984375,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.8515625,
            "end_logit": -5.34765625,
            "text": "\u03b1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.21484375,
            "end_logit": 11.171875,
            "text": "3",
            "probability": 0.0
        },
        {
            "start_logit": 12.8515625,
            "end_logit": -6.93359375,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25",
            "probability": 0.0
        },
        {
            "start_logit": 12.8515625,
            "end_logit": -7.17578125,
            "text": "\u03b1v\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 12.8515625,
            "end_logit": -8.1171875,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins thanks to a specific peptide called RGD",
            "probability": 0.0
        },
        {
            "start_logit": 12.8515625,
            "end_logit": -8.15625,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins thanks to a specific peptide called RGD sequence",
            "probability": 0.0
        },
        {
            "start_logit": 12.8515625,
            "end_logit": -8.796875,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins thanks to a",
            "probability": 0.0
        },
        {
            "start_logit": 12.8515625,
            "end_logit": -8.8046875,
            "text": "\u03b1v\u03b23 and",
            "probability": 0.0
        },
        {
            "start_logit": 12.8515625,
            "end_logit": -8.90625,
            "text": "\u03b1v\u03b23 and \u03b1v",
            "probability": 0.0
        },
        {
            "start_logit": 12.8515625,
            "end_logit": -9.25,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 12.8515625,
            "end_logit": -9.3828125,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins thanks to a specific peptide",
            "probability": 0.0
        },
        {
            "start_logit": 12.8515625,
            "end_logit": -9.5703125,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins thanks to",
            "probability": 0.0
        },
        {
            "start_logit": 12.8515625,
            "end_logit": -9.6796875,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins thanks",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": 11.171875,
            "text": "\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 11.171875,
            "text": "KGaA, Darmstadt, Germany) is a new drug targeting \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 11.171875,
            "text": "Merck KGaA, Darmstadt, Germany) is a new drug targeting \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 11.171875,
            "text": "itide (EMD121974; Merck KGaA, Darmstadt, Germany) is a new drug targeting \u03b1v\u03b23",
            "probability": 0.0
        }
    ],
    "54cf705ff693c3b16b000014_14": [
        {
            "start_logit": 12.8203125,
            "end_logit": 11.34375,
            "text": "\u03b1v\u03b23",
            "probability": 1.0
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -3.833984375,
            "text": "\u03b1v",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -4.73828125,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -5.36328125,
            "text": "\u03b1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -6.92578125,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25",
            "probability": 0.0
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -7.15625,
            "text": "\u03b1v\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -5.703125,
            "end_logit": 11.34375,
            "text": "3",
            "probability": 0.0
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -8.0078125,
            "text": "\u03b1v\u03b23 and",
            "probability": 0.0
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -8.7578125,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -8.953125,
            "text": "\u03b1v\u03b23 and \u03b1v",
            "probability": 0.0
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -9.046875,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins is in advanced clinical development in glioblastoma",
            "probability": 0.0
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -9.3828125,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins is",
            "probability": 0.0
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -9.4453125,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins is in advanced clinical development in",
            "probability": 0.0
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -9.6171875,
            "text": "\u03b1v\u03b23 and \u03b1",
            "probability": 0.0
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -9.671875,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins is in",
            "probability": 0.0
        },
        {
            "start_logit": -9.0859375,
            "end_logit": 11.34375,
            "text": "\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 11.34375,
            "text": "Cilengitide, a cyclic RGD-mimetic peptide of \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 11.34375,
            "text": "engitide, a cyclic RGD-mimetic peptide of \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 11.34375,
            "text": "itide, a cyclic RGD-mimetic peptide of \u03b1v\u03b23",
            "probability": 0.0
        },
        {
            "start_logit": -5.703125,
            "end_logit": -4.73828125,
            "text": "3 and \u03b1v\u03b25 integrins",
            "probability": 0.0
        }
    ],
    "5324cca79b2d7acc7e00001d_1": [
        {
            "start_logit": 8.6796875,
            "end_logit": 12.8046875,
            "text": "obesity",
            "probability": 0.9990234375
        },
        {
            "start_logit": 1.580078125,
            "end_logit": 12.8046875,
            "text": "pediatric obesity",
            "probability": 0.0008230209350585938
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -2.9140625,
            "text": "obesity prevention and treatment",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -9.109375,
            "end_logit": 12.8046875,
            "text": "for pediatric obesity",
            "probability": 0.0
        },
        {
            "start_logit": -9.5234375,
            "end_logit": 12.8046875,
            "text": "Mobile apps for pediatric obesity",
            "probability": 0.0
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -5.46484375,
            "text": "obesity prevention and treatment, healthy eating, and physical activity promotion",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": 12.8046875,
            "text": "apps for pediatric obesity",
            "probability": 0.0
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -6.6015625,
            "text": "obesity prevention",
            "probability": 0.0
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -7.46484375,
            "text": "obesity prevention and treatment, healthy eating, and physical activity",
            "probability": 0.0
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -8.9375,
            "text": "obesity prevention and treatment, healthy eating, and",
            "probability": 0.0
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -9.015625,
            "text": "obesity prevention and treatment, healthy eating",
            "probability": 0.0
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -9.7109375,
            "text": "obesity prevention and",
            "probability": 0.0
        },
        {
            "start_logit": 1.580078125,
            "end_logit": -2.9140625,
            "text": "pediatric obesity prevention and treatment",
            "probability": 0.0
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -10.0546875,
            "text": "obesity prevention and treatment, healthy eating, and physical",
            "probability": 0.0
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -10.2578125,
            "text": "obesity prevention and treatment, healthy eating,",
            "probability": 0.0
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -10.28125,
            "text": "obesity prevention and treatment, healthy",
            "probability": 0.0
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -10.9296875,
            "text": "obesity prevention and treatment,",
            "probability": 0.0
        },
        {
            "start_logit": 1.580078125,
            "end_logit": -5.46484375,
            "text": "pediatric obesity prevention and treatment, healthy eating, and physical activity promotion",
            "probability": 0.0
        },
        {
            "start_logit": 1.580078125,
            "end_logit": -6.6015625,
            "text": "pediatric obesity prevention",
            "probability": 0.0
        },
        {
            "start_logit": 1.580078125,
            "end_logit": -7.46484375,
            "text": "pediatric obesity prevention and treatment, healthy eating, and physical activity",
            "probability": 0.0
        }
    ],
    "5324cca79b2d7acc7e00001d_2": [
        {
            "start_logit": -6.91796875,
            "end_logit": 11.4609375,
            "text": "dermatology",
            "probability": 0.8271484375
        },
        {
            "start_logit": -8.8203125,
            "end_logit": 11.4609375,
            "text": "Mobile applications in dermatology",
            "probability": 0.1234130859375
        },
        {
            "start_logit": -9.7421875,
            "end_logit": 11.4609375,
            "text": "in dermatology",
            "probability": 0.049102783203125
        },
        {
            "start_logit": -8.8203125,
            "end_logit": -9.34375,
            "text": "Mobile applications in",
            "probability": 0.0
        },
        {
            "start_logit": -8.8203125,
            "end_logit": -9.5234375,
            "text": "Mobile applications",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": -9.34375,
            "text": "in",
            "probability": 0.0
        }
    ],
    "5324cca79b2d7acc7e00001d_3": [
        {
            "start_logit": 12.21875,
            "end_logit": 12.625,
            "text": "VisualDx",
            "probability": 1.0
        },
        {
            "start_logit": 12.21875,
            "end_logit": -1.6435546875,
            "text": "VisualDx (306), SPF (128), iSore (61), and SpotMole",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -3.1171875,
            "end_logit": 12.625,
            "text": ", VisualDx",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.33984375,
            "end_logit": 12.625,
            "text": "x",
            "probability": 0.0
        },
        {
            "start_logit": 12.21875,
            "end_logit": -5.3046875,
            "text": "Visual",
            "probability": 0.0
        },
        {
            "start_logit": 12.21875,
            "end_logit": -6.3359375,
            "text": "VisualDx (306), SPF (128), iSore",
            "probability": 0.0
        },
        {
            "start_logit": -7.5,
            "end_logit": 12.625,
            "text": "Dx",
            "probability": 0.0
        },
        {
            "start_logit": -7.734375,
            "end_logit": 12.625,
            "text": "~ UV Index (355 reviews), VisualDx",
            "probability": 0.0
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 12.625,
            "text": "UV Index (355 reviews), VisualDx",
            "probability": 0.0
        },
        {
            "start_logit": -3.32421875,
            "end_logit": -0.87890625,
            "text": "dermatology-related apps were identified in the following categories: general dermatology reference (61 [26.6%]), self-surveillance/diagnosis",
            "probability": 0.0
        },
        {
            "start_logit": -3.1171875,
            "end_logit": -1.6435546875,
            "text": ", VisualDx (306), SPF (128), iSore (61), and SpotMole",
            "probability": 0.0
        },
        {
            "start_logit": -3.32421875,
            "end_logit": -3.43359375,
            "text": "dermatology-related apps were identified in the following categories: general dermatology",
            "probability": 0.0
        },
        {
            "start_logit": -5.93359375,
            "end_logit": -0.822265625,
            "text": "teledermatology",
            "probability": 0.0
        },
        {
            "start_logit": -5.33984375,
            "end_logit": -1.6435546875,
            "text": "x (306), SPF (128), iSore (61), and SpotMole",
            "probability": 0.0
        },
        {
            "start_logit": -6.296875,
            "end_logit": -0.87890625,
            "text": "apps were identified in the following categories: general dermatology reference (61 [26.6%]), self-surveillance/diagnosis",
            "probability": 0.0
        },
        {
            "start_logit": -6.45703125,
            "end_logit": -0.822265625,
            "text": "gy",
            "probability": 0.0
        },
        {
            "start_logit": -6.6953125,
            "end_logit": -0.87890625,
            "text": ", self-surveillance/diagnosis",
            "probability": 0.0
        },
        {
            "start_logit": -6.25,
            "end_logit": -1.6435546875,
            "text": "iSore (61), and SpotMole",
            "probability": 0.0
        },
        {
            "start_logit": -7.015625,
            "end_logit": -0.87890625,
            "text": "self-surveillance/diagnosis",
            "probability": 0.0
        },
        {
            "start_logit": -3.32421875,
            "end_logit": -4.65625,
            "text": "dermatology-related apps were identified in the following categories: general dermatology reference",
            "probability": 0.0
        }
    ],
    "5324cca79b2d7acc7e00001d_4": [
        {
            "start_logit": 10.46875,
            "end_logit": 3.767578125,
            "text": "myFitnessCompanion\u00ae",
            "probability": 0.9990234375
        },
        {
            "start_logit": 10.46875,
            "end_logit": -2.8515625,
            "text": "myFitnessCompanion",
            "probability": 0.0013360977172851562
        },
        {
            "start_logit": 10.46875,
            "end_logit": -6.23828125,
            "text": "myFitness",
            "probability": 4.5359134674072266e-05
        },
        {
            "start_logit": 10.46875,
            "end_logit": -6.47265625,
            "text": "myFitnessCompan",
            "probability": 3.5881996154785156e-05
        },
        {
            "start_logit": 10.46875,
            "end_logit": -7.1171875,
            "text": "my",
            "probability": 1.8775463104248047e-05
        },
        {
            "start_logit": 10.46875,
            "end_logit": -7.32421875,
            "text": "myFit",
            "probability": 1.519918441772461e-05
        },
        {
            "start_logit": 10.46875,
            "end_logit": -8.46875,
            "text": "myFitnessCom",
            "probability": 4.887580871582031e-06
        },
        {
            "start_logit": 10.46875,
            "end_logit": -9.109375,
            "text": "myFi",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": -8.046875,
            "end_logit": 3.767578125,
            "text": "health and fitness app called myFitnessCompanion\u00ae",
            "probability": 0.0
        },
        {
            "start_logit": -8.6875,
            "end_logit": 3.767578125,
            "text": "fitness app called myFitnessCompanion\u00ae",
            "probability": 0.0
        },
        {
            "start_logit": -8.9375,
            "end_logit": 3.767578125,
            "text": "app called myFitnessCompanion\u00ae",
            "probability": 0.0
        },
        {
            "start_logit": -9.203125,
            "end_logit": 3.767578125,
            "text": "and fitness app called myFitnessCompanion\u00ae",
            "probability": 0.0
        },
        {
            "start_logit": -9.21875,
            "end_logit": 3.767578125,
            "text": "mobile health and fitness app called myFitnessCompanion\u00ae",
            "probability": 0.0
        },
        {
            "start_logit": -9.4375,
            "end_logit": 3.767578125,
            "text": "FitnessCompanion\u00ae",
            "probability": 0.0
        },
        {
            "start_logit": -9.9921875,
            "end_logit": 3.767578125,
            "text": "Companion\u00ae",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 3.767578125,
            "text": "tnessCompanion\u00ae",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 3.767578125,
            "text": "called myFitnessCompanion\u00ae",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 3.767578125,
            "text": "panion\u00ae",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 1.1826171875,
            "text": "health and fitness app",
            "probability": 0.0
        },
        {
            "start_logit": -8.6875,
            "end_logit": 1.1826171875,
            "text": "fitness app",
            "probability": 0.0
        }
    ],
    "5324cca79b2d7acc7e00001d_5": [
        {
            "start_logit": 3.18359375,
            "end_logit": 4.9375,
            "text": "alcohol-use behavior change or recovery",
            "probability": 0.98193359375
        },
        {
            "start_logit": -1.326171875,
            "end_logit": 4.9375,
            "text": "apps addressed alcohol-use behavior change or recovery",
            "probability": 0.0107421875
        },
        {
            "start_logit": 3.18359375,
            "end_logit": -0.70458984375,
            "text": "alcohol-use behavior change",
            "probability": 0.0034580230712890625
        },
        {
            "start_logit": -2.69140625,
            "end_logit": 4.9375,
            "text": "recovery",
            "probability": 0.00274658203125
        },
        {
            "start_logit": 3.18359375,
            "end_logit": -2.005859375,
            "text": "alcohol-use behavior change or recovery. Aside from tracking drinking consumption",
            "probability": 0.0009455680847167969
        },
        {
            "start_logit": -1.326171875,
            "end_logit": -0.70458984375,
            "text": "apps addressed alcohol-use behavior change",
            "probability": 3.814697265625e-05
        },
        {
            "start_logit": -1.326171875,
            "end_logit": -1.5341796875,
            "text": "apps",
            "probability": 1.6689300537109375e-05
        },
        {
            "start_logit": 3.18359375,
            "end_logit": -6.3203125,
            "text": "alcohol-use",
            "probability": 1.2576580047607422e-05
        },
        {
            "start_logit": -1.326171875,
            "end_logit": -2.005859375,
            "text": "apps addressed alcohol-use behavior change or recovery. Aside from tracking drinking consumption",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": -8.890625,
            "end_logit": 4.9375,
            "text": "addressed alcohol-use behavior change or recovery",
            "probability": 5.543231964111328e-06
        },
        {
            "start_logit": 3.18359375,
            "end_logit": -7.8359375,
            "text": "alcohol",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": -9.59375,
            "end_logit": 4.9375,
            "text": "behavior change or recovery",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": -2.69140625,
            "end_logit": -2.005859375,
            "text": "recovery. Aside from tracking drinking consumption",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": 3.18359375,
            "end_logit": -8.0703125,
            "text": "alcohol-use behavior change or recovery. Aside from tracking drinking consumption, a minority utilized empirically based components of alcohol treatment",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 3.18359375,
            "end_logit": -8.125,
            "text": "alcohol-use behavior change or recovery. Aside from tracking drinking",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -10.25,
            "end_logit": 4.9375,
            "text": "few apps addressed alcohol-use behavior change or recovery",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 3.18359375,
            "end_logit": -8.6328125,
            "text": "alcohol-use behavior",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 3.18359375,
            "end_logit": -8.8515625,
            "text": "alcohol-use behavior change or",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 3.18359375,
            "end_logit": -9.4609375,
            "text": "alcohol-use behavior change or recovery. Aside from tracking drinking consumption, a minority utilized empirically based components",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -4.30859375,
            "end_logit": -2.005859375,
            "text": "drinking consumption",
            "probability": 5.364418029785156e-07
        }
    ],
    "5324cca79b2d7acc7e00001d_6": [
        {
            "start_logit": 1.126953125,
            "end_logit": 0.343505859375,
            "text": "urine flow",
            "probability": 0.98828125
        },
        {
            "start_logit": -4.58984375,
            "end_logit": 0.343505859375,
            "text": "mHealth apps now are available for smart phones and other devices, and they do everything from monitoring urine flow",
            "probability": 0.003246307373046875
        },
        {
            "start_logit": -4.87890625,
            "end_logit": 0.343505859375,
            "text": "monitoring urine flow",
            "probability": 0.002429962158203125
        },
        {
            "start_logit": -5.24609375,
            "end_logit": 0.343505859375,
            "text": "apps now are available for smart phones and other devices, and they do everything from monitoring urine flow",
            "probability": 0.0016832351684570312
        },
        {
            "start_logit": -4.58984375,
            "end_logit": -0.701171875,
            "text": "mHealth apps",
            "probability": 0.001148223876953125
        },
        {
            "start_logit": 1.126953125,
            "end_logit": -6.421875,
            "text": "urine flow for patients with enlarged prostates",
            "probability": 0.0011396408081054688
        },
        {
            "start_logit": 1.126953125,
            "end_logit": -6.8203125,
            "text": "urine flow for patients with enlarged prostates to reminding people prone to kidney stones",
            "probability": 0.0007648468017578125
        },
        {
            "start_logit": -5.24609375,
            "end_logit": -0.701171875,
            "text": "apps",
            "probability": 0.0005955696105957031
        },
        {
            "start_logit": 1.126953125,
            "end_logit": -8.5,
            "text": "urine flow for patients with enlarged prostate",
            "probability": 0.00014257431030273438
        },
        {
            "start_logit": 1.126953125,
            "end_logit": -9.1953125,
            "text": "urine flow for patients with enlarged prostates to reminding people prone to kidney stones to drink more water",
            "probability": 7.11679458618164e-05
        },
        {
            "start_logit": 1.126953125,
            "end_logit": -9.5859375,
            "text": "urine flow for patients with enlarged prostates to",
            "probability": 4.8160552978515625e-05
        },
        {
            "start_logit": 1.126953125,
            "end_logit": -9.59375,
            "text": "urine flow for",
            "probability": 4.780292510986328e-05
        },
        {
            "start_logit": -8.9765625,
            "end_logit": 0.343505859375,
            "text": "smart phones and other devices, and they do everything from monitoring urine flow",
            "probability": 4.0531158447265625e-05
        },
        {
            "start_logit": 1.126953125,
            "end_logit": -10.03125,
            "text": "urine",
            "probability": 3.081560134887695e-05
        },
        {
            "start_logit": 1.126953125,
            "end_logit": -10.046875,
            "text": "urine flow for patients with enlarged prostates to reminding people prone",
            "probability": 3.0338764190673828e-05
        },
        {
            "start_logit": 1.126953125,
            "end_logit": -10.0703125,
            "text": "urine flow for patients with enlarged prostates to reminding people prone to kidney stones to drink",
            "probability": 2.962350845336914e-05
        },
        {
            "start_logit": -9.3203125,
            "end_logit": 0.343505859375,
            "text": ",000 mHealth apps now are available for smart phones and other devices, and they do everything from monitoring urine flow",
            "probability": 2.872943878173828e-05
        },
        {
            "start_logit": 1.126953125,
            "end_logit": -10.2265625,
            "text": "urine flow for patients with enlarged prostates to reminding people prone to",
            "probability": 2.5391578674316406e-05
        },
        {
            "start_logit": -9.484375,
            "end_logit": 0.343505859375,
            "text": "More than 17,000 mHealth apps now are available for smart phones and other devices, and they do everything from monitoring urine flow",
            "probability": 2.4378299713134766e-05
        },
        {
            "start_logit": -9.640625,
            "end_logit": 0.343505859375,
            "text": "than 17,000 mHealth apps now are available for smart phones and other devices, and they do everything from monitoring urine flow",
            "probability": 2.086162567138672e-05
        }
    ],
    "587d2700fe8a08052f000001_1": [
        {
            "start_logit": 13.15625,
            "end_logit": 14.0546875,
            "text": "dbSUPER",
            "probability": 1.0
        },
        {
            "start_logit": -3.56640625,
            "end_logit": 14.0546875,
            "text": "ER",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.15625,
            "end_logit": -4.7890625,
            "text": "dbS",
            "probability": 0.0
        },
        {
            "start_logit": 13.15625,
            "end_logit": -6.81640625,
            "text": "dbSUPER: a database of super-enhancers in mouse and human genome",
            "probability": 0.0
        },
        {
            "start_logit": 13.15625,
            "end_logit": -7.1640625,
            "text": "dbSUP",
            "probability": 0.0
        },
        {
            "start_logit": 13.15625,
            "end_logit": -7.97265625,
            "text": "dbSUPER: a database",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": 14.0546875,
            "text": "UPER",
            "probability": 0.0
        },
        {
            "start_logit": 13.15625,
            "end_logit": -9.1484375,
            "text": "dbSUPER: a database of super-enhancers",
            "probability": 0.0
        },
        {
            "start_logit": 13.15625,
            "end_logit": -9.3203125,
            "text": "dbSUPER: a database of super-enhancers in mouse and human",
            "probability": 0.0
        },
        {
            "start_logit": 13.15625,
            "end_logit": -9.5625,
            "text": "dbSUPER: a database of super-enhancers in",
            "probability": 0.0
        },
        {
            "start_logit": 13.15625,
            "end_logit": -9.578125,
            "text": "dbSUPER: a database of",
            "probability": 0.0
        },
        {
            "start_logit": 13.15625,
            "end_logit": -9.6015625,
            "text": "dbSUPER: a",
            "probability": 0.0
        },
        {
            "start_logit": 13.15625,
            "end_logit": -9.640625,
            "text": "dbSUPER: a database of super-enhancers in mouse",
            "probability": 0.0
        },
        {
            "start_logit": 13.15625,
            "end_logit": -9.7578125,
            "text": "dbSUPER: a database of super-enhancers in mouse and",
            "probability": 0.0
        },
        {
            "start_logit": 13.15625,
            "end_logit": -10.0078125,
            "text": "dbSUPER:",
            "probability": 0.0
        },
        {
            "start_logit": 13.15625,
            "end_logit": -10.1328125,
            "text": "dbSUPER: a database of super-",
            "probability": 0.0
        },
        {
            "start_logit": -3.56640625,
            "end_logit": -6.81640625,
            "text": "ER: a database of super-enhancers in mouse and human genome",
            "probability": 0.0
        },
        {
            "start_logit": -3.56640625,
            "end_logit": -7.97265625,
            "text": "ER: a database",
            "probability": 0.0
        },
        {
            "start_logit": -3.56640625,
            "end_logit": -9.1484375,
            "text": "ER: a database of super-enhancers",
            "probability": 0.0
        },
        {
            "start_logit": -3.56640625,
            "end_logit": -9.3203125,
            "text": "ER: a database of super-enhancers in mouse and human",
            "probability": 0.0
        }
    ],
    "587d2700fe8a08052f000001_2": [
        {
            "start_logit": 14.0703125,
            "end_logit": 14.5234375,
            "text": "dbSUPER",
            "probability": 1.0
        },
        {
            "start_logit": -2.822265625,
            "end_logit": 14.5234375,
            "text": "ER",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.0703125,
            "end_logit": -3.705078125,
            "text": "dbS",
            "probability": 0.0
        },
        {
            "start_logit": 14.0703125,
            "end_logit": -8.046875,
            "text": "dbSUP",
            "probability": 0.0
        },
        {
            "start_logit": 14.0703125,
            "end_logit": -8.2890625,
            "text": "dbSUPER (http:/",
            "probability": 0.0
        },
        {
            "start_logit": 14.0703125,
            "end_logit": -8.46875,
            "text": "dbSUPER (http://bioinfo.au.tsinghua.edu.cn/dbsuper",
            "probability": 0.0
        },
        {
            "start_logit": 14.0703125,
            "end_logit": -8.484375,
            "text": "dbSUPER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/)",
            "probability": 0.0
        },
        {
            "start_logit": 14.0703125,
            "end_logit": -8.578125,
            "text": "dbSUPER (http://bioinfo.au.tsinghua.edu.cn",
            "probability": 0.0
        },
        {
            "start_logit": -9.453125,
            "end_logit": 14.5234375,
            "text": "UPER",
            "probability": 0.0
        },
        {
            "start_logit": -5.5859375,
            "end_logit": -4.265625,
            "text": "GeneCards, UniProt and Entrez",
            "probability": 0.0
        },
        {
            "start_logit": -5.5859375,
            "end_logit": -4.49609375,
            "text": "GeneCards",
            "probability": 0.0
        },
        {
            "start_logit": -5.6171875,
            "end_logit": -5.20703125,
            "text": "Cistrome web-servers for downstream analysis, and can also be visualized in the UCSC genome browser",
            "probability": 0.0
        },
        {
            "start_logit": -2.822265625,
            "end_logit": -8.2890625,
            "text": "ER (http:/",
            "probability": 0.0
        },
        {
            "start_logit": -2.822265625,
            "end_logit": -8.46875,
            "text": "ER (http://bioinfo.au.tsinghua.edu.cn/dbsuper",
            "probability": 0.0
        },
        {
            "start_logit": -2.822265625,
            "end_logit": -8.484375,
            "text": "ER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/)",
            "probability": 0.0
        },
        {
            "start_logit": -2.822265625,
            "end_logit": -8.578125,
            "text": "ER (http://bioinfo.au.tsinghua.edu.cn",
            "probability": 0.0
        },
        {
            "start_logit": -7.58984375,
            "end_logit": -4.265625,
            "text": "Entrez",
            "probability": 0.0
        },
        {
            "start_logit": -5.6171875,
            "end_logit": -6.2578125,
            "text": "Cistrome",
            "probability": 0.0
        },
        {
            "start_logit": -5.6171875,
            "end_logit": -7.640625,
            "text": "Cistrome web-servers for downstream analysis, and can also be visualized in the UCSC genome browse",
            "probability": 0.0
        },
        {
            "start_logit": -9.203125,
            "end_logit": -4.265625,
            "text": "UniProt and Entrez",
            "probability": 0.0
        }
    ],
    "587d2700fe8a08052f000001_3": [
        {
            "start_logit": 11.9453125,
            "end_logit": 11.0,
            "text": "SEA",
            "probability": 1.0
        },
        {
            "start_logit": 11.9453125,
            "end_logit": -5.79296875,
            "text": "SEA: a super-enhancer archive",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.9453125,
            "end_logit": -8.5625,
            "text": "SEA: a super-enhancer arch",
            "probability": 0.0
        },
        {
            "start_logit": 11.9453125,
            "end_logit": -9.015625,
            "text": "SEA: a super-enhancer",
            "probability": 0.0
        },
        {
            "start_logit": 11.9453125,
            "end_logit": -9.0625,
            "text": "SEA: a",
            "probability": 0.0
        },
        {
            "start_logit": 11.9453125,
            "end_logit": -10.1640625,
            "text": "SEA: a super",
            "probability": 0.0
        },
        {
            "start_logit": 11.9453125,
            "end_logit": -10.1640625,
            "text": "SEA: a super-",
            "probability": 0.0
        },
        {
            "start_logit": 11.9453125,
            "end_logit": -10.265625,
            "text": "SEA:",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": -5.79296875,
            "text": "archive",
            "probability": 0.0
        },
        {
            "start_logit": -9.65625,
            "end_logit": -5.79296875,
            "text": "super-enhancer archive",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": -5.79296875,
            "text": ": a super-enhancer archive",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": -8.5625,
            "text": "arch",
            "probability": 0.0
        },
        {
            "start_logit": -9.65625,
            "end_logit": -8.5625,
            "text": "super-enhancer arch",
            "probability": 0.0
        },
        {
            "start_logit": -9.65625,
            "end_logit": -9.015625,
            "text": "super-enhancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": -8.5625,
            "text": ": a super-enhancer arch",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": -9.015625,
            "text": ": a super-enhancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": -9.0625,
            "text": ": a",
            "probability": 0.0
        },
        {
            "start_logit": -9.65625,
            "end_logit": -10.1640625,
            "text": "super",
            "probability": 0.0
        },
        {
            "start_logit": -9.65625,
            "end_logit": -10.1640625,
            "text": "super-",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": -10.1640625,
            "text": ": a super",
            "probability": 0.0
        }
    ],
    "587d2700fe8a08052f000001_4": [
        {
            "start_logit": 10.765625,
            "end_logit": 11.7265625,
            "text": "SEA",
            "probability": 0.998046875
        },
        {
            "start_logit": 4.64453125,
            "end_logit": 11.7265625,
            "text": "Super-Enhancer Archive (SEA",
            "probability": 0.0021839141845703125
        },
        {
            "start_logit": 4.64453125,
            "end_logit": 7.4609375,
            "text": "Super-Enhancer Archive",
            "probability": 3.063678741455078e-05
        },
        {
            "start_logit": -6.41015625,
            "end_logit": 11.7265625,
            "text": "Archive (SEA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.765625,
            "end_logit": -6.87109375,
            "text": "SEA, http:/",
            "probability": 0.0
        },
        {
            "start_logit": 10.765625,
            "end_logit": -6.90625,
            "text": "SEA, http://sea.edbc.org). SEA focuses on integrating super-enhancers in multiple species",
            "probability": 0.0
        },
        {
            "start_logit": 10.765625,
            "end_logit": -7.2265625,
            "text": "SEA, http://sea.edbc",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 11.7265625,
            "text": ", Super-Enhancer Archive (SEA",
            "probability": 0.0
        },
        {
            "start_logit": 10.765625,
            "end_logit": -7.4609375,
            "text": "SEA, http://sea.edbc.org",
            "probability": 0.0
        },
        {
            "start_logit": 10.765625,
            "end_logit": -7.90625,
            "text": "SEA,",
            "probability": 0.0
        },
        {
            "start_logit": 10.765625,
            "end_logit": -8.3984375,
            "text": "SEA, http",
            "probability": 0.0
        },
        {
            "start_logit": 10.765625,
            "end_logit": -8.5,
            "text": "SEA, http://sea",
            "probability": 0.0
        },
        {
            "start_logit": 10.765625,
            "end_logit": -8.7265625,
            "text": "SEA, http://sea.edbc.org)",
            "probability": 0.0
        },
        {
            "start_logit": -6.41015625,
            "end_logit": 7.4609375,
            "text": "Archive",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 7.4609375,
            "text": ", Super-Enhancer Archive",
            "probability": 0.0
        },
        {
            "start_logit": 4.64453125,
            "end_logit": -6.87109375,
            "text": "Super-Enhancer Archive (SEA, http:/",
            "probability": 0.0
        },
        {
            "start_logit": 4.64453125,
            "end_logit": -6.90625,
            "text": "Super-Enhancer Archive (SEA, http://sea.edbc.org). SEA focuses on integrating super-enhancers in multiple species",
            "probability": 0.0
        },
        {
            "start_logit": 4.64453125,
            "end_logit": -7.2265625,
            "text": "Super-Enhancer Archive (SEA, http://sea.edbc",
            "probability": 0.0
        },
        {
            "start_logit": 4.64453125,
            "end_logit": -7.4609375,
            "text": "Super-Enhancer Archive (SEA, http://sea.edbc.org",
            "probability": 0.0
        },
        {
            "start_logit": 4.64453125,
            "end_logit": -7.90625,
            "text": "Super-Enhancer Archive (SEA,",
            "probability": 0.0
        }
    ],
    "587d2700fe8a08052f000001_5": [
        {
            "start_logit": 11.0234375,
            "end_logit": 12.140625,
            "text": "SEA",
            "probability": 1.0
        },
        {
            "start_logit": 11.0234375,
            "end_logit": -8.1953125,
            "text": "SEA focuses on integrating super-enhancers in multiple species",
            "probability": 0.0
        },
        {
            "start_logit": 11.0234375,
            "end_logit": -8.703125,
            "text": "SEA focuses on integrating super-enhancers in multiple species and annotating their potential roles in the regulation of cell identity",
            "probability": 0.0
        },
        {
            "start_logit": 11.0234375,
            "end_logit": -9.296875,
            "text": "SEA focuses",
            "probability": 0.0
        },
        {
            "start_logit": 11.0234375,
            "end_logit": -9.359375,
            "text": "SEA focuses on integrating super-enhancers in multiple species and annotating their potential roles in the regulation of cell identity gene expression.",
            "probability": 0.0
        },
        {
            "start_logit": 11.0234375,
            "end_logit": -9.6328125,
            "text": "SEA focuses on integrating super-enhancers in multiple species and annotating their potential roles in the",
            "probability": 0.0
        },
        {
            "start_logit": 11.0234375,
            "end_logit": -9.765625,
            "text": "SEA focuses on integrating super-enhancers",
            "probability": 0.0
        },
        {
            "start_logit": 11.0234375,
            "end_logit": -9.96875,
            "text": "SEA focuses on integrating super-enhancers in multiple species and annotating their potential roles in the regulation of cell identity gene expression",
            "probability": 0.0
        },
        {
            "start_logit": 11.0234375,
            "end_logit": -10.078125,
            "text": "SEA focuses on integrating super-enhancers in multiple species and annotating their potential roles in the regulation of cell identity gene",
            "probability": 0.0
        },
        {
            "start_logit": 11.0234375,
            "end_logit": -10.09375,
            "text": "SEA focuses on integrating super-",
            "probability": 0.0
        },
        {
            "start_logit": 11.0234375,
            "end_logit": -10.1484375,
            "text": "SEA focuses on integrating super-enhancers in",
            "probability": 0.0
        },
        {
            "start_logit": 11.0234375,
            "end_logit": -10.171875,
            "text": "SEA focuses on integrating super-enhancers in multiple species and annotating their potential roles in",
            "probability": 0.0
        },
        {
            "start_logit": 11.0234375,
            "end_logit": -10.1796875,
            "text": "SEA focuses on integrating super-enhancers in multiple species and annotating their potential roles",
            "probability": 0.0
        },
        {
            "start_logit": 11.0234375,
            "end_logit": -10.1875,
            "text": "SEA focuses on integrating super-enhancers in multiple species and",
            "probability": 0.0
        },
        {
            "start_logit": 11.0234375,
            "end_logit": -10.1953125,
            "text": "SEA focuses on integrating super-enhancers in multiple species and annot",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": -8.1953125,
            "text": "super-enhancers in multiple species",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": -8.1953125,
            "text": "integrating super-enhancers in multiple species",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": -8.1953125,
            "text": "species",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": -8.1953125,
            "text": "multiple species",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": -8.703125,
            "text": "cell identity",
            "probability": 0.0
        }
    ],
    "587d2700fe8a08052f000001_6": [
        {
            "start_logit": 11.515625,
            "end_logit": 11.640625,
            "text": "SEA",
            "probability": 1.0
        },
        {
            "start_logit": 11.515625,
            "end_logit": -9.390625,
            "text": "SEA incorporates",
            "probability": 0.0
        },
        {
            "start_logit": 11.515625,
            "end_logit": -9.5,
            "text": "SEA incorporates 83 996 super-enhancers computationally or experimentally identified in 134 cell types/tissues/diseases, including human (75 439",
            "probability": 0.0
        },
        {
            "start_logit": 11.515625,
            "end_logit": -9.578125,
            "text": "SEA incorporates 83 996 super-enhancers computationally or experimentally identified in 134 cell types/tissues/diseases,",
            "probability": 0.0
        },
        {
            "start_logit": 11.515625,
            "end_logit": -9.65625,
            "text": "SEA incorporates 83 996 super-enhancers",
            "probability": 0.0
        },
        {
            "start_logit": 11.515625,
            "end_logit": -9.96875,
            "text": "SEA incorporates 83 996 super-enhancers computationally or experimentally identified in 134 cell types/tissues/diseases, including human (75 439, three",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": -8.484375,
            "text": "Caenorhabditis elegans",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": -8.484375,
            "text": ", mouse (5879, five of which were experimentally identified), Drosophila melanogaster (1774) and Caenorhabditis elegans",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": -8.484375,
            "text": "4) and Caenorhabditis elegans",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": -8.484375,
            "text": "and Caenorhabditis elegans",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": -8.484375,
            "text": "three of which were experimentally identified), mouse (5879, five of which were experimentally identified), Drosophila melanogaster (1774) and Caenorhabditis elegans",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": -8.484375,
            "text": "experimentally identified), mouse (5879, five of which were experimentally identified), Drosophila melanogaster (1774) and Caenorhabditis elegans",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": -8.484375,
            "text": "experimentally identified), Drosophila melanogaster (1774) and Caenorhabditis elegans",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": -8.484375,
            "text": "5879, five of which were experimentally identified), Drosophila melanogaster (1774) and Caenorhabditis elegans",
            "probability": 0.0
        },
        {
            "start_logit": -9.8046875,
            "end_logit": -9.4296875,
            "text": "439, three of which were experimentally identified), mouse",
            "probability": 0.0
        },
        {
            "start_logit": -9.8046875,
            "end_logit": -9.5,
            "text": "439, three of which were experimentally identified)",
            "probability": 0.0
        },
        {
            "start_logit": -9.8046875,
            "end_logit": -9.5,
            "text": "439",
            "probability": 0.0
        },
        {
            "start_logit": -9.828125,
            "end_logit": -9.5,
            "text": "996 super-enhancers computationally or experimentally identified in 134 cell types/tissues/diseases, including human (75 439",
            "probability": 0.0
        },
        {
            "start_logit": -9.828125,
            "end_logit": -9.578125,
            "text": "996 super-enhancers computationally or experimentally identified in 134 cell types/tissues/diseases,",
            "probability": 0.0
        },
        {
            "start_logit": -9.828125,
            "end_logit": -9.65625,
            "text": "996 super-enhancers",
            "probability": 0.0
        }
    ],
    "587d2700fe8a08052f000001_7": [
        {
            "start_logit": 13.40625,
            "end_logit": 14.171875,
            "text": "dbSUPER",
            "probability": 1.0
        },
        {
            "start_logit": -3.447265625,
            "end_logit": 14.171875,
            "text": "ER",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.40625,
            "end_logit": -4.7265625,
            "text": "dbS",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -7.70703125,
            "text": "dbSUP",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -8.1015625,
            "text": "dbSUPER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/)",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -8.15625,
            "text": "dbSUPER (http://bioinfo.au.tsinghua.edu.cn/dbsuper",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -8.2109375,
            "text": "dbSUPER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -8.2734375,
            "text": "dbSUPER (http://bioinfo.au.tsinghua.edu.cn",
            "probability": 0.0
        },
        {
            "start_logit": -9.1875,
            "end_logit": 14.171875,
            "text": "UPER",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -8.5390625,
            "text": "dbSUPER (http:/",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -8.890625,
            "text": "dbSUPER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/),",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -9.1953125,
            "text": "dbSUPER (",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -9.3046875,
            "text": "dbSUPER (http://bioinfo.au.tsinghua.edu",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -9.3046875,
            "text": "dbSUPER (http",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 14.171875,
            "text": "developed dbSUPER",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -9.5,
            "text": "dbSUPER (http://bioinfo",
            "probability": 0.0
        },
        {
            "start_logit": -3.447265625,
            "end_logit": -8.1015625,
            "text": "ER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/)",
            "probability": 0.0
        },
        {
            "start_logit": -3.447265625,
            "end_logit": -8.15625,
            "text": "ER (http://bioinfo.au.tsinghua.edu.cn/dbsuper",
            "probability": 0.0
        },
        {
            "start_logit": -3.447265625,
            "end_logit": -8.2109375,
            "text": "ER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/",
            "probability": 0.0
        },
        {
            "start_logit": -3.447265625,
            "end_logit": -8.2734375,
            "text": "ER (http://bioinfo.au.tsinghua.edu.cn",
            "probability": 0.0
        }
    ],
    "587d2700fe8a08052f000001_8": [
        {
            "start_logit": 14.0,
            "end_logit": 14.328125,
            "text": "dbSUPER",
            "probability": 1.0
        },
        {
            "start_logit": -3.095703125,
            "end_logit": 14.328125,
            "text": "ER",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.0,
            "end_logit": -3.83203125,
            "text": "dbS",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -5.37890625,
            "text": "dbSUPER lists genes associated with super-enhancers and also links to external databases such as GeneCards, UniProt and Entrez",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -6.0390625,
            "text": "dbSUPER lists genes associated with super-enhancers and also links to external databases such as GeneCards",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -7.67578125,
            "text": "dbSUP",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -7.93359375,
            "text": "dbSUPER lists genes associated with super-enhancers and also links to external databases such as GeneCards, UniProt",
            "probability": 0.0
        },
        {
            "start_logit": -8.7890625,
            "end_logit": 14.328125,
            "text": "UPER",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -8.6171875,
            "text": "dbSUPER lists genes associated with super-enhancers and also links to external databases",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -8.6328125,
            "text": "dbSUPER lists genes associated with super-enhancers and also links to external databases such as GeneCar",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -9.171875,
            "text": "dbSUPER lists genes associated with super-enhancers and also links to external databases such as GeneCards, UniProt and Entr",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -9.265625,
            "text": "dbSUPER lists genes",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -9.3984375,
            "text": "dbSUPER lists genes associated with super-enhancers and also links",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -9.3984375,
            "text": "dbSUPER lists genes associated with super-enhancers and also links to external databases such as Gene",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -9.40625,
            "text": "dbSUPER lists genes associated",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -9.40625,
            "text": "dbSUPER lists genes associated with super-enhancers",
            "probability": 0.0
        },
        {
            "start_logit": -3.095703125,
            "end_logit": -5.37890625,
            "text": "ER lists genes associated with super-enhancers and also links to external databases such as GeneCards, UniProt and Entrez",
            "probability": 0.0
        },
        {
            "start_logit": -3.095703125,
            "end_logit": -6.0390625,
            "text": "ER lists genes associated with super-enhancers and also links to external databases such as GeneCards",
            "probability": 0.0
        },
        {
            "start_logit": -3.095703125,
            "end_logit": -7.93359375,
            "text": "ER lists genes associated with super-enhancers and also links to external databases such as GeneCards, UniProt",
            "probability": 0.0
        },
        {
            "start_logit": -3.095703125,
            "end_logit": -8.6171875,
            "text": "ER lists genes associated with super-enhancers and also links to external databases",
            "probability": 0.0
        }
    ],
    "587d2700fe8a08052f000001_9": [
        {
            "start_logit": 13.453125,
            "end_logit": 14.203125,
            "text": "dbSUPER",
            "probability": 1.0
        },
        {
            "start_logit": -3.37890625,
            "end_logit": 14.203125,
            "text": "ER",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.453125,
            "end_logit": -4.640625,
            "text": "dbS",
            "probability": 0.0
        },
        {
            "start_logit": 13.453125,
            "end_logit": -7.73046875,
            "text": "dbSUP",
            "probability": 0.0
        },
        {
            "start_logit": 13.453125,
            "end_logit": -7.90234375,
            "text": "dbSUPER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/)",
            "probability": 0.0
        },
        {
            "start_logit": 13.453125,
            "end_logit": -8.2734375,
            "text": "dbSUPER (http://bioinfo.au.tsinghua.edu.cn/dbsuper",
            "probability": 0.0
        },
        {
            "start_logit": 13.453125,
            "end_logit": -8.3125,
            "text": "dbSUPER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/",
            "probability": 0.0
        },
        {
            "start_logit": 13.453125,
            "end_logit": -8.359375,
            "text": "dbSUPER (http://bioinfo.au.tsinghua.edu.cn",
            "probability": 0.0
        },
        {
            "start_logit": -9.1640625,
            "end_logit": 14.203125,
            "text": "UPER",
            "probability": 0.0
        },
        {
            "start_logit": 13.453125,
            "end_logit": -8.6875,
            "text": "dbSUPER (http:/",
            "probability": 0.0
        },
        {
            "start_logit": 13.453125,
            "end_logit": -9.0859375,
            "text": "dbSUPER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/),",
            "probability": 0.0
        },
        {
            "start_logit": 13.453125,
            "end_logit": -9.28125,
            "text": "dbSUPER (http://bioinfo.au.tsinghua.edu",
            "probability": 0.0
        },
        {
            "start_logit": 13.453125,
            "end_logit": -9.359375,
            "text": "dbSUPER (",
            "probability": 0.0
        },
        {
            "start_logit": 13.453125,
            "end_logit": -9.5546875,
            "text": "dbSUPER (http://bioinfo",
            "probability": 0.0
        },
        {
            "start_logit": -3.37890625,
            "end_logit": -7.90234375,
            "text": "ER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/)",
            "probability": 0.0
        },
        {
            "start_logit": -3.37890625,
            "end_logit": -8.2734375,
            "text": "ER (http://bioinfo.au.tsinghua.edu.cn/dbsuper",
            "probability": 0.0
        },
        {
            "start_logit": -3.37890625,
            "end_logit": -8.3125,
            "text": "ER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/",
            "probability": 0.0
        },
        {
            "start_logit": -3.37890625,
            "end_logit": -8.359375,
            "text": "ER (http://bioinfo.au.tsinghua.edu.cn",
            "probability": 0.0
        },
        {
            "start_logit": -3.37890625,
            "end_logit": -8.6875,
            "text": "ER (http:/",
            "probability": 0.0
        },
        {
            "start_logit": -3.37890625,
            "end_logit": -9.0859375,
            "text": "ER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/),",
            "probability": 0.0
        }
    ],
    "587d2700fe8a08052f000001_10": [
        {
            "start_logit": 13.328125,
            "end_logit": 14.171875,
            "text": "dbSUPER",
            "probability": 1.0
        },
        {
            "start_logit": -3.328125,
            "end_logit": 14.171875,
            "text": "ER",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.328125,
            "end_logit": -4.66015625,
            "text": "dbS",
            "probability": 0.0
        },
        {
            "start_logit": 13.328125,
            "end_logit": -7.27734375,
            "text": "dbSUP",
            "probability": 0.0
        },
        {
            "start_logit": 13.328125,
            "end_logit": -8.125,
            "text": "dbSUPER: a database",
            "probability": 0.0
        },
        {
            "start_logit": 13.328125,
            "end_logit": -8.390625,
            "text": "dbSUPER: a database of super-enhancers in mouse and human genome",
            "probability": 0.0
        },
        {
            "start_logit": -9.328125,
            "end_logit": 14.171875,
            "text": "UPER",
            "probability": 0.0
        },
        {
            "start_logit": 13.328125,
            "end_logit": -9.0234375,
            "text": "dbSUPER: a database of super-enhancers in mouse and human genome.",
            "probability": 0.0
        },
        {
            "start_logit": 13.328125,
            "end_logit": -9.296875,
            "text": "dbSUPER: a database of super-enhancers",
            "probability": 0.0
        },
        {
            "start_logit": 13.328125,
            "end_logit": -9.6796875,
            "text": "dbSUPER: a",
            "probability": 0.0
        },
        {
            "start_logit": 13.328125,
            "end_logit": -9.7109375,
            "text": "dbSUPER: a database of",
            "probability": 0.0
        },
        {
            "start_logit": 13.328125,
            "end_logit": -9.9140625,
            "text": "dbSUPER: a database of super-enhancers in",
            "probability": 0.0
        },
        {
            "start_logit": 13.328125,
            "end_logit": -9.9609375,
            "text": "dbSUPER: a database of super-enhancers in mouse and human",
            "probability": 0.0
        },
        {
            "start_logit": 13.328125,
            "end_logit": -10.046875,
            "text": "dbSUPER: a database of super-enhancers in mouse",
            "probability": 0.0
        },
        {
            "start_logit": 13.328125,
            "end_logit": -10.0546875,
            "text": "dbSUPER:",
            "probability": 0.0
        },
        {
            "start_logit": 13.328125,
            "end_logit": -10.203125,
            "text": "dbSUPER: a database of super-enhancers in mouse and",
            "probability": 0.0
        },
        {
            "start_logit": -3.328125,
            "end_logit": -8.125,
            "text": "ER: a database",
            "probability": 0.0
        },
        {
            "start_logit": -3.328125,
            "end_logit": -8.390625,
            "text": "ER: a database of super-enhancers in mouse and human genome",
            "probability": 0.0
        },
        {
            "start_logit": -3.328125,
            "end_logit": -9.0234375,
            "text": "ER: a database of super-enhancers in mouse and human genome.",
            "probability": 0.0
        },
        {
            "start_logit": -3.328125,
            "end_logit": -9.296875,
            "text": "ER: a database of super-enhancers",
            "probability": 0.0
        }
    ],
    "571f2b5bbb137a4b0c000010_1": [
        {
            "start_logit": 11.25,
            "end_logit": 11.2734375,
            "text": "CCM3",
            "probability": 1.0
        },
        {
            "start_logit": 11.25,
            "end_logit": 1.4375,
            "text": "CCM3/PDCD10",
            "probability": 5.3048133850097656e-05
        },
        {
            "start_logit": 11.25,
            "end_logit": -3.759765625,
            "text": "CCM",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 11.25,
            "end_logit": -5.8359375,
            "text": "CCM3/PDC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.078125,
            "end_logit": 11.2734375,
            "text": "3",
            "probability": 0.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -6.23828125,
            "text": "CC",
            "probability": 0.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -6.69140625,
            "text": "CCM3/PDCD1",
            "probability": 0.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -6.92578125,
            "text": "CCM3/",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 11.2734375,
            "text": "Surveying genetic variants and molecular phylogeny of cerebral cavernous malformation gene, CCM3",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": 11.2734375,
            "text": "M3",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 11.2734375,
            "text": "ing genetic variants and molecular phylogeny of cerebral cavernous malformation gene, CCM3",
            "probability": 0.0
        },
        {
            "start_logit": -11.0703125,
            "end_logit": 11.2734375,
            "text": "cavernous malformation gene, CCM3",
            "probability": 0.0
        },
        {
            "start_logit": -11.21875,
            "end_logit": 11.2734375,
            "text": "cerebral cavernous malformation gene, CCM3",
            "probability": 0.0
        },
        {
            "start_logit": -11.3046875,
            "end_logit": 11.2734375,
            "text": "genetic variants and molecular phylogeny of cerebral cavernous malformation gene, CCM3",
            "probability": 0.0
        },
        {
            "start_logit": -11.3515625,
            "end_logit": 11.2734375,
            "text": "molecular phylogeny of cerebral cavernous malformation gene, CCM3",
            "probability": 0.0
        },
        {
            "start_logit": -5.13671875,
            "end_logit": 1.4375,
            "text": "PDCD10",
            "probability": 0.0
        },
        {
            "start_logit": -6.078125,
            "end_logit": 1.4375,
            "text": "3/PDCD10",
            "probability": 0.0
        },
        {
            "start_logit": -9.2578125,
            "end_logit": 1.4375,
            "text": "0",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 1.4375,
            "text": "Surveying genetic variants and molecular phylogeny of cerebral cavernous malformation gene, CCM3/PDCD10",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": 1.4375,
            "text": "M3/PDCD10",
            "probability": 0.0
        }
    ],
    "571f2b5bbb137a4b0c000010_2": [
        {
            "start_logit": 13.2421875,
            "end_logit": 13.3828125,
            "text": "CCM1",
            "probability": 1.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -2.09765625,
            "text": "CCM1/KRIT1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -3.109375,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and CCM3/PDCD10",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -3.314453125,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and CCM3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.93359375,
            "end_logit": 13.3828125,
            "text": "M1",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -5.01171875,
            "text": "CC",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -6.23046875,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and CCM",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -7.046875,
            "text": "CCM1/KRIT1, CCM2",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -7.3359375,
            "text": "CCM1/KRIT1, CCM2/MGC4607",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -7.37109375,
            "text": "CCM1/",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -7.62890625,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and CCM3/PDC",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -7.6328125,
            "text": "CCM1/KR",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -7.69921875,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and CCM3/PDCD1",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -7.78515625,
            "text": "CCM1/KRIT",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -8.21875,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and CC",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -8.53125,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and CCM3/PDCD10 have been identified",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -8.640625,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": 13.3828125,
            "text": "namely CCM1",
            "probability": 0.0
        },
        {
            "start_logit": -4.93359375,
            "end_logit": -2.09765625,
            "text": "M1/KRIT1",
            "probability": 0.0
        },
        {
            "start_logit": -4.93359375,
            "end_logit": -3.109375,
            "text": "M1/KRIT1, CCM2/MGC4607 and CCM3/PDCD10",
            "probability": 0.0
        }
    ],
    "571f2b5bbb137a4b0c000010_3": [
        {
            "start_logit": 12.875,
            "end_logit": 13.0625,
            "text": "CCM1",
            "probability": 1.0
        },
        {
            "start_logit": 12.875,
            "end_logit": -1.3525390625,
            "text": "CCM1/KRIT1",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 12.875,
            "end_logit": -3.083984375,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and CCM3",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.875,
            "end_logit": -3.208984375,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and CCM3/PDCD10",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.32421875,
            "end_logit": 13.0625,
            "text": "M1",
            "probability": 0.0
        },
        {
            "start_logit": 12.875,
            "end_logit": -5.33984375,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and CCM",
            "probability": 0.0
        },
        {
            "start_logit": 12.875,
            "end_logit": -5.41796875,
            "text": "CC",
            "probability": 0.0
        },
        {
            "start_logit": 12.875,
            "end_logit": -6.3359375,
            "text": "CCM1/KRIT1, CCM2",
            "probability": 0.0
        },
        {
            "start_logit": 12.875,
            "end_logit": -6.97265625,
            "text": "CCM1/KRIT",
            "probability": 0.0
        },
        {
            "start_logit": 12.875,
            "end_logit": -7.0390625,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and CCM3/PDCD10 genes",
            "probability": 0.0
        },
        {
            "start_logit": 12.875,
            "end_logit": -7.0546875,
            "text": "CCM1/KR",
            "probability": 0.0
        },
        {
            "start_logit": 12.875,
            "end_logit": -7.09765625,
            "text": "CCM1/",
            "probability": 0.0
        },
        {
            "start_logit": 12.875,
            "end_logit": -7.5859375,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and CC",
            "probability": 0.0
        },
        {
            "start_logit": 12.875,
            "end_logit": -7.609375,
            "text": "CCM1/KRIT1, CC",
            "probability": 0.0
        },
        {
            "start_logit": 12.875,
            "end_logit": -7.65625,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and CCM3/PDC",
            "probability": 0.0
        },
        {
            "start_logit": 12.875,
            "end_logit": -7.66015625,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and CCM3/PDCD1",
            "probability": 0.0
        },
        {
            "start_logit": 12.875,
            "end_logit": -8.0078125,
            "text": "CCM1/KRIT1, CCM2/MGC4607",
            "probability": 0.0
        },
        {
            "start_logit": 12.875,
            "end_logit": -8.1953125,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and",
            "probability": 0.0
        },
        {
            "start_logit": 12.875,
            "end_logit": -8.5234375,
            "text": "CCM1/KRIT1, CCM2/MG",
            "probability": 0.0
        },
        {
            "start_logit": 12.875,
            "end_logit": -8.6171875,
            "text": "CCM1/KRIT1, CCM2/MGC",
            "probability": 0.0
        }
    ],
    "571f2b5bbb137a4b0c000010_4": [
        {
            "start_logit": 12.5546875,
            "end_logit": 12.1171875,
            "text": "CCM1",
            "probability": 1.0
        },
        {
            "start_logit": 12.5546875,
            "end_logit": -5.3359375,
            "text": "CC",
            "probability": 0.0
        },
        {
            "start_logit": -6.078125,
            "end_logit": 12.1171875,
            "text": "M1",
            "probability": 0.0
        },
        {
            "start_logit": 12.5546875,
            "end_logit": -6.9140625,
            "text": "CCM1 (krev interaction trapped 1/cerebral cavernous malformations 1), cerebral cavernous malformations 2, osmosensing scaffold for MEKK3",
            "probability": 0.0
        },
        {
            "start_logit": 12.5546875,
            "end_logit": -6.94140625,
            "text": "CCM1 (krev interaction trapped 1",
            "probability": 0.0
        },
        {
            "start_logit": 12.5546875,
            "end_logit": -7.83984375,
            "text": "CCM1 (krev interaction trapped",
            "probability": 0.0
        },
        {
            "start_logit": 12.5546875,
            "end_logit": -8.203125,
            "text": "CCM1 (krev interaction trapped 1/cerebral cavernous malformations 1), cerebral cavernous malformations 2, osmosensing scaffold for MEK",
            "probability": 0.0
        },
        {
            "start_logit": 12.5546875,
            "end_logit": -8.296875,
            "text": "CCM1 (krev interaction trapped 1/cerebral cavernous malformations 1), cerebral cavernous malformations 2, osmosensing scaffold for MEKK3 (CCM2",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 12.1171875,
            "text": "KRIT1/CCM1",
            "probability": 0.0
        },
        {
            "start_logit": -6.34765625,
            "end_logit": -1.74609375,
            "text": "PDCD10",
            "probability": 0.0
        },
        {
            "start_logit": -8.9609375,
            "end_logit": -1.74609375,
            "text": "0",
            "probability": 0.0
        },
        {
            "start_logit": -9.375,
            "end_logit": -1.74609375,
            "text": "CCM3/PDCD10",
            "probability": 0.0
        },
        {
            "start_logit": -9.5859375,
            "end_logit": -1.74609375,
            "text": "D10",
            "probability": 0.0
        },
        {
            "start_logit": -9.7890625,
            "end_logit": -1.74609375,
            "text": "/PDCD10",
            "probability": 0.0
        },
        {
            "start_logit": -9.828125,
            "end_logit": -1.74609375,
            "text": "malcavernin/OSM), and cerebral cavernous malformations 3/programmed cell death 10 (CCM3/PDCD10",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": -1.74609375,
            "text": "CCM2/malcavernin/OSM), and cerebral cavernous malformations 3/programmed cell death 10 (CCM3/PDCD10",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": -1.74609375,
            "text": "3/PDCD10",
            "probability": 0.0
        },
        {
            "start_logit": -6.078125,
            "end_logit": -6.9140625,
            "text": "M1 (krev interaction trapped 1/cerebral cavernous malformations 1), cerebral cavernous malformations 2, osmosensing scaffold for MEKK3",
            "probability": 0.0
        },
        {
            "start_logit": -6.078125,
            "end_logit": -6.94140625,
            "text": "M1 (krev interaction trapped 1",
            "probability": 0.0
        },
        {
            "start_logit": -6.34765625,
            "end_logit": -6.94140625,
            "text": "PDC",
            "probability": 0.0
        }
    ],
    "571f2b5bbb137a4b0c000010_5": [
        {
            "start_logit": 12.234375,
            "end_logit": 12.0078125,
            "text": "CCM1",
            "probability": 1.0
        },
        {
            "start_logit": 12.234375,
            "end_logit": 0.2100830078125,
            "text": "CCM1 (krev interaction trapped 1/cerebral cavernous malformations 1), cerebral cavernous malformations 2, osmosensing scaffold for MEKK3 (CCM2",
            "probability": 7.450580596923828e-06
        },
        {
            "start_logit": 12.234375,
            "end_logit": -5.109375,
            "text": "CCM1 (krev interaction trapped 1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.234375,
            "end_logit": -5.6875,
            "text": "CC",
            "probability": 0.0
        },
        {
            "start_logit": 12.234375,
            "end_logit": -5.734375,
            "text": "CCM1 (krev interaction trapped 1/cerebral cavernous malformations 1), cerebral cavernous malformations 2, osmosensing scaffold for MEKK3 (CC",
            "probability": 0.0
        },
        {
            "start_logit": -6.15625,
            "end_logit": 12.0078125,
            "text": "M1",
            "probability": 0.0
        },
        {
            "start_logit": 12.234375,
            "end_logit": -6.86328125,
            "text": "CCM1 (krev interaction trapped",
            "probability": 0.0
        },
        {
            "start_logit": 12.234375,
            "end_logit": -7.0703125,
            "text": "CCM1 (krev interaction trapped 1/cerebral cavernous malformations 1), cerebral cavernous malformations 2, osmosensing scaffold for MEKK3",
            "probability": 0.0
        },
        {
            "start_logit": 12.234375,
            "end_logit": -8.1484375,
            "text": "CCM1 (krev",
            "probability": 0.0
        },
        {
            "start_logit": 12.234375,
            "end_logit": -8.2109375,
            "text": "CCM1 (kre",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 12.0078125,
            "text": "KRIT1/CCM1",
            "probability": 0.0
        },
        {
            "start_logit": -3.216796875,
            "end_logit": 0.2100830078125,
            "text": "CCM2",
            "probability": 0.0
        },
        {
            "start_logit": -5.96484375,
            "end_logit": 0.2100830078125,
            "text": "krev interaction trapped 1/cerebral cavernous malformations 1), cerebral cavernous malformations 2, osmosensing scaffold for MEKK3 (CCM2",
            "probability": 0.0
        },
        {
            "start_logit": -6.15625,
            "end_logit": 0.2100830078125,
            "text": "M1 (krev interaction trapped 1/cerebral cavernous malformations 1), cerebral cavernous malformations 2, osmosensing scaffold for MEKK3 (CCM2",
            "probability": 0.0
        },
        {
            "start_logit": -3.216796875,
            "end_logit": -3.21484375,
            "text": "CCM2/malcavernin/OSM), and cerebral cavernous malformations 3/programmed cell death 10 (CCM3/PDCD10",
            "probability": 0.0
        },
        {
            "start_logit": -3.216796875,
            "end_logit": -4.2109375,
            "text": "CCM2/malcavernin/OSM), and cerebral cavernous malformations 3/programmed cell death 10 (CCM3",
            "probability": 0.0
        },
        {
            "start_logit": -9.1328125,
            "end_logit": 0.2100830078125,
            "text": "MEKK3 (CCM2",
            "probability": 0.0
        },
        {
            "start_logit": -3.216796875,
            "end_logit": -5.734375,
            "text": "CC",
            "probability": 0.0
        },
        {
            "start_logit": -3.216796875,
            "end_logit": -5.8671875,
            "text": "CCM2/malcavernin/OSM), and cerebral cavernous malformations 3/programmed cell death 10 (CCM",
            "probability": 0.0
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 0.2100830078125,
            "text": "cerebral cavernous malformations 1), cerebral cavernous malformations 2, osmosensing scaffold for MEKK3 (CCM2",
            "probability": 0.0
        }
    ],
    "5547d700f35db75526000007_1": [
        {
            "start_logit": 1.8671875,
            "end_logit": 8.875,
            "text": "flaccid dysarthria associated with lower motor neuron impairment",
            "probability": 0.9921875
        },
        {
            "start_logit": -3.259765625,
            "end_logit": 8.875,
            "text": "lower motor neuron impairment",
            "probability": 0.005901336669921875
        },
        {
            "start_logit": -5.12109375,
            "end_logit": 8.875,
            "text": "with lower motor neuron impairment",
            "probability": 0.00091552734375
        },
        {
            "start_logit": -6.66796875,
            "end_logit": 8.875,
            "text": "motor neuron impairment",
            "probability": 0.00019562244415283203
        },
        {
            "start_logit": -7.6875,
            "end_logit": 8.875,
            "text": "impairment",
            "probability": 7.033348083496094e-05
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 8.875,
            "text": "associated with lower motor neuron impairment",
            "probability": 6.866455078125e-05
        },
        {
            "start_logit": 1.8671875,
            "end_logit": -0.7197265625,
            "text": "flaccid",
            "probability": 6.759166717529297e-05
        },
        {
            "start_logit": -8.328125,
            "end_logit": 8.875,
            "text": "types of dysarthria: flaccid dysarthria associated with lower motor neuron impairment",
            "probability": 3.707408905029297e-05
        },
        {
            "start_logit": -8.5859375,
            "end_logit": 8.875,
            "text": "a associated with lower motor neuron impairment",
            "probability": 2.86102294921875e-05
        },
        {
            "start_logit": -8.78125,
            "end_logit": 8.875,
            "text": "neuron impairment",
            "probability": 2.3543834686279297e-05
        },
        {
            "start_logit": -8.78125,
            "end_logit": 8.875,
            "text": ": flaccid dysarthria associated with lower motor neuron impairment",
            "probability": 2.3543834686279297e-05
        },
        {
            "start_logit": 1.8671875,
            "end_logit": -5.171875,
            "text": "flaccid dysarthria associated with lower motor neuron",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 1.8671875,
            "end_logit": -6.05859375,
            "text": "flaccid dysarthria",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 1.8671875,
            "end_logit": -8.75,
            "text": "flacc",
            "probability": 0.0
        },
        {
            "start_logit": 1.8671875,
            "end_logit": -8.9375,
            "text": "flaccid dysarthria associated with lower motor",
            "probability": 0.0
        },
        {
            "start_logit": 1.8671875,
            "end_logit": -9.1875,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic dysarthria associated with damaged upper motor neurons linked to the motor areas",
            "probability": 0.0
        },
        {
            "start_logit": 1.8671875,
            "end_logit": -9.3125,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic dysarthria associated with damaged upper motor neurons linked",
            "probability": 0.0
        },
        {
            "start_logit": 1.8671875,
            "end_logit": -9.4296875,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic",
            "probability": 0.0
        },
        {
            "start_logit": -4.44140625,
            "end_logit": -3.599609375,
            "text": "neuropathology",
            "probability": 0.0
        },
        {
            "start_logit": -3.259765625,
            "end_logit": -5.171875,
            "text": "lower motor neuron",
            "probability": 0.0
        }
    ],
    "5547d700f35db75526000007_2": [
        {
            "start_logit": 0.884765625,
            "end_logit": -0.7109375,
            "text": "stroke patients with mixed dysarthria",
            "probability": 0.61767578125
        },
        {
            "start_logit": 0.884765625,
            "end_logit": -1.1962890625,
            "text": "stroke",
            "probability": 0.38037109375
        },
        {
            "start_logit": 0.884765625,
            "end_logit": -7.5390625,
            "text": "stroke patients",
            "probability": 0.0006685256958007812
        },
        {
            "start_logit": -6.71875,
            "end_logit": -0.7109375,
            "text": "dysarthria",
            "probability": 0.00030875205993652344
        },
        {
            "start_logit": 0.884765625,
            "end_logit": -8.4140625,
            "text": "stroke patients with",
            "probability": 0.00027871131896972656
        },
        {
            "start_logit": -7.3671875,
            "end_logit": -0.7109375,
            "text": "voice problems of stroke patients with mixed dysarthria",
            "probability": 0.0001614093780517578
        },
        {
            "start_logit": 0.884765625,
            "end_logit": -9.09375,
            "text": "stroke patients with mixed",
            "probability": 0.00014126300811767578
        },
        {
            "start_logit": -7.3671875,
            "end_logit": -1.1962890625,
            "text": "voice problems of stroke",
            "probability": 9.942054748535156e-05
        },
        {
            "start_logit": 0.884765625,
            "end_logit": -9.9609375,
            "text": "stroke patients with mixed dysarth",
            "probability": 5.936622619628906e-05
        },
        {
            "start_logit": 0.884765625,
            "end_logit": -10.171875,
            "text": "stroke patients with mixed dysarthri",
            "probability": 4.8100948333740234e-05
        },
        {
            "start_logit": -9.890625,
            "end_logit": -0.7109375,
            "text": "mixed dysarthria",
            "probability": 1.2934207916259766e-05
        },
        {
            "start_logit": -10.1484375,
            "end_logit": -0.7109375,
            "text": "of stroke patients with mixed dysarthria",
            "probability": 1.0013580322265625e-05
        },
        {
            "start_logit": -10.1640625,
            "end_logit": -0.7109375,
            "text": "address voice problems of stroke patients with mixed dysarthria",
            "probability": 9.834766387939453e-06
        },
        {
            "start_logit": -10.2109375,
            "end_logit": -0.7109375,
            "text": "arthria",
            "probability": 9.357929229736328e-06
        },
        {
            "start_logit": -10.4765625,
            "end_logit": -0.7109375,
            "text": "ria",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": -10.1484375,
            "end_logit": -1.1962890625,
            "text": "of stroke",
            "probability": 6.139278411865234e-06
        },
        {
            "start_logit": -10.1640625,
            "end_logit": -1.1962890625,
            "text": "address voice problems of stroke",
            "probability": 6.079673767089844e-06
        },
        {
            "start_logit": -7.3671875,
            "end_logit": -7.5390625,
            "text": "voice problems of stroke patients",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.3671875,
            "end_logit": -8.4140625,
            "text": "voice problems of stroke patients with",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3671875,
            "end_logit": -8.6171875,
            "text": "voice",
            "probability": 5.960464477539063e-08
        }
    ],
    "5547d700f35db75526000007_3": [
        {
            "start_logit": 6.37890625,
            "end_logit": 4.57421875,
            "text": "hypokinetic dysarthria, ataxic",
            "probability": 0.853515625
        },
        {
            "start_logit": 6.37890625,
            "end_logit": 2.68359375,
            "text": "hypokinetic",
            "probability": 0.12890625
        },
        {
            "start_logit": 6.37890625,
            "end_logit": 0.59033203125,
            "text": "hypokinetic dysarthria",
            "probability": 0.015869140625
        },
        {
            "start_logit": 0.1817626953125,
            "end_logit": 4.57421875,
            "text": "ataxic",
            "probability": 0.001739501953125
        },
        {
            "start_logit": 6.37890625,
            "end_logit": -4.828125,
            "text": "hypokinetic dysarthria, ataxic dysarthria",
            "probability": 7.015466690063477e-05
        },
        {
            "start_logit": 6.37890625,
            "end_logit": -5.8359375,
            "text": "hypokinetic dysarthria, atax",
            "probability": 2.580881118774414e-05
        },
        {
            "start_logit": 6.37890625,
            "end_logit": -8.5703125,
            "text": "hypok",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 6.37890625,
            "end_logit": -8.6015625,
            "text": "hypokinetic dysarthria,",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": 6.37890625,
            "end_logit": -10.1171875,
            "text": "hypokinetic dysarthri",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 6.37890625,
            "end_logit": -10.2109375,
            "text": "hypokinetic dysarthria, ataxic dysarthri",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -8.7890625,
            "end_logit": 4.57421875,
            "text": "ic",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -9.0859375,
            "end_logit": 4.57421875,
            "text": ", ataxic",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -9.15625,
            "end_logit": 4.57421875,
            "text": "autosegmental-metrical analysis of spontaneous speech in hypokinetic dysarthria, ataxic",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 0.1817626953125,
            "end_logit": -4.828125,
            "text": "ataxic dysarthria",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -9.375,
            "end_logit": 4.57421875,
            "text": "dysarthria, ataxic",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.984375,
            "end_logit": 4.57421875,
            "text": "motor speech disorders: an autosegmental-metrical analysis of spontaneous speech in hypokinetic dysarthria, ataxic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": 2.68359375,
            "text": "intonation deficit in motor speech disorders: an autosegmental-metrical analysis of spontaneous speech in hypokinetic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 0.1817626953125,
            "end_logit": -5.8359375,
            "text": "atax",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.3125,
            "end_logit": 4.57421875,
            "text": "arthria, ataxic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.15625,
            "end_logit": 2.68359375,
            "text": "autosegmental-metrical analysis of spontaneous speech in hypokinetic",
            "probability": 0.0
        }
    ],
    "5547d700f35db75526000007_4": [
        {
            "start_logit": 5.29296875,
            "end_logit": 5.578125,
            "text": "ataxic",
            "probability": 1.0
        },
        {
            "start_logit": 5.29296875,
            "end_logit": -3.34765625,
            "text": "ataxic dysarthria",
            "probability": 0.00013244152069091797
        },
        {
            "start_logit": 5.29296875,
            "end_logit": -3.8984375,
            "text": "ataxic dysarthria (AT",
            "probability": 7.605552673339844e-05
        },
        {
            "start_logit": 5.29296875,
            "end_logit": -5.296875,
            "text": "ataxic dysarthria (AT)",
            "probability": 1.895427703857422e-05
        },
        {
            "start_logit": 5.29296875,
            "end_logit": -8.3125,
            "text": "atax",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 5.29296875,
            "end_logit": -8.5,
            "text": "ataxic dysarthria (",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 5.29296875,
            "end_logit": -9.6328125,
            "text": "ataxic dys",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 5.578125,
            "text": "ic",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.29296875,
            "end_logit": -10.609375,
            "text": "ataxic dysarthri",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.29296875,
            "end_logit": -10.703125,
            "text": "ataxic dysarth",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -3.34765625,
            "text": "dysarthria",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -3.8984375,
            "text": "AT",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -3.8984375,
            "text": "dysarthria (AT",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -5.296875,
            "text": "AT)",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -5.296875,
            "text": "dysarthria (AT)",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": -3.34765625,
            "text": "arthria",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": -3.34765625,
            "text": "ic dysarthria",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": -3.34765625,
            "text": "ria",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": -3.8984375,
            "text": "arthria (AT",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": -3.8984375,
            "text": "ic dysarthria (AT",
            "probability": 0.0
        }
    ],
    "5547d700f35db75526000007_5": [
        {
            "start_logit": 5.19140625,
            "end_logit": 7.9765625,
            "text": "spastic dysarthria",
            "probability": 0.9970703125
        },
        {
            "start_logit": -0.8115234375,
            "end_logit": 7.9765625,
            "text": "apraxia of speech and spastic dysarthria",
            "probability": 0.0024509429931640625
        },
        {
            "start_logit": -4.85546875,
            "end_logit": 7.9765625,
            "text": "speech and spastic dysarthria",
            "probability": 4.32133674621582e-05
        },
        {
            "start_logit": -5.875,
            "end_logit": 7.9765625,
            "text": "between apraxia of speech and spastic dysarthria",
            "probability": 1.5497207641601562e-05
        },
        {
            "start_logit": 5.19140625,
            "end_logit": -3.263671875,
            "text": "spastic",
            "probability": 1.3053417205810547e-05
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 7.9765625,
            "text": "ia of speech and spastic dysarthria",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 7.9765625,
            "text": "dysarthria",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -0.8115234375,
            "end_logit": 0.80517578125,
            "text": "apraxia of speech",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -9.34375,
            "end_logit": 7.9765625,
            "text": "and spastic dysarthria",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -9.3671875,
            "end_logit": 7.9765625,
            "text": "of speech and spastic dysarthria",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -9.390625,
            "end_logit": 7.9765625,
            "text": "a",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -0.8115234375,
            "end_logit": -1.009765625,
            "text": "apraxia",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -9.984375,
            "end_logit": 7.9765625,
            "text": "axia of speech and spastic dysarthria",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -10.109375,
            "end_logit": 7.9765625,
            "text": "speech, more specifically between apraxia of speech and spastic dysarthria",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 5.19140625,
            "end_logit": -9.0546875,
            "text": "spastic dysarth",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.19140625,
            "end_logit": -9.1640625,
            "text": "spastic dysarthri",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.85546875,
            "end_logit": 0.80517578125,
            "text": "speech",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.8115234375,
            "end_logit": -3.263671875,
            "text": "apraxia of speech and spastic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.19140625,
            "end_logit": -9.9765625,
            "text": "spastic dys",
            "probability": 0.0
        },
        {
            "start_logit": -5.875,
            "end_logit": 0.80517578125,
            "text": "between apraxia of speech",
            "probability": 0.0
        }
    ],
    "5547d700f35db75526000007_6": [
        {
            "start_logit": 9.703125,
            "end_logit": 6.5546875,
            "text": "ataxic",
            "probability": 0.9931640625
        },
        {
            "start_logit": 9.703125,
            "end_logit": 1.564453125,
            "text": "ataxic dysarthria",
            "probability": 0.00679779052734375
        },
        {
            "start_logit": 9.703125,
            "end_logit": -6.45703125,
            "text": "atax",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": 9.703125,
            "end_logit": -8.5625,
            "text": "ataxic dysarthria.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.703125,
            "end_logit": -10.78125,
            "text": "ataxic dys",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.703125,
            "end_logit": -10.78125,
            "text": "ataxic dysarthri",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.703125,
            "end_logit": -10.796875,
            "text": "ataxic dysarth",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 6.5546875,
            "text": "phonatory instability in ataxic",
            "probability": 0.0
        },
        {
            "start_logit": -10.1171875,
            "end_logit": 6.5546875,
            "text": "Long-term phonatory instability in ataxic",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": 6.5546875,
            "text": "ic",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 6.5546875,
            "text": "-term phonatory instability in ataxic",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 6.5546875,
            "text": "atory instability in ataxic",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 1.564453125,
            "text": "phonatory instability in ataxic dysarthria",
            "probability": 0.0
        },
        {
            "start_logit": -9.1796875,
            "end_logit": 1.564453125,
            "text": "dysarthria",
            "probability": 0.0
        },
        {
            "start_logit": -10.0234375,
            "end_logit": 1.564453125,
            "text": "arthria",
            "probability": 0.0
        },
        {
            "start_logit": -10.1171875,
            "end_logit": 1.564453125,
            "text": "Long-term phonatory instability in ataxic dysarthria",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": 1.564453125,
            "text": "ic dysarthria",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 1.564453125,
            "text": "ria",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 1.564453125,
            "text": "-term phonatory instability in ataxic dysarthria",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 1.564453125,
            "text": "atory instability in ataxic dysarthria",
            "probability": 0.0
        }
    ],
    "5547d700f35db75526000007_7": [
        {
            "start_logit": 10.328125,
            "end_logit": 10.2421875,
            "text": "ataxic dysarthria",
            "probability": 0.9990234375
        },
        {
            "start_logit": 10.328125,
            "end_logit": 2.98046875,
            "text": "ataxic",
            "probability": 0.00070953369140625
        },
        {
            "start_logit": 10.328125,
            "end_logit": -6.95703125,
            "text": "atax",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 10.2421875,
            "text": "a",
            "probability": 0.0
        },
        {
            "start_logit": -8.9375,
            "end_logit": 10.2421875,
            "text": "dysarthria",
            "probability": 0.0
        },
        {
            "start_logit": -8.984375,
            "end_logit": 10.2421875,
            "text": "phonation in ataxic dysarthria",
            "probability": 0.0
        },
        {
            "start_logit": 10.328125,
            "end_logit": -9.3046875,
            "text": "ataxic dysarthria and a",
            "probability": 0.0
        },
        {
            "start_logit": 10.328125,
            "end_logit": -9.5078125,
            "text": "ataxic dysarthria and a control",
            "probability": 0.0
        },
        {
            "start_logit": 10.328125,
            "end_logit": -9.6484375,
            "text": "ataxic dysarthria and a control group",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 10.2421875,
            "text": "arthria",
            "probability": 0.0
        },
        {
            "start_logit": 10.328125,
            "end_logit": -10.078125,
            "text": "ataxic dysarthria and a control group of normal speakers",
            "probability": 0.0
        },
        {
            "start_logit": 10.328125,
            "end_logit": -10.1171875,
            "text": "ataxic dys",
            "probability": 0.0
        },
        {
            "start_logit": 10.328125,
            "end_logit": -10.21875,
            "text": "ataxic dysarthria and a control group of normal",
            "probability": 0.0
        },
        {
            "start_logit": 10.328125,
            "end_logit": -10.25,
            "text": "ataxic dysarthria and",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": 10.2421875,
            "text": "ria",
            "probability": 0.0
        },
        {
            "start_logit": 10.328125,
            "end_logit": -10.34375,
            "text": "ataxic dysarthri",
            "probability": 0.0
        },
        {
            "start_logit": 10.328125,
            "end_logit": -10.34375,
            "text": "ataxic dysarthria and a control group of",
            "probability": 0.0
        },
        {
            "start_logit": 10.328125,
            "end_logit": -10.3828125,
            "text": "ataxic dysarth",
            "probability": 0.0
        },
        {
            "start_logit": -8.984375,
            "end_logit": 2.98046875,
            "text": "phonation in ataxic",
            "probability": 0.0
        },
        {
            "start_logit": -8.984375,
            "end_logit": -6.95703125,
            "text": "phonation in atax",
            "probability": 0.0
        }
    ],
    "5547d700f35db75526000007_8": [
        {
            "start_logit": 12.390625,
            "end_logit": 8.5703125,
            "text": "hypokinetic dysarthria",
            "probability": 0.82177734375
        },
        {
            "start_logit": 12.390625,
            "end_logit": 7.04296875,
            "text": "hypokinetic",
            "probability": 0.177734375
        },
        {
            "start_logit": 12.390625,
            "end_logit": -5.40234375,
            "text": "hypok",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 12.390625,
            "end_logit": -9.6953125,
            "text": "hypokinetic dysarthria.",
            "probability": 0.0
        },
        {
            "start_logit": 12.390625,
            "end_logit": -10.1796875,
            "text": "hypokinetic dysarth",
            "probability": 0.0
        },
        {
            "start_logit": 12.390625,
            "end_logit": -10.2109375,
            "text": "hypokinetic dysarthri",
            "probability": 0.0
        },
        {
            "start_logit": 12.390625,
            "end_logit": -10.3046875,
            "text": "hypokinetic dys",
            "probability": 0.0
        },
        {
            "start_logit": -9.2421875,
            "end_logit": 8.5703125,
            "text": "a",
            "probability": 0.0
        },
        {
            "start_logit": -9.3125,
            "end_logit": 8.5703125,
            "text": "Dysprosody is a common feature in speakers with hypokinetic dysarthria",
            "probability": 0.0
        },
        {
            "start_logit": -9.8515625,
            "end_logit": 8.5703125,
            "text": "inetic dysarthria",
            "probability": 0.0
        },
        {
            "start_logit": -9.9296875,
            "end_logit": 8.5703125,
            "text": "speakers with hypokinetic dysarthria",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 8.5703125,
            "text": "dysarthria",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 8.5703125,
            "text": "rosody is a common feature in speakers with hypokinetic dysarthria",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 8.5703125,
            "text": "arthria",
            "probability": 0.0
        },
        {
            "start_logit": -9.3125,
            "end_logit": 7.04296875,
            "text": "Dysprosody is a common feature in speakers with hypokinetic",
            "probability": 0.0
        },
        {
            "start_logit": -9.8515625,
            "end_logit": 7.04296875,
            "text": "inetic",
            "probability": 0.0
        },
        {
            "start_logit": -9.9296875,
            "end_logit": 7.04296875,
            "text": "speakers with hypokinetic",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 7.04296875,
            "text": "rosody is a common feature in speakers with hypokinetic",
            "probability": 0.0
        },
        {
            "start_logit": -9.3125,
            "end_logit": -4.9296875,
            "text": "Dysprosody",
            "probability": 0.0
        },
        {
            "start_logit": -9.3125,
            "end_logit": -5.40234375,
            "text": "Dysprosody is a common feature in speakers with hypok",
            "probability": 0.0
        }
    ],
    "5547d700f35db75526000007_9": [
        {
            "start_logit": 12.3984375,
            "end_logit": 10.53125,
            "text": "hypokinetic dysarthria",
            "probability": 0.9990234375
        },
        {
            "start_logit": 12.3984375,
            "end_logit": 3.35546875,
            "text": "hypokinetic",
            "probability": 0.0007548332214355469
        },
        {
            "start_logit": 12.3984375,
            "end_logit": -5.10546875,
            "text": "hypok",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 12.3984375,
            "end_logit": -6.0703125,
            "text": "hypokinetic dysarthria is similar to those of other languages (for example, English",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.3984375,
            "end_logit": -8.2734375,
            "text": "hypokinetic dysarthria is similar to those of other languages",
            "probability": 0.0
        },
        {
            "start_logit": 12.3984375,
            "end_logit": -8.5,
            "text": "hypokinetic dysarthria is similar",
            "probability": 0.0
        },
        {
            "start_logit": 12.3984375,
            "end_logit": -9.46875,
            "text": "hypokinetic dysarthri",
            "probability": 0.0
        },
        {
            "start_logit": 12.3984375,
            "end_logit": -9.6875,
            "text": "hypokinetic dys",
            "probability": 0.0
        },
        {
            "start_logit": 12.3984375,
            "end_logit": -9.765625,
            "text": "hypokinetic dysarth",
            "probability": 0.0
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 10.53125,
            "text": "a",
            "probability": 0.0
        },
        {
            "start_logit": 12.3984375,
            "end_logit": -9.8203125,
            "text": "hypokinetic dysarthria is similar to those of other languages (for example,",
            "probability": 0.0
        },
        {
            "start_logit": 12.3984375,
            "end_logit": -9.8203125,
            "text": "hypokinetic dysarthria is similar to those of other languages (for example, English)",
            "probability": 0.0
        },
        {
            "start_logit": 12.3984375,
            "end_logit": -9.8359375,
            "text": "hypokinetic dysarthria is similar to those of other",
            "probability": 0.0
        },
        {
            "start_logit": 12.3984375,
            "end_logit": -9.921875,
            "text": "hypokinetic dysarthria is",
            "probability": 0.0
        },
        {
            "start_logit": -8.9765625,
            "end_logit": 10.53125,
            "text": "dysarthria",
            "probability": 0.0
        },
        {
            "start_logit": -9.453125,
            "end_logit": 10.53125,
            "text": "Cantonese speakers with hypokinetic dysarthria",
            "probability": 0.0
        },
        {
            "start_logit": -9.796875,
            "end_logit": 10.53125,
            "text": "prosodic profile of Cantonese speakers with hypokinetic dysarthria",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 10.53125,
            "text": "speakers with hypokinetic dysarthria",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 10.53125,
            "text": "arthria",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 10.53125,
            "text": "with hypokinetic dysarthria",
            "probability": 0.0
        }
    ],
    "5547d700f35db75526000007_10": [
        {
            "start_logit": 5.40625,
            "end_logit": 7.1875,
            "text": "flaccid",
            "probability": 0.71826171875
        },
        {
            "start_logit": 9.171875,
            "end_logit": 2.453125,
            "text": "spastic",
            "probability": 0.272705078125
        },
        {
            "start_logit": 5.40625,
            "end_logit": 2.453125,
            "text": "flaccid, spastic",
            "probability": 0.00630950927734375
        },
        {
            "start_logit": 9.171875,
            "end_logit": -2.080078125,
            "text": "spastic, ataxic",
            "probability": 0.002933502197265625
        },
        {
            "start_logit": 9.171875,
            "end_logit": -5.08203125,
            "text": "spastic, atax",
            "probability": 0.0001461505889892578
        },
        {
            "start_logit": 5.40625,
            "end_logit": -2.080078125,
            "text": "flaccid, spastic, ataxic",
            "probability": 6.794929504394531e-05
        },
        {
            "start_logit": 9.171875,
            "end_logit": -6.90234375,
            "text": "spastic, ataxic, hypo- and hyperkinetic",
            "probability": 2.3484230041503906e-05
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.84375,
            "text": "spastic, ataxic, hypo",
            "probability": 9.179115295410156e-06
        },
        {
            "start_logit": 9.171875,
            "end_logit": -8.28125,
            "text": "spastic, ataxic, hypo- and hyperkinetic and mixed",
            "probability": 5.9604644775390625e-06
        },
        {
            "start_logit": 9.171875,
            "end_logit": -8.328125,
            "text": "spastic, ataxic, hypo- and hyperkinetic and mixed dysarthria",
            "probability": 5.662441253662109e-06
        },
        {
            "start_logit": 9.171875,
            "end_logit": -8.5625,
            "text": "spastic, ataxic, hypo- and hyper",
            "probability": 4.470348358154297e-06
        },
        {
            "start_logit": 5.40625,
            "end_logit": -5.08203125,
            "text": "flaccid, spastic, atax",
            "probability": 3.3974647521972656e-06
        },
        {
            "start_logit": 9.171875,
            "end_logit": -9.546875,
            "text": "spastic, ataxic, hypo- and hyperkinetic and",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 9.171875,
            "end_logit": -9.9375,
            "text": "spastic, ataxic, hypo- and",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 9.171875,
            "end_logit": -10.1640625,
            "text": "spastic, ataxic,",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -10.375,
            "text": "spastic,",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 5.40625,
            "end_logit": -6.90234375,
            "text": "flaccid, spastic, ataxic, hypo- and hyperkinetic",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -8.71875,
            "end_logit": 7.1875,
            "text": "id",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 5.40625,
            "end_logit": -7.84375,
            "text": "flaccid, spastic, ataxic, hypo",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -9.671875,
            "end_logit": 7.1875,
            "text": "accid",
            "probability": 2.384185791015625e-07
        }
    ],
    "5547d700f35db75526000007_11": [
        {
            "start_logit": 4.203125,
            "end_logit": 9.109375,
            "text": "flaccid dysarthria associated with lower motor neuron impairment",
            "probability": 0.9990234375
        },
        {
            "start_logit": -2.697265625,
            "end_logit": 9.109375,
            "text": "lower motor neuron impairment",
            "probability": 0.0010080337524414062
        },
        {
            "start_logit": -6.61328125,
            "end_logit": 9.109375,
            "text": "with lower motor neuron impairment",
            "probability": 2.014636993408203e-05
        },
        {
            "start_logit": 4.203125,
            "end_logit": -2.064453125,
            "text": "flaccid",
            "probability": 1.4066696166992188e-05
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 9.109375,
            "text": "motor neuron impairment",
            "probability": 9.298324584960938e-06
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.109375,
            "text": "impairment",
            "probability": 4.76837158203125e-06
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.109375,
            "text": "dysarthria associated with lower motor neuron impairment",
            "probability": 4.231929779052734e-06
        },
        {
            "start_logit": -8.4296875,
            "end_logit": 9.109375,
            "text": "associated with lower motor neuron impairment",
            "probability": 3.2782554626464844e-06
        },
        {
            "start_logit": -9.0,
            "end_logit": 9.109375,
            "text": "types of dysarthria: flaccid dysarthria associated with lower motor neuron impairment",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": -9.3984375,
            "end_logit": 9.109375,
            "text": "accid dysarthria associated with lower motor neuron impairment",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 4.203125,
            "end_logit": -4.5546875,
            "text": "flaccid dysarthria",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 4.203125,
            "end_logit": -6.34765625,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 4.203125,
            "end_logit": -6.41796875,
            "text": "flaccid dysarthria associated with lower motor neuron",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 4.203125,
            "end_logit": -8.671875,
            "text": "flaccid dysarthria associated with lower motor",
            "probability": 0.0
        },
        {
            "start_logit": 4.203125,
            "end_logit": -9.1953125,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic dysarthria associated with damaged",
            "probability": 0.0
        },
        {
            "start_logit": 4.203125,
            "end_logit": -9.3359375,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic dysarthria associated with damaged upper motor neurons",
            "probability": 0.0
        },
        {
            "start_logit": 4.203125,
            "end_logit": -9.375,
            "text": "flacc",
            "probability": 0.0
        },
        {
            "start_logit": 4.203125,
            "end_logit": -9.421875,
            "text": "flaccid dysarthri",
            "probability": 0.0
        },
        {
            "start_logit": 4.203125,
            "end_logit": -9.4921875,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic dysarthria associated with damaged upper motor neurons linked",
            "probability": 0.0
        },
        {
            "start_logit": 4.203125,
            "end_logit": -9.4921875,
            "text": "fl",
            "probability": 0.0
        }
    ],
    "5547d700f35db75526000007_12": [
        {
            "start_logit": 4.203125,
            "end_logit": 9.109375,
            "text": "flaccid dysarthria associated with lower motor neuron impairment",
            "probability": 0.9990234375
        },
        {
            "start_logit": -2.697265625,
            "end_logit": 9.109375,
            "text": "lower motor neuron impairment",
            "probability": 0.0010080337524414062
        },
        {
            "start_logit": -6.61328125,
            "end_logit": 9.109375,
            "text": "with lower motor neuron impairment",
            "probability": 2.014636993408203e-05
        },
        {
            "start_logit": 4.203125,
            "end_logit": -2.064453125,
            "text": "flaccid",
            "probability": 1.4066696166992188e-05
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 9.109375,
            "text": "motor neuron impairment",
            "probability": 9.298324584960938e-06
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.109375,
            "text": "impairment",
            "probability": 4.76837158203125e-06
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.109375,
            "text": "dysarthria associated with lower motor neuron impairment",
            "probability": 4.231929779052734e-06
        },
        {
            "start_logit": -8.4296875,
            "end_logit": 9.109375,
            "text": "associated with lower motor neuron impairment",
            "probability": 3.2782554626464844e-06
        },
        {
            "start_logit": -9.0,
            "end_logit": 9.109375,
            "text": "types of dysarthria: flaccid dysarthria associated with lower motor neuron impairment",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": -9.3984375,
            "end_logit": 9.109375,
            "text": "accid dysarthria associated with lower motor neuron impairment",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 4.203125,
            "end_logit": -4.5546875,
            "text": "flaccid dysarthria",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 4.203125,
            "end_logit": -6.34765625,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 4.203125,
            "end_logit": -6.41796875,
            "text": "flaccid dysarthria associated with lower motor neuron",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 4.203125,
            "end_logit": -8.671875,
            "text": "flaccid dysarthria associated with lower motor",
            "probability": 0.0
        },
        {
            "start_logit": 4.203125,
            "end_logit": -9.1953125,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic dysarthria associated with damaged",
            "probability": 0.0
        },
        {
            "start_logit": 4.203125,
            "end_logit": -9.3359375,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic dysarthria associated with damaged upper motor neurons",
            "probability": 0.0
        },
        {
            "start_logit": 4.203125,
            "end_logit": -9.375,
            "text": "flacc",
            "probability": 0.0
        },
        {
            "start_logit": 4.203125,
            "end_logit": -9.421875,
            "text": "flaccid dysarthri",
            "probability": 0.0
        },
        {
            "start_logit": 4.203125,
            "end_logit": -9.4921875,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic dysarthria associated with damaged upper motor neurons linked",
            "probability": 0.0
        },
        {
            "start_logit": 4.203125,
            "end_logit": -9.4921875,
            "text": "fl",
            "probability": 0.0
        }
    ],
    "5547d700f35db75526000007_13": [
        {
            "start_logit": 3.904296875,
            "end_logit": 8.4296875,
            "text": "flaccid dysarthria associated with lower motor neuron impairment",
            "probability": 0.9990234375
        },
        {
            "start_logit": -3.771484375,
            "end_logit": 8.4296875,
            "text": "lower motor neuron impairment",
            "probability": 0.000461578369140625
        },
        {
            "start_logit": 3.904296875,
            "end_logit": -2.361328125,
            "text": "flaccid",
            "probability": 2.0444393157958984e-05
        },
        {
            "start_logit": -7.16796875,
            "end_logit": 8.4296875,
            "text": "with lower motor neuron impairment",
            "probability": 1.5437602996826172e-05
        },
        {
            "start_logit": -7.703125,
            "end_logit": 8.4296875,
            "text": "motor neuron impairment",
            "probability": 9.059906005859375e-06
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.4296875,
            "text": "dysarthria associated with lower motor neuron impairment",
            "probability": 5.245208740234375e-06
        },
        {
            "start_logit": -8.5234375,
            "end_logit": 8.4296875,
            "text": "associated with lower motor neuron impairment",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": -8.5703125,
            "end_logit": 8.4296875,
            "text": "impairment",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": -9.046875,
            "end_logit": 8.4296875,
            "text": "types of dysarthria: flaccid dysarthria associated with lower motor neuron impairment",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": 3.904296875,
            "end_logit": -4.55859375,
            "text": "flaccid dysarthria",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": -9.2734375,
            "end_logit": 8.4296875,
            "text": "accid dysarthria associated with lower motor neuron impairment",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 3.904296875,
            "end_logit": -6.3203125,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 3.904296875,
            "end_logit": -6.56640625,
            "text": "flaccid dysarthria associated with lower motor neuron",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 3.904296875,
            "end_logit": -8.71875,
            "text": "flaccid dysarthria associated with lower motor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 3.904296875,
            "end_logit": -9.375,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic dysarthria associated with damaged",
            "probability": 0.0
        },
        {
            "start_logit": 3.904296875,
            "end_logit": -9.4765625,
            "text": "flaccid dysarthri",
            "probability": 0.0
        },
        {
            "start_logit": 3.904296875,
            "end_logit": -9.4921875,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic dysarthria associated with damaged upper motor neurons",
            "probability": 0.0
        },
        {
            "start_logit": 3.904296875,
            "end_logit": -9.5390625,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic dysarthria associated with damaged upper motor neurons linked",
            "probability": 0.0
        },
        {
            "start_logit": 3.904296875,
            "end_logit": -9.5703125,
            "text": "flacc",
            "probability": 0.0
        },
        {
            "start_logit": -2.015625,
            "end_logit": -6.3203125,
            "text": "spastic",
            "probability": 0.0
        }
    ],
    "5c61cdd7e842deac67000004_1": [
        {
            "start_logit": 14.1171875,
            "end_logit": 13.7734375,
            "text": "Dolutegravir",
            "probability": 1.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -3.50390625,
            "text": "Dol",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.1953125,
            "end_logit": 13.7734375,
            "text": "ir",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -6.51953125,
            "text": "Dolutegravir/rilpivirine",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -6.53515625,
            "text": "Dolute",
            "probability": 0.0
        },
        {
            "start_logit": -7.7734375,
            "end_logit": 13.7734375,
            "text": "gravir",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -8.5,
            "text": "Dolutegravir/ril",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -8.6875,
            "text": "Dolutegrav",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -8.96875,
            "text": "Dolutegravir/rilpivirine (Juluca\u00ae)",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -9.171875,
            "text": "Dolutegravir/rilpi",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -9.4140625,
            "text": "Dolutegravir/rilpivir",
            "probability": 0.0
        },
        {
            "start_logit": -9.078125,
            "end_logit": 13.7734375,
            "text": "utegravir",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -9.4296875,
            "text": "Dolutegravir/",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -9.5390625,
            "text": "Dolutegravir/rilpivirine (Juluca\u00ae) is the first two-drug",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -9.6171875,
            "text": "Dolutegravir/rilpivirine (Juluca\u00ae) is the first two-drug single-tablet regimen (STR)",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -9.6875,
            "text": "Dolutegravir/rilpivirine (Juluca\u00ae) is the first",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -9.6953125,
            "text": "Dolutegravir/rilpivirine (Juluca\u00ae) is",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -9.84375,
            "text": "Dolutegravir/rilpivirine (Juluca\u00ae) is the first two-drug single-tablet regimen (STR",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -9.9921875,
            "text": "Dolutegravir/rilpivirine (Juluca\u00ae) is the first two-drug single-tablet",
            "probability": 0.0
        },
        {
            "start_logit": -4.1953125,
            "end_logit": -6.51953125,
            "text": "ir/rilpivirine",
            "probability": 0.0
        }
    ],
    "61f7d017882a024a1000002f_1": [
        {
            "start_logit": 11.5859375,
            "end_logit": 11.71875,
            "text": "atenolol",
            "probability": 1.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -3.939453125,
            "text": "atenolol, ramipril, hydrochlorothiazide",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -5.921875,
            "text": "atenolol, ramipril",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -5.94921875,
            "text": "atenolol, ramipril, hydrochlorothiazide, and a statin",
            "probability": 0.0
        },
        {
            "start_logit": -8.6015625,
            "end_logit": 11.71875,
            "text": "Polycap (comprised of atenolol",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -8.828125,
            "text": "atenolol, ramipril, hydrochlor",
            "probability": 0.0
        },
        {
            "start_logit": -9.078125,
            "end_logit": 11.71875,
            "text": "CV outcomes in a primary prevention population. This study aims to determine whether the Polycap (comprised of atenolol",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -8.96875,
            "text": "atenolol, ramipril, hydrochlorothiazide, and a statin) reduces CV events in persons without a history",
            "probability": 0.0
        },
        {
            "start_logit": -9.203125,
            "end_logit": 11.71875,
            "text": "FDC polypill on major CV outcomes in a primary prevention population. This study aims to determine whether the Polycap (comprised of atenolol",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -9.53125,
            "text": "atenolol, ramipril, hydrochlorothiazide, and a statin) reduces CV events in persons without a history of CVD",
            "probability": 0.0
        },
        {
            "start_logit": -9.7890625,
            "end_logit": 11.71875,
            "text": "whether the Polycap (comprised of atenolol",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -9.671875,
            "text": "atenolol, ramipr",
            "probability": 0.0
        },
        {
            "start_logit": -9.859375,
            "end_logit": 11.71875,
            "text": "a primary prevention population. This study aims to determine whether the Polycap (comprised of atenolol",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -9.7421875,
            "text": "atenolol, ramipril, hydrochlorothiazide, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -9.921875,
            "text": "atenolol, ram",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -10.0,
            "text": "atenolol, ramipril, hydrochlorothiazide, and a statin)",
            "probability": 0.0
        },
        {
            "start_logit": -3.814453125,
            "end_logit": -3.939453125,
            "text": "hydrochlorothiazide",
            "probability": 0.0
        },
        {
            "start_logit": -3.814453125,
            "end_logit": -5.94921875,
            "text": "hydrochlorothiazide, and a statin",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -3.939453125,
            "text": "ramipril, hydrochlorothiazide",
            "probability": 0.0
        },
        {
            "start_logit": -8.6015625,
            "end_logit": -3.939453125,
            "text": "Polycap (comprised of atenolol, ramipril, hydrochlorothiazide",
            "probability": 0.0
        }
    ],
    "621215ec3a8413c653000012_1": [
        {
            "start_logit": 9.53125,
            "end_logit": 11.3984375,
            "text": "single-targeted antibodies",
            "probability": 1.0
        },
        {
            "start_logit": -5.92578125,
            "end_logit": 11.3984375,
            "text": "antibodies",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.53125,
            "end_logit": -5.703125,
            "text": "single-targeted antibodies, bi-specific antibodies (BsAbs), and antibody-drug conjugates (ADCs",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.53125,
            "end_logit": -7.33203125,
            "text": "single-targeted",
            "probability": 0.0
        },
        {
            "start_logit": -9.28125,
            "end_logit": 11.3984375,
            "text": "targeted antibodies",
            "probability": 0.0
        },
        {
            "start_logit": 9.53125,
            "end_logit": -7.75,
            "text": "single-targeted antibodies, bi-specific antibodies (BsAbs), and antibody-drug conjugates (ADC",
            "probability": 0.0
        },
        {
            "start_logit": -9.640625,
            "end_logit": 11.3984375,
            "text": "including single-targeted antibodies",
            "probability": 0.0
        },
        {
            "start_logit": 9.53125,
            "end_logit": -7.88671875,
            "text": "single",
            "probability": 0.0
        },
        {
            "start_logit": 9.53125,
            "end_logit": -7.96875,
            "text": "single-targeted antibodies, bi-specific antibodies (BsAbs",
            "probability": 0.0
        },
        {
            "start_logit": 9.53125,
            "end_logit": -8.0234375,
            "text": "single-targeted antibodies, bi-specific antibodies (BsAbs), and antibody-drug",
            "probability": 0.0
        },
        {
            "start_logit": 9.53125,
            "end_logit": -8.328125,
            "text": "single-targeted antibodies, bi-specific antibodies (BsAbs), and antibody-drug conjugates",
            "probability": 0.0
        },
        {
            "start_logit": 9.53125,
            "end_logit": -8.3984375,
            "text": "single-targeted antibodies, bi-specific antibodies",
            "probability": 0.0
        },
        {
            "start_logit": 9.53125,
            "end_logit": -8.3984375,
            "text": "single-targeted antibodies, bi-specific antibodies (BsA",
            "probability": 0.0
        },
        {
            "start_logit": 9.53125,
            "end_logit": -8.6953125,
            "text": "single-targeted antibodies, bi-specific antibodies (BsAbs)",
            "probability": 0.0
        },
        {
            "start_logit": 9.53125,
            "end_logit": -9.09375,
            "text": "single-targeted antibodies, bi",
            "probability": 0.0
        },
        {
            "start_logit": 9.53125,
            "end_logit": -9.34375,
            "text": "single-targeted antibodies, bi-specific antibodies (",
            "probability": 0.0
        },
        {
            "start_logit": 2.94140625,
            "end_logit": -5.703125,
            "text": ", bi-specific antibodies (BsAbs), and antibody-drug conjugates (ADCs",
            "probability": 0.0
        },
        {
            "start_logit": 2.94140625,
            "end_logit": -7.63671875,
            "text": ", bi-specific antibodies (BsAbs), and antibody-drug conjugates (ADCs), many factors, such as target biology",
            "probability": 0.0
        },
        {
            "start_logit": 2.94140625,
            "end_logit": -7.75,
            "text": ", bi-specific antibodies (BsAbs), and antibody-drug conjugates (ADC",
            "probability": 0.0
        },
        {
            "start_logit": 2.94140625,
            "end_logit": -7.96875,
            "text": ", bi-specific antibodies (BsAbs",
            "probability": 0.0
        }
    ],
    "621eb93b3a8413c65300005b_1": [
        {
            "start_logit": 7.6328125,
            "end_logit": 6.4765625,
            "text": "VEGF-A",
            "probability": 0.9990234375
        },
        {
            "start_logit": 7.6328125,
            "end_logit": -0.294677734375,
            "text": "VEGF-A and Ang-2",
            "probability": 0.0011472702026367188
        },
        {
            "start_logit": 7.6328125,
            "end_logit": -4.55078125,
            "text": "VEGF",
            "probability": 1.621246337890625e-05
        },
        {
            "start_logit": 7.6328125,
            "end_logit": -6.140625,
            "text": "VEGF-",
            "probability": 3.337860107421875e-06
        },
        {
            "start_logit": 7.6328125,
            "end_logit": -6.58984375,
            "text": "VEGF-A and Ang",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 7.6328125,
            "end_logit": -7.1328125,
            "text": "VEGF-A and Ang-",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 7.6328125,
            "end_logit": -7.453125,
            "text": "VEGF-A and Ang-2, is in phase 3 trials for nAMD",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 7.6328125,
            "end_logit": -8.203125,
            "text": "VEGF-A and Ang-2,",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.6328125,
            "end_logit": -9.078125,
            "text": "VEGF-A and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 6.4765625,
            "text": "A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.6328125,
            "end_logit": -9.4140625,
            "text": "VEGF-A and Ang-2, is in phase 3 trials for",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.6328125,
            "end_logit": -9.5625,
            "text": "VEGF-A and Ang-2, is in phase 3 trials for nAMD and DME",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.6328125,
            "end_logit": -9.9296875,
            "text": "VEGF-A and Ang-2, is in phase 3 trials for nAMD and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.6328125,
            "end_logit": -9.96875,
            "text": "VEGF-A and Ang-2, is in phase 3 trials",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.060546875,
            "end_logit": -0.294677734375,
            "text": "Ang-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.6328125,
            "end_logit": -10.0859375,
            "text": "VEGF-A and Ang-2, is in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.6328125,
            "end_logit": -10.234375,
            "text": "VEGF-A and Ang-2, is in phase 3 trials for nAMD and DME.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 6.4765625,
            "text": "inhibits VEGF-A",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 6.4765625,
            "text": "icimab, a bispecific antibody that inhibits VEGF-A",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 6.4765625,
            "text": "bispecific antibody that inhibits VEGF-A",
            "probability": 0.0
        }
    ],
    "621eb93b3a8413c65300005b_2": [
        {
            "start_logit": 12.328125,
            "end_logit": 11.5390625,
            "text": "VEGF-A",
            "probability": 1.0
        },
        {
            "start_logit": 12.328125,
            "end_logit": -1.8173828125,
            "text": "VEGF-A and the Ang-Tie/pathway",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 12.328125,
            "end_logit": -2.8046875,
            "text": "VEGF-A and the Ang-Tie",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 12.328125,
            "end_logit": -4.0234375,
            "text": "VEGF",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.62109375,
            "end_logit": 11.5390625,
            "text": "A",
            "probability": 0.0
        },
        {
            "start_logit": 12.328125,
            "end_logit": -6.625,
            "text": "VEGF-",
            "probability": 0.0
        },
        {
            "start_logit": 12.328125,
            "end_logit": -6.63671875,
            "text": "VEGF-A and the Ang-Tie/",
            "probability": 0.0
        },
        {
            "start_logit": 12.328125,
            "end_logit": -6.88671875,
            "text": "VEGF-A and the Ang",
            "probability": 0.0
        },
        {
            "start_logit": 12.328125,
            "end_logit": -8.09375,
            "text": "VEGF-A and the Ang-",
            "probability": 0.0
        },
        {
            "start_logit": 12.328125,
            "end_logit": -8.453125,
            "text": "VEGF-A and the",
            "probability": 0.0
        },
        {
            "start_logit": 12.328125,
            "end_logit": -9.40625,
            "text": "VEGF-A and",
            "probability": 0.0
        },
        {
            "start_logit": 12.328125,
            "end_logit": -9.9921875,
            "text": "VEGF-A and the Ang-Tie/pathway.",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 11.5390625,
            "text": "icimab is a promising bispecific drug targeting VEGF-A",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 11.5390625,
            "text": "bispecific drug targeting VEGF-A",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 11.5390625,
            "text": "Faricimab is a promising bispecific drug targeting VEGF-A",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 11.5390625,
            "text": "mab is a promising bispecific drug targeting VEGF-A",
            "probability": 0.0
        },
        {
            "start_logit": -4.65234375,
            "end_logit": -1.8173828125,
            "text": "Ang-Tie/pathway",
            "probability": 0.0
        },
        {
            "start_logit": -5.62109375,
            "end_logit": -1.8173828125,
            "text": "A and the Ang-Tie/pathway",
            "probability": 0.0
        },
        {
            "start_logit": -4.65234375,
            "end_logit": -2.8046875,
            "text": "Ang-Tie",
            "probability": 0.0
        },
        {
            "start_logit": -5.62109375,
            "end_logit": -2.8046875,
            "text": "A and the Ang-Tie",
            "probability": 0.0
        }
    ],
    "621eb93b3a8413c65300005b_3": [
        {
            "start_logit": 10.34375,
            "end_logit": 9.6328125,
            "text": "Tie-2",
            "probability": 1.0
        },
        {
            "start_logit": 10.34375,
            "end_logit": -1.001953125,
            "text": "Tie-2/angiopoietin pathway",
            "probability": 2.4318695068359375e-05
        },
        {
            "start_logit": 10.34375,
            "end_logit": -4.984375,
            "text": "Tie",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 10.34375,
            "end_logit": -5.04296875,
            "text": "Tie-2/angiopoietin",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 10.34375,
            "end_logit": -5.3046875,
            "text": "Tie-2/angiopoietin pathway and VEGF-A",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 10.34375,
            "end_logit": -5.33203125,
            "text": "Tie-",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 10.34375,
            "end_logit": -5.859375,
            "text": "Tie-2/angiopoietin pathway and VEGF",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 10.34375,
            "end_logit": -6.6484375,
            "text": "Tie-2/angiopo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.34375,
            "end_logit": -7.13671875,
            "text": "Tie-2/angio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.25390625,
            "end_logit": 9.6328125,
            "text": "2",
            "probability": 0.0
        },
        {
            "start_logit": 10.34375,
            "end_logit": -8.453125,
            "text": "Tie-2/angiopoietin pathway and VEGF-",
            "probability": 0.0
        },
        {
            "start_logit": 10.34375,
            "end_logit": -8.78125,
            "text": "Tie-2/",
            "probability": 0.0
        },
        {
            "start_logit": 10.34375,
            "end_logit": -8.9140625,
            "text": "Tie-2/angiopoietin pathway and",
            "probability": 0.0
        },
        {
            "start_logit": 10.34375,
            "end_logit": -9.578125,
            "text": "Tie-2/angiopoietin pathway and VEGF-A for",
            "probability": 0.0
        },
        {
            "start_logit": 10.34375,
            "end_logit": -10.09375,
            "text": "Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases.",
            "probability": 0.0
        },
        {
            "start_logit": 10.34375,
            "end_logit": -10.1015625,
            "text": "Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases",
            "probability": 0.0
        },
        {
            "start_logit": 10.34375,
            "end_logit": -10.1953125,
            "text": "Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 9.6328125,
            "text": "targeting the Tie-2",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 9.6328125,
            "text": "icimab: an investigational agent targeting the Tie-2",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 9.6328125,
            "text": "Faricimab: an investigational agent targeting the Tie-2",
            "probability": 0.0
        }
    ],
    "621eb93b3a8413c65300005b_4": [
        {
            "start_logit": 12.828125,
            "end_logit": 11.296875,
            "text": "Ang-2",
            "probability": 1.0
        },
        {
            "start_logit": 12.828125,
            "end_logit": -3.1015625,
            "text": "Ang-2 and VEGF-A",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 12.828125,
            "end_logit": -3.576171875,
            "text": "Ang-2 and VEGF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 12.828125,
            "end_logit": -3.677734375,
            "text": "Ang",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 12.828125,
            "end_logit": -5.7265625,
            "text": "Ang-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.8359375,
            "end_logit": 11.296875,
            "text": "2",
            "probability": 0.0
        },
        {
            "start_logit": 12.828125,
            "end_logit": -7.875,
            "text": "Ang-2 and VEGF-",
            "probability": 0.0
        },
        {
            "start_logit": 12.828125,
            "end_logit": -9.0078125,
            "text": "Ang-2 and VEGF-A for treatment of diabetic eye",
            "probability": 0.0
        },
        {
            "start_logit": 12.828125,
            "end_logit": -9.515625,
            "text": "Ang-2 and VEGF-A for",
            "probability": 0.0
        },
        {
            "start_logit": 12.828125,
            "end_logit": -9.703125,
            "text": "Ang-2 and",
            "probability": 0.0
        },
        {
            "start_logit": 12.828125,
            "end_logit": -9.7578125,
            "text": "Ang-2 and VEGF-A for treatment of diabetic eye disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": 11.296875,
            "text": "identified faricimab, a novel bispecific antibody designed for intravitreal use, to simultaneously bind and neutralize Ang-2",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 11.296875,
            "text": "intravitreal use, to simultaneously bind and neutralize Ang-2",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 11.296875,
            "text": "icimab, a novel bispecific antibody designed for intravitreal use, to simultaneously bind and neutralize Ang-2",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 11.296875,
            "text": "faricimab, a novel bispecific antibody designed for intravitreal use, to simultaneously bind and neutralize Ang-2",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 11.296875,
            "text": "Clinical studies have identified faricimab, a novel bispecific antibody designed for intravitreal use, to simultaneously bind and neutralize Ang-2",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 11.296875,
            "text": "bispecific antibody designed for intravitreal use, to simultaneously bind and neutralize Ang-2",
            "probability": 0.0
        },
        {
            "start_logit": -1.9462890625,
            "end_logit": -3.1015625,
            "text": "VEGF-A",
            "probability": 0.0
        },
        {
            "start_logit": -1.9462890625,
            "end_logit": -3.576171875,
            "text": "VEGF",
            "probability": 0.0
        },
        {
            "start_logit": -5.8359375,
            "end_logit": -3.1015625,
            "text": "2 and VEGF-A",
            "probability": 0.0
        }
    ],
    "621eb93b3a8413c65300005b_5": [
        {
            "start_logit": 5.515625,
            "end_logit": 12.4140625,
            "text": "VEGF",
            "probability": 1.0
        },
        {
            "start_logit": 5.515625,
            "end_logit": 2.9453125,
            "text": "VEGF/Ang-2 antibody that upregulates the Tie-2",
            "probability": 7.665157318115234e-05
        },
        {
            "start_logit": 1.625,
            "end_logit": 2.9453125,
            "text": "Tie-2",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 5.515625,
            "end_logit": -1.962890625,
            "text": "VEGF/Ang-2",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 12.4140625,
            "text": "bispecific anti-VEGF",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.046875,
            "end_logit": 12.4140625,
            "text": "anti-VEGF",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 12.4140625,
            "text": "icimab is a bispecific anti-VEGF",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 12.4140625,
            "text": "Faricimab is a bispecific anti-VEGF",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.515625,
            "end_logit": -4.87890625,
            "text": "VEGF/Ang-2 antibody that upregulates the Tie-2 signaling pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.515625,
            "end_logit": -5.34375,
            "text": "VEGF/Ang-2 antibody that upregulates the Tie",
            "probability": 0.0
        },
        {
            "start_logit": 5.515625,
            "end_logit": -6.6640625,
            "text": "VEGF/Ang-2 antibody that upregulates the Tie-",
            "probability": 0.0
        },
        {
            "start_logit": 5.515625,
            "end_logit": -6.84375,
            "text": "VEGF/Ang-2 antibody that upregulates the Tie-2 signaling pathway and promotes vascular stability",
            "probability": 0.0
        },
        {
            "start_logit": 5.515625,
            "end_logit": -7.72265625,
            "text": "VEGF/Ang-2 antibody that upregulates the Tie-2 signaling",
            "probability": 0.0
        },
        {
            "start_logit": 5.515625,
            "end_logit": -7.8828125,
            "text": "VEGF/Ang-",
            "probability": 0.0
        },
        {
            "start_logit": 5.515625,
            "end_logit": -8.1484375,
            "text": "VEGF/Ang",
            "probability": 0.0
        },
        {
            "start_logit": 5.515625,
            "end_logit": -8.6953125,
            "text": "VEGF/Ang-2 antibody",
            "probability": 0.0
        },
        {
            "start_logit": 1.625,
            "end_logit": -4.87890625,
            "text": "Tie-2 signaling pathway",
            "probability": 0.0
        },
        {
            "start_logit": 5.515625,
            "end_logit": -9.0859375,
            "text": "VEGF/Ang-2 antibody that upregulates the",
            "probability": 0.0
        },
        {
            "start_logit": 1.625,
            "end_logit": -5.34375,
            "text": "Tie",
            "probability": 0.0
        },
        {
            "start_logit": 5.515625,
            "end_logit": -9.4453125,
            "text": "VEGF/Ang-2 antibody that upregulates the Tie-2 signaling pathway and promotes vascular",
            "probability": 0.0
        }
    ],
    "621eb93b3a8413c65300005b_6": [
        {
            "start_logit": 9.9609375,
            "end_logit": 9.984375,
            "text": "angiopoietin 2 (Ang-2)",
            "probability": 0.97998046875
        },
        {
            "start_logit": 9.9609375,
            "end_logit": 5.58984375,
            "text": "angiopoietin 2",
            "probability": 0.01213836669921875
        },
        {
            "start_logit": 9.9609375,
            "end_logit": 5.01953125,
            "text": "angiopoietin 2 (Ang-2) and vascular endothelial growth factor A",
            "probability": 0.00691986083984375
        },
        {
            "start_logit": 9.9609375,
            "end_logit": 3.123046875,
            "text": "angiopoietin 2 (Ang-2) and vascular endothelial growth factor",
            "probability": 0.0010366439819335938
        },
        {
            "start_logit": 1.830078125,
            "end_logit": 5.01953125,
            "text": "vascular endothelial growth factor A",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -3.94921875,
            "text": "angiopoietin",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -4.13671875,
            "text": "angiopo",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -4.89453125,
            "text": "angiopoietin 2 (Ang-2) and vascular endothelial growth",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 1.830078125,
            "end_logit": 3.123046875,
            "text": "vascular endothelial growth factor",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -5.328125,
            "text": "angiopoietin 2 (Ang-2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -5.9765625,
            "text": "angio",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.07421875,
            "text": "angiopoietin 2 (Ang-2) and vascular endothelial",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 9.984375,
            "text": ")",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8046875,
            "end_logit": 9.984375,
            "text": "2 (Ang-2)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.8828125,
            "text": "angiopoietin 2 (Ang-2) and vascular",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.484375,
            "text": "angiopoietin 2 (",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.53125,
            "text": "angiopoietin 2 (Ang-",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.75,
            "text": "angiopoietin 2 (Ang",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -9.4375,
            "text": "angiopoietin 2 (Ang-2) and",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 9.984375,
            "text": "Ang-2)",
            "probability": 0.0
        }
    ],
    "621eb93b3a8413c65300005b_7": [
        {
            "start_logit": 11.9140625,
            "end_logit": 11.1015625,
            "text": "VEGF-A",
            "probability": 1.0
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -2.45703125,
            "text": "VEGF-A and the Ang-Tie",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -3.7265625,
            "text": "VEGF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.7578125,
            "end_logit": 11.1015625,
            "text": "A",
            "probability": 0.0
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -6.79296875,
            "text": "VEGF-",
            "probability": 0.0
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -6.90625,
            "text": "VEGF-A and the Ang",
            "probability": 0.0
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -7.54296875,
            "text": "VEGF-A and the Ang-Tie/",
            "probability": 0.0
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -7.7890625,
            "text": "VEGF-A and the",
            "probability": 0.0
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -8.1328125,
            "text": "VEGF-A and the Ang-",
            "probability": 0.0
        },
        {
            "start_logit": 11.9140625,
            "end_logit": -8.609375,
            "text": "VEGF-A and",
            "probability": 0.0
        },
        {
            "start_logit": -8.5703125,
            "end_logit": 11.1015625,
            "text": "gimen. Faricimab is a promising bispecific drug targeting VEGF-A",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 11.1015625,
            "text": "Faricimab is a promising bispecific drug targeting VEGF-A",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 11.1015625,
            "text": "icimab is a promising bispecific drug targeting VEGF-A",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 11.1015625,
            "text": "mab is a promising bispecific drug targeting VEGF-A",
            "probability": 0.0
        },
        {
            "start_logit": -4.421875,
            "end_logit": -2.45703125,
            "text": "Ang-Tie",
            "probability": 0.0
        },
        {
            "start_logit": -5.7578125,
            "end_logit": -2.45703125,
            "text": "A and the Ang-Tie",
            "probability": 0.0
        },
        {
            "start_logit": -8.5703125,
            "end_logit": -2.45703125,
            "text": "gimen. Faricimab is a promising bispecific drug targeting VEGF-A and the Ang-Tie",
            "probability": 0.0
        },
        {
            "start_logit": -4.421875,
            "end_logit": -6.90625,
            "text": "Ang",
            "probability": 0.0
        },
        {
            "start_logit": -4.421875,
            "end_logit": -7.54296875,
            "text": "Ang-Tie/",
            "probability": 0.0
        },
        {
            "start_logit": -8.5703125,
            "end_logit": -3.7265625,
            "text": "gimen. Faricimab is a promising bispecific drug targeting VEGF",
            "probability": 0.0
        }
    ],
    "621eb93b3a8413c65300005b_8": [
        {
            "start_logit": 13.484375,
            "end_logit": 12.4375,
            "text": "Ang-2",
            "probability": 1.0
        },
        {
            "start_logit": 13.484375,
            "end_logit": -3.724609375,
            "text": "Ang",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.484375,
            "end_logit": -3.9609375,
            "text": "Ang-2 and VEGF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.484375,
            "end_logit": -4.5625,
            "text": "Ang-2 and VEGF-A for treatment of diabetic eye disease. By targeting both Ang-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.484375,
            "end_logit": -5.18359375,
            "text": "Ang-2 and VEGF-A",
            "probability": 0.0
        },
        {
            "start_logit": 13.484375,
            "end_logit": -6.453125,
            "text": "Ang-",
            "probability": 0.0
        },
        {
            "start_logit": -5.46875,
            "end_logit": 12.4375,
            "text": "2",
            "probability": 0.0
        },
        {
            "start_logit": 13.484375,
            "end_logit": -7.26953125,
            "text": "Ang-2 and VEGF-A for treatment of diabetic eye disease. By targeting both Ang-2 a",
            "probability": 0.0
        },
        {
            "start_logit": 13.484375,
            "end_logit": -7.58984375,
            "text": "Ang-2 and VEGF-A for treatment of diabetic eye disease. By targeting both Ang",
            "probability": 0.0
        },
        {
            "start_logit": 13.484375,
            "end_logit": -8.3203125,
            "text": "Ang-2 and VEGF-A for treatment of diabetic eye disease. By targeting both Ang-",
            "probability": 0.0
        },
        {
            "start_logit": 13.484375,
            "end_logit": -8.609375,
            "text": "Ang-2 and VEGF-",
            "probability": 0.0
        },
        {
            "start_logit": 13.484375,
            "end_logit": -9.046875,
            "text": "Ang-2 and VEGF-A for treatment of diabetic eye disease. By targeting both",
            "probability": 0.0
        },
        {
            "start_logit": 13.484375,
            "end_logit": -9.4765625,
            "text": "Ang-2 and",
            "probability": 0.0
        },
        {
            "start_logit": 13.484375,
            "end_logit": -9.578125,
            "text": "Ang-2 and VEGF-A for treatment of diabetic eye",
            "probability": 0.0
        },
        {
            "start_logit": 13.484375,
            "end_logit": -9.9453125,
            "text": "Ang-2 and VEGF-A for treatment of diabetic eye disease. By targeting",
            "probability": 0.0
        },
        {
            "start_logit": -9.1640625,
            "end_logit": 12.4375,
            "text": "ntified faricimab, a novel bispecific antibody designed for intravitreal use, to simultaneously bind and neutralize Ang-2",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 12.4375,
            "text": "ified faricimab, a novel bispecific antibody designed for intravitreal use, to simultaneously bind and neutralize Ang-2",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": 12.4375,
            "text": "icimab, a novel bispecific antibody designed for intravitreal use, to simultaneously bind and neutralize Ang-2",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 12.4375,
            "text": "faricimab, a novel bispecific antibody designed for intravitreal use, to simultaneously bind and neutralize Ang-2",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 12.4375,
            "text": "bispecific antibody designed for intravitreal use, to simultaneously bind and neutralize Ang-2",
            "probability": 0.0
        }
    ],
    "621eb93b3a8413c65300005b_9": [
        {
            "start_logit": 12.8671875,
            "end_logit": 11.7265625,
            "text": "angiopoietin-2",
            "probability": 1.0
        },
        {
            "start_logit": 12.8671875,
            "end_logit": -3.03125,
            "text": "angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A), with ranibizumab in patients with diabetic macular edema",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 12.8671875,
            "end_logit": -3.79296875,
            "text": "angio",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 12.8671875,
            "end_logit": -4.53515625,
            "text": "angiopoietin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.8671875,
            "end_logit": -4.5859375,
            "text": "angiopoietin-2 and vascular endothelial growth factor-A (VEGF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.8671875,
            "end_logit": -5.78125,
            "text": "angiopo",
            "probability": 0.0
        },
        {
            "start_logit": -5.4296875,
            "end_logit": 11.7265625,
            "text": "2",
            "probability": 0.0
        },
        {
            "start_logit": 12.8671875,
            "end_logit": -6.68359375,
            "text": "angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A)",
            "probability": 0.0
        },
        {
            "start_logit": 12.8671875,
            "end_logit": -6.76171875,
            "text": "angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A",
            "probability": 0.0
        },
        {
            "start_logit": 12.8671875,
            "end_logit": -7.0234375,
            "text": "angiopoietin-2 and vascular endothelial growth factor",
            "probability": 0.0
        },
        {
            "start_logit": 12.8671875,
            "end_logit": -7.03515625,
            "text": "angiopoietin-",
            "probability": 0.0
        },
        {
            "start_logit": 12.8671875,
            "end_logit": -7.4609375,
            "text": "angiopoietin-2 and vascular endothelial growth factor-A (",
            "probability": 0.0
        },
        {
            "start_logit": 12.8671875,
            "end_logit": -7.5703125,
            "text": "angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A), with ranibizumab in patients with diabetic",
            "probability": 0.0
        },
        {
            "start_logit": 12.8671875,
            "end_logit": -7.578125,
            "text": "angiopoietin-2 and vascular",
            "probability": 0.0
        },
        {
            "start_logit": 12.8671875,
            "end_logit": -7.6171875,
            "text": "angiopoietin-2 and vascular endothelial growth factor-A",
            "probability": 0.0
        },
        {
            "start_logit": 12.8671875,
            "end_logit": -8.0625,
            "text": "angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A), with ranibizumab in patients with diabetic macular",
            "probability": 0.0
        },
        {
            "start_logit": 12.8671875,
            "end_logit": -8.203125,
            "text": "angiopoietin-2 and vascular endothelial growth",
            "probability": 0.0
        },
        {
            "start_logit": 12.8671875,
            "end_logit": -8.9296875,
            "text": "angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A), with ranibizumab",
            "probability": 0.0
        },
        {
            "start_logit": 12.8671875,
            "end_logit": -8.9453125,
            "text": "angiopoietin-2 and vascular endothelial",
            "probability": 0.0
        },
        {
            "start_logit": 12.8671875,
            "end_logit": -9.2421875,
            "text": "angiopoietin-2 and vascular endothelial growth factor-A (VEGF-",
            "probability": 0.0
        }
    ],
    "621eb93b3a8413c65300005b_10": [
        {
            "start_logit": 2.791015625,
            "end_logit": 4.4375,
            "text": "Ang-2",
            "probability": 0.7490234375
        },
        {
            "start_logit": 1.5849609375,
            "end_logit": 4.4375,
            "text": "VEGF-A and Ang-2",
            "probability": 0.2249755859375
        },
        {
            "start_logit": 1.5849609375,
            "end_logit": 2.28515625,
            "text": "VEGF-A",
            "probability": 0.026123046875
        },
        {
            "start_logit": 1.5849609375,
            "end_logit": -3.734375,
            "text": "VEGF",
            "probability": 6.35385513305664e-05
        },
        {
            "start_logit": 2.791015625,
            "end_logit": -5.08984375,
            "text": "Ang",
            "probability": 5.4776668548583984e-05
        },
        {
            "start_logit": 2.791015625,
            "end_logit": -5.90625,
            "text": "Ang-",
            "probability": 2.4139881134033203e-05
        },
        {
            "start_logit": 1.5849609375,
            "end_logit": -5.08984375,
            "text": "VEGF-A and Ang",
            "probability": 1.627206802368164e-05
        },
        {
            "start_logit": -8.109375,
            "end_logit": 4.4375,
            "text": "2",
            "probability": 1.3828277587890625e-05
        },
        {
            "start_logit": 1.5849609375,
            "end_logit": -5.90625,
            "text": "VEGF-A and Ang-",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": -9.5234375,
            "end_logit": 4.4375,
            "text": "A and Ang-2",
            "probability": 3.337860107421875e-06
        },
        {
            "start_logit": 1.5849609375,
            "end_logit": -6.76171875,
            "text": "VEGF-",
            "probability": 3.0994415283203125e-06
        },
        {
            "start_logit": 2.791015625,
            "end_logit": -8.0625,
            "text": "Ang-2, is in phase 3 trials fo",
            "probability": 2.8014183044433594e-06
        },
        {
            "start_logit": 2.791015625,
            "end_logit": -8.15625,
            "text": "Ang-2,",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": -10.25,
            "end_logit": 4.4375,
            "text": "inhibits VEGF-A and Ang-2",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": -10.515625,
            "end_logit": 4.4375,
            "text": "Areas covered: Faricimab, a bispecific antibody that inhibits VEGF-A and Ang-2",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 4.4375,
            "text": "icimab, a bispecific antibody that inhibits VEGF-A and Ang-2",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 2.791015625,
            "end_logit": -8.921875,
            "text": "Ang-2, is in phase 3 trials",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 4.4375,
            "text": "bispecific antibody that inhibits VEGF-A and Ang-2",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 4.4375,
            "text": "and Ang-2",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 4.4375,
            "text": "Faricimab, a bispecific antibody that inhibits VEGF-A and Ang-2",
            "probability": 1.0728836059570312e-06
        }
    ],
    "621eb93b3a8413c65300005b_11": [
        {
            "start_logit": 4.09765625,
            "end_logit": 10.5546875,
            "text": "VEGF",
            "probability": 1.0
        },
        {
            "start_logit": 4.09765625,
            "end_logit": 1.2900390625,
            "text": "VEGF/Ang-2 antibody that upregulates the Tie-2",
            "probability": 9.459257125854492e-05
        },
        {
            "start_logit": 1.1689453125,
            "end_logit": 1.2900390625,
            "text": "Tie-2",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": -8.515625,
            "end_logit": 10.5546875,
            "text": "anti-VEGF",
            "probability": 3.337860107421875e-06
        },
        {
            "start_logit": 4.09765625,
            "end_logit": -2.357421875,
            "text": "VEGF/Ang-2 antibody that upregulates the Tie-2 signaling pathway",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": -9.5703125,
            "end_logit": 10.5546875,
            "text": "c anti-VEGF",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 4.09765625,
            "end_logit": -3.962890625,
            "text": "VEGF/Ang-2",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -10.546875,
            "end_logit": 10.5546875,
            "text": "-VEGF",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 1.1689453125,
            "end_logit": -2.357421875,
            "text": "Tie-2 signaling pathway",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 4.09765625,
            "end_logit": -6.03125,
            "text": "VEGF/Ang-2 antibody",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.09765625,
            "end_logit": -6.05859375,
            "text": "VEGF/Ang-2 antibody that upregulates the Tie-2 signaling pathway and promotes vascular stability",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.09765625,
            "end_logit": -6.203125,
            "text": "VEGF/Ang-2 antibody that upregulates the Tie-2 signaling",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.09765625,
            "end_logit": -6.6484375,
            "text": "VEGF/Ang-2 antibody that upregulates the Tie",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.09765625,
            "end_logit": -6.984375,
            "text": "VEGF/Ang-2 antibody that upregulates the Tie-",
            "probability": 0.0
        },
        {
            "start_logit": 4.09765625,
            "end_logit": -8.7421875,
            "text": "VEGF/Ang-",
            "probability": 0.0
        },
        {
            "start_logit": 4.09765625,
            "end_logit": -8.9375,
            "text": "VEGF/Ang-2 antibody that upregulates the",
            "probability": 0.0
        },
        {
            "start_logit": 1.1689453125,
            "end_logit": -6.05859375,
            "text": "Tie-2 signaling pathway and promotes vascular stability",
            "probability": 0.0
        },
        {
            "start_logit": 1.1689453125,
            "end_logit": -6.203125,
            "text": "Tie-2 signaling",
            "probability": 0.0
        },
        {
            "start_logit": 4.09765625,
            "end_logit": -9.171875,
            "text": "VEGF/Ang-2 antibody that upregulates the Tie-2 signaling pathway and promotes vascular",
            "probability": 0.0
        },
        {
            "start_logit": 4.09765625,
            "end_logit": -9.203125,
            "text": "VEGF/Ang",
            "probability": 0.0
        }
    ],
    "621eb93b3a8413c65300005b_12": [
        {
            "start_logit": 4.8359375,
            "end_logit": 4.3125,
            "text": "VEGF-A",
            "probability": 0.8642578125
        },
        {
            "start_logit": 4.8359375,
            "end_logit": 2.44140625,
            "text": "VEGF-A and Ang-2",
            "probability": 0.133056640625
        },
        {
            "start_logit": 0.767578125,
            "end_logit": 2.44140625,
            "text": "Ang-2",
            "probability": 0.0022792816162109375
        },
        {
            "start_logit": 4.8359375,
            "end_logit": -4.25,
            "text": "VEGF",
            "probability": 0.00016510486602783203
        },
        {
            "start_logit": 4.8359375,
            "end_logit": -5.54296875,
            "text": "VEGF-A and Ang",
            "probability": 4.5180320739746094e-05
        },
        {
            "start_logit": 4.8359375,
            "end_logit": -6.3515625,
            "text": "VEGF-",
            "probability": 2.0205974578857422e-05
        },
        {
            "start_logit": 4.8359375,
            "end_logit": -6.4140625,
            "text": "VEGF-A and Ang-",
            "probability": 1.895427703857422e-05
        },
        {
            "start_logit": 4.8359375,
            "end_logit": -7.7734375,
            "text": "VEGF-A and Ang-2, is in phase 3 trials for nAMD",
            "probability": 4.887580871582031e-06
        },
        {
            "start_logit": 4.8359375,
            "end_logit": -8.3828125,
            "text": "VEGF-A and Ang-2,",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": 4.8359375,
            "end_logit": -9.1171875,
            "text": "VEGF-A and Ang-2, is in phase 3 trials for nAMD and DME",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 4.8359375,
            "end_logit": -9.5234375,
            "text": "VEGF-A and",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 0.767578125,
            "end_logit": -5.54296875,
            "text": "Ang",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 4.8359375,
            "end_logit": -9.65625,
            "text": "VEGF-A and Ang-2, is in phase 3 trials for",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -9.2578125,
            "end_logit": 4.3125,
            "text": "A",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 4.8359375,
            "end_logit": -10.0078125,
            "text": "VEGF-A and Ang-2, is",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 4.8359375,
            "end_logit": -10.078125,
            "text": "VEGF-A and Ang-2, is in phase 3 trials for nAMD and",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 4.8359375,
            "end_logit": -10.1015625,
            "text": "VEGF-A and Ang-2, is in phase 3 trials",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -9.8046875,
            "end_logit": 4.3125,
            "text": "inhibits VEGF-A",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 0.767578125,
            "end_logit": -6.4140625,
            "text": "Ang-",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -10.40625,
            "end_logit": 4.3125,
            "text": "Areas covered: Faricimab, a bispecific antibody that inhibits VEGF-A",
            "probability": 1.7881393432617188e-07
        }
    ],
    "621eb93b3a8413c65300005b_13": [
        {
            "start_logit": 9.7890625,
            "end_logit": 11.578125,
            "text": "vascular endothelial growth factor-A (VEGF-A)",
            "probability": 0.9990234375
        },
        {
            "start_logit": 2.658203125,
            "end_logit": 11.578125,
            "text": "Ang-2 and vascular endothelial growth factor-A (VEGF-A)",
            "probability": 0.0007910728454589844
        },
        {
            "start_logit": 2.658203125,
            "end_logit": 5.3359375,
            "text": "Ang-2",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -5.4375,
            "end_logit": 11.578125,
            "text": ")",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -4.71875,
            "text": "vascular endothelial growth factor-A (VEGF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -5.0703125,
            "text": "vascular endothelial growth factor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -5.56640625,
            "text": "vascular",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 11.578125,
            "text": "VEGF-A)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -6.25390625,
            "text": "vascular endothelial growth factor-A",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 11.578125,
            "text": "2 and vascular endothelial growth factor-A (VEGF-A)",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -7.05859375,
            "text": "vascular endothelial growth",
            "probability": 0.0
        },
        {
            "start_logit": -9.03125,
            "end_logit": 11.578125,
            "text": "targeting both Ang-2 and vascular endothelial growth factor-A (VEGF-A)",
            "probability": 0.0
        },
        {
            "start_logit": -9.625,
            "end_logit": 11.578125,
            "text": "endothelial growth factor-A (VEGF-A)",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": 11.578125,
            "text": "both Ang-2 and vascular endothelial growth factor-A (VEGF-A)",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.1328125,
            "text": "vascular endothelial growth factor-A (VEGF-A",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 11.578125,
            "text": "A (VEGF-A)",
            "probability": 0.0
        },
        {
            "start_logit": -9.9453125,
            "end_logit": 11.578125,
            "text": "A)",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.3125,
            "text": "vascular endothelial growth factor-A (",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 11.578125,
            "text": "(VEGF-A)",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 11.578125,
            "text": "and vascular endothelial growth factor-A (VEGF-A)",
            "probability": 0.0
        }
    ],
    "621eb93b3a8413c65300005b_14": [
        {
            "start_logit": 13.203125,
            "end_logit": 11.5390625,
            "text": "angiopoietin-2",
            "probability": 1.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -3.328125,
            "text": "angiopoietin",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 13.203125,
            "end_logit": -3.697265625,
            "text": "angio",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 13.203125,
            "end_logit": -5.8359375,
            "text": "angiopoietin-2 and vascular endothelial growth factor-A (VEGF",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -6.01953125,
            "text": "angiopo",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -6.5703125,
            "text": "angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A)",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -6.7109375,
            "text": "angiopoietin-",
            "probability": 0.0
        },
        {
            "start_logit": -5.625,
            "end_logit": 11.5390625,
            "text": "2",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -7.55078125,
            "text": "angiopoietin-2 and vascular",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -7.77734375,
            "text": "angiopoietin-2 and vascular endothelial growth factor",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -7.90625,
            "text": "angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A",
            "probability": 0.0
        },
        {
            "start_logit": -9.4609375,
            "end_logit": 11.5390625,
            "text": "ietin-2",
            "probability": 0.0
        },
        {
            "start_logit": -3.25,
            "end_logit": -2.87890625,
            "text": "intravitreal 6.0 mg faricimab",
            "probability": 0.0
        },
        {
            "start_logit": -3.25,
            "end_logit": -3.939453125,
            "text": "intravitreal 6.0 mg faricimab, 1.5 mg faricimab, or 0.3 mg ranibizumab",
            "probability": 0.0
        },
        {
            "start_logit": -3.25,
            "end_logit": -5.00390625,
            "text": "intravitreal 6.0 mg faricimab, 1.5 mg faricimab, or 0.3 mg ranibiz",
            "probability": 0.0
        },
        {
            "start_logit": -3.708984375,
            "end_logit": -5.8359375,
            "text": "vascular endothelial growth factor-A (VEGF",
            "probability": 0.0
        },
        {
            "start_logit": -3.25,
            "end_logit": -6.3203125,
            "text": "intravitreal 6.0",
            "probability": 0.0
        },
        {
            "start_logit": -3.25,
            "end_logit": -6.88671875,
            "text": "intravitreal 6.0 mg faricimab, 1.5 mg faricimab, or 0.3",
            "probability": 0.0
        },
        {
            "start_logit": -3.708984375,
            "end_logit": -6.5703125,
            "text": "vascular endothelial growth factor-A (VEGF-A)",
            "probability": 0.0
        },
        {
            "start_logit": -3.25,
            "end_logit": -7.05078125,
            "text": "intravitreal 6.0 mg faricimab, 1.5 mg faricimab, or 0.3 mg ran",
            "probability": 0.0
        }
    ],
    "621eb93b3a8413c65300005b_15": [
        {
            "start_logit": 12.375,
            "end_logit": 11.1640625,
            "text": "angiopoietin 2 (Ang-2)",
            "probability": 0.98291015625
        },
        {
            "start_logit": 12.375,
            "end_logit": 7.140625,
            "text": "angiopoietin 2",
            "probability": 0.017730712890625
        },
        {
            "start_logit": 12.375,
            "end_logit": -0.0526123046875,
            "text": "angiopoietin 2 (Ang-2) and vascular endothelial growth factor A (VEGF-A)",
            "probability": 1.329183578491211e-05
        },
        {
            "start_logit": 12.375,
            "end_logit": -4.5078125,
            "text": "angiopo",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 12.375,
            "end_logit": -4.609375,
            "text": "angio",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.375,
            "end_logit": -5.1328125,
            "text": "angiopoietin 2 (Ang-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.375,
            "end_logit": -5.62109375,
            "text": "angiopoietin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.375,
            "end_logit": -5.625,
            "text": "angiopoietin 2 (Ang-2) and vascular endothelial growth factor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.375,
            "end_logit": -5.6328125,
            "text": "angiopoietin 2 (Ang-2) and vascular endothelial growth factor A (VEGF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.375,
            "end_logit": -7.0703125,
            "text": "angiopoietin 2 (Ang-2) and vascular endothelial growth factor A",
            "probability": 0.0
        },
        {
            "start_logit": 12.375,
            "end_logit": -7.078125,
            "text": "angiopoietin 2 (Ang-2) and vascular",
            "probability": 0.0
        },
        {
            "start_logit": -6.12109375,
            "end_logit": 11.1640625,
            "text": ")",
            "probability": 0.0
        },
        {
            "start_logit": 12.375,
            "end_logit": -7.47265625,
            "text": "angiopoietin 2 (Ang-2) and vascular endothelial growth",
            "probability": 0.0
        },
        {
            "start_logit": -6.4296875,
            "end_logit": 11.1640625,
            "text": "2 (Ang-2)",
            "probability": 0.0
        },
        {
            "start_logit": 12.375,
            "end_logit": -8.0234375,
            "text": "angiopoietin 2 (Ang",
            "probability": 0.0
        },
        {
            "start_logit": 12.375,
            "end_logit": -8.140625,
            "text": "angiopoietin 2 (",
            "probability": 0.0
        },
        {
            "start_logit": 12.375,
            "end_logit": -8.140625,
            "text": "angiopoietin 2 (Ang-2) and vascular endothelial growth factor A (",
            "probability": 0.0
        },
        {
            "start_logit": 12.375,
            "end_logit": -8.171875,
            "text": "angiopoietin 2 (Ang-2) and vascular endothelial growth factor A (VEGF-A",
            "probability": 0.0
        },
        {
            "start_logit": 12.375,
            "end_logit": -8.453125,
            "text": "angiopoietin 2 (Ang-2) and vascular endothelial",
            "probability": 0.0
        },
        {
            "start_logit": -9.71875,
            "end_logit": 11.1640625,
            "text": "Ang-2)",
            "probability": 0.0
        }
    ],
    "5e4f0a4f6d0a277941000031_1": [
        {
            "start_logit": 10.6484375,
            "end_logit": 1.814453125,
            "text": "gamma",
            "probability": 0.89111328125
        },
        {
            "start_logit": 10.6484375,
            "end_logit": -0.307861328125,
            "text": "gamma, alpha, mu, delta or epsilon chain",
            "probability": 0.10723876953125
        },
        {
            "start_logit": 10.6484375,
            "end_logit": -5.51953125,
            "text": "gamma, alpha, mu, delta or epsilon",
            "probability": 0.0005831718444824219
        },
        {
            "start_logit": 10.6484375,
            "end_logit": -6.00390625,
            "text": "gamma, alpha",
            "probability": 0.0003592967987060547
        },
        {
            "start_logit": 10.6484375,
            "end_logit": -6.421875,
            "text": "gamma, alpha, mu",
            "probability": 0.00023651123046875
        },
        {
            "start_logit": 10.6484375,
            "end_logit": -7.66015625,
            "text": "gamma, alpha, mu, delta",
            "probability": 6.884336471557617e-05
        },
        {
            "start_logit": 10.6484375,
            "end_logit": -9.515625,
            "text": "gamma, alpha, mu, delta or",
            "probability": 1.0728836059570312e-05
        },
        {
            "start_logit": 10.6484375,
            "end_logit": -9.828125,
            "text": "gamma,",
            "probability": 7.867813110351562e-06
        },
        {
            "start_logit": -8.125,
            "end_logit": 1.814453125,
            "text": "he neoplastic proliferation of single clones of plasma cells causes synthesis of very large amount of monoclonal immunoglobulins consisting of only one type of heavy either the gamma",
            "probability": 0.0
        },
        {
            "start_logit": -6.79296875,
            "end_logit": -0.307861328125,
            "text": "alpha, mu, delta or epsilon chain",
            "probability": 0.0
        },
        {
            "start_logit": -6.96484375,
            "end_logit": -0.307861328125,
            "text": "mu, delta or epsilon chain",
            "probability": 0.0
        },
        {
            "start_logit": -7.69140625,
            "end_logit": -0.307861328125,
            "text": "epsilon chain",
            "probability": 0.0
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 1.814453125,
            "text": "neoplastic proliferation of single clones of plasma cells causes synthesis of very large amount of monoclonal immunoglobulins consisting of only one type of heavy either the gamma",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 1.814453125,
            "text": "the gamma",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 1.814453125,
            "text": "monoclonal immunoglobulins consisting of only one type of heavy either the gamma",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 1.814453125,
            "text": "clones of plasma cells causes synthesis of very large amount of monoclonal immunoglobulins consisting of only one type of heavy either the gamma",
            "probability": 0.0
        },
        {
            "start_logit": -10.0234375,
            "end_logit": -0.307861328125,
            "text": "or epsilon chain",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": -0.307861328125,
            "text": "the gamma, alpha, mu, delta or epsilon chain",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": -0.307861328125,
            "text": ", mu, delta or epsilon chain",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": -0.307861328125,
            "text": "monoclonal immunoglobulins consisting of only one type of heavy either the gamma, alpha, mu, delta or epsilon chain",
            "probability": 0.0
        }
    ],
    "5e4f0a4f6d0a277941000031_2": [
        {
            "start_logit": 10.7265625,
            "end_logit": 8.3125,
            "text": "alpha",
            "probability": 1.0
        },
        {
            "start_logit": 10.7265625,
            "end_logit": -3.736328125,
            "text": "alpha, mu",
            "probability": 5.900859832763672e-06
        },
        {
            "start_logit": 10.7265625,
            "end_logit": -6.41796875,
            "text": "alpha, mu, delta and epsilon",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -4.515625,
            "end_logit": 8.3125,
            "text": "gamma, alpha",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 10.7265625,
            "end_logit": -7.9140625,
            "text": "alpha, mu, delta",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.7265625,
            "end_logit": -9.609375,
            "text": "alpha, mu, delta and",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": 8.3125,
            "text": "using heavy chain specific gamma, alpha",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": 8.3125,
            "text": "heavy chain specific gamma, alpha",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 8.3125,
            "text": ", alpha",
            "probability": 0.0
        },
        {
            "start_logit": -2.150390625,
            "end_logit": -3.736328125,
            "text": "mu",
            "probability": 0.0
        },
        {
            "start_logit": -4.515625,
            "end_logit": -2.578125,
            "text": "gamma",
            "probability": 0.0
        },
        {
            "start_logit": -4.515625,
            "end_logit": -3.736328125,
            "text": "gamma, alpha, mu",
            "probability": 0.0
        },
        {
            "start_logit": -2.150390625,
            "end_logit": -6.41796875,
            "text": "mu, delta and epsilon",
            "probability": 0.0
        },
        {
            "start_logit": -2.150390625,
            "end_logit": -7.9140625,
            "text": "mu, delta",
            "probability": 0.0
        },
        {
            "start_logit": -4.515625,
            "end_logit": -6.41796875,
            "text": "gamma, alpha, mu, delta and epsilon",
            "probability": 0.0
        },
        {
            "start_logit": -2.150390625,
            "end_logit": -9.609375,
            "text": "mu, delta and",
            "probability": 0.0
        },
        {
            "start_logit": -4.515625,
            "end_logit": -7.9140625,
            "text": "gamma, alpha, mu, delta",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": -2.578125,
            "text": "using heavy chain specific gamma",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": -2.578125,
            "text": "heavy chain specific gamma",
            "probability": 0.0
        },
        {
            "start_logit": -9.7578125,
            "end_logit": -3.736328125,
            "text": ", mu",
            "probability": 0.0
        }
    ],
    "52f88d292059c6d71c000036_1": [
        {
            "start_logit": 13.40625,
            "end_logit": 12.4609375,
            "text": "growth hormone",
            "probability": 1.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -2.849609375,
            "text": "growth hormone deficiency",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 13.40625,
            "end_logit": -4.703125,
            "text": "growth",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.17578125,
            "end_logit": 12.4609375,
            "text": "hormone",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -10.0,
            "text": "growth hormone deficiency and",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -10.046875,
            "text": "growth hormone deficiency and responded well to growth hormone therapy",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -10.140625,
            "text": "growth hormone deficiency and responded well to growth hormone therapy.",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -10.3125,
            "text": "growth hormone deficiency and responded well to growth hormone",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -10.328125,
            "text": "growth hormone deficiency and responded well to",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 12.4609375,
            "text": "found to have classical growth hormone",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 12.4609375,
            "text": "boy with confirmed Williams-Beuren syndrome, who was found to have classical growth hormone",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 12.4609375,
            "text": "Williams-Beuren syndrome, who was found to have classical growth hormone",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 12.4609375,
            "text": "Beuren syndrome, who was found to have classical growth hormone",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 12.4609375,
            "text": "uren syndrome, who was found to have classical growth hormone",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 12.4609375,
            "text": "classical growth hormone",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 12.4609375,
            "text": "ams-Beuren syndrome, who was found to have classical growth hormone",
            "probability": 0.0
        },
        {
            "start_logit": -6.17578125,
            "end_logit": -2.849609375,
            "text": "hormone deficiency",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": -2.849609375,
            "text": "found to have classical growth hormone deficiency",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": -2.849609375,
            "text": "boy with confirmed Williams-Beuren syndrome, who was found to have classical growth hormone deficiency",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": -2.849609375,
            "text": "deficiency",
            "probability": 0.0
        }
    ],
    "52f88d292059c6d71c000036_2": [
        {
            "start_logit": 6.73046875,
            "end_logit": 8.75,
            "text": "elevated TSH",
            "probability": 1.0
        },
        {
            "start_logit": -4.37890625,
            "end_logit": 8.75,
            "text": "TSH",
            "probability": 1.4960765838623047e-05
        },
        {
            "start_logit": -6.89453125,
            "end_logit": 8.75,
            "text": "a population of 95 WS patients, half of them followed for more than 5 years. Our study confirms the increased incidence of both elevated TSH",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 6.73046875,
            "end_logit": -5.69140625,
            "text": "elevated TSH serum values (37",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 6.73046875,
            "end_logit": -6.33984375,
            "text": "elevated TSH serum values (37.9%",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 6.73046875,
            "end_logit": -6.875,
            "text": "elevated TSH serum values (37.9% in our sample)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 6.73046875,
            "end_logit": -6.97265625,
            "text": "elevated TSH serum values",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.73046875,
            "end_logit": -7.21484375,
            "text": "elevated TSH serum values (37.9",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.6171875,
            "end_logit": 8.75,
            "text": "95 WS patients, half of them followed for more than 5 years. Our study confirms the increased incidence of both elevated TSH",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.7734375,
            "end_logit": 8.75,
            "text": "population of 95 WS patients, half of them followed for more than 5 years. Our study confirms the increased incidence of both elevated TSH",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.859375,
            "end_logit": 8.75,
            "text": "WS patients, half of them followed for more than 5 years. Our study confirms the increased incidence of both elevated TSH",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.171875,
            "end_logit": 8.75,
            "text": "of them followed for more than 5 years. Our study confirms the increased incidence of both elevated TSH",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.390625,
            "end_logit": 8.75,
            "text": "increased incidence of both elevated TSH",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.73046875,
            "end_logit": -8.546875,
            "text": "elevated TSH serum values (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.73046875,
            "end_logit": -8.8984375,
            "text": "elevated TSH serum values (37.9% in our sample",
            "probability": 0.0
        },
        {
            "start_logit": 6.73046875,
            "end_logit": -9.5,
            "text": "elevated TSH serum values (37.9% in",
            "probability": 0.0
        },
        {
            "start_logit": 6.73046875,
            "end_logit": -9.8203125,
            "text": "elevated",
            "probability": 0.0
        },
        {
            "start_logit": -4.37890625,
            "end_logit": -5.69140625,
            "text": "TSH serum values (37",
            "probability": 0.0
        },
        {
            "start_logit": -4.37890625,
            "end_logit": -6.33984375,
            "text": "TSH serum values (37.9%",
            "probability": 0.0
        },
        {
            "start_logit": -4.37890625,
            "end_logit": -6.875,
            "text": "TSH serum values (37.9% in our sample)",
            "probability": 0.0
        }
    ],
    "52f88d292059c6d71c000036_3": [
        {
            "start_logit": 10.5546875,
            "end_logit": 10.921875,
            "text": "GHD",
            "probability": 1.0
        },
        {
            "start_logit": 10.5546875,
            "end_logit": -6.05078125,
            "text": "GH",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 10.921875,
            "text": "D",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": 10.921875,
            "text": "infant with confirmed WBS who, through provocative testing, was found to have GHD",
            "probability": 0.0
        },
        {
            "start_logit": -9.390625,
            "end_logit": 10.921875,
            "text": "female infant with confirmed WBS who, through provocative testing, was found to have GHD",
            "probability": 0.0
        },
        {
            "start_logit": -10.03125,
            "end_logit": 10.921875,
            "text": "have GHD",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 10.921875,
            "text": "found to have GHD",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 10.921875,
            "text": "WBS who, through provocative testing, was found to have GHD",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 10.921875,
            "text": "provocative testing, was found to have GHD",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 10.921875,
            "text": "through provocative testing, was found to have GHD",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 10.921875,
            "text": "testing, was found to have GHD",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": -6.05078125,
            "text": "infant with confirmed WBS who, through provocative testing, was found to have GH",
            "probability": 0.0
        },
        {
            "start_logit": -9.390625,
            "end_logit": -6.05078125,
            "text": "female infant with confirmed WBS who, through provocative testing, was found to have GH",
            "probability": 0.0
        },
        {
            "start_logit": -10.03125,
            "end_logit": -6.05078125,
            "text": "have GH",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": -6.05078125,
            "text": "found to have GH",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": -6.05078125,
            "text": "WBS who, through provocative testing, was found to have GH",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": -6.05078125,
            "text": "provocative testing, was found to have GH",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": -6.05078125,
            "text": "through provocative testing, was found to have GH",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": -6.05078125,
            "text": "testing, was found to have GH",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": -8.0703125,
            "text": "infant",
            "probability": 0.0
        }
    ],
    "52f88d292059c6d71c000036_4": [
        {
            "start_logit": 5.81640625,
            "end_logit": 11.578125,
            "text": "cortisol",
            "probability": 1.0
        },
        {
            "start_logit": -7.0859375,
            "end_logit": 11.578125,
            "text": "elevated cortisol",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 11.578125,
            "text": "while participants with WS had elevated cortisol",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -9.828125,
            "end_logit": 11.578125,
            "text": "participants with WS had elevated cortisol",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 11.578125,
            "text": "TD participants had similar profiles in a familiar setting, while participants with WS had elevated cortisol",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.109375,
            "end_logit": 11.578125,
            "text": "WS and TD participants had similar profiles in a familiar setting, while participants with WS had elevated cortisol",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.296875,
            "end_logit": 11.578125,
            "text": "WS had elevated cortisol",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.5,
            "end_logit": 11.578125,
            "text": "participants had similar profiles in a familiar setting, while participants with WS had elevated cortisol",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.53125,
            "end_logit": 11.578125,
            "text": "a familiar setting, while participants with WS had elevated cortisol",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 11.578125,
            "text": "and TD participants had similar profiles in a familiar setting, while participants with WS had elevated cortisol",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.71875,
            "end_logit": 11.578125,
            "text": "with WS had elevated cortisol",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.81640625,
            "end_logit": -8.1015625,
            "text": "cortisol late in the day",
            "probability": 0.0
        },
        {
            "start_logit": 5.81640625,
            "end_logit": -8.859375,
            "text": "cortisol late",
            "probability": 0.0
        },
        {
            "start_logit": 5.81640625,
            "end_logit": -9.046875,
            "text": "cortisol late in the day in the novel setting when social",
            "probability": 0.0
        },
        {
            "start_logit": 5.81640625,
            "end_logit": -9.34375,
            "text": "cortisol late in the day in the novel setting when social demands",
            "probability": 0.0
        },
        {
            "start_logit": 5.81640625,
            "end_logit": -9.3984375,
            "text": "cortisol late in the day in the novel",
            "probability": 0.0
        },
        {
            "start_logit": 5.81640625,
            "end_logit": -9.65625,
            "text": "cortisol late in the day in the novel setting",
            "probability": 0.0
        },
        {
            "start_logit": 5.81640625,
            "end_logit": -9.6796875,
            "text": "cortisol late in",
            "probability": 0.0
        },
        {
            "start_logit": 5.81640625,
            "end_logit": -9.765625,
            "text": "cortisol late in the day in the",
            "probability": 0.0
        },
        {
            "start_logit": 5.81640625,
            "end_logit": -9.796875,
            "text": "cortisol late in the day in the novel setting when social demands were higher",
            "probability": 0.0
        }
    ],
    "531b1e3cb166e2b80600003b_1": [
        {
            "start_logit": 14.4921875,
            "end_logit": 13.1796875,
            "text": "H3K27me3",
            "probability": 1.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -2.669921875,
            "text": "H3K",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.93359375,
            "end_logit": 13.1796875,
            "text": "me3",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -7.55078125,
            "text": "H3K27",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -8.65625,
            "text": "H3K27me3, was not enriched at promoters found previously to be enriched for H3K27me3",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -8.921875,
            "text": "H3K27me3, was not enriched at promoters found previously to be enriched for",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -9.1328125,
            "text": "H3K27me3,",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": 13.1796875,
            "text": "Bmi1), which binds to H3K27me3",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -9.484375,
            "text": "H3K27me3, was not enriched at promoters found previously to be",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -9.6171875,
            "text": "H3K27me3, was not enriched",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -9.6484375,
            "text": "H3K27me3, was",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -9.7265625,
            "text": "H3K27me3, was not enriched at promoters found previously to be enriched",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": 13.1796875,
            "text": "PRC1 complex (Bmi1), which binds to H3K27me3",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": 13.1796875,
            "text": "27me3",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 13.1796875,
            "text": "C1 complex (Bmi1), which binds to H3K27me3",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": -2.669921875,
            "text": "Bmi1), which binds to H3K",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": -2.669921875,
            "text": "PRC1 complex (Bmi1), which binds to H3K",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": -2.669921875,
            "text": "C1 complex (Bmi1), which binds to H3K",
            "probability": 0.0
        },
        {
            "start_logit": -4.93359375,
            "end_logit": -8.65625,
            "text": "me3, was not enriched at promoters found previously to be enriched for H3K27me3",
            "probability": 0.0
        },
        {
            "start_logit": -4.93359375,
            "end_logit": -8.921875,
            "text": "me3, was not enriched at promoters found previously to be enriched for",
            "probability": 0.0
        }
    ],
    "531b1e3cb166e2b80600003b_2": [
        {
            "start_logit": 14.125,
            "end_logit": 13.203125,
            "text": "H3K27me3",
            "probability": 1.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -2.845703125,
            "text": "H3K",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.125,
            "end_logit": -4.05859375,
            "text": "H3K27me3), a modification associated with heterochromatin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.58203125,
            "end_logit": 13.203125,
            "text": "me3",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -6.8125,
            "text": "H3K27",
            "probability": 0.0
        },
        {
            "start_logit": -6.21484375,
            "end_logit": 13.203125,
            "text": "trimethylation of the lysine 27 residue of histone H3 (H3K27me3",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -8.4921875,
            "text": "H3K27me3),",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -8.578125,
            "text": "H3K27me3), a",
            "probability": 0.0
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 13.203125,
            "text": "H3, with later recruitment of Polycomb repressor complex 2 (PRC2) and trimethylation of the lysine 27 residue of histone H3 (H3K27me3",
            "probability": 0.0
        },
        {
            "start_logit": -8.453125,
            "end_logit": 13.203125,
            "text": "H3 (H3K27me3",
            "probability": 0.0
        },
        {
            "start_logit": -9.1875,
            "end_logit": 13.203125,
            "text": "lysine 27 residue of histone H3 (H3K27me3",
            "probability": 0.0
        },
        {
            "start_logit": -9.671875,
            "end_logit": 13.203125,
            "text": "histone H3 (H3K27me3",
            "probability": 0.0
        },
        {
            "start_logit": -9.703125,
            "end_logit": 13.203125,
            "text": "Polycomb repressor complex 2 (PRC2) and trimethylation of the lysine 27 residue of histone H3 (H3K27me3",
            "probability": 0.0
        },
        {
            "start_logit": -9.78125,
            "end_logit": 13.203125,
            "text": "PRC2) and trimethylation of the lysine 27 residue of histone H3 (H3K27me3",
            "probability": 0.0
        },
        {
            "start_logit": -4.58203125,
            "end_logit": -4.05859375,
            "text": "me3), a modification associated with heterochromatin",
            "probability": 0.0
        },
        {
            "start_logit": -6.21484375,
            "end_logit": -2.845703125,
            "text": "trimethylation of the lysine 27 residue of histone H3 (H3K",
            "probability": 0.0
        },
        {
            "start_logit": -6.21484375,
            "end_logit": -4.05859375,
            "text": "trimethylation of the lysine 27 residue of histone H3 (H3K27me3), a modification associated with heterochromatin",
            "probability": 0.0
        },
        {
            "start_logit": -7.8828125,
            "end_logit": -2.845703125,
            "text": "H3, with later recruitment of Polycomb repressor complex 2 (PRC2) and trimethylation of the lysine 27 residue of histone H3 (H3K",
            "probability": 0.0
        },
        {
            "start_logit": -5.31640625,
            "end_logit": -5.6875,
            "text": "HSV DNA",
            "probability": 0.0
        },
        {
            "start_logit": -5.31640625,
            "end_logit": -5.765625,
            "text": "HSV DNA first associates with histone H3, with later recruitment of Polycomb repressor complex 2 (PRC2) and trimethylation of the lysine 27",
            "probability": 0.0
        }
    ],
    "531b1e3cb166e2b80600003b_3": [
        {
            "start_logit": 14.1328125,
            "end_logit": 11.96875,
            "text": "H3K36me",
            "probability": 1.0
        },
        {
            "start_logit": 14.1328125,
            "end_logit": -2.0546875,
            "text": "H3K36me), a mark associated with activation, by the PRC2 subunit Phf19",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 14.1328125,
            "end_logit": -2.59765625,
            "text": "H3K",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 14.1328125,
            "end_logit": -6.4296875,
            "text": "H3K36",
            "probability": 0.0
        },
        {
            "start_logit": -5.80859375,
            "end_logit": 11.96875,
            "text": "me",
            "probability": 0.0
        },
        {
            "start_logit": -5.8359375,
            "end_logit": 11.96875,
            "text": "H3 Lys36 (H3K36me",
            "probability": 0.0
        },
        {
            "start_logit": 14.1328125,
            "end_logit": -8.390625,
            "text": "H3K36me)",
            "probability": 0.0
        },
        {
            "start_logit": 14.1328125,
            "end_logit": -8.453125,
            "text": "H3K36me), a mark associated with activation, by the PRC2 subunit Phf19 is required",
            "probability": 0.0
        },
        {
            "start_logit": 14.1328125,
            "end_logit": -9.0546875,
            "text": "H3K36me), a mark associated with activation, by the PRC2 subunit Phf19 is",
            "probability": 0.0
        },
        {
            "start_logit": 14.1328125,
            "end_logit": -9.484375,
            "text": "H3K36me), a",
            "probability": 0.0
        },
        {
            "start_logit": 14.1328125,
            "end_logit": -9.515625,
            "text": "H3K36me), a mark associated with activation,",
            "probability": 0.0
        },
        {
            "start_logit": 14.1328125,
            "end_logit": -9.5234375,
            "text": "H3K36me), a mark associated with activation, by",
            "probability": 0.0
        },
        {
            "start_logit": 14.1328125,
            "end_logit": -9.5546875,
            "text": "H3K36me),",
            "probability": 0.0
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 11.96875,
            "text": "Lys36 (H3K36me",
            "probability": 0.0
        },
        {
            "start_logit": -9.5,
            "end_logit": 11.96875,
            "text": "methylated histone H3 Lys36 (H3K36me",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": 11.96875,
            "text": "(H3K36me",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 11.96875,
            "text": "36 (H3K36me",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 11.96875,
            "text": "histone H3 Lys36 (H3K36me",
            "probability": 0.0
        },
        {
            "start_logit": -5.0859375,
            "end_logit": -2.0546875,
            "text": "Phf19",
            "probability": 0.0
        },
        {
            "start_logit": -5.80859375,
            "end_logit": -2.0546875,
            "text": "me), a mark associated with activation, by the PRC2 subunit Phf19",
            "probability": 0.0
        }
    ],
    "531b1e3cb166e2b80600003b_4": [
        {
            "start_logit": 13.3515625,
            "end_logit": 11.53125,
            "text": "H3K27me3",
            "probability": 1.0
        },
        {
            "start_logit": 13.3515625,
            "end_logit": -3.44140625,
            "text": "H3K",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 13.3515625,
            "end_logit": -5.26953125,
            "text": "H3K27",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.3515625,
            "end_logit": -6.234375,
            "text": "H3K27me3 deposition",
            "probability": 0.0
        },
        {
            "start_logit": -6.3203125,
            "end_logit": 11.53125,
            "text": "me3",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 11.53125,
            "text": "Phf19 binds to a subset of PRC2 targets in mouse embryonic stem cells and that this is required for their repression and for H3K27me3",
            "probability": 0.0
        },
        {
            "start_logit": -10.03125,
            "end_logit": 11.53125,
            "text": "PRC2 targets in mouse embryonic stem cells and that this is required for their repression and for H3K27me3",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 11.53125,
            "text": "embryonic stem cells and that this is required for their repression and for H3K27me3",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 11.53125,
            "text": "27me3",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 11.53125,
            "text": "their repression and for H3K27me3",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 11.53125,
            "text": "that this is required for their repression and for H3K27me3",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 11.53125,
            "text": "mouse embryonic stem cells and that this is required for their repression and for H3K27me3",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -3.44140625,
            "text": "Phf19 binds to a subset of PRC2 targets in mouse embryonic stem cells and that this is required for their repression and for H3K",
            "probability": 0.0
        },
        {
            "start_logit": -6.3203125,
            "end_logit": -6.234375,
            "text": "me3 deposition",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -4.984375,
            "text": "Phf19",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -5.26953125,
            "text": "Phf19 binds to a subset of PRC2 targets in mouse embryonic stem cells and that this is required for their repression and for H3K27",
            "probability": 0.0
        },
        {
            "start_logit": -10.03125,
            "end_logit": -3.44140625,
            "text": "PRC2 targets in mouse embryonic stem cells and that this is required for their repression and for H3K",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": -3.44140625,
            "text": "embryonic stem cells and that this is required for their repression and for H3K",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": -3.44140625,
            "text": "their repression and for H3K",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": -3.44140625,
            "text": "that this is required for their repression and for H3K",
            "probability": 0.0
        }
    ],
    "531b1e3cb166e2b80600003b_5": [
        {
            "start_logit": 11.3671875,
            "end_logit": 10.59375,
            "text": "K27me3",
            "probability": 1.0
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -3.294921875,
            "text": "K2",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -3.990234375,
            "text": "K27me3; rather, some display affinity towards both histone H3",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -4.19921875,
            "text": "K27me3; rather, some display affinity towards both histone H3 trimethylated at K9 and H3K27me3",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -5.0546875,
            "text": "K27me3; rather, some display affinity towards both histone H3 trimethylated at K9",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -6.2734375,
            "text": "K27",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.109375,
            "end_logit": 10.59375,
            "text": "me3",
            "probability": 0.0
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -7.640625,
            "text": "K27me3; rather, some display affinity towards both histone H3 trimethyl",
            "probability": 0.0
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -7.80859375,
            "text": "K27me3; rather, some display affinity towards both histone H3 trimethylated at K9 and",
            "probability": 0.0
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -8.2421875,
            "text": "K27me3; rather, some display affinity towards both histone H3 trimethylated at K9 and H3K27me3, and one CD prefer",
            "probability": 0.0
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -8.3359375,
            "text": "K27me3; rather, some display affinity towards both histone",
            "probability": 0.0
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -8.46875,
            "text": "K27me3; rather, some display affinity towards both histone H3 trimethylated at K9 and H3K",
            "probability": 0.0
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -9.03125,
            "text": "K27me3; rather, some display affinity towards both histone H3 trimethylated",
            "probability": 0.0
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -9.0859375,
            "text": "K27me3; rather, some display affinity towards both histone H3 trimethylated at K9 and H3K27",
            "probability": 0.0
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -9.1484375,
            "text": "K27me3; rather, some display affinity towards both histone H3 trimethylated at K",
            "probability": 0.0
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -9.21875,
            "text": "K27me3; rather, some display affinity towards both histone H3 trimethylated at K9 and H3K27me3,",
            "probability": 0.0
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -9.640625,
            "text": "K27me3; rather",
            "probability": 0.0
        },
        {
            "start_logit": -9.5546875,
            "end_logit": 10.59375,
            "text": "7me3",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": 10.59375,
            "text": "Not all CDs bind preferentially to K27me3",
            "probability": 0.0
        },
        {
            "start_logit": -5.33203125,
            "end_logit": -4.19921875,
            "text": "H3K27me3",
            "probability": 0.0
        }
    ],
    "61f7d535882a024a10000034_1": [
        {
            "start_logit": 11.453125,
            "end_logit": 11.859375,
            "text": "KIT",
            "probability": 1.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -5.44921875,
            "text": "KIT/PDGFRA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.453125,
            "end_logit": -7.1640625,
            "text": "KIT/PDGF",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -8.765625,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842V",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -8.953125,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842V genotype",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -9.140625,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842V genotype. To date, only a minority of PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -9.15625,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -9.3203125,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -9.328125,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842V genotype. To date,",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -9.421875,
            "text": "KIT/",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -9.453125,
            "text": "KIT/PDGFRA inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -9.46875,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842V genotype.",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -9.4921875,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in patients with the",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -9.6015625,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842V genotype. To date, only a minority",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -9.6015625,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842V genotype. To date, only a minority of PDGF",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 11.859375,
            "text": "Avapritinib is a novel, potent KIT",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 11.859375,
            "text": "potent KIT",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -5.44921875,
            "text": "PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -7.1640625,
            "text": "PDGF",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": -5.44921875,
            "text": "RA",
            "probability": 0.0
        }
    ],
    "61f7d535882a024a10000034_2": [
        {
            "start_logit": 11.1953125,
            "end_logit": 12.125,
            "text": "KIT",
            "probability": 1.0
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -5.3828125,
            "text": "KIT and PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -6.58203125,
            "text": "KIT and PDGFRA, in patients with unresectable or metastatic GIST",
            "probability": 0.0
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -7.15234375,
            "text": "KIT and PDGFRA,",
            "probability": 0.0
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -7.51953125,
            "text": "KIT and PDGF",
            "probability": 0.0
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -8.53125,
            "text": "KIT and",
            "probability": 0.0
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -8.9921875,
            "text": "KIT and PDGFRA, in patients with unresectable or metastatic GIST.",
            "probability": 0.0
        },
        {
            "start_logit": 11.1953125,
            "end_logit": -9.3359375,
            "text": "KIT and PDGFRA, in patients with unresectable or metastatic",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 12.125,
            "text": "antineoplastic activity of avapritinib, a selective, potent inhibitor of KIT",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 12.125,
            "text": "safety and antineoplastic activity of avapritinib, a selective, potent inhibitor of KIT",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 12.125,
            "text": "single-arm, dose escalation and expansion study designed to evaluate safety and antineoplastic activity of avapritinib, a selective, potent inhibitor of KIT",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 12.125,
            "text": "avapritinib, a selective, potent inhibitor of KIT",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 12.125,
            "text": "inhibitor of KIT",
            "probability": 0.0
        },
        {
            "start_logit": -7.15234375,
            "end_logit": -5.3828125,
            "text": "PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -7.15234375,
            "end_logit": -6.58203125,
            "text": "PDGFRA, in patients with unresectable or metastatic GIST",
            "probability": 0.0
        },
        {
            "start_logit": -7.15234375,
            "end_logit": -7.15234375,
            "text": "PDGFRA,",
            "probability": 0.0
        },
        {
            "start_logit": -7.15234375,
            "end_logit": -7.51953125,
            "text": "PDGF",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": -6.58203125,
            "text": "GIST",
            "probability": 0.0
        },
        {
            "start_logit": -9.7265625,
            "end_logit": -5.3828125,
            "text": "RA",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": -5.3828125,
            "text": "antineoplastic activity of avapritinib, a selective, potent inhibitor of KIT and PDGFRA",
            "probability": 0.0
        }
    ],
    "61f7d535882a024a10000034_3": [
        {
            "start_logit": 13.7265625,
            "end_logit": 13.3984375,
            "text": "PDGFRA",
            "probability": 1.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -4.13671875,
            "text": "PDGF",
            "probability": 0.0
        },
        {
            "start_logit": -4.91015625,
            "end_logit": 13.3984375,
            "text": "RA",
            "probability": 0.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -6.85546875,
            "text": "PDGFRA D842V-mutant GIST",
            "probability": 0.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -9.0546875,
            "text": "PDGFRA D842V-mutant GIST with avapritinib resulted in an unprecedented, durable clinical benefit, with a manageable safety profile",
            "probability": 0.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -9.078125,
            "text": "PDGFRA D842V",
            "probability": 0.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -9.0859375,
            "text": "PDGFRA D842",
            "probability": 0.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -9.1171875,
            "text": "PDGFRA D",
            "probability": 0.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -9.171875,
            "text": "PDGFRA D842V-mutant GIST with avapritinib resulted in an unprecedented, durable clinical benefit,",
            "probability": 0.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -9.171875,
            "text": "PDGFRA D842V-",
            "probability": 0.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -9.203125,
            "text": "PDGFRA D842V-mutant",
            "probability": 0.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -9.2890625,
            "text": "PDGFRA D842V-mutant GIST with avapritinib resulted in an unprecedented, durable clinical benefit",
            "probability": 0.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -9.34375,
            "text": "PDGFRA D842V-mutant GIST with avapritinib resulted in an unprecedented, durable clinical benefit, with a",
            "probability": 0.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -9.7734375,
            "text": "PDGFRA D842V-mutant GIST with avapritinib resulted in an unprecedented, durable clinical benefit, with a manageable safety",
            "probability": 0.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -9.90625,
            "text": "PDGFRA D842V-mutant GIST with avapritinib resulted in an unprecedented, durable clinical benefit, with a manageable safety profile.",
            "probability": 0.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -9.921875,
            "text": "PDGFRA D842V-mutant GIST with avapritinib",
            "probability": 0.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -9.9375,
            "text": "PDGFRA D84",
            "probability": 0.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -9.984375,
            "text": "PDGFRA D842V-mutant GIST with avapritinib resulted in an",
            "probability": 0.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -10.078125,
            "text": "PDGFRA D842V-mutant GIST with",
            "probability": 0.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -10.1328125,
            "text": "PDGFRA D842V-mutant GIST with avapritinib resulted",
            "probability": 0.0
        }
    ],
    "61f7d535882a024a10000034_4": [
        {
            "start_logit": 11.1796875,
            "end_logit": 12.0859375,
            "text": "KIT",
            "probability": 1.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -6.65234375,
            "text": "KIT/PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -7.5625,
            "text": "KIT/PDGF",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -8.7578125,
            "text": "KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -9.0,
            "text": "KIT/",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -9.0859375,
            "text": "KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA exon 18",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -9.15625,
            "text": "KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA exon 18-mutant",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 12.0859375,
            "text": ": Avapritinib, a novel inhibitor of KIT",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -9.296875,
            "text": "KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGF",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -9.359375,
            "text": "KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA exon 18-mutant unresectable or metastatic",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -9.4921875,
            "text": "KIT/PDGFRA,",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -9.8359375,
            "text": "KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA exon 18-",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -9.9296875,
            "text": "KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA exon 18-mutant unresectable or metastatic gastrointestinal stromal",
            "probability": 0.0
        },
        {
            "start_logit": -8.8203125,
            "end_logit": -6.65234375,
            "text": "PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -8.8203125,
            "end_logit": -7.5625,
            "text": "PDGF",
            "probability": 0.0
        },
        {
            "start_logit": -10.0859375,
            "end_logit": -6.65234375,
            "text": "RA",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": -6.65234375,
            "text": ": Avapritinib, a novel inhibitor of KIT/PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -8.8046875,
            "end_logit": -8.6328125,
            "text": "PDGFRA exon 18-mutant unresectable or metastatic gastrointestinal stromal tumors (U/M GISTs)",
            "probability": 0.0
        },
        {
            "start_logit": -8.8046875,
            "end_logit": -8.7578125,
            "text": "PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -8.8203125,
            "end_logit": -8.7578125,
            "text": "PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA",
            "probability": 0.0
        }
    ],
    "61f7d535882a024a10000034_5": [
        {
            "start_logit": 11.0078125,
            "end_logit": 11.796875,
            "text": "KIT",
            "probability": 1.0
        },
        {
            "start_logit": 0.382568359375,
            "end_logit": 11.796875,
            "text": "platelet-derived growth factor receptor alpha (PDGFRA) and KIT",
            "probability": 2.4139881134033203e-05
        },
        {
            "start_logit": -7.32421875,
            "end_logit": 11.796875,
            "text": "PDGFRA) and KIT",
            "probability": 0.0
        },
        {
            "start_logit": 11.0078125,
            "end_logit": -8.078125,
            "text": "KIT activation loop mutants",
            "probability": 0.0
        },
        {
            "start_logit": 11.0078125,
            "end_logit": -8.9375,
            "text": "KIT activation loop",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": 11.796875,
            "text": "and KIT",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 11.796875,
            "text": "receptor alpha (PDGFRA) and KIT",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 11.796875,
            "text": "RA) and KIT",
            "probability": 0.0
        },
        {
            "start_logit": -10.328125,
            "end_logit": 11.796875,
            "text": "alpha (PDGFRA) and KIT",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 11.796875,
            "text": "of platelet-derived growth factor receptor alpha (PDGFRA) and KIT",
            "probability": 0.0
        },
        {
            "start_logit": 11.0078125,
            "end_logit": -9.7421875,
            "text": "KIT activation loop mutants.",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 11.796875,
            "text": "(PDGFRA) and KIT",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 11.796875,
            "text": "tyrosine kinase inhibitor of platelet-derived growth factor receptor alpha (PDGFRA) and KIT",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 11.796875,
            "text": "AYVAKIT\u2122) is a potent and selective tyrosine kinase inhibitor of platelet-derived growth factor receptor alpha (PDGFRA) and KIT",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 11.796875,
            "text": "VAKIT\u2122) is a potent and selective tyrosine kinase inhibitor of platelet-derived growth factor receptor alpha (PDGFRA) and KIT",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 11.796875,
            "text": "growth factor receptor alpha (PDGFRA) and KIT",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 11.796875,
            "text": "KIT\u2122) is a potent and selective tyrosine kinase inhibitor of platelet-derived growth factor receptor alpha (PDGFRA) and KIT",
            "probability": 0.0
        },
        {
            "start_logit": 0.382568359375,
            "end_logit": -3.228515625,
            "text": "platelet-derived growth factor receptor alpha (PDGFRA)",
            "probability": 0.0
        },
        {
            "start_logit": 0.382568359375,
            "end_logit": -4.20703125,
            "text": "platelet-derived growth factor receptor alpha (PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": 0.382568359375,
            "end_logit": -5.96875,
            "text": "platelet-derived growth factor receptor alpha (PDGF",
            "probability": 0.0
        }
    ],
    "61f7d535882a024a10000034_6": [
        {
            "start_logit": 11.265625,
            "end_logit": 12.0390625,
            "text": "KIT",
            "probability": 1.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -6.88671875,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -7.3203125,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA)",
            "probability": 0.0
        },
        {
            "start_logit": -8.7890625,
            "end_logit": 12.0390625,
            "text": "oncogenic KIT",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -8.046875,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA) mutants",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -8.0859375,
            "text": "KIT and platelet",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -8.453125,
            "text": "KIT and platelet-derived growth factor receptor",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -8.71875,
            "text": "KIT and platelet-derived growth factor receptor alpha",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -8.765625,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA) mutants by targeting the active conformation of the kinase",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -8.8359375,
            "text": "KIT and platelet-derived growth factor",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -8.8671875,
            "text": "KIT and platelet-derived growth factor receptor alpha (",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -8.875,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGF",
            "probability": 0.0
        },
        {
            "start_logit": -9.796875,
            "end_logit": 12.0390625,
            "text": "inhibit oncogenic KIT",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -9.1484375,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA) mutants by targeting the active conformation of the",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -9.171875,
            "text": "KIT and platelet-",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -9.578125,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA) mutants by targeting the active conformation of the kinase.",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -9.640625,
            "text": "KIT and platelet-derived",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -9.6484375,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA) mutants by targeting the active conformation of",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -9.75,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA) mutants by targeting the",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 12.0390625,
            "text": "protein kinase inhibitor designed to selectively inhibit oncogenic KIT",
            "probability": 0.0
        }
    ],
    "61f7d535882a024a10000034_7": [
        {
            "start_logit": 10.7734375,
            "end_logit": 12.3046875,
            "text": "KIT",
            "probability": 1.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": 12.3046875,
            "text": "D816V mutant KIT",
            "probability": 0.0
        },
        {
            "start_logit": -9.109375,
            "end_logit": 12.3046875,
            "text": "BLU-285), which targets D816V mutant KIT",
            "probability": 0.0
        },
        {
            "start_logit": 10.7734375,
            "end_logit": -7.60546875,
            "text": "KIT, for the treatment of advanced systemic mastocytosis",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": 12.3046875,
            "text": "mutant KIT",
            "probability": 0.0
        },
        {
            "start_logit": 10.7734375,
            "end_logit": -8.3046875,
            "text": "KIT,",
            "probability": 0.0
        },
        {
            "start_logit": 10.7734375,
            "end_logit": -8.3125,
            "text": "KIT, for the treatment of advanced systemic mast",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 12.3046875,
            "text": "targets D816V mutant KIT",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": 12.3046875,
            "text": "V mutant KIT",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 12.3046875,
            "text": "avapritinib (formerly BLU-285), which targets D816V mutant KIT",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 12.3046875,
            "text": "phase I trial of avapritinib (formerly BLU-285), which targets D816V mutant KIT",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 12.3046875,
            "text": "816V mutant KIT",
            "probability": 0.0
        },
        {
            "start_logit": 10.7734375,
            "end_logit": -9.2421875,
            "text": "KIT, for the treatment of advanced systemic mastocytosis, patients experienced rapid and durable disease control",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 12.3046875,
            "text": "apritinib (formerly BLU-285), which targets D816V mutant KIT",
            "probability": 0.0
        },
        {
            "start_logit": 10.7734375,
            "end_logit": -9.6875,
            "text": "KIT, for the treatment of advanced systemic mastocytosis,",
            "probability": 0.0
        },
        {
            "start_logit": 10.7734375,
            "end_logit": -9.8671875,
            "text": "KIT, for",
            "probability": 0.0
        },
        {
            "start_logit": -8.8046875,
            "end_logit": -7.60546875,
            "text": "mastocytosis",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": -7.60546875,
            "text": "D816V mutant KIT, for the treatment of advanced systemic mastocytosis",
            "probability": 0.0
        },
        {
            "start_logit": -9.109375,
            "end_logit": -7.60546875,
            "text": "BLU-285), which targets D816V mutant KIT, for the treatment of advanced systemic mastocytosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.8046875,
            "end_logit": -8.3125,
            "text": "mast",
            "probability": 0.0
        }
    ],
    "61f7d535882a024a10000034_8": [
        {
            "start_logit": 11.2734375,
            "end_logit": 12.046875,
            "text": "KIT",
            "probability": 1.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -5.4765625,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -5.95703125,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA), attenuates the transport function of both ABCB1 and ABCG2",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -6.35546875,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA), attenuates the transport function of both ABCB1",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -6.578125,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA)",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -7.23046875,
            "text": "KIT and platelet",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -7.609375,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGF",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -7.90234375,
            "text": "KIT and platelet-derived growth factor receptor alpha (",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -7.921875,
            "text": "KIT and platelet-derived growth factor receptor",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -8.2578125,
            "text": "KIT and platelet-derived growth factor",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -8.734375,
            "text": "KIT and platelet-derived growth factor receptor alpha",
            "probability": 0.0
        },
        {
            "start_logit": -9.5078125,
            "end_logit": 12.046875,
            "text": "mutant forms of KIT",
            "probability": 0.0
        },
        {
            "start_logit": -9.671875,
            "end_logit": 12.046875,
            "text": "against mutant forms of KIT",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -9.0078125,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA), attenuates the transport function of both ABCB1 and ABC",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -9.0546875,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA), attenuates the transport function of both ABC",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -9.1875,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA),",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -9.2421875,
            "text": "KIT and platelet-derived",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -9.40625,
            "text": "KIT and platelet-derived growth",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": 12.046875,
            "text": "tyrosine kinase inhibitor against mutant forms of KIT",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 12.046875,
            "text": "forms of KIT",
            "probability": 0.0
        }
    ],
    "61f7d535882a024a10000034_9": [
        {
            "start_logit": 12.640625,
            "end_logit": 11.6328125,
            "text": "PDGFRA",
            "probability": 1.0
        },
        {
            "start_logit": 12.640625,
            "end_logit": -4.3515625,
            "text": "PDGFRA exon 18",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.640625,
            "end_logit": -5.2109375,
            "text": "PDGF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.640625,
            "end_logit": -5.296875,
            "text": "PDGFRA exon 18 (including D842V) mutant GIST",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.640625,
            "end_logit": -6.3359375,
            "text": "PDGFRA exon 18 (including D842V)",
            "probability": 0.0
        },
        {
            "start_logit": 12.640625,
            "end_logit": -7.75,
            "text": "PDGFRA exon 18 (including D842V",
            "probability": 0.0
        },
        {
            "start_logit": 12.640625,
            "end_logit": -7.80859375,
            "text": "PDGFRA exon 18 (including D842V) mutant GIST and is undergoing regulatory assessment in the USA as a 4th-line treatment for GIST",
            "probability": 0.0
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 11.6328125,
            "text": "RA",
            "probability": 0.0
        },
        {
            "start_logit": 12.640625,
            "end_logit": -7.98046875,
            "text": "PDGFRA exon 18 (including D842V) mutant",
            "probability": 0.0
        },
        {
            "start_logit": 12.640625,
            "end_logit": -8.3828125,
            "text": "PDGFRA exon",
            "probability": 0.0
        },
        {
            "start_logit": 12.640625,
            "end_logit": -8.4765625,
            "text": "PDGFRA exon 18 (including D",
            "probability": 0.0
        },
        {
            "start_logit": 12.640625,
            "end_logit": -8.8046875,
            "text": "PDGFRA exon 18 (including D842V) mutant GIST and is undergoing regulatory assessment in the USA as a",
            "probability": 0.0
        },
        {
            "start_logit": 12.640625,
            "end_logit": -8.8671875,
            "text": "PDGFRA exon 18 (",
            "probability": 0.0
        },
        {
            "start_logit": 12.640625,
            "end_logit": -9.0625,
            "text": "PDGFRA exon 18 (including D842",
            "probability": 0.0
        },
        {
            "start_logit": 12.640625,
            "end_logit": -9.5546875,
            "text": "PDGFRA exon 18 (including D84",
            "probability": 0.0
        },
        {
            "start_logit": 12.640625,
            "end_logit": -9.609375,
            "text": "PDGFRA exon 18 (including D842V) mutant GIST and",
            "probability": 0.0
        },
        {
            "start_logit": 12.640625,
            "end_logit": -9.7890625,
            "text": "PDGFRA exon 18 (including D842V) mutant GIST and is undergoing regulatory assessment in the USA as a 4th-",
            "probability": 0.0
        },
        {
            "start_logit": 12.640625,
            "end_logit": -9.7890625,
            "text": "PDGFRA exon 18 (including",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 11.6328125,
            "text": "Avapritinib is approved in the USA for PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 11.6328125,
            "text": "for PDGFRA",
            "probability": 0.0
        }
    ],
    "61f7d535882a024a10000034_10": [
        {
            "start_logit": 7.671875,
            "end_logit": 8.6953125,
            "text": "platelet-derived growth factor receptor alpha (PDGFRA",
            "probability": 0.87744140625
        },
        {
            "start_logit": 5.6796875,
            "end_logit": 8.6953125,
            "text": "PDGFRA",
            "probability": 0.1187744140625
        },
        {
            "start_logit": 7.671875,
            "end_logit": 3.068359375,
            "text": "platelet-derived growth factor receptor alpha (PDGFRA)",
            "probability": 0.003139495849609375
        },
        {
            "start_logit": 5.6796875,
            "end_logit": 3.068359375,
            "text": "PDGFRA)",
            "probability": 0.00042819976806640625
        },
        {
            "start_logit": 7.671875,
            "end_logit": 0.192626953125,
            "text": "platelet-derived growth factor receptor alpha (PDGFRA) exon 18",
            "probability": 0.00017571449279785156
        },
        {
            "start_logit": 7.671875,
            "end_logit": -0.1749267578125,
            "text": "platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation",
            "probability": 0.0001226663589477539
        },
        {
            "start_logit": 5.6796875,
            "end_logit": 0.192626953125,
            "text": "PDGFRA) exon 18",
            "probability": 2.4139881134033203e-05
        },
        {
            "start_logit": 5.6796875,
            "end_logit": -0.1749267578125,
            "text": "PDGFRA) exon 18 mutation",
            "probability": 1.6629695892333984e-05
        },
        {
            "start_logit": -4.4296875,
            "end_logit": 8.6953125,
            "text": "gastrointestinal stromal tumors harboring a platelet-derived growth factor receptor alpha (PDGFRA",
            "probability": 4.827976226806641e-06
        },
        {
            "start_logit": 7.671875,
            "end_logit": -5.55078125,
            "text": "platelet",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.671875,
            "end_logit": -5.9296875,
            "text": "platelet-derived growth factor receptor alpha (PDGF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.9609375,
            "end_logit": 8.6953125,
            "text": "(PDGFRA",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.671875,
            "end_logit": -6.09765625,
            "text": "platelet-derived growth factor receptor alpha",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.671875,
            "end_logit": -6.46875,
            "text": "platelet-derived growth factor",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.671875,
            "end_logit": -6.83203125,
            "text": "platelet-derived growth factor receptor",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.09375,
            "end_logit": 8.6953125,
            "text": "RA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.671875,
            "end_logit": -7.5703125,
            "text": "platelet-derived growth factor receptor alpha (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.671875,
            "end_logit": -7.875,
            "text": "platelet-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.6796875,
            "end_logit": -5.9296875,
            "text": "PDGF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.671875,
            "end_logit": -8.1953125,
            "text": "platelet-derived growth",
            "probability": 5.960464477539063e-08
        }
    ],
    "61f7d535882a024a10000034_11": [
        {
            "start_logit": 11.3671875,
            "end_logit": 11.9921875,
            "text": "KIT",
            "probability": 1.0
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -7.84375,
            "text": "KIT and PDGFR\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -8.1328125,
            "text": "KIT and PDGFR\u03b1 that Reverses ABCB1 and ABCG2",
            "probability": 0.0
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -8.1640625,
            "text": "KIT and PDGF",
            "probability": 0.0
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -8.5078125,
            "text": "KIT and PDGFR",
            "probability": 0.0
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -8.703125,
            "text": "KIT and",
            "probability": 0.0
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -9.0546875,
            "text": "KIT and PDGFR\u03b1 that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance",
            "probability": 0.0
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -9.15625,
            "text": "KIT and PDGFR\u03b1 that Reverses ABCB1",
            "probability": 0.0
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -9.7265625,
            "text": "KIT and PDGFR\u03b1 that Reverses ABCB1 and ABCG2-",
            "probability": 0.0
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -9.7578125,
            "text": "KIT and PDGFR\u03b1 that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines.",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 11.9921875,
            "text": "Avapritinib: A Selective Inhibitor of KIT",
            "probability": 0.0
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -9.953125,
            "text": "KIT and PDGFR\u03b1 that Reverses ABCB1 and ABC",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 11.9921875,
            "text": "Inhibitor of KIT",
            "probability": 0.0
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -10.140625,
            "text": "KIT and PDGFR\u03b1 that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell",
            "probability": 0.0
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -10.140625,
            "text": "KIT and PDGFR\u03b1 that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines",
            "probability": 0.0
        },
        {
            "start_logit": -7.3828125,
            "end_logit": -7.84375,
            "text": "PDGFR\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -7.3828125,
            "end_logit": -8.1328125,
            "text": "PDGFR\u03b1 that Reverses ABCB1 and ABCG2",
            "probability": 0.0
        },
        {
            "start_logit": -7.3828125,
            "end_logit": -8.1640625,
            "text": "PDGF",
            "probability": 0.0
        },
        {
            "start_logit": -7.3828125,
            "end_logit": -8.5078125,
            "text": "PDGFR",
            "probability": 0.0
        },
        {
            "start_logit": -7.3828125,
            "end_logit": -9.0546875,
            "text": "PDGFR\u03b1 that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance",
            "probability": 0.0
        }
    ],
    "61f7d535882a024a10000034_12": [
        {
            "start_logit": 13.96875,
            "end_logit": 13.8359375,
            "text": "PDGFRA",
            "probability": 1.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -3.705078125,
            "text": "PDGF",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -3.97265625,
            "text": "PDGFRA exon 18 mutation including D842V mutations) and ripretinib (a broad-spectrum kinase inhibitor of c-Kit",
            "probability": 0.0
        },
        {
            "start_logit": -4.21484375,
            "end_logit": 13.8359375,
            "text": "RA",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -8.1171875,
            "text": "PDGFRA exon 18 mutation including D842V mutations) and ripretinib (a broad-spectrum kinase inhibitor of c",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -8.203125,
            "text": "PDGFRA exon 18",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -8.34375,
            "text": "PDGFRA exon 18 mutation including D842V mutations) and ripretinib",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -8.3984375,
            "text": "PDGFRA exon 18 mutation",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -8.5625,
            "text": "PDGFRA exon 18 mutation including D842V mutations) and ripretinib (a broad-spectrum kinase inhibitor of c-Kit and PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -8.5234375,
            "end_logit": 13.8359375,
            "text": "GIST including avapritinib (a selective inhibitor for PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -8.875,
            "text": "PDGFRA exon 18 mutation including D842V mutations)",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -9.390625,
            "text": "PDGFRA exon 18 mutation including D842V",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -9.40625,
            "text": "PDGFRA exon 18 mutation including D842V mutations) and ripretinib (a broad-spectrum kinase inhibitor of c-",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -9.578125,
            "text": "PDGFRA exon 18 mutation including D842V mutations",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -9.59375,
            "text": "PDGFRA exon",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -9.6171875,
            "text": "PDGFRA exon 18 mutation including D842V mutations) and ripretinib (a broad-spectrum kinase inhibitor of c-Kit and PDGF",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": 13.8359375,
            "text": "FDA) approved two new tyrosine kinase inhibitors for the treatment of heavily pretreated advanced/unresectable GIST including avapritinib (a selective inhibitor for PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -4.21484375,
            "end_logit": -3.97265625,
            "text": "RA exon 18 mutation including D842V mutations) and ripretinib (a broad-spectrum kinase inhibitor of c-Kit",
            "probability": 0.0
        },
        {
            "start_logit": -6.90625,
            "end_logit": -3.97265625,
            "text": "c-Kit",
            "probability": 0.0
        },
        {
            "start_logit": -8.5234375,
            "end_logit": -3.705078125,
            "text": "GIST including avapritinib (a selective inhibitor for PDGF",
            "probability": 0.0
        }
    ],
    "61f7d535882a024a10000034_13": [
        {
            "start_logit": 10.6640625,
            "end_logit": 12.359375,
            "text": "KIT",
            "probability": 1.0
        },
        {
            "start_logit": -8.9296875,
            "end_logit": 12.359375,
            "text": "D816V mutant KIT",
            "probability": 0.0
        },
        {
            "start_logit": 10.6640625,
            "end_logit": -7.5390625,
            "text": "KIT, for the treatment of advanced systemic mastocytosis",
            "probability": 0.0
        },
        {
            "start_logit": -9.546875,
            "end_logit": 12.359375,
            "text": "mutant KIT",
            "probability": 0.0
        },
        {
            "start_logit": -9.5546875,
            "end_logit": 12.359375,
            "text": "BLU-285), which targets D816V mutant KIT",
            "probability": 0.0
        },
        {
            "start_logit": 10.6640625,
            "end_logit": -8.2734375,
            "text": "KIT, for the treatment of advanced systemic mast",
            "probability": 0.0
        },
        {
            "start_logit": 10.6640625,
            "end_logit": -8.3828125,
            "text": "KIT,",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 12.359375,
            "text": "avapritinib (formerly BLU-285), which targets D816V mutant KIT",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": 12.359375,
            "text": "targets D816V mutant KIT",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 12.359375,
            "text": "phase I trial of avapritinib (formerly BLU-285), which targets D816V mutant KIT",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 12.359375,
            "text": "V mutant KIT",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 12.359375,
            "text": "apritinib (formerly BLU-285), which targets D816V mutant KIT",
            "probability": 0.0
        },
        {
            "start_logit": 10.6640625,
            "end_logit": -9.2109375,
            "text": "KIT, for the treatment of advanced systemic mastocytosis, patients experienced rapid and durable disease control",
            "probability": 0.0
        },
        {
            "start_logit": 10.6640625,
            "end_logit": -9.3359375,
            "text": "KIT, for the treatment of advanced systemic mastocytosis, patients experienced rapid and durable disease control.",
            "probability": 0.0
        },
        {
            "start_logit": 10.6640625,
            "end_logit": -9.65625,
            "text": "KIT, for the treatment of advanced systemic mastocytosis,",
            "probability": 0.0
        },
        {
            "start_logit": -8.7734375,
            "end_logit": -7.5390625,
            "text": "mastocytosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.9296875,
            "end_logit": -7.5390625,
            "text": "D816V mutant KIT, for the treatment of advanced systemic mastocytosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.7734375,
            "end_logit": -8.2734375,
            "text": "mast",
            "probability": 0.0
        },
        {
            "start_logit": -9.546875,
            "end_logit": -7.5390625,
            "text": "mutant KIT, for the treatment of advanced systemic mastocytosis",
            "probability": 0.0
        },
        {
            "start_logit": -9.5546875,
            "end_logit": -7.5390625,
            "text": "BLU-285), which targets D816V mutant KIT, for the treatment of advanced systemic mastocytosis",
            "probability": 0.0
        }
    ],
    "61f7d535882a024a10000034_14": [
        {
            "start_logit": 11.46875,
            "end_logit": 11.8828125,
            "text": "KIT",
            "probability": 1.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -7.234375,
            "text": "KIT and PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -8.3046875,
            "text": "KIT and PDGFRA inhibitor that potently inhibits PDGFRA D842V, in patients with advanced gastrointestinal stromal tumours, including patients with KIT",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -8.375,
            "text": "KIT and PDGFRA inhibitor that potently inhibits PDGFRA D842V,",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -8.6328125,
            "text": "KIT and PDGF",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -8.65625,
            "text": "KIT and PDGFRA inhibitor that potently inhibits PDGFRA D842V",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -8.8125,
            "text": "KIT and PDGFRA inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -8.890625,
            "text": "KIT and PDGFRA inhibitor that potently inhibits PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -9.140625,
            "text": "KIT and PDGFRA inhibitor that potently inhibits PDGFRA D842V, in patients with advanced gastrointestinal stromal tumours",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -9.171875,
            "text": "KIT and",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -9.1875,
            "text": "KIT and PDGFRA inhibitor that potently inhibits PDGFRA D842V, in patients with advanced gastrointestinal stromal tumours, including patients with KIT and PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -9.296875,
            "text": "KIT and PDGFRA inhibitor that potently inhibits PDGFRA D842",
            "probability": 0.0
        },
        {
            "start_logit": -9.796875,
            "end_logit": 11.8828125,
            "text": "ibitors. We aimed to assess the safety, tolerability, and antitumour activity of avapritinib, a novel KIT",
            "probability": 0.0
        },
        {
            "start_logit": -10.1171875,
            "end_logit": 11.8828125,
            "text": "antitumour activity of avapritinib, a novel KIT",
            "probability": 0.0
        },
        {
            "start_logit": -7.80078125,
            "end_logit": -7.234375,
            "text": "PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -7.80078125,
            "end_logit": -8.3046875,
            "text": "PDGFRA inhibitor that potently inhibits PDGFRA D842V, in patients with advanced gastrointestinal stromal tumours, including patients with KIT",
            "probability": 0.0
        },
        {
            "start_logit": -7.80078125,
            "end_logit": -8.375,
            "text": "PDGFRA inhibitor that potently inhibits PDGFRA D842V,",
            "probability": 0.0
        },
        {
            "start_logit": -7.80078125,
            "end_logit": -8.6328125,
            "text": "PDGF",
            "probability": 0.0
        },
        {
            "start_logit": -7.80078125,
            "end_logit": -8.65625,
            "text": "PDGFRA inhibitor that potently inhibits PDGFRA D842V",
            "probability": 0.0
        },
        {
            "start_logit": -7.80078125,
            "end_logit": -8.8125,
            "text": "PDGFRA inhibitor",
            "probability": 0.0
        }
    ],
    "61f7d535882a024a10000034_15": [
        {
            "start_logit": 11.265625,
            "end_logit": 12.046875,
            "text": "KIT",
            "probability": 1.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -5.7578125,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -6.3046875,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA), attenuates the transport function of both ABCB1 and ABCG2. Moreover, ava",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -6.56640625,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA), attenuates the transport function of both ABCB1 and ABCG2",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -6.62109375,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA)",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -6.92578125,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA), attenuates the transport function of both ABCB1",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -7.00390625,
            "text": "KIT and platelet",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -7.7109375,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGF",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -7.8203125,
            "text": "KIT and platelet-derived growth factor receptor alpha (",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -8.0,
            "text": "KIT and platelet-derived growth factor",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -8.140625,
            "text": "KIT and platelet-derived growth factor receptor",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -8.6953125,
            "text": "KIT and platelet-derived growth factor receptor alpha",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": 12.046875,
            "text": "against mutant forms of KIT",
            "probability": 0.0
        },
        {
            "start_logit": -9.703125,
            "end_logit": 12.046875,
            "text": "tyrosine kinase inhibitor against mutant forms of KIT",
            "probability": 0.0
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 12.046875,
            "text": "mutant forms of KIT",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -9.09375,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA), attenuates the transport function of both ABCB1 and ABC",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -9.1953125,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA),",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -9.2265625,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA), attenuates the transport function of both ABC",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 12.046875,
            "text": "avapritinib (BLU-285), a potent, selective, and orally bioavailable tyrosine kinase inhibitor against mutant forms of KIT",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 12.046875,
            "text": "orally bioavailable tyrosine kinase inhibitor against mutant forms of KIT",
            "probability": 0.0
        }
    ],
    "61f7d535882a024a10000034_16": [
        {
            "start_logit": 11.3828125,
            "end_logit": 11.90625,
            "text": "KIT",
            "probability": 1.0
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -5.7421875,
            "text": "KIT/PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -6.703125,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842V genoty",
            "probability": 0.0
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -7.37109375,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842V",
            "probability": 0.0
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -7.48828125,
            "text": "KIT/PDGF",
            "probability": 0.0
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -7.6875,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842",
            "probability": 0.0
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -8.28125,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842V gen",
            "probability": 0.0
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -8.390625,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in patients with the",
            "probability": 0.0
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -8.609375,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D",
            "probability": 0.0
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -8.90625,
            "text": "KIT/",
            "probability": 0.0
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -8.9296875,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D84",
            "probability": 0.0
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -9.0546875,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in",
            "probability": 0.0
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -9.2109375,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in patients with",
            "probability": 0.0
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -9.4375,
            "text": "KIT/PDGFRA inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 11.90625,
            "text": "V. Avapritinib is a novel, potent KIT",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": 11.90625,
            "text": ". Avapritinib is a novel, potent KIT",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 11.90625,
            "text": "Avapritinib is a novel, potent KIT",
            "probability": 0.0
        },
        {
            "start_logit": -8.5234375,
            "end_logit": -5.7421875,
            "text": "PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -8.5234375,
            "end_logit": -6.703125,
            "text": "PDGFRA inhibitor with substantial clinical activity in patients with the D842V genoty",
            "probability": 0.0
        },
        {
            "start_logit": -8.5234375,
            "end_logit": -7.37109375,
            "text": "PDGFRA inhibitor with substantial clinical activity in patients with the D842V",
            "probability": 0.0
        }
    ],
    "61f7d535882a024a10000034_17": [
        {
            "start_logit": 8.7109375,
            "end_logit": 10.09375,
            "text": "PDGFRA",
            "probability": 0.9931640625
        },
        {
            "start_logit": 3.720703125,
            "end_logit": 10.09375,
            "text": "platelet-derived growth factor receptor alpha (PDGFRA",
            "probability": 0.00669097900390625
        },
        {
            "start_logit": 8.7109375,
            "end_logit": 1.49609375,
            "text": "PDGFRA)",
            "probability": 0.0001811981201171875
        },
        {
            "start_logit": 8.7109375,
            "end_logit": 0.57421875,
            "text": "PDGFRA) exon 18",
            "probability": 7.206201553344727e-05
        },
        {
            "start_logit": 8.7109375,
            "end_logit": -1.5400390625,
            "text": "PDGFRA) exon 18 mutation",
            "probability": 8.761882781982422e-06
        },
        {
            "start_logit": 3.720703125,
            "end_logit": 1.49609375,
            "text": "platelet-derived growth factor receptor alpha (PDGFRA)",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -5.5625,
            "end_logit": 10.09375,
            "text": "gastrointestinal stromal tumors harboring a platelet-derived growth factor receptor alpha (PDGFRA",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 3.720703125,
            "end_logit": 0.57421875,
            "text": "platelet-derived growth factor receptor alpha (PDGFRA) exon 18",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.7109375,
            "end_logit": -5.88671875,
            "text": "PDGF",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 10.09375,
            "text": "RA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.7265625,
            "end_logit": 10.09375,
            "text": "(PDGFRA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 3.720703125,
            "end_logit": -1.5400390625,
            "text": "platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.7109375,
            "end_logit": -6.80859375,
            "text": "PDGFRA) exon 18 mutation. Muta",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.796875,
            "end_logit": 10.09375,
            "text": "stromal tumors harboring a platelet-derived growth factor receptor alpha (PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 10.09375,
            "text": "a platelet-derived growth factor receptor alpha (PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 10.09375,
            "text": "harboring a platelet-derived growth factor receptor alpha (PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 10.09375,
            "text": "and Drug Administration (FDA) approval for the treatment of metastatic or unresectable gastrointestinal stromal tumors harboring a platelet-derived growth factor receptor alpha (PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": 3.720703125,
            "end_logit": -5.51171875,
            "text": "platelet-derived growth factor receptor alpha",
            "probability": 0.0
        },
        {
            "start_logit": 3.720703125,
            "end_logit": -5.62109375,
            "text": "platelet",
            "probability": 0.0
        },
        {
            "start_logit": 3.720703125,
            "end_logit": -5.88671875,
            "text": "platelet-derived growth factor receptor alpha (PDGF",
            "probability": 0.0
        }
    ],
    "61f7d535882a024a10000034_18": [
        {
            "start_logit": 11.1875,
            "end_logit": 12.0859375,
            "text": "KIT",
            "probability": 1.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -5.99609375,
            "text": "KIT/PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -7.078125,
            "text": "KIT/PDGF",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -8.6640625,
            "text": "KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -8.7109375,
            "text": "KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA exon 18",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -8.84375,
            "text": "KIT/",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -8.96875,
            "text": "KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA exon 18-mutant",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -9.1640625,
            "text": "KIT/PDGFRA,",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -9.2109375,
            "text": "KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGF",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -9.21875,
            "text": "KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA exon 18-mutant unresectable or metastatic gastrointestinal stromal",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -9.3203125,
            "text": "KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA exon 18-mutant unresectable or metastatic",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -9.390625,
            "text": "KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA exon 18-",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 12.0859375,
            "text": ": Avapritinib, a novel inhibitor of KIT",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 12.0859375,
            "text": "Avapritinib, a novel inhibitor of KIT",
            "probability": 0.0
        },
        {
            "start_logit": -8.40625,
            "end_logit": -5.99609375,
            "text": "PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -8.40625,
            "end_logit": -7.078125,
            "text": "PDGF",
            "probability": 0.0
        },
        {
            "start_logit": -9.859375,
            "end_logit": -5.99609375,
            "text": "RA",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": -5.99609375,
            "text": ": Avapritinib, a novel inhibitor of KIT/PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": -5.99609375,
            "text": "Avapritinib, a novel inhibitor of KIT/PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -8.40625,
            "end_logit": -8.109375,
            "text": "PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA exon 18-mutant unresectable or metastatic gastrointestinal stromal tumors",
            "probability": 0.0
        }
    ],
    "61f7d535882a024a10000034_19": [
        {
            "start_logit": 12.1640625,
            "end_logit": 9.515625,
            "text": "c-KIT",
            "probability": 1.0
        },
        {
            "start_logit": 12.1640625,
            "end_logit": -2.93359375,
            "text": "c",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": 12.1640625,
            "end_logit": -4.3359375,
            "text": "c-KIT mutation",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 12.1640625,
            "end_logit": -7.71875,
            "text": "c-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.1640625,
            "end_logit": -8.7578125,
            "text": "c-KIT mutation, treated with avapritinib (BLU-285) - a highly potent and selective oral kinase",
            "probability": 0.0
        },
        {
            "start_logit": 12.1640625,
            "end_logit": -9.3125,
            "text": "c-KIT mutation, treated with avapritinib (BLU-285) - a highly potent and selective oral kinase inhibitor designed to treat imatinib",
            "probability": 0.0
        },
        {
            "start_logit": 12.1640625,
            "end_logit": -9.328125,
            "text": "c-KIT mutation, treated with avapritinib (BLU-285)",
            "probability": 0.0
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 9.515625,
            "text": "KIT",
            "probability": 0.0
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 9.515625,
            "text": "vulvar melanoma, harboring an exon 17 c-KIT",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 9.515625,
            "text": "exon 17 c-KIT",
            "probability": 0.0
        },
        {
            "start_logit": -8.6953125,
            "end_logit": 9.515625,
            "text": "melanoma, harboring an exon 17 c-KIT",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": 9.515625,
            "text": "patient with metastatic vulvar melanoma, harboring an exon 17 c-KIT",
            "probability": 0.0
        },
        {
            "start_logit": -9.359375,
            "end_logit": 9.515625,
            "text": "metastatic vulvar melanoma, harboring an exon 17 c-KIT",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": 9.515625,
            "text": "an exon 17 c-KIT",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 9.515625,
            "text": "harboring an exon 17 c-KIT",
            "probability": 0.0
        },
        {
            "start_logit": -7.91796875,
            "end_logit": -2.93359375,
            "text": "vulvar melanoma, harboring an exon 17 c",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": -2.93359375,
            "text": "exon 17 c",
            "probability": 0.0
        },
        {
            "start_logit": -8.6953125,
            "end_logit": -2.93359375,
            "text": "melanoma, harboring an exon 17 c",
            "probability": 0.0
        },
        {
            "start_logit": -7.7109375,
            "end_logit": -4.3359375,
            "text": "KIT mutation",
            "probability": 0.0
        },
        {
            "start_logit": -7.91796875,
            "end_logit": -4.17578125,
            "text": "vulvar melanoma",
            "probability": 0.0
        }
    ],
    "61f7d535882a024a10000034_20": [
        {
            "start_logit": 11.2578125,
            "end_logit": 12.0625,
            "text": "KIT",
            "probability": 1.0
        },
        {
            "start_logit": 11.2578125,
            "end_logit": -5.609375,
            "text": "KIT and PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": 11.2578125,
            "end_logit": -6.44921875,
            "text": "KIT and PDGFRA, in three patient-derived xenograft (PDX) GIST models carrying different KIT",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 12.0625,
            "text": "mutated KIT",
            "probability": 0.0
        },
        {
            "start_logit": 11.2578125,
            "end_logit": -7.4765625,
            "text": "KIT and PDGF",
            "probability": 0.0
        },
        {
            "start_logit": 11.2578125,
            "end_logit": -7.546875,
            "text": "KIT and PDGFRA, in three patient-derived xenograft (PDX) GIST",
            "probability": 0.0
        },
        {
            "start_logit": 11.2578125,
            "end_logit": -8.2578125,
            "text": "KIT and",
            "probability": 0.0
        },
        {
            "start_logit": 11.2578125,
            "end_logit": -8.5078125,
            "text": "KIT and PDGFRA, in three patient-derived xenograft (PDX) GIST models carrying different KIT mutations",
            "probability": 0.0
        },
        {
            "start_logit": 11.2578125,
            "end_logit": -8.765625,
            "text": "KIT and PDGFRA,",
            "probability": 0.0
        },
        {
            "start_logit": 11.2578125,
            "end_logit": -8.7734375,
            "text": "KIT and PDGFRA, in three patient-derived xenograft (PDX) GIST models carrying different KIT mutations, with differential sensitivity to standard TK",
            "probability": 0.0
        },
        {
            "start_logit": 11.2578125,
            "end_logit": -9.0,
            "text": "KIT and PDGFRA, in three patient-derived xenograft (PDX)",
            "probability": 0.0
        },
        {
            "start_logit": -6.984375,
            "end_logit": -5.609375,
            "text": "PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -6.984375,
            "end_logit": -6.44921875,
            "text": "PDGFRA, in three patient-derived xenograft (PDX) GIST models carrying different KIT",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -5.609375,
            "text": "mutated KIT and PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -7.6484375,
            "end_logit": -6.6484375,
            "text": "KIT",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": -6.44921875,
            "text": "GIST models carrying different KIT",
            "probability": 0.0
        },
        {
            "start_logit": -6.984375,
            "end_logit": -7.4765625,
            "text": "PDGF",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -6.44921875,
            "text": "KIT",
            "probability": 0.0
        },
        {
            "start_logit": -6.984375,
            "end_logit": -7.546875,
            "text": "PDGFRA, in three patient-derived xenograft (PDX) GIST",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": -5.609375,
            "text": "RA",
            "probability": 0.0
        }
    ],
    "61f7d535882a024a10000034_21": [
        {
            "start_logit": 11.390625,
            "end_logit": 11.9375,
            "text": "KIT",
            "probability": 1.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -6.87890625,
            "text": "KIT and PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -7.921875,
            "text": "KIT and PDGFRA inhibitor that potently inhibits PDGFRA D842V, in patients with advanced gastrointestinal stromal tumours, including patients with KIT",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -8.1953125,
            "text": "KIT and PDGF",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -8.7578125,
            "text": "KIT and PDGFRA inhibitor that potently inhibits PDGFRA D842V,",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -8.953125,
            "text": "KIT and PDGFRA inhibitor that potently inhibits PDGFRA D842V, in patients with advanced gastrointestinal stromal tumours, including patients with KIT and PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -9.0390625,
            "text": "KIT and PDGFRA inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -9.0859375,
            "text": "KIT and PDGFRA inhibitor that potently inhibits PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -9.3203125,
            "text": "KIT and PDGFRA inhibitor that potently inhibits PDGFRA D842V",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -9.390625,
            "text": "KIT and",
            "probability": 0.0
        },
        {
            "start_logit": -7.37109375,
            "end_logit": -6.87890625,
            "text": "PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -7.37109375,
            "end_logit": -7.921875,
            "text": "PDGFRA inhibitor that potently inhibits PDGFRA D842V, in patients with advanced gastrointestinal stromal tumours, including patients with KIT",
            "probability": 0.0
        },
        {
            "start_logit": -7.37109375,
            "end_logit": -8.1953125,
            "text": "PDGF",
            "probability": 0.0
        },
        {
            "start_logit": -7.37109375,
            "end_logit": -8.7578125,
            "text": "PDGFRA inhibitor that potently inhibits PDGFRA D842V,",
            "probability": 0.0
        },
        {
            "start_logit": -7.37109375,
            "end_logit": -8.953125,
            "text": "PDGFRA inhibitor that potently inhibits PDGFRA D842V, in patients with advanced gastrointestinal stromal tumours, including patients with KIT and PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -7.37109375,
            "end_logit": -9.0390625,
            "text": "PDGFRA inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -7.37109375,
            "end_logit": -9.0859375,
            "text": "PDGFRA inhibitor that potently inhibits PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -7.37109375,
            "end_logit": -9.3203125,
            "text": "PDGFRA inhibitor that potently inhibits PDGFRA D842V",
            "probability": 0.0
        },
        {
            "start_logit": -10.0859375,
            "end_logit": -6.87890625,
            "text": "RA",
            "probability": 0.0
        },
        {
            "start_logit": -9.40625,
            "end_logit": -7.921875,
            "text": "KIT",
            "probability": 0.0
        }
    ]
}
